

# EXHIBIT 98

1 UNITED STATES DISTRICT COURT  
2 NORTHERN DISTRICT OF CALIFORNIA

3 MDL No. 2741, Case No. 16-md-02741-VC

4 VIDEOTAPE DEPOSITION OF:  
5 CHARLES W. JAMESON, Ph.D. - September 21, 2017

6 IN RE: ROUNDUP PRODUCTS  
7 LIABILITY LITIGATION

8 This document relates to:  
9 ALL ACTIONS

10  
11 PURSUANT TO NOTICE, the videotape  
12 deposition of CHARLES W. JAMESON, Ph.D., was taken  
13 on behalf of the Defendant, Monsanto Company, at  
14 7171 W. Alaska Drive, Lakewood, Colorado  
15 80226, on September 21, 2017 at 9:03 a.m., before  
16 Tracy R. Stonehocker, Certified Realtime Reporter,  
17 Registered Professional Reporter and Notary Public  
18 within Colorado.  
19  
20  
21  
22  
23  
24

25 JOB NO. 130141

Page 2

1 A P P E A R A N C E S.  
 2 For the Plaintiffs:  
 3 AIMEE WAGSTAFF, ESQ.  
 4 Andrus Wagstaff  
 5 7171 W. Alaska Drive  
 6 Lakewood, Colorado 80226

7 PEARL ROBERTSON, ESQ.  
 8 Weitz & Luxenberg  
 9 700 Broadway  
 10 New York, New York 10003  
 11 PEDRAM ESFANDIARY, ESQ.  
 12 Baum Hedlund Aristei Goldman  
 13 12100 Wilshire Boulevard  
 14 Los Angeles, California 90025  
 15 (Appearing telephonically)

16 For the Defendant:  
 17 JOE HOLLINGSWORTH, ESQ.  
 18 CHRISTOPHER HAAKE, ESQ.  
 19 ERICA KLENICKI, ESQ.  
 20 Hollingsworth  
 21 1350 I Street, N.W.  
 22 Washington, DC 20005

23 Also Present:  
 24 John Jensen, Videographer  
 25 Robyn Buck, Esq.

Page 4

1 (All exhibits were marked by  
 2 Mr. Hollingsworth.)  
 3 WHEREUPON, the following proceedings  
 4 were taken pursuant to the Federal Rules of Civil  
 5 Procedure.  
 6 \* \* \* \* \*

7 THE VIDEOGRAPHER: This is the start of  
 8 media labeled number one of the video-recorded  
 9 deposition of Dr. Charles W. Jameson In Re: Roundup  
 10 Products Liability Litigation in the United States  
 11 District Court, Northern District of California,  
 12 Number 16-md-02741-VC.  
 13 This deposition is being held at 7171  
 14 West Alaska Drive, Lakewood, Colorado on September 21,  
 15 2017 at approximately 9:03 a.m.  
 16 My name is John Jensen. I am the legal  
 17 video specialist for TSG Reporting, Inc. headquartered  
 18 at 747 Third Avenue, New York, New York. The court  
 19 reporter is Tracy Stonehocker in association with TSG  
 20 Reporting. Counsel, please introduce yourselves.  
 21 MS. WAGSTAFF: Good morning. Aimee  
 22 Wagstaff on behalf of the plaintiffs.  
 23 MS. ROBERTSON: Pearl Robertson on  
 24 behalf of plaintiffs.  
 25 MR. HOLLINGSWORTH: Joe Hollingsworth,

Page 3

1 I N D E X  
 2 EXAMINATION OF CHARLES W. JAMESON, Ph.D.: PAGE  
 3 September 21, 2017  
 4 By Mr. Hollingsworth 7, 303  
 5 By Ms. Wagstaff 286

6 INITIAL  
 7 DEPOSITION EXHIBITS: REFERENCE

8 Exhibit 22-1 Expert Report of Dr. Charles W. 11  
 9 Jameson, Ph.D. in Support of General  
 10 Causation on Behalf of Plaintiffs

11 Exhibit 22-2 CWJ/Greim Experimental Animal 120  
 12 Summary, Mouse

13 Exhibit 22-3 CWJ/Greim Experimental Animal 121  
 14 Summary, Rat

15 Exhibit 22-4 11th Report on Carcinogens 2004 259

16 Exhibit 22-5 E-mail from drjameson to 266  
 17 Chris Portier, Re: IARC Monograph  
 18 vol 112-EFSA Review of Glyphosate,  
 19 11/10/15

20 Exhibit 22-6 Letter from Hunter Lundy to 278  
 21 Dr. Portier, 3/29/15

22 Exhibit 22-7 Christopher Portier Invoice, 279  
 23 10/19/15

24 Exhibit 22-8 E-mail from Consolato Sergi to 279  
 25 Portier, et al. Re: IARC Monograph vol  
 112-EFSA Review of Glyphosate, 11/9/15

Exhibit 22-9 E-mail from drjameson to Portier, 281  
 Re: Final Glyphosate Letter, 11/16/15

Exhibit 22-10 E-mail from Portier to Portier, 284  
 Subject: Glyphosate, 12/6/15

Page 5

1 Hollingsworth, LLP on behalf of Monsanto.  
 2 MR. HAAKE: Christopher Haake also with  
 3 Hollingsworth, LLP on behalf of Monsanto.  
 4 MS. BUCK: Robyn Buck with Monsanto.  
 5 MS. WAGSTAFF: I believe we have some  
 6 folks on the telephone.  
 7 MR. ESFANDIARY: Pedram Esfandiary with  
 8 plaintiffs.  
 9 MS. KLENICKI: Erica Klenicki from  
 10 Hollingsworth on behalf of Monsanto.  
 11 \* \* \* \* \*

12 CHARLES W. JAMESON, Ph.D.,  
 13 having been first duly sworn to state the whole truth,  
 14 testified as follows:  
 15 (Deponent's reply to oath: I do.)  
 16 MS. WAGSTAFF: Mr. Hollingsworth, before  
 17 we get started, I'd like to correct three typos from  
 18 Dr. Jameson's expert report and they all three are the  
 19 same word that was auto-corrected or somehow changed.  
 20 On page 22, and this is the report dated -- it's not  
 21 dated, but it's his MDL report. On page 22, about  
 22 third of the way down, if you want to look over here,  
 23 like right there.  
 24 MR. HOLLINGSWORTH: Yup.  
 25 MS. WAGSTAFF: It says,

Page 6

1 "Hemangiosarcomas" and it should say "hemangiomas" and  
 2 the correct line should read, "The EPA also reported,"  
 3 footnote 86, "that hemangiosarcomas in female mice  
 4 were found to occur with a statistically significant  
 5 trend in the study," and then it gives a parenthesis  
 6 with a bunch of numbers, "and the tumor incidence in  
 7 the high dose female mice was statistically  
 8 significant with p=0.028 as compared to concurrent  
 9 controls."  
 10 The next one is on page 28. And it's  
 11 the same correction on the very bottom line of page  
 12 28. Once again, it says, "hemangiosarcomas" and it  
 13 should say "hemangiomas." The correct sentence should  
 14 read, "There was also a significant positive trend for  
 15 the formation of adenocarcinomas of the lung in male  
 16 CD-1 mice in one study," footnote 78, "and hemangiomas  
 17 in female CD-1 mice in another study."  
 18 And the last typo related to this is on  
 19 page 29 in the second paragraph, the first sentence in  
 20 the second paragraph, which is really long, right  
 21 after the footnote 78, it says, and "hemangiosarcomas"  
 22 and it should say and "hemangiomas" and those are the  
 23 three. I love that word.  
 24 MR. HOLLINGSWORTH: What's the last one?  
 25 MS. WAGSTAFF: Okay. Page 29.

Page 8

1 Q. The hypothesis that mouse renal tumors  
 2 are predictive of human NHL has never been tested, has  
 3 it?  
 4 A. Well, in any rodent bioassay, the  
 5 purpose of doing the study is to see if a material  
 6 that you're investigating can cause cancer in the  
 7 experimental animal, and it's been shown that most  
 8 chemicals that have been shown to be carcinogens in  
 9 experimental animals are also carcinogens in humans.  
 10 Not all, but a large majority. If they're positive in  
 11 animals, it's likely they will cause cancer in humans.  
 12 That's why you perform the study to see if they cause  
 13 cancers in the animal as kind of a predictive tool to  
 14 say, well, there's potential that this chemical will  
 15 cause cancer in humans.  
 16 Q. I'm asking a slightly different thing.  
 17 I'm talking about a specific kind of cancer in humans,  
 18 do you understand that, called non-Hodgkin's lymphoma  
 19 or NHL?  
 20 A. Uh-huh.  
 21 Q. My question is whether the hypothesis  
 22 that mouse renal tumors are predictive of  
 23 non-Hodgkin's lymphoma specifically in humans has ever  
 24 been tested?  
 25 A. Again, this -- you know, the purpose of

Page 7

1 MR. HOLLINGSWORTH: Yep.  
 2 MS. WAGSTAFF: It's right here.  
 3 MR. HOLLINGSWORTH: Right in the middle?  
 4 MS. WAGSTAFF: The first --  
 5 MR. HOLLINGSWORTH: Okay. I see.  
 6 MS. WAGSTAFF: -- sentence right after  
 7 footnote 78 in parenthesis, "study 74," and it should  
 8 say "hemangiomas in female in one study period." Got  
 9 it?  
 10 MR. HOLLINGSWORTH: Yep.  
 11 EXAMINATION  
 12 BY MR. HOLLINGSWORTH:  
 13 Q. Good morning, again, Dr. Jameson.  
 14 A. Morning.  
 15 Q. If you don't understand one of my  
 16 questions or you want me to repeat it, feel free to do  
 17 so. If you want to take a break, just let me know.  
 18 A. Okay.  
 19 Q. As you know, we'll be proceeding in a  
 20 question and answer format here. I'm going to ask the  
 21 questions and I hope you'll give me the answers.  
 22 Listen carefully to what they said -- what I ask you  
 23 and I'll be happy to repeat a question or clarify it  
 24 for you if you'd like. Okay?  
 25 A. Okay.

Page 9

1 a bioassay is to see if the chemical can cause cancer  
 2 in the animals as a predictive tool for what it -- if  
 3 it causes cancer in humans. Now, I mean, the fact  
 4 that something causes a kidney tumor in a mouse, I  
 5 don't know what that says about causing non-Hodgkin's  
 6 lymphoma in humans. I don't know that's been  
 7 investigated. I don't know that anyone has actually  
 8 done a study to see if you cause a renal tumor in a  
 9 mouse, if there's some kind of mechanism in the mouse  
 10 that is similar to a mechanism -- known mechanism in  
 11 humans that goes on to non-Hodgkin's lymphoma. I  
 12 don't know if any type of study like that has been  
 13 done.  
 14 So, again, it's really not a relevant  
 15 question to say, well, you got kidney tumors in a  
 16 mouse, what does that say about non-Hodgkin's  
 17 lymphoma. The purpose of doing the study in the mouse  
 18 is to see if it causes cancer and that's used as a  
 19 predictive tool to see if it causes cancer in humans.  
 20 Q. You understand the proceeding that we're  
 21 about to embark in in the MDL part of this case has  
 22 the specific question whether glyphosate can cause  
 23 non-Hodgkin's lymphoma in humans?  
 24 MS. WAGSTAFF: Object to form.  
 25 A. I'm sorry, could you ask that again?

Page 10

1 Q. (BY MR. HOLLINGSWORTH) Sure. You  
 2 understand that the procedure -- the legal proceeding  
 3 that we're about to embark on in the multidistrict  
 4 litigation case that your report has been submitted in  
 5 states that the purpose of the proceeding is to  
 6 determine whether glyphosate can cause non-Hodgkin's  
 7 lymphoma in humans.  
 8 MS. WAGSTAFF: Object to the form.  
 9 Q. (BY MR. HOLLINGSWORTH) Do you understand  
 10 that?  
 11 A. Well, the litigation, yeah, I -- that's  
 12 my understanding that the litigation is over -- --  
 13 that exposure to glyphosate caused non-Hodgkin's  
 14 lymphoma in an exposed population or exposed  
 15 individual.  
 16 Q. And your testimony is that the question  
 17 of whether renal tumors are predictive of  
 18 non-Hodgkin's lymphoma, that is, mouse renal tumors is  
 19 predictive of non-Hodgkin's lymphoma has not been  
 20 studied as far as you know?  
 21 A. I'm not aware of any publications or any  
 22 research that has been done. That's not to say that  
 23 it hadn't, but I haven't come across it yet.  
 24 Q. You didn't cite any publication or study  
 25 in your report in this case which says that renal

Page 12

1 A. The typo was -- originally said  
 2 "hemangiosarcoma" and it should have read  
 3 "hemangioma."  
 4 Q. Is there any data that you've cited in  
 5 your report that records what the error rate would be  
 6 in predicting non-Hodgkin's lymphoma based on renal  
 7 tumors in mice?  
 8 A. Could you please define what you mean by  
 9 "error rate."  
 10 Q. What I mean by error rate is the rate of  
 11 error in a test -- in a study that's been done  
 12 involving renal tumors in mice that are predictive for  
 13 non-Hodgkin's lymphoma. And I take it since you said  
 14 it hadn't been published in your prior answer that  
 15 there is no such study involving what the rate of  
 16 error is in such a situation?  
 17 MS. WAGSTAFF: Object to form.  
 18 A. I do not know of any published studies  
 19 that have looked at that. That's not to say there  
 20 isn't, but I haven't found any. But, again, I would  
 21 say the purpose of the study in the mouse was to see  
 22 if the glyphosate would cause cancer. That was the  
 23 purpose of the study.  
 24 Q. (BY MR. HOLLINGSWORTH) Yes.  
 25 A. The purpose of the study wasn't to see

Page 11

1 tumors in mice are predictive of non-Hodgkin's  
 2 lymphoma in humans, did you?  
 3 A. No. I did not have any citations in my  
 4 report to that effect, no.  
 5 Q. Sir, I have your report here, what I  
 6 think is your report and I've marked it as 22-1 and  
 7 it's titled "Expert Report of Dr. Charles Jameson,  
 8 Ph.D. in Support of General Causation on Behalf of  
 9 Plaintiffs." Do you see this?  
 10 A. Uh-huh.  
 11 Q. And I hand -- in my handwritten notes in  
 12 that version of your report, which you have before  
 13 you, I marked in the corrections that were made in  
 14 three or four different places from the term  
 15 "hemangiosarcoma" to "hemangioma," which is what you  
 16 wanted to do, right?  
 17 A. Right.  
 18 Q. That's the correction you wanted to  
 19 correct, you wanted to change the "hemangiosarcomas"  
 20 that you referred to in those four places to the word  
 21 "hemangiomas"?  
 22 MS. WAGSTAFF: Three.  
 23 A. In three places in the study in female  
 24 CD-1 mice.  
 25 Q. (BY MR. HOLLINGSWORTH) Yes.

Page 13

1 if -- if -- if you got a -- cancer in the kidneys of  
 2 the mouse it was related to non-Hodgkin's lymphoma.  
 3 Q. Yes.  
 4 A. So that wasn't the purpose of the study.  
 5 Q. I understand that. But the purpose of  
 6 this hearing is to determine whether glyphosate causes  
 7 non-Hodgkin's lymphoma in humans and that's why I'm  
 8 asking you these questions. Do you understand that,  
 9 Dr. Jameson?  
 10 MS. WAGSTAFF: Object to form. By the  
 11 way, plaintiffs are alleging that glyphosate  
 12 formulations is what is causing NHL, as well as just  
 13 glyphosate.  
 14 Q. (BY MR. HOLLINGSWORTH) Can you answer my  
 15 question?  
 16 A. I'm sorry, could you repeat it?  
 17 MR. HOLLINGSWORTH: Can you read it  
 18 back, please, Tracy?  
 19 (The question was read back as follows:  
 20 "I understand that. But the purpose of this hearing  
 21 is to determine whether glyphosate causes  
 22 non-Hodgkin's lymphoma in humans and that's why I'm  
 23 asking you these questions. Do you understand that,  
 24 Dr. Jameson?")  
 25 MS. WAGSTAFF: Object to form.

1 A. I'm sorry, are you saying the purpose  
2 of -- of today of this deposition is to do that?

3 Q. (BY MR. HOLLINGSWORTH) I'm referring to  
4 the legal proceeding, the hearing that we're having  
5 eventually in which your report is going to be  
6 introduced and I assume you're going to testify.

7 MS. WAGSTAFF: Objection, calls for a  
8 legal conclusion.

9 Q. (BY MR. HOLLINGSWORTH) The purpose of  
10 that hearing is to determine whether glyphosate can  
11 cause non-Hodgkin's lymphoma in humans and you  
12 understand that, right?

13 MS. WAGSTAFF: Objection, calls for a  
14 legal conclusion.

15 A. I understand that I've been asked my  
16 expert opinion about if -- if glyphosate and  
17 glyphosate formulations cause non-Hodgkin's lymphoma  
18 in humans.

19 Q. (BY MR. HOLLINGSWORTH) Your report says  
20 in the last sentence, if you look at it, that your  
21 opinion is based on a reasonable degree of scientific  
22 certainty is that glyphosate can cause non-Hodgkin's  
23 lymphoma in humans, doesn't it? Can't you remember  
24 that without looking at your report?

25 MS. WAGSTAFF: Objection. Don't get

1 lectures and seminars about the results of animal  
2 bioassay studies where the material being investigated  
3 had caused kidney tumors in mice, but to the best of  
4 my knowledge, I don't recall that any of the  
5 investigators that were -- that -- that were  
6 performing this study were investigating the -- any  
7 type of an association between the possible formation  
8 of kidney tumors in mice and non-Hodgkin's lymphoma in  
9 humans. I just don't think anybody has looked into  
10 that.

11 Q. Okay. Thank you. When IARC's committee  
12 on monograph 112 met, it wasn't your purpose to sit  
13 down and decide whether glyphosate caused  
14 non-Hodgkin's lymphoma in humans, was it?

15 A. Well --

16 MS. WAGSTAFF: I'm going to allow this  
17 question, but I will note for the record that you guys  
18 have already deposed him on the deliberations and the  
19 purpose of the IARC 112 meeting. That is not what he  
20 is being presented for today. So if you go too far  
21 into it, I'm going to instruct him not to answer. You  
22 can answer.

23 A. Okay. So -- I'm sorry, could you repeat  
24 the question?

25 Q. (BY MR. HOLLINGSWORTH) When the IARC

1 aggressive.

2 A. You're asking what my report says,  
3 so. . .

4 Q. (BY MR. HOLLINGSWORTH) The last  
5 sentence. The last sentence --

6 MS. WAGSTAFF: Go to the last page.

7 A. The last page, last sentence of my  
8 conclusion?

9 Q. (BY MR. HOLLINGSWORTH) Yes.

10 A. The last page of my conclusion says, "I  
11 also conclude to a reasonable degree of scientific  
12 certainty that glyphosate and glyphosate-based  
13 formulations cause non-Hodgkin's lymphoma in humans."

14 Q. Okay. Have you ever published a study  
15 that says mouse renal tumors are predictive of  
16 non-Hodgkin's lymphoma in humans?

17 A. Okay. Me, personally, I have not  
18 published a paper that addresses the issue of the  
19 relationship of kidney tumors in mice to non-Hodgkin's  
20 lymphoma in humans.

21 Q. Have you ever attended a lecture where  
22 there was a discussion of whether or not mouse renal  
23 tumors are predictive of non-Hodgkin's lymphoma in  
24 humans?

25 A. Not that I recall. I've attended many

1 monograph committee on -- monograph 112 sat down to  
2 deliberate, it was not your purpose to determine  
3 whether glyphosate can cause NHL in humans, was it?

4 A. Well, the IARC monograph or the  
5 International Agency for Research on Cancer holds  
6 these working group meetings to evaluate the potential  
7 carcinogenesis or the potential cancer-causing ability  
8 of particular materials that they had identified for  
9 review. Now, the reviews are based on publicly  
10 available information and the peer-reviewed literature  
11 and it's also made -- also from government  
12 publications. And also publicly available information  
13 that -- that other -- any individual could submit for  
14 review by the working group.

15 Now, the working group is instructed to  
16 review all the data, and then in the preamble of the  
17 IARC monograph, there is a set of criteria that the  
18 individuals are instructed to evaluate the data based  
19 on the criteria that is outlined in the preamble. The  
20 preamble -- and the data that is looked at for a  
21 monograph includes human data, animal data and  
22 mechanistic data.

23 So in investigating the human data for a  
24 chemical, the epidemiology is investigated. All the  
25 epidemiology data that's available is evaluated and

Page 18

1 it's determined if there is evidence that the  
 2 particular material causes cancer in exposed human  
 3 populations, and it is also part of this evaluation  
 4 that they identify the tumor sites where the chemical  
 5 caused the increase in tumors in the human population.  
 6 So following that line of logic, if you  
 7 will, it was the purpose of the IARC monograph to  
 8 evaluate the human epidemiology data and to determine  
 9 if it did cause cancer in humans and at what  
 10 particular sites in humans or what particular type of  
 11 tumors in humans the cancer is -- is formed.  
 12 Q. Okay. The IARC committee was not able  
 13 to determine that there was sufficient epidemiologic  
 14 evidence to say that glyphosate causes non-Hodgkin's  
 15 Lymphoma in humans, was it?  
 16 MS. WAGSTAFF: Object to form.  
 17 A. Well --  
 18 Q. (BY MR. HOLLINGSWORTH) Can you answer  
 19 my question yes or no?  
 20 MS. WAGSTAFF: Objection. Can you let  
 21 him answer before --  
 22 MR. HOLLINGSWORTH: Sorry.  
 23 A. The --  
 24 Q. (BY MR. HOLLINGSWORTH) My question  
 25 is --

Page 20

1 Q. Sufficient evidence.  
 2 A. Okay. The criteria, as I indicated  
 3 previously, that is -- that is listed in the preamble  
 4 of the IARC monograph has definitions of what is meant  
 5 for sufficient evidence, for limited evidence, for  
 6 inadequate evidence and what have you. And so if you  
 7 look at the different definitions, sufficient evidence  
 8 means that their causation is credible and there are  
 9 no confounders.  
 10 I'm paraphrasing, but basically it --  
 11 the data is positive and confounders and what have you  
 12 have been accounted for and do not affect that  
 13 observation.  
 14 The second one, which is limited says  
 15 a -- an association between the material and cancer is  
 16 a very credible -- means that there's evidence that it  
 17 causes -- that the material causes cancer in humans.  
 18 The evidence is there. But there are some issues of,  
 19 you know, bias or confounding or chance that just  
 20 haven't been adequate -- just can't be adequately  
 21 addressed, so that's why they say that the evidence is  
 22 limited. So that's why IARC came up with -- had to  
 23 say limited because of the restrictions of the  
 24 criteria.  
 25 Q. IARC was not able to say that there was

Page 19

1 A. The criteria --  
 2 Q. My question arises not from -- I'm  
 3 not -- I don't want to go into your prior deposition.  
 4 I really didn't intend to. But I'm referring back to  
 5 the last sentence of your report, which you read into  
 6 the record.  
 7 And my question is, whether the IARC  
 8 committee determined that there was sufficient  
 9 evidence to say that glyphosate causes non-Hodgkin's  
 10 Lymphoma in humans?  
 11 A. Okay. Well, that was --  
 12 MS. WAGSTAFF: Hang on. I object to  
 13 that because you are suggesting that his expert report  
 14 is based on what the IARC determined and this is an  
 15 expert report from Dr. Jameson. It's not a  
 16 regurgitation of the IARC and he wasn't constrained by  
 17 the IARC rules, definitions and preamble in his expert  
 18 report, but answer if you can.  
 19 A. Okay. Well, that's what I was basically  
 20 going to say. The opinion in my report is my opinion.  
 21 Q. (BY MR. HOLLINGSWORTH) Okay.  
 22 A. It has nothing to do with the -- with  
 23 what IARC did or with what IARC said. Now, as far as  
 24 the IARC not finding -- I'm sorry, what did he say,  
 25 sufficient evidence?

Page 21

1 sufficient evidence that glyphosate causes NHL in  
 2 humans, correct?  
 3 MS. WAGSTAFF: Objection, asked and  
 4 answered.  
 5 A. Again, if you look at the preamble, the  
 6 IARC has criteria and the criteria that you are  
 7 required to evaluate the data against is listed -- is  
 8 in there and the working group members are told you  
 9 have to use -- apply this criteria in your overall  
 10 evaluation.  
 11 So -- and the overall evaluation, the  
 12 IARC working group -- now, this is a whole working  
 13 group, it's not just the human subgroup. The whole  
 14 working group came to the conclusion that causation  
 15 of -- between glyphosate, glyphosate formulations and  
 16 non-Hodgkin's lymphoma is a credible evaluation that  
 17 the data says that glyphosate and glyphosate  
 18 formulations cause non-Hodgkin's lymphoma in the  
 19 exposed population.  
 20 But there were some -- some other issues  
 21 like bias or chance or what have you that came into  
 22 play that they could not explain away, so it met the  
 23 limited criteria.  
 24 Q. (BY MR. HOLLINGSWORTH) And the IARC  
 25 committee, therefore, was not able to say that there

1 was sufficient evidence that glyphosate can cause NHL  
2 in humans?

3 MS. WAGSTAFF: Objection, this is the  
4 third time that you've asked that question.

5 MR. HOLLINGSWORTH: Well, he's not  
6 answering my question.

7 MS. WAGSTAFF: He is answering. If you  
8 don't like --

9 MR. HOLLINGSWORTH: Despite your  
10 coaching.

11 MS. WAGSTAFF: If you don't like his  
12 response, I'm sorry, but he's answered very  
13 sufficiently.

14 A. I'm going to give you the same answer.

15 Q. (BY MR. HOLLINGSWORTH) Can you show me  
16 from the IARC report where they say that glyphosate  
17 can cause non-Hodgkin's Lymphoma in humans?

18 A. I can show you where it says it is  
19 evidence -- yeah, that there is evidence -- the  
20 evidence is credible that glyphosate and glyphosate  
21 formulations cause non-Hodgkin's lymphoma.

22 Q. You're saying that the IARC committee  
23 said that?

24 A. In the monograph.

25 Q. That there was sufficient evidence

1 to --

2 A. No.

3 MS. WAGSTAFF: Objection.

4 A. I did not say that.

5 Q. (BY MR. HOLLINGSWORTH) Okay. So there  
6 wasn't sufficient evidence to say that, but they said  
7 it never -- nevertheless, is that what you're  
8 testifying to here today?

9 A. I did not say that either.

10 MS. WAGSTAFF: Objection, asked and  
11 answered five times.

12 Q. (BY MR. HOLLINGSWORTH) Sir, is the --  
13 has the hypothesis that mouse hemangiosarcomas are  
14 predictive of non-Hodgkin's lymphoma been tested?

15 A. Again, you have a similar situation to  
16 what you have with the kidney tumors in mice. The  
17 studies were conducted to see if particular material  
18 would cause cancer in animals. The study indicated  
19 that hemangiosarcomas were caused in this particular  
20 study. And there was a significant increase in these  
21 tumors in the animals, so there's -- it can be said  
22 that glyphosate caused the hemangiosarcomas in that  
23 particular study.

24 But to my knowledge, I don't know that  
25 anybody has done an investigation to see -- to see if

1 there is a correlation between the formation of  
2 hemangiosarcomas in laboratory animals and  
3 non-Hodgkin's lymphoma in humans, but the study does  
4 say that glyphosate causes hemangiosarcomas in  
5 experimental animals, so it's an animal carcinogen  
6 and, therefore, it could possibly cause cancer in  
7 humans.

8 Q. Has anybody done an investigation of  
9 whether or not findings of mouse hemangiomas are  
10 predictive of non-Hodgkin's lymphoma in humans?

11 A. Again, the study was conducted to see if  
12 glyphosate could cause hemangiomas or any cancers, in  
13 this case, I believe it was in female mice. The  
14 results of the study indicated that exposure to  
15 glyphosate did cause hemangiomas to be formed in the  
16 female mice, so, therefore, it -- glyphosate caused  
17 hemangiomas in mice, so it's an animal carcinogen and  
18 a potential carcinogen in humans.

19 To the best of my knowledge, I don't  
20 know that anybody has done an investigation where they  
21 exposed animals to glyphosate and to investigate if  
22 there was an association between formation of  
23 hemangiomas in female mice and non-Hodgkin's lymphoma  
24 in humans. I don't think it -- I'm not aware that  
25 anybody has done and/or published any research in that

1 particular area.

2 Q. Are you aware whether anybody has done  
3 or published research in the area of an investigation  
4 of lung adenocarcinomas and their predict -- their  
5 predictability of non-Hodgkin's lymphoma in humans?  
6 I'm talking about lung adenocarcinomas.

7 A. Lung adenocarcinomas?

8 Q. Yes.

9 A. The study was conducted to see if  
10 glyphosate caused cancer in the experimental animals.  
11 The result of the study was lung adenocarcinomas were  
12 formed, so therefore glyphosate caused lung  
13 adenocarcinomas in the experimental animals. It is  
14 therefore an animal carcinogen and a potential human  
15 carcinogen.

16 I do not know if anybody has done an  
17 experiment to investigate any type of association of  
18 the formation of hemangiomas -- I'm sorry, lung  
19 adenocarcinomas in the experimental animals and  
20 non-Hodgkin's lymphoma in humans.

21 Q. Has anybody done an investigation of the  
22 relationship between rat testicular interstitial cell  
23 tumors and non-Hodgkin's lymphoma in humans to your  
24 knowledge?

25 A. I'm -- I'm going to give you a similar

1 answer to what I've given to all of them. The study  
2 was conducted on experimental animals to see if  
3 glyphosate caused cancer in the experiment. In this  
4 particular study, I believe it's in male rats, the  
5 glyphosate was found to cause an increased incidence  
6 of interstitial tumors of the testes in the male rats.  
7 Therefore, exposure to glyphosate caused interstitial  
8 tumors in the male rats.

9 It is positive animal carcinogen for  
10 male rats because of the tumors and is, therefore, a  
11 potential human carcinogen.

12 Again, I'm not aware of anyone doing any  
13 research or publishing any papers that did an  
14 investigation of the formation of interstitial cell  
15 tumors of the testes in male rats and non-Hodgkin's  
16 lymphoma in humans.

17 Q. Would you give the same answer for rat  
18 hepatocellular adenomas?

19 A. I would.

20 Q. Would you give the same answer for rat  
21 pancreatic -- pancreatic islet cell tumors?

22 A. I would.

23 Q. And would you give the same answer for  
24 rat thyroid follicular tumors?

25 A. I would.

1 Q. Would you give the same answer for  
2 rat -- excuse me, for mouse -- mouse lymphoma?

3 A. I would give the same answer for mouse  
4 lymphoma, but I might give a little side comment that  
5 the lymphomas are a particular tumor type that is  
6 similar to the lymphoma -- non-Hodgkin's lymphoma that  
7 is humans.

8 In other words, you're forming a  
9 lymphoma in the animals and what you're talking about  
10 is non-Hodgkin's lymphoma in humans, so that's a  
11 little more closely associated with the actual human  
12 tumor site and -- but, again, I'm not aware of anybody  
13 doing any research or publishing any paper where  
14 they -- they investigated the formation of the mouse  
15 lymphomas and its association to non-Hodgkin's  
16 lymphoma in humans, but there may be, but I'm not  
17 aware of any.

18 Q. You didn't cite anything in your report  
19 in this case, sir, in which you relied on any  
20 publication that states that the experimental mouse  
21 system is a valid model for predicting non-Hodgkin's  
22 lymphoma in humans, did you?

23 A. No, I did not use any reference to that  
24 effect, no.

25 Q. Isn't it true that the current

1 literature indicates that the mouse system is not a  
2 good -- not a good predictor of lymphoma in humans?

3 MS. WAGSTAFF: Object to form.

4 Q. (BY MR. HOLLINGSWORTH) For a number of  
5 reasons?

6 MS. WAGSTAFF: Object to form.

7 A. There may have -- may be some  
8 publications in the literature to that effect, but,  
9 again, the purpose of doing these studies is --  
10 most -- the studies -- the purpose of doing an animal  
11 bioassay study is to determine if the chemical can  
12 cause cancer in the experimental animals. And it's  
13 not -- not looking to investigate does it form a  
14 specific kind of tumor that is the same as found in  
15 humans. At least routinely that's not the case.

16 Now, sometimes -- I think the state of  
17 the art is that you can develop genetically modified  
18 test species, transplant human genes into an animal or  
19 something like that and do some studies that may give  
20 you some more information as to the formation of the  
21 cancer in humans based on the special -- special  
22 animals, but I'm not familiar with that research, and  
23 I can't speak to that right now, but I know that type  
24 of research is being done.

25 I have no idea if there's anything being

1 done with non-Hodgkin's lymphoma. I haven't looked  
2 into that, to be honest.

3 Q. Your paper doesn't cite any study  
4 involving genetically modified mice who've been  
5 injected with human genes to determine whether or not  
6 there's a relationship between mouse lymphoma and  
7 non-Hodgkin's lymphoma in humans?

8 A. I'm not aware of any, and I don't have  
9 any. I did not cite any in my report.

10 Q. So the answer to my question is no?

11 MS. WAGSTAFF: Objection, argumentative.

12 A. I don't have any in my report.

13 Q. (BY MR. HOLLINGSWORTH) Okay. In fact,  
14 doesn't the current literature say that the mouse  
15 system -- the mouse system is not a good model for  
16 predicting non-Hodgkin's lymphoma or any lymphoma in  
17 humans because malignant lymphoma in mice has such a  
18 high background incidence in control animals that have  
19 not been fed any substance?

20 MS. WAGSTAFF: Objection, asked and  
21 answered.

22 A. I'm -- I'm not aware of the arguments  
23 that it's not a good model. I mean, of -- I'm not  
24 aware of the arguments that it's a not a good model  
25 for non-Hodgkin's lymphoma because of the high

Page 30

1 background incidence of lymphomas in mice. It's an  
 2 argument that the mouse isn't a good model for looking  
 3 for lymphomas for the cause -- for a chemical to cause  
 4 lymphomas in mice because of the high background level  
 5 in mice.  
 6 Q. (BY MR. HOLLINGSWORTH) Thank you. You  
 7 have -- you have written papers on -- when you were at  
 8 the NTP down at research triangle park about the  
 9 interpretation of experimental animal studies in order  
 10 to decide whether or not a substance is a carcinogen  
 11 or not, haven't you?  
 12 A. True.  
 13 Q. And you've written those papers with  
 14 people like Joe Haseman?  
 15 A. I've -- I am co-author of a couple of  
 16 papers with Joe Haseman, yes.  
 17 Q. And Dr. Huff?  
 18 A. And James Huff.  
 19 Q. Is Dr. Huff still living?  
 20 A. Yes. I believe he is.  
 21 Q. In -- in those papers, you and your  
 22 colleagues at NTP said that to determine whether an  
 23 experimental animal results in truth supports a  
 24 finding of carcinogenesis, the -- the result in a  
 25 study should be represented or replicated in other

Page 32

1 MS. WAGSTAFF: Objection.  
 2 Q. (BY MR. HOLLINGSWORTH) You've written  
 3 that, haven't you?  
 4 MS. WAGSTAFF: Objection to your  
 5 colleagues at NTP and the same objection from before.  
 6 A. That was written quite awhile ago. In a  
 7 perfect world, that would be a -- a -- a preferred  
 8 situation, I guess. If you had unlimited resources  
 9 and unlimited funds and what have you to repeat it --  
 10 to repeat these million-dollar animal bioassay  
 11 studies, that data would strengthen the observation of  
 12 a chemical causing cancer in that particular strain  
 13 of -- of a particular species of animal. But it's not  
 14 necessary to -- for the interpretation of does the --  
 15 does the chemical cause cancer in experimental animals  
 16 and is it an animal carcinogenic carcinogen.  
 17 Q. Well, you have -- you've referred to 12  
 18 different studies in your report, I think, five mice  
 19 and seven rats, true?  
 20 A. Uh-huh.  
 21 Q. That's an immense amount of data, isn't  
 22 it, on glyphosate?  
 23 A. That's more than you usually see for a  
 24 particular compound.  
 25 Q. There's a --

Page 31

1 experiments similarly situated and designed by  
 2 different laboratories, true?  
 3 A. If possible, that would -- would  
 4 strengthen the data.  
 5 Q. Yep. And you and your colleagues at NTP  
 6 also wrote that to determine the truth about the  
 7 carcinogenicity about a study -- additional studies of  
 8 other strains of the same animal species should be  
 9 done if the same finding has been made in the same  
 10 strain in a different strain of the same species,  
 11 right?  
 12 MS. WAGSTAFF: Object, I would ask if  
 13 you're reading from something he wrote that you afford  
 14 him the pleasure of being able to see what he wrote.  
 15 Q. (BY MR. HOLLINGSWORTH) Do you understand  
 16 my question?  
 17 A. I think I understand -- would you repeat  
 18 it? I'm sorry.  
 19 Q. Sure. You and your colleagues at NTP  
 20 have also suggested that in order to determine the  
 21 truth of whether a substance under test is  
 22 carcinogenic from an experimental animal that the same  
 23 test should show carcinogenicity in other strains of  
 24 the same animal species like a different strain of  
 25 mouse, for example?

Page 33

1 A. I'll agree to that.  
 2 Q. It's two different species of animals  
 3 and various strains of rats and mice involved?  
 4 A. I think it's two strains of rats and two  
 5 strains of mice --  
 6 Q. Right.  
 7 A. -- we have data for.  
 8 Q. Right. You and your colleagues at NTP  
 9 said that results in a carcinogen study in order to  
 10 determine the truth of the carcinogenicity of the test  
 11 compound should be replicated in different species  
 12 like in the mouse and in the rat, true?  
 13 MS. WAGSTAFF: Object to form of the  
 14 question.  
 15 A. To be honest with you, I'd prefer to  
 16 see -- see the publication and let me read through it  
 17 to see -- to refresh my memory. Like I said, this was  
 18 published some time ago. I don't recall the exact  
 19 wording.  
 20 Q. (BY MR. HOLLINGSWORTH) Well, doesn't it  
 21 seem reasonable to you that you and your colleagues  
 22 said in the same paper that the replication of a  
 23 result in a mouse study in a different study in the  
 24 rat would be powerful evidence of whether or not the  
 25 carcinogen -- the substance is truly a carcinogen in

1 truth, isn't that what you said in the paper?

2 MS. WAGSTAFF: Objection, you're asking  
3 him about a publication that you clearly have a copy  
4 of and you're refusing to give it to him. I've asked  
5 you to give it to him now and he requested it. If  
6 you're going to keep asking him about it, I would ask  
7 that you give him a copy of the publication.

8 MR. HOLLINGSWORTH: I'm just here to  
9 test his expertise and his opinion.

10 MS. WAGSTAFF: You're testing his memory  
11 on something he wrote probably decades ago.

12 MR. HOLLINGSWORTH: My question went to  
13 whether or not it was reasonable to say among  
14 scientists that are your peers to determine the truth  
15 if a compound was a carcinogen, it would be very  
16 valuable to have results that are replicated in  
17 different species both in the mouse and the rat?

18 MS. WAGSTAFF: Hang on. I repeat my  
19 request to give him a copy of the publication that  
20 you're apparently trying to trip him up on.

21 A. It -- if you could get results in two  
22 species of animals, that strengthens the observation  
23 that the chemical causes cancer in experimental  
24 animals, but under the current criteria that people  
25 use for hazard identification, be it the IARC or the

1 whether in truth a substance was carcinogenic if the  
2 results of a finding of cancer in a laboratory animal  
3 were repeated in a different or in the opposite sex as  
4 well in the same study or in different studies, isn't  
5 that what you -- isn't that what you guys thought?

6 MS. WAGSTAFF: Objection, once again.

7 A. I'd have to read the paper to see if  
8 that's what was actually said.

9 Q. (BY MR. HOLLINGSWORTH) You don't  
10 remember stating that?

11 A. Like I said, this was 1988. I don't  
12 remember what we said in the publication. I'd really  
13 like to see it so I could refresh my memory.

14 Q. You said previously that whether animal  
15 study results with the same chemical are repeated in  
16 animals of a different sex should be considered in an  
17 attempt to assess the truth of whether or not the  
18 substance is carcinogenic, haven't you?

19 A. Again, without looking at the paper, I  
20 can't recall exactly what the wording that was said in  
21 the paper -- what we said. Sorry.

22 Q. Does that sound wrong to you, what I  
23 just said, is that something you wouldn't subscribe to  
24 you?

25 A. Like I said, I really would like to see

1 NTP for the reported carcinogens, it's not necessary  
2 to have a positive response in two species.

3 Q. (BY MR. HOLLINGSWORTH) So the paper I  
4 was referring to was published in 1988, you and Huff  
5 and Joe Haseman.

6 A. Haseman and about 10 other people.

7 Q. Are you saying that the criteria at NTP  
8 has changed since 1988?

9 MS. WAGSTAFF: Object to form.

10 A. You're referring to a publication,  
11 you're not referring to criteria that was used at the  
12 time for -- for either IARC or the report on  
13 carcinogens, so I mean, it's apples and oranges.

14 Q. (BY MR. HOLLINGSWORTH) Would your  
15 opinion today be different than it was in 1988?

16 MS. WAGSTAFF: Objection, please let him  
17 see the publication if you're asking if his opinion is  
18 the same so he can read the publication. That's 19  
19 (sic) years ago.

20 A. I'd have to read everything that was  
21 said in the publication to really give you a good  
22 answer to that.

23 Q. (BY MR. HOLLINGSWORTH) You and your  
24 colleagues at NTP also wrote that it would -- it  
25 would -- it would strengthen the opinion to determine

1 the paper, please.

2 Q. Okay.

3 A. So I can refresh my memory.

4 Q. Now, you claim in your report that there  
5 is evidence of lymphoma in three studies in mice that  
6 is sufficient to support your opinion, right?

7 A. I believe that's what I said.

8 Q. Yep.

9 MS. WAGSTAFF: Is there a question on  
10 the table?

11 MR. HOLLINGSWORTH: Yes. Yeah, that is.

12 Q. (BY MR. HOLLINGSWORTH) I said you state  
13 in your report that there is evidence of lymphoma in  
14 three studies in mice that supports your opinion;  
15 isn't that right?

16 A. This is in -- what's the tumor site,  
17 please?

18 Q. Lymphoma --

19 A. Lymphoma.

20 Q. -- in mice.

21 A. I say that glyphosate caused a --

22 THE REPORTER: I'm sorry.

23 A. I'm sorry. Glyphosate caused a  
24 significant increase in the incidence of malignant  
25 lymphoma in male CD-1 mice in two studies and I give

1 references to the two studies. And in male and female  
2 Swiss albino mice in another study.

3 Q. (BY MR. HOLLINGSWORTH) What page is  
4 that, sir?

5 A. 28.

6 Q. You cite to no evidence anywhere in your  
7 report that glyphosate causes lymphoma in rats, do  
8 you?

9 MS. WAGSTAFF: Object to form.

10 A. No, I don't believe I did, but if I may,  
11 it caused lymphoma in two different studies in CD-1  
12 mice and it also caused lymphoma in male and female  
13 Swiss mice, so that's very strong evidence that it  
14 caused lymphoma in mice, so --

15 Q. (BY MR. HOLLINGSWORTH) I'm going to talk  
16 to you in detail about the Swiss albino mice study and  
17 the other two studies, but my question is whether that  
18 evidence of lymphoma that you cite in your case in  
19 mice involving mice was replicated in rats -- in the  
20 rat studies that you cite involving seven different  
21 rat studies?

22 A. I don't believe -- I'd have to go back  
23 and read in more detail. There may have been  
24 lymphomas caused, but it may not have been significant  
25 increase in lymphomas in the rats, so I have to -- I'd

1 have to go back and look to say specifically that no  
2 lymphomas were caused in the rats.

3 Q. You don't cite to findings of lymphoma  
4 in any of the rat studies that you reviewed, do you?

5 A. I did not mention it. If I did not  
6 mention it, it doesn't mean that they weren't formed.  
7 It just means that they weren't significantly  
8 increased in that -- in the rats.

9 Q. So you don't recall finding any  
10 significant increases of lymphoma in rats?

11 A. I -- based on what the -- my summary  
12 here, I do not, but I need to go back and look at the  
13 studies in a little more detail to say absolutely that  
14 no lymphomas were caused. They may -- again, like I  
15 said, there may have been some, but it may not have  
16 reached the level of significance for me to include it  
17 in my writeup.

18 Q. Well, you agree with me that you don't  
19 say anything about lymphomas being found anywhere in  
20 any of the 11 rat studies that you reviewed, true?

21 A. I don't say anything in the summary that  
22 I look at right now, no.

23 Q. Okay. So your report does not say that  
24 the findings of malignant lymphoma in mice have been  
25 replicated across species that is to include rats?

1 MS. WAGSTAFF: Object to form.

2 A. No, I did not say that it -- that --  
3 that lymphomas were found -- were a significant  
4 increase in lymphomas were found in rats. I did not  
5 state that. That's correct.

6 Q. You also claim in your report that there  
7 is evidence of kidney tumors in male mice in three  
8 different studies, right? I believe you already  
9 testified to that this morning, sir.

10 A. To the same three studies?

11 Q. The same three studies. I'm referring  
12 to the same three studies now that you've already  
13 talked about. So my question is, whether you claim in  
14 your report that there is evidence of kidney tumors in  
15 males in three studies, three mouse studies and your  
16 answer is yes, right?

17 MS. WAGSTAFF: You can read your report  
18 if you need to.

19 A. Repeat the question, please.

20 Q. (BY MR. HOLLINGSWORTH) Sure. You claim  
21 in your report that there is evidence of malignant  
22 lymphoma in three different studies involving the  
23 mouse?

24 A. Three different studies in mice. Okay.  
25 Yes. I thought you were talking about kidney tumors.

1 I'm sorry.

2 Q. Yeah.

3 MS. WAGSTAFF: I think you originally  
4 said kidney tumors.

5 Q. (BY MR. HOLLINGSWORTH) Sorry. I said  
6 the wrong thing. My apologies.

7 A. So we were talking about the lymphomas?

8 Q. No, I've changed to kidney tumors.

9 MS. WAGSTAFF: Start the question over.

10 MR. HOLLINGSWORTH: My apologies.

11 A. Okay. Repeat the question just so we're  
12 clear.

13 Q. (BY MR. HOLLINGSWORTH) You claim in  
14 your report that there is evidence of kidney tumors in  
15 three different mouse studies?

16 A. I don't believe so, no. Oh, I  
17 apologize. I apologize.

18 Q. Yeah.

19 A. It is three. I apologize.

20 Q. Yeah. You've got renal tubule lesions  
21 that you say were caused by glyphosate in the Monsanto  
22 1983 study and you have renal cell adenomas in males  
23 in the Feinchemie Swiss albino mouse study?

24 A. Right.

25 Q. And then you have said you have claimed

Page 42

1 that there are malignant renal or -- I'm sorry, not  
 2 malignant, but renal adenomas in the Arysta, that's  
 3 A-r-y-s-t-a, true?  
 4 A. Okay. Yes, I'm sorry.  
 5 Q. Okay. You cite to no evidence anywhere  
 6 in your report involving renal tumors in rats, do you?  
 7 MS. WAGSTAFF: Object to form.  
 8 A. I know there was one study in rats where  
 9 they did see some renal tumors. I'd have to go back  
 10 and find that. I don't know -- again, I don't know if  
 11 there were -- if it reached the level of statistical  
 12 significance, but I know there was one study in rats  
 13 where there was an increase in renal tumors observed,  
 14 which is a pretty rare finding in rats.  
 15 Q. (BY MR. HOLLINGSWORTH) Sir, that's not  
 16 my question. My question is whether your report cites  
 17 to a finding anywhere in your report of renal tumors  
 18 in rats and it doesn't, does it?  
 19 A. I need to look through the report in a  
 20 little more detail to see that because I remember  
 21 seeing renal tumors in rats -- in one rat study at  
 22 least.  
 23 Q. Well, your -- your report does not  
 24 indicate that there are renal tumors in rats and that  
 25 you found and that you rely on as a basis of a

Page 44

1 and in skimming through this, I don't see where I  
 2 refer to that, so in my report, I don't know that I  
 3 referred to it.  
 4 Q. (BY MR. HOLLINGSWORTH) Okay. Thank  
 5 you. My question was whether you cited to that in  
 6 your report, and your answer is no, right?  
 7 MS. WAGSTAFF: Objection, misstates his  
 8 testimony.  
 9 A. After -- with just a quick skimming  
 10 through it, I can't -- I don't see it right now.  
 11 Q. (BY MR. HOLLINGSWORTH) Okay. Based on  
 12 that review of your report, in which we found no  
 13 mention of a kidney tumor in rats --  
 14 MS. WAGSTAFF: Objection, you have not  
 15 given him the opportunity to look through his report  
 16 in detail. He says that he remembers citing to it. I  
 17 asked if you want him to look through and you said no  
 18 and now you've making a record that we scoured the  
 19 report to look for it. If you want him to look for  
 20 it, you can.  
 21 Q. (BY MR. HOLLINGSWORTH) Can you find any  
 22 reference in your report, sir, to the existence of  
 23 renal tumors in the rat that you've relied on in your  
 24 report?  
 25 A. Okay. Give me a minute to read through

Page 43

1 conclusion in your report?  
 2 MS. WAGSTAFF: Do you want him to take  
 3 the time to look through it?  
 4 MR. HOLLINGSWORTH: I thought he would  
 5 know his report better than this.  
 6 MS. WAGSTAFF: He knows his report fine,  
 7 but you're asking him minutia and you guys disagree  
 8 and he said let me look at something.  
 9 MR. HOLLINGSWORTH: Well, it's not  
 10 minutia, it's serious evidence.  
 11 MS. WAGSTAFF: It's very serious  
 12 evidence, I agree with that, and he disagreed with  
 13 something you said and he said, if I can look through  
 14 my report and I can tell you better, and if you want  
 15 him to take the time to do that, he will. Do you want  
 16 him to take the time to do that?  
 17 Q. (BY MR. HOLLINGSWORTH) Sir, as you sit  
 18 here today, you don't recall citing any evidence of  
 19 renal tumors in the rat out of the seven studies that  
 20 you looked at, do you?  
 21 MS. WAGSTAFF: Object to form. He just  
 22 said he recalled that there was one.  
 23 A. I -- I recall that in one study there  
 24 were renal tumors seen in rats. Again, I don't recall  
 25 if it reached the level of statistical significance,

Page 45

1 this and I'll let you know. Okay. I don't see any  
 2 reference to a kidney tumor in the rats in my report.  
 3 I do remember in reading -- in looking -- in reading  
 4 the study, the actual studies that I did see an IARC  
 5 study that reported increases in kidney tumors, but it  
 6 wasn't statistically significant, so that's probably  
 7 why I didn't include it in the report. But that's --  
 8 also I would state that it is not that unusual when  
 9 you do a study in mice and rats that you see a tumor  
 10 at one site in one species and you don't see the  
 11 corresponding tumor site in the other species.  
 12 I think if you go through and look at  
 13 the incidences of tumors in, take for example, the NCP  
 14 bioassay program and the technical report series, I  
 15 think it's usually the case. I won't say that it's --  
 16 that it's always the case, but I think it's usually  
 17 the case that if you see a tumor in one species, you  
 18 don't see the same tumor in the same corresponding  
 19 tumors in the other species all the time, so the fact  
 20 that you see kidney tumors in mice and you didn't see  
 21 it in rats is -- is not all that surprising.  
 22 Q. Sir, you didn't -- your answer is that  
 23 you didn't cite to any evidence of kidney tumors in  
 24 rats in your report?  
 25 MS. WAGSTAFF: Object to form.

Page 46

1 A. In my report, I did not.  
 2 Q. (BY MR. HOLLINGSWORTH) So you haven't  
 3 cited to any evidence that the findings of kidney  
 4 tumors in three -- three mouse studies that you  
 5 referred to were replicated in the rat?  
 6 MS. WAGSTAFF: Object to form.  
 7 Q. (BY MR. HOLLINGSWORTH) Did you?  
 8 A. Again, I will state that that is not  
 9 that unusual that you see corresponding tumor sites in  
 10 two different species when you do a study. A lot of  
 11 times you get certain types of tumors in the mouse and  
 12 you'll get a completely different set of tumors in the  
 13 rats in the study conducted at the same laboratory at  
 14 the same time with the same chemical, so that's not a  
 15 surprising finding to me, but that's correct.  
 16 Q. (BY MR. HOLLINGSWORTH) So the answer is  
 17 that there's no evidence in your report that the  
 18 findings that you refer to involving kidney tumors in  
 19 male mice were replicated in the rat species, true?  
 20 MS. WAGSTAFF: Objection, asked and  
 21 answered.  
 22 A. That is correct.  
 23 Q. (BY MR. HOLLINGSWORTH) Thank you.  
 24 A. But the incidence of kidney tumors was  
 25 replicated in two different strains of mice.

Page 48

1 lymphomas. I'm sorry.  
 2 Q. (BY MR. HOLLINGSWORTH) My question is  
 3 whether this summary at 28 and 29 is an accurate  
 4 summary?  
 5 A. Is an accurate summary?  
 6 Q. Of your opinion.  
 7 A. To the best of my knowledge, it is.  
 8 Q. Did you write this?  
 9 A. Yes.  
 10 Q. Okay. Now, you say that there is  
 11 evidence of kidney tumors in female mice and that's  
 12 where from the Swiss albino mouse study, because I  
 13 don't find anything in your study that says that -- I  
 14 mean in your report that says that.  
 15 A. Like I said, I was mistaking -- I was  
 16 confusing that with the lymphomas.  
 17 Q. That's understandable. But there -- you  
 18 cite to no evidence in your study, sir, that says that  
 19 there are kidney tumors in the female mice studies  
 20 that you reviewed, true?  
 21 A. I don't think we found any, no.  
 22 Q. So, therefore, the evidence that you  
 23 rely on involving kidney tumors in male mice was not  
 24 replicated across sexes, was it?  
 25 MS. WAGSTAFF: Object to form.

Page 47

1 Q. I understand that.  
 2 A. CD-1 mice and the Swiss mouse.  
 3 Q. But that wasn't my question. My  
 4 question went to whether or not it was replicated in  
 5 the rat, do you understand that?  
 6 A. Right. But that's not a surprising  
 7 finding.  
 8 Q. Okay. You cite no evidence in your  
 9 report that the kidney tumors that you refer to in  
 10 male mice were replicated in female mice, do you?  
 11 A. I say that there were kidney tumors  
 12 observed in the female Swiss mice, I believe.  
 13 Q. Sir, would you look at page 28 of your  
 14 report which says "Summary for Experimental Animal  
 15 Data."  
 16 A. Okay.  
 17 Q. Now, this is an accurate summary of your  
 18 report, right, on experimental animals?  
 19 MS. WAGSTAFF: You can read it if you  
 20 need to. Are you talking about all of page 29 as  
 21 well?  
 22 MR. HOLLINGSWORTH: Yes.  
 23 MS. WAGSTAFF: Okay.  
 24 A. I'm sorry. I misspoke again. I was  
 25 thinking of the lymphomas. It's the -- yeah, it's the

Page 49

1 Q. (BY MR. HOLLINGSWORTH) You were wrong  
 2 when you indicated that earlier in your testimony?  
 3 A. When I stated --  
 4 MS. WAGSTAFF: He wasn't wrong. He  
 5 already admitted that he was confusing it with  
 6 lymphomas.  
 7 A. I was confusing it with the lymphoma  
 8 data. Again, it's a situation where there -- I  
 9 believe, there were kidney tumors observed in females,  
 10 but it didn't reach a significant level, so,  
 11 therefore, I didn't include it in the report.  
 12 Q. (BY MR. HOLLINGSWORTH) Okay. So you  
 13 didn't state in your report that the evidence of  
 14 kidney tumors in mice had been replicated in the  
 15 female mice specifically, true?  
 16 A. I did not say that, that's correct.  
 17 Q. Now, you claim that there is evidence of  
 18 hemangiosarcoma in males in two studies in mice,  
 19 correct?  
 20 A. I believe that's right.  
 21 Q. And you cite to no evidence in your  
 22 report of any hemangiosarcoma in rats, do you?  
 23 A. Correct.  
 24 Q. And, therefore, you cite no evidence  
 25 that hemangiosarcomas have been replicated across

1 species, do you?

2 MS. WAGSTAFF: Object to form.

3 A. Again, that's what I said, but as I  
4 stated before, I wouldn't consider that all that  
5 unusual. You don't always see the same tumor in one  
6 animal species that you observe in a different animal  
7 species, even in studies conducted under -- at the  
8 same time with the same chemical.

9 Q. (BY MR. HOLLINGSWORTH) I understand  
10 that, but in this specific report, you don't refer  
11 to -- you didn't refer the Court to any evidence that  
12 the hemangiosarcomas that you claim existed in two  
13 male mouse studies have been replicated in rats, true?

14 MS. WAGSTAFF: Object to form. Asked  
15 and answered.

16 A. Like I said, I -- I don't -- I did not  
17 report any hemangiosarcomas in rats in my report.

18 Q. (BY MR. HOLLINGSWORTH) Okay. You cite  
19 no evidence of hemangiosarcomas in female mice either,  
20 do you?

21 A. That's correct, I corrected my report to  
22 say -- initially the report submitted said  
23 hemangiosarcomas, but I corrected that. It was  
24 hemangiomas.

25 Q. So you haven't cited the Court to any

1 evidence that hemangiosarcomas in male mice have been  
2 replicated across sexes in the same species, true?

3 A. That is correct.

4 Q. You claim that there is evidence of  
5 pancreatic cell tumors in males in two different rat  
6 studies, true?

7 A. Pancreatic?

8 Q. The Monsanto 1990 rat, do you see that?

9 MS. WAGSTAFF: What page are you looking  
10 at?

11 MR. HOLLINGSWORTH: I've memorized it.

12 MS. WAGSTAFF: I wouldn't be surprised.

13 A. Are we talking about pancreatic tumors?

14 Q. (BY MR. HOLLINGSWORTH) I'm talking  
15 about pancreatic cell tumors. They're referred to in  
16 your report sometimes as pancreatic islet cell  
17 adenomas.

18 A. Okay.

19 Q. And you referred to two studies. The  
20 1990 Sprague-Dawley study and the 1981 Sprague-Dawley  
21 study, correct?

22 A. To be honest, I thought I only referred  
23 to one study where there were pancreatic islet tumors.

24 MS. WAGSTAFF: If you have a specific  
25 page or a reference for him, that may speed it up.

1 Q. (BY MR. HOLLINGSWORTH) Sir, are you  
2 looking at your report regarding the Monsanto 1990  
3 Sprague-Dawley rat study? You refer to pancreatic  
4 islet cell adenomas in there.

5 A. For one study?

6 Q. The 1990 study and then there's the 1981  
7 study. Also in Sprague-Dawley rats. That's one of  
8 the seven rat studies you referred to also and you  
9 mentioned pancreatic islet cell evidence in that study  
10 as well, true?

11 A. Which page is that on? Oh, you don't  
12 have that?

13 Q. I don't have a page.

14 A. I didn't refer to the studies by their  
15 date. I referred to them basically by their Greim  
16 study number.

17 Q. Okay. The 1981 rat study is referred to  
18 by you at page 24, I think.

19 A. Okay.

20 Q. Isn't that the 1981 study?

21 MS. WAGSTAFF: Are you talking about  
22 this last paragraph on page 24?

23 MR. HOLLINGSWORTH: Yeah, and it  
24 proceeds over to page 25 and it mentions that he  
25 believed there was a -- the author of the report

1 Dr. Jameson believes there was a significant increase  
2 in the incidence of pancreatic islet cell adenoma from  
3 this study.

4 A. Okay.

5 Q. (BY MR. HOLLINGSWORTH) Okay. And then  
6 if you look at the study involving the 1990  
7 Sprague-Dawley rat study, which --

8 A. Okay.

9 Q. -- that's the study you report as by the  
10 author called Dr. Stout?

11 A. Stout, uh-huh.

12 Q. And you refer to pancreatic islet cell  
13 adenomas there as well, right?

14 A. Correct.

15 Q. Okay. So there's two --

16 A. Two studies.

17 Q. -- two studies involving what you claim  
18 are pancreatic cell tumors in rats?

19 A. Uh-huh.

20 Q. Right?

21 A. Correct.

22 Q. Those two studies, one in 1981 and one  
23 in 1990, both in the Sprague-Dawley rat, true?

24 A. True.

25 Q. Those pancreatic cell tumors weren't

1 replicated in any other rat studies, were they?  
 2 A. I don't believe so, no.  
 3 Q. And they weren't replicated in any mouse  
 4 studies?  
 5 A. I believe that's correct.  
 6 Q. So there's no evidence of pancreatic  
 7 cell tumors in mice that you have reported in your  
 8 report, true?  
 9 A. There -- there were no statistically  
 10 significant increases in pancreatic islet cell tumors  
 11 in mice, so, therefore, I didn't include it in my  
 12 report.  
 13 Q. And, therefore, have you -- you haven't  
 14 cited in your report any evidence that these  
 15 pancreatic cell tumors were replicated across species,  
 16 true?  
 17 MS. WAGSTAFF: Object to form.  
 18 A. That's correct, but, again, I'll say as  
 19 I said before, that's not a surprising finding because  
 20 you don't always see the same tumor sites in animals  
 21 tested at the same time by the same -- in the same  
 22 laboratory under the same conditions.  
 23 Q. (BY MR. HOLLINGSWORTH) There's --  
 24 there's no evidence anywhere in your report that  
 25 you've cited that the pancreatic tumors that were seen

1 in the male rat studies were replicated across sexes  
 2 into female rats or female mice, are there?  
 3 A. I did not report any -- I'm sorry.  
 4 There were probably no -- there were no statistically  
 5 significant increased incidences in those tumors in  
 6 the female rats or mice reported, so I did not include  
 7 that in my report.  
 8 Q. Sir, you claim that there is evidence of  
 9 hepatocellular adenomas and you claim that those  
 10 occurred in statistically significant numbers in male  
 11 rats, two different studies, true?  
 12 A. Yes, in two studies. Male rats.  
 13 Q. Did you cite us to any published  
 14 literature that says hepatocellular carcinomas in male  
 15 rats are predictive of non-Hodgkin's lymphoma in  
 16 humans?  
 17 A. Again, the studies were conducted to see  
 18 if glyphosate caused cancer in experimental animals.  
 19 Q. Okay.  
 20 A. The studies showed that there were  
 21 hepatocellular carcinomas formed in the studies, in  
 22 this case, in the rats, and significantly increased  
 23 and so, therefore, it was positive in the male rats as  
 24 an animal carcinogen. Being an animal carcinogen  
 25 is -- is -- indicates that it is -- could be -- it

1 could be a human carcinogen.  
 2 I'm not aware of any studies that have  
 3 been conducted that were investigating any association  
 4 between the formation of hepatocellular adenomas in  
 5 rats -- in male rats and non-Hodgkin's lymphoma. I  
 6 don't know if anybody has done any research in that  
 7 area or published in that particular.  
 8 Q. All right. Thank you.  
 9 MS. WAGSTAFF: We've been going a little  
 10 over an hour. Whenever you find a good stopping  
 11 point, if we can take a break.  
 12 MR. HOLLINGSWORTH: Any time is fine  
 13 with me.  
 14 MS. WAGSTAFF: It's your depo.  
 15 MR. HOLLINGSWORTH: All right. Let me  
 16 ask a couple more questions about these hepatocellular  
 17 adenomas in rats. I won't be long.  
 18 Q. (BY MR. HOLLINGSWORTH) There's no  
 19 evidence of hepatocellular carcinoma in mice that you  
 20 have reported in your report to the -- to the Court in  
 21 this case, is there, Dr. Jameson?  
 22 A. No. I didn't report any, which would  
 23 indicate to me that there were no statistically  
 24 significant increases in those tumors reported in the  
 25 studies, so I did not include it in my report. It's

1 not to say there weren't some I've seen, but they were  
 2 probably not statistically significant.  
 3 Q. So there's no evidence in your report  
 4 that these results you have cited to involving male  
 5 rats have been replicated across species?  
 6 MS. WAGSTAFF: Object to form.  
 7 A. That -- that is correct. But, again, I  
 8 would state that's not unusual to see a tumor in one  
 9 species and not in another -- the same tumor in  
 10 another species in the studies done with the same  
 11 chemical at the same laboratory at the same time.  
 12 Q. (BY MR. HOLLINGSWORTH) You don't cite to  
 13 any study or evidence in your report that states that  
 14 the hepatocellular adenomosis effect that you say  
 15 exists in male rats has been replicated across sexes  
 16 in any study anywhere, do you?  
 17 A. None of the data that I reviewed  
 18 indicated that, no.  
 19 MR. HOLLINGSWORTH: All right. We can  
 20 stop now. Thank you, sir.  
 21 THE VIDEOGRAPHER: Going off the record.  
 22 The time is 10:17 a.m.  
 23 (Recess taken, 10:17 a.m. to 10:34 a.m.)  
 24 THE VIDEOGRAPHER: We are back on the  
 25 record. The time is 10:34 a.m.

Page 58

1 Q. (BY MR. HOLLINGSWORTH) Sir, you claim in  
 2 your report that there is evidence of lung  
 3 adenocarcinoma in male mice in one study, true?  
 4 A. Yes.  
 5 Q. And you rely on that in support of  
 6 your -- your opinion that glyphosate can cause  
 7 non-Hodgkin's lymphoma, right?  
 8 A. I use that to -- in my opinion that  
 9 glyphosate causes cancer in laboratory animals because  
 10 it causes significant increase in that particular  
 11 tumor there.  
 12 Q. You -- in the last sentence of your  
 13 report, you state that it's your opinion to a  
 14 reasonable degree of scientific certainty that  
 15 glyphosate can cause non-Hodgkin's lymphoma in humans,  
 16 right?  
 17 A. That's what I state, yes.  
 18 Q. And does this study -- this single mouse  
 19 study finding adenocarcinoma or adenomas in male mice  
 20 is supportive of that opinion that last sentence in  
 21 your report?  
 22 A. That particular opinion that I made in  
 23 my report is based on an evaluation of all the  
 24 available data on glyphosate and glyphosate  
 25 formulations that -- that the data -- all the data

Page 60

1 the association of lung adenocarcinoma with  
 2 non-Hodgkin's lymphoma or published any -- any papers  
 3 on that.  
 4 Q. Sir, thank you. You cite to no evidence  
 5 in your report of lung adenocarcinoma in any other rat  
 6 or mouse study in your report and there are 11 other  
 7 rodent studies that you rely on in your report.  
 8 A. I don't cite to any significant  
 9 increases in lung adenocarcinomas in any of the  
 10 studies. If I think -- in reviewing all the data,  
 11 there were several studies where lung tumors were  
 12 observed, but they weren't significant enough to  
 13 include in my particular report.  
 14 Q. In your report, you only included  
 15 findings that were statistically significant in the 12  
 16 rodent studies that you looked at, true?  
 17 A. The -- the only ones that I included in  
 18 my report were the -- were the -- were the tumor sites  
 19 where there was an increase in the incidence over  
 20 the -- over the controls, so, yes, it was -- it was  
 21 those where you saw a significant increase over the  
 22 controls.  
 23 Q. You claim that there is evidence of  
 24 testicular interstitial cell tumor in -- of course,  
 25 that's in male rats in one study, right?

Page 59

1 taken together state in -- it's my opinion that all  
 2 the data indicates that glyphosate and glyphosate  
 3 formulations cause non-Hodgkin's lymphoma.  
 4 Q. Okay. But you understand my question  
 5 here is -- my question here goes to the evidence that  
 6 you cite in your report of adenocarcinoma in male mice  
 7 in a single study?  
 8 A. That's one piece of the data. One piece  
 9 of the information that I used in my overall  
 10 evaluation.  
 11 Q. Did you cite to any evidence or  
 12 investigation that's been published anywhere on the  
 13 planet that discusses whether lung adenocarcinoma in  
 14 male mice is predictive of human cancer involving  
 15 non-Hodgkin's lymphoma?  
 16 A. Well, the study that I evaluated was  
 17 conducted to see if glyphosate would cause cancer in  
 18 experimental animals, and in this particular study, it  
 19 caused lung adenocarcinomas, and so, therefore, since  
 20 it caused a significant increase of lung  
 21 adenocarcinomas, in this particular study, it's an  
 22 animal carcinogen, and being an animal carcinogen, it  
 23 could -- it indicates that it potentially could be a  
 24 human carcinogen, so -- but I am not aware of anybody  
 25 that has designed or conducted a study to investigate

Page 61

1 A. Correct.  
 2 Q. And did you consider whether the  
 3 existence of interstitial cell tumors in the testes of  
 4 rats has ever been studied to determine whether it is  
 5 predictive of non-Hodgkin's lymphoma in humans?  
 6 A. Well, the -- the -- for this particular  
 7 study, glyphosate was tested to see if it caused  
 8 cancer in the male rats. It caused these interstitial  
 9 testicular cell tumors in the male rats. It was  
 10 increased significantly increased and therefore,  
 11 glyphosate caused cancer in laboratory -- in -- in  
 12 these male rats, so, therefore, it's an animal  
 13 carcinogen. Being an animal carcinogen is -- it's a  
 14 potential human carcinogen.  
 15 I'm not aware that anybody has designed  
 16 or conducted a study to investigate any association  
 17 between male testicular tumors in rats and  
 18 non-Hodgkin's lymphoma in humans or published  
 19 any -- any papers on that.  
 20 Q. You cite to no evidence that the  
 21 testicular interstitial cell tumors that you refer to  
 22 in the single rat study was replicated in any of the  
 23 five mice studies, do you?  
 24 MS. WAGSTAFF: Object to form.  
 25 A. That's correct. There -- there were not

Page 62

1 testicular tumors reported in any of the mice studies,  
 2 but, again, I'll point out that that's not an unusual  
 3 finding to find one tumor site in one strain of  
 4 animals or one species and not find the same tumor  
 5 site in another species, studies conducted with the  
 6 same chemical at the same laboratory at the same time.  
 7 Q. (BY MR. HOLLINGSWORTH) But you cite to  
 8 no evidence that that interstitial testicular cell  
 9 tumor in single rat study was replicated in any of the  
 10 other four rat studies, do you?  
 11 A. No. It wasn't observed in any of the  
 12 other rat studies.  
 13 Q. And it wasn't replicated in any of the  
 14 five mouse studies in male mice?  
 15 MS. WAGSTAFF: Object, asked and  
 16 answered.  
 17 Q. (BY MR. HOLLINGSWORTH) True?  
 18 A. It wasn't seen in mice, no.  
 19 Q. (BY MR. HOLLINGSWORTH) You claim that  
 20 there's evidence of thyroid follicular cell tumors in  
 21 female rats, true?  
 22 A. True.  
 23 Q. And that was in one study. Do you cite  
 24 any evidence that the finding of follicular cell  
 25 tumors in female rats is predictive of non-Hodgkin's

Page 64

1 A. -- so I didn't include it in my report.  
 2 Q. So there's no replication across species  
 3 that you've cited in your report?  
 4 MS. WAGSTAFF: Object to form. He's  
 5 already indicated that a tumor site does not have to  
 6 be the same to equal replication.  
 7 A. True. And just -- just to point out, I  
 8 mean, when you're talking about replication, you don't  
 9 necessarily have to have replication between sexes or  
 10 between species. If you have replication in a number  
 11 of the tumor sites that we've discussed earlier,  
 12 the -- the tumor was -- the tumor was replicated in  
 13 different studies. It may have been in the same  
 14 species, but they were in different studies conducted  
 15 at different times, at different laboratories, so that  
 16 is a replication of an experiment and gives extremely  
 17 strong evidence that this particular compound causes  
 18 that tumor in that -- in experimental animals, and  
 19 that's something we have done in my 30 plus years'  
 20 experience as a toxicologist has always been if you  
 21 can replicate the study in the same sex -- in the same  
 22 sex or same species, if you replicate it at a  
 23 different laboratory, it's very strong evidence that  
 24 it is an animal carcinogen at that tumor site in that  
 25 sex and species of animal.

Page 63

1 lymphoma in humans?  
 2 A. Well, in this particular study,  
 3 glyphosate was -- was exposed -- tested in the rats to  
 4 see if it would cause cancer. The glyphosate caused  
 5 these follicular cell tumors in the female rats to a  
 6 significant -- there was a significant effect,  
 7 therefore, glyphosate caused cancer, caused these  
 8 tumors in the female rats. It, therefore, is an  
 9 animal carcinogen and a potential -- therefore, and  
 10 also, therefore, a human -- potential human  
 11 carcinogen.  
 12 And I'm not aware of anybody who has  
 13 designed or conducted a study to investigate any  
 14 association between these follicular cell tumors in  
 15 female rats and non-Hodgkin's lymphoma or published  
 16 any studies for that or published any papers to that  
 17 effect.  
 18 Q. Sir, you haven't cited anything in your  
 19 report of the other 11 rodent studies that you refer  
 20 to in your report in which female follicular cell  
 21 tumors were replicated, true?  
 22 A. I did not see any -- in any of the other  
 23 studies that there was a significant increase in  
 24 follicular cell tumors in the female animals --  
 25 Q. So there's --

Page 65

1 Q. (BY MR. HOLLINGSWORTH) Sir, the  
 2 follicular cell tumors in female rats that you were  
 3 referring to weren't replicated in any study you've  
 4 reported anywhere in your report to this case, true?  
 5 MS. WAGSTAFF: Object to form.  
 6 A. I'm sorry, could you repeat that?  
 7 Q. (BY MR. HOLLINGSWORTH) I said the female  
 8 follicular cell tumors that you're referring to in  
 9 your report and in your prior recent answers involving  
 10 follicular cell tumors in female rats aren't reported  
 11 anywhere in your report to have been seen in any study  
 12 involving rats or mice of either sex anywhere else in  
 13 your report, true?  
 14 A. In any other study?  
 15 MS. WAGSTAFF: Object to form.  
 16 Q. (BY MR. HOLLINGSWORTH) Yes.  
 17 A. In the other studies I reviewed, that  
 18 particular tumor was not increased significantly over  
 19 controls and so while they may have been -- those  
 20 tumors may have been induced in those studies, if it  
 21 wasn't significantly increased over the control  
 22 incidence, I didn't include it in any report.  
 23 Q. You've previously said that historical  
 24 control data should be considered in an attempt to  
 25 assess the truth whether or not there is an actual

Page 66

1 carcinogenic effect in a mouse or a rat species, true?  
 2 A. Did I say that in my report? I don't  
 3 remember.  
 4 Q. No, I said that you have -- you have  
 5 published that, you've said that before that  
 6 historical control data should be considered in an  
 7 attempt to assess the truth whether or not an agent is  
 8 actually carcinogenic?  
 9 MS. WAGSTAFF: I would request that you  
 10 allow Dr. Jameson to review the publication in total  
 11 before asking him questions about piecemeal.  
 12 A. I was -- yeah, where -- I was going  
 13 to --  
 14 Q. (BY MR. HOLLINGSWORTH) Do you recall  
 15 stating that?  
 16 A. Do I recall stating that?  
 17 Q. Yes. That historical control data  
 18 should be considered in an attempt to assess the truth  
 19 about the frequency of a tumor type among control  
 20 animals in a particular strain of animal?  
 21 MS. WAGSTAFF: Same objection.  
 22 A. It may have been in a publication  
 23 sometime ago. I just don't remember.  
 24 Q. (BY MR. HOLLINGSWORTH) Do you disagree  
 25 with that proposition as you sit here today?

Page 68

1 publications. I don't remember how it -- how I worded  
 2 it or what I said, but. . .  
 3 Q. (BY MR. HOLLINGSWORTH) So do you  
 4 disagree today that the presence or absence of  
 5 preneoplastic lesions involving an agent under test is  
 6 a key factor in determining whether or not there's a  
 7 carcinogenic effect?  
 8 A. It's a factor. I mean, the fact that  
 9 you see preneoplastic lesions are, again, a helpful  
 10 indication that you're going to see a carcinogenic  
 11 effect, but it is not absolutely required that you see  
 12 preneoplastic lesions to say that something is or is  
 13 not a carcinogen.  
 14 There are instances in the literature  
 15 where tumors are seen in the absence of preneoplastic  
 16 lesions, so preneoplastic lesions are an important  
 17 part of any study if you see them, but if you don't  
 18 see them, you may say, wow, that's surprising, I  
 19 didn't see preneoplastic lesions, but that's no reason  
 20 to discount the finding of tumors being formed because  
 21 you didn't see any preneoplastic lesions.  
 22 Q. Let me ask you specifically about the  
 23 1983 mouse study that you refer to. Do you have that  
 24 in mind?  
 25 A. Okay.

Page 67

1 A. Historical control -- consideration of  
 2 historical controls is an important consideration in  
 3 any toxicology or bioassay study, but the most  
 4 appropriate controls to use in any study is the  
 5 concurrent controls that you have for that particular  
 6 study. Historical controls can help you evaluate the  
 7 data, but they are not as important as the concurrent  
 8 controls.  
 9 Q. You've referred to historical controls  
 10 in your report and you've relied on historical  
 11 controls in the report that you've given to the Court  
 12 in this case, haven't you?  
 13 A. That's correct. I'm not saying --  
 14 again, like I said, the historical controls are  
 15 important and they aid in the evaluation of the data.  
 16 Q. You've also said before, haven't you,  
 17 Dr. Jameson, that the presence or absence of  
 18 preneoplastic lesions is a key factor when determining  
 19 what conclusion can be drawn from a long-term animal  
 20 bioassay?  
 21 MS. WAGSTAFF: I would repeat my same  
 22 request, if you are quoting from a publication that  
 23 Dr. Jameson be afforded the opportunity to read the  
 24 entire publication.  
 25 A. I -- it may appear in some of my earlier

Page 69

1 Q. Did you read that study by Knezevich and  
 2 Hogan? Knezevich is K-n-e-z-e-v-i-c-h.  
 3 A. Did I read the study? I looked at the  
 4 data from that study, yes.  
 5 Q. But you didn't read the actual study?  
 6 A. The study report that was submitted by  
 7 the lab? For that particular one, I don't know if I  
 8 had access to the entire report or not, but I did have  
 9 access to a lot of it, a lot of the actual report from  
 10 the laboratory.  
 11 Q. But you don't think you read the actual  
 12 report?  
 13 MS. WAGSTAFF: Objection.  
 14 A. I saw excerpts of the actual report,  
 15 yes.  
 16 Q. (BY MR. HOLLINGSWORTH) Did plaintiffs'  
 17 counsel show you that report?  
 18 A. It was provided to me by plaintiffs'  
 19 counsel, yes.  
 20 Q. The entire report?  
 21 A. Again, I'd have to go back and look in  
 22 my files and see if I have the entire report, but I  
 23 had a very large portion of it.  
 24 Q. Did you read the author's statement  
 25 that, quote, there were no suspected test substance

Page 70

1 associated trends in the incidence of  
 2 bronchioalveolar, hepatocellular neoplasms and tumors  
 3 of the lymphoreticular symptoms or any of the other  
 4 spontaneous occurring neoplasms, unquote, did you read  
 5 that statement in their report?  
 6 A. I -- I think I remember that statement.  
 7 Yeah. This is the -- excuse me. This is the mouse  
 8 study, the CD-1 mouse study.  
 9 Q. Yes. 1983?  
 10 A. '83.  
 11 Q. Knezevich and Hogan were the  
 12 investigators --  
 13 A. Investigators.  
 14 Q. -- on that report, right?  
 15 A. Uh-huh.  
 16 Q. They're doctors of veterinary medicine,  
 17 aren't they?  
 18 A. I'm sorry, I don't know their  
 19 background.  
 20 Q. Okay.  
 21 MS. WAGSTAFF: I'd request that you  
 22 allow him to look at the report if you're questioning  
 23 if he saw the entire thing and you're quoting from it.  
 24 MR. HOLLINGSWORTH: Well, I'm just  
 25 asking if he recalls because I'm going to investigate

Page 72

1 Would it -- would it be fair in your report to this  
 2 Court, this MDL Court, for you to have included the  
 3 original reports of the original authors of that study  
 4 so that the judge could see them?  
 5 A. For me to include them in my report?  
 6 Q. Yeah. Wouldn't it have been fair for  
 7 you to include the conclusions of the original authors  
 8 of the study in the report that you made to the Court  
 9 in this case?  
 10 MS. WAGSTAFF: Objection, that calls for  
 11 a legal conclusion. How is he supposed to know what's  
 12 fair to the MDL judge?  
 13 A. Plus the -- well, you know, I don't  
 14 know. I don't know if -- I mean, I'm sure if the  
 15 judge would want to see that, we could make that  
 16 available to him. I would point out that this study  
 17 is included in the Greim publication, and all the  
 18 relevant data supposedly from this study is included  
 19 in the Greim paper and it -- the EPA refers to the  
 20 Greim paper when they made their recent evaluation,  
 21 so -- and I reference the Greim paper in this report.  
 22 Q. (BY MR. HOLLINGSWORTH) Sir, I'm not  
 23 asking about the Greim paper. I'll talk about Greim  
 24 later.  
 25 My question is whether it would be fair

Page 71

1 the extent of his knowledge about this report.  
 2 A. Okay.  
 3 Q. (BY MR. HOLLINGSWORTH) Do you recall  
 4 that the conclusion of the report was regarding the  
 5 renal tubule lesions that were observed in that  
 6 report, that, quote, the distribution of these benign  
 7 tumors was considered spurious and unrelated to  
 8 treatment, unquote?  
 9 MS. WAGSTAFF: And hang on a second.  
 10 This is not supposed to be a memory test. If you  
 11 would like to know his knowledge of it, why don't you  
 12 give him a copy of the report and let him follow along  
 13 with you as you read from it.  
 14 Q. (BY MR. HOLLINGSWORTH) I'd just like to  
 15 know, sir, whether you remember whether that was the  
 16 conclusion of the people who did the original report  
 17 and conducted the original study.  
 18 MS. WAGSTAFF: So why don't you let him  
 19 see the report.  
 20 MR. HOLLINGSWORTH: You've given him the  
 21 report, he says I'm asking for his knowledge about the  
 22 report and I'm entitled to do that.  
 23 A. I remember that was the bottom -- that  
 24 that was their conclusion, yes.  
 25 Q. (BY MR. HOLLINGSWORTH) Okay. Thank you.

Page 73

1 in your opinion, as a scientist, to have included the  
 2 conclusions of the original investigators of this 1983  
 3 study on CD-1 mice in your report to the judge of the  
 4 Court in this multidistrict litigation?  
 5 MS. WAGSTAFF: Objection, asked and  
 6 answered and this is becoming argumentative, and he  
 7 already has stated if the judge would like this  
 8 report, then he can give it to him and I'm sure your  
 9 experts have included it in their report.  
 10 Q. (BY MR. HOLLINGSWORTH) No, my question  
 11 is whether it would be fair as a scientist in your  
 12 opinion to have included the conclusions of the  
 13 original authors.  
 14 MS. WAGSTAFF: Objection, asked and  
 15 answered. That's a legal conclusion.  
 16 A. I was asked to provide my opinion of the  
 17 data as it relates to glyphosate and glyphosate  
 18 formulations and non-Hodgkin's lymphoma. And as part  
 19 of evaluate -- as a part of doing my evaluation  
 20 and -- and reviewing all the available information  
 21 pertaining to that, I looked at the study and I  
 22 summarize it in my report and I put the -- what I felt  
 23 were the appropriate references in my report for this  
 24 particular study, so --  
 25 Q. (BY MR. HOLLINGSWORTH) But you did not

Page 74

1 in your report include these two conclusions of the  
 2 original authors of the study that you were reporting  
 3 about, did you?  
 4 A. Again, I was asked to give my opinion,  
 5 not somebody else's opinion, so I looked at the data,  
 6 formulated my opinion and put it in my report.  
 7 Q. Well, your opinion is different than the  
 8 original investigators, isn't it?  
 9 MS. WAGSTAFF: Objection argumentative.  
 10 Q. (BY MR. HOLLINGSWORTH) Isn't it?  
 11 A. Yes.  
 12 Q. But you didn't tell the Court what the  
 13 original authors had concluded after reviewing the  
 14 data that they reviewed, did you?  
 15 A. I was not asked to put everybody's  
 16 opinion in my report. I was asked to review the data  
 17 and give my opinion and that's what I did.  
 18 Q. Did you review in connection with your  
 19 report any of the morphologic slides, any morphology  
 20 at all?  
 21 A. I -- first of all, I'm not a  
 22 pathologist. I don't read slides. So I -- I  
 23 couldn't. I would not be able to look at the slides  
 24 and evaluate them. That's not my background, so it  
 25 wouldn't -- it would not be appropriate for me to do

Page 76

1 of the slides or any single animal from the 1983 mouse  
 2 study?  
 3 A. Did I look at any of the slides?  
 4 Q. Did you look at any slides or reports on  
 5 the review of slides?  
 6 A. I looked at the tumor tables and the  
 7 tables in the report of individual animals evaluation.  
 8 I looked at all that data, yes.  
 9 Q. Where did you find the individual animal  
 10 evaluations?  
 11 A. They have tables -- in the report they  
 12 have tumor tables or individual animal tumor tables  
 13 where they list the animals by their animal number and  
 14 it has a -- in tabular form, it gives you the organ  
 15 site and what they found.  
 16 Q. In this case, did you do that from the  
 17 materials that plaintiffs' counsel gave you?  
 18 A. From the report of the -- of the -- of  
 19 the Knezevich report.  
 20 Q. Okay. You know that the 1983 report was  
 21 submitted to the EPA, right?  
 22 A. That's correct.  
 23 Q. And you talked in your report about some  
 24 of the regulatory history of that 1983 mouse study,  
 25 true?

Page 75

1 that.  
 2 Q. Dr. Knezevich and Hogan were veterinary  
 3 medical doctors who looked at the actual slides from  
 4 this study themselves, didn't they?  
 5 MS. WAGSTAFF: Objection, already  
 6 testified he didn't know their background.  
 7 A. I -- I assume that's what they did, but  
 8 I don't know.  
 9 Q. (BY MR. HOLLINGSWORTH) How long does it  
 10 take a veterinary pathologist to review slides from a  
 11 long-term bioassay?  
 12 MS. WAGSTAFF: Objection, speculation.  
 13 A. I can only -- I can only speak to my  
 14 past experience from the NTP bioassay where -- you  
 15 know, it would depend on the design of the study. It  
 16 depends on how many -- how many dose groups you have,  
 17 how many animals per dose group, how many interim  
 18 sacrifices you have, if it's in both rats and mice, I  
 19 mean, you could -- you could be looking at upwards of  
 20 10,000 or more slides. So in my past experience, it's  
 21 taken them six to nine months to evaluate a rodent  
 22 bioassay, so it's a very involved process.  
 23 Q. (BY MR. HOLLINGSWORTH) In the -- in  
 24 the -- with respect to the 1983 mouse study, did you  
 25 look at their individual animal reviews of any -- any

Page 77

1 A. True, where the EPA did their initial  
 2 evaluation and came up with a category C as a  
 3 carcinogen for glyphosate initially.  
 4 Q. Initially?  
 5 A. Yes.  
 6 Q. Did they change that -- that regulatory  
 7 finding later?  
 8 A. Over the years -- over the years, they  
 9 appeared to have changed it.  
 10 Q. "They" meaning EPA has changed it?  
 11 A. EPA. Sorry.  
 12 Q. This was a 24-month typical long-term  
 13 chronic bioassay of mice that we're referring to,  
 14 right?  
 15 A. Yes.  
 16 Q. And your report -- in your report, you  
 17 say that the renal tubule was found in among the four  
 18 treatment groups in the -- in the -- in the order as  
 19 follows zero, zero, zero, one, three, right?  
 20 A. Okay. That was -- that was the initial  
 21 evaluation --  
 22 Q. Yes.  
 23 A. -- from the lab, yes.  
 24 Q. Yes. And then -- and you said that the  
 25 finding of renal tubules adenomas or carcinomas is a

Page 78

1 rare event; is that right?

2 A. Yes, for the CD-1 mouse.

3 Q. And for the CD-1 mouse, you rely on the

4 publication Chandra and Firth for your conclusion that

5 it is a rare lesion?

6 MS. WAGSTAFF: Object to form.

7 A. That's a reference I used, yes.

8 Q. (BY MR. HOLLINGSWORTH) In your report?

9 A. In the report.

10 Q. That's the same reference that IARC used

11 in the monograph 112, true?

12 A. I believe it is.

13 Q. Did you read in the materials that you

14 reviewed that the Biodynamic's lab itself had three

15 incidents of renal tubule adenomas or adenocarcinomas

16 in control animals prior to this study?

17 A. I remember seeing that they did have a

18 historical incidence in their lab, but I don't

19 remember to be honest the specific numbers or, you

20 know, how many studies that included.

21 Q. Did you read also that the Hazleton

22 laboratory, which is a big laboratory in the United

23 States -- you're familiar with that, right?

24 A. Correct.

25 Q. They had an incidence of 7.1 percent in

Page 80

1 any of that data with any confidence. I'm sorry.

2 Q. (BY MR. HOLLINGSWORTH) Are you saying

3 that Biodynamics and Hazleton are not reliable?

4 MS. WAGSTAFF: Objection, misstates

5 testimony.

6 A. I don't have -- I don't have experience

7 with them. I do have some past experience with IRDC,

8 so that's where my opinion is going from.

9 Q. (BY MR. HOLLINGSWORTH) Do you have

10 experience with the data that Chandra and Firth relied

11 on, personal experience?

12 A. I don't have any personal experience but

13 that's in a peer-reviewed publication, so I -- I put a

14 lot of confidence in that since it's --

15 Q. Okay. There was no consistent finding

16 for renal tubule adenomas or carcinomas in the female

17 mice at all, was there?

18 MS. WAGSTAFF: Object to form.

19 A. I think there was -- I think they might

20 have found one tumor in the female mice, but I'd have

21 to go back and look at the report to confirm that.

22 Q. (BY MR. HOLLINGSWORTH) Well, you don't

23 have to do that. The incidence in female mice was

24 actually, zero, zero, zero, wasn't it?

25 A. Again, I'd have to go back and look at

Page 79

1 control animals involving renal tubule lesions at the

2 time, true?

3 MS. WAGSTAFF: Object to form,

4 foundation.

5 A. I think I remember seeing something to

6 that effect in the report, yes.

7 Q. (BY MR. HOLLINGSWORTH) And the -- you

8 also saw a reference to IRDC, which was also a big

9 contract laboratory in the 1970's and '80's and '90's,

10 I think that stands for International Research --

11 A. And Development --

12 Q. -- Development Corporation, you're

13 familiar with that group?

14 A. Yes.

15 Q. They also had a much higher incidence of

16 renal tubule adenomas or carcinomas in control animals

17 that Chandra and Firth reported; isn't that right?

18 MS. WAGSTAFF: Object to form of the

19 phraseology of "much higher."

20 A. Well, they did have a higher incidence,

21 but to be honest, I wouldn't put a whole lot of faith

22 in any of the data that came out of IRDC because of

23 their history and the litigations brought against them

24 and what have you. I -- in my experience with IRDC,

25 they're a very unreliable lab, so I just can't take

Page 81

1 the report. Like I said, I don't recall -- I don't

2 remember.

3 Q. Did you rely on what plaintiffs' counsel

4 had given you about this report or the Greim study and

5 the Greim tables about this 1983 mouse study?

6 A. I used both.

7 MS. WAGSTAFF: Object to form.

8 Q. (BY MR. HOLLINGSWORTH) Is Greim

9 reliable?

10 A. From the standpoint that it is -- comes

11 from a peer-reviewed source, I would say it is fairly

12 reliable. Although, in my review of the information

13 from the Greim report, I was able to find additional

14 tumor incidences that were not emphasized in his

15 report that I included in mine. But coming from a

16 peer-reviewed source, you have to accept that it is

17 fairly reliable.

18 Q. Sir, you've cited Greim in your report

19 over 10 times, haven't you?

20 A. Yeah, I use that as a method of

21 identifying the studies. I -- I use that as -- as a

22 manner of convenience more than anything else to keep

23 straight which studies I was looking at.

24 Q. So you cited Greim, but you don't think

25 it's -- you don't think it's necessarily reliable; is

1 that right?

2 A. I didn't say that. I said it comes from  
3 a peer-reviewed source, so it should be considered a  
4 reliable source. The data should be in there -- at  
5 least should be accurate.

6 Q. So you haven't knowingly cited an  
7 unreliable source in your report to the judge in this  
8 case, right?

9 MS. WAGSTAFF: Objection, argumentative.

10 A. I hope not. Not that I'm aware of.

11 Q. (BY MR. HOLLINGSWORTH) Well, I just  
12 understood you to say that you had reservations about  
13 Greim, but then I counted up about 11 references to  
14 Greim from your report just sitting here and I was  
15 wondering why you were citing --

16 A. I'm sorry.

17 MS. WAGSTAFF: Objection, misstates the  
18 testimony.

19 A. I don't remember saying that.

20 Q. (BY MR. HOLLINGSWORTH) Okay. Now, the  
21 renal tubule adenomas in this case were -- after this  
22 report was completed, were the subject of some  
23 controversy, weren't they?

24 A. Correct.

25 Q. And Monsanto sent all the male kidney

1 slides off to a guy by the name of Dr. Marvin  
2 Kuschner, right?

3 A. That's my understanding.

4 Q. And that was in around 1983 or '84,  
5 true?

6 A. The time frame sounds about right.

7 Q. Okay. And you know who Marvin Kuschner  
8 was, right?

9 A. No. Sorry.

10 Q. He was preeminent in the field of  
11 veterinary pathology and experimental pathology  
12 testing in the United States. You didn't know that?

13 A. No, sir.

14 Q. Okay. All right. You know he was at  
15 Stoneybrook?

16 A. I didn't know where he was from. Sorry.

17 Q. Okay. And Dr. Kuschner, when he went  
18 through all of these mouse kidney slides, including  
19 the controls, the low dose, the mid dose and the high  
20 dose, found a renal tubule adenoma in a control animal  
21 that hadn't been reported before; isn't that right?

22 MS. WAGSTAFF: Objection, misstates the  
23 evidence.

24 A. That's what the information indicated  
25 that I got, yes.

1 Q. (BY MR. HOLLINGSWORTH) Yeah. And he  
2 also did a statistical analysis on the data and he  
3 concluded in his report at the time that there was no  
4 statistically significant increase in renal tubule  
5 adenomas from the 1983 mouse study, right?

6 A. The report that I saw indicated that,  
7 yes.

8 Q. Yes. And -- sorry. And, yes -- and  
9 then the EPA wanted to have six additional sections  
10 cut from each -- I'm sorry. Let me start over. Sorry  
11 about that, Tracy.

12 The EPA wanted to have three additional  
13 sections cut from each kidney of each male mouse in  
14 the entire study, and that was carried out at some  
15 point after Kuschner did his review, true?

16 A. Was it additional step sections of every  
17 kidney from every dose level?

18 Q. It was from every dose level -- it  
19 was -- it was three sections from each kidney of each  
20 male mouse for each dose level. And the control.

21 A. Okay. I --

22 Q. You refer to some of this history in  
23 your report, don't you?

24 A. Uh-huh.

25 Q. Okay. And those were reviewed by

1 pathologists and no further -- including the original  
2 pathologist, Dr. Knezevich or whatever the  
3 pronunciation is and his colleague, and they found no  
4 lesions whatsoever out of the additional study slides  
5 from that?

6 A. The report that came back indicated they  
7 found no additional tumors, correct.

8 Q. And to come up with three additional  
9 sections of each kidney in each male mouse involving  
10 60 animals and four different groups comes out to  
11 about 1,500 additional slides, right?

12 A. Do the math, yes.

13 Q. 1,500 additional sections on those  
14 kidneys, and they found no cancer, no adenomas, no  
15 lesion of any -- of any kind that they reported, true?

16 A. That's what the report says.

17 Q. Yes. And -- and do you know who  
18 Dr. Klaus Stemmer was?

19 A. No, sorry.

20 Q. You never heard of him?

21 A. Klaus.

22 Q. Klaus Stemmer, S-t-e-m-m-e-r.

23 A. (Deponent shook head from side to side.)

24 Q. He was the head of medical pathology at  
25 the University of Cincinnati Medical School and you

1 know from reading what you've read, I think, that he  
2 reviewed these slides in the control animals and in  
3 the high dose animals, and he said -- and also -- also  
4 the other two treatment groups, low and mid dose, and  
5 he said that he agreed with Dr. Kuschner that the  
6 lesions that he saw, if you took them in the order of  
7 treatment were one in the control, zero in the low  
8 dose, one in the mid dose and three in the high dose  
9 and that that was not statistically significant either  
10 in his opinion?

11 MS. WAGSTAFF: Objection to counsel  
12 testifying. There's no question on the table and  
13 you're just reading into the record your version of  
14 events.

15 Q. (BY MR. HOLLINGSWORTH) True?

16 A. I don't recall reading a report from --

17 Q. Stemmer, Klaus Stemmer.

18 A. I don't remember.

19 Q. Do you recall reading a report from  
20 Dr. Robert Squire, Bob Squire?

21 A. Yeah, I did see something from  
22 Dr. Squire.

23 Q. You probably knew Bob Squire?

24 A. Yes, I do.

25 Q. He was a famous guy in Washington,

1 wasn't he?

2 A. Famous, infamous, yes.

3 Q. He was the head of the NCI  
4 carcinogenesis program?

5 A. That's correct.

6 Q. For a long time?

7 A. That's correct.

8 Q. And he looked at these slides himself,  
9 he was an experimental pathologist, right?

10 A. Correct.

11 Q. And he agreed with Dr. Stemmer and Dr.  
12 Kuschner, right?

13 A. The report I read from him, he did,  
14 yes.

15 Q. Yes. His conclusion was that the renal  
16 tumors were not treatment related and there was no  
17 statistical significance, right?

18 A. That's what he wrote in his report.

19 Q. Did you read the report of Dr. Robert  
20 Olson and Dr. Andre Varma?

21 A. I'd have to go back to my files and see.  
22 I mean, I read as many of the reports that I could  
23 find.

24 Q. All those reports are on the internet,  
25 aren't they?

1 MS. WAGSTAFF: Objection, form.

2 A. On the internet?

3 Q. (BY MR. HOLLINGSWORTH) They're online  
4 through EPA's website.

5 A. Through EPA?

6 Q. Excuse me.

7 A. I'm sorry. My -- I've always had  
8 difficulty with the EPA websites. It's very difficult  
9 to find information from their website, at least in my  
10 experience. So --

11 Q. Okay.

12 A. -- I get very frustrated when I go there  
13 and try to find something. But anyway, they're  
14 probably available on the website.

15 Q. (BY MR. HOLLINGSWORTH) Okay.

16 A. Are they submitted as part of the  
17 submission for registration?

18 Q. Yes, they were.

19 MS. WAGSTAFF: If you don't know, don't  
20 speculate on whether or not they're available.

21 Q. (BY MR. HOLLINGSWORTH) That's okay. We  
22 can go on.

23 I want to ask you because you mentioned  
24 it in your report about the pathology working group  
25 that was convened. Do you recall that?

1 A. I do.

2 Q. Okay. And I don't want to go back  
3 through stuff that was already a part of your first  
4 deposition, but since you --

5 A. May I --

6 Q. Sure.

7 A. May I ask a question?

8 Q. Sure.

9 A. Are you going to ask about the report  
10 from the EPA pathologist?

11 Q. Yes, I am.

12 A. Okay.

13 Q. Okay.

14 A. Okay.

15 Q. The EPA pathologist looked at that  
16 control lesion, right?

17 A. That's correct.

18 Q. And he didn't make a diagnosis of it,  
19 did he?

20 A. He said he could not confirm that there  
21 was a tumor there or not, and he had other  
22 pathologists look at it and they could not confirm  
23 that was a tumor.

24 Q. Well, the other pathologists aren't  
25 mentioned in Dr. -- you're referring to Dr. Kosza,

Page 90

1 right, the EPA pathologist?  
 2 A. Oh, yeah.  
 3 Q. Dr. Kosza, K-o-s-z-a; is that right?  
 4 A. Yes.  
 5 Q. He doesn't refer to other pathologists  
 6 in that report?  
 7 A. Again, I -- I remember him referring to  
 8 a Dr. McConnell, I believe. Looking at it.  
 9 Q. Wasn't Dr. McConnell his boss?  
 10 A. I don't know.  
 11 Q. Okay. You're not suggesting that Kosza  
 12 formed a pathology working group?  
 13 A. No, no, no, no, no. All I'm saying is  
 14 he was -- he -- my understanding of the information I  
 15 got pertaining to this particular activity is EPA  
 16 wanted one of their pathologists to look at the slides  
 17 to -- to get their own opinion, to give their own  
 18 opinion of what the tumor incidence was in the kidneys  
 19 of these male CD-1 mice.  
 20 Q. Yep.  
 21 A. And the EPA pathologist looked at -- got  
 22 the slides, looked at them and confirmed that there  
 23 was three adenomas in the high dose, one in the mid  
 24 dose, none in the low dose and none -- well, and he  
 25 said he could not confirm that there was an additional

Page 92

1 know, nobody knows. But --  
 2 MS. WAGSTAFF: Objection. If you  
 3 haven't seen it and you have it, maybe it would be  
 4 helpful if you saw it.  
 5 THE DEPONENT: Yeah.  
 6 Q. (BY MR. HOLLINGSWORTH) Sir, so this  
 7 pathology working group was convened, right, and you  
 8 mentioned that in your report to the judge in this  
 9 case?  
 10 A. Correct.  
 11 Q. And the pathology working group is  
 12 something you're familiar with because you've actually  
 13 written about what pathology working groups are and  
 14 how they should proceed and what their procedure  
 15 should be, haven't you?  
 16 A. Written about what pathology working  
 17 groups should do?  
 18 Q. Yes.  
 19 A. I -- sorry, I don't recall that.  
 20 Q. Okay. This pathology working group was  
 21 made up of five veterinary pathologists, right?  
 22 A. I believe that's right, and I  
 23 believe -- now, this was a pathology working group  
 24 convened by Monsanto, correct?  
 25 Q. Well, EPA required Monsanto to convene

Page 91

1 tumor in the control animals.  
 2 Q. Well, he saw something that he said --  
 3 A. He said something that may or may not be  
 4 preneoplastic.  
 5 Q. Yeah.  
 6 A. But he could not confirm that there was  
 7 an adenoma in the controls.  
 8 Q. Yeah.  
 9 A. And I believe in his report he also says  
 10 that he asked another pathologist or maybe two to look  
 11 at the slides and they concurred with what he said  
 12 that they couldn't confirm that there was a tumor in  
 13 the control group.  
 14 Q. Well, I'll come back to that, but did  
 15 you read the report about that control adenoma which  
 16 said that it was as wide as five renal tubules?  
 17 A. I don't recall reading that, no.  
 18 Q. I mean, something that is as wide as  
 19 five renal tubules is a pretty significant lesion,  
 20 isn't it?  
 21 A. It is.  
 22 MS. WAGSTAFF: Object to form.  
 23 A. So why was it missed in the initial  
 24 review?  
 25 Q. (BY MR. HOLLINGSWORTH) Well, I -- you

Page 93

1 this pathology working group, didn't it?  
 2 A. Yes.  
 3 Q. And, of course, Monsanto -- nothing  
 4 happens for free and Monsanto had to convene it,  
 5 right? Nothing happens for free and Monsanto convened  
 6 this group --  
 7 MS. WAGSTAFF: Object to form. Some  
 8 things happen for free.  
 9 Q. (BY MR. HOLLINGSWORTH) -- in response to  
 10 EPA's requirement, is that a fair statement?  
 11 A. Okay. Yes.  
 12 Q. And this group included five doctors. I  
 13 think, some of them you may know. Doctor, did you  
 14 know Dr. R.M. Sauer?  
 15 A. Sauer?  
 16 Q. Yeah, S-a-u-e-r?  
 17 A. No, sir.  
 18 Q. He had been the pathologist for the  
 19 National Zoo in Washington for years and was a  
 20 professor at George Washington University.  
 21 A. I'm not familiar with him.  
 22 Q. Another one was Dr. Marion Anver  
 23 (phonetic), did you see her name in those notes?  
 24 A. I believe I saw her name, yes.  
 25 Q. Do you know her?

Page 94

1 A. No.  
 2 Q. She was at NCI, National Cancer  
 3 Institute, for many years. You were there, too,  
 4 right?  
 5 A. Yes.  
 6 Q. But it's a big place and you didn't  
 7 encounter --  
 8 A. Right. No, I didn't.  
 9 Q. Another member of the PWG was  
 10 Dr. Strandberg?  
 11 A. Strandberg, Strandberg. I saw his name  
 12 there, too, but I'm not familiar with him.  
 13 Q. You don't know Dr. Strandberg?  
 14 A. Not that I recall.  
 15 Q. Okay. He was at Johns Hopkins  
 16 experimental laboratory for 30 years, very well known  
 17 in Washington.  
 18 MS. WAGSTAFF: Object to form  
 19 testifying.  
 20 Q. (BY MR. HOLLINGSWORTH) You don't  
 21 remember him?  
 22 A. I don't personally know him, no.  
 23 Q. Another guy on this pathology working  
 24 group that looked at the 1983 mouse renal kidney  
 25 slides was Dr. Jerry Ward. You know him, right?

Page 96

1 what do you mean?  
 2 Q. All the mouse male kidney slides.  
 3 MS. WAGSTAFF: Objection to counsel  
 4 testifying and making a declaratory statement as if  
 5 they are evidence or true.  
 6 A. Okay. I'm -- in my -- all I can state  
 7 in my experience with the PWGs --  
 8 Q. (BY MR. HOLLINGSWORTH) Okay.  
 9 A. -- they don't necessarily look at all  
 10 slides.  
 11 Q. I'm going to get to that. Because in  
 12 the -- in the literature about how PWGs are set up,  
 13 it's stated -- and I won't remind you that you're an  
 14 author of this -- it's stated that the chairman of the  
 15 PWG should look at all the slides and then with  
 16 respect to the disputed or controversial lesions, he  
 17 gives those out in a blinded format to the other four  
 18 members. That's the way PWGs are set up?  
 19 A. Right.  
 20 Q. True?  
 21 A. Right.  
 22 Q. And that's what happened here, isn't it?  
 23 A. Okay. That's why with when you said all  
 24 the slides it didn't ring a bell.  
 25 Q. Yeah. Sorry. That was my fault.

Page 95

1 A. I know Jerry Ward, yes.  
 2 Q. You've published with him before,  
 3 haven't you?  
 4 A. Yes.  
 5 Q. You don't have any question -- any  
 6 reason to question his ability as a --  
 7 A. Oh, Jerry Ward?  
 8 Q. -- experimental pathologist?  
 9 A. No.  
 10 Q. He's very well known and very well  
 11 respected, correct?  
 12 A. Correct.  
 13 Q. He's still living?  
 14 A. I believe so.  
 15 Q. The fifth person was Dr. Dawn Goodman,  
 16 did you know her?  
 17 A. Yes, I knew -- I knew Dawn Goodman.  
 18 Not -- I mean, I knew of her, I guess I should say. I  
 19 didn't know her personally.  
 20 Q. Now, the chairman Dr. Sauer read all  
 21 these slides again, the same ones that Dr. -- that  
 22 Dr. Kuschner reviewed and then Dr. Stemmer reviewed  
 23 and these guys are all looking at these slides through  
 24 a microscope?  
 25 A. I'm sorry, when you say all the slides,

Page 97

1 Dr. Sauer looked at them all and then he gave out to  
 2 the other four people, including Jerry Ward and Dawn  
 3 Goodman and the others, the slides that he thought  
 4 that they should look at and he asked them to look at  
 5 all the four lesions, the one -- the five lesions,  
 6 one, zero, one, three and some other things within  
 7 those mouse -- mouse kidney slides. And they wrote a  
 8 report about it, didn't they?  
 9 MS. WAGSTAFF: Objection to counsel  
 10 testifying.  
 11 A. They wrote a report of their findings,  
 12 correct.  
 13 Q. (BY MR. HOLLINGSWORTH) Okay. And their  
 14 conclusion was that there was no oncogenic effect that  
 15 they saw based on their review because they confirmed  
 16 that there was an adenoma in the control animal, true?  
 17 A. They confirmed -- they -- their report  
 18 indicated that there was an adenoma in the controls,  
 19 but they also reported that there were two carcinomas  
 20 in the high dose and one carcinoma in the mid dose, so  
 21 they diagnosed malignant tumors in the kidney as  
 22 opposed to the adenomas, which are non-malignant  
 23 tumors, so what they did was they confirmed the number  
 24 of tumors, but they upgrade the tumors from  
 25 adenomas -- three of the five tumors, they upgraded

Page 98

1 from adenomas to carcinomas.  
 2 Q. Yeah. Okay. Well, I don't think that's  
 3 quite right but I'm not going to dispute that with  
 4 you. The conclusion of the five people was unanimous  
 5 that there was no oncogenic effect from glyphosate  
 6 that they saw based on their review of the slides,  
 7 isn't that true?  
 8 A. That was their conclusion, I believe,  
 9 yes.  
 10 Q. Now, there was a science advisory panel  
 11 that was convened by the United States EPA thereafter,  
 12 an SAP to look at the question of the -- of whether or  
 13 not glyphosate was carcinogenic in this mouse study in  
 14 1983, true?  
 15 A. Correct.  
 16 Q. And you saw in what you read that there  
 17 were two members of that scientific advisory panel who  
 18 looked at these mouse lesions from the male mice  
 19 kidneys that were part of the controversy, true?  
 20 A. I'm sorry, could you repeat that?  
 21 Q. There were two members of the science  
 22 advisory panel at EPA who looked at the same male  
 23 mouse slides from the 1983 studies as part of the  
 24 Fifro (phonetic) science advisory science review in  
 25 1986, true?

Page 100

1 Q. And you published with him, too, didn't  
 2 you?  
 3 A. I think maybe one or two papers.  
 4 Q. Jim Swenberg looked at one of those --  
 5 was one of the two pathologists on the science  
 6 advisory panel to EPA in 1986 that looked at those  
 7 mouse kidney lesions under the microscope, right,  
 8 you've read that?  
 9 A. I -- again, I'd need to look at the  
 10 report to refresh my memory. I'm sorry.  
 11 Q. Okay. There's another mouse study that  
 12 you looked at and the author is Dr. Atkinson from 1993  
 13 and the sponsor of that study was a company called  
 14 Cheminova.  
 15 A. Okay.  
 16 Q. And the authors, Atkinson and others,  
 17 concluded that there were no compound related  
 18 neoplastic lesions in that mouse study, true?  
 19 A. Okay.  
 20 Q. Did you report that to the judge in this  
 21 case in your expert witness report?  
 22 A. I -- again, I was asked to give my  
 23 opinion of what the data was and my report contains my  
 24 independent opinion of what the data says, and so I  
 25 did not put that in the report. It's -- what

Page 99

1 MS. WAGSTAFF: Object to the suggestion  
 2 that it was the same slides.  
 3 A. I -- I -- I don't recall that. I don't  
 4 know.  
 5 Q. (BY MR. HOLLINGSWORTH) I thought that  
 6 you already testified that the -- you were aware that  
 7 EPA convened a scientific advisory panel to evaluate  
 8 the 1983 mouse study data in 1986?  
 9 A. I read -- yeah, I read the report.  
 10 Q. Yes. And there were two members of that  
 11 committee who were veterinary pathologists who  
 12 actually got the microscopes out and looked at those  
 13 mouse kidney tumors that the EPA had asked them to  
 14 evaluate in 1986 as part of the scientific advisory  
 15 panel, right?  
 16 A. Is that in their report?  
 17 Q. Yes, it is.  
 18 A. I'd have to --  
 19 Q. You didn't see that?  
 20 A. I'd have to look at the report again to  
 21 refresh my memory.  
 22 Q. Okay. You knew a guy who sat on that  
 23 panel who was an experimental pathologist, a DVM by  
 24 the name of Swenberg (phonetic), right?  
 25 A. Oh, Jim Swenberg, yes.

Page 101

1 I -- I'll just leave it at that.  
 2 MS. WAGSTAFF: No. If you have more to  
 3 say, go ahead.  
 4 A. What I was going to say it -- in doing  
 5 that is not unlike what is done in a number of -- in  
 6 my past experience as a toxicologist over the past 30  
 7 plus years, it's not unusual to convene a -- either a  
 8 panel or ask somebody to give their opinion of what a  
 9 data or a set of data says, and when the people,  
 10 either the group or the individual puts together their  
 11 report, it is accepted and anticipated that they will  
 12 put in the report their opinion because that's what's  
 13 being asked and they will not include other  
 14 people's -- other author's interpretation of the data  
 15 because that's not what they're asked to do. They're  
 16 asked to give their opinion, so the report contains  
 17 their opinion.  
 18 Q. (BY MR. HOLLINGSWORTH) Well, the --  
 19 Dr. Atkinson wasn't just an author, he was the  
 20 original investigator who actually looked at all the  
 21 slides, wasn't he?  
 22 A. I believe he was the pathologist that  
 23 looked at the slides in this study, yes.  
 24 Q. Yeah. But you didn't think that it was  
 25 necessary, as a scientist, to tell the judge that his

1 conclusion was that there were no compound-related  
2 lesions, neoplastic or otherwise in the study?

3 A. Again, I wasn't asked to give other  
4 people's opinion of what the data said. I was asked  
5 to give my opinion.

6 Q. Okay. You didn't review the full study  
7 report for the -- this 1993 Atkinson mouse study that  
8 was sponsored by Cheminova, did you?

9 A. I reviewed all of the study reports and  
10 information that was provided to me.

11 Q. What was provided to you on this study,  
12 sir?

13 A. There were parts of the actual report.  
14 Again, I'd have to go back to my files and see exactly  
15 all the pieces that I had, but there were -- there  
16 were portions of the report, there were -- and  
17 usual -- and tables, tumor tables.

18 Q. Okay. Were these materials provided to  
19 you by plaintiffs' counsel?

20 A. Yes, sir.

21 Q. Did you rely on Dr. Greim's published  
22 review article as a basis for your opinions on the  
23 Atkinson --

24 A. What I would do is I would take the  
25 materials provided to me by plaintiff, the reports I

1 got from this particular study. I would review those  
2 and then I would also look at the Greim paper and any  
3 additional supporting information from the Greim paper  
4 and compare, and then put the information -- and  
5 usually -- and I would -- I would say in just about  
6 every case, there was correspondence between what was  
7 in the Greim and what I was able to glean from the  
8 study reports and I used that to prepare my report.

9 Q. So Greim was reliable in that respect?

10 A. I told you before, Greim -- I consider  
11 Greim reliable because it's a published -- a peer-  
12 reviewed paper.

13 Q. Okay. So you were aware of  
14 Dr. Atkinson's and his collaborator's conclusion that  
15 this study did not show any neoplastic effect based on  
16 administration of glyphosate?

17 A. I read their opinion, yes.

18 Q. How did you go -- and you rejected that  
19 opinion?

20 A. I -- I looked at the data, and looking  
21 at the results of this particular study, I concluded  
22 that there was a significant increase in the  
23 particular tumors, in this case, I believe it was  
24 hemangiosarcomas. There was a significant increase in  
25 the treated animals versus the controlled and it was

1 due to the exposure to glyphosate and there may have  
2 been other cites too.

3 Q. Did you read -- do you know what JMPR  
4 is?

5 A. That is a -- another regulatory agency  
6 of -- I'm not --

7 Q. It's called the Joint Meeting of  
8 Pesticide Residues and it's a part of EFSA?

9 A. EFSA.

10 Q. Are you aware that they evaluated the  
11 1993 Atkinson study?

12 A. Yes, I had seen their report as part of  
13 my review and when I participated in the IARC working  
14 group.

15 Q. And you knew that the European  
16 regulators at JMPR concluded that this study was not  
17 considered to be -- excuse me. You knew that the JMPR  
18 regulators reviewed these hemangiosarcomas that you're  
19 referring to in the Atkinson report, and they  
20 concluded that they -- that those lesions were not  
21 considered to be caused by administration of  
22 glyphosate, true?

23 A. I saw that they had done their review,  
24 they did a risk assessment for -- for that, and based  
25 on their risk assessment of the data, they said it

1 wasn't -- they did not consider it a carcinogen.  
2 However, I did a hazard assessment for glyphosate in  
3 my report, and in the hazard assessment you look at  
4 the results of the particular study, you evaluate the  
5 incidence of the tumors caused by exposure to the  
6 compound, and so there was a significant increase in  
7 the hemangiosarcomas from this study, and so in my  
8 opinion, glyphosate caused those hemangiosarcomas and,  
9 therefore, it's carcinogenic in animals.

10 Q. The -- this same JMPR review that you're  
11 referring to or that I referred to in my prior  
12 question concluded that glyphosate produced, quote, no  
13 signs of carcinogenic potential at any dose, unquote,  
14 didn't they?

15 A. That was in their report, correct.

16 Q. How did you discount that?

17 A. I didn't agree with them discounting the  
18 hemangiosarcomas as not being compound related. My  
19 interpretation was they were compound related, so for  
20 the purpose of this hazard identification that I  
21 did --

22 Q. Okay. Did you notice that in the  
23 Atkinson report, the incidence of renal tubule  
24 adenomas in mice, male mice was two, two, zero, zero?

25 A. Yeah, I believe I remember that, yeah.

1 Q. Yeah. So -- so that is another study  
2 that finds additional renal tubule lesions in control  
3 animals, right?

4 MS. WAGSTAFF: Object to form.

5 A. They reported additional -- they had  
6 reported tumors in the control animals, that's  
7 correct.

8 Q. (BY MR. HOLLINGSWORTH) When you did your  
9 report and made the conclusions that you made about  
10 the 1983 mouse study and renal tubule adenomas and  
11 carcinomas, did you take into consideration the  
12 Cheminova 1993 mouse study authored by Atkinson where  
13 they found two renal tubule adenomas in the control  
14 animals?

15 A. For the purpose of my hazard  
16 identification, I look at each study individually and  
17 I didn't compare them, and, you know, the Atkinson  
18 study was done 10 years after the Knezevich or  
19 whatever study, so they're not contemporary studies,  
20 so. . .

21 Q. But -- but they would be included in the  
22 category of control -- of -- of historic controls,  
23 wouldn't they?

24 A. They would be, but as I indicated  
25 before, the most appropriate controls for any study is

1 the concurrent controls. First, you look at the  
2 results of the exposure to the treated animals versus  
3 the concurrent controls, and see if there is an  
4 increase in tumor formation in the treated animals,  
5 that is the most appropriate control to use in any  
6 study. Then after you've done that evaluation, you go  
7 and look at the historical control data to see if  
8 well, maybe this was a spurious result or something,  
9 so -- but, you still have to look at the -- the study  
10 that, as it was performed, and the concurrent  
11 controls, that is the most important thing to do in  
12 your evaluation of a particular study.

13 Q. Haven't you published that using the  
14 historic controls is a piece of quote, key data --

15 MS. WAGSTAFF: Objection, asked and  
16 answered already.

17 Q. (BY MR. HOLLINGSWORTH) -- in doing that  
18 evaluation?

19 A. I don't recall that. I'd have to see  
20 the publication.

21 Q. All right. Now, on -- regarding your  
22 opinion on the hemangiosarcomas in these male mice in  
23 the Atkinson study, the data that you were looking at  
24 going from control to low dose to mid dose to high,  
25 was zero in the controls, zero in the low dose, zero

1 in the mid dose and four hemangiosarcomas in the high  
2 dose animals, right?

3 A. Correct.

4 Q. And you're talking about male mice here,  
5 true?

6 A. Correct.

7 Q. And you refer this -- to this in your  
8 report as a dose-related increase, right?

9 A. Well, it was a positive trend test. It  
10 was positive in the trend test, so. . . There was a  
11 positive increase in trend of the tumor as you  
12 increased dose.

13 Q. Isn't -- isn't it true that the  
14 incidence in the high dose group was not statistically  
15 significant when it was done in comparison to the  
16 control animals?

17 A. In a pair-wise comparison, it did not  
18 reach statistical significance that's controlled,  
19 that's correct, but in a pair-wise comparison for  
20 trend, it was positive. So there was an increase in  
21 the trend in the formation of these hemangiosarcomas  
22 in these animals, so, therefore, it's a positive  
23 effect, a positive response to the glyphosate causing  
24 an increase in the trend in the formation of these  
25 tumors in these animals.

1 Q. You didn't do that trend test yourself,  
2 did you?

3 A. No, I didn't.

4 Q. You relied on someone else?

5 A. Yes.

6 Q. Who did you rely on?

7 A. I think it was -- I think it was the  
8 EPA. I don't know. I don't remember. I'd have  
9 to -- I really actually need my other sheet to -- I  
10 put on there where I got the trend test from.

11 Q. Are you talking about one of your cheat  
12 sheets?

13 A. The sheet that I prepared where I just  
14 summarized all of the information as a quick reference  
15 so I wouldn't have to go leafing through this.

16 MS. WAGSTAFF: If it's important to you  
17 to get an answer to that, he can reference it if you  
18 want.

19 MR. HOLLINGSWORTH: No, you know, I can  
20 understand why you might need a cheat sheet to get  
21 through this kind of stuff.

22 MS. WAGSTAFF: Sort of a dense  
23 deposition.

24 A. A lot of information to remember.

25 Q. (BY MR. HOLLINGSWORTH) I've got a few of

Page 110

1 them myself.  
 2 Now, you didn't find any consistent --  
 3 any finding consistent with males with  
 4 hemangiosarcomas when you looked at female animals,  
 5 did you?  
 6 A. For the females, there was an increase,  
 7 but it was -- it was only zero, zero, one, so one  
 8 tumor was found in the high dose females. Just seeing  
 9 one tumor in the females was not enough to infer  
 10 any -- anything, really, but the fact of the matter is  
 11 there was one seen in the female mice.  
 12 Q. But there was no replication of the  
 13 finding of hemangiosarcomas in males that you report  
 14 on in this report that you gave to the judge in the  
 15 MDL when you looked at the female mice, true?  
 16 MS. WAGSTAFF: Object to form --  
 17 A. In this study --  
 18 MS. WAGSTAFF: -- with the word  
 19 "replication."  
 20 A. Sorry. In this study, I didn't see, no.  
 21 Q. (BY MR. HOLLINGSWORTH) You didn't see  
 22 replication in it -- in the other sex?  
 23 A. In the female.  
 24 MS. WAGSTAFF: Object to form.  
 25 Q. (BY MR. HOLLINGSWORTH) Okay. And you

Page 112

1 A. I don't know that they had more data  
 2 than I did or not. I wasn't at the EPA reviews, so  
 3 I -- I really am not, I guess, privy to all the -- to  
 4 all the data -- knowing all the data that they had, so  
 5 I really can't say.  
 6 Q. (BY MR. HOLLINGSWORTH) Has your opinion  
 7 that these hemangiosarcomas in the male mice in the  
 8 Atkinson study is related to glyphosate been published  
 9 and peer reviewed?  
 10 A. Has my opinion?  
 11 Q. Yes.  
 12 A. No. My opinion has just been, I guess,  
 13 quote, published in this report.  
 14 Q. Do you know of anywhere in the peer-  
 15 reviewed literature where the finding of  
 16 hemangiosarcomas in male mice has been published and  
 17 peer reviewed?  
 18 A. I'm sorry, could you repeat?  
 19 Q. Sure. Do you know of any published  
 20 peer-reviewed report in the medical literature  
 21 anywhere that the findings of hemangiosarcoma that you  
 22 describe in your report, which you claim are  
 23 attributable to glyphosate has been published and peer  
 24 reviewed?  
 25 A. I'm not aware of any report published in

Page 111

1 know that this Atkinson study that we're talking about  
 2 now was submitted to EPA?  
 3 A. Yes, sir.  
 4 Q. And you know that EPA didn't consider  
 5 the increase in hemangiosarcomas to be treatment  
 6 related, that is related to the administration of the  
 7 test compound glyphosate?  
 8 MS. WAGSTAFF: Object to form.  
 9 A. When the EPA did their risk assessment  
 10 of this particular study, for glyphosate, that was  
 11 their conclusion for the purposes of their risk  
 12 assessment. Again, what I performed was a hazard  
 13 identification for this particular study evaluation,  
 14 and I felt that the -- the increased incidences and  
 15 trend of the hemangiosarcomas in the male mice was due  
 16 to the treatment of glyphosate. So for my  
 17 interpretation is that it was compound related or  
 18 related to glyphosate exposure and a positive  
 19 response.  
 20 Q. (BY MR. HOLLINGSWORTH) Did you have the  
 21 impression when you were reviewing the materials that  
 22 you reviewed on the Atkinson Cheminova -- Cheminova is  
 23 C-h-e-m-i-n-o-v-a, mouse study that the EPA had more  
 24 data available to it than what you reviewed?  
 25 MS. WAGSTAFF: Object to form.

Page 113

1 the peer-reviewed literature to that effect, no.  
 2 Q. Okay. I'd like to ask you about the  
 3 third mouse study which is by Arysta as the sponsor.  
 4 A-r-y-s-t-a. And Dr. Sugimoto was the lead veterinary  
 5 pathologist on that study. Are you familiar with that  
 6 study?  
 7 A. Yes.  
 8 Q. And are you aware that the study authors  
 9 and investigators concluded that there was no  
 10 compound-related neoplastic or oncogenic or  
 11 carcinogenic effect from glyphosate in the  
 12 administration to mice in this study?  
 13 A. Of the -- I'm sorry. Could you repeat?  
 14 Q. Sure. Are you aware that the original  
 15 authors and investigators on this study wrote a  
 16 conclusion stating that there were no compound-related  
 17 neoplastic or oncogenic effects from the  
 18 administration of glyphosate to these mice?  
 19 A. I did read that in their report, yes.  
 20 Q. Did you report that to the judge in this  
 21 case in your expert report?  
 22 A. Again, I was asked to give my opinion of  
 23 the data and so that is what I put in my report and  
 24 not the opinion of anybody else.  
 25 Q. Now, the Arysta or Sugimoto report was

1 submitted to the United States Environmental  
2 Protection Agency, right?

3 A. Correct.

4 Q. What data did you rely on specifically  
5 in making your evaluation of this?

6 A. Similar to the other report, I looked at  
7 the study report or the study reports or the portions  
8 of the study reports that were provided to me by  
9 plaintiffs' attorney. That included portions of  
10 the -- of the actual report and/or tumor tables. I  
11 looked at that, and then I went and looked at the  
12 Greim publication. Looked at the data that was  
13 provided in that. I would compare, and like I said  
14 before, they usually matched pretty well. And then I  
15 would take that information and wrote my report  
16 accordingly.

17 Q. Okay. Did you read the actual pathology  
18 report from this study?

19 A. Again, I'd have to go back to my files  
20 and see if -- if I had the actual pathology report. I  
21 know I had -- I know I had the tumor tables from the  
22 report. I don't recall for this particular study if I  
23 had the pathology report or not. I'd have to go back  
24 to my files to look at it. If I had it, I definitely  
25 read it, but I -- to be honest, I just -- for this

1 administration of glyphosate to these rats, I mean,  
2 excuse me, these mice in 1997?

3 A. I -- I'm sorry, I missed the first part  
4 of that question. Could you repeat? I'm sorry.

5 Q. All right.

6 MR. HOLLINGSWORTH: Tracy, here is a  
7 test for you.

8 MS. WAGSTAFF: This is not nice.

9 (The question was read back as follows:  
10 "What piece of information informed you that you  
11 were -- and that made you aware that the original  
12 investigator, Dr. Sugimoto and his collaborators,  
13 concluded that there were no compound-related  
14 neoplastic or oncogenic effects from administration of  
15 glyphosate to these rats, I mean, excuse me, these  
16 mice in 1997?")

17 A. So for that it -- it would have been in  
18 the -- in the report that I got from -- from  
19 plaintiffs' attorneys. It would have been in  
20 the -- in -- in the -- probably in the summary of the  
21 report or what have you. I -- you know --

22 Q. Okay.

23 A. -- I can't remember.

24 MS. WAGSTAFF: Can I ask just an  
25 administrative question? It's 11:45, so I don't know

1 study, I just don't recall.

2 Q. Isn't it always important to read the  
3 original pathology report from an author like -- or  
4 investigator like Dr. Sugimoto?

5 MS. WAGSTAFF: Objection to form.

6 A. If -- if I -- if the pathology report is  
7 available, yes, you should read the pathology report  
8 to see what the original pathologist said. And like I  
9 said, if the report was there, I read it, but I just  
10 don't remember for this study.

11 Q. (BY MR. HOLLINGSWORTH) Did you ask  
12 counsel for the plaintiffs to provide you with the  
13 original pathology reports in each of these 12 written  
14 studies that you looked at?

15 A. I asked them to provide me all the  
16 data -- all the information they had and I relied on  
17 them to provide me that -- what information they had  
18 available to them. And I'm confident if they had  
19 anything on any of these studies, they forwarded it on  
20 to me for my review.

21 Q. What piece of information informed you  
22 that you were -- and that made you aware that the  
23 original investigator, Dr. Sugimoto and his  
24 collaborators, concluded that there were no compound-  
25 related neoplastic or oncogenic effects from

1 if you want to -- if you want to take a late lunch, we  
2 should probably break now, but if you want to eat  
3 earlier, I don't know. You guys are on East Coast  
4 time, so what do you want to do?

5 MR. HOLLINGSWORTH: We're -- we're--  
6 we're good.

7 MS. WAGSTAFF: Okay. So do you want to  
8 take a small break and eat lunch at 1:00 or do you  
9 want to go --

10 MR. HOLLINGSWORTH: You want to take  
11 another break now?

12 MS. WAGSTAFF: If we're going to go  
13 another hour and something. I'm saying it's 11:50, so  
14 we can either take a short break and -- do you want to  
15 take a little break right now? Let's take a little  
16 break.

17 THE DEPONENT: Okay. We can take a  
18 little break right now if --

19 MR. HOLLINGSWORTH: Okay.

20 MS. WAGSTAFF: Yeah.

21 THE VIDEOGRAPHER: Going off the record.  
22 The time is 11:50 a.m.

23 (Recess taken, 11:50 a.m. to 12:02 p.m.)

24 THE VIDEOGRAPHER: We are back on the  
25 record. The time is 12:02 p.m.

1 MR. HOLLINGSWORTH: All right. Counsel,  
2 when did you want to adjourn for lunch?

3 MS. WAGSTAFF: Well, what do you think?  
4 I would leave it most up to Dr. Jameson, who --

5 MR. HOLLINGSWORTH: Sure.

6 THE DEPONENT: I mean, I'm good. We  
7 could adjourn at 1:00 if that's okay with everybody  
8 or --

9 MR. HOLLINGSWORTH: Is that all right  
10 with everybody?

11 THE DEPONENT: Or sooner if they need  
12 it.

13 MS. WAGSTAFF: I'm the only one that  
14 lives on mountain here.

15 MR. HOLLINGSWORTH: If I need to stop  
16 before lunch, I'll let you know that, but I'll  
17 probably be all right.

18 Q. (BY MR. HOLLINGSWORTH) Sir, we were  
19 talking about the Sugimoto 1997 mouse study?

20 A. Uh-huh.

21 Q. Sponsor was Arysta. Did you say that  
22 you had reviewed the pathology study for this? Sorry  
23 if you already testified.

24 A. The pathology study?

25 Q. I'm sorry, the pathology report within

1 the study.

2 A. Again, specific to this particular  
3 study, I don't remember if I had the pathology report.  
4 If I did, I'm -- I did review it.

5 Q. Do you have in mind your review of the  
6 hemangiosarcomas in this study?

7 A. Yeah, the incidences, yes.

8 Q. The incidence was zero in the control,  
9 zero in low dose and zero in mid dose and two in high  
10 dose males? Zero, zero, zero, two.

11 A. Four.

12 Q. Not four, two.

13 A. 4 percent. I'm sorry.

14 Q. When you said 4 percent, you're  
15 referring to the high dose percentage right?

16 A. Right.

17 Q. And you said that this results in a  
18 significant P value using the Chi-Square test?

19 A. Yes.

20 Q. Why did you use the Chi-Square test  
21 here, sir?

22 A. Again, I'd have to go back and look. I  
23 did not perform the statistics myself, I don't  
24 believe. I'd have to go back and see the source of  
25 this. It -- I just don't recall where -- where --

1 where I got it from.

2 Q. Who performed the statistics using the  
3 Chi-Square test?

4 A. Again, I'm going to need my other sheet.

5 MS. WAGSTAFF: All right. Counsel, I'd  
6 like to -- I'm going to give him a copy of his cheat  
7 sheet and I'll give you a copy as well if you'd like  
8 one.

9 MR. HOLLINGSWORTH: Okay. I've been  
10 dying to get that.

11 MS. WAGSTAFF: You have been, I know.

12 MR. HOLLINGSWORTH: You notice I  
13 specifically did not ask for it.

14 MS. WAGSTAFF: Okay. So I'm looking for  
15 ones that don't have handwriting on it.

16 THE DEPONENT: I have --

17 MS. WAGSTAFF: Okay. Here is yours.  
18 Here is one for rat and for mouse.

19 MR. HOLLINGSWORTH: Thank you.

20 MS. WAGSTAFF: If you want to mark those  
21 as an exhibit or whatever you'd like to do.

22 A. I got the numbers from -- from  
23 something I got from Chris Portier.

24 Q. (BY MR. HOLLINGSWORTH) Okay. Thank you.  
25 Let's mark this --

1 MS. WAGSTAFF: There's two separate  
2 ones.

3 Q. (BY MR. HOLLINGSWORTH) Okay. We'll  
4 mark the first one of these two page documents as two  
5 Exhibit 22-2 and you referred to this earlier this  
6 morning euphemistically as a cheat sheet. I haven't  
7 looked at it yet and I believe and then I'll mark the  
8 next one as --

9 MS. WAGSTAFF: You can see one is  
10 labeled rat and one is mouse up on the left.

11 Q. (BY MR. HOLLINGSWORTH) Okay. Good.  
12 22-3 is the --

13 A. The upper left-hand corner.

14 MR. HOLLINGSWORTH: 22-3.

15 MS. WAGSTAFF: Is rat. It's upper left.  
16 22-2 is mouse and I'm just making sure this is the  
17 same one before I hand it over. Which one did I give  
18 you before, the rat or the mouse?

19 MR. HAAKE: Rat.

20 MR. HOLLINGSWORTH: Thank you.

21 Q. (BY MR. HOLLINGSWORTH) So you think the  
22 Chi-Square test came from Dr. Portier?

23 A. Yes, sir.

24 Q. Did you rely on Chi-Square test for  
25 renal tubule tumors as well? Or renal tumors as

Page 122

1 well?  
 2 A. Are you talking about for the Knezevich?  
 3 Q. No, I'm talking about the Sugimoto on  
 4 1997 Arysta. I'm still talking about the  
 5 hemangiosarcomas.  
 6 A. Hemangiosarcomas?  
 7 Q. In the male mice, and then I was  
 8 wondering whether you had also run a Chi-Squared P  
 9 value case for renal tumors?  
 10 A. I believe that's the case, yes.  
 11 Q. Okay. Now, are you -- are you aware  
 12 that Dr. Portier submitted an amended report in this  
 13 case?  
 14 MS. WAGSTAFF: Object to form.  
 15 A. I'm not sure what report you're  
 16 referring to.  
 17 Q. (BY MR. HOLLINGSWORTH) Okay. He has  
 18 two reports. He has a report -- an opening report  
 19 like yours and then he submitted an amended report in  
 20 addition. Have you read both of his reports?  
 21 MS. WAGSTAFF: Object to form.  
 22 A. I'm sorry, are you referring to his  
 23 expert report?  
 24 Q. (BY MR. HOLLINGSWORTH) Yes. In this  
 25 case.

Page 124

1 and prior to his expert report. So if he has a number  
 2 in his expert report that is different than this, it's  
 3 probably due to the fact that he did additional  
 4 analysis or subsequent analysis of the data because  
 5 being a statistician, they always evaluate and  
 6 reevaluate the data, so that --  
 7 MS. WAGSTAFF: If you don't know, don't  
 8 speculate.  
 9 A. But I don't know.  
 10 Q. (BY MR. HOLLINGSWORTH) Would you defer  
 11 to Dr. Portier and his opinion based on the issues of  
 12 statistics and biostatistics?  
 13 A. Okay. Since Chris is a well-known  
 14 biostatistician, I would have to defer to him,  
 15 correct.  
 16 Q. And would you agree that the Chi-Squared  
 17 test is not a traditional method that's used to  
 18 evaluate the incidence of tumors in long-term chronic  
 19 bioassays in rodents?  
 20 MS. WAGSTAFF: Object to form.  
 21 A. There are a number of different  
 22 statistical methods used in the evaluation of data for  
 23 animal toxicity and chronic carcinogenicity studies  
 24 and they all are used frequently in all the  
 25 publications that I see, so . . .

Page 123

1 A. I'm sorry.  
 2 Q. Sorry.  
 3 A. That's okay. Yes.  
 4 Q. Okay. And are you aware that for the  
 5 incidence of hemangiosarcomas in male mice in this  
 6 study, the Arysta 1997 study by Sugimoto, Dr. Portier  
 7 reported a non-statistically significant trend with a  
 8 P value of .06?  
 9 A. I'm trying to remember if I saw that in  
 10 his report or not. The value that I have here is  
 11 based on some -- how shall I -- I don't know if it's  
 12 communication or what. After -- let me back up. As  
 13 you know, or are aware, I've known Chris Portier for a  
 14 long time. In fact, we worked together for a very  
 15 long time and Chris was also a special -- I forget  
 16 what his title was, but at the monograph 12, he was  
 17 also a special invitee who attended the meeting. And  
 18 after the meeting, he and I and a number of other  
 19 people also published some -- some -- some work in  
 20 response to the -- the findings that we made at the  
 21 IARC meeting.  
 22 And he and I kept in contact about  
 23 glyphosate because of that and this -- this particular  
 24 number came from some -- some of the conversations we  
 25 had when we were putting together that publication,

Page 125

1 Q. (BY MR. HOLLINGSWORTH) Okay. You can do  
 2 the Chi-Squared test yourself, can't you?  
 3 A. I could.  
 4 Q. I mean, I can do it on the back of an  
 5 envelope, right, it's an easy thing to do?  
 6 MS. WAGSTAFF: Object to form.  
 7 A. If you say you can, I guess, I don't  
 8 know.  
 9 Q. (BY MR. HOLLINGSWORTH) Okay. You can do  
 10 one?  
 11 A. If I had to, I could do one.  
 12 Q. And were you also aware -- we were just  
 13 referring to the hemangiosarcomas and your opinion  
 14 that they were statistically significant and Dr.  
 15 Portier's opinion that they were not statistically  
 16 significant. Do you understand that?  
 17 A. Yeah, that's what we were talking about.  
 18 MS. WAGSTAFF: Form.  
 19 Q. (BY MR. HOLLINGSWORTH) Okay. He  
 20 also -- he, Dr. Portier, also ran statistics on the  
 21 renal adenomas, and, of course, you concluded that  
 22 using the Chi-Squared test that the renal adenomas  
 23 that were found in the male mice in 1997 study were  
 24 statistically significant. Did you know that?  
 25 MS. WAGSTAFF: I'm going to object

1 to -- to quoting or paraphrasing Dr. Portier's expert  
2 testimony and/or report. I think that you are cherry  
3 picking pieces of his report out of context and not  
4 giving the full context of his report. If you'd like  
5 him to opine on Dr. Portier's report, let's pull out  
6 Dr. Portier's report and let him read the whole thing.

7 Q. (BY MR. HOLLINGSWORTH) I'm not asking  
8 that. My question is whether he's aware that Dr.  
9 Portier also ran statistics on the renal adenomas and  
10 other renal lesions seen in the 1997 Arysta study.

11 MS. WAGSTAFF: Same objection.

12 A. I -- I don't know if he did or didn't.

13 Q. (BY MR. HOLLINGSWORTH) Okay. You don't  
14 know that he found a P value of 0.62 also for the  
15 renal adenomas which was not statistically  
16 significant?

17 MS. WAGSTAFF: Same objection and  
18 throughout this deposition, we've asked for documents  
19 that you've been citing to and every time you have  
20 refused to provide a document, so if you want him to  
21 opine on Dr. Portier's testimony, I would request that  
22 you allow him to read the deposition transcript right  
23 now or the expert report of which you cite.

24 MR. HOLLINGSWORTH: Well, when he's at  
25 lunch he can look at page 42 -- 41 and 42 of Portier's

1 report because that's where I got that information  
2 from. So if I'm wrong, you can tell me after lunch.

3 MS. WAGSTAFF: No, that's not how it's  
4 going to happen. If you want him to look at  
5 something, it will be on the record and will go  
6 against your time as your lawyers have made in our  
7 depositions, specifically including the Mark Martinez  
8 deposition when I asked him to read something off the  
9 record, and it was counted against my time, so if you  
10 want him to read something, he will for sure do it,  
11 but it's going to be on the record.

12 MR. HOLLINGSWORTH: Okay.

13 Q. (BY MR. HOLLINGSWORTH) My question,  
14 though, is are you aware that your friend Chris  
15 Portier, your long-time friend, had run statistics on  
16 the renal adenomas that were recorded in male mice in  
17 the Arysta study?

18 MS. WAGSTAFF: Object to the form of the  
19 question.

20 A. I -- I'd like to see his report before I  
21 respond to that.

22 Q. (BY MR. HOLLINGSWORTH) Okay. It's at 41  
23 and 42 if you want to look at it over the lunch  
24 period.

25 MS. WAGSTAFF: Objection. I just told

1 you if you want him to read something and to respond  
2 to one of your questions, provide him with the  
3 document and he'll do it on the record.

4 Q. (BY MR. HOLLINGSWORTH) Sir, you also  
5 considered this Arysta 1997 study by Dr. Sugimoto and  
6 others to show an increased incidence of what you say  
7 is malignant lymphoma, true?

8 A. Correct.

9 Q. And the incidence that you report in  
10 your report to the judge is two, two, zero, six,  
11 right?

12 A. Correct.

13 Q. 12 percent in the high dose animals?

14 A. (Deponent nodded head up and down.)

15 Q. 12 percent incidences is what you  
16 report, right?

17 A. Correct.

18 Q. And the incidence of six in the high  
19 dose animals was not statistically significant when  
20 compared with the concurrent controls, was it?

21 A. The incidence in the high dose was not  
22 statistically significantly different from the  
23 controls.

24 Q. Correct.

25 A. Correct.

1 Q. Do you report that?

2 MS. WAGSTAFF: Object to form.

3 A. Do I report that?

4 Q. (BY MR. HOLLINGSWORTH) Yes. At 22 and  
5 23.

6 A. Are you talking about the  
7 hemangiomas -- lymphomas?

8 Q. Yes. You report that, don't you?

9 A. I'm looking.

10 MS. WAGSTAFF: Object to the phraseology  
11 of "report that."

12 A. Okay. Could you repeat the sentence  
13 again, please?

14 Q. (BY MR. HOLLINGSWORTH) I said do you  
15 report that the incidence of six in the high dose  
16 group regarding malignant lymphoma was not  
17 statistically significant when compared with current  
18 controls?

19 MS. WAGSTAFF: Object to form.

20 A. That's what I report, yes.

21 Q. (BY MR. HOLLINGSWORTH) Are you aware  
22 that the European regulators did an analysis of the  
23 Arysta 1997 report, including statistical analyses?

24 MS. WAGSTAFF: Object to the form.

25 A. Okay. I'm sorry. I was looking at

Page 130

1 something.  
 2 Q. (BY MR. HOLLINGSWORTH) Okay.  
 3 A. I'd like to add something to the -- to  
 4 my last response, but I'll answer this first.  
 5 Q. Okay.  
 6 A. So if you could repeat the question.  
 7 Q. The question was this, you are aware  
 8 that the European regulators reviewed this report and  
 9 did a statistical analysis of the Arysta study -- I  
 10 shouldn't say report. It's a study.  
 11 A. Yes.  
 12 Q. Okay. And let me just finish my  
 13 question --  
 14 A. Sure.  
 15 Q. -- and you can go back and correct. And  
 16 you're aware that the historical control rate that  
 17 they report for malignant lymphoma is 4 to 19 percent  
 18 in control animals as a range?  
 19 A. For historical control?  
 20 Q. Yes.  
 21 A. In the -- I'm sorry -- in the -- in  
 22 their report?  
 23 Q. Yes.  
 24 A. Yes. Okay.  
 25 Q. You've read their report, right?

Page 132

1 A. But if I can continue on with that, I  
 2 also state in my report --  
 3 Q. Where are you now?  
 4 A. On page 22.  
 5 Q. Yep.  
 6 A. Towards the end of the paragraph.  
 7 Q. Yep.  
 8 A. I also state in my report that I also  
 9 reviewed the Tier II summary for glyphosate  
 10 carcinogenicity --  
 11 THE REPORTER: I'm sorry, I didn't  
 12 understand that. --  
 13 Q. (BY MR. HOLLINGSWORTH) Where are you  
 14 now on page 22?  
 15 A. Page 22.  
 16 Q. I see. Okay. Thank you.  
 17 A. I also reviewed the Tier II summaries --  
 18 Q. Yes.  
 19 A. -- for glyphosate carcinogenicity  
 20 studies from Greim, et al., for study 12, which is  
 21 Sugimoto.  
 22 Q. Sugimoto.  
 23 A. Sugimoto, excuse me. Which showed a  
 24 reported statistically significant increase in  
 25 malignant lymphoma in high dose male mice.

Page 131

1 A. Yes.  
 2 Q. You responded to their report partially,  
 3 you and Chris Portier did, didn't you?  
 4 A. Yes.  
 5 Q. So you're familiar with that control  
 6 range that they reported and -- and you would agree  
 7 that the 12 percent rate that was found in the high  
 8 dose males is within that control rate --  
 9 MS. WAGSTAFF: Object to form.  
 10 Q. (BY MR. HOLLINGSWORTH) -- that the  
 11 European regulators reported?  
 12 A. It's within that -- that report,  
 13 indicated in the report. As I indicated before, the  
 14 most appropriate controls for this study and any study  
 15 is the concurrent controls. So -- and based on the  
 16 concurrent controls is an increase in trend with this  
 17 incidence.  
 18 Q. Well, the -- you -- you determined that  
 19 the incidence was not statistically significant,  
 20 didn't you?  
 21 A. In the high dose?  
 22 Q. Yeah.  
 23 A. That's what -- in this particular case,  
 24 yes.  
 25 Q. Okay.

Page 133

1 Q. I understand that. I was getting ready  
 2 to ask you about that, but I haven't asked you about  
 3 that.  
 4 A. Okay.  
 5 MS. WAGSTAFF: Do you want to correct  
 6 your previous answer before we get too far down the  
 7 road? You put a note on the record that --  
 8 THE DEPONENT: This is the --  
 9 MR. HOLLINGSWORTH: That's the  
 10 correction --  
 11 A. This is what I wanted to add that I  
 12 found additional information from the Greim that  
 13 actually had a different tumor incidence and that  
 14 particular tumor incidence was statistically  
 15 significant in the high dose. That was the point I  
 16 wanted to make.  
 17 Q. (BY MR. HOLLINGSWORTH) Yeah. You're  
 18 aware of literature and you've already testified to it  
 19 this morning, I think, that there is a -- that  
 20 malignant lymphoma is among the most commonly  
 21 occurring spontaneous neoplasm in mice?  
 22 MS. WAGSTAFF: Object to form.  
 23 Q. (BY MR. HOLLINGSWORTH) Isn't that  
 24 right?  
 25 A. It depends on the strain.

Page 134

1 Q. In CD-1 mice.  
 2 A. In CD-1 mice, there's a fairly high  
 3 incidence.  
 4 Q. Yeah. I mean, it goes up to 50 percent,  
 5 doesn't it?  
 6 A. I don't know. I don't know what -- how  
 7 high it goes up to off the top of my head. But I know  
 8 it has a high spontaneous incidence.  
 9 Q. We had figured out that your report was  
 10 wrong where it referred to hemangiosarcoma --  
 11 A. Oh, hemangiosarcoma --  
 12 THE REPORTER: Please don't speak at the  
 13 same time.  
 14 THE DEPONENT: I'm so sorry.  
 15 MS. WAGSTAFF: Object, it wasn't wrong.  
 16 We told you that there was a typo that changed it in  
 17 three places, and I object to you calling it wrong.  
 18 MR. HOLLINGSWORTH: I said we thought it  
 19 was wrong based on the way his report was written and  
 20 the way that we received it and we went back to all  
 21 the data and we could see that the numbers were  
 22 completely wrong, so thanks for making that  
 23 correction.  
 24 Q. (BY MR. HOLLINGSWORTH) Now, as to  
 25 Nufarm, which is the next study I'd like to ask you

Page 136

1 respect to oncogenic or neoplastic effects, true?  
 2 A. I recall reading that in the report that  
 3 I reviewed.  
 4 Q. Okay. Did you review all of the data  
 5 from this study, including the pathology report?  
 6 MS. WAGSTAFF: Object to form.  
 7 A. For this particular study, I think I did  
 8 not have -- I know I did not have the full study  
 9 report. I know I had some tumor tables to look at.  
 10 And some other documents from the -- from the report,  
 11 but I -- I did not have the pathology report for this  
 12 one, I'm sure.  
 13 Q. (BY MR. HOLLINGSWORTH) Where did you get  
 14 the information that you did have about the Nufarm  
 15 study by Dr. Wood?  
 16 A. Well, again, I got -- I got some  
 17 information from plaintiffs' lawyers and -- but  
 18 probably for this particular one, I think I relied  
 19 heavily on the information in the Greim publication.  
 20 Q. And you know that the Nufarm study in  
 21 2009 by Dr. Wood was submitted to EPA, right?  
 22 A. Yes.  
 23 Q. And you -- you say in your report at  
 24 page 23, that the formation of malignant lymphomas and  
 25 the formation of adenocarcinomas of the lung -- do you

Page 135

1 about, Dr. Jameson. I think that's the fourth of five  
 2 mouse studies which you have referred to in your  
 3 report.  
 4 A. Uh-huh.  
 5 Q. And the investigator was Dr. Wood and  
 6 others. Did you know Dr. Wood?  
 7 A. No.  
 8 Q. Okay. Did you know anyone at that  
 9 laboratory?  
 10 A. Which laboratory was this?  
 11 Q. No. I don't have that information.  
 12 A. Okay.  
 13 Q. Now, the study authors, the original  
 14 study authors of the Nufarm 2009 study, Nufarm was the  
 15 sponsor, right?  
 16 MS. WAGSTAFF: Object to form.  
 17 A. That's what it said in the Greim  
 18 publication. They identified it as that, yes.  
 19 Q. (BY MR. HOLLINGSWORTH) Was Nufarm a  
 20 company that wanted to manufacture glyphosate and get  
 21 a registration for it?  
 22 A. I know nothing about that company.  
 23 Q. Okay. Now, the original authors,  
 24 Dr. Wood and others, concluded that there was no  
 25 compound-related effect whatsoever in this study with

Page 137

1 see that?  
 2 A. Yes.  
 3 Q. -- in this study was due to treatment  
 4 with glyphosate in male mice. Do you see that?  
 5 A. Yes.  
 6 Q. And then you make a reference to  
 7 malignant lymphoma and high dose -- in the high dose  
 8 male treatment group, right?  
 9 A. Yes.  
 10 Q. And an increase in the trend of  
 11 formation of adenocarcinomas of the lung and --  
 12 sorry -- malignant lymphomas as your third point,  
 13 right?  
 14 A. I'm sorry, I didn't hear that last part.  
 15 Q. You make a reference to an increase in  
 16 the trend of formation of the adenocarcinomas of the  
 17 lung -- lung -- lung?  
 18 A. Yes.  
 19 Q. I have a question about, and then you  
 20 say and malignant lymphomas in males, true?  
 21 A. Yes.  
 22 Q. Now -- now, the incidence of lung  
 23 adenomas or I should say adenocarcinoma that you refer  
 24 to in the high dose males was not statistically  
 25 significant when compared to controls, was it?

1 A. When compared to the concurrent  
2 controls, it was not statistically significant, that's  
3 correct. It was positive -- it was statistically  
4 significant increase in trend for the formation of  
5 these tumors in the male mice.

6 Q. Have you read the EPA's Office of  
7 Pesticide Programs' report on glyphosate and the  
8 re-registration of glyphosate in 2016?

9 A. Yes.

10 Q. They -- they do an analysis and state  
11 that that -- that those lung adenocarcinomas in high  
12 dose males are not statistically significant, don't  
13 they?

14 A. That the incidence of tumors is not  
15 statistically significant?

16 Q. Yes.

17 A. Yes. They say the -- the incidence is  
18 not statistically significant.

19 Q. And they say that there were no  
20 treatment-related preneoplastic lesions that were  
21 observed in that study?

22 A. I have to look at the -- at that report  
23 again to say definitely that they -- that they said  
24 no -- no preneoplastic lesions, but I -- I -- I think  
25 that's correct.

1 A. Are you -- I don't know where you're  
2 getting that quote from. You're probably getting it  
3 from a publication.

4 Q. John Booker was a long-time friend of  
5 yours, right?

6 A. John is, yes.

7 Q. Yep. And he was -- was he your boss?

8 A. Yes.

9 Q. Okay. These -- going back to the  
10 adenocarcinomas in high dose males, they weren't  
11 repeated or seen in any other mouse studies, were  
12 they?

13 MS. WAGSTAFF: Object to form.

14 A. I'd have to go back and check and see.  
15 Are you talking about in the mice?

16 Q. (BY MR. HOLLINGSWORTH) Yes.

17 A. No. I don't believe it was seen in any  
18 other studies in a significant manner. That's not to  
19 say that there weren't some lung tumors seen, some  
20 adenocarcinomas seen in some of the other studies, but  
21 they -- they were not at a significant -- they weren't  
22 significant compared to controls and I didn't include  
23 them in my report.

24 Q. Okay. So there was no replication of  
25 the adenocarcinomas in other mouse studies that you

1 Q. You didn't comment on that in your  
2 report to the judge, did you?

3 A. No.

4 Q. Now, did you tell me that you -- that  
5 you don't think that the existence and progression of  
6 and incidence of preneoplastic lesions is as important  
7 today as you thought it was years ago?

8 MS. WAGSTAFF: Object to form.

9 A. I don't recall saying I didn't think  
10 it's as important today as it was before. I don't  
11 remember saying that particular thing.

12 Q. (BY MR. HOLLINGSWORTH) Is it fair to  
13 state that the interpretation of tumor responses in  
14 two-year assays is an art?

15 A. The interpretation of --

16 MS. WAGSTAFF: Object to form.

17 A. I'm sorry, could you rephrase that  
18 question?

19 Q. (BY MR. HOLLINGSWORTH) Is it fair to  
20 state that the interpretation of tumor responses in  
21 two-year assays is an art?

22 MS. WAGSTAFF: Same objection.

23 A. I -- well, some individuals might think  
24 it's an art.

25 Q. (BY MR. HOLLINGSWORTH) Okay.

1 reviewed, the four other mouse studies I'm referring  
2 to, of course?

3 A. Like I said, there -- I don't recall the  
4 specifics, but I -- I -- I vaguely remember seeing  
5 lung tumors reported in some of these other studies,  
6 but they weren't significantly different than what was  
7 found in the control, so I didn't include them in my  
8 report. So -- but no -- no other study had a  
9 statistically significant increase in lung  
10 adenocarcinomas.

11 Q. That's including rats, too, isn't it?

12 A. Yes, I think that's probably correct for  
13 rats, but, again, it may have been tumors, lung tumors  
14 seen in some of the studies, but they weren't  
15 significantly different than what was observed in the  
16 controls --

17 Q. I'm --

18 A. -- so I didn't include them in my  
19 report.

20 Q. So you didn't report the replication of  
21 findings of adenocarcinoma in the lung in any other  
22 mouse or rat study besides the Nufarm 2009 study that  
23 we're referring to now?

24 MS. WAGSTAFF: Object to form.

25 Q. (BY MR. HOLLINGSWORTH) True?

1 A. The -- that was the only study that I  
2 reviewed where there was a significant increase in  
3 lung adenocarcinomas reported.

4 Q. Are you aware that Dr. Portier has  
5 determined on his own statistical evaluation that the  
6 incidence of lung adenocarcinomas in this study that  
7 you reported about in your report to the judge is due  
8 to chance?

9 MS. WAGSTAFF: Objection.

10 A. I'd have to see Chris' report to comment  
11 on that. I don't know.

12 Q. (BY MR. HOLLINGSWORTH) No one has -- no  
13 one has pointed that out to you?

14 A. No one has pointed that out to me, no.

15 Q. Okay. And you're aware that the United  
16 States EPA's Office of Pesticide Programs report in  
17 2016 concluded that the lung adenocarcinomas in this  
18 study was not treatment related?

19 MS. WAGSTAFF: Objection.

20 Q. (BY MR. HOLLINGSWORTH) Excuse me.

21 A. I'm sorry, could you repeat that?

22 Q. The United States Office of Pesticide  
23 Programs determined in 2016 in their report, which you  
24 said you had read, right?

25 A. Yes.

1 Q. That the lung adenocarcinoma that you  
2 state -- you stated in your report is statistically  
3 significant in the Nufarm 2009 study was not a  
4 positive finding based on -- based on administration  
5 of glyphosate to these male mice?

6 MS. WAGSTAFF: Objection, misstates the  
7 report.

8 A. Well, that finding by the EPA was based  
9 on their risk assessment that they were doing for  
10 glyphosate. And I -- and evidently based on the  
11 criteria that they used for doing a risk assessment,  
12 it did not meet that criteria to be called a  
13 carcinogen.

14 What I have done is a hazard  
15 identification assessment of this particular study,  
16 and based on my evaluation of the data for the  
17 adenocarcinomas, there was a positive trend in the  
18 formation of the lung adenocarcinomas in the male  
19 mice, and it is that increased -- that trend is  
20 attributed to the glyphosate, so, therefore,  
21 glyphosate caused those tumors or caused cancer in the  
22 experimental animals, so it's an animal carcinogen and  
23 therefore a potential human carcinogen.

24 Q. (BY MR. HOLLINGSWORTH) So you disagree  
25 with the EPA when they stated that the incidence of

1 lung adenocarcinomas in this study, the Nufarm study  
2 in 2009, is not due to treatment with glyphosate?

3 MS. WAGSTAFF: Objection, misstates the  
4 report.

5 A. Again, the EPA did a risk assessment,  
6 and based on their risk assessment, evidently, they  
7 did not feel that the adenocarcinomas could be called  
8 a carcinogen for their risk assessment. But for the  
9 push of the hazard identification that I did, I  
10 determined that the adenocarcinomas seen in the male  
11 mice in this study were caused by glyphosate, so  
12 glyphosate caused an increase in the trend of these  
13 tumors, therefore it's an animal carcinogen and a  
14 potential human carcinogen.

15 Q. (BY MR. HOLLINGSWORTH) So you disagree  
16 with EPA's report by the Office of Pesticide Programs  
17 in 2016?

18 MS. WAGSTAFF: Objection, asked and  
19 answered.

20 A. They -- they are -- you're asking me to  
21 compare apples and oranges.

22 Q. (BY MR. HOLLINGSWORTH) Okay.

23 A. They did -- they did a risk assessment,  
24 I did a hazard assessment. For the purpose of my  
25 hazard assessment, I don't agree with the way they

1 threw out that particular study.

2 Q. (BY MR. HOLLINGSWORTH) Okay. Now, again  
3 in this study you refer to malignant lymphoma. Do you  
4 have that in mind?

5 A. Yes.

6 Q. Have you read Jerry Ward's publication  
7 on the incidence of malignant lymphoma in aging mice?

8 A. I don't think I've read that particular  
9 paper, no.

10 Q. Okay. How would you rate, in -- given  
11 your experience, your vast experience, how would you  
12 rate the incidence of malignant or the ranking of  
13 malignant lymphoma in mice from most common to least  
14 common lesion or tumor?

15 MS. WAGSTAFF: Object to form.

16 Q. (BY MR. HOLLINGSWORTH) In other words,  
17 would you say it is the first, most common tumor seen  
18 in mice, it meaning malignant lymphoma or the second  
19 or third or the 15th or what?

20 A. Well, there, again, it depends on what  
21 strain of mouse you're talking about.

22 Q. We're talking about CD-1.

23 A. And male or female.

24 Q. Talking about CD-1 males and females.

25 A. Males and females?

1 Q. Yes.

2 A. I know that malignant lymphomas are  
3 found in -- let me rephrase that. I know that  
4 spontaneous incidence of malignant lymphomas in CD-1  
5 mice is -- is relatively high, but I don't know how it  
6 ranks amongst all of the various different types of  
7 spontaneous tumors seen in that strain of mouse. I'd  
8 have to go look it up, but I know -- I know it's one  
9 of the high -- highest ones, but I don't know how it  
10 ranks compared to the rest of the spontaneous tumors  
11 seen in those animals.

12 But just because something occurs  
13 because of a spontaneous rate is no reason to discount  
14 it from being an effect in a carcinogenicity study.

15 Q. (BY MR. HOLLINGSWORTH) Well, would -- if  
16 you were doing a risk assessment instead of a hazard  
17 assessment, would you have reason to discount the high  
18 level of -- the extremely high background incidence of  
19 malignant lymphoma in mice?

20 MS. WAGSTAFF: Object to form. It's  
21 outside the scope of his expert testimony.

22 A. I haven't done a risk assessment on  
23 that, so I can't comment on that until I've done one.

24 Q. (BY MR. HOLLINGSWORTH) Is there  
25 something in the hazard assessment protocol that

1 allows you to discount a high background incidence of  
2 tumors that occurs spontaneously in mice like  
3 malignant lymphomas?

4 A. Well, if -- if you will -- if you look  
5 in my report, I think there was a -- a study in rats  
6 where there was a -- an increase in the incidence  
7 of -- is it liver tumors? I think it was liver tumors  
8 in rats. That was -- that was a positive increase in  
9 the incidence of liver tumors in rats, but I  
10 discounted it because of the high background -- high  
11 historical incidence.

12 So I have discounted studies because of  
13 high historical rates, but for this particular case,  
14 and for this mouse study, I didn't think it was  
15 appropriate to do.

16 Q. Why?

17 A. Because the -- the -- the incidence --  
18 are you talking about the lymphomas?

19 Q. Yes.

20 A. Because first of all, for the malignant  
21 lymphomas, there was a statistically significant  
22 increase in the incidence of malignant lymphomas in  
23 the high dose animals compared to control. So that  
24 was a statistically significant increase in the high  
25 dose animals. Then in addition to that, there was

1 also a statistically significant increase for trend  
2 for formation of this tumor in malignant lymphomas in  
3 the mice in this study.

4 So because you had a significant  
5 increase in the incidence in the high dose and you  
6 also had a significant increase in the trend for the  
7 formation of this tumor in the animals, I felt it  
8 wasn't appropriate to discount this particular study.

9 I mean, I'll grant you that zero out of  
10 51 in the controls is a low -- is -- is -- is low for  
11 this -- for CD-1 mouse in the study, but that's what  
12 the concurrent controls are. They found no malignant  
13 lymphomas in the controls, so, therefore, this is --  
14 this is a very -- in my mind, this is a very strong  
15 finding and I really am surprised to the point of  
16 shock that the EPA would throw out something like  
17 that, so, but -- enough said.

18 Q. Okay.

19 A. And just -- I'm sorry. I don't mean to  
20 interrupt, but just for your reference, that study  
21 that I was referring to or I threw out -- where I  
22 discounted the study because of the incidence was  
23 within the historical rate, it is the Bramer  
24 (phonetic) study in rats. 2001. This was in the  
25 Wistar rat. It's the Greim study seven.

1 And they had a significantly -- a  
2 significant increase in -- in the liver tumors in this  
3 one, but the -- it was within the historical control,  
4 so I discounted it.

5 Q. Well, your -- are you aware that the  
6 German or EFSA, European regulators, show an incidence  
7 of lymphoma ranging from zero to 32 on a spontaneous  
8 basis, that is 32 percent at the high, in CD-1 mice?

9 A. I'd have to look at the report to  
10 refresh my memory on that, but I'm -- okay.

11 Q. They found a study that had zero in the  
12 controls in Europe, too.

13 A. Okay.

14 Q. And they -- but they saw a range of zero  
15 to 32.

16 A. I'm sorry. I didn't mean to interrupt.

17 Q. No, go ahead.

18 A. In this particular study, you're talking  
19 about?

20 Q. No, I'm talking about when they did  
21 their -- the European assessment of the IARC report to  
22 which you responded. They made the observation that  
23 their own historical control from nine studies  
24 involving the CD-1 mice, all from the same period by  
25 sister laboratories, included a range of malignant

<p style="text-align: right;">Page 150</p> <p>1 lymphomas from zero to 32, which tells me that it's 2 not so surprising that you might have a study out 3 there, an outlier, that has zero lymphomas in one of 4 the either control or treatment groups. 5 A. Okay. 6 MS. WAGSTAFF: Wait. Objection, I move 7 to strike that testimony from counsel about what he 8 finds surprising and doesn't find surprising. 9 MR. HOLLINGSWORTH: Well, that's in 10 reference to the witness's answer to a prior question 11 indicating that he was shocked at what EPA did with 12 respect to this data. 13 MS. WAGSTAFF: But, Dr. Jameson is a 14 witness in this case and Joe Hollingsworth is not. So 15 what Joe Hollingsworth finds is surprising or not is 16 really irrelevant. And what Dr. Jameson finds is 17 surprising is relevant. So I move to strike your 18 testimony, Counsel. 19 Q. (BY MR. HOLLINGSWORTH) Can you answer my 20 question? 21 MS. WAGSTAFF: I'm not sure there's a 22 question pending. 23 A. Yeah, could you repeat it, please? 24 Q. (BY MR. HOLLINGSWORTH) Well, my question 25 is that the fact that the European regulators found a</p>	<p style="text-align: right;">Page 151</p> <p>1 background incidence and a range involving lymphoma in 2 CD-1 mice to be zero to 32 percent in 2016 means that 3 your statement that you're shocked that EPA would not 4 take into consideration a zero finding in concurrent 5 controls is really not so shocking? 6 MS. WAGSTAFF: Objection to form. 7 Background incidence does not equal background range, 8 so object to the form of the question. 9 A. What I was -- what I was trying to 10 convey my surprise, rather than shock, I guess, is the 11 fact that not only was there a low -- a low incidence 12 in the controls, but the fact that my -- my surprise 13 is the fact that you got a positive -- a statistically 14 significant positive response in the high dose 15 animals. 16 There was a high -- there was a 17 statistically significant increase in the tumors, in 18 malignant lymphomas in the high dose animals in this 19 study, so that's a positive response. And you have a 20 positive trend in the formation of these tumors in the 21 mice. So two positive findings in this study in male 22 mice for malignant lymphomas, and I'm just surprised 23 the EPA would throw that out because you have two 24 positive responses for malignant lymphomas in the male 25 mice. Positive -- significant increase in the high</p>
<p style="text-align: right;">Page 152</p> <p>1 dose animals and a significant increase in the trend 2 for the formation of this tumor in the animals. 3 That's what I was saying. 4 Q. (BY MR. HOLLINGSWORTH) Well, you know 5 that EPA, in addition to what you did statistically, 6 did an adjustment for multiple comparisons, right, you 7 read about that? 8 A. Uh-huh. 9 Q. And when they adjusted that finding for 10 multiple comparisons in the high dose animal, the 11 increased incidence in the high dose animal was not 12 statistically significant, and that was the basis of 13 what EPA did, and you knew that, didn't you? 14 MS. WAGSTAFF: Objection, argumentative. 15 A. I guess I knew that. 16 Q. (BY MR. HOLLINGSWORTH) Yeah. You 17 didn't report that to the judge in this case, though? 18 A. No. Again, EPA did their risk 19 assessment, and I was asked to do a hazard assessment 20 and to give my opinion and that's what's in my report. 21 Q. Do you know how to adjust for multiple 22 comparisons when you're doing studies involving long- 23 term bioassays? 24 A. Do I know how -- I'm sorry, could you 25 repeat?</p>	<p style="text-align: right;">Page 153</p> <p>1 Q. Do you know how to do an adjustment for 2 multiple comparisons when you're doing a statistical 3 significance analysis involving long-term bioassays? 4 MS. WAGSTAFF: Object to form. 5 A. I couldn't do it for you right here and 6 now, no, but given the data, I could -- I could find a 7 program to calculate that. 8 Q. (BY MR. HOLLINGSWORTH) Were you aware 9 that the German regulators and the European regulators 10 at EFSA reported a range of malignant lymphomas in 11 female CD-1 mouse of between 4 and 32 percent? 12 A. I have to look at the -- their report to 13 refresh my memory, but that sounds possible, yes. 14 Q. The fact that they -- the European 15 regulators found a range for malignant lymphomas in 16 control animals, that is, control CD-1 mice, in 17 females of between 4 and 32 percent would not surprise 18 you based on your overall experience in the field, 19 right? 20 MS. WAGSTAFF: Objection, outside the 21 scope of Dr. Jameson's testimony. He's not a 22 statistician, he's testifying as a toxicologist. 23 A. Based on -- based on my experience, I 24 think I've seen studies that have fairly high 25 incidences in their controls. I don't know if it is</p>

1 up to 32 percent, but I -- I could accept that level.  
 2 Q. (BY MR. HOLLINGSWORTH) You're referring  
 3 to incidence of malignant lymphoma in mice?  
 4 A. Lymphoma in mice.  
 5 Q. Okay. Is it fair to state that there's  
 6 a high variability of lymphoma, spontaneous lymphoma  
 7 in CD-1 mice generally?  
 8 A. Well, based on the range that you gave  
 9 me there, I would -- I would think that that's  
 10 possible.  
 11 Q. EFSA considered this -- that is the  
 12 European regulators, the European Food Safety Agent  
 13 considered this same study you're opining about as  
 14 showing no carcinogenic effect, true?  
 15 MS. WAGSTAFF: Objection, misstates the  
 16 report.  
 17 A. I think for the purpose of their risk  
 18 assessment, that's what they concluded, but, again,  
 19 they were doing risk assessment and I was -- I was  
 20 asked to do, and I did a hazard assessment for  
 21 glyphosate, and so it's apples and oranges.  
 22 Q. (BY MR. HOLLINGSWORTH) Well, EFSA's  
 23 statement that there was no carcinogenic effect comes  
 24 from its conclusion on pesticide peer review, right?  
 25 MS. WAGSTAFF: Object to form.

1 know that I had a copy of their final report, to be  
 2 honest. I know I did have tumor tables to look at and  
 3 I looked at the tumor tables, and then I went to the  
 4 Greim paper and compared the information in there and  
 5 got a lot of information from the Greim paper.  
 6 Q. (BY MR. HOLLINGSWORTH) Did you -- are  
 7 you sure you read anything other than Greim?  
 8 A. For the Kumar?  
 9 Q. Yeah.  
 10 A. Yeah, I had some of the -- some of the  
 11 tumor tables from Kumar.  
 12 Q. Okay. Did you read the pathology  
 13 report?  
 14 A. I don't believe I had access to the  
 15 pathology report.  
 16 Q. Did you read the author's -- I shouldn't  
 17 say author's -- the veterinarian pathologists'  
 18 conclusions about the Feinchemie study?  
 19 A. Well, I don't have the pathology report,  
 20 so . . .  
 21 Q. Okay. Did you know that the authors  
 22 concluded that there were no compound-related  
 23 neoplastic lesions in this study on mice, Swiss albino  
 24 mice?  
 25 A. Like I said, I didn't have -- I didn't

1 A. But they were doing their risk  
 2 assessment. My understanding is they were performing  
 3 a risk assessment.  
 4 Q. (BY MR. HOLLINGSWORTH) Okay. The fifth  
 5 mouse study is the Swiss albino mice study that I said  
 6 I was going to ask you about, Dr. Jameson. Do you  
 7 remember that?  
 8 A. Yes, sir.  
 9 Q. This was a company sponsored study by a  
 10 company called Feinchemie, F-e-i-n-c-h-e-m-i-e in  
 11 2001?  
 12 A. Uh-huh.  
 13 Q. And I think the lead or one of the lead  
 14 investigators was Kumar, right?  
 15 A. Yes.  
 16 Q. Do you have that study in mind?  
 17 A. Yes, sir.  
 18 Q. Have you read the conclusions of the  
 19 authors of that study, I mean, the investigators of  
 20 that study?  
 21 MS. WAGSTAFF: Object to form.  
 22 A. As I recall, I think this is -- I can't  
 23 remember if I did or not. This is one of the studies  
 24 where there wasn't a whole lot of original data from  
 25 the lab available to me for -- to review. So I don't

1 have excerpts -- I didn't have the study reports, so  
 2 I -- I did not read that -- could not read that.  
 3 Q. Did you ask plaintiffs' counsel to give  
 4 you a copy of the study report?  
 5 A. I -- like I said before, I asked the  
 6 plaintiffs' counsel to provide me with all the  
 7 information that they had available to them and that  
 8 is -- I'm sure that's what they did. So any of the  
 9 information that was made available to me, I reviewed.  
 10 Q. So you didn't read the full data from  
 11 this study by Kumar, Dr. Jameson?  
 12 MS. WAGSTAFF: Object to form.  
 13 A. I said I had the tumor tables that I  
 14 could refer to and the Greim -- and the Greim paper  
 15 that had a description of the -- of the study and the  
 16 details of the study in that.  
 17 Q. (BY MR. HOLLINGSWORTH) Does your report  
 18 refer to anything more than just Greim?  
 19 A. It refers to the --  
 20 MS. WAGSTAFF: Object to form.  
 21 A. I think Greim is the only -- only  
 22 reference I have for this.  
 23 Q. (BY MR. HOLLINGSWORTH) And you're  
 24 looking at page 24, right?  
 25 A. Wait a minute. Hold on.

Page 158

1 Q. Greim is the only source you refer to;  
 2 isn't that right, Doctor?  
 3 A. No. I also refer to some Tier II  
 4 summaries from the Greim --  
 5 Q. Where is that, sir?  
 6 A. Okay. In the -- on page 24.  
 7 Q. Okay.  
 8 A. In about the fifth or sixth line down  
 9 talking about the --  
 10 Q. Okay.  
 11 A. -- incidence as well as above the  
 12 historical rate, and that particular reference is 87,  
 13 which is the Tier II summaries for glyphosate  
 14 carcinogenicity studies from Greim. And then a little  
 15 bit further down, I think I say it is referring to the  
 16 claim of a viral infection in the colony of these  
 17 animals. I refer to the Kumar summary table 20 and  
 18 21.  
 19 Q. Okay. The Kumar summary table that you  
 20 just mentioned, who gave you that?  
 21 A. That had to be provided to me by  
 22 counsel.  
 23 Q. Okay. But counsel didn't provide you  
 24 with the pathology report that Dr. Kumar prepared?  
 25 MS. WAGSTAFF: Object to form.

Page 160

1 THE VIDEOGRAPHER: We are back on the  
 2 record. The time is 2:06 p.m.  
 3 Q. (BY MR. HOLLINGSWORTH) Okay.  
 4 Dr. Jameson, we were talking before lunch about the  
 5 Kumar study, do you recall that?  
 6 A. Yes, sir.  
 7 Q. That's the 2001 mouse study and it's the  
 8 fifth of five mouse studies that you considered?  
 9 A. Uh-huh.  
 10 Q. And the sponsor was Feinchemie Schwebda,  
 11 who I hope someone spelled for Tracy, because I can't  
 12 spell that. But this was the study -- this was the  
 13 study on Swiss albino mice; is that right?  
 14 A. Yes.  
 15 Q. And I had already asked you about the  
 16 study investigator's conclusion in that study. Excuse  
 17 me.  
 18 MS. WAGSTAFF: Object to form.  
 19 Q. (BY MR. HOLLINGSWORTH) And I was going  
 20 to ask you if you knew whether this study was  
 21 submitted to EPA, U.S. EPA?  
 22 A. Yes, it was.  
 23 Q. And are you aware that EPA did not  
 24 evaluate the study because of the confounding factor  
 25 of the presence of the viral infection and -- and

Page 159

1 A. I do not -- no, I don't believe they  
 2 did.  
 3 Q. (BY MR. HOLLINGSWORTH) Okay. Now, have  
 4 you read recently the reevaluation of the Swiss albino  
 5 mouse study?  
 6 A. I'm not -- I don't know what you're  
 7 referring to.  
 8 Q. I'm referring to a report by -- I think  
 9 his name is Dr. Klaus Weber, W-e-b-e-r. It's called  
 10 reanalysis of the Kumar study and it's dated  
 11 January 23, 2017.  
 12 A. I'm not familiar with that, no.  
 13 Q. Okay.  
 14 MS. WAGSTAFF: Counsel, it's 1 o'clock.  
 15 What do you want to do?  
 16 MR. HOLLINGSWORTH: Okay.  
 17 MS. WAGSTAFF: I mean, if you want to  
 18 finish the Kumar study, if you have a few more  
 19 minutes, or do you want to break?  
 20 MR. HOLLINGSWORTH: Doesn't matter to  
 21 me. We can break now.  
 22 MS. WAGSTAFF: Okay.  
 23 THE VIDEOGRAPHER: Going off the record.  
 24 The time is 1:00 p.m.  
 25 (Recess taken, 1:00 p.m. to 2:06 p.m.)

Page 161

1 other infections?  
 2 MS. WAGSTAFF: Objection.  
 3 Q. (BY MR. HOLLINGSWORTH) In the -- in the  
 4 study animals.  
 5 A. I -- I read the EPA report that said  
 6 that based on information they received, and I think  
 7 it was based on information that they had been  
 8 provided in the Greim report that because they assumed  
 9 that there was a viral infection in the colony, that  
 10 they thought the study was invalid, however, I think  
 11 I've indicated in my report that in my review of the  
 12 particular study, it's not clear whether or not a  
 13 viral component may have contributed to the incident  
 14 value reported in the lower survival seen in the high  
 15 dose in the study.  
 16 I had access to an internal Monsanto  
 17 e-mail, among the authors of Greim, that would  
 18 indicate there was no viral infection in the mouse  
 19 colony during the study.  
 20 Further, if you look at the Greim  
 21 publication, Greim reports that this study is GLP and  
 22 OECD compliant, so I thought this was a very  
 23 acceptable study to consider, so that's why I included  
 24 it in my evaluation.  
 25 Q. Now, you were reading from a document

Page 162

1 that you have in your hands in front of you. What is  
 2 that?  
 3 A. This is my report.  
 4 Q. Okay. In fact, you agree that there's a  
 5 possibility of contamination of this or confounding of  
 6 the results of this study by viral infection; isn't  
 7 that right?  
 8 A. From the materials that I had to review  
 9 this study and the documents that I reviewed from this  
 10 study, I have no reason to think that there was a  
 11 viral infection in the colony and that -- in my  
 12 opinion, this is a -- is a sufficient study and not  
 13 compromised in any way by a viral infection.  
 14 Q. Okay. So you don't agree with me that  
 15 you agree that there's a possibility of a viral  
 16 infection that confounded this study?  
 17 A. I'm sorry, you're going to have to make  
 18 that question a little more clearer. I think I heard  
 19 a couple of double negatives in there or something.  
 20 Q. Okay. So you -- you -- you've stated  
 21 that you did not agree in your expert report that  
 22 there was a possibility of confounding of this report  
 23 by viral infections?  
 24 A. Well, in any given situation, there's  
 25 always a possibility of something happening.

Page 164

1 MS. WAGSTAFF: I will object.  
 2 Q. (BY MR. HOLLINGSWORTH) -- in many  
 3 strains of mice?  
 4 MS. WAGSTAFF: Sorry. I will object to  
 5 the counsel is reading from a 300-page document and if  
 6 you'd like Dr. Jameson to opine, I would request the  
 7 document be given to him.  
 8 Q. (BY MR. HOLLINGSWORTH) Can you answer my  
 9 question?  
 10 A. I mean, you're reading that from an EPA  
 11 document, but --  
 12 Q. Yeah.  
 13 A. I'd really like to see in what context  
 14 that statement is being made before I comment on it.  
 15 Q. Okay. You know that EPA excluded from  
 16 consideration this Kumar albino mice study due to the  
 17 presence of a viral infection in the colony?  
 18 MS. WAGSTAFF: Object to form.  
 19 A. What I can state is in their report,  
 20 that's what they said -- that's the reason they gave  
 21 for not evaluating it. In my evaluation of the study,  
 22 I found no evidence that there was a viral infection  
 23 in this particular colony, and this was based on  
 24 documents that I saw coming from the principal  
 25 investigator at the laboratory who said he was not --

Page 163

1 Q. But that's not what I asked you.  
 2 A. Based on my evaluation of the  
 3 information I had that from the -- from the data that  
 4 was obtained from the testing laboratory itself in the  
 5 Monsanto document that I looked at, that was made  
 6 available to me, there was no indication of a viral  
 7 infection in this particular colony.  
 8 In addition, Greim published in his  
 9 paper that he felt that the study was GLP and OECD  
 10 compliant. So from that standpoint, I felt this  
 11 was -- this study was sufficient to consider for my  
 12 evaluation and it was not compromised by a viral  
 13 infection.  
 14 Q. Well, the Office of Pesticide Programs  
 15 disagrees with you, right?  
 16 A. In their report, they discounted it and  
 17 it was mainly because of a statement in -- I believe a  
 18 statement in the Greim publication that implied that  
 19 there may be a viral infection, but my evaluation of  
 20 the available information does not point to a viral  
 21 infection at all, so I feel it's an adequate study to  
 22 consider.  
 23 Q. Do you agree with the statement that  
 24 Murine leukemia viruses are also a common cause of  
 25 lymphoma --

Page 165

1 he did not feel there was a viral infection in the  
 2 colony. So I thought there was no reason to discount  
 3 this study, so I included it in my evaluation.  
 4 Q. (BY MR. HOLLINGSWORTH) Did you read the  
 5 individual animal reports from the pathology report?  
 6 A. I did not have the pathology report for  
 7 this study, but I did have animal tumor tables.  
 8 Q. Did you ask anyone for the pathology  
 9 report?  
 10 A. I asked for all of the -- as much -- for  
 11 all the information that plaintiffs' counsel had  
 12 available for this particular study, and I'm confident  
 13 they provided me with all the information they had.  
 14 Q. Have you seen a reference to the  
 15 existence of skin lesions and bacterial infections in  
 16 individual animals in this study?  
 17 A. I don't recall seeing that, no.  
 18 Q. You'd agree that if there was a viral  
 19 infection or some kind of other infection in this  
 20 colony, that it might confound the results of the --  
 21 and the statistical analysis of this study, true?  
 22 A. My evaluation of all the documents I  
 23 could find relating to the study indicated that there  
 24 was no viral infection in the colony, so in my  
 25 opinion, and my past experience in evaluating animal

Page 166

1 bioassays, I saw no reason to discount the study.  
 2 There was no evidence that there was a viral  
 3 infection, so I think it's perfectly -- this is a good  
 4 study and that's why I considered it in my evaluation.  
 5 Q. Have you read what the U.S. EPA's Office  
 6 of Pesticide Program says about this study?  
 7 A. The document you have in your hand, I  
 8 have read, yes.  
 9 Q. Okay. Have you read what EFSA said  
 10 about this study, the European regulatory agency?  
 11 A. I remember reading the EFSA report. I  
 12 can't recall exactly what it said. I'd have to look  
 13 at the report to -- to tell you what -- what exactly  
 14 is said about that study.  
 15 Q. Do you recall that EFSA said that this  
 16 animal study by Kumar was not acceptable due to viral  
 17 infections that could influence the survival as well  
 18 as tumor incidence, especially lymphomas?  
 19 A. I -- I -- as I said, I -- I don't  
 20 absolute -- I'm not absolutely certain, but that  
 21 sounds like what I remember reading from the EFSA  
 22 study. I -- you know, I have no idea other than  
 23 perhaps what they read in the Greim report for their  
 24 rationale for discounting the study. My evaluation of  
 25 the data and the documents available to me from this

Page 168

1 A. Yes.  
 2 MS. WAGSTAFF: Just answer the question  
 3 he asks.  
 4 THE DEPONENT: Sorry.  
 5 Q. (BY MR. HOLLINGSWORTH) Is it fair to  
 6 state that the higher incidence of lymphoma that  
 7 other -- that other authors have seen from the effect  
 8 of virus in a colony is due to the effect of the virus  
 9 on the animal's immune system, which leads to more  
 10 lymphoma?  
 11 A. Sorry. Would you repeat that? Sorry.  
 12 Q. Would you agree that the background  
 13 literature states that the higher incidence of  
 14 lymphoma that is seen in experimental animal colonies  
 15 that have been infected by viral infections is due to  
 16 the adverse effect on the animal's immune system?  
 17 MS. WAGSTAFF: Object to form.  
 18 A. I -- I don't -- the question is not  
 19 clear to me, so I -- I can't comment. I don't know --  
 20 Q. (BY MR. HOLLINGSWORTH) What's unclear  
 21 about the question?  
 22 A. You're saying about something -- did you  
 23 mention something about historical data or control  
 24 incidence? I'm sorry.  
 25 Q. No, I was just saying the background

Page 167

1 report shows that there was no viral infection in the  
 2 colony. The principal investigator of the study said  
 3 in a memo or a document that I read that in his  
 4 opinion, his colony had no viral infection, and so I  
 5 saw no reason not to accept this study. It's a  
 6 perfectly acceptable study.  
 7 Q. Aren't there publications in the general  
 8 background literature on long-term animal bioassays  
 9 and their interpretation that state that the incidence  
 10 of lymphoma due to the effect of viral contamination  
 11 of a colony can increase the amount of malignant  
 12 lymphoma found in the animals?  
 13 A. There is publications to that effect.  
 14 In fact, in my experience, my long experience with the  
 15 National Toxicology Program and its animal bioassay  
 16 studies, we have conducted studies where -- where  
 17 really -- we could not ultimately evaluate because of  
 18 infections in the colony, because of poor animal  
 19 husbandry. It happens. It happens not frequently,  
 20 but it does happen, and it's just part of doing  
 21 toxicology, part of doing toxicology studies, so there  
 22 are studies that have been done that are compromised  
 23 because of different viral infections and it's been  
 24 documented in the literature. Sorry.  
 25 Q. Right. Thanks. Are you done?

Page 169

1 publicly available information.  
 2 A. Oh, the information that's available?  
 3 Q. Yes.  
 4 A. Okay. Would indicate? I'm sorry.  
 5 Q. Would indicate that where virus has  
 6 infected an animal colony, the increased findings of  
 7 lymphoma, malignant lymphomas in those colonies is  
 8 caused by the effect on the animal's immune systems?  
 9 MS. WAGSTAFF: Object to the form.  
 10 A. That could be one of the effects.  
 11 Q. (BY MR. HOLLINGSWORTH) Okay. In the  
 12 mouse, the malignant lymphoma findings are mediated by  
 13 the immune system of the mouse in part, aren't they?  
 14 A. It plays a role in the formation of the  
 15 lymphoma.  
 16 Q. Did the mouse have the same kind of  
 17 immune system, the CD-1 mice or the Swiss albino  
 18 mouse, as humans?  
 19 A. I would not say yes to that, no.  
 20 Q. Okay. So you accepted this study as  
 21 proper and appropriate for evaluation even though EFSA  
 22 and EPA did not, right?  
 23 A. That's correct.  
 24 Q. And you state that the formation of  
 25 malignant lymphoma in male and female mice occurred in

Page 170

1 the Kumar study, right?

2 A. Yes.

3 Q. Okay. And you say that there was an

4 increased incidence of renal cell adenomas in male

5 mice in this study, correct?

6 A. That's correct.

7 Q. Are you aware of any literature that

8 says that renal cell adenomas are affected by --

9 by -- by the infection of a mouse colony by viruses?

10 A. Sitting here today, I don't -- I don't

11 recall any, but that's not to say there isn't any.

12 Q. You didn't consider the historical

13 control rate in both males and females in Swiss albino

14 mice, did you?

15 A. For this particular study, I didn't

16 indicate that, no, I -- I did not.

17 Q. Were you aware that the range of

18 malignant lymphoma observed by the same laboratory

19 during the same time frame was 6 to 30 percent for

20 males?

21 A. I don't remember that, no.

22 Q. Do you recall that the range of

23 malignant lymphoma observed by this same laboratory

24 during the same time frame was 14 to 58 percent for

25 females?

Page 172

1 Q. (BY MR. HOLLINGSWORTH) You still haven't

2 looked at his amended report?

3 A. This is from his expert report?

4 Q. Yes.

5 MS. WAGSTAFF: Objection.

6 A. To be honest with you, I skimmed through

7 it, but I didn't read it in detail.

8 Q. (BY MR. HOLLINGSWORTH) Okay. It's

9 always good to be honest.

10 MS. WAGSTAFF: Objection, argumentative.

11 Have you not been honest today, Dr. Jameson?

12 THE DEPONENT: I hope I've been.

13 MR. HOLLINGSWORTH: You can ask him that

14 when you have your chance.

15 MS. WAGSTAFF: You just suggested he

16 hasn't been honest.

17 MR. HOLLINGSWORTH: He said, well, "to

18 be honest with you." I thought that indicated to me

19 he wasn't being honest with me previously.

20 MS. WAGSTAFF: Are you kidding?

21 MR. HOLLINGSWORTH: That's what I

22 thought.

23 MS. WAGSTAFF: I'm glad I corrected the

24 record.

25 THE DEPONENT: I've got to remember not

Page 171

1 A. No, my -- the data that I had, as I

2 indicated in my report, that the incidence of

3 malignant lymphoma in the high dose male was double

4 the historic rate reported to be 18 percent from males

5 and for high dose female mice was well above the

6 historical rate of 41 percent, and the reference I

7 used for that was the Tier II summaries for glyphosate

8 carcinogenicity studies from Greim, 2015.

9 Q. That's Greim, Greim at page 201?

10 A. I didn't put the page number.

11 Q. Doesn't Greim state that the -- that the

12 malignant lymphoma observed by this same laboratory

13 involving other studies in the same Swiss albino mice

14 was between 6 and 30 percent for males?

15 A. This was taken from the Greim Tier II

16 tables that I -- that I had access to. That's the

17 reference that I used. I wasn't using the Greim paper

18 itself.

19 Q. Okay. You're aware that Dr. Portier

20 found no statistically significant trend from this

21 data involving malignant lymphoma, aren't you?

22 MS. WAGSTAFF: Objection, misstates

23 testimony.

24 A. I wasn't -- I'm not familiar

25 with -- with what Chris reported.

Page 173

1 to editorialize, I guess.

2 MS. WAGSTAFF: Have you been honest

3 today?

4 THE DEPONENT: I have been honest to the

5 best of my ability.

6 MS. WAGSTAFF: Okay.

7 Q. (BY MR. HOLLINGSWORTH) So has your

8 disagreement with EPA and EFSA about this Swiss albino

9 mouse study by Kumar and the conclusions you've

10 reached been published and peer reviewed anywhere?

11 MS. WAGSTAFF: Object to form.

12 A. They've only been published in my

13 report, my expert report, that I submitted for this

14 litigation.

15 Q. (BY MR. HOLLINGSWORTH) Did you talk to

16 Dr. Portier about this Kumar study?

17 A. No, I did not.

18 Q. Okay. Okay. Sir, you -- you also

19 reviewed and include in your report as a basis for

20 your opinion the Lankas, L-a-n-k-a-s, Dr. Lankas' 1981

21 rat study.

22 A. Okay.

23 Q. And you concluded that the incidences of

24 testicular interstitial cell tumors was within

25 the -- I'm sorry. Let me -- let me -- let me rephrase

Page 174

1 that.

2 Did you read the authors of the Lankas

3 study or the investigator's report of what their

4 conclusions were from this study? Do you understand my

5 question?

6 A. Yes, I'm just trying to find where I am.

7 Bear with me. Sorry. So you asked if I could -- if

8 I read the report?

9 Q. Yes. We're on 1981 Sprague-Dawley rat

10 study that was sponsored by Monsanto.

11 A. For this particular report, I think I

12 did have the report to review -- to to read.

13 Q. Did you read the pathology report within

14 the study?

15 A. If it was in the report that I had, I

16 did read it.

17 Q. The report was four or 5,000 pages?

18 A. Four or 5,000?

19 Q. Yeah. The report by the laboratory.

20 A. I know it was long, but the report --

21 the document I had wasn't that long. It was probably

22 about six or 700 pages.

23 Q. Who gave you the document that you read?

24 A. It was provided by counsel.

25 Q. Okay. Were you familiar with that study

Page 176

1 you looking at, sir?

2 A. This is -- okay. I'm looking on page

3 25.

4 Q. Okay.

5 A. Okay. What I'm reading -- at the top of

6 page 25, I state in my report, that the incidence of

7 interstitial cell tumors in the testes in the high

8 dose animals in this study is almost twice that seen

9 in the range of tumors, 3.4 percent to 6.7 percent in

10 control animals, historical controls in five

11 contemporary studies, and I reference the Greim Tier

12 II tables.

13 Q. You didn't answer my question. My

14 question was whether you were aware of the conclusion

15 of the original investigators of this study that the

16 interstitial cell tumors of the testes, which you were

17 talking about were, quote, within the normal biologic

18 variations for tumors at this site in this strain of

19 rat, unquote?

20 MS. WAGSTAFF: Again, I would request

21 that you give the document to Dr. Jameson if you're

22 quoting from something so he can see the context of

23 the document. And without that, it's hard to opine.

24 A. I'd like to see the report, but I don't

25 remember seeing -- reading that.

Page 175

1 before you read it in preparation for this litigation?

2 A. I'd have to go back and check. I

3 believe -- I believe this was one of the studies that

4 was reviewed as part of the IARC monographs. But that

5 review was based on the EPA reports for their review

6 of that study.

7 Q. But your review was based on a

8 different -- different dataset than what IARC had?

9 A. I had more data to look at than what was

10 available. As I indicated for the IARC review, as I

11 recall, it was EPA documents that were made available

12 to -- to the IARC that we used in our review.

13 Q. Since you read the report, you're aware

14 that the investigators, including Dr. Lankas and

15 others, wrote a conclusion which was that the

16 interstitial cell tumors, that you refer to in your

17 expert report, were within the normal biological

18 variation observed for tumors at this site in this

19 strain of rat, and, therefore, they said that the

20 testicular tumors were not compound related, true?

21 MS. WAGSTAFF: Objection to counsel

22 testifying again.

23 A. Oops, looking at the wrong thing.

24 Sorry. Okay. In my report --

25 Q. (BY MR. HOLLINGSWORTH) What page are

Page 177

1 Q. (BY MR. HOLLINGSWORTH) You don't

2 remember reading that the authors of the report looked

3 at the interstitial testicular tumors in particular

4 and said that they were within the normal biologic

5 variation observed for tumors at this site in this

6 strain of rat?

7 MS. WAGSTAFF: Hang on. We all know

8 that everyone has looked at dozens and dozens, if not

9 hundreds, of reports. You mentioned earlier this one

10 was 4,000 pages. You have something in your hand that

11 you're reading from. Why don't you just let

12 Dr. Jameson look at it.

13 MR. HOLLINGSWORTH: I would just like to

14 know if he can answer my question whether if he was

15 aware of that original conclusion by the authors or

16 not when he started preparing his opinion in this

17 case.

18 MS. WAGSTAFF: This is not a memory

19 test.

20 A. I -- I -- like I said, I don't recall

21 reading that. In looking at the documents I had.

22 Q. (BY MR. HOLLINGSWORTH) Do you recall

23 that the authors, the actual investigators of this

24 report from 1981, the veterinary pathologist who did

25 the report said that the gross and microscopic changes

Page 178

1 that otherwise occurred besides the interstitial cell  
 2 tumors occurred sporadically in the control and/or  
 3 treated rats and were considered unrelated to  
 4 administration of glyphosate?  
 5 MS. WAGSTAFF: Same objection.  
 6 A. I remember reading something to that  
 7 effect.  
 8 Q. (BY MR. HOLLINGSWORTH) Did you tell the  
 9 judge about the conclusions of the original  
 10 investigators of this report in 1981 that you're --  
 11 opining about?  
 12 MS. WAGSTAFF: Objection, he wasn't  
 13 retained to tell the judge about other people's  
 14 conclusions.  
 15 A. I -- I -- as I've indicated in previous  
 16 questions about this same issue, I was asked to give  
 17 my opinion of the data and do a hazard identification  
 18 exercise on the data for the exposure of glyphosate  
 19 and glyphosate formulations and its association with  
 20 non-Hodgkin's lymphoma.  
 21 As part of that evaluation, I looked at  
 22 these animal studies. So what I did was gave my  
 23 opinion as to what the adequacy of the studies and the  
 24 results of the studies, so what I was asked to do was  
 25 give my opinion, and that's what I did in this report.

Page 180

1 they are asked to do is to be given a dataset and gave  
 2 their opinion of what the dataset says. That's what I  
 3 was retained to do. That's what I did when I reviewed  
 4 these studies and that's what I wrote in my report was  
 5 my opinion.  
 6 Q. (BY MR. HOLLINGSWORTH) Did you know that  
 7 EPA had reviewed this study?  
 8 A. Yes, sir.  
 9 Q. And did you know that EPA considered it  
 10 to not show a carcinogenic effect in any of the  
 11 treated groups of animals?  
 12 MS. WAGSTAFF: Object to form.  
 13 A. Again, the EPA did their risk assessment  
 14 of this particular -- of glyphosate from this  
 15 particular study, and based on that their criteria for  
 16 risk assessments, evidently, they decided that these  
 17 interstitial cell tumors were -- were not relevant to  
 18 their exercise of doing a risk assessment.  
 19 I am doing or I did a hazard  
 20 identification. For the purpose of the hazard  
 21 identification, it's appropriate to consider these  
 22 tumors, these tumors caused -- the glyphosate caused  
 23 the formation of these tumors in the rats, and, so,  
 24 therefore, it's an animal carcinogen and a potential  
 25 human carcinogen.

Page 179

1 Q. (BY MR. HOLLINGSWORTH) You had in -- in  
 2 this case you had the entire report, you said, you had  
 3 seven or 800 pages?  
 4 A. I had a large document to look at, yes.  
 5 Q. Did you look at what the authors'  
 6 conclusions were about the carcinogenicity of the --  
 7 A. I'm sure I did if I -- from the full  
 8 report. I would read what the authors or  
 9 investigators would have said.  
 10 Q. Do you think that a fair scientist  
 11 should have reported to the judge in this case what  
 12 the original investigators said about the conclusions  
 13 they got from their own study?  
 14 MS. WAGSTAFF: Objection, calls for a  
 15 legal conclusion and asking him what's fair to report  
 16 in a legal context is just inappropriate.  
 17 MR. HOLLINGSWORTH: I'm asking in a  
 18 scientific context.  
 19 A. Again, as I --  
 20 MS. WAGSTAFF: He's not -- it's a legal  
 21 conclusion.  
 22 A. Sorry. As I stated before, this is not  
 23 unlike what I had done in the past and what other  
 24 scientists, toxicologists, pathologists,  
 25 epidemiologists, what have you, it's not unlike what

Page 181

1 Q. (BY MR. HOLLINGSWORTH) Didn't you say  
 2 that this study was not valid for reviewing purposes  
 3 because the high dose in these rats was only 300 parts  
 4 per million?  
 5 A. No.  
 6 MS. WAGSTAFF: Object to form.  
 7 Q. (BY MR. HOLLINGSWORTH) Did you review  
 8 summary animal data and individual animal data in this  
 9 report or I should say this study report?  
 10 A. Did my report?  
 11 Q. Did your review --  
 12 A. Did my review?  
 13 Q. -- include summary animal data and  
 14 individual animal data?  
 15 A. You're going to need to define "summary"  
 16 versus "individual" for me, please.  
 17 Q. Well, I just -- I think summary animal  
 18 data and individual animal data as it relates to a  
 19 pathology report from a long-term bioassay is standard  
 20 terminology. You don't know what that means?  
 21 A. That's not what you asked me. You  
 22 didn't say anything about a pathology table.  
 23 Q. I said, did you review -- did your  
 24 review include summary animal data and individual  
 25 animal data from this report --

Page 182

1 MS. WAGSTAFF: Object to form.  
 2 Q. (BY MR. HOLLINGSWORTH) -- by these  
 3 investigators.  
 4 A. In my report, no, not specifically my  
 5 report.  
 6 Q. (BY MR. HOLLINGSWORTH) You're aware that  
 7 these interstitial cell tumors in the testes are known  
 8 to be age related, right?  
 9 A. There are a number of different tumors  
 10 in experimental animals as in humans that the  
 11 incidence of the tumors increase as the animal ages.  
 12 Q. I'm --  
 13 A. So --  
 14 Q. I'm talking about testicular tumors in  
 15 particular.  
 16 A. Well, I mean, just like -- just like you  
 17 and I will get prostate cancer if we live long enough,  
 18 it is the case in rats that the older they are, the  
 19 more likely it is that you may see testicular tumors  
 20 in the aging male rats.  
 21 Q. Did you observe when you reviewed the  
 22 data that you reserved about the Lankas 1981 rat study  
 23 that the survival in the control group was  
 24 significantly decreased from survival in the high dose  
 25 group?

Page 184

1 the data and looking at all of the data.  
 2 Q. (BY MR. HOLLINGSWORTH) You don't  
 3 remember that the long-term -- the high dose animals  
 4 had -- had one-eighth the number of deaths that the  
 5 control animals who weren't fed any glyphosate had?  
 6 MS. WAGSTAFF: Object to form.  
 7 A. Again, that is contrary to what I have  
 8 written in my report.  
 9 Q. (BY MR. HOLLINGSWORTH) Okay.  
 10 A. I'd have to look at the full report,  
 11 again, to see what you're talking about.  
 12 Q. Okay. Well, if the high dose males  
 13 out-survive the control males and you're considering a  
 14 tumor like testicular tumor in rats, it wouldn't be  
 15 surprising that there would be a higher rate of  
 16 testicular cancer in the high dose group, would  
 17 there -- would it?  
 18 A. All I can say is what I have stated in  
 19 my report was there was no significant difference in  
 20 survival in any of the dose groups, so. . .  
 21 Q. Okay. Now, you also say that in this  
 22 study that there was an increased incidence of  
 23 pancreatic islet cell adenomas, correct?  
 24 A. Right.  
 25 Q. Pancreatic islet cell adenomas, and the

Page 183

1 A. In this study?  
 2 Q. Yeah.  
 3 A. According to my report, there was no  
 4 treatment-related effect on body rate or survival at  
 5 any dose level in this study, so I --  
 6 Q. So you disagree with that?  
 7 A. Based on what I have written in my  
 8 report, I -- I can't agree with that.  
 9 Q. Okay. You don't remember that for the  
 10 18-month-old males eight control animals had died and  
 11 only one high dose animal had died?  
 12 MS. WAGSTAFF: Objection, again if you  
 13 want to show him the study, that would help refresh  
 14 his memory.  
 15 A. Again, I don't -- I don't -- I can't  
 16 speak to that because I -- I didn't memorize the  
 17 interim death rates in this particular study. I need  
 18 to see the tables and what the -- and what the final  
 19 survival data looked like as well.  
 20 Q. (BY MR. HOLLINGSWORTH) Is the -- is the  
 21 survival at 18 months not significant to you in  
 22 connection with a 24-month chronic bioassay in rats?  
 23 A. Again --  
 24 MS. WAGSTAFF: Object to form.  
 25 A. -- I can't comment without looking at

Page 185

1 incidence was zero, five, two, two, according to your  
 2 report, correct?  
 3 A. Correct.  
 4 Q. And that doesn't demonstrate a dose  
 5 response, does it?  
 6 A. No, it doesn't demonstrate a dose  
 7 response, but it demonstrates a statistically  
 8 significant increase in the low dose animals, so  
 9 that's a positive response caused by glyphosate in  
 10 this study.  
 11 Q. Zero, five, two, two is not a  
 12 statistically significant difference, is it?  
 13 MS. WAGSTAFF: Object to form.  
 14 A. It is not a trend, but it's a  
 15 significant increase in the low dose animals compared  
 16 to the controls by a pair-wise comparison. And that  
 17 comparison is statistically significant.  
 18 Q. (BY MR. HOLLINGSWORTH) Now, the IARC  
 19 monograph reported that there was no evidence in this  
 20 study of progression from adenomas to carcinomas for  
 21 the pancreatic islet tumors, true?  
 22 A. That's what was reported.  
 23 Q. And you have written in the past that  
 24 the evidence of progression from benign to malignant  
 25 to neoplasia is an important factor to be considered

Page 186

1 in rodent bioassay evaluations; isn't that right?  
 2 A. That sounds like something I would have  
 3 written awhile ago.  
 4 Q. So as you sit here today, do you  
 5 disagree with that?  
 6 A. Disagree with again? I'm sorry.  
 7 Q. Have you changed your view on that issue  
 8 now?  
 9 MS. WAGSTAFF: Object to form.  
 10 A. On the issue?  
 11 MR. HOLLINGSWORTH: Yeah.  
 12 A. Would you repeat?  
 13 Q. (BY MR. HOLLINGSWORTH) You said in  
 14 answer to the question I asked you just previously,  
 15 you said it sounded like something that I would have  
 16 written long ago. And my question -- follow-up  
 17 question on that is are you suggesting that you've  
 18 changed your opinion on that issue now?  
 19 A. And the issue is?  
 20 Q. That the evidence of progression from  
 21 benign to malignant neoplasia is a factor that should  
 22 be considered in evaluating rodent bioassay data?  
 23 A. I agree it is a factor that is as it  
 24 should be considered in rodent bioassay studies, but  
 25 it is not necessary to have that progression in order

Page 188

1 Q. And other studies in rats involving  
 2 glyphosate that you reviewed had high dose  
 3 administrations of 10,000 parts per million or 30,000  
 4 parts per million or up to 3 percent of the rat's  
 5 total diet, right?  
 6 A. That's correct.  
 7 Q. And none of those studies had any  
 8 evidence of interstitial testicular -- interstitial  
 9 cell testicular carcinoma, did they?  
 10 A. Not that I recall.  
 11 Q. You didn't report a single one?  
 12 A. That's not to say that there wasn't some  
 13 of those tumors found in one or two of those studies,  
 14 but it wasn't significantly different than the  
 15 controls, so I didn't include it in the report.  
 16 Q. With given those high doses of 10,000 or  
 17 up to 30,000 or 3 percent of the animal's total diet  
 18 and no interstitial cell testicular tumors from any of  
 19 those studies, don't you think that's biologically  
 20 significant in the evaluation of the overall  
 21 carcinogenic effect of glyphosate on rats?  
 22 MS. WAGSTAFF: Object to form, misstates  
 23 evidence.  
 24 A. What -- again, what I've been doing or  
 25 do in this report is a hazard identification, so I

Page 187

1 to say that there's a positive effect of tumor  
 2 formation.  
 3 Q. Did you tell the Court that you had  
 4 published before the fact that it's important to  
 5 consider evidence of progression for benign to  
 6 malignant neoplasia in evaluating rodent bioassay  
 7 data?  
 8 A. Did I tell the Court?  
 9 Q. Did you tell the Court in your report  
 10 that?  
 11 A. I don't -- I don't recall putting that  
 12 in my report, no.  
 13 Q. You know that the original investigators  
 14 who were the pathologist, the experimental  
 15 pathologists that evaluated the histopathology from  
 16 the study determined that this study did not produce  
 17 any compound-related changes due to glyphosate  
 18 administration, true?  
 19 MS. WAGSTAFF: Object to form.  
 20 A. That sounds like what they may have  
 21 written in the report.  
 22 Q. (BY MR. HOLLINGSWORTH) I've asked you  
 23 about this before, but the high dose here was 300  
 24 parts per million, right?  
 25 A. 300, that's correct.

Page 189

1 take the studies and evaluate them individually as to  
 2 their adequacy and if they showed a positive response.  
 3 In this particular study, glyphosate was given to rats  
 4 and the male rats got interstitial cell tumors, so for  
 5 this particular study, there was a significant  
 6 increase in interstitial tumors in the male rats, so  
 7 therefore, glyphosate caused these tumors in male rats  
 8 and from that, it is an animal carcinogen and a  
 9 potential human carcinogen.  
 10 Q. (BY MR. HOLLINGSWORTH) That's not  
 11 exactly my question, Dr. Jameson. My question is  
 12 whether the fact that the later rat studies in which  
 13 rats in the high dose groups were fed up to actually  
 14 40,000 parts per million in their diet, but who, when  
 15 evaluated, had no testicular carcinoma caused you to  
 16 rethink your conclusion about testicular cancer in a  
 17 study where the high dose animals only received 300  
 18 parts per million in their diet?  
 19 MS. WAGSTAFF: Object to form and asked  
 20 and answered.  
 21 A. I've already answered what my thought is  
 22 on that.  
 23 Q. (BY MR. HOLLINGSWORTH) Okay. That  
 24 didn't cause you to change your -- to go back and  
 25 question your opinion --

Page 190

1 A. No.  
 2 Q. -- about the Lankas cell -- Lankas rat  
 3 study when you saw that rats in all the other rat  
 4 studies had been fed in the high doses 10 to 40,000  
 5 parts per million, whereas Lankas only -- the Lankas  
 6 study only fed the high dose rats at 300 parts per  
 7 million?  
 8 A. Right. But not knowing the mechanism of  
 9 action or how the high doses affected the metabolism  
 10 or absorption or the immune system of the animals,  
 11 it's -- you know, all these different variables have  
 12 to be taken into consideration. But, no, it didn't.  
 13 Q. Is there any evidence from the rat  
 14 studies that the immune systems of these rats in these  
 15 nine studies that you looked at -- I'm sorry, seven  
 16 studies that you looked at were affected?  
 17 A. I don't recall. I'd have to go back and  
 18 look at the studies. I don't -- I don't know if they  
 19 did any studies to investigate the effect on the  
 20 immune system.  
 21 Q. Have you --  
 22 MS. WAGSTAFF: Can you guys put it on  
 23 mute, please.  
 24 Q. (BY MR. HOLLINGSWORTH) Do you recall  
 25 your review of the 1990 rat study? It's another

Page 192

1 right?  
 2 A. Correct.  
 3 Q. And you read all that stuff?  
 4 A. I looked through all of that, yes.  
 5 Q. Did you tell the Court in your report  
 6 what the individual authors or investigators actually  
 7 reported about the tumors that were observed in this  
 8 study on serial sacrifice or at the time of mortality  
 9 before sacrifice or at final sacrifice at 24 months?  
 10 MS. WAGSTAFF: Object to the form of the  
 11 question.  
 12 A. I concentrated on the final sacrifice  
 13 data, the terminal sacrifice data and any data that  
 14 any -- any pathology that had been conducted on the  
 15 animals that had died earlier as included in the tumor  
 16 tables.  
 17 Q. (BY MR. HOLLINGSWORTH) You know that  
 18 this report was submitted to EPA, true?  
 19 A. That's correct.  
 20 Q. And you know that EPA published a report  
 21 about this rat study in 1990 in connection with the  
 22 registration of glyphosate, right?  
 23 A. Correct.  
 24 Q. And the EPA concluded that there were no  
 25 treatment-related neoplastic or carcinogenic or cancer

Page 191

1 Sprague-Dawley rat study, I believe, by Dr. Stout and  
 2 others.  
 3 A. Dr. Stout?  
 4 Q. Yes, S-t-o-u-t.  
 5 A. Uh-huh. Okay.  
 6 Q. The original investigators in that  
 7 study, which included Dr. Stout and others, concluded  
 8 that an oncogenic effect or carcinogenic effect was  
 9 not seen or observed in that study at all; isn't that  
 10 right?  
 11 A. I remember -- I recall that that's what  
 12 they said in their report.  
 13 Q. And that full study report, including  
 14 the pathology report, was provided to you by  
 15 plaintiffs' counsel, right?  
 16 A. I did get a study report for this. And  
 17 I know the report also included tumor tables. So I  
 18 reviewed all the information that was in the report  
 19 and tumor tables.  
 20 Q. The -- there was a pathology report in  
 21 this overall study report as well, too, true?  
 22 A. Okay. I believe there was.  
 23 Q. Yeah. And there were individual animal  
 24 data and lots of summaries on various tumors that were  
 25 found when these animals died or were sacrificed,

Page 193

1 changes in these animals in any dose group, true?  
 2 A. That's what they reported as a result of  
 3 their risk assessment, but, again, I did not do a risk  
 4 assessment, I did a hazard identification.  
 5 Q. Now, the high dose group in this study  
 6 received 20,000 parts per million?  
 7 A. Correct.  
 8 Q. Or 2 percent of their total diet of  
 9 glyphosate?  
 10 A. Correct.  
 11 Q. And Lankas and the other authors  
 12 reported that out in the reports that you read about  
 13 this study, true?  
 14 A. I'm sorry, who?  
 15 MS. WAGSTAFF: Object to form.  
 16 Q. (BY MR. HOLLINGSWORTH) I'm sorry, excuse  
 17 me. We're talking about Dr. Stout now. I apologize.  
 18 A. Right.  
 19 Q. Dr. Stout reported in various places in  
 20 this report that the top -- the high dose group had  
 21 received 20,000 parts per million of glyphosate in  
 22 their diet and that compares to the 300 parts per  
 23 million high dose group that -- that we talked about  
 24 from the Lankas study in 1981, right?  
 25 A. Correct.

1 Q. And are you aware that the incidence of  
2 testicular interstitial cell tumors from Dr. Stout's  
3 study in 1991 on the same strain of mouse,  
4 Sprague-Dawley. Sprague, S-p-r-a-g-u-e dash Dawley,  
5 D-a-w-l-e-y, rats was two, zero, three, two?

6 A. Two --

7 Q. Two, zero, three, two.

8 A. Okay.

9 Q. You're aware of that, right?

10 A. That was in the report.

11 Q. So this study didn't repeat the  
12 testicular interstitial cell tumors or replicate the  
13 study done by Lankas in 1981, did it?

14 MS. WAGSTAFF: Object to form.

15 A. Well, no, I mean, the -- the Lankas  
16 study was done at much lower doses.

17 Q. (BY MR. HOLLINGSWORTH) Isn't it  
18 biologically sound to expect the higher dose animals  
19 to have more testicular tumors than the lower dosed  
20 animals? Isn't that what biologic significance means  
21 to an experimental pathologist?

22 MS. WAGSTAFF: Object to form.

23 A. Well, I mean, you would -- you would --  
24 you would expect to see more tumors at higher doses,  
25 but that doesn't preclude the fact that at lower

1 doses, you may be seeing different biological events  
2 happening in the animals at lower doses than -- than  
3 what happens in the higher doses. The higher doses  
4 could be blocking a particular type of activity, so  
5 the fact that you see something in lower doses that  
6 you don't see something in higher doses is -- is seen  
7 in -- in toxicology and carcinogenicity studies.

8 Q. (BY MR. HOLLINGSWORTH) Has anyone  
9 published a study, a peer-reviewed study anywhere on  
10 the planet that says the effects of glyphosate at  
11 lower doses may be more virulent in terms of cancer  
12 than the effects of -- at higher doses in rats?

13 A. I'm not aware of any, no.

14 Q. None of the other six rat studies  
15 besides the 1981 Lankas study had any increased  
16 incidence of testicular interstitial cell tumors, did  
17 they?

18 A. No. No significant increase in those  
19 tumors, correct.

20 Q. In this -- in this 1990 study by  
21 Dr. Stout and others, you report in your expert  
22 witness report an increased incidence of pancreatic  
23 cell adenomas, true?

24 A. Correct.

25 Q. And that's in the low dose males, right?

1 A. In the low dose males, correct.

2 Q. And you can see that there's no apparent  
3 progression to carcinoma in these lesions?

4 MS. WAGSTAFF: Object to form.

5 Q. (BY MR. HOLLINGSWORTH) True?

6 A. I'm sorry, say again. I was reading  
7 something.

8 Q. You can see that there's no apparent  
9 progression to carcinoma from your review of the  
10 information on these lesions?

11 A. In these studies there was no apparent  
12 progression to the carcinoma, correct.

13 Q. So the adenoma did not progress to  
14 carcinoma?

15 MS. WAGSTAFF: Object to form.

16 A. I'm sorry, say again.

17 Q. (BY MR. HOLLINGSWORTH) The adenoma in  
18 these pancreatic islet cell lesions, the adenomas, did  
19 not progress to cancer in any of these animals?

20 A. It appears that way, yes.

21 Q. And you have written that that is a  
22 significant effect to be reviewed in connection with  
23 evaluating rodent bioassay data, true?

24 MS. WAGSTAFF: Object to form. He  
25 testified moments ago differently, but. . .

1 A. That progression is important?

2 Q. (BY MR. HOLLINGSWORTH) Yes.

3 A. Well, if you see progression, that's an  
4 important observation. But it's not necessary  
5 to -- to indicate that a particular material causes a  
6 tumor.

7 Q. So there was no progression from adenoma  
8 to something more virulent like carcinoma in the  
9 animals that were treated with glyphosate and who  
10 developed pancreatic islet cell adenomas, true?

11 A. That's correct in this.

12 Q. Are you aware that there was, in fact, a  
13 carcinoma found in the control group?

14 A. In this control group?

15 Q. Yes.

16 MS. WAGSTAFF: Object to form.

17 A. There was one carcinoma found.

18 Q. (BY MR. HOLLINGSWORTH) In fact, the  
19 only pancreatic carcinoma occurred in the control  
20 group in this study; is that right?

21 A. I'd have to go back and look. I don't  
22 have that information in my report, so I'd have to go  
23 back and look at the reports.

24 MS. WAGSTAFF: Once again, I mean, if  
25 you're asking him these sort of details, we would

1 request that you give him a copy of the report as this  
2 is not a memory test.

3 Q. (BY MR. HOLLINGSWORTH) There was also  
4 no -- no dose response that you could observe in these  
5 pancreatic islet cell adenomas that you saw in the  
6 treated groups, true? 8, 5, 7 is not a dose response,  
7 is it?

8 A. No, it's not a true dose response, but  
9 then, again, if you -- if you look at the incidence  
10 here, originally as reported, there was a  
11 statistically significant increase in the low dose  
12 animals, but if you read the EPA's evaluation of this  
13 particular study, the EPA performed additional  
14 analyses which they included the animals that were  
15 killed or died before 54 or 55 weeks, and during that  
16 particular evaluation, they found an incidence of one  
17 in 43 for -- these are for the pancreatic cell --  
18 islet cell adenomas. They found one in 43 for the  
19 controls, eight in 45 for the low dose, which is  
20 also -- which is significant. Five of 49 in the mid  
21 dose and seven of 48 in the high dose, which now  
22 becomes significant.

23 So when the EPA reevaluated the studies,  
24 excluding the early deaths, you found a significant  
25 increase in tumors in both the low and the high dose

1 little more closely to give you an adequate answer to  
2 that. I'd have to see, you know, what time the  
3 animal -- what time, when the animal died, if it was  
4 an early death. If it was an early death, then there  
5 may have been something genetically wrong with the  
6 animal to cause it to be -- to have an early onset of  
7 a tumor like that.

8 Q. (BY MR. HOLLINGSWORTH) This --

9 A. I'm sorry.

10 Q. This result that you talk about in the  
11 male animals with respect to pancreatic islet cell  
12 adenomas was not replicated in the female animals, was  
13 it?

14 A. In this study, no.

15 MS. WAGSTAFF: Object to form.

16 Q. (BY MR. HOLLINGSWORTH) Yes. The  
17 pancreatic islet cell adenomas in the females was six,  
18 one, four, zero, right?

19 A. I'd have to look at the report to see  
20 what the incidence was.

21 Q. Well, if the -- if the incidence, in  
22 fact, was six, one, four, zero, that indicates there's  
23 no replication between the sexes in terms of  
24 pancreatic islet cell adenoma findings from the study,  
25 true?

1 animals from this particular study for the pancreatic  
2 islet cell tumors.

3 Q. Assuming the control animal had a  
4 carcinoma, it's not surprising that that male died  
5 early, is it?

6 MS. WAGSTAFF: Object to form.

7 A. Well, you -- you can't argue one way or  
8 the other for that.

9 Q. (BY MR. HOLLINGSWORTH) Does that have  
10 biologic significance to you that the only animal in  
11 this study that had actual carcinoma was a control  
12 animal?

13 MS. WAGSTAFF: Objection. The doctor  
14 has asked to see the data and you're prefacing an  
15 entire line of questioning on an assumption that he  
16 would like to look at the report and determine the  
17 significance of it.

18 Q. (BY MR. HOLLINGSWORTH) Do you want to  
19 hear my question again?

20 A. Please.

21 Q. Would it have biologic significance to  
22 you that in a case where the control animal is the  
23 only animal that has actual cancer?

24 MS. WAGSTAFF: Object to form.

25 A. I'd have to look at the -- at the data

1 A. Between the --

2 MS. WAGSTAFF: Object to form.

3 A. Between the males and the females?

4 Q. (BY MR. HOLLINGSWORTH) Yes.

5 A. Correct, as I indicated earlier, it's  
6 not unusual to see a different incidence or a  
7 significant incidence of a tumor in one sex and not in  
8 the other sex. That's -- that's found in a lot of  
9 different studies.

10 Q. (BY MR. HOLLINGSWORTH) If the  
11 pancreatic islet cell adenomas in the female rats is  
12 six, one, four, zero, it's true that the control  
13 animals had more pancreatic islet cell carcinomas in  
14 toto than any of the three control groups, true?

15 MS. WAGSTAFF: Object to form.

16 A. Okay. Well, the females had more  
17 carcinomas in them than the males, but then, again,  
18 that -- that is an instance where you might want to  
19 bring in historical control incidences to see what the  
20 historical incidence of pancreatic cell carcinomas in  
21 male and female rats are, so that you can make an  
22 evaluation of that.

23 Q. (BY MR. HOLLINGSWORTH) Okay. In the  
24 female rats, there were the -- the pancreatic islet  
25 cell adenomas were one, four, zero. And if there --

Page 202

1 A. Pancreatic islet cell adenomas?  
 2 Q. Yes.  
 3 A. In the female rats?  
 4 Q. Yes. Control was six.  
 5 A. I don't have the data in front of me, so  
 6 I'm just trying to keep up.  
 7 MS. WAGSTAFF: What -- I'll make about  
 8 my 25th request today to please show him the data.  
 9 You're asking him if he's memorized these random  
 10 string of numbers that --  
 11 MR. HOLLINGSWORTH: Well, he's relied on  
 12 Greim.  
 13 MS. WAGSTAFF: Of course he relied on  
 14 Greim, but --  
 15 MR. HOLLINGSWORTH: It's right out of  
 16 Greim. I'm asking if he remembers.  
 17 MS. WAGSTAFF: Do you think he's  
 18 memorized it? You've got it right in front of him.  
 19 It wouldn't be that hard to give him the data instead  
 20 of trying to trip him up on numbers.  
 21 MR. HOLLINGSWORTH: I'm not tripping him  
 22 up.  
 23 MS. WAGSTAFF: Just saying, I'd like the  
 24 record to reflect that we've asked for the data to  
 25 look at it about 25 times and you've refused every

Page 204

1 and non-Hodgkin's lymphoma in humans or I'm not aware  
 2 of anybody publishing any data or articles on that.  
 3 Q. Are you aware that -- are you aware that  
 4 Dr. Portier has concluded that the increase in  
 5 hepatocellular adenomas that you report in your expert  
 6 report could be due to chance?  
 7 MS. WAGSTAFF: Object to form.  
 8 A. I -- I -- I don't recall that.  
 9 Q. (BY MR. HOLLINGSWORTH) Now, do you  
 10 recall what the incidences were of follicular cell  
 11 adenomas, which you say in your report based on this  
 12 1990 rat study by Stout were caused by administration  
 13 of glyphosate?  
 14 MS. WAGSTAFF: Once again, another  
 15 request to please provide the witness with the data.  
 16 A. Follicular cell?  
 17 MS. WAGSTAFF: It's not surprising you  
 18 haven't memorized them.  
 19 A. Okay. Yes.  
 20 Q. (BY MR. HOLLINGSWORTH) Do you report  
 21 what the incidences were of follicular cell adenoma?  
 22 A. No, when I was reading through my  
 23 report, I noticed that I neglected to put the  
 24 incidences in and that's a deficiency in the report  
 25 that I need to correct.

Page 203

1 time.  
 2 Q. (BY MR. HOLLINGSWORTH) You also note  
 3 significant trends in three additional tumor types in  
 4 this study, don't you, Doctor?  
 5 A. Significant trends?  
 6 Q. Yes.  
 7 A. In -- okay -- in which particular tumor  
 8 sites?  
 9 Q. Hepatocellular adenoma.  
 10 A. Okay.  
 11 Q. Do you know of any study that says  
 12 hepatocellular rates that are increased in treated  
 13 animals in a long-term bioassay has a relationship to  
 14 non-Hodgkin's lymphoma in humans?  
 15 A. The purpose of this study was to see if  
 16 glyphosate caused cancer in the Sprague-Dawley rats.  
 17 When glyphosate was given to the animals, it caused  
 18 liver -- an increase in the trend in liver  
 19 hepatocellular adenomas in the male rats. So,  
 20 therefore, the exposure or treatment with glyphosate  
 21 caused liver tumors in rats and, therefore, it's an  
 22 animal carcinogen and a potential human carcinogen.  
 23 I am not aware of any -- anybody who has  
 24 designed or conducted a study to investigate the  
 25 association between hepatocellular adenomas in rats

Page 205

1 Q. Did you look at what the -- in  
 2 preparation for your testimony, did you look at what  
 3 the incidence of thyroid follicular cell adenoma is as  
 4 you report it to be in -- in your report?  
 5 A. Did I -- I'm sorry, did I do what?  
 6 Q. Did you look at the incidence of  
 7 follicular cell adenoma? I'm sorry, did you look at  
 8 the incidence of thyroid follicular cell adenomas in  
 9 the four groups within this rat study?  
 10 A. In preparation for this?  
 11 Q. Yes.  
 12 A. I did not. No.  
 13 Q. Did you state in your report that the  
 14 incidence of thyroid cell follicular cell adenoma is  
 15 significant by pair-wise comparison?  
 16 MS. WAGSTAFF: Object to form.  
 17 A. I did. And the reference for that is  
 18 there's an EPA report is where I got that information  
 19 from. It's a glyphosate issue paper, evaluation of --  
 20 THE REPORTER: I'm sorry.  
 21 A. I'm sorry I read too fast. I'm so  
 22 sorry. Glyphosate, it's EPA 2016, glyphosate issue  
 23 paper. Evaluation of carcinogenic potential. And  
 24 it's EPA's Office of Pesticide Program, September  
 25 2016. That's the reference I used in my paper. I

1 apologize, like I said, I noticed when I was reading  
 2 through it last night, that I forgot to put the  
 3 incidences in and that was my oversight and I will  
 4 correct it.

5 Q. (BY MR. HOLLINGSWORTH) Okay. Sir,  
 6 you're well aware that EPA after considering all the  
 7 data within the Office of Pesticides Program actually  
 8 did not consider the increases in pancreatic islet  
 9 cell adenomas or carcinomas to be significant, aren't  
 10 you?

11 MS. WAGSTAFF: Object to form.

12 A. Again, the EPA in performing their risk  
 13 assessment and looking at these particular tumors in  
 14 this study, evidently it did not meet their criteria  
 15 for inclusion for the purposes of risk assessment.

16 I did a hazard identification, and in my  
 17 evaluation for a hazard identification, this  
 18 observation is significant. And so that's why I  
 19 included it in my report.

20 Q. (BY MR. HOLLINGSWORTH) Did the EPA use a  
 21 different statistical different method of analysis  
 22 than what you used?

23 A. No, the statistics that I report here in  
 24 my report come from EPA.

25 Q. And didn't the EPA also conclude that

1 assessment, that's why they did not consider them.

2 For the purpose of my hazard  
 3 identification, I evaluated the increase in trends of  
 4 these thyroid C cell adenomas in the females. It was  
 5 sufficient and, therefore, I included it in my report.

6 Q. (BY MR. HOLLINGSWORTH) That increase  
 7 that you talk about in thyroid C cell tumors, was not  
 8 statistically significant by pair-wise comparison, was  
 9 it?

10 A. It was significant for trend, but not  
 11 pair-wise.

12 Q. Yes. EFSA looked at this data, too,  
 13 didn't they?

14 A. I believe they did.

15 Q. And EFSA concluded that there was no  
 16 evidence that the pancreatic islet cell tumors in this  
 17 study were compound related or related to treatment by  
 18 glyphosate, right?

19 MS. WAGSTAFF: Object to form.

20 A. Again, EFSA was doing a risk assessment,  
 21 so evidently the data there did not meet their  
 22 criteria for doing a risk assessment. That's why they  
 23 discounted these tumors.

24 For my hazard identification, I felt it  
 25 was showing that this trend was due to exposure to

1 that hepatocellular tumors that you refer to in your  
 2 expert witness reports were not compound related?

3 A. Again, the EPA was doing their risk  
 4 assessment, and evidently for the risk assessment,  
 5 the -- these particular tumors did not meet their  
 6 criteria for inclusion in their risk assessment or  
 7 however, for the purpose of the hazard identification  
 8 I did, these liver tumors -- I consider these liver  
 9 tumors to be associated with exposure to glyphosate  
 10 and, therefore, I included them in my report.

11 Q. You also said in your report that in  
 12 this 1990 rat study by Dr. Stout, thyroid C cell  
 13 tumors that you observed were related to treatment  
 14 with glyphosate; isn't that right?

15 A. That's correct.

16 Q. And EPA -- EPA's Office of Pesticide  
 17 Programs, after considering all the study data,  
 18 concluded that the thyroid C cell tumors were not  
 19 treatment related, that is not related to glyphosate,  
 20 didn't they?

21 MS. WAGSTAFF: Object to form.

22 A. This is the same argument. The EPA were  
 23 conducting a risk assessment. Evidently, the results  
 24 for the thyroid C cell adenomas in the females did not  
 25 meet their criteria for inclusion in their risk

1 glyphosate, so therefore, I included it in my report.

2 Q. (BY MR. HOLLINGSWORTH) Do you think  
 3 that you had as much data about this report as EPA and  
 4 EFSA had?

5 MS. WAGSTAFF: Objection.

6 A. I -- to be honest, I don't know what  
 7 data EFSA and EPA had, so I can't comment.

8 Q. (BY MR. HOLLINGSWORTH) There's no  
 9 published peer review anywhere on this planet that  
 10 says any one of the findings you refer to individually  
 11 or all the findings you refer to jointly about tumors  
 12 in the rats studied by Dr. Stout and others are  
 13 compound related or caused by glyphosate, true?

14 A. There -- other than the Greim paper,  
 15 which lists the Stout study, which is a peer-reviewed  
 16 published -- publication, no other study refers to  
 17 this -- no other publication refers to this Stout  
 18 study.

19 Q. Does Greim make a conclusion about the  
 20 carcinogenicity of glyphosate in connection with he  
 21 and his authors, his co-authors' review of the 1990  
 22 Monsanto sponsored study by Dr. Stout?

23 A. I believe his conclusion was there was  
 24 no effect of glyphosate.

25 Q. And the conclusion that you have, which

<p style="text-align: right;">Page 210</p> <p>1 is the opposite, that there is an effect of glyphosate 2 that's shown by this study has not been subjected to 3 any kind of peer review, has it? 4 MS. WAGSTAFF: Object to form. 5 A. Not that I'm aware of. 6 Q. (BY MR. HOLLINGSWORTH) Do you remember 7 reviewing a rat study that was reported out in 1996 by 8 Feinchemie, F-e-i-n-c-h-e-m-i-e? 9 A. What was the date? 10 Q. 1996, sir. 11 A. Is that the Suresh study on Wistar rats? 12 Q. Yes. 13 A. Okay. 14 Q. We're going from Sprague-Dawley rats to 15 Wistar rats. 16 A. Correct. 17 Q. Did that make a difference to you in the 18 way that you interpreted the Feinchemie study? 19 MS. WAGSTAFF: Object to form. 20 A. I'm sorry, would you repeat that? 21 Q. (BY MR. HOLLINGSWORTH) Did the fact that 22 the Feinchemie study involved Wistar rats rather than 23 Sprague-Dawley rats make a difference to you in the 24 way that you interpreted the results of the Feinchemie 25 study?</p>	<p style="text-align: right;">Page 211</p> <p>1 A. The fact that one used Sprague-Dawley as 2 on opposed to Wistar? 3 Q. Yes. 4 A. That wouldn't make a -- no. Should not. 5 Q. The different strains of rats would not 6 make a difference to you? 7 A. As to the way I evaluate it? 8 Q. Yeah. 9 A. Not necessarily. The only consideration 10 would be, you know, historical background rates for 11 the Wistar would be different than the Sprague-Dawley 12 rats, but both of those strains of rats are very 13 widely used in toxicology carcinogenicity studies, so 14 there's a large database for both of them. 15 Q. You know that the authors of Feinchemie 16 study concluded there are no compound-related 17 neoplastic lesions anywhere in this study? 18 A. Correct. 19 Q. Did you have the full study report from 20 the Feinchemie 1996 rat bioassay? 21 A. Again, I'd have to go back and look at 22 my files to see just what exactly all I had. I don't 23 recall that I had a full report for this particular 24 study. 25 Q. Did you tell the Court in your expert</p>
<p style="text-align: right;">Page 212</p> <p>1 witness report that the original investigators of the 2 Feinchemie 1996 rat study concluded that there were no 3 compound-related neoplastic lesions in any of the 4 treated animals in this study? 5 MS. WAGSTAFF: Object to the form of the 6 question. 7 A. I was asked to give my opinion, do a 8 hazard assessment and give my opinion for glyphosate 9 and glyphosate formulations, and so I reviewed the 10 data and my report reflects my opinion. 11 Q. (BY MR. HOLLINGSWORTH) You didn't tell 12 the judge what the original authors had concluded, did 13 you? 14 A. No. 15 MS. WAGSTAFF: Objection, asked and 16 answered. 17 A. I -- like I said, I -- I was asked to 18 give my opinion and I gave my opinion. 19 Q. (BY MR. HOLLINGSWORTH) Now, this was -- 20 this study was submitted to the U.S. EPA, correct? 21 A. Correct. 22 Q. And have you looked on the EPA online 23 database to see what's there about this study? 24 A. I looked on the online database for a 25 number of these studies, I don't recall that this was</p>	<p style="text-align: right;">Page 213</p> <p>1 one -- this one in particular I looked for or not. 2 Q. Okay. You relied totally on -- you 3 relied totally on Greim's published data in your 4 evaluation of the 1996 Feinchemie rat study, didn't 5 you? 6 MS. WAGSTAFF: Object to form on the use 7 of "totally." 8 A. The Suresh study? No. I had some 9 additional documents to look at from that study. 10 Q. (BY MR. HOLLINGSWORTH) Did the 11 plaintiffs' counsel give you those documents? 12 A. They provided me with all the 13 information they had on this particular study. 14 Q. Now, isn't it true that this study 15 stated there were no treatment-related deaths or 16 clinical signs in any of the dose groups and there 17 were no treatment-related effects on body weight gain 18 or food consumption? 19 A. Correct. 20 Q. Did you look at the original pathology 21 report from the overall study? 22 A. I'd have to go back and look at my files 23 to see if we had -- if I had the original pathology 24 report. If I had, I did look at it, but I can't 25 remember.</p>

1 Q. Now, these animals were treated with --  
2 in the high dose group with over 1,000 milligrams per  
3 kilogram per day doses of glyphosate; isn't that  
4 right?

5 A. In the high dose?

6 Q. Yes.

7 A. Much higher than the 1,000, yes.

8 Q. But you concluded that the -- that the  
9 maximum tolerated dose was not reached, right?

10 A. Based on my observations or the reported  
11 survival and body weight gains for these animals, it  
12 would appear that an MTD was not reached.

13 Q. I didn't say that -- in my prior  
14 question about 1,000 milligrams per kilograms per day,  
15 I'm talking about mgs per kgs, you understand that  
16 right?

17 A. I'm sorry.

18 Q. Mgs per kgs is something different?

19 A. Right. I -- I heard parts per million.  
20 I apologize.

21 Q. And the acceptable OECD and EPA standard  
22 regimen for treating -- for the high doses in  
23 experimental mouse studies is to reach 1,000 mgs per  
24 kgs per day; is that right?

25 A. That is their criteria, per day.

1 Q. In this study, Feinchemie -- Feinchemie  
2 that we're talking about now, the 1996 rat study  
3 reached 1,000 mgs per kgs per day in the high dose  
4 animals; isn't that right?

5 A. That's what was reported.

6 Q. Mgs per kgs is m-g slash k-g slash day,  
7 right?

8 A. Yes, sir.

9 Q. Has your conclusion that the MTD,  
10 maximum tolerated dose, was not reached in this study  
11 been subject to peer review and publication?

12 A. My opinion?

13 Q. Yes.

14 A. Not that I'm aware of, but this -- this  
15 1,000 milligrams per kilogram body weight that is the  
16 upper limit for, is this -- what agency is this for  
17 EFSA? No.

18 Q. It's for EPA.

19 A. EPA. That's for their purposes of doing  
20 risk assessment. If you look at chronic bioassay  
21 studies, at least in my long experience with the  
22 National Toxicology Program, Animal Bioassay Program,  
23 there's not an upper limit. The only upper limit in a  
24 chronic two-year animal bioassay in the NTP is -- for  
25 feed would be 50,000 parts per million. 5 percent of

1 the diet is the maximum dose that do for a study.

2 Now, I'm giving you too much  
3 information. But the dose of -- that is limited at 5  
4 percent because once you go over 5 percent in the  
5 diet, you're going to start impacting nutritional  
6 content of the food that the animals are eating, so  
7 the effects you see may be due to nutritional effect  
8 as opposed to just to the chemical, so it is not  
9 uncommon to go up to 50,000 parts per million if the  
10 animals will tolerate it for chronic bioassay study.

11 So this 1,000 mgs per kgs that the EPA  
12 has is their value in assessing risk assessment, but  
13 for chronic animal bioassays and for hazard  
14 identification, much higher levels are tolerated for  
15 those studies.

16 Q. Excuse me. The OECD guidelines of  
17 reaching at least a 1,000 mgs per kgs per day in the  
18 high dose animals is worldwide standard, isn't it?

19 MS. WAGSTAFF: Object to form. Standard  
20 for what?

21 A. I can't talk --

22 Q. (BY MR. HOLLINGSWORTH) It's a standard  
23 that EFSA, the European regulatory authorities also  
24 adhere to, isn't it?

25 A. That may very well be. And, again,

1 that's for their purposes of risk assessment. But  
2 we -- what I have done is hazard identification.

3 Q. You didn't find any evidence of an  
4 increased incidence of adenoma or carcinoma in any  
5 organ in any of these rats, did you, in the Feinchemie  
6 study?

7 A. In the Feinchemie study, no, I found no  
8 evidence of that, but I also determined that the  
9 tolerated dose was not reached, and so in my opinion,  
10 this was an inadequate study to evaluate the  
11 carcinogenicity of glyphosate.

12 Q. It's not a negative study?

13 A. It's an inadequate study.

14 Q. And that is based on a standard that's  
15 imposed by the National Tox Program project?

16 A. Based on my many years of experience  
17 within the National Toxicology Program and also that  
18 would be a -- something that would also be considered  
19 by the IARC monograph program as an indication that  
20 the study is inadequate because the doses were too low  
21 to see an effect.

22 Q. Is the National Tox Program standard  
23 published?

24 A. Absolutely.

25 Q. So where do you find that?

Page 218

1 A. You can go online to the NTP.com or dot  
 2 gov, excuse me.  
 3 Q. And then what you do you do?  
 4 A. Just look from their site you go to  
 5 study reports.  
 6 Q. And you'll find there that the maximum  
 7 tolerated dose that NTP wants to see is 50,000 parts  
 8 per million?  
 9 A. I didn't say that that's what they want  
 10 to see. I mean, sometimes -- you have to do your dose  
 11 setting to see what doses the animals will tolerate  
 12 and you do a series of studies to evaluate what doses  
 13 the animals will study -- will tolerate. And based on  
 14 that, you set your doses. But if the animals appear  
 15 to be able to tolerate acutely a dose greater than 5  
 16 percent, the NTP will not do a study above 5 percent  
 17 because once you add more than 5 percent to the feed,  
 18 you're going to start affecting the nutritional value  
 19 and, therefore, the effects you see may be due to the  
 20 restriction of the feed or restriction on nutritional  
 21 intake as opposed to solely the chemical that you're  
 22 studying.  
 23 Q. What was the high dose group in the  
 24 Feinchemie rat study receiving in parts per million in  
 25 the diet?

Page 220

1 2009 rat study by Dr. Wood, the sponsor was Nufarm.  
 2 A. Okay. Now we're going on to Wood.  
 3 Okay. Okay.  
 4 Q. Now, is this another study where you say  
 5 that the maximum tolerated dose or MTD was not reached  
 6 and therefore it is inadequate for evaluation?  
 7 A. That's what I said in my report,  
 8 correct.  
 9 Q. Did you think that the 300 parts per  
 10 million high dose level for the Monsanto 1981 rat  
 11 study by Dr. Lankas was at a high enough level to be  
 12 adequate for review?  
 13 A. The Lankas study?  
 14 Q. Yes.  
 15 A. It's adequate for review because you saw  
 16 an effect. So, therefore, you can -- you can make an  
 17 evaluation. The fact that you saw an effect in the  
 18 Lankas study indicates that you can make an evaluation  
 19 of the study because an effect was observed and it was  
 20 a significant effect in the testes, interstitial cell  
 21 tissues of the rats. So even though an MTD wasn't  
 22 reached, it's still an adequate study for evaluation  
 23 because you saw an effect.  
 24 But in these other studies, you saw no  
 25 effect. You saw no effect on body weight. You saw no

Page 219

1 A. 40,000 parts per million is what I have  
 2 in my report.  
 3 Q. So they were receiving 40,000 parts per  
 4 million?  
 5 A. Right.  
 6 Q. And you're telling us that the NTP  
 7 program would go to 50,000 parts per million?  
 8 A. If the animals would tolerate.  
 9 MS. WAGSTAFF: Objection, misstates  
 10 testimony.  
 11 Q. (BY MR. HOLLINGSWORTH) Okay. Okay. So  
 12 you don't think 40,000 parts per million is a  
 13 sufficiently high dose to test glyphosate with in  
 14 Wistar rats?  
 15 A. Based on the results of this study after  
 16 two years, you saw no effect on body weight or  
 17 survival of the controls versus the high dose treated  
 18 animals, so, therefore, it appears the animals could  
 19 have tolerated a higher dose. So, therefore, you did  
 20 not dose the animals at a high enough level to see an  
 21 effect if an effect -- if, you know, if it was  
 22 present. So . . .  
 23 Q. Are you aware of the conclusion reached  
 24 by the original authors, that is, the investigators,  
 25 the veterinary pathologists who conducted the -- the

Page 221

1 effect on survival. You saw no increased incidences  
 2 of any type of tumors, so you got -- essentially you  
 3 got no effect. So since you saw no effect, and you  
 4 didn't test them at the -- at a top dose that they  
 5 could tolerate, it's an inadequate study for the  
 6 evaluation of the carcinogenic potential in this  
 7 particular study.  
 8 Q. Are you aware that the Wood 2009 rat  
 9 study was submitted to EPA?  
 10 A. Yes.  
 11 Q. And EPA did not consider there to be any  
 12 treatment-related incidence of cancer in any organ in  
 13 any animal, true?  
 14 A. That was their conclusion, because in my  
 15 opinion --  
 16 MS. WAGSTAFF: Object to form.  
 17 A. -- it was their opinion because it was  
 18 an inadequate study. My opinion that it's an  
 19 inadequate study, therefore --  
 20 Q. (BY MR. HOLLINGSWORTH) Okay. What was  
 21 the high dose group receiving by way of parts per  
 22 million glyphosate in the diet?  
 23 A. In --  
 24 MS. WAGSTAFF: In which case?  
 25 A. In the Wood study?

Page 222

1 Q. (BY MR. HOLLINGSWORTH) Yes.  
 2 A. Parts per million was 15 parts per  
 3 million for 24 months.  
 4 MS. WAGSTAFF: Did you say 15 or 50?  
 5 THE DEPONENT: 15, 1-5.  
 6 Q. (BY MR. HOLLINGSWORTH) Okay. The EPA  
 7 did not conclude that the motion -- that the  
 8 maximum -- motion -- maximum tolerated dose was  
 9 reached, did they?  
 10 MS. WAGSTAFF: Object to form.  
 11 Q. (BY MR. HOLLINGSWORTH) Was not reached,  
 12 did they?  
 13 A. I didn't see anything in the EPA report  
 14 addressing maximum tolerated dose, no.  
 15 Q. They didn't say -- they didn't make the  
 16 observation that this study is invalid because the  
 17 maximum tolerated dose was not reached, did they?  
 18 MS. WAGSTAFF: Object to form.  
 19 A. No, but there again, you have to  
 20 consider that the EPA was doing a risk assessment, so  
 21 for the purposes of their risk assessment, the fact  
 22 that the MTD was not reached may not be a part of  
 23 their criteria or part of their evaluation. So that's  
 24 why they would not address that issue.  
 25 But for the purpose of a hazard

Page 224

1 studies, didn't you?  
 2 A. Okay.  
 3 Q. Cheminova, 1993; Syngenta, 2001 and  
 4 Arysta, A-r-y-s-t-a, 1997.  
 5 A. Okay.  
 6 Q. And you concede that those three studies  
 7 are negative for the carcinogenicity of glyphosate,  
 8 true?  
 9 A. Which ones are they again? I'm sorry.  
 10 Q. I believe they're Cheminova, 1993.  
 11 A. Okay.  
 12 Q. You concluded with respect to that  
 13 study, which was a two-year rat study in  
 14 Sprague-Dawley rats, right?  
 15 A. Correct.  
 16 Q. That there was no evidence of  
 17 carcinogenic activity that you could see based on your  
 18 review of that study?  
 19 A. Right, no statistically significant  
 20 increase versus control.  
 21 Q. And you said the same thing for the  
 22 Syngenta -- the sponsor is Syngenta in 2001, right?  
 23 And the Syngenta study is in a slightly different  
 24 strain of rat, isn't it?  
 25 A. This is a 2001?

Page 223

1 identification, if you're going to do a  
 2 carcinogenicity study, you need to treat the animals  
 3 at a level that they can tolerate without showing  
 4 overt toxicity, and that is to find a maximum  
 5 tolerated dose. And my evaluation of the Wood study  
 6 is the MTD was not reached, so, therefore, it's not a  
 7 valid study for determining carcinogenicity because  
 8 you saw no effect.  
 9 Q. That report has been submitted to EFSA  
 10 also, hasn't it?  
 11 A. I believe it has.  
 12 Q. And EFSA concluded there was no  
 13 carcinogenic effect of that study due to the  
 14 administration of glyphosate, didn't they?  
 15 A. Again --  
 16 MS. WAGSTAFF: Object to form.  
 17 Q. (BY MR. HOLLINGSWORTH) Is that right?  
 18 A. Again, the EFSA are doing risk  
 19 assessment and their criteria for risk assessment  
 20 evidently say that this study is -- is negative.  
 21 Q. Didn't EFSA say that the study showed no  
 22 carcinogenic effect?  
 23 A. No carcinogenic effect, that's what they  
 24 said for the purpose of their risk assessment.  
 25 Q. Now, you looked at three additional rat

Page 225

1 Q. I believe so.  
 2 A. It's in the Wistar rat.  
 3 Q. Okay. No, wait a minute.  
 4 A. Yes, and I said that was negative.  
 5 Q. Yup. And that's in the Wistar rat?  
 6 A. Correct.  
 7 Q. Okay. And so you said that the Syngenta  
 8 2001 study is negative?  
 9 A. Correct.  
 10 Q. And the Arysta 1997 study, do you have  
 11 that in mind?  
 12 A. Syngenta 1997?  
 13 Q. Arysta.  
 14 A. Arysta, okay.  
 15 Q. Arysta is a Japanese -- no.  
 16 A. Okay. Yes.  
 17 Q. Is Arysta a Japanese company or an  
 18 Israeli company?  
 19 A. I do not know.  
 20 Q. Anyway, the Arysta study in 1997 was  
 21 conducted in Sprague-Dawley rats, true?  
 22 A. Correct.  
 23 Q. And you concluded that there was no  
 24 evidence of carcinogenic activity in that study at  
 25 all, correct?

Page 226

1 A. That's correct.  
 2 Q. Greim and his co-authors reviewed all  
 3 the studies that you have reviewed, true?  
 4 A. Yes. Yes. I think the only one that  
 5 I'm -- yes. That's correct.  
 6 Q. Do you know how much time Dr. Greim and  
 7 his co-authors spent reviewing the studies that they  
 8 reference in their paper?  
 9 MS. WAGSTAFF: Objection, calls for  
 10 speculation.  
 11 A. I have no idea.  
 12 Q. (BY MR. HOLLINGSWORTH) You didn't  
 13 inquire into that?  
 14 A. No, sir.  
 15 Q. Isn't that something that you'd like to  
 16 know as a scientist?  
 17 A. How much time they spent going through  
 18 the data?  
 19 Q. Yes. How much time did the authors  
 20 spend evaluating the data?  
 21 A. I mean, I'm sure they took as much time  
 22 as they needed to get the data together and put in the  
 23 publication.  
 24 Q. Do you know how Dr. Greim and his  
 25 co-authors selected the specific tumor data that they

Page 228

1 Q. Do you know where or why they chose the  
 2 particular statistic methods that they chose?  
 3 A. Again, I'd have to look at the paper and  
 4 see the rationale that they would have used -- that  
 5 they would have stated. I don't recall. I'd have to  
 6 look at the paper again.  
 7 Q. Wouldn't you want to know that as a  
 8 scientific evaluator?  
 9 A. Well, sure.  
 10 Q. Doing the kind of report you were doing?  
 11 A. Sure. But that's what I said. You look  
 12 at the paper, you read the Greim paper and when you  
 13 read the paper, they should have outlined in there  
 14 their method for selecting the studies, for putting  
 15 together the table and their selection of the  
 16 statistics that they used in the paper if they did the  
 17 statistics, so I would have read that when I read the  
 18 Greim paper.  
 19 Q. And you relied on that?  
 20 A. Well, I -- I relied on that or I relied  
 21 on EPA or I relied on information I had obtained from  
 22 Chris Portier, and I referenced that in my report  
 23 where the source of the statistics that I used in my  
 24 report.  
 25 Q. Did you know that Dr. Portier also

Page 227

1 chose to report for their study?  
 2 A. No.  
 3 Q. Isn't that something that you'd like to  
 4 know before you rely on their opinions?  
 5 A. Well, they --  
 6 MS. WAGSTAFF: Object to form.  
 7 A. They -- they did explain in the -- in  
 8 the beginning of their paper how they went about  
 9 gathering the data and putting the data together. So  
 10 that type of information was available in the  
 11 publication. I assume since it's a peer-reviewed  
 12 publication that the people who peer reviewed the  
 13 paper were satisfied that the methods that were  
 14 outlined in the Greim paper as to how they put  
 15 together the tables and chose the studies and what  
 16 have you were acceptable.  
 17 Q. (BY MR. HOLLINGSWORTH) Do you know  
 18 whether Dr. Greim and his co-authors conducted their  
 19 own statistical evaluation of the tumor data from the  
 20 nine rat studies and five mouse studies that they  
 21 reviewed -- I'm sorry, from the seven rat studies and  
 22 the five mouse studies that they reviewed, excuse me?  
 23 A. I'd have to go back and look at the data  
 24 to refresh my memory. I can't recall if they did the  
 25 statistics or where they got the statistics from.

Page 229

1 relied on data from Dr. Greim's publication?  
 2 A. Well, of course. I mean, that was --  
 3 that was the only publicly available source of -- for  
 4 a lot of these studies. So of course he would use  
 5 that. Now --  
 6 MS. WAGSTAFF: We've been going almost  
 7 two hours. When you get a chance, can we take a  
 8 break?  
 9 MR. HOLLINGSWORTH: Sure, we can break  
 10 now.  
 11 MS. WAGSTAFF: Okay.  
 12 THE VIDEOGRAPHER: Going off the record.  
 13 The time is 3:46 p.m.  
 14 (Recess taken, 3:46 p.m. to 4:08 p.m.)  
 15 THE VIDEOGRAPHER: We are back on the  
 16 record. The time is 4:08 p.m.  
 17 Q. (BY MR. HOLLINGSWORTH) Can we assume  
 18 that Dr. Greim and his co-authors had the summary  
 19 tables for tumors in each of the 12 long-term  
 20 bioassays that they evaluated in their published  
 21 paper?  
 22 MS. WAGSTAFF: Objection, calls for  
 23 speculation and assumption.  
 24 A. I -- I'd -- I really need to take a look  
 25 at the Greim paper to make sure that it was true for

1 all the studies. I know they had summary tables for a  
2 number of the studies, but I can't say that they had  
3 them for all of them.

4 And while we're on the Greim, if I may,  
5 first I want to make it -- make it clear that -- that  
6 I did not rely totally on the Greim for my report. I  
7 use the Greim to get some information on tumor  
8 incidences and that type of thing, but I did not rely  
9 on that exclusively or totally.

10 And while we're on the subject of the  
11 Greim paper, I hate to express my unhappiness or my  
12 anger about something, but Monsanto has been making it  
13 sound like when the review of glyphosate took place at  
14 IARC that they totally ignored the Greim paper and  
15 that is absolutely not true.

16 The Greim paper was provided to us, it  
17 was provided to me, kind of, as I testified, at the  
18 last minute. But we did review the paper as best we  
19 could with the time we had and we also addressed it in  
20 the monograph, so the Greim paper is addressed in the  
21 monograph. So to say that IARC ignored all of the  
22 data that Greim provided is absolutely not true and  
23 you need to stop it. You need to stop telling the  
24 media that IARC didn't look at it. They did.

25 In fact, it's in the monograph. If you

1 look at the monograph, it addresses the Greim paper in  
2 several of the studies in the Greim paper, so I just  
3 wanted to express my displeasure with the way my  
4 testimony was given to the press and then  
5 misrepresented, so stop with the fake news.

6 Q. (BY MR. HOLLINGSWORTH) Well, thanks for  
7 your advice, Dr. Jameson, I read your deposition, the  
8 so-called fact deposition, and I know what you said  
9 there and I know you expressed tremendous surprise  
10 when you saw that the Greim paper had been provided to  
11 the other members of the IARC committee but not to you  
12 and I'll leave the record at that unless you want to  
13 argue about it.

14 A. No, no, no, it's -- it is what it is.

15 Q. It is what it is.

16 A. I -- and I was -- as I -- as you can  
17 tell and the expression I made is going to haunt me  
18 forever because that's what got in the media, of  
19 course. But I was just surprised that IARC had access  
20 to it, little bit further -- little bit earlier than I  
21 was made aware of it. That's all.

22 Q. Okay. I'll move to strike everything  
23 that you said because it wasn't in response to any  
24 question I had.

25 A. That's up to you.

1 Q. Sir, we can assume -- you can fairly  
2 assume as --

3 MS. WAGSTAFF: Before we move on, I will  
4 say that that is absolutely in response to your  
5 questions about asking about Greim all day long, but  
6 go ahead.

7 MR. HOLLINGSWORTH: Okay. That's okay.

8 Q. (BY MR. HOLLINGSWORTH) Sir, you know  
9 from your reading of the Greim materials that  
10 they -- those authors had at least the summary --  
11 tumor summary table for every single study that they  
12 talked about, didn't they?

13 A. To the best of my recollection,  
14 they -- that's what they stated.

15 Q. And didn't you say that you relied on  
16 Greim totally for the tumor incidences?

17 A. No. I did not say that.

18 MS. WAGSTAFF: Objection, misstates  
19 testimony.

20 A. No, I absolutely did not say that.

21 Q. (BY MR. HOLLINGSWORTH) Okay.

22 A. I relied -- to be honest, I relied on  
23 the study reports that I received from the individual  
24 studies from the laboratories, the laboratory reports.  
25 That would be my first source of getting the tumor

1 data. I would take that information and I would  
2 compare it to what was in Greim. I think that's what  
3 I said. I would look at the tumor data, tumor tables,  
4 get the information and then take the opportunity to  
5 compare it to Greim to make sure they -- they were the  
6 same and -- and that would be my first source.

7 To be honest, my second source would be  
8 if the EPA had written a report or published a  
9 document on their review of a particular study, I  
10 would also go to that and use that as a source for  
11 tumor incidences if it was included in their report.

12 Again, I would take that information,  
13 compare it to Greim, but, no, Greim was definitely not  
14 my primary source for the information.

15 Q. Isn't it true that in your report, you  
16 referred -- you referred to 14 rodent studies and 11  
17 times you referred to Greim?

18 A. True. But I think as I indicated  
19 before, I used that more as -- for convenience to keep  
20 straight all the different studies than -- than  
21 anything else.

22 Q. When you were comparing the studies --  
23 excuse me, when you were comparing the tumor tables  
24 from the actual studies themselves to what Greim said  
25 about them, did you find any material differences

1 between what Greim said was a tumor incidence and what  
2 the actual original studies themselves said?

3 A. Sitting here today, I don't recall that  
4 I did see any -- any differences. Although, I think I  
5 mentioned in my -- in one place in my report that I  
6 looked at the Greim Tier II report and got some  
7 incidences from that, and that was a little bit --  
8 that was different than what was listed in the actual  
9 study tumor tables that I got, but that -- and I  
10 indicated I couldn't resolve why one was different  
11 from the other, but that -- that's the only one I  
12 addressed in my report.

13 Q. Which study was that?

14 A. I'm going to have to go through my  
15 report to find it, but it is listed in my report.  
16 That's for the Sugimoto study, study 12 in Greim.  
17 Talking about the -- it started midway, do you want me  
18 to read it --

19 Q. Just tell me what you're referring to,  
20 what page.

21 A. This is on page 22.

22 Q. Yep.

23 A. The Sugimoto, it's the second paragraph,  
24 and about midway down it starts talking about review  
25 of nine tumor tables shows that there was significant

1 trend in development of hemangiosarcomas.

2 Q. Yep.

3 A. And then about a third -- seven or eight  
4 lines, I'd say I also reviewed the Tier II summaries  
5 for glyphosate from Greim, which showed a reported  
6 statistically significant increase in lymphoma.

7 Q. Yep.

8 A. In mice. However, I could not resolve  
9 the difference in the tumor incidence between the  
10 Greim summary and the published Greim, et al. and the  
11 Sugimoto tumor tables that's the discrepancy that I  
12 found.

13 Q. That wasn't a significant discrepancy  
14 even if it was a discrepancy, was it?

15 A. A significant discrepancy?

16 Q. Yeah.

17 A. Well, it depends on what you -- I mean,  
18 it affected --

19 Q. It wasn't a material discrepancy, was  
20 it?

21 A. Well, it was a discrepancy in the  
22 incidence, reported incidence.

23 Q. Okay. How did you get ahold of the  
24 Sugimoto study report?

25 A. That was provided to me by counsel.

1 And, again -- well, by counsel.

2 Q. Okay. So you had reports on these  
3 pathology studies, these long-term bioassays on more  
4 than just the three Monsanto studies?

5 MS. WAGSTAFF: Object to form.

6 A. Okay. I had -- I had some information  
7 on all of the studies. The amount of information I  
8 had depended on who the -- who the study was performed  
9 for. And if memory serves me correctly, if it was a  
10 Monsanto study, I had a lot more -- a lot more  
11 documents to look at than from the other -- from the  
12 studies that were performed in support of other  
13 organizations.

14 Q. (BY MR. HOLLINGSWORTH) Well, the  
15 Sugimoto study and all the other studies other than  
16 the Monsanto study are not publicly available, so I'm  
17 wondering how you got those study reports, the actual  
18 study reports.

19 A. Like I said, I -- I -- for -- other than  
20 the Monsanto studies, the information I had was a lot  
21 less, so -- and I think as I indicated earlier in my  
22 testimony, some of them I didn't have much  
23 information. I may not have even had the report or  
24 much more than some tumor tables.

25 Q. You just told us that you had the actual

1 study report for Sugimoto?

2 A. Did I say that?

3 Q. Yeah.

4 A. Then I misspoke. I apologize.

5 Q. Because you said you had the study from  
6 which you compared the Sugimoto actual report data to  
7 the Sugimoto data reported out by the Greim  
8 publication.

9 A. But that was the data from the tumor  
10 tables that I had.

11 Q. What were -- do those tumor tables come  
12 from Greim too?

13 A. There were tumor tables in Greim.

14 Q. Yeah. There were online -- they were  
15 tables of actual animal by animal data?

16 A. Right.

17 Q. In the Greim online supplement?

18 A. Correct.

19 Q. Is that what you're referring to?

20 A. Usually I refer -- I would -- like I  
21 said, I would look at the tumor tables from the actual  
22 study lab because I think I had tumor tables for every  
23 study. And then I would take that and I -- actually,  
24 I compared it to what Greim had in his publication and  
25 usually they compared very well and I didn't go any

Page 238

1 further.

2 Q. Okay. Do you know whether Dr. Greim and

3 his co-authors actually reviewed the underlying study

4 reports for each of the studies they report in their

5 publication?

6 A. I don't recall if they indicated they

7 did that in their publication or not.

8 Q. Wouldn't you want to know that

9 information before you made an opinion about it?

10 A. Well, like I said, the Greim paper is

11 published in a peer-reviewed journal. The fact that

12 it was peer reviewed and accepted for publication

13 indicates that the methodology that they explained in

14 their -- in their paper was adequate for the peer

15 reviewers to accept the publication, so -- and like I

16 said, sitting here today, I don't remember exactly

17 what -- what they said in the Greim paper, but I -- so

18 I'd have to look at the Greim paper to say if they

19 indicated in there they looked at all the study

20 reports.

21 Q. Do you know whether the authors with

22 Dr. Greim and his co-authors reinterpreted the 12

23 studies that they included in the Greim published

24 report or did they recount exactly what the

25 pathologist who originally investigated those reports

Page 240

1 at what they said about each one to answer that.

2 Q. Wouldn't you like to know that?

3 A. Well, I'm -- I assume they addressed

4 that in the -- they addressed that issue in their

5 report, so I'm sure it's in -- I would assume that it

6 is -- what they did is in the report, so, again, I

7 need to look at the report to adequately respond to

8 that question.

9 Q. Do you agree with Dr. Greim and his

10 co-authors that there is no evidence of a carcinogenic

11 effect related to glyphosate treatment in any of the

12 14 long-term bioassays which they reviewed in their

13 paper? Instead of 14, I should have said 12. Sorry.

14 MS. WAGSTAFF: Object to form.

15 A. Obviously in my report I indicated a

16 number of the studies showed a positive response to

17 glyphosate in both rats and mice. So obviously I do

18 not agree.

19 Q. (BY MR. HOLLINGSWORTH) How many peer-

20 reviewed studies have you authored in the published

21 literature which state that glyphosate can cause

22 non-Hodgkin's lymphoma in humans?

23 A. Peer-reviewed articles in the

24 literature, I have authored none.

25 Q. Is this issue of whether glyphosate can

Page 239

1 had concluded?

2 A. I know that they -- in the Greim paper,

3 they made comment on the adequacy of each study. In

4 other words, they had some criteria based on some -- I

5 don't know if it's from a publication or from an

6 industry source or a government source, but they did

7 have some criteria by which they measured the validity

8 and what have you of each study and so indicated in

9 their reports, so they did do an evaluation of the

10 study from that standpoint.

11 As far as reinterpreting the actual

12 data, the tumor data or what have you, I -- I --

13 again, I'd have to look at the paper to say definitely

14 what they did because I'm sure they describe in the

15 paper what they did. I'm under the impression they

16 didn't change anything or try to change anything.

17 MS. WAGSTAFF: I'll make an additional

18 request to please provide the study to Dr. Jameson if

19 you're going to be asking this level of detail. It's

20 not a memory test.

21 Q. (BY MR. HOLLINGSWORTH) The Greim authors

22 did not reject the original investigators' conclusions

23 in any single one of the 14 studies that they reviewed

24 in their peer-reviewed publication, did they?

25 A. I'd have to get the paper out and look

Page 241

1 cause non-Hodgkin's lymphoma in humans something that

2 you had studied before your work on monograph 112?

3 A. No, monograph 112 was the first time I

4 addressed the issue of the potential carcinogenicity

5 of glyphosate.

6 Q. And there's nothing in your curriculum

7 vitae that indicates anywhere that you studied the

8 issue of whether glyphosate can cause non-Hodgkin's

9 lymphoma in humans prior to your work in -- starting

10 in 2015 or late 2014 in connection with monograph 112

11 by IARC?

12 A. Specific to glyphosate, that would be an

13 accurate statement. However, in my career with the

14 National Toxicology Program, I spent many years

15 evaluating many different chemicals for listing in the

16 report carcinogens where I evaluated the same type of

17 data that is available for glyphosate to decide if

18 sufficient evidence or inadequate evidence in mice or

19 in laboratory animals, and also if there was limited

20 or sufficient evidence in humans based on review of

21 epidemiology data and made recommendations for listing

22 that in the report on carcinogens and/or the IARC

23 monographs.

24 Q. You worked on the National Tox Program

25 for many years, true?

1 A. That's correct.  
 2 Q. And you were in charge for eight years  
 3 of the reports to Congress about what carcinogens the  
 4 National Tox Program had studied, true?  
 5 A. Well, that's not quite accurate. I --  
 6 for the eight years I was director of the program, I  
 7 was director of report on carcinogens. For about five  
 8 years prior to that, I worked on the report on  
 9 carcinogens at the -- at the National -- for the  
 10 National Toxicology Program. But -- so what was the  
 11 question? I'm sorry.  
 12 Q. That's -- I'll take that as an answer.  
 13 A. Okay.  
 14 Q. Here is my next question, during the  
 15 time that you worked on the National Program, National  
 16 Tox Program, is that NIEHS?  
 17 A. NIEHS, yes.  
 18 Q. Did the NTP ever report that glyphosate  
 19 can cause non-Hodgkin's lymphoma in humans?  
 20 A. To the best of my recollection, they  
 21 never addressed that issue, no.  
 22 Q. Has anyone in the United States  
 23 government, Department of Health or FDA or EPA or any  
 24 health agency reported to Congress that glyphosate can  
 25 cause non-Hodgkin's lymphoma --

1 MS. WAGSTAFF: Object to form.  
 2 Q. (BY MR. HOLLINGSWORTH) -- in humans?  
 3 A. I am -- I don't know that I can answer  
 4 that. That nobody has said nothing to Congress. To  
 5 my knowledge, I don't know of anyone that has.  
 6 Q. When you were at the National Tox  
 7 Program, you did not -- as far as you know, the  
 8 National Tox Program did not report to Congress that  
 9 glyphosate can cause non-Hodgkin's lymphoma in humans,  
 10 true?  
 11 A. They did not while I was there, that's  
 12 correct.  
 13 Q. Does the IARC preamble allow the  
 14 monograph collaborators to consider potential human  
 15 exposures when they do their hazard assessment?  
 16 A. Do they allow them to consider potential  
 17 human?  
 18 Q. Yes. Does the -- do you understand my  
 19 question?  
 20 A. Yes, sir. I think I do. It's part of  
 21 the review process for the working group at IARC.  
 22 When they're evaluating a chemical to address the  
 23 issue of exposure and that is a section that is in  
 24 each monograph. That is an important part of the  
 25 review.

1 Q. So the IARC preamble does not permit  
 2 IARC committee participants to fail to consider  
 3 potential human exposure in the real world  
 4 environment, true?  
 5 MS. WAGSTAFF: I'm just going to say  
 6 that we're starting to get into testimony that related  
 7 to his fact witness deposition that's already taken  
 8 place. I think if we go much further, I'm going to  
 9 have to instruct him not to answer.  
 10 A. Could you repeat the question, I didn't  
 11 quite understand what you were driving at.  
 12 Q. (BY MR. HOLLINGSWORTH) Just listen to my  
 13 question, please, and see if you can answer it.  
 14 A. Does the IARC monograph standards or the  
 15 IARC preamble permit IARC committee participants to  
 16 refuse to consider real world potential exposure to  
 17 the substance under review?  
 18 MS. WAGSTAFF: Object to the form of the  
 19 question.  
 20 A. So does it prevent them from not  
 21 considering, is that what you're saying?  
 22 Q. (BY MR. HOLLINGSWORTH) Yes.  
 23 A. So it's like a double negative. I mean,  
 24 it's in the preamble and the process that exposure is  
 25 a major part of the review of a chemical by the IARC

1 monograph program, and so exposure data is -- is  
 2 investigated, they -- there is a section in each  
 3 monograph on exposure. Turns out that exposure is an  
 4 extremely important area for the epidemiologists.  
 5 They need to know how people are exposed, where  
 6 they're exposed, what the -- the levels that are being  
 7 processed so they get an idea of the levels that  
 8 people are exposed to. So exposure is a very  
 9 important part of the IARC monograph.  
 10 So, yes, they are asked to review the  
 11 exposure information for each chemical that they  
 12 review for the monograph. So -- but, you know, they  
 13 don't twist people's arm and say you have to -- have  
 14 to look at this. But they ask for their opinion and  
 15 they ask -- ask to make sure that they agree with  
 16 what's written in the monograph because the monograph  
 17 is a product of the whole working group, not just an  
 18 individual or not just a subgroup.  
 19 It's the whole working group is -- is  
 20 responsible for producing that monograph, so the  
 21 monograph is a product of every person on that  
 22 monograph, so every person on the monograph votes on  
 23 the acceptability of each section, so I'm not aware of  
 24 that a monograph review has ever taken place where  
 25 exposure wasn't an important aspect of the review.

1 Q. You recall my questions about the three  
2 negative rat studies that you reviewed in connection  
3 with the report, the expert report that you prepared?

4 A. The ones that -- that I indicated that  
5 were --

6 Q. Yes, were negative?

7 A. No effect. Were negative.

8 Q. Yes.

9 A. Yes.

10 Q. Did the IARC preamble preclude IARC  
11 committee members from looking and considering --  
12 looking at and considering negative data --

13 A. No.

14 Q. -- such as those three studies?

15 A. No.

16 Q. Does the IARC report itself provide a  
17 sufficient scientific basis for your opinion in this  
18 case that glyphosate can cause non-Hodgkin's lymphoma  
19 in humans?

20 A. What I can say is my participation on  
21 the IARC working group -- I formed my initial opinion  
22 of glyphosate based on my work with the IARC monograph  
23 and the IARC -- we, as the IARC monograph working  
24 group, agreed that it met the criteria for a two-way  
25 human carcinogen -- I'm sorry, possible -- probable

1 Q. Yes.

2 A. No. I'm sorry, I guess maybe it's  
3 getting late in the day.

4 Q. Let me reask the question.

5 A. Yes, please.

6 Q. Does the hazard assessment that you made  
7 based on animal studies in your expert witness report  
8 take into account that effects on animals are seen or  
9 not seen at doses that are relevant to the human  
10 environment?

11 MS. WAGSTAFF: Object to form.

12 A. Well, doing a hazard assessment, the  
13 purpose of the hazard assessment is to evaluate the  
14 material to see if it can cause cancer in animals.  
15 Let's just address the animal part, because that's  
16 what you -- the question was about in animals. So the  
17 hazard identification is performed to identify if a  
18 chemical under the most extreme conditions can cause  
19 cancer in experimental animals, it does not worry  
20 about the levels that are -- humans are exposed to.

21 The first question is can it cause  
22 cancer, is it an animal carcinogen, so under standard  
23 process of doing a hazard identification, you look at  
24 animal bioassays, and bioassays, as I identified  
25 before, are done trying to use the maximum tolerated

1 human carcinogen, and that there was an association of  
2 exposure to glyphosate in glyphosate formulations to  
3 non-Hodgkin's lymphoma in humans based on the  
4 epidemiology studies, so that's where I formed my  
5 initial opinion.

6 But after asking to review all of the  
7 available data, I was -- I had the opportunity to  
8 delve into it into more detail, look at new data. It  
9 gave me the opportunity to take the Greim -- the  
10 studies in the Greim paper and the Greim paper itself  
11 and the tables in the Greim paper, and I had the time  
12 to sit down, look at the data and evaluate it and the  
13 Greim paper just strengthened my opinion that it --  
14 that glyphosate is an animal carcinogen because we  
15 found more tumors from that -- from those studies that  
16 are -- were identified in the Greim paper.

17 And so that's how I formed my opinion  
18 that glyphosate -- on glyphosate in non-Hodgkin's  
19 lymphoma.

20 Q. Do the hazard assessments that the IARC  
21 monograph committees may take into account whether any  
22 effects seen from studies that are reviewed by the  
23 IARC committees regarding carcinogenicity are  
24 conducted at human relevant doses?

25 A. Are you implying -- the animal studies?

1 dose. So the maximum tolerated dose is the dose the  
2 animals can tolerate without showing overt toxicity,  
3 so that is the purpose of the bioassay and that is  
4 what the hazard identification uses to establish if  
5 something is an animal carcinogen or not.

6 So I mean, that is -- that argument  
7 about human relevant doses is -- is -- goes on -- has  
8 been going on for years and years and years in  
9 toxicology, but the state of the science is first we  
10 have to establish is it an animal carcinogen and then  
11 you do additional studies. You do the risk analysis  
12 to see what happens at the human relevant doses.

13 Q. (BY MR. HOLLINGSWORTH) When you do your  
14 hazard assessment, I think you say that the -- you  
15 said that the hazard assessment does not worry about  
16 levels that a human is exposed to; is that right?

17 A. Well, maybe I -- maybe I -- I used the  
18 wrong term about not worry about. When you do a  
19 hazard assessment, first you have to determine, you  
20 know, is it an animal carcinogen, is it a human  
21 carcinogen. And since your question spoke directly  
22 about animals, to -- the best way to identify if it's  
23 an animal carcinogen is to look at the bioassay data.  
24 And by definition, when you do a carcinogenesis  
25 bioassay, you try to expose the animals to the MTD.

1 You have to do things in steps and so  
2 that's why the doses are high for the -- initially for  
3 the animal studies, but it's based on the animal  
4 studies that limits are set and risk assessments are  
5 done.

6 Q. Does a hazard assessment based on  
7 animals consider whether the substance being studied  
8 by the review committee is -- is a carcinogen at  
9 levels that humans are exposed to?

10 MS. WAGSTAFF: Object to form.

11 A. I'm trying to formulate the question in  
12 my mind. I'm sorry, what was it again?

13 Q. (BY MR. HOLLINGSWORTH) Does the hazard  
14 assessment that the IARC committee members look at  
15 when they're evaluating animal data consider whether  
16 the substance, the test substance, is a carcinogen at  
17 levels which humans are exposed to?

18 A. As part of the evaluation of all of the  
19 data that is done, they always -- the working group,  
20 the people of the working group are always -- try to  
21 make themselves, at least in my experience with the  
22 working group, you try to make yourself familiar with  
23 what the human exposure levels are.

24 That's why there's a whole section in  
25 IARC monograph on exposure. That gives you an idea of

1 what the potential exposure could be, and so that's  
2 always in the back -- they always know, if you will,  
3 based on the exposure assessment what human levels  
4 are -- what levels are that humans are exposed to. So  
5 they're aware of that. But, again, like I said, for  
6 the purpose of hazard identification, the question  
7 asked is, is it an animal carcinogen, and the  
8 best -- and the data that is used for that is from an  
9 animal bioassay study, so for animal bioassay studies,  
10 they use high levels.

11 Now, a lot of times the lower levels  
12 that are used in a bioassay are, you know, may be an  
13 order or two of magnitude of the high dose and  
14 sometimes the low dose approaches a human exposure  
15 level, but that just depends on the design of the  
16 study.

17 MS. WAGSTAFF: For the reasons I set  
18 forth on the break, can we take another break here in  
19 a few minutes?

20 MR. HOLLINGSWORTH: Sure, when this is  
21 done. Tracy, can you read back my question, please,  
22 because he didn't answer my question.

23 (The question was read back as follows:  
24 "Does the hazard assessment that the IARC committee  
25 members look at when they're evaluating animal data

1 consider whether the substance, the test substance, is  
2 a carcinogen at levels which humans are exposed to?")

3 MS. WAGSTAFF: I'm going to object to  
4 the fact that this is related to questions already  
5 asked at his fact witness deposition and he just asked  
6 and answered it.

7 Q. (BY MR. HOLLINGSWORTH) Can you give me a  
8 yes or no answer to that?

9 MS. WAGSTAFF: He's answered the  
10 question.

11 A. I gave you an answer before. I stick to  
12 that answer. Sorry.

13 Q. (BY MR. HOLLINGSWORTH) What did you mean  
14 when you said that the hazard assessment group that  
15 you worked with does not worry about what levels  
16 humans are exposed to when they make their hazard  
17 assessment?

18 MS. WAGSTAFF: Objection. He already  
19 testified that he misspoke when he said does not  
20 worry.

21 Q. (BY MR. HOLLINGSWORTH) What did you mean  
22 does not worry?

23 A. What I --

24 Q. It seems to me like you mean does not  
25 take into consideration what actual human exposures

1 are, that's what it seems like to me?

2 MS. WAGSTAFF: Misstates testimony.  
3 Argumentative.

4 A. That's not what I meant. I shouldn't  
5 have said don't worry about. The purpose is to -- the  
6 first step in a hazard identification, one of the  
7 first steps, as far as animals are concerned, is to  
8 determine if it causes -- if it's an animal  
9 carcinogen, and an animal bioassay is the main study  
10 that addresses the issue of can a chemical cause  
11 cancer in animals.

12 And the standard protocol for an animal  
13 bioassay study is to do it at the maximum tolerated  
14 dose and increments below the maximum tolerated dose  
15 to see if it does -- if it can cause cancer under any  
16 circumstances. That's the question that's being  
17 addressed. So the working group will consider all the  
18 doses that are -- that are studied in a particular  
19 bioassay and they will make an observation of, oh,  
20 look at the low dose level, it's within an order of  
21 magnitude of what the humans are exposed to, so they  
22 take that -- they are cognizant of that and they take  
23 that into consideration.

24 And, in fact, sometimes -- I can't quote  
25 to a particular place, but sometimes, in -- in the

1 monograph, if it is -- if it is the case, they will  
2 say, you know, exposure at dose such and such  
3 parenthesis or brackets, if it's a comment from the  
4 work group, a level that's less than order of  
5 magnitude greater than what humans -- the EPA standard  
6 or the OSHA standard for it is, those particular types  
7 of comments are made in the study, so they do take  
8 into account -- they do consider the human exposure.

9 It's just that the design of the study  
10 for animal carcinogenicity is to find out if the  
11 study -- if the chemical can cause cancer in the  
12 animals.

13 Q. Did you cite any evidence in your  
14 report, your expert report to the judge in the MDL,  
15 that says that any one of the feeding levels in any of  
16 the 12 studies you reviewed in your report was close  
17 to the human doses in the real world environment?

18 A. I did not address that in my report, no.

19 Q. Do you know of anybody who has published  
20 such a report in the peer-reviewed medical literature?

21 A. I'm not aware of any, but to be honest  
22 with you, I haven't searched for that.

23 Q. Are you aware of any published case  
24 report from a medical doctor or a scientist that says  
25 that he or she had seen a patient whom he or she

1 thought had non-Hodgkin's lymphoma that was caused by  
2 exposure to glyphosate?

3 A. A report -- a clinical report -- a  
4 report from a clinician?

5 Q. A case report from a clinician, yes.  
6 Have you seen that?

7 A. I -- I'd have to go back and look at  
8 some of the epidemiology studies to see what they had  
9 in those reports, where they got some of the  
10 information for the case control studies. But sitting  
11 here today, I can't recall, but I'd have to go back  
12 and look at the literature again.

13 Q. You don't cite any study in the  
14 published peer-reviewed literature or any material  
15 that you have considered that states there is a case  
16 report that has been published by a clinician that  
17 says that glyphosate caused non-Hodgkin's lymphoma in  
18 a patient anywhere on the planet, do you?

19 MS. WAGSTAFF: Object to the form of the  
20 question.

21 A. I don't have it in my report, no, but  
22 that's because I haven't done a search for that. It's  
23 not to say that there isn't some reports out there in  
24 the literature.

25 Q. (BY MR. HOLLINGSWORTH) My question --

1 A. But I haven't searched for one.

2 Q. My question went to whether there was  
3 such a report in your materials considered list that's  
4 attached to your expert report.

5 A. And I said no, there isn't.

6 MS. WAGSTAFF: Can we take that break  
7 now?

8 MR. HOLLINGSWORTH: Sure.

9 THE VIDEOGRAPHER: Going off the record.  
10 The time is 4:47 p.m.

11 (Recess taken, 4:47 p.m. to 5:01 p.m.)

12 THE VIDEOGRAPHER: We are back on the  
13 record. The time is 5:01 p.m.

14 Q. (BY MR. HOLLINGSWORTH) Sir, when you and  
15 your colleagues at the National Tox Program made the  
16 reports you made to Congress for the -- regarding the  
17 list of carcinogens, you were reporting on what you  
18 had determined based on a hazard assessment, right?

19 A. What we were -- what we reported on was  
20 our review of the available data based on the criteria  
21 that had been established and approved by the  
22 Secretary of Health and Human Services for listing  
23 substances in the report as either known or reasonably  
24 anticipated to be human carcinogens.

25 Q. The hazard assessment that the National

1 Tox Program did and reported to Congress did not take  
2 into account whether any effect seen that support  
3 carcinogenicity from the studies, the animal studies  
4 are at human real relevant doses, true?

5 A. In the animal studies?

6 Q. Yes.

7 A. Again, the criteria for listing in the  
8 report on carcinogens, as far as the animals are  
9 concerned, is sufficient evidence in animals from  
10 studies in -- in -- in animals by multiple rounds of  
11 exposure, I could go -- I'd have to look at the thing  
12 to remember all of the criteria -- exactly what the  
13 criteria said, but they did the hazard assessment  
14 based on data in animals, and data in -- in humans and  
15 the data in animals was based on the carcinogenicity  
16 studies that are conducted in animals.

17 And as I indicated before, the  
18 carcinogenicity studies standard in toxicology for the  
19 35 plus years I've been doing this type of work, the  
20 standard is to do an animal bioassay carcinogenicity  
21 study at the maximum tolerated dose.

22 Q. Isn't --

23 A. The purpose is to identify if under  
24 whatever the -- you know, if you want the most extreme  
25 circumstance, but can the chemical cause cancer in

1 experimental animals.

2 Q. Isn't it true that the listing of a  
3 substance within the report to Congress by the  
4 National Tox Program only indicates a potential hazard  
5 and does not establish the exposure conditions that  
6 would pose cancer risks to individuals in their daily  
7 lives?

8 A. That is what you're reading from  
9 the -- probably the introduction to the report on  
10 carcinogens.

11 Q. Correct.

12 A. I remember writing that.

13 Q. Yes. I'm reading from the one in 2004.

14 A. Uh-huh.

15 Q. That's the one that you wrote, right?

16 A. Uh-huh.

17 Q. So you wrote that "thus listing of the  
18 substances in the report on carcinogens only indicates  
19 a potential hazard," right?

20 A. That's what it says, yes.

21 Q. And it does not establish the exposure  
22 conditions that would pose cancer risks from that  
23 substance to individuals in their daily lives, true?

24 A. That is -- that is saying that we --  
25 what was performed was a hazard identification and

1 paragraph on the left-hand column, do you see that?

2 A. Yes.

3 Q. And you wrote this, right?

4 A. Correct.

5 Q. And you also wrote the sentence which  
6 says, "Such formal risk assessments, referring to  
7 cancer risks to individuals in their daily lives, are  
8 the responsibility of the appropriate federal, state  
9 and local regulatory and research agencies," correct,  
10 did I read that correctly?

11 A. That is what was -- is written in the  
12 introduction. And as I indicated before, the reason  
13 for that being in there is to -- to let the reader  
14 know that what was -- what the reported carcinogens is  
15 all about is a hazard identification of the  
16 material -- of the substance that are listed in there  
17 as either known or reasonably anticipated to be a  
18 human carcinogen, and that it is not a risk assessment  
19 and the risk assessments are routinely done by the  
20 state, federal and local regulatory authorities.

21 Q. And what you have done in your report,  
22 your expert witness report, in this case is a hazard  
23 assessment?

24 A. That's as I indicated in my report,  
25 that's what I did.

1 that the report on carcinogens is not a risk  
2 assessment document.

3 Q. The -- the determination of what would  
4 pose cancer risks to individuals in their daily lives  
5 is a formal risk assessment according to your report  
6 to Congress, right?

7 A. That's correct.

8 MS. WAGSTAFF: I would request that you  
9 provide him with a copy of the 2004 document.

10 MR. HOLLINGSWORTH: Sure. I'll mark  
11 this as Exhibit 22-4 and this appears to be the 11th  
12 report on carcinogens which Dr. Jameson just testified  
13 that he wrote dated 2004.

14 THE DEPONENT: Do you need to stamp this  
15 or anything?

16 MS. WAGSTAFF: He put the sticker on it.

17 THE DEPONENT: I'm sorry.

18 Q. (BY MR. HOLLINGSWORTH) You're correct  
19 when you testified that I'm reading from the  
20 introduction at the bottom of the left-hand column.

21 A. First page of the introduction?

22 Q. Yes.

23 A. Okay.

24 Q. And I was reading from the next to  
25 last -- the penultimate sentence in the last full

1 Q. And that's the same type of hazard  
2 assessment that's identified in the report to Congress  
3 that you just read?

4 MS. WAGSTAFF: Object to the form.

5 A. The report on carcinogen is a hazard  
6 assessment document, correct.

7 Q. (BY MR. HOLLINGSWORTH) All right. Thank  
8 you. Would you agree that hazard assessments err on  
9 the side of caution in designating a compound a  
10 probable carcinogen?

11 A. What do you mean by "err on the side of  
12 caution"?

13 Q. Err on the side of protection.

14 A. "Err on the side of protection" of -- of  
15 what?

16 Q. Of the public.

17 A. Of the public?

18 Q. Yes.

19 A. I don't know I would say that it errs on  
20 the side of protection of the public. The purpose of  
21 this hazard identification document is to get the  
22 information to the public that these materials have  
23 been found to be, based on the available data, have  
24 been found to be either known or reasonably  
25 anticipated to be human carcinogens.

1 This is information that the general  
 2 public needs to know so that they can make an  
 3 assessment as to if are, A, are they in danger by  
 4 being exposed to these materials or are these  
 5 materials something they see in their daily lives or  
 6 is this material something that you use either in your  
 7 work or at home that you can't avoid, but now that I  
 8 know -- now they know it's a possibility or reasonably  
 9 anticipated or known human carcinogen, they can then  
 10 take steps to protect themselves.

11 So the document is to get the  
 12 information out to the public that, hey, this has been  
 13 shown to be a known human carcinogen or a reasonably  
 14 anticipated to be a human carcinogen, you need to know  
 15 this information so that you can make your own -- can  
 16 make an assessment of the -- your particular risk and  
 17 take steps to protect yourself. And that's my  
 18 interpretation of why -- of what the report is  
 19 supposed to be doing.

20 Q. Are -- so you don't agree that hazard  
 21 assessments err on the side of caution?

22 MS. WAGSTAFF: Objection, asked and  
 23 answered.

24 A. I don't know how to respond to that.

25 Q. (BY MR. HOLLINGSWORTH) Okay.

1 circumstances, while a cancer risk is the estimate of  
 2 the carcinogenic effects expected from exposure to a  
 3 cancer hazard?

4 MS. WAGSTAFF: Can you state what page  
 5 you're reading from?

6 MR. HOLLINGSWORTH: Page 5 of his expert  
 7 witness report.

8 MS. WAGSTAFF: Okay.

9 Q. (BY MR. HOLLINGSWORTH) Do you remember  
 10 making that statement in your report, sir?

11 MS. WAGSTAFF: Are you talking about  
 12 where he's quoting IARC right there?

13 MR. HOLLINGSWORTH: Yes.

14 A. Okay. That's what IARC says.

15 Q. (BY MR. HOLLINGSWORTH) It's in your  
 16 report, right?

17 A. It's in my report, but as I said in  
 18 reference to IARC preamble, that's what they state in  
 19 defining a cancer hazard and a cancer risk.

20 Q. Do you subscribe to that definition?

21 A. That's -- that's pretty accurate, but,  
 22 again, it's in the IARC preamble and continuing  
 23 they're using that to -- to explain what it is that  
 24 the -- that the -- what the IARC monographs are i.e.  
 25 they are a hazard identification document. And, also,

1 A. It's getting the information out to the  
 2 public that they need to know in order to assess their  
 3 risk and make judgments as to what they want to do  
 4 about it.

5 Q. Would you agree with the statement that  
 6 a cancer hazard is an agent that is capable of causing  
 7 cancer under some circumstances, while a cancer risk  
 8 is an estimate of the carcinogenic effects expected  
 9 from exposure to a cancer hazard?

10 A. May I ask where you're reading that  
 11 from?

12 Q. It's from your report.

13 A. From my report?

14 Q. Yep.

15 A. Okay. Can you tell me where in the  
 16 report -- is it in the introduction?

17 MS. WAGSTAFF: Are you talking about his  
 18 expert report?

19 Q. (BY MR. HOLLINGSWORTH) That's not from  
 20 your expert witness report, that statement?

21 A. That's why I'm asking. I don't -- I  
 22 don't recall.

23 Q. Don't you state in your expert witness  
 24 report exactly what I asked, which is that a cancer  
 25 hazard is an agent that can cause cancer under certain

1 I think it is an attempt of them -- I think if you  
 2 look at the title of the IARC monographs, it's --  
 3 it -- the title -- the actual title of the IARC  
 4 monographs includes the word "risk." And they wanted  
 5 to make it clear to the reader that -- that while the  
 6 title, which is something they're stuck with, if you  
 7 will, has the word "risk" in it.

8 The documents that they prepare are not  
 9 risk assessments, they're hazard identifications and  
 10 this is what they are presenting in their preamble,  
 11 but it's an accurate statement.

12 Q. Is your report based on a hazard  
 13 assessment as defined by the National Tox Program to  
 14 Congress or is it based on a hazard identification as  
 15 defined by IARC?

16 MS. WAGSTAFF: Object to form.

17 A. It's based -- my assessment is based on  
 18 the criteria that I outlined in my report.

19 Q. (BY MR. HOLLINGSWORTH) Is that based on  
 20 the National Tox Program's identification of hazard  
 21 assessment?

22 MS. WAGSTAFF: Object to form.

23 A. I can read the exact wording, but  
 24 basically I said I developed the criteria for this  
 25 particular report based on the criteria that I

1 developed for the report on carcinogen and similar to  
2 that as outlined by IARC.

3 Q. (BY MR. HOLLINGSWORTH) Okay. Is it a  
4 better definition of what your report defines hazard  
5 assessment as to refer to IARC or to refer to the  
6 report to Congress by the National Tox Program?

7 A. It's best to refer --

8 MS. WAGSTAFF: Objection.

9 A. -- to the criteria that I have in my  
10 document.

11 Q. (BY MR. HOLLINGSWORTH) Okay. And that's  
12 your criteria, that doesn't really belong to the  
13 National Tox Program or to IARC, is that fair?

14 A. It's very similar to it, but I came -- I  
15 developed those specifically for this -- for my expert  
16 report.

17 Q. Okay. Thank you. Now, Dr. Jameson, I'd  
18 like to show you an e-mail which we received in  
19 response to the subpoena that we issued to you in  
20 connection with this deposition, and I've marked this  
21 as Exhibit 22-5. I'm handing a copy to you, a copy to  
22 counsel. And this is an e-mail from Chris Portier who  
23 you described as your long-time friend and colleague,  
24 right?

25 A. Yes.

1 Q. Dated Tuesday, November 10, 2015. Do  
2 you see that?

3 A. Okay.

4 Q. And it refers to IARC monograph volume  
5 112.

6 A. Well, IARC monograph 112 EFSA review of  
7 glyphosate.

8 Q. Yes. I see. Monograph 112 and EFSA  
9 review of glyphosate, both?

10 A. Right.

11 Q. That's important. And you cc'd Kate  
12 Guyton, right, and she's someone at IARC?

13 A. Correct. That's correct.

14 Q. And you're letting Chris Portier know in  
15 response to his invitation that you'd like to have the  
16 opportunity to participate in this IARC monograph  
17 process, right?

18 A. Well, that's what I told him then.

19 MS. WAGSTAFF: Object to form.  
20 Misstates the evidence.

21 Q. (BY MR. HOLLINGSWORTH) Okay. And then  
22 the -- the rest of this e-mail that's attached here is  
23 an e-mail from Chris Portier to a bunch of people  
24 including you and Aaron Blair and Matt Martin and  
25 other people that were on the IARC monograph

1 committee, right?

2 A. Right.

3 Q. But not all members of the IARC  
4 monograph committee, true?

5 A. I -- I'd have to read through all the  
6 list and see, but I can't say for sure.

7 MS. WAGSTAFF: Are our exhibits 21 or  
8 22?

9 Q. (BY MR. HOLLINGSWORTH) Do you recall  
10 receiving this e-mail?

11 A. Yes.

12 Q. When was the last time you read it?

13 A. When was the last time I read it?

14 Q. Yes. The most recent time.

15 A. This particular e-mail?

16 Q. Yes.

17 A. Let's see, I got it on November -- I  
18 sent it to Chris on November 10 of 2015. I don't  
19 know. Maybe a week or two later after that would have  
20 been the last time I saw it.

21 Q. Chris' e-mail to you is dated  
22 November 9, 2015, right?

23 A. That's what it says.

24 Q. And in his e-mail he's discussing  
25 developments within EFSA, the European Food Safety

1 Agency, right?

2 A. Yes, that's what it says.

3 Q. And the developments that he's  
4 discussing are in connection with -- in connection  
5 with the assessment for regulatory purposes of the  
6 safety of glyphosate?

7 A. That's what EFSA is doing, trying to do.

8 Q. And he notes in the second paragraph of  
9 this e-mail that the German Federation Institute for  
10 Risk Assessment had taken the lead in drafting the  
11 reassessment of glyphosate and that its report had  
12 been drafted prior to the IARC review or prior to what  
13 was going to be the IARC review, true?

14 A. That's what it says.

15 Q. And he says that following the IARC  
16 review, the German regulators went back and analyzed  
17 glyphosate again, right?

18 A. That's what it says.

19 Q. And this time taking into account the  
20 IARC assessment specifically, right?

21 A. That's what it says.

22 Q. So this was -- this e-mail was something  
23 that was received by you after you had concluded your  
24 meeting of monograph 112?

25 A. After the IARC meeting in.

Page 270

1 MS. WAGSTAFF: Object to form.  
 2 A. Based on the date.  
 3 Q. (BY MR. HOLLINGSWORTH) Yes.  
 4 A. Yes.  
 5 Q. And Dr. Portier reports in this e-mail  
 6 that the German regulators confirmed their original  
 7 conclusion and had, again, found that glyphosate does  
 8 not have any carcinogenic potential, right?  
 9 MS. WAGSTAFF: Where are you reading  
 10 that from?  
 11 A. I don't see that, but --  
 12 Q. (BY MR. HOLLINGSWORTH) I'm reading that  
 13 from this e-mail.  
 14 A. Where in this e-mail?  
 15 MS. WAGSTAFF: I'm going to object to  
 16 that question because that's not what the e-mail  
 17 states.  
 18 A. I don't see that in this e-mail.  
 19 Q. (BY MR. HOLLINGSWORTH) This e-mail says  
 20 that the European Food Agency -- Safety Agency was  
 21 about to release its reassessment of glyphosate  
 22 concluding that glyphosate had no carcinogenic  
 23 potential, right?  
 24 A. That's EFSA, yes.  
 25 Q. Yes. I said the European Food Safety

Page 272

1 re-assessment by EFSA will weaken the strength of the  
 2 IARC monograph program?  
 3 MS. WAGSTAFF: To stimulate change.  
 4 A. To stimulate change --  
 5 Q. (BY MR. HOLLINGSWORTH) Yeah.  
 6 A. -- in how some of these agents are  
 7 reviewed and addressed.  
 8 Q. That's what he says.  
 9 MS. WAGSTAFF: You're reading half the  
 10 sentence.  
 11 A. That's what he said.  
 12 Q. (BY MR. HOLLINGSWORTH) And the second  
 13 problem that he says exists due to EFSA's report is  
 14 that it suggests is that IARC did not do our  
 15 assessment adequately. Do you see that?  
 16 A. Correct.  
 17 Q. And that had we seen all of the data  
 18 they saw, we would have gotten a different answer, is  
 19 that what he says?  
 20 A. That's what he says, and, again, this is  
 21 relating to something I brought up before of my anger  
 22 over the way Monsanto is expressing the -- in the  
 23 press how IARC did not look at the Greim papers and  
 24 the information in the Greim papers, which is not  
 25 true. The Greim paper was looked at by IARC and we

Page 271

1 Agency?  
 2 A. Before you said BfR.  
 3 Q. Sorry.  
 4 MS. WAGSTAFF: Before you said BfR  
 5 before IARC.  
 6 Q. (BY MR. HOLLINGSWORTH) Excuse me.  
 7 Sorry. I meant EFSA.  
 8 A. Okay. That's what it says.  
 9 Q. And then Dr. Portier, if you go back to  
 10 the first paragraph of this e-mail, says that his  
 11 opinion is that the EFSA conclusion creates two  
 12 problems, do you see that?  
 13 A. Uh-huh.  
 14 Q. One, that it weakens the strength of the  
 15 IARC assessment. Do you see that?  
 16 A. It --  
 17 MS. WAGSTAFF: That's not the full --  
 18 A. No.  
 19 MS. WAGSTAFF: Object to -- you need to  
 20 read the whole sentence.  
 21 Q. (BY MR. HOLLINGSWORTH) The -- the EFSA  
 22 re-assessment of glyphosate creates two problems, he  
 23 says, as he sees it, right?  
 24 A. Okay.  
 25 Q. And the first is that this -- that this

Page 273

1 evaluated it to the best of our ability with the time  
 2 we had and we addressed the Greim paper in the  
 3 monograph, so the monograph addresses the Greim paper,  
 4 so that's another indication of where this -- this  
 5 false information that got out into the media has  
 6 affected what other people think we did, that IARC  
 7 did.  
 8 Q. Your testimony is that the IARC  
 9 committee relied on the Greim paper?  
 10 A. They looked at the Greim paper.  
 11 Q. Did they rely on it?  
 12 A. They said -- if you look at the  
 13 monograph and read what's in the monograph as it  
 14 relates to the Greim paper, we summarize several of  
 15 the studies in the Greim paper indicating what was  
 16 reported in the Greim paper, but indicate that because  
 17 we did not have enough time to adequately evaluate it,  
 18 we can't really -- can't really include it as a study  
 19 in the evaluation.  
 20 Q. Well, the IARC monograph says that it  
 21 looked at the Greim paper refers to the Greim paper,  
 22 excuse me. The IARC monograph refers to the Greim  
 23 paper several times, doesn't it?  
 24 A. Yes, it does.  
 25 Q. Did you ask Chris Portier what he meant

1 when he said, "I do not intend to let this happen"?

2 A. Well, he was -- he was concerned that,  
3 you know.

4 MS. WAGSTAFF: Objection, calls for  
5 speculation.

6 Q. (BY MR. HOLLINGSWORTH) Did you talk to  
7 him about it?

8 A. I had a -- to be very honest with you,  
9 to the best of my recollection, this is my response to  
10 him that I -- hey, I'd like to see what you write and  
11 maybe I'd like to contribute to it, maybe I wouldn't,  
12 but I told him I was busy until, what, the 12th and  
13 the time frame that I had was not good for Chris.

14 He needed -- he wanted to get something  
15 out sooner than that so basically this is -- this was  
16 the end of it for this, for me.

17 Q. So you didn't participate any further in  
18 this?

19 A. I don't recall that I participated in  
20 this, no.

21 Q. Didn't you sign the letter that --

22 A. Was this the one with the letter that  
23 went out?

24 Q. Yes. Didn't you sign that?

25 A. There was so many, I can't remember.

1 MS. WAGSTAFF: Object to form. Calls  
2 for speculation.

3 A. I can't remember.

4 Q. (BY MR. HOLLINGSWORTH) You can't  
5 remember?

6 A. I know there were a number of things.  
7 These mostly had to do with the regulatory agencies in  
8 Europe.

9 Q. Did you understand that IARC and EFSA  
10 had conducted different kinds of analyses of  
11 glyphosate?

12 A. Well, my understanding is EFSA was doing  
13 a risk analysis and IARC did a hazard identification.

14 Q. Do the risk assessments like EFSA  
15 conducted on glyphosate consider exposure in real  
16 world scenarios?

17 A. I am not familiar with what protocol  
18 they use when they're doing their risk assessment, so  
19 I really can't address that.

20 Q. Okay. After Chris and you and others  
21 sent the letter regarding EFSA's evaluation or  
22 reevaluation of glyphosate which disagreed with IARC,  
23 did you and Dr. Portier send a reply to that letter?

24 MS. WAGSTAFF: Object to the form of the  
25 question. Dr. Jameson has asked to see the open

1 Q. Well, you signed the letter that he's  
2 talking about here, didn't you?

3 A. If -- if this is to EFSA --

4 Q. Yes.

5 A. -- that might be -- that must be the one  
6 that I signed.

7 Q. I mean, Chris Portier drafted up a  
8 letter that he proposed to send to EFSA and that he  
9 wanted the people on this e-mail chain and others to  
10 sign?

11 A. And that was an open letter to EFSA?

12 Q. Yes.

13 A. Okay. I'd like to see that before I say  
14 anything else that I signed it or not. Like I said,  
15 there were a number of things coming out around this  
16 time and Chris was throwing things -- Chris was  
17 spearheading a number of issues, a number of things  
18 related to this, and I know there was one that I was  
19 able to comment on and then there was another one that  
20 I just didn't have time to work with. So before I  
21 comment any further, I'd like to see this open letter  
22 to EFSA.

23 Q. What -- what other things was Chris  
24 doing that you did not participate in that you're  
25 referring to?

1 letter before he comments more.

2 A. I can't respond to that until I see the  
3 first letter and the response you're referring to.

4 Q. (BY MR. HOLLINGSWORTH) You don't  
5 remember -- you didn't remember sending a response?

6 A. I can't address that --

7 MS. WAGSTAFF: Object to the form of the  
8 question.

9 A. -- until I see the documents. I'm  
10 sorry.

11 Q. (BY MR. HOLLINGSWORTH) Okay. Now,  
12 before you started participating in -- with  
13 Dr. Portier in these responses to EFSA in November of  
14 2015, did you ask Dr. Portier if he had any personal  
15 interest in that effort to respond to EFSA that went  
16 beyond just being a scientist, an interested  
17 scientist?

18 A. No, Chris contacted me because I was a  
19 member of the working group at IARC. As you can see,  
20 he contacted most everybody that was on IARC and it  
21 was based on his concern that what EFSA was doing  
22 would -- would reflect badly on IARC and he was trying  
23 to protect IARC, basically.

24 Q. Did you know that as of March 29, 2015  
25 or about nine days after the monograph was issued on

1 about March 15 or March 20 or somewhere thereabouts in  
2 2015 that Dr. Portier had started working for  
3 plaintiffs' lawyers who were intending to bring suit  
4 against Monsanto?

5 A. No. I wasn't aware of that.

6 Q. I've marked for the record as 22-6 a  
7 letter from a lawyer named Hunter Lundy to Dr. Portier  
8 which lays out an agreement that they had for  
9 Dr. Portier to consult the law firm in connection with  
10 glyphosate.

11 MS. WAGSTAFF: Can I have a copy?

12 Q. (BY MR. HOLLINGSWORTH) Have you ever  
13 seen that before?

14 MS. WAGSTAFF: Wait. Can I have a copy?

15 MR. HOLLINGSWORTH: Sure.

16 MS. WAGSTAFF: I'm going to object to  
17 asking him questions on a contractual agreement that  
18 he's not a party to.

19 MR. HOLLINGSWORTH: I'm just asking him  
20 if he's aware of this.

21 MS. WAGSTAFF: We've asked for documents  
22 that you've been questioning him on all day and this  
23 is the one that you decide to give him?

24 MR. HOLLINGSWORTH: That's right. It's  
25 my deposition.

1 Q. (BY MR. HOLLINGSWORTH) So my question is  
2 were you aware that Dr. Portier was working as a  
3 consultant to a law firm that represents plaintiffs in  
4 this MDL as of March 29, 2015?

5 A. No, I wasn't.

6 MS. WAGSTAFF: I'll object to the fact  
7 that this is an unsigned contract.

8 Q. (BY MR. HOLLINGSWORTH) Did you know that  
9 as of June of 2015 Dr. Portier was billing these  
10 lawyers to represent plaintiffs in this MDL in  
11 connection with issues involving glyphosate? And I'm  
12 handing you a document that I've identified for the  
13 record as 22-7.

14 MS. WAGSTAFF: Can I have one, please?

15 MR. HOLLINGSWORTH: Oh, sure.

16 Q. (BY MR. HOLLINGSWORTH) Were you aware of  
17 that, sir?

18 A. Was I aware that he got paid?

19 Q. Yes.

20 A. No, sir, I was not aware.

21 Q. I'm going to mark for the record as 22-8  
22 a copy of an e-mail that Mr. Portier originated to a  
23 list of folks that includes you, Dr. Jameson, Bill  
24 Jameson is the name that's dated November 9, 2015.

25 A. November 9, 2015.

1 Q. Yes.

2 MS. WAGSTAFF: Can I please have a copy?

3 MR. HOLLINGSWORTH: Yes.

4 A. Okay. So this is the original e-mail  
5 that is on the first -- on document 22-5 --

6 Q. (BY MR. HOLLINGSWORTH) Yes, that's  
7 right.

8 MS. WAGSTAFF: There's no question on  
9 the table.

10 THE DEPONENT: I'm sorry.

11 Q. (BY MR. HOLLINGSWORTH) What is that  
12 e-mail, sir?

13 A. This was the original e-mail from Chris  
14 to the -- all or most of the participants of the IARC  
15 monograph 112 about this EFSA and the BfR activities.

16 Q. And that was in connection with the  
17 letter that you were signing on to criticizing EFSA  
18 because of its --

19 A. Yeah, that was the original letter from  
20 Chris saying what he wanted to do.

21 Q. Now, did you know that when Chris  
22 wrote -- Chris Portier wrote that letter in November  
23 of 2015 that he was working for plaintiffs' lawyers  
24 here in the United States who were representing  
25 plaintiffs suing Monsanto in connection with

1 glyphosate?

2 MS. WAGSTAFF: Objection, in Chris  
3 Portier's testimony he clearly testified that his work  
4 on this was unrelated and was not paid by plaintiffs'  
5 counsel, so it's a misrepresentation of the evidence  
6 and of the testimony.

7 Q. (BY MR. HOLLINGSWORTH) Can you answer my  
8 question?

9 A. I really have no idea what relevance  
10 this has to this deposition, but I didn't know he was  
11 being paid or that he was -- had been retained by this  
12 law firm.

13 Q. Okay. I'm attaching a -- I have marked  
14 as 22-9 an e-mail exchange between you and Chris  
15 Portier around Thanksgiving of 2015 in which he says  
16 he attaches the -- his version of the final glyphosate  
17 letter. Does that --

18 MS. WAGSTAFF: Can I have one, please?

19 Q. (BY MR. HOLLINGSWORTH) Is that something  
20 that you recall?

21 MS. WAGSTAFF: You just -- I think this  
22 is -- you just gave me 22-8 again.

23 MR. HOLLINGSWORTH: Oh, sorry.

24 MS. WAGSTAFF: I wrote 22-9 on it.

25 MR. HOLLINGSWORTH: Sorry.

1 MS. WAGSTAFF: That's okay.  
 2 MR. HOLLINGSWORTH: Here you go.  
 3 A. Okay. The question again?  
 4 Q. (BY MR. HOLLINGSWORTH) This is an e-mail  
 5 exchange between you and Chris Portier around  
 6 November 26, 2015, do you recall this?  
 7 A. I see this, yes.  
 8 Q. And in it he says he has attached the  
 9 final version of the glyphosate letter. Do you see  
 10 that?  
 11 A. I see that. That's what it says.  
 12 Q. And in that paragraph he's referring to  
 13 a letter that he drafted and he was asking his group  
 14 to sign on to, that is a response to EFSA's critique  
 15 to IARC, true?  
 16 A. That's what it says.  
 17 Q. Does this help refresh your recollection  
 18 as to whether you actually signed onto that letter or  
 19 not?  
 20 A. No. Because the final paragraph reads,  
 21 "For those of you who will be co-authors on the  
 22 commentary, I plan to submit to JCEH, I hope to have  
 23 it available to you." He was sending this to  
 24 everybody because the original message is from Chris  
 25 Portier to Chris Portier, so I don't know who he sent

1 Q. Yes.  
 2 A. I never learned that he was a consultant  
 3 to this law firm, no.  
 4 Q. Did you ever learn that he was a  
 5 consultant to any law firm representing plaintiffs in  
 6 the United States against Monsanto?  
 7 A. Are you asking me -- say -- was I --  
 8 Q. Did you ever learn that he was a  
 9 consultant?  
 10 A. I did learn, yes.  
 11 Q. When did you learn that?  
 12 A. I think I learned that sometime within  
 13 the last six months.  
 14 Q. Okay.  
 15 A. To the best of my recollection. It  
 16 might have been sooner than that. It might have been  
 17 later than that. It wasn't much more than about six  
 18 months ago.  
 19 Q. Okay. I'm going to mark as Exhibit  
 20 22-10 another e-mail from Chris Portier. It's a one-  
 21 page, one-paragraph, seven-line e-mail, do you see  
 22 that?  
 23 A. Uh-huh.  
 24 Q. Have you seen that before?  
 25 A. Have I seen this before?

1 the original message to and until I see the -- the --  
 2 the letters that you are referring to, I can't  
 3 comment.  
 4 Q. Were you aware at the time this e-mail  
 5 was -- e-mail exchange was had between you and  
 6 Dr. Portier that Dr. Portier was working for  
 7 plaintiffs' lawyers in the United States in lawsuits  
 8 that were being brought against Monsanto involving  
 9 glyphosate?  
 10 MS. WAGSTAFF: I have the same  
 11 objection. This is misstating Chris Portier's  
 12 testimony.  
 13 MR. HOLLINGSWORTH: I'm not referring to  
 14 Chris Portier's testimony. I'm just asking you --  
 15 MS. WAGSTAFF: The suggestion you're  
 16 leaving in the air is that -- is misstating his  
 17 testimony, so. . .  
 18 MR. HOLLINGSWORTH: Okay.  
 19 A. I have no idea who Chris Portier was  
 20 working for at this time.  
 21 Q. (BY MR. HOLLINGSWORTH) When -- did you  
 22 ever learn that he was working on a consulting  
 23 arrangement with a plaintiffs' law firm in the United  
 24 States in connection with lawsuits against Monsanto?  
 25 A. With this -- with this law firm?

1 MS. WAGSTAFF: Can I have one, please?  
 2 MR. HOLLINGSWORTH: Sure.  
 3 MS. WAGSTAFF: This is 22-10?  
 4 MR. HOLLINGSWORTH: Yes.  
 5 A. Okay. This is an e-mail from Chris  
 6 Portier to C Portier. So I may have gotten this.  
 7 I -- but to be honest, it was so long ago, I don't  
 8 remember.  
 9 Q. (BY MR. HOLLINGSWORTH) Okay.  
 10 MS. WAGSTAFF: Counsel, there's no Bates  
 11 on this. I'm just wondering if that's -- it's  
 12 probably an oversight or it got cut off on the  
 13 printing. Is there supposed to be Bates on this.  
 14 There is on all your other e-mails. Just so we know  
 15 where it came from. Like, for example, 22-5 has  
 16 Portier, so does 7. 8 has Mississippi State and 9 has  
 17 Jameson.  
 18 MR. HOLLINGSWORTH: I don't know.  
 19 MS. WAGSTAFF: I would request a Bates  
 20 number for that one.  
 21 MR. HOLLINGSWORTH: Okay.  
 22 Q. (BY MR. HOLLINGSWORTH) All right.  
 23 MR. HOLLINGSWORTH: All right. How  
 24 much -- are you going to be asking questions?  
 25 MS. WAGSTAFF: Uh-huh.

1 MR. HOLLINGSWORTH: How long do you  
2 think it'll take?

3 MS. WAGSTAFF: Well, if you stop right  
4 now, probably 20, 25 minutes. Maybe not.

5 MR. HOLLINGSWORTH: Okay. I'll stop.

6 MS. WAGSTAFF: Okay.

7 THE DEPONENT: Can I take a break first?

8 MR. HOLLINGSWORTH: Sure.

9 THE VIDEOGRAPHER: Going off the record  
10 the time is 5:41 p.m.

11 (Recess taken, 5:41 p.m. to 6:02 p.m.)

12 THE VIDEOGRAPHER: We are back on the  
13 record. The time is 6:02 p.m.

14 EXAMINATION

15 BY MS. WAGSTAFF:

16 Q. Good evening, Dr. Jameson. You've had  
17 quite a long day, I know we've been going for about  
18 nine hours on a very dense subject, so I'll try to  
19 make this quick for you.

20 In relation to MDL 2741, which is the  
21 federal litigation in the Roundup litigation, you  
22 produced an expert report which has been labeled 22-1,  
23 Exhibit 22-1 to this deposition, correct?

24 A. Correct.

25 Q. And my reading of that testimony is that

1 it -- or that expert report is that it is typed,  
2 single-spaced typed and it goes on to the 32nd page,  
3 correct?

4 A. Correct.

5 Q. And it has on there my brief review is  
6 it had about 101 citations to different medical  
7 literature; is that correct?

8 A. Toxicology literature.

9 Q. Toxicology?

10 A. And cancer literature.

11 Q. Okay. And it had, I think, somewhere  
12 around five medical pieces of information or  
13 literature that you considered, but didn't -- but you  
14 discounted for one reason or another; is that correct?

15 A. You're referring to some of the animal  
16 studies that I discounted?

17 Q. Yes.

18 A. Yes, that's correct.

19 Q. When you were reading this report, this  
20 32-page typed report, you actually read each of those  
21 101 studies, correct?

22 A. All the references that I have in there,  
23 I've read, yes.

24 Q. And when you were writing your report,  
25 you had access to those documents and you would

1 reference those documents as you were writing the  
2 report in real time, correct?

3 A. Yes.

4 MR. HOLLINGSWORTH: Leading. Objection,  
5 leading.

6 Q. (BY MS. WAGSTAFF) Did you have access to  
7 those medical records -- I mean, I'm sorry -- strike  
8 that.

9 Did you have access to that medical  
10 literature when you were writing your report?

11 A. Can I -- just for clarification, you're  
12 referring to them as medical.

13 Q. I'm sorry. Scientific literature.

14 A. Right.

15 Q. Let me --

16 A. Not specifically medical.

17 Q. Let me rephrase that.

18 A. Okay.

19 Q. This pharma lawyer is --

20 A. I just want to be clear.

21 Q. Did you have access to the scientific  
22 literature cited in your expert report while you were  
23 writing your expert report?

24 A. Yes.

25 Q. Okay. And today, for the past six and a

1 half hours, Monsanto's lawyers have asked you about  
2 that medical -- that scientific literature, correct?

3 A. Yes.

4 MR. HOLLINGSWORTH: Objection, leading.

5 Q. (BY MS. WAGSTAFF) And during those  
6 questions you were -- you were often asked about  
7 specific details of the scientific literature; is that  
8 right?

9 MR. HOLLINGSWORTH: Objection leading.

10 A. Yes.

11 Q. (BY MS. WAGSTAFF) Okay. And did  
12 you -- have you memorized those -- that scientific  
13 literature?

14 A. No. I have not memorized it.

15 Q. Okay. And did you ask Monsanto's  
16 lawyers to provide you with that scientific literature  
17 to refresh your recollection?

18 A. Yes.

19 Q. Okay. And did Monsanto's lawyers  
20 refuse?

21 MR. HOLLINGSWORTH: Objection, leading.

22 A. Yes.

23 Q. (BY MS. WAGSTAFF) So Monsanto's lawyers  
24 refused to provide the medical literature -- or the  
25 scientific literature that you cited in your expert

Page 290

1 report despite asking you specific questions about it,  
 2 correct?  
 3 MR. HOLLINGSWORTH: Objection, leading.  
 4 A. Yes.  
 5 Q. (BY MS. WAGSTAFF) Would it have been  
 6 helpful to have that scientific literature to refresh  
 7 your recollection and provide better or more  
 8 comprehensive answers?  
 9 MR. HOLLINGSWORTH: Objection, leading.  
 10 A. Yes.  
 11 Q. (BY MS. WAGSTAFF) Excellent. And in  
 12 fact, there were 101 scientific literature cited in  
 13 your expert report; is that correct?  
 14 A. Yes.  
 15 Q. And only one of those was the Greim  
 16 study; is that correct?  
 17 MR. HOLLINGSWORTH: Objection, leading.  
 18 A. Yes, only one was -- had Greim as the  
 19 primary author.  
 20 Q. (BY MS. WAGSTAFF) Okay. I'm going to  
 21 take you back to the beginning of the deposition,  
 22 about eight or nine hours ago when this started. And  
 23 do you remember Mr. Hollingsworth, Monsanto's lawyers,  
 24 asking you questions about whether -- whether there  
 25 have been studies to specifically test or investigate

Page 292

1 particular tumor that the question was about in -- in  
 2 that animal, so therefore, glyphosate in that study  
 3 glyphosate caused that cancer in experimental animals,  
 4 so it's an experimental animal carcinogen, and as a --  
 5 as an animal carcinogen, it is a potential human  
 6 carcinogen, so -- and to the best of my knowledge, I'm  
 7 not aware of anybody that has designed studies to  
 8 investigate the association of those particular tumors  
 9 in the rats or the mice in non-Hodgkin's lymphoma, nor  
 10 am I aware that anybody has published an article  
 11 addressing that issue.  
 12 Q. Okay. So even though no -- even though  
 13 to the best of your knowledge, no one has specifically  
 14 tested whether those particular rodent tumors are a  
 15 good predicate for NHL in humans, is this the type of  
 16 information that toxicologists rely on to make a  
 17 determination of whether a chemical is a human  
 18 carcinogen?  
 19 MR. HOLLINGSWORTH: Objection, leading.  
 20 A. Absolutely. That is the premise of  
 21 doing the bioassay that if it is shown to be a  
 22 carcinogen in experimental animals, then it is  
 23 potential a human carcinogen.  
 24 Q. (BY MS. WAGSTAFF) All right. Isn't it  
 25 true, Dr. Jameson, that we conduct testing on

Page 291

1 whether a particular tumor in a rat or a mice is a  
 2 good predicate for NHL in humans? Do you remember  
 3 those questions?  
 4 A. Yes.  
 5 Q. And do you remember I wrote down the  
 6 list of about eight or nine of them and then I  
 7 quit -- I quit writing them down because the questions  
 8 were throughout the entire day, but some of them were  
 9 do you remember if there have been studies designed to  
 10 test whether rat testicular interstitial tumors is a  
 11 good predicate to cause NHL in tumors? Do you  
 12 remember that question?  
 13 MR. HOLLINGSWORTH: Objection, leading.  
 14 A. Yes.  
 15 Q. (BY MS. WAGSTAFF) Do you remember the  
 16 question on whether anyone has studied whether lung  
 17 adenocarcinoma is a good predicate for NHL in humans?  
 18 A. Yes.  
 19 Q. And there was about four or five other  
 20 ones, and what was your response to those questions?  
 21 A. Well, it was pretty much the same  
 22 answer, the -- the studies that I reviewed were  
 23 designed to see if glyphosate would cause cancer in  
 24 the experimental animals, so the animals were exposed  
 25 to glyphosate, there was an increased incidence of the

Page 293

1 experimental animals because tumors in rodents may  
 2 indicate carcinogenesis of a test chemical?  
 3 A. That's correct.  
 4 Q. And isn't it true that rodent  
 5 carcinogenesis is applied to the potential for an  
 6 agent to cause cancer in humans?  
 7 A. Yes.  
 8 Q. And isn't it true we test  
 9 carcinogenicity of an agent in this way because it's  
 10 unethical to test on humans?  
 11 A. Yes.  
 12 MR. HOLLINGSWORTH: Leading.  
 13 Q. (BY MS. WAGSTAFF) So it's accurate to  
 14 say that animal bioassay general screening tests are  
 15 best way for us as human to test to carcinogenicity of  
 16 a chemical, correct?  
 17 MR. HOLLINGSWORTH: Objection, leading.  
 18 A. That's correct.  
 19 Q. (BY MS. WAGSTAFF) And this is very  
 20 common -- is this very common in the toxicology world?  
 21 A. Yes.  
 22 MR. HOLLINGSWORTH: Objection, leading.  
 23 A. This is -- this is kind of the standard  
 24 in the toxicology world used by government, academia,  
 25 industry, that that is the process by which they test

1 a chemical to see if it causes cancer in -- cancer  
2 causes in experimental animals as a predictor of  
3 cancer in humans.

4 Q. (BY MS. WAGSTAFF) Okay. Isn't it true  
5 that males and females have different organs?

6 A. Yes, that's true. Thank goodness.

7 Q. And that's true in rodents and in  
8 humans?

9 A. Yes.

10 Q. Isn't it true that replication across  
11 studies doesn't look to compare males and females for  
12 tumor incidence?

13 A. Yes.

14 Q. All right. Let's talk a little bit  
15 about statistical significance --

16 A. Okay.

17 Q. -- for a moment. That phrase was tossed  
18 around a lot today by Monsanto's counsel and by  
19 yourself. Will you tell me or tell the jury and the  
20 judge sort of what your idea of statistical  
21 significance means?

22 A. Statistical significance is when you see  
23 a -- for example, when you're comparing tumor  
24 incidences. Statistical significance means that the  
25 incidence that you observe in the control animals --

1 let me turn that around.

2 Statistical significance is when the  
3 incidence that you see in the treated animals is  
4 higher than what you observe in the control animals,  
5 and if the incidence in the treated animals is much  
6 larger based on the mathematical calculation, much  
7 larger than in the controlled animals, then it is said  
8 to reach the statistical significance.

9 But what we are seeing now in the state  
10 of the science in both toxicology and epidemiology  
11 statistical significance is not playing as crucial a  
12 role in the evaluation of the data as it has in the  
13 past because people have learned to look at the -- at  
14 increased incidence as a real effect, even though it  
15 may not reach statistical significance, but it is a  
16 significant finding because it demonstrates that an  
17 increase is more than what you get when you are not  
18 exposed to the particular chemical.

19 Q. Okay. Now, you testified earlier today  
20 and it's in your CV that you spent a lot of time  
21 working at the NTP, right?

22 A. Correct.

23 Q. Okay. What does the NTP stand for?

24 A. NTP stands for the National Toxicology  
25 Program.

1 Q. Okay. I believe you testified earlier  
2 that while you were working for the NTP, you didn't  
3 look at glyphosate and human data; is that correct?

4 A. I did not look at glyphosate in human  
5 data because it was not nominated for consideration  
6 and it never came up for consideration while I was  
7 there.

8 Q. Okay. And how long were you at NTP  
9 roughly?

10 A. I was a member of the NTP from its  
11 inception in I believe it was 197 -- '77 or '78, I may  
12 be wrong, but any way, from the early '70s until I  
13 retired from the government in 2008.

14 Q. Okay. So that's like 35 --

15 A. 35, 40 years.

16 Q. So between 35 and 40 years you were at  
17 NTP?

18 A. Yes.

19 Q. During those 35 to 40 years at NTP, did  
20 you look at chemicals other than glyphosate and human  
21 data?

22 A. Absolutely. We -- as part of the review  
23 for the report on carcinogens, we routinely looked at  
24 all the available carcinogenicity data, the animal and  
25 the human epidemiology data. And as I indicated in my

1 report, we have criteria for sufficient -- for the  
2 human data, and for the animal data, so when we were  
3 reviewing chemicals for the report on carcinogens, we  
4 would have to evaluate the human epidemiology data to  
5 see if there was an increased incidence in tumors in  
6 humans, if it was increased, and also the same for the  
7 animals, so I -- I've looked at the epidemiology data  
8 for -- I can't estimate a number -- between 75 and 100  
9 chemicals for the report on carcinogens.

10 Q. As part of your job?

11 A. At part of any job at the NTP, right.

12 Q. Do you remember numerous times today  
13 when Monsanto's lawyer would ask you whether or not  
14 you had the full study data or the pathology report  
15 when talking about a particular study?

16 A. Yes.

17 Q. And sometimes I believe you testified  
18 that you had that data and sometimes you testified  
19 that it wasn't available to you; is that correct?

20 A. The full data -- the full study report,  
21 yes.

22 Q. And in the instances when you did not  
23 have the full study data because it was not available  
24 to you or the pathology report, does that make your  
25 reliance on that study or that material unreliable?

Page 298

1 MR. HOLLINGSWORTH: Objection, leading.  
 2 A. Does it make my -- if I didn't have the  
 3 report?  
 4 Q. (BY MS. WAGSTAFF) Uh-huh.  
 5 A. If I didn't have the full report -- if I  
 6 had the tumor data, tumor tables and what have you and  
 7 could -- could -- could verify the -- the incidences  
 8 in either the EPA or the Greim publication, the data  
 9 was reliable. In no case did I feel the data wasn't  
 10 reliable.  
 11 Q. I think I wrote down a quote that you  
 12 said earlier which was that you had a, quote,  
 13 deficiency in your report because you didn't include  
 14 incidence rates -- incident -- incidence rates. Do  
 15 you remember that testimony?  
 16 A. Yes.  
 17 Q. Okay. Can you tell the Court what an  
 18 incidence rate is?  
 19 A. That -- the incidence rate would be  
 20 listing of the incidence of the tumors in the controls  
 21 and the treated animals indicating the number of  
 22 tumors observed in each -- in each dose group.  
 23 Q. Okay. And even though that wasn't in  
 24 your report, did you rely on that information?  
 25 A. Oh, I -- I looked at that information.

Page 300

1 Q. All right. You testified also at some  
 2 point today that you developed criteria specifically  
 3 for your expert report in this MDL, correct?  
 4 A. Correct.  
 5 Q. But the method -- the methodology that  
 6 you created and that you used is widely recognized in  
 7 the toxicology field, correct?  
 8 MR. HOLLINGSWORTH: Objection, leading.  
 9 A. That's correct.  
 10 Q. (BY MS. WAGSTAFF) Let me reask the  
 11 question.  
 12 A. Okay.  
 13 Q. Does the toxicology field recognize the  
 14 methodology that you used as a sound method?  
 15 A. I would --  
 16 MR. HOLLINGSWORTH: Objection.  
 17 A. I would say yes.  
 18 MR. HOLLINGSWORTH: Calls for  
 19 speculation.  
 20 A. When I was writing my expert report, I  
 21 wanted to make it clear within the report the criteria  
 22 that I was using in evaluating the data and making --  
 23 and giving my opinion, so I -- I said I developed this  
 24 criteria, but basically this criteria is based on the  
 25 criteria I developed for the report on carcinogens

Page 299

1 Q. Okay.  
 2 A. And maybe I used the wrong word in  
 3 describing that, but, no, the numbers that I put in my  
 4 report are based on the incidence rates that I  
 5 reviewed in the reports. I just didn't include it in  
 6 the report for some reason. But I should have.  
 7 Q. Sorry. So the incidence rates that you  
 8 relied on in drafting your expert reports are in the  
 9 studies themselves, correct?  
 10 A. Absolutely.  
 11 Q. Okay. Does IARC -- isn't it true that  
 12 IARC does not heavily consider or weigh expert review  
 13 summaries?  
 14 A. They -- well, that is true. They --  
 15 they will review or use expert summaries or review  
 16 papers. That's what you're referring to are review  
 17 papers. They will use review papers or look at review  
 18 papers, but if they have the opportunity to go back to  
 19 the original papers that the reviews were written  
 20 from, they will definitely get the original papers and  
 21 place more weight on the original papers than on the  
 22 review of them.  
 23 Q. Is the Greim paper an expert review  
 24 summary paper?  
 25 A. Yes.

Page 301

1 that was approved by the Secretary of Health and Human  
 2 Services for preparing the report on carcinogens and  
 3 listing materials in there as known or reasonably  
 4 anticipated to be human carcinogens and also to let  
 5 people know that the criteria that I developed are  
 6 quite similar to also what IARC uses in their  
 7 evaluation of materials and both NTP, ROC report on  
 8 carcinogens criteria and IARC criteria are both widely  
 9 recognized and accepted throughout the world.  
 10 Q. (BY MS. WAGSTAFF) All right. And  
 11 during those IARC deliberations, the panelists knew  
 12 that the AHS study did not show a statistically  
 13 significant increase odds ratio, although it did show  
 14 a slight increase of 1.1, was that known?  
 15 MR. HOLLINGSWORTH: Objection, leading  
 16 and beyond the scope.  
 17 A. In the IARC review, AHS study was -- was  
 18 discussed. It was pointed out that while there was an  
 19 increase in the incidence of non-Hodgkin's lymphoma  
 20 observed in that study, it was not -- not  
 21 statistically significant, and so all of that  
 22 information was from that study that was available at  
 23 the time was considered and reviewed and is so  
 24 referenced in the monograph.  
 25 Q. (BY MS. WAGSTAFF) So that information

1 wasn't withheld from the IARC?

2 A. No, it was -- no.

3 Q. All right. I may be -- okay.

4 Isn't it true that the -- let's talk  
5 about Exhibit 22-4 which Monsanto's counsel has  
6 identified as an exhibit. 22-4. Isn't it true the  
7 NTP updates its reports on carcinogens?

8 A. Yeah, the report is updated -- it's  
9 supposed to be updated every two years now.

10 Q. Okay. So if this one was dated 2004,  
11 and here we sit in the end of 2017, that means roughly  
12 at least six more versions of this have come out, give  
13 or take?

14 A. Well, I said it's supposed to be  
15 published every two years. I think the latest version  
16 of the report on carcinogens was the 14th, so they  
17 haven't quite made the two year cut off but that's not  
18 unusual.

19 Q. So at least there's three more updated  
20 versions?

21 A. Yes.

22 Q. Than this 11th version?

23 A. Correct.

24 Q. So this 11th version that we have as  
25 Exhibit 22-4 is not the most current version?

1 Q. You said that if a substance is shown to  
2 be a carcinogen in a experimental animal, it is a  
3 potential human carcinogen, right?

4 A. Correct.

5 Q. And that's based on the IARC and the  
6 National Tox Program evaluation?

7 A. Well --

8 Q. Excuse me.

9 A. I'm sorry.

10 Q. That's based on the IARC and National  
11 Tox Program evaluation standards; is that right?

12 A. I think that's pretty much an accepted  
13 premises of toxicology, that if you -- if something is  
14 found to cause cancer in experimental animals, then  
15 it's -- potentially could cause cancer in humans and  
16 should be investigated.

17 Q. And the word "potential" means that that  
18 if an -- if a -- if a -- excuse me. Let me start  
19 over.

20 By the use of the term "potential," you  
21 mean that if an experimental animal study shows  
22 cancer, it has a more than 50 percent likelihood of  
23 being a human carcinogen, true?

24 A. I don't know that you can put a  
25 percentage on it.

1 A. Not the most current, that's correct.

2 MS. WAGSTAFF: No more questions. I  
3 reserve some -- any if you have something new.

4 MR. HOLLINGSWORTH: Okay.

5 EXAMINATION

6 BY MR. HOLLINGSWORTH:

7 Q. Sir, you said that as an animal  
8 carcinogen as determined by the National Tox Program  
9 or IARC, then that means that it is a potential human  
10 carcinogen, true?

11 A. Right.

12 Q. What is the -- what does the term  
13 "potential" mean?

14 A. Means that the -- the chemical has  
15 the -- has the potential of causing cancer in humans.

16 Q. Does it mean that it's more probable  
17 than not that the chemical will cause cancer in  
18 humans?

19 A. That's the implication, yes.

20 Q. That's what "potential" means?

21 A. That's what "potential" means.

22 Q. Does the IARC monograph or the National  
23 Tox Program define the word "potential" in that way?

24 A. I'm not sure. I'd have to look at the  
25 IARC preamble to see if they define potential.

1 Q. When you say in your report that you've  
2 used the -- you have cited to incidence rates when you  
3 have referred in your expert witness reports to  
4 various studies, do you have that in mind?

5 A. Yes.

6 Q. Did you mean to state in your  
7 examination by Ms. Wagstaff that incidence rates are  
8 equivalent to statistical significance as used in your  
9 report?

10 A. No.

11 Q. Okay. Just wanted to make sure.

12 MR. HOLLINGSWORTH: Okay. That's all I  
13 have.

14 MS. WAGSTAFF: Really?

15 MR. HOLLINGSWORTH: Yeah.

16 MS. WAGSTAFF: Let's go off the record  
17 before I say how excited I am that we're done with  
18 this.

19 THE DEPONENT: Not as excited as me.

20 MS. WAGSTAFF: Oh, dang it, you got that  
21 on the record.

22 THE VIDEOGRAPHER: Going off the record.  
23 This concludes the videotape deposition of Charles W.  
24 Jameson. The time is 6:25 p.m. We are off the  
25 record.

Page 306

1 WHEREUPON, the within proceedings were  
 2 concluded at the approximate hour of 6:25 p.m. on the  
 3 21st day of September, 2017.  
 4 \* \* \* \* \*

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

Page 307

1 REPORTER'S CERTIFICATE  
 2 STATE OF COLORADO )  
 ) ss.  
 3 CITY AND COUNTY OF DENVER )  
 4

5 I, TRACY R. STONEHOCKER, Certified  
 6 Realtime Reporter, Registered Professional Reporter  
 7 and Notary Public ID 19924009337, State of Colorado,  
 8 do hereby certify that previous to the commencement of  
 9 the examination, the said CHARLES W. JAMESON, Ph.D.,  
 10 was duly sworn by me to testify to the truth in  
 11 relation to the matters in controversy between the  
 12 parties hereto; that the said deposition was taken in  
 13 machine shorthand by me at the time and place  
 14 aforesaid and was thereafter reduced to typewritten  
 15 form; that the foregoing is a true transcript of the  
 16 questions asked, testimony given, and proceedings had.  
 17 I further certify that I am not employed  
 18 by, related to, nor of counsel for any of the parties  
 19 herein, nor otherwise interested in the outcome of  
 20 this litigation.  
 21 IN WITNESS WHEREOF, I have affixed my  
 22 signature this 22nd day of September, 2017.  
 23  
 24  
 25

\_\_\_\_\_  
 TRACY R. STONEHOCKER  
 My commission expires June 12, 2020.

\_\_\_\_ Reading and Signing was requested.  
 \_\_\_\_ Reading and Signing was waived.  
 X  Reading and Signing is not required.

Page 308

1 ERRATA SHEET  
 2 Case Name:  
 3 Deposition Date:  
 4 Deponent:  
 5 Pg. No. Now Reads Should Read Reason  
 6 \_\_\_\_\_  
 7 \_\_\_\_\_  
 8 \_\_\_\_\_  
 9 \_\_\_\_\_  
 10 \_\_\_\_\_  
 11 \_\_\_\_\_  
 12 \_\_\_\_\_  
 13 \_\_\_\_\_  
 14 \_\_\_\_\_  
 15 \_\_\_\_\_  
 16 \_\_\_\_\_  
 17 \_\_\_\_\_  
 18 \_\_\_\_\_  
 19 \_\_\_\_\_  
 20 \_\_\_\_\_

\_\_\_\_\_  
 Signature of Deponent

21  
 22  
 23 SUBSCRIBED AND SWORN BEFORE ME  
 24 THIS \_\_\_\_ DAY OF \_\_\_\_\_, 2017.  
 25 \_\_\_\_\_  
 (Notary Public) MY COMMISSION EXPIRES: \_\_\_\_\_

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

<b>A</b>	1:9	144:10	<b>admitted (1)</b> 49:5	86:5 87:11 246:24
<b>A-r-y-s-t-a (3)</b> 42:3 113:4 224:4	<b>activities (1)</b> 280:15	<b>adenoma (16)</b> 53:2 83:20 91:7,15	<b>adverse (1)</b> 168:16	<b>agreement (2)</b> 278:8,17
<b>a.m (8)</b> 1:12 4:15 57:22,23,23 57:25 117:22,23	<b>activity (4)</b> 90:15 195:4 224:17 225:24	97:16,18 196:13,17 197:7 200:24 203:9 204:21 205:3,7,14 217:4	<b>advice (1)</b> 231:7	<b>ahead (3)</b> 101:3 149:17 232:6
<b>Aaron (1)</b> 267:24	<b>actual (26)</b> 27:11 45:4 65:25 69:5 69:9,11,14 75:3 102:13 114:10,17 114:20 177:23 199:11,23 233:24 234:2,8 236:17,25 237:6,15,21 239:11 252:25 265:3	<b>adenomas (53)</b> 26:18 41:22 42:2 51:17 52:4 53:13 55:9 56:4,17 58:19 77:25 78:15 79:16 80:16 82:21 84:5 85:14 90:23 97:22 97:25 98:1 105:24 106:10,13 125:21 125:22 126:9,15 127:16 137:23 170:4,8 184:23,25 185:20 195:23 196:18 197:10 198:5,18 200:12,17 201:11,25 202:1 203:19,25 204:5,11 205:8 206:9 207:24 208:4	<b>advisory (7)</b> 98:10,17,22,24 99:7 99:14 100:6	<b>ahold (1)</b> 235:23
<b>ability (4)</b> 17:7 95:6 173:5 273:1	<b>acutely (1)</b> 218:15	<b>adenomotis (1)</b> 57:14	<b>affect (1)</b> 20:12	<b>AHS (2)</b> 301:12,17
<b>able (9)</b> 18:12 20:25 21:25 31:14 74:23 81:13 103:7 218:15 275:19	<b>add (3)</b> 130:3 133:11 218:17	<b>adequacy (3)</b> 178:23 189:2 239:3	<b>affixed (1)</b> 307:14	<b>aid (1)</b> 67:15
<b>absence (3)</b> 67:17 68:4,15	<b>addition (4)</b> 122:20 147:25 152:5 163:8	<b>adequate (7)</b> 20:20 163:21 200:1 220:12,15,22 238:14	<b>afford (1)</b> 31:13	<b>Aimee (2)</b> 2:3 4:21
<b>absolute (1)</b> 166:20	<b>additional (22)</b> 31:7 81:13 84:9,12,16 85:4,7,8,11,13 90:25 103:3 106:2,5 124:3 133:12 198:13 203:3 213:9 223:25 239:17 249:11	<b>adhere (1)</b> 216:24	<b>afforded (1)</b> 67:23	<b>air (1)</b> 283:16
<b>absolutely (11)</b> 39:13 68:11 166:20 217:24 230:15,22 232:4,20 292:20 296:22 299:10	<b>address (6)</b> 222:24 243:22 248:15 254:18 276:19 277:6	<b>adjoin (2)</b> 118:2,7	<b>aforsaid (1)</b> 307:9	<b>al (3)</b> 3:18 132:20 235:10
<b>absorption (1)</b> 190:10	<b>addressed (11)</b> 20:21 230:19,20 234:12 240:3,4 241:4 242:21 253:17 272:7 273:2	<b>adjust (1)</b> 152:21	<b>age (1)</b> 182:8	<b>Alaska (3)</b> 1:12 2:4 4:14
<b>academia (1)</b> 293:24	<b>addresses (4)</b> 15:18 231:1 253:10 273:3	<b>adjusted (1)</b> 152:9	<b>ages (1)</b> 182:11	<b>albino (13)</b> 38:2,16 41:23 48:12 155:5 156:23 159:4 160:13 164:16 169:17 170:13 171:13 173:8
<b>accept (4)</b> 81:16 154:1 167:5 238:15	<b>addressing (2)</b> 222:14 292:11	<b>adjustment (2)</b> 152:6 153:1	<b>agency (10)</b> 17:5 104:5 114:2 166:10 215:16 242:24 269:1 270:20,20 271:1	<b>alleging (1)</b> 13:11
<b>acceptability (1)</b> 245:23	<b>adenocarcinoma (10)</b> 58:3,19 59:6,13 60:1 60:5 137:23 141:21 143:1 291:17	<b>admission (12)</b> 103:16 104:21 111:6 113:12,18 116:1,14 143:4 178:4 187:18 204:12 223:14	<b>agent (7)</b> 66:7 68:5 154:12 263:6,25 293:6,9	<b>allow (6)</b> 16:16 66:10 70:22 126:22 243:13,16
<b>acceptable (5)</b> 161:23 166:16 167:6 214:21 227:16	<b>adenocarcinomas (...)</b> 6:15 25:4,6,7,11,13 25:19 59:19,21 60:9 78:15 136:25 137:11,16 138:11 140:10,20,25 141:10 142:3,6,17 143:17,18 144:1,7	<b>admission (1)</b> 188:3	<b>agency (10)</b> 17:5 104:5 114:2 166:10 215:16 242:24 269:1 270:20,20 271:1	<b>allows (1)</b> 147:1
<b>accepted (5)</b> 101:11 169:20 238:12 301:9 304:12		<b>admission (1)</b> 188:3	<b>agent (7)</b> 66:7 68:5 154:12 263:6,25 293:6,9	<b>amended (3)</b> 122:12,19 172:2
<b>access (10)</b> 69:8,9 156:14 161:16 171:16 231:19 287:25 288:6,9,21		<b>administrative (1)</b> 116:25	<b>ages (1)</b> 182:11	<b>amount (3)</b> 32:21 167:11 236:7
<b>account (5)</b> 247:21 248:8 254:8 257:2 269:19			<b>aggressive (1)</b> 15:1	<b>analyses (3)</b> 129:23 198:14 276:10
<b>accounted (1)</b> 20:12			<b>aging (2)</b> 145:7 182:20	<b>analysis (11)</b> 84:2 124:4,4 129:22 130:9 138:10 153:3 165:21 206:21 249:11 276:13
<b>accurate (9)</b> 47:17 48:3,5 82:5 241:13 242:5 264:21 265:11 293:13			<b>ago (12)</b> 32:6 33:18 34:11 35:19 66:23 139:7 186:3,16 196:25 284:18 285:7 290:22	<b>analyzed (1)</b> 269:16
<b>action (1)</b> 190:9			<b>agree (22)</b> 33:1 39:18 43:12 105:17 124:16 131:6 144:25 162:4 162:14,15,21 163:23 165:18 168:12 183:8 186:23 240:9,18 245:15 261:8 262:20 263:5	<b>and/or (5)</b> 24:25 114:10 126:2 178:2 241:22
<b>ACTIONS (1)</b>			<b>agreed (3)</b>	<b>Andre (1)</b> 87:20

<p><b>animal (120)</b> 3:8,10 8:7,13 16:1 17:21 24:5,17 25:14 26:9 28:10,18 30:9 30:23 31:8,22,24 32:10,13,16 36:2,14 47:14 50:6,6 55:24 55:24 59:22,22 61:12,13 63:9 64:24 64:25 66:20 67:19 75:25 76:1,9,12,13 83:20 97:16 124:23 143:22 144:13 152:10,11 165:5,7 165:25 166:16 167:8,15,18 168:14 169:6 178:22 180:24 181:8,8,13 181:14,17,18,24,25 182:11 183:11 189:8 191:23 199:3 199:10,12,22,23 200:3,3,6 203:22 215:22,24 216:13 221:13 237:15,15 247:14,25 248:7,15 248:22,24 249:5,10 249:20,23 250:3,3 250:15 251:7,9,9,25 253:8,9,12 254:10 257:3,5,20 287:15 292:2,4,5 293:14 296:24 297:2 303:7 304:2,21</p> <p><b>animal's (4)</b> 168:9,16 169:8 188:17</p> <p><b>animals (144)</b> 8:9,11 9:2 23:18,21 24:2,5,21 25:10,13 25:19 26:2 27:9 28:12,22 29:18 32:15 33:2 34:22,24 36:16 47:18 54:20 55:18 58:9 59:18 62:4 63:24 64:18 66:20 75:17 76:7,13 78:16 79:1,16 85:10 86:2,3 91:1 103:25 105:9 106:3,6,14 107:2,4 108:2,16,22 108:25 110:4 128:13,19 130:18 143:22 146:11 147:23,25 148:7 151:15,18 152:1,2</p>	<p>153:16 158:17 161:4 165:16 167:12 176:8,10 180:11 182:10 183:10 184:3,5 185:8,15 189:17 190:10 191:25 192:15 193:1 194:18,20 195:2 196:19 197:9 198:12,14 199:1 200:11,12 201:13 203:13,17 212:4 214:1,11 215:4 216:6,10,18 218:11 218:13,14 219:8,18 219:18,20 223:2 241:19 248:8,14,16 248:19 249:2,22,25 250:7 253:7,11 254:12 257:8,9,10 257:14,15,16 258:1 291:24,24 292:3,22 293:1 294:2,25 295:3,4,5,7 297:7 298:21 304:14</p> <p><b>answer (44)</b> 7:20 12:14 13:14 16:21,22 18:18,21 19:18 22:14 26:1,17 26:20,23 27:1,3 29:10 35:22 40:16 44:6 45:22 46:16 109:17 130:4 133:6 150:10,19 164:8 168:2 176:13 177:14 186:14 200:1 240:1 242:12 243:3 244:9,13 251:22 252:8,11,12 272:18 281:7 291:22</p> <p><b>answered (17)</b> 21:4 22:12 23:11 29:21 46:21 50:15 62:16 73:6,15 107:16 144:19 189:20,21 212:16 252:6,9 262:23</p> <p><b>answering (2)</b> 22:6,7</p> <p><b>answers (3)</b> 7:21 65:9 290:8</p> <p><b>anticipated (7)</b> 101:11 256:24 260:17 261:25 262:9,14</p>	<p>301:4</p> <p><b>Anver (1)</b> 93:22</p> <p><b>anybody (19)</b> 16:9 23:25 24:8,20,25 25:2,16,21 27:12 56:6 59:24 61:15 63:12 113:24 203:23 204:2 254:19 292:7,10</p> <p><b>anyway (2)</b> 88:13 225:20</p> <p><b>apologies (2)</b> 41:6,10</p> <p><b>apologize (7)</b> 41:17,17,19 193:17 206:1 214:20 237:4</p> <p><b>apparent (3)</b> 196:2,8,11</p> <p><b>apparently (1)</b> 34:20</p> <p><b>appear (3)</b> 67:25 214:12 218:14</p> <p><b>appeared (1)</b> 77:9</p> <p><b>Appearing (1)</b> 2:10</p> <p><b>appears (3)</b> 196:20 219:18 259:11</p> <p><b>apples (3)</b> 35:13 144:21 154:21</p> <p><b>applied (1)</b> 293:5</p> <p><b>apply (1)</b> 21:9</p> <p><b>approaches (1)</b> 251:14</p> <p><b>appropriate (11)</b> 67:4 73:23 74:25 106:25 107:5 131:14 147:15 148:8 169:21 180:21 260:8</p> <p><b>approved (2)</b> 256:21 301:1</p> <p><b>approximate (1)</b> 306:2</p> <p><b>approximately (1)</b> 4:15</p> <p><b>area (4)</b> 25:1,3 56:7 245:4</p> <p><b>argue (2)</b> 199:7 231:13</p> <p><b>argument (3)</b> 30:2 207:22 249:6</p> <p><b>argumentative (7)</b></p>	<p>29:11 73:6 74:9 82:9 152:14 172:10 253:3</p> <p><b>arguments (2)</b> 29:22,24</p> <p><b>arises (1)</b> 19:2</p> <p><b>Aristei (1)</b> 2:8</p> <p><b>arm (1)</b> 245:13</p> <p><b>arrangement (1)</b> 283:23</p> <p><b>art (4)</b> 28:17 139:14,21,24</p> <p><b>article (2)</b> 102:22 292:10</p> <p><b>articles (2)</b> 204:2 240:23</p> <p><b>Arysta (18)</b> 42:2 113:3,25 118:21 122:4 123:6 126:10 127:17 128:5 129:23 130:9 224:4 225:10,13,14,15,17 225:20</p> <p><b>asked (62)</b> 14:15 21:3 22:4 23:10 29:20 34:4 44:17 46:20 50:14 62:15 73:5,14,16 74:4,15 74:16 91:10 97:4 99:13 100:22 101:13,15,16 102:3 102:4 107:15 113:22 115:15 126:18 127:8 133:2 144:18 152:19 154:20 157:5 160:15 163:1 165:10 174:7 178:16,24 180:1 181:21 186:14 187:22 189:19 199:14 202:24 212:7,15,17 245:10 251:7 252:5,5 262:22 263:24 276:25 278:21 289:1,6 307:10</p> <p><b>asking (31)</b> 8:16 13:8,23 15:2 34:2,6 35:17 43:7 66:11 70:25 71:21 72:23 126:7 144:20 179:15,17 197:25</p>	<p>202:9,16 232:5 239:19 247:6 263:21 278:17,19 282:13 283:14 284:7 285:24 290:1 290:24</p> <p><b>asks (1)</b> 168:3</p> <p><b>aspect (1)</b> 245:25</p> <p><b>assays (2)</b> 139:14,21</p> <p><b>assess (5)</b> 36:17 65:25 66:7,18 263:2</p> <p><b>assessment (1)</b> 216:12</p> <p><b>assessment (83)</b> 104:24,25 105:2,3 111:9,12 143:9,11 143:15 144:5,6,8,23 144:24,25 146:16 146:17,22,25 149:21 152:19,19 154:18,19,20 155:2 155:3 180:13,18 193:3,4 206:13,15 207:4,4,6,23 208:1 208:20,22 212:8 215:20 216:12 217:1 222:20,21 223:19,19,24 243:15 248:6,12,13 249:14,15,19 250:6 250:14 251:3,24 252:14,17 256:18 256:25 257:13 259:2,5 260:18,23 261:2,6 262:3,16 265:13,17,21 266:5 269:5,10,20 271:15 272:15 276:18</p> <p><b>assessments (9)</b> 180:16 247:20 250:4 260:6,19 261:8 262:21 265:9 276:14</p> <p><b>associated (3)</b> 27:11 70:1 207:9</p> <p><b>association (14)</b> 4:19 16:7 20:15 24:22 25:17 27:15 56:3 60:1 61:16 63:14 178:19 203:25 247:1 292:8</p> <p><b>assume (8)</b></p>
--	--	--	--	---

14:6 75:7 227:11 229:17 232:1,2 240:3,5	212:12 219:24 226:19 232:10 238:21 239:21	39:1,12 42:9 57:24 69:21 80:21,25 85:6 87:21 89:2 91:14 102:14 114:19,23 116:9 117:24 119:22,24 123:12 125:4 130:15 134:20 140:9,14 160:1 175:2 189:24 190:17 197:21,23 211:21 213:22 227:23 229:15 251:2,21,23 255:7 255:11 256:12 269:16 271:9 286:12 290:21 299:18	42:25 102:22 149:8 152:12 173:19 246:17 <b>Bates (3)</b> 285:10,13,19 <b>Baum (1)</b> 2:8 <b>Bear (1)</b> 174:7 <b>becoming (1)</b> 73:6 <b>beginning (2)</b> 227:8 290:21 <b>behalf (8)</b> 1:11 3:7 4:22,24 5:1,3 5:10 11:8 <b>believe (44)</b> 5:5 24:13 26:4 30:20 37:7 38:10,22 40:8 41:16 47:12 49:9,20 54:2,5 78:12 90:8 91:9 92:22,23 93:24 95:14 98:8 101:22 103:23 105:25 119:24 121:7 122:10 140:17 156:14 159:1 163:17 175:3,3 191:1,22 208:14 209:23 223:11 224:10 225:1 296:1 296:11 297:17	<b>bias (2)</b> 20:19 21:21 <b>big (3)</b> 78:22 79:8 94:6 <b>Bill (1)</b> 279:23 <b>billing (1)</b> 279:9 <b>bioassay (38)</b> 8:4 9:1 16:2 28:11 32:10 45:14 67:3,20 75:11,14,22 77:13 167:15 181:19 183:22 186:1,22,24 187:6 196:23 203:13 211:20 215:20,22,24 216:10 249:3,23,25 251:9,9,12 253:9,13 253:19 257:20 292:21 293:14 <b>bioassays (11)</b> 124:19 152:23 153:3 166:1 167:8 216:13 229:20 236:3 240:12 248:24,24 <b>Biodynamic's (1)</b> 78:14 <b>Biodynamics (1)</b> 80:3 <b>biologic (5)</b> 176:17 177:4 194:20 199:10,21 <b>biological (2)</b> 175:17 195:1 <b>biologically (2)</b> 188:19 194:18 <b>biostatistician (1)</b> 124:14 <b>biostatistics (1)</b> 124:12 <b>bit (5)</b> 158:15 231:20,20 234:7 294:14 <b>Blair (1)</b> 267:24 <b>blinded (1)</b> 96:17 <b>blocking (1)</b> 195:4 <b>Bob (2)</b> 86:20,23 <b>body (6)</b> 183:4 213:17 214:11 215:15 219:16 220:25
<b>assumed (1)</b> 161:8 <b>Assuming (1)</b> 199:3 <b>assumption (2)</b> 199:15 229:23 <b>Atkinson (14)</b> 100:12,16 101:19 102:7,23 104:11,19 105:23 106:12,17 107:23 111:1,22 112:8 <b>Atkinson's (1)</b> 103:14 <b>attached (3)</b> 256:4 267:22 282:8 <b>attaches (1)</b> 281:16 <b>attaching (1)</b> 281:13 <b>attempt (5)</b> 36:17 65:24 66:7,18 265:1 <b>attended (3)</b> 15:21,25 123:17 <b>attorney (1)</b> 114:9 <b>attorneys (1)</b> 116:19 <b>attributable (1)</b> 112:23 <b>attributed (1)</b> 143:20 <b>author (7)</b> 52:25 53:10 96:14 100:12 101:19 115:3 290:19 <b>author's (4)</b> 69:24 101:14 156:16 156:17 <b>authored (3)</b> 106:12 240:20,24 <b>authorities (2)</b> 216:23 260:20 <b>authors (31)</b> 72:3,7 73:13 74:2,13 100:16 113:8,15 135:13,14,23 155:19 156:21 161:17 168:7 174:2 177:2,15,23 179:5,8 192:6 193:11 209:21 211:15	<b>auto-corrected (1)</b> 5:19 <b>available (34)</b> 17:10,12,25 58:24 72:16 73:20 88:14 88:20 111:24 115:7 115:18 155:25 157:7,9 163:6,20 165:12 166:25 169:1,2 175:10,11 227:10 229:3 236:16 241:17 247:7 256:20 261:23 282:23 296:24 297:19,23 301:22 <b>Avenue (1)</b> 4:18 <b>avoid (1)</b> 262:7 <b>aware (71)</b> 10:21 24:24 25:2 26:12 27:12,17 29:8 29:22,24 56:2 59:24 61:15 63:12 82:10 99:6 103:13 104:10 112:25 113:8,14 115:22 116:11 122:11 123:4,13 125:12 126:8 127:14 129:21 130:7,16 133:18 142:4,15 149:5 153:8 160:23 170:7 170:17 171:19 175:13 176:14 177:15 182:6 194:1 194:9 195:13 197:12 203:23 204:1,3,3 206:6 210:5 215:14 219:23 221:8 231:21 245:23 251:5 254:21,23 278:5,20 279:2,16 279:18,20 283:4 292:7,10 <b>awhile (2)</b> 32:6 186:3 <hr/> <b>B</b> <hr/> <b>back (49)</b> 13:18,19 19:4 38:22	<b>background (16)</b> 29:18 30:1,4 70:19 74:24 75:6 146:18 147:1,10 151:1,7,7 167:8 168:12,25 211:10 <b>bacterial (1)</b> 165:15 <b>badly (1)</b> 277:22 <b>based (68)</b> 12:6 14:21 17:9,18 19:14 28:21 39:11 44:11 58:23 97:15 98:6 103:15 104:24 123:11 124:11 131:15 134:19 143:4,4,8,10,16 144:6 153:18,23,23 154:8 161:6,7 163:2 164:23 175:5,7 180:15 183:7 204:11 214:10 217:14,16 218:13 219:15 224:17 239:4 241:20 246:22 247:3 248:7 250:3,6 251:3 256:18,20 257:14 257:15 261:23 265:12,14,17,17,19 265:25 270:2 277:21 295:6 299:4 300:24 304:5,10 <b>basically (7)</b> 19:19 20:10 52:15 265:24 274:15 277:23 300:24 <b>basis (6)</b>	<b>believed (1)</b> 52:25 <b>believes (1)</b> 53:1 <b>bell (1)</b> 96:24 <b>belong (1)</b> 266:12 <b>benign (4)</b> 71:6 185:24 186:21 187:5 <b>best (16)</b> 16:3 24:19 48:7 173:5 230:18 232:13 242:20 249:22 251:8 266:7 273:1 274:9 284:15 292:6 292:13 293:15 <b>better (4)</b> 43:5,14 266:4 290:7 <b>beyond (2)</b> 277:16 301:16 <b>BfR (3)</b> 271:2,4 280:15	

<b>Booker (1)</b> 140:4	276:1 300:18	66:1,8 68:7,10 98:13 105:9,13 113:11 154:14,23 180:10 188:21 191:8 192:25 205:23 221:6 223:13,22,23 224:17 225:24 240:10 263:8 264:2 270:8,22	150:14 152:17 177:17 179:2,11 182:18 199:22 221:24 246:18 254:1,23 255:5,10 255:15 260:22 298:9 308:2	<b>caution (3)</b> 261:9,12 262:21
<b>boss (2)</b> 90:9 140:7	<b>cancer (79)</b> 8:6,11,15,17 9:1,3,18 9:19 12:22 13:1 17:5 18:2,9,11 20:15,17 23:18 24:6 25:10 26:3 28:12,21 32:12,15 34:23 36:2 55:18 58:9 59:14,17 61:8,11 63:4,7 85:14 94:2 143:21 182:17 184:16 189:16 192:25 195:11 196:19 199:23 203:16 221:12 248:14,19 248:22 253:11,15 254:11 257:25 258:6,22 259:4 260:7 263:6,7,7,9 263:24,25 264:1,3 264:19,19 287:10 291:23 292:3 293:6 294:1,1,3 303:15,17 304:14,15,22	<b>carcinogenicity (27)</b> 31:7,23 33:10 124:23 132:10,19 146:14 158:14 171:8 179:6 195:7 209:20 211:13 217:11 223:2,7 224:7 241:4 247:23 254:10 257:3,15,18,20 293:9,15 296:24	<b>category (2)</b> 77:2 106:22	<b>cc'd (1)</b> 267:11
<b>bottom (3)</b> 6:11 71:23 259:20		<b>carcinogens (28)</b> 3:11 8:8,9 35:1,13 241:16,22 242:3,7,9 256:17,24 257:8 258:10,18 259:1,12 260:14 261:25 296:23 297:3,9 300:25 301:2,4,8 302:7,16	<b>causation (4)</b> 3:7 11:8 20:8 21:14	<b>CD-1 (24)</b> 6:16,17 11:24 37:25 38:11 47:2 70:8 73:3 78:2,3 90:19 134:1,2 145:22,24 146:4 148:11 149:8 149:24 151:2 153:11,16 154:7 169:17
<b>Boulevard (1)</b> 2:9		<b>carcinomas (13)</b> 55:14,21 77:25 79:16 80:16 97:19 98:1 106:11 185:20 201:13,17,20 206:9	<b>cause (57)</b> 8:6,11,12,15 9:1,8,22 10:6 12:22 14:11,17 14:22 15:13 17:3 18:9 21:18 22:1,17 22:21 23:18 24:6,12 24:15 26:5 28:12 30:3,3 32:15 58:6 58:15 59:3,17 63:4 163:24 189:24 200:6 240:21 241:1 241:8 242:19,25 243:9 246:18 248:14,18,21 253:10,15 254:11 257:25 263:25 291:11,23 293:6 303:17 304:14,15	<b>cell (79)</b> 25:22 26:14,21 41:22 51:5,15,16 52:4,9 53:2,12,18,25 54:7 54:10,15 60:24 61:3 61:9,21 62:8,20,24 63:5,14,20,24 65:2 65:8,10 170:4,8 173:24 175:16 176:7,16 178:1 180:17 182:7 184:23,25 188:9,18 189:4 190:2 194:2 194:12 195:16,23 196:18 197:10 198:5,17,18 199:2 200:11,17,24 201:11,13,20,25 202:1 204:10,16,21 205:3,7,8,14,14 206:9 207:12,18,24 208:4,7,16 220:20
<b>brackets (1)</b> 254:3		<b>career (1)</b> 241:13	<b>caused (50)</b> 10:13 16:3,13 18:5 23:19,22 24:16 25:10,12 26:3,7 37:21,23 38:11,12 38:14,24 39:2,14 41:21 55:18 59:19 59:20 61:7,8,11 63:4,7,7 104:21 105:5,8 143:21,21 144:11,12 169:8 180:22,22 185:9 189:7,15 203:16,17 203:21 204:12 209:13 255:1,17 292:3	<b>CERTIFICATE (1)</b> 307:1
<b>Bramer (1)</b> 148:23	<b>cancer-causing (1)</b> 17:7	<b>carefully (1)</b> 7:22	<b>causes (22)</b> 9:3,4,18,19 13:6,21 18:2,14 19:9 20:17 20:17 21:1 24:4 34:23 38:7 58:9,10 64:17 197:5 253:8 294:1,2	<b>certified (2)</b> 1:13 307:4
<b>break (17)</b> 7:17 56:11 117:2,8,11 117:14,15,16,18 159:19,21 229:8,9 251:18,18 256:6 286:7	<b>cancers (2)</b> 8:13 24:12	<b>carried (1)</b> 84:14	<b>causing (6)</b> 9:5 13:12 32:12 108:23 263:6 303:15	<b>change (7)</b> 11:19 77:6 189:24
<b>brief (1)</b> 287:5	<b>capable (1)</b> 263:6	<b>case (47)</b> 1:2 9:21 10:4,25 24:13 27:19 28:15 38:18 45:15,16,17 55:22 56:21 65:4 67:12 72:9 76:16 82:8,21 92:9 100:21 103:6,23 113:21 122:9,10,13,25 131:23 147:13		
<b>bring (2)</b> 201:19 278:3	<b>cancer (72)</b> 24:5,17,18 25:14,15 26:9,11 30:10 32:16 33:9,25,25 34:15 55:24,24 56:1 59:22 59:22,24 61:13,13 61:14 63:9,11 64:24 68:13 77:3 105:1 143:13,22,23 144:8 144:13,14 180:24 180:25 189:8,9 203:22,22 246:25 247:1,14 248:22 249:5,10,20,21,23 250:8,16 251:7 252:2 253:9 260:18 261:5,10 262:9,13 262:14 266:1 292:4 292:5,6,18,22,23 303:8,10 304:2,3,23			
<b>Broadway (1)</b> 2:6	<b>carcinogenesis (6)</b> 17:7 30:24 87:4 249:24 293:2,5			
<b>bronchioalveolar (1)</b> 70:2	<b>carcinogenic (30)</b> 31:22 32:16 36:1,18			
<b>brought (3)</b> 79:23 272:21 283:8				
<b>Buck (3)</b> 2:19 5:4,4				
<b>bunch (2)</b> 6:6 267:23				
<b>busy (1)</b> 274:12				
<b>C</b>				
<b>C (8)</b> 2:1 77:2 207:12,18,24 208:4,7 285:6				
<b>C-h-e-m-i-n-o-v-a (1)</b> 111:23				
<b>calculate (1)</b> 153:7				
<b>calculation (1)</b> 295:6				
<b>California (3)</b> 1:1 2:9 4:11				
<b>called (8)</b> 8:18 53:10 100:13 104:7 143:12 144:7 155:10 159:9				
<b>calling (1)</b> 134:17				
<b>calls (9)</b> 14:7,13 72:10 179:14 226:9 229:22 274:4				

239:16,16 272:3,4 <b>changed (8)</b> 5:19 35:8 41:8 77:9 77:10 134:16 186:7 186:18 <b>changes (3)</b> 177:25 187:17 193:1 <b>charge (1)</b> 242:2 <b>Charles (9)</b> 1:4,11 3:1,6 4:9 5:12 11:7 305:23 307:6 <b>cheat (4)</b> 109:11,20 120:6 121:6 <b>check (2)</b> 140:14 175:2 <b>chemical (30)</b> 8:14 9:1 17:24 18:4 28:11 30:3 32:12,15 34:23 36:15 46:14 50:8 57:11 62:6 216:8 218:21 243:22 244:25 245:11 248:18 253:10 254:11 257:25 292:17 293:2,16 294:1 295:18 303:14,17 <b>chemicals (5)</b> 8:8 241:15 296:20 297:3,9 <b>Cheminova (7)</b> 100:14 102:8 106:12 111:22,22 224:3,10 <b>cherry (1)</b> 126:2 <b>Chi-Square (5)</b> 119:18,20 120:3 121:22,24 <b>Chi-Squared (4)</b> 122:8 124:16 125:2 125:22 <b>chose (4)</b> 227:1,15 228:1,2 <b>Chris (37)</b> 3:13 120:23 123:13 123:15 124:13 127:14 131:3 142:10 171:25 228:22 266:22 267:14,23 268:18 268:21 273:25 274:13 275:7,16,16 275:23 276:20 277:18 280:13,20	280:21,22 281:2,14 282:5,24,25 283:11 283:14,19 284:20 285:5 <b>Christopher (3)</b> 2:13 3:16 5:2 <b>chronic (8)</b> 77:13 124:18,23 183:22 215:20,24 216:10,13 <b>Cincinnati (1)</b> 85:25 <b>circumstance (1)</b> 257:25 <b>circumstances (3)</b> 253:16 263:7 264:1 <b>citations (2)</b> 11:3 287:6 <b>cite (27)</b> 10:24 27:18 29:3,9 38:6,18,20 39:3 42:5 45:23 47:8 48:18 49:21,24 50:18 55:13 57:12 59:6,11 60:4,8 61:20 62:7,23 126:23 254:13 255:13 <b>cited (16)</b> 12:4 44:5 46:3 50:25 54:14,25 57:4 63:18 64:3 81:18,24 82:6 288:22 289:25 290:12 305:2 <b>cites (2)</b> 42:16 104:2 <b>citing (4)</b> 43:18 44:16 82:15 126:19 <b>CITY (1)</b> 307:3 <b>Civil (1)</b> 4:4 <b>claim (16)</b> 37:4 40:6,13,20 41:13 49:17 50:12 51:4 53:17 55:8,9 58:1 60:23 62:19 112:22 158:16 <b>claimed (1)</b> 41:25 <b>clarification (1)</b> 288:11 <b>clarify (1)</b> 7:23 <b>clear (7)</b>	41:12 161:12 168:19 230:5 265:5 288:20 300:21 <b>clearer (1)</b> 162:18 <b>clearly (2)</b> 34:3 281:3 <b>clinical (2)</b> 213:16 255:3 <b>clinician (3)</b> 255:4,5,16 <b>close (1)</b> 254:16 <b>closely (2)</b> 27:11 200:1 <b>co-author (1)</b> 30:15 <b>co-authors (10)</b> 209:21 226:2,7,25 227:18 229:18 238:3,22 240:10 282:21 <b>coaching (1)</b> 22:10 <b>Coast (1)</b> 117:3 <b>cognizant (1)</b> 253:22 <b>collaborator's (1)</b> 103:14 <b>collaborators (3)</b> 115:24 116:12 243:14 <b>colleague (2)</b> 85:3 266:23 <b>colleagues (8)</b> 30:22 31:5,19 32:5 33:8,21 35:24 256:15 <b>colonies (2)</b> 168:14 169:7 <b>colony (17)</b> 158:16 161:9,19 162:11 163:7 164:17,23 165:2,20 165:24 167:2,4,11 167:18 168:8 169:6 170:9 <b>Colorado (6)</b> 1:12,14 2:4 4:14 307:2,5 <b>column (2)</b> 259:20 260:1 <b>come (6)</b> 10:23 85:8 91:14 206:24 237:11 302:12	<b>comes (4)</b> 81:10 82:2 85:10 154:23 <b>coming (3)</b> 81:15 164:24 275:15 <b>commencement (1)</b> 307:6 <b>comment (13)</b> 27:4 139:1 142:10 146:23 164:14 168:19 183:25 209:7 239:3 254:3 275:19,21 283:3 <b>commentary (1)</b> 282:22 <b>comments (2)</b> 254:7 277:1 <b>commission (2)</b> 307:19 308:25 <b>committee (17)</b> 16:11 17:1 18:12 19:8 21:25 22:22 99:11 231:11 244:2,15 246:11 250:8,14 251:24 268:1,4 273:9 <b>committees (2)</b> 247:21,23 <b>common (6)</b> 145:13,14,17 163:24 293:20,20 <b>commonly (1)</b> 133:20 <b>communication (1)</b> 123:12 <b>company (8)</b> 1:11 100:13 135:20 135:22 155:9,10 225:17,18 <b>compare (8)</b> 103:4 106:17 114:13 144:21 233:2,5,13 294:11 <b>compared (13)</b> 6:8 128:20 129:17 137:25 138:1 140:22 146:10 147:23 156:4 185:15 237:6,24,25 <b>compares (1)</b> 193:22 <b>comparing (3)</b> 233:22,23 294:23 <b>comparison (7)</b> 108:15,17,19 185:16 185:17 205:15	208:8 <b>comparisons (4)</b> 152:6,10,22 153:2 <b>completed (1)</b> 82:22 <b>completely (2)</b> 46:12 134:22 <b>compliant (2)</b> 161:22 163:10 <b>component (1)</b> 161:13 <b>compound (16)</b> 32:24 33:11 34:15 64:17 100:17 105:6 105:18,19 111:7,17 115:24 175:20 207:2 208:17 209:13 261:9 <b>compound-related (...)</b> 102:1 113:10,16 116:13 135:25 156:22 187:17 211:16 212:3 <b>comprehensive (1)</b> 290:8 <b>compromised (3)</b> 162:13 163:12 167:22 <b>concede (1)</b> 224:6 <b>concentrated (1)</b> 192:12 <b>concern (1)</b> 277:21 <b>concerned (3)</b> 253:7 257:9 274:2 <b>conclude (3)</b> 15:11 206:25 222:7 <b>concluded (31)</b> 74:13 84:3 100:17 103:21 104:16,20 105:12 113:9 115:24 116:13 125:21 135:24 142:17 154:18 156:22 173:23 191:7 192:24 204:4 207:18 208:15 211:16 212:2,12 214:8 223:12 224:12 225:23 239:1 269:23 306:2 <b>concludes (1)</b> 305:23 <b>concluding (1)</b> 270:22 <b>conclusion (37)</b>
---	---	---	---	--

14:8,14 15:8,10 21:14 43:1 67:19 71:4,16,24 72:11 73:15 78:4 87:15 97:14 98:4,8 102:1 103:14 111:11 113:16 154:24 160:16 175:15 176:14 177:15 179:15,21 189:16 209:19,23,25 215:9 219:23 221:14 270:7 271:11 <b>conclusions (14)</b> 72:7 73:2,12 74:1 106:9 155:18 156:18 173:9 174:4 178:9,14 179:6,12 239:22 <b>concurred (1)</b> 91:11 <b>concurrent (12)</b> 6:8 67:5,7 107:1,3,10 128:20 131:15,16 138:1 148:12 151:4 <b>conditions (4)</b> 54:22 248:18 258:5 258:22 <b>conduct (1)</b> 292:25 <b>conducted (25)</b> 23:17 24:11 25:9 26:2 46:13 50:7 55:17 56:3 59:17,25 61:16 62:5 63:13 64:14 71:17 167:16 192:14 203:24 219:25 225:21 227:18 247:24 257:16 276:10,15 <b>conducting (1)</b> 207:23 <b>confidence (2)</b> 80:1,14 <b>confident (2)</b> 115:18 165:12 <b>confirm (6)</b> 80:21 89:20,22 90:25 91:6,12 <b>confirmed (5)</b> 90:22 97:15,17,23 270:6 <b>confound (1)</b> 165:20 <b>confounded (1)</b> 162:16	<b>confounders (2)</b> 20:9,11 <b>confounding (4)</b> 20:19 160:24 162:5 162:22 <b>confusing (3)</b> 48:16 49:5,7 <b>Congress (11)</b> 242:3,24 243:4,8 256:16 257:1 258:3 259:6 261:2 265:14 266:6 <b>connection (15)</b> 74:18 183:22 192:21 196:22 209:20 241:10 246:2 266:20 269:4,4 278:9 279:11 280:16,25 283:24 <b>consider (27)</b> 50:4 61:2 103:10 105:1 111:4 161:23 163:11,22 170:12 180:21 187:5 206:8 207:8 208:1 221:11 222:20 243:14,16 244:2,16 250:7,15 252:1 253:17 254:8 276:15 299:12 <b>consideration (11)</b> 67:1,2 106:11 151:4 164:16 190:12 211:9 252:25 253:23 296:5,6 <b>considered (23)</b> 36:16 65:24 66:6,18 71:7 82:3 104:17,21 128:5 154:11,13 160:8 166:4 178:3 180:9 185:25 186:22,24 217:18 255:15 256:3 287:13 301:23 <b>considering (6)</b> 184:13 206:6 207:17 244:21 246:11,12 <b>consistent (3)</b> 80:15 110:2,3 <b>Consolato (1)</b> 3:18 <b>constrained (1)</b> 19:16 <b>consult (1)</b> 278:9 <b>consultant (4)</b> 279:3 284:2,5,9	<b>consulting (1)</b> 283:22 <b>consumption (1)</b> 213:18 <b>contact (1)</b> 123:22 <b>contacted (2)</b> 277:18,20 <b>contains (2)</b> 100:23 101:16 <b>contamination (2)</b> 162:5 167:10 <b>contemporary (2)</b> 106:19 176:11 <b>content (1)</b> 216:6 <b>content (6)</b> 126:3,4 164:13 176:22 179:16,18 <b>continue (1)</b> 132:1 <b>continuing (1)</b> 264:22 <b>contract (2)</b> 79:9 279:7 <b>contractual (1)</b> 278:17 <b>contrary (1)</b> 184:7 <b>contribute (1)</b> 274:11 <b>contributed (1)</b> 161:13 <b>control (62)</b> 29:18 65:21,24 66:6 66:17,19 67:1 78:16 79:1,16 83:20 84:20 86:2,7 89:16 91:1 91:13,15 97:16 106:2,6,13,22 107:5 107:7,24 108:16 119:8 130:16,18,19 131:5,8 141:7 147:23 149:3,23 150:4 153:16,16 168:23 170:13 176:10 178:2 182:23 183:10 184:5,13 197:13,14 197:19 199:3,11,22 201:12,14,19 202:4 224:20 255:10 294:25 295:4 <b>controlled (3)</b> 103:25 108:18 295:7 <b>controls (45)</b>	6:9 60:20,22 65:19 67:2,4,5,6,8,9,11,14 83:19 91:7 97:18 106:22,25 107:1,3 107:11,14,25 128:20,23 129:18 131:14,15,16 137:25 138:2 140:22 141:16 148:10,12,13 149:12 151:5,12 153:25 176:10 185:16 188:15 198:19 219:17 298:20 <b>controversial (1)</b> 96:16 <b>controversy (3)</b> 82:23 98:19 307:7 <b>convene (3)</b> 92:25 93:4 101:7 <b>convened (6)</b> 88:25 92:7,24 93:5 98:11 99:7 <b>convenience (2)</b> 81:22 233:19 <b>conversations (1)</b> 123:24 <b>convey (1)</b> 151:10 <b>copy (16)</b> 34:3,7,19 71:12 120:6 120:7 156:1 157:4 198:1 259:9 266:21 266:21 278:11,14 279:22 280:2 <b>corner (1)</b> 121:13 <b>Corporation (1)</b> 79:12 <b>correct (128)</b> 5:17 6:2,13 11:19 21:2 40:5 46:15,22 49:16,19,23 50:21 51:3,21 53:14,21 54:5,18 57:7 61:1 61:25 67:13 76:22 78:24 82:24 85:7 87:5,7,10 89:17 92:10,24 95:11,12 97:12 98:15 105:15 106:7 108:3,6,19 114:3 124:15 128:8 128:12,17,24,25 130:15 133:5 138:3 138:25 141:12	169:23 170:5,6 184:23 185:2,3 187:25 188:6 192:2 192:19,23 193:7,10 193:25 195:19,24 196:1,12 197:11 201:5 204:25 206:4 207:15 210:16 211:18 212:20,21 213:19 220:8 224:15 225:6,9,22 225:25 226:1,5 237:18 242:1 243:12 258:11 259:7,18 260:4,9 261:6 267:13,13 272:16 286:23,24 287:3,4,7,14,18,21 288:2 289:2 290:2 290:13,16 293:3,16 293:18 295:22 296:3 297:19 299:9 300:3,4,7,9 302:23 303:1 304:4 <b>corrected (3)</b> 50:21,23 172:23 <b>correction (4)</b> 6:11 11:18 133:10 134:23 <b>corrections (1)</b> 11:13 <b>correctly (2)</b> 236:9 260:10 <b>correlation (1)</b> 24:1 <b>correspondence (1)</b> 103:6 <b>corresponding (3)</b> 45:11,18 46:9 <b>counsel (33)</b> 4:20 69:17,19 76:17 81:3 86:11 96:3 97:9 102:19 115:12 118:1 120:5 150:7 150:18 157:3,6 158:22,23 159:14 164:5 165:11 174:24 175:21 191:15 213:11 235:25 236:1 266:22 281:5 285:10 294:18 302:5 307:11 <b>counted (2)</b> 82:13 127:9 <b>COUNTY (1)</b>
---	---	---	--	--

307:3	194:5	272:17 295:12	265:13,15	231:7,8 244:7 252:5
<b>couple (3)</b>	<b>daily (5)</b>	296:3,5,21,24,25	<b>defines (1)</b>	266:20 278:25
30:15 56:16 162:19	258:6,23 259:4 260:7	297:2,2,4,7,14,18	266:4	281:10 286:23
<b>course (8)</b>	262:5	297:20,23 298:6,8,9	<b>defining (1)</b>	290:21 305:23
60:24 93:3 125:21	<b>dang (1)</b>	300:22	264:19	307:8 308:3
141:2 202:13 229:2	305:20	<b>database (3)</b>	<b>definitely (5)</b>	<b>depositions (1)</b>
229:4 231:19	<b>danger (1)</b>	211:14 212:23,24	114:24 138:23 233:13	127:7
<b>court (18)</b>	262:3	<b>dataset (3)</b>	239:13 299:20	<b>describe (2)</b>
1:1 4:11,18 50:11,25	<b>dash (1)</b>	175:8 180:1,2	<b>definition (3)</b>	112:22 239:14
56:20 67:11 72:2,2	194:4	<b>date (4)</b>	249:24 264:20 266:4	<b>described (1)</b>
72:8 73:4 74:12	<b>data (170)</b>	52:15 210:9 270:2	<b>definitions (3)</b>	266:23
187:3,8,9 192:5	12:4 17:16,18,20,21	308:3	19:17 20:4,7	<b>describing (1)</b>
211:25 298:17	17:21,22,23,25 18:8	<b>dated (8)</b>	<b>degree (3)</b>	299:3
<b>created (1)</b>	20:11 21:7,17 31:4	5:20,21 159:10	14:21 15:11 58:14	<b>description (1)</b>
300:6	32:11,21 33:7 47:15	259:13 267:1	<b>deliberate (1)</b>	157:15
<b>creates (2)</b>	49:8 57:17 58:24,25	268:21 279:24	17:2	<b>design (3)</b>
271:11,22	58:25 59:2,8 60:10	302:10	<b>deliberations (2)</b>	75:15 251:15 254:9
<b>credible (4)</b>	65:24 66:6,17 67:7	<b>Dawley (1)</b>	16:18 301:11	<b>designating (1)</b>
20:8,16 21:16 22:20	67:15 69:4 72:18	194:4	<b>delve (1)</b>	261:9
<b>criteria (43)</b>	73:17 74:5,14,16	<b>Dawn (3)</b>	247:8	<b>designed (8)</b>
17:17,19 19:1 20:2,24	76:8 79:22 80:1,10	95:15,17 97:2	<b>demonstrate (2)</b>	31:1 59:25 61:15
21:6,6,9,23 34:24	82:4 84:2 99:8	<b>day (15)</b>	185:4,6	63:13 203:24 291:9
35:7,11 143:11,12	100:23,24 101:9,9	214:3,14,24,25 215:3	<b>demonstrates (2)</b>	291:23 292:7
180:15 206:14	101:14 102:4	215:6 216:17 232:5	185:7 295:16	<b>despite (2)</b>
207:6,25 208:22	103:20 104:25	248:3 278:22	<b>dense (2)</b>	22:9 290:1
214:25 222:23	107:7,14,23 111:24	286:17 291:8 306:3	109:22 286:18	<b>detail (8)</b>
223:19 239:4,7	112:1,4,4 113:23	307:15 308:23	<b>DENVER (1)</b>	38:16,23 39:13 42:20
246:24 256:20	114:4,12 115:16	<b>days (1)</b>	307:3	44:16 172:7 239:19
257:7,12,13 265:18	124:4,6,22 134:21	277:25	<b>Department (1)</b>	247:8
265:24,25 266:9,12	136:4 143:16	<b>DC (1)</b>	242:23	<b>details (3)</b>
297:1 300:2,21,24	150:12 153:6	2:15	<b>depend (1)</b>	157:16 197:25 289:7
300:24,25 301:5,8,8	155:24 157:10	<b>death (3)</b>	75:15	<b>determination (2)</b>
<b>criticizing (1)</b>	163:3 166:25	183:17 200:4,4	<b>depended (1)</b>	259:3 292:17
280:17	168:23 171:1,21	<b>deaths (3)</b>	236:8	<b>determine (19)</b>
<b>critique (1)</b>	175:9 178:17,18	184:4 198:24 213:15	<b>depends (5)</b>	10:6 13:6,21 14:10
282:14	181:8,8,13,14,18,18	<b>decades (1)</b>	75:16 133:25 145:20	17:2 18:8,13 28:11
<b>crucial (1)</b>	181:24,25 182:22	34:11	235:17 251:15	29:5 30:22 31:6,20
295:11	183:19 184:1,1	<b>decide (4)</b>	<b>depo (1)</b>	33:10 34:14 35:25
<b>current (6)</b>	186:22 187:7	16:13 30:10 241:17	56:14	61:4 199:16 249:19
27:25 29:14 34:24	191:24 192:13,13	278:23	<b>Deponent (21)</b>	253:8
129:17 302:25	192:13 196:23	<b>decided (1)</b>	85:23 92:5 117:17	<b>determined (11)</b>
303:1	199:14,25 202:5,8	180:16	118:6,11 120:16	18:1 19:8,14 131:18
<b>curriculum (1)</b>	202:19,24 204:2,15	<b>declaratory (1)</b>	128:14 133:8	142:5,23 144:10
241:6	206:7 207:17	96:4	134:14 168:4	187:16 217:8
<b>cut (4)</b>	208:12,21 209:3,7	<b>deceased (1)</b>	172:12,25 173:4	256:18 303:8
84:10,13 285:12	212:10 213:3	182:24	222:5 259:14,17	<b>determining (3)</b>
302:17	226:18,20,22,25	<b>Defendant (2)</b>	280:10 286:7	67:18 68:6 223:7
<b>CV (1)</b>	227:9,9,19,23 229:1	1:11 2:12	305:19 308:4,21	<b>develop (1)</b>
295:20	230:22 233:1,3	<b>defer (2)</b>	<b>Deponent's (1)</b>	28:17
<b>CWJ/Greim (2)</b>	237:6,7,9,15 239:12	124:10,14	5:15	<b>developed (8)</b>
3:8,10	239:12 241:17,21	<b>deficiency (2)</b>	<b>deposed (1)</b>	197:10 265:24 266:1
	245:1 246:12 247:7	204:24 298:13	16:18	266:15 300:2,23,25
	247:8,12 249:23	<b>define (4)</b>	<b>deposition (24)</b>	301:5
<b>D (1)</b>	250:15,19 251:8,25	12:8 181:15 303:23	1:4,11 3:5 4:9,13 14:2	<b>development (3)</b>
3:1	256:20 257:14,14	303:25	19:3 89:4 109:23	79:11,12 235:1
<b>D-a-w-l-e-y (1)</b>	257:15 261:23	<b>defined (2)</b>	126:18,22 127:8	<b>developments (2)</b>

268:25 269:3 <b>diagnosed (1)</b> 97:21 <b>diagnosis (1)</b> 89:18 <b>died (7)</b> 183:10,11 191:25 192:15 198:15 199:4 200:3 <b>diet (10)</b> 188:5,17 189:14,18 193:8,22 216:1,5 218:25 221:22 <b>difference (6)</b> 184:19 185:12 210:17 210:23 211:6 235:9 <b>differences (2)</b> 233:25 234:4 <b>different (64)</b> 8:16 11:14 20:7 31:2 31:10,24 32:18 33:2 33:11,23 34:17 35:15 36:3,4,16 38:11,20 40:8,22,24 41:15 46:10,12,25 50:6 51:5 55:11 64:13,14,15,15,23 74:7 85:10 124:2,21 128:22 133:13 141:6,15 146:6 167:23 175:8,8 182:9 188:14 190:11 195:1 201:6 201:9 206:21,21 211:5,11 214:18 224:23 233:20 234:8,10 241:15 272:18 276:10 287:6 294:5 <b>differently (1)</b> 196:25 <b>difficult (1)</b> 88:8 <b>difficulty (1)</b> 88:8 <b>directly (1)</b> 249:21 <b>director (2)</b> 242:6,7 <b>disagree (8)</b> 43:7 66:24 68:4 143:24 144:15 183:6 186:5,6 <b>disagreed (2)</b> 43:12 276:22 <b>disagreement (1)</b>	173:8 <b>disagrees (1)</b> 163:15 <b>discount (8)</b> 68:20 105:16 146:13 146:17 147:1 148:8 165:2 166:1 <b>discounted (8)</b> 147:10,12 148:22 149:4 163:16 208:23 287:14,16 <b>discounting (2)</b> 105:17 166:24 <b>discrepancy (6)</b> 235:11,13,14,15,19 235:21 <b>discussed (2)</b> 64:11 301:18 <b>discusses (1)</b> 59:13 <b>discussing (2)</b> 268:24 269:4 <b>discussion (1)</b> 15:22 <b>displeasure (1)</b> 231:3 <b>dispute (1)</b> 98:3 <b>disputed (1)</b> 96:16 <b>distribution (1)</b> 71:6 <b>District (4)</b> 1:1,1 4:11,11 <b>doctor (5)</b> 93:13 158:2 199:13 203:4 254:24 <b>doctors (3)</b> 70:16 75:3 93:12 <b>document (25)</b> 1:8 126:20 128:3 161:25 163:5 164:5 164:7,11 166:7 167:3 174:21,23 176:21,23 179:4 233:9 259:2,9 261:6 261:21 262:11 264:25 266:10 279:12 280:5 <b>documented (1)</b> 167:24 <b>documents (17)</b> 121:4 126:18 136:10 162:9 164:24 165:22 166:25 175:11 177:21	213:9,11 236:11 265:8 277:9 278:21 287:25 288:1 <b>doing (39)</b> 8:5 9:17 26:12 27:13 28:9,10 73:19 101:4 107:17 143:9,11 146:16 152:22 153:2 154:19 155:1 167:20,21 180:18 180:19 188:24 207:3 208:20,22 215:19 222:20 223:18 228:10,10 248:12,23 257:19 262:19 269:7 275:24 276:12,18 277:21 292:21 <b>dose (126)</b> 6:7 75:16,17 83:19,19 83:20 84:17,18,20 86:3,4,8,8,8 90:23 90:24,24 97:20,20 105:13 107:24,24 107:25 108:1,2,12 108:14 110:8 119:9 119:9,10,15 128:13 128:19,21 129:15 131:8,21 132:25 133:15 137:7,7,24 138:12 140:10 147:23,25 148:5 151:14,18 152:1,10 152:11 161:15 171:3,5 176:8 181:3 182:24 183:5,11 184:3,12,16,20 185:4,6,8,15 187:23 188:2 189:13,17 190:6 193:1,5,20,23 194:18 195:25 196:1 198:4,6,8,11 198:19,21,21,25 213:16 214:2,5,9 215:3,10 216:1,3,18 217:9 218:7,10,15 218:23 219:13,17 219:19,20 220:5,10 221:4,21 222:8,14 222:17 223:5 249:1 249:1,1 251:13,14 253:14,14,20 254:2 257:21 298:22 <b>dose-related (1)</b> 108:8 <b>dosed (1)</b>	194:19 <b>doses (27)</b> 188:16 190:4,9 194:16,24 195:1,2,3 195:3,5,6,11,12 214:3,22 217:20 218:11,12,14 247:24 248:9 249:7 249:12 250:2 253:18 254:17 257:4 <b>dot (1)</b> 218:1 <b>double (3)</b> 162:19 171:3 244:23 <b>dozens (2)</b> 177:8,8 <b>Dr (132)</b> 3:6,15 4:9 5:18 7:13 11:7 13:9,24 19:15 30:17,19 53:1,10 56:21 66:10 67:17 67:23 75:2 83:1,17 85:2,18 86:5,20,22 87:11,11,19,20 89:25,25 90:3,8,9 93:14,22 94:10,13 94:25 95:15,20,21 95:22,22 97:1 100:12 101:19 102:21 103:14 113:4 115:4,23 116:12 118:4 121:22 122:12 123:6 124:11 125:14,20 126:1,5,6 126:8,21 128:5 135:1,5,6,24 136:15 136:21 142:4 150:13,16 153:21 155:6 157:11 158:24 159:9 160:4 164:6 171:19 172:11 173:16,20 175:14 176:21 177:12 189:11 191:1,3,7 193:17,19 194:2 195:21 204:4 207:12 209:12,22 220:1,11 226:6,24 227:18 228:25 229:1,18 231:7 238:2,22 239:18 240:9 259:12 266:17 270:5 271:9 276:23,25 277:13	277:14 278:2,7,9 279:2,9,23 283:6,6 286:16 292:25 <b>drafted (3)</b> 269:12 275:7 282:13 <b>drafting (2)</b> 269:10 299:8 <b>drawn (1)</b> 67:19 <b>Drive (3)</b> 1:12 2:4 4:14 <b>driving (1)</b> 244:11 <b>drjameson (2)</b> 3:12,20 <b>due (18)</b> 104:1 111:15 124:3 137:3 142:7 144:2 164:16 166:16 167:10 168:8,15 187:17 204:6 208:25 216:7 218:19 223:13 272:13 <b>duly (2)</b> 5:13 307:7 <b>DVM (1)</b> 99:23 <b>dying (1)</b> 120:10
<b>E</b>				
<b>E (3)</b> 2:1,1 3:1				
<b>e-mail (34)</b> 3:12,18,20,21 161:17 266:18,22 267:22 267:23 268:10,15 268:21,24 269:9,22 270:5,13,14,16,18 270:19 271:10 275:9 279:22 280:4 280:12,13 281:14 282:4 283:4,5 284:20,21 285:5				
<b>e-mails (1)</b> 285:14				
<b>earlier (13)</b> 49:2 64:11 67:25 117:3 121:5 177:9 192:15 201:5 231:20 236:21 295:19 296:1 298:12				
<b>early (6)</b> 198:24 199:5 200:4,4				

<p>200:6 296:12</p> <p><b>East (1)</b> 117:3</p> <p><b>easy (1)</b> 125:5</p> <p><b>eat (2)</b> 117:2,8</p> <p><b>eating (1)</b> 216:6</p> <p><b>editorialize (1)</b> 173:1</p> <p><b>effect (60)</b> 11:4 27:24 28:8 57:14 63:6,17 66:1 68:7 68:11 79:6 97:14 98:5 103:15 108:23 113:1,11 135:25 146:14 154:14,23 167:10,13 168:7,8 168:16 169:8 178:7 180:10 183:4 187:1 188:21 190:19 191:8,8 196:22 209:24 210:1 216:7 217:21 219:16,21 219:21 220:16,17 220:19,20,23,25,25 221:1,3,3 223:8,13 223:22,23 240:11 246:7 257:2 295:14</p> <p><b>effects (14)</b> 113:17 115:25 116:14 136:1 169:10 195:10,12 213:17 216:7 218:19 247:22 248:8 263:8 264:2</p> <p><b>effort (1)</b> 277:15</p> <p><b>EFSA (43)</b> 104:8,9 149:6 153:10 154:11 166:9,11,15 166:21 169:21 173:8 208:12,15,20 209:4,7 215:17 216:23 223:9,12,18 223:21 267:6,8 268:25 269:7 270:24 271:7,11,21 272:1 275:3,8,11,22 276:9,12,14 277:13 277:15,21 280:15 280:17</p> <p><b>EFSA's (4)</b> 154:22 272:13 276:21 282:14</p>	<p><b>eight (7)</b> 183:10 198:19 235:3 242:2,6 290:22 291:6</p> <p><b>either (14)</b> 23:9 35:12 50:19 65:12 86:9 101:7,10 117:14 150:4 256:23 260:17 261:24 262:6 298:8</p> <p><b>else's (1)</b> 74:5</p> <p><b>embark (2)</b> 9:21 10:3</p> <p><b>emphasized (1)</b> 81:14</p> <p><b>employed (1)</b> 307:11</p> <p><b>encounter (1)</b> 94:7</p> <p><b>entire (9)</b> 67:24 69:8,20,22 70:23 84:14 179:2 199:15 291:8</p> <p><b>entitled (1)</b> 71:22</p> <p><b>envelope (1)</b> 125:5</p> <p><b>environment (3)</b> 244:4 248:10 254:17</p> <p><b>Environmental (1)</b> 114:1</p> <p><b>EPA (84)</b> 6:2 72:19 76:21 77:1 77:10,11 84:9,12 88:5,8 89:10,15 90:1,15,21 92:25 98:11,22 99:7,13 100:6 109:8 111:2,4 111:9,23 112:2 136:21 143:8,25 144:5 148:16 150:11 151:3,23 152:5,13,18 160:21 160:21,23 161:5 164:10,15 169:22 173:8 175:5,11 180:7,9,13 192:18 192:20,24 198:13 198:23 205:18,22 206:6,12,20,24,25 207:3,16,22 209:3,7 212:20,22 214:21 215:18,19 216:11 221:9,11 222:6,13 222:20 228:21</p>	<p>233:8 242:23 254:5 298:8</p> <p><b>EPA's (9)</b> 88:4 93:10 138:6 142:16 144:16 166:5 198:12 205:24 207:16</p> <p><b>epidemiologic (1)</b> 18:13</p> <p><b>epidemiologists (2)</b> 179:25 245:4</p> <p><b>epidemiology (10)</b> 17:24,25 18:8 241:21 247:4 255:8 295:10 296:25 297:4,7</p> <p><b>equal (2)</b> 64:6 151:7</p> <p><b>equivalent (1)</b> 305:8</p> <p><b>Erica (2)</b> 2:14 5:9</p> <p><b>err (5)</b> 261:8,11,13,14 262:21</p> <p><b>ERRATA (1)</b> 308:1</p> <p><b>error (5)</b> 12:5,9,10,11,16</p> <p><b>errs (1)</b> 261:19</p> <p><b>Esfandiary (3)</b> 2:8 5:7,7</p> <p><b>especially (1)</b> 166:18</p> <p><b>Esq (7)</b> 2:3,5,8,13,13,14,19</p> <p><b>essentially (1)</b> 221:2</p> <p><b>establish (4)</b> 249:4,10 258:5,21</p> <p><b>established (1)</b> 256:21</p> <p><b>estimate (3)</b> 263:8 264:1 297:8</p> <p><b>et (3)</b> 3:18 132:20 235:10</p> <p><b>euphemistically (1)</b> 121:6</p> <p><b>Europe (2)</b> 149:12 276:8</p> <p><b>European (16)</b> 104:15 129:22 130:8 131:11 149:6,21 150:25 153:9,14 154:12,12 166:10 216:23 268:25</p>	<p>270:20,25</p> <p><b>evaluate (23)</b> 17:6,18 18:8 21:7 67:6 73:19 74:24 75:21 99:7,14 105:4 124:5,18 160:24 167:17 189:1 211:7 217:10 218:12 247:12 248:13 273:17 297:4</p> <p><b>evaluated (9)</b> 17:25 59:16 104:10 187:15 189:15 208:3 229:20 241:16 273:1</p> <p><b>evaluating (11)</b> 164:21 165:25 186:22 187:6 196:23 226:20 241:15 243:22 250:15 251:25 300:22</p> <p><b>evaluation (55)</b> 18:3 21:10,11,16 58:23 59:10 67:15 72:20 73:19 76:7 77:2,21 107:6,12,18 111:13 114:5 124:22 142:5 143:16 161:24 163:2,12,19 164:21 165:3,22 166:4,24 169:21 178:21 188:20 198:12,16 201:22 205:19,23 206:17 213:4 220:6 220:17,18,22 221:6 222:23 223:5 227:19 239:9 250:18 273:19 276:21 295:12 301:7 304:6,11</p> <p><b>evaluations (2)</b> 76:10 186:1</p> <p><b>evaluator (1)</b> 228:8</p> <p><b>evening (1)</b> 286:16</p> <p><b>event (1)</b> 78:1</p> <p><b>events (2)</b> 86:14 195:1</p> <p><b>eventually (1)</b> 14:5</p> <p><b>everybody (4)</b> 118:7,10 277:20 282:24</p>	<p><b>everybody's (1)</b> 74:15</p> <p><b>evidence (91)</b> 18:1,14 19:9,25 20:1 20:5,5,6,7,16,18,21 21:1 22:1,19,19,20 22:25 23:6 33:24 37:5,13 38:6,13,18 40:7,14,21 41:14 42:5 43:10,12,18 45:23 46:3,17 47:8 48:11,18,22 49:13 49:17,21,24 50:11 50:19 51:1,4 52:9 54:6,14,24 55:8 56:19 57:3,13 58:2 59:5,11 60:4,23 61:20 62:8,20,24 64:17,23 83:23 96:5 164:22 166:2 185:19,24 186:20 187:5 188:8,23 190:13 208:16 217:3,8 224:16 225:24 240:10 241:18,18,20 254:13 257:9 267:20 281:5</p> <p><b>evidently (8)</b> 143:10 144:6 180:16 206:14 207:4,23 208:21 223:20</p> <p><b>exact (2)</b> 33:18 265:23</p> <p><b>exactly (10)</b> 36:20 102:14 166:12 166:13 189:11 211:22 238:16,24 257:12 263:24</p> <p><b>examination (6)</b> 3:1 7:11 286:14 303:5 305:7 307:6</p> <p><b>example (4)</b> 31:25 45:13 285:15 294:23</p> <p><b>Excellent (1)</b> 290:11</p> <p><b>excerpts (2)</b> 69:14 157:1</p> <p><b>exchange (3)</b> 281:14 282:5 283:5</p> <p><b>excited (2)</b> 305:17,19</p> <p><b>excluded (1)</b> 164:15</p> <p><b>excluding (1)</b></p>
--	---	---	--	--

198:24 <b>exclusively (1)</b> 230:9 <b>excuse (18)</b> 27:2 70:7 88:6 104:17 116:2,15 132:23 142:20 160:16 193:16 216:16 218:2 227:22 233:23 271:6 273:22 304:8,18 <b>exercise (2)</b> 178:18 180:18 <b>exhibit (19)</b> 3:6,8,10,11,12,15,16 3:18,20,21 120:21 121:5 259:11 266:21 284:19 286:23 302:5,6,25 <b>exhibits (3)</b> 3:5 4:1 268:7 <b>existed (1)</b> 50:12 <b>existence (4)</b> 44:22 61:3 139:5 165:15 <b>exists (2)</b> 57:15 272:13 <b>expect (2)</b> 194:18,24 <b>expected (2)</b> 263:8 264:2 <b>experience (22)</b> 64:20 75:14,20 79:24 80:6,7,10,11,12 88:10 96:7 101:6 145:11,11 153:18 153:23 165:25 167:14,14 215:21 217:16 250:21 <b>experiment (3)</b> 25:17 26:3 64:16 <b>experimental (43)</b> 3:8,10 8:7,9 24:5 25:10,13,19 26:2 27:20 28:12 30:9,23 31:22 32:15 34:23 47:14,18 55:18 59:18 64:18 83:11 87:9 94:16 95:8 99:23 143:22 168:14 182:10 187:14 194:21 214:23 248:19 258:1 291:24 292:3 292:4,22 293:1	294:2 304:2,14,21 <b>experiments (1)</b> 31:1 <b>expert (46)</b> 3:6 5:18 11:7 14:16 19:13,15,17 100:21 113:21 122:23 124:1,2 126:1,23 146:21 162:21 172:3 173:13 175:17 195:21 204:5 207:2 211:25 246:3 248:7 254:14 256:4 260:22 263:18,20,23 264:6 266:15 286:22 287:1 288:22,23 289:25 290:13 299:8,12,15,23 300:3,20 305:3 <b>expertise (1)</b> 34:9 <b>experts (1)</b> 73:9 <b>expires (2)</b> 307:19 308:25 <b>explain (3)</b> 21:22 227:7 264:23 <b>explained (1)</b> 238:13 <b>expose (1)</b> 249:25 <b>exposed (20)</b> 10:14,14 18:2 21:19 24:21 63:3 245:5,6 245:8 248:20 249:16 250:9,17 251:4 252:2,16 253:21 262:4 291:24 295:18 <b>exposure (36)</b> 10:13 24:14 26:7 104:1 105:5 107:2 111:18 178:18 203:20 207:9 208:25 243:23 244:3,16,24 245:1,3 245:3,8,11,25 247:2 250:23,25 251:1,3 251:14 254:2,8 255:2 257:11 258:5 258:21 263:9 264:2 276:15 <b>exposures (2)</b> 243:15 252:25 <b>express (2)</b>	230:11 231:3 <b>expressed (1)</b> 231:9 <b>expressing (1)</b> 272:22 <b>expression (1)</b> 231:17 <b>extent (1)</b> 71:1 <b>extreme (2)</b> 248:18 257:24 <b>extremely (3)</b> 64:16 146:18 245:4 <hr/> <b>F</b> <hr/> <b>F-e-i-n-c-h-e-m-i-e ...</b> 155:10 210:8 <b>fact (34)</b> 9:3 29:13 45:19 68:8 110:10 123:14 124:3 150:25 151:11,12,13 153:14 162:4 167:14 187:4 189:12 194:25 195:5 197:12,18 200:22 210:21 211:1 220:17 222:21 230:25 231:8 238:11 244:7 252:4,5 253:24 279:6 290:12 <b>factor (7)</b> 67:18 68:6,8 160:24 185:25 186:21,23 <b>fail (1)</b> 244:2 <b>fair (13)</b> 72:1,6,12,25 73:11 93:10 139:12,19 154:5 168:5 179:10 179:15 266:13 <b>fairly (5)</b> 81:11,17 134:2 153:24 232:1 <b>faith (1)</b> 79:21 <b>fake (1)</b> 231:5 <b>false (1)</b> 273:5 <b>familiar (13)</b> 28:22 78:23 79:13 92:12 93:21 94:12 113:5 131:5 159:12 171:24 174:25	250:22 276:17 <b>famous (2)</b> 86:25 87:2 <b>far (8)</b> 10:20 16:20 19:23 133:6 239:11 243:7 253:7 257:8 <b>fast (1)</b> 205:21 <b>fault (1)</b> 96:25 <b>FDA (1)</b> 242:23 <b>fed (5)</b> 29:19 184:5 189:13 190:4,6 <b>federal (4)</b> 4:4 260:8,20 286:21 <b>Federation (1)</b> 269:9 <b>feed (3)</b> 215:25 218:17,20 <b>feeding (1)</b> 254:15 <b>feel (5)</b> 7:16 144:7 163:21 165:1 298:9 <b>Finchemie (17)</b> 41:23 155:10 156:18 160:10 210:8,18,22 210:24 211:15,20 212:2 213:4 215:1,1 217:5,7 218:24 <b>felt (6)</b> 73:22 111:14 148:7 163:9,10 208:24 <b>female (45)</b> 6:3,7,17 7:8 11:23 24:13,16,23 38:1,12 47:10,12 48:11,19 49:15 50:19 55:2,2 55:6 62:21,25 63:5 63:8,15,20,24 65:2 65:7,10 80:16,20,23 110:4,11,15,23 145:23 153:11 169:25 171:5 200:12 201:11,21 201:24 202:3 <b>females (16)</b> 49:9 110:6,8,9 145:24 145:25 153:17 170:13,25 200:17 201:3,16 207:24 208:4 294:5,11 <b>field (4)</b>	83:10 153:18 300:7 300:13 <b>Fifro (1)</b> 98:24 <b>fifth (4)</b> 95:15 155:4 158:8 160:8 <b>figured (1)</b> 134:9 <b>files (7)</b> 69:22 87:21 102:14 114:19,24 211:22 213:22 <b>final (8)</b> 3:20 156:1 183:18 192:9,12 281:16 282:9,20 <b>find (23)</b> 42:10 44:21 48:13 56:10 62:3,4 76:9 81:13 87:23 88:9,13 110:2 150:8 153:6 165:23 174:6 217:3 217:25 218:6 223:4 233:25 234:15 254:10 <b>finding (26)</b> 19:24 30:24 31:9 36:2 39:9 42:14,17 46:15 47:7 54:19 58:19 62:3,24 68:20 77:7 77:25 80:15 110:3 110:13 112:15 143:4,8 148:15 151:4 152:9 295:16 <b>findings (16)</b> 24:9 39:3,24 46:3,18 60:15 97:11 112:21 123:20 141:21 151:21 169:6,12 200:24 209:10,11 <b>finds (4)</b> 106:2 150:8,15,16 <b>fine (2)</b> 43:6 56:12 <b>finish (2)</b> 130:12 159:18 <b>firm (7)</b> 278:9 279:3 281:12 283:23,25 284:3,5 <b>first (26)</b> 5:13 6:19 7:4 74:21 89:3 107:1 116:3 121:4 130:4 145:17 147:20 230:5 232:25 233:6 241:3
--	---	---	---	--

248:21 249:9,19 253:6,7 259:21 271:10,25 277:3 280:5 286:7	110:24 111:8,25 115:5 122:14,21 124:20 125:6,18 127:18 129:2,19,24 131:9 133:22 135:16 136:6 139:8 139:16 140:13 141:24 145:15 146:20 151:6,8 153:4 154:25 155:21 157:12,20 158:25 160:18 164:18 168:17 169:9 173:11 180:12 181:6 182:1 183:24 184:6 185:13 186:9 187:19 188:22 189:19 192:10 193:15 194:14,22 196:4,15,24 197:16 199:6,24 200:15 201:2,15 204:7 205:16 206:11 207:21 208:19 210:4,19 212:5 213:6 216:19 221:16 222:10,18 223:16 227:6 236:5 240:14 243:1 244:18 248:11 250:10 255:19 261:4 265:16,22 267:19 270:1 276:1 276:24 277:7 307:9	<b>formulate (1)</b> 250:11 <b>formulated (1)</b> 74:6 <b>formulations (12)</b> 13:12 14:17 15:13 21:15,18 22:21 58:25 59:3 73:18 178:19 212:9 247:2 <b>forth (1)</b> 251:18 <b>forwarded (1)</b> 115:19 <b>found (47)</b> 6:4 12:20 26:5 28:14 39:19 40:3,4 42:25 44:12 48:21 76:15 77:17 80:20 83:20 85:3,7,14 106:13 110:8 125:23 126:14 131:7 133:12 141:7 146:3 148:12 149:11 150:25 153:15 164:22 167:12 171:20 188:13 191:25 197:13,17 198:16,18,24 201:8 217:7 235:12 247:15 261:23,24 270:7 304:14 <b>foundation (1)</b> 79:4 <b>four (20)</b> 11:14,20 62:10 77:17 85:10 96:17 97:2,5 108:1 119:11,12 141:1 174:17,18 200:18,22 201:12 201:25 205:9 291:19 <b>fourth (1)</b> 135:1 <b>frame (4)</b> 83:6 170:19,24 274:13 <b>free (4)</b> 7:16 93:4,5,8 <b>frequency (1)</b> 66:19 <b>frequently (2)</b> 124:24 167:19 <b>friend (4)</b> 127:14,15 140:4 266:23 <b>front (3)</b>	162:1 202:5,18 <b>frustrated (1)</b> 88:12 <b>full (16)</b> 102:6 126:4 136:8 157:10 179:7 184:10 191:13 211:19,23 259:25 271:17 297:14,20 297:20,23 298:5 <b>funds (1)</b> 32:9 <b>further (9)</b> 85:1 158:15 161:20 231:20 238:1 244:8 274:17 275:21 307:11	252:7 278:23 302:12 <b>given (15)</b> 26:1 44:15 67:11 71:20 81:4 145:10 153:6 162:24 164:7 180:1 188:16 189:3 203:17 231:4 307:10 <b>gives (5)</b> 6:5 64:16 76:14 96:17 250:25 <b>giving (3)</b> 126:4 216:2 300:23 <b>glad (1)</b> 172:23 <b>glean (1)</b> 103:7 <b>GLP (2)</b> 161:21 163:9 <b>glyphosate (187)</b> 3:13,19,20,22 9:22 10:6,13 12:22 13:6 13:11,13,21 14:10 14:16,17,22 15:12 16:13 17:3 18:14 19:9 21:1,15,15,17 21:17 22:1,16,20,20 23:22 24:4,12,15,16 24:21 25:10,12 26:3 26:5,7 32:22 37:21 37:23 38:7 41:21 55:18 58:6,9,15,24 58:24 59:2,2,17 61:7,11 63:3,4,7 73:17,17 77:3 98:5 98:13 103:16 104:1 104:22 105:2,8,12 108:23 111:7,10,16 111:18 112:8,23 113:11,18 116:1,15 123:23 132:9,19 135:20 137:4 138:7 138:8 143:5,10,20 143:21 144:2,11,12 154:21 158:13 171:7 178:4,18,19 180:14,22 184:5 185:9 187:17 188:2 188:21 189:3,7 192:22 193:9,21 195:10 197:9 203:16,17,20 204:13 205:19,22 205:22 207:9,14,19 208:18 209:1,13,20
			<b>G</b>	
				<b>gain (1)</b> 213:17 <b>gains (1)</b> 214:11 <b>gathering (1)</b> 227:9 <b>general (5)</b> 3:7 11:8 167:7 262:1 293:14 <b>generally (1)</b> 154:7 <b>genes (2)</b> 28:18 29:5 <b>genetically (3)</b> 28:17 29:4 200:5 <b>George (1)</b> 93:20 <b>German (5)</b> 149:6 153:9 269:9,16 270:6 <b>getting (6)</b> 133:1 140:2,2 232:25 248:3 263:1 <b>give (46)</b> 7:21 22:14 25:25 26:17,20,23 27:1,3 27:4 28:19 34:4,5,7 34:19 35:21 37:25 44:25 71:12 73:8 74:4,17 90:17 100:22 101:8,16 102:3,5 113:22 120:6,7 121:17 152:20 157:3 176:21 178:16,25 198:1 200:1 202:19 212:7,8,18 213:11

209:24 210:1 212:8 212:9 214:3 217:11 219:13 221:22 223:14 224:7 230:13 235:5 240:11,17,21,25 241:5,8,12,17 242:18,24 243:9 246:18,22 247:2,2 247:14,18,18 255:2 255:17 267:7,9 269:6,11,17 270:7 270:21,22 271:22 276:11,15,22 278:10 279:11 281:1,16 282:9 283:9 291:23,25 292:2,3 296:3,4,20	160:19 162:17 181:15 210:14 216:5 218:18 220:2 223:1 226:17 229:6 229:12 231:17 234:14 239:19 244:5,8 249:8 252:3 256:9 269:13 270:15 278:16 279:21 284:19 285:24 286:9,17 290:20 305:22	230:14,16,20,22 231:1,2,10 232:5,9 232:16 233:2,5,13 233:13,17,24 234:1 234:6,16 235:5,10 235:10 237:7,12,13 237:17,24 238:2,10 238:17,18,22,23 239:2,21 240:9 247:9,10,10,11,13 247:16 272:23,24 272:25 273:2,3,9,10 273:14,15,16,21,21 273:22 290:15,18 298:8 299:23	117:3 190:22 <b>Guyton (1)</b> 267:12	249:15,19 250:6,13 251:6,24 252:14,16 253:6 256:18,25 257:13 258:4,19,25 260:15,22 261:1,5,8 261:21 262:20 263:6,9,25 264:3,19 264:25 265:9,12,14 265:20 266:4 276:13
<b>glyphosate-based (1)</b> 15:12	<b>Goldman (1)</b> 2:8	<b>Greim's (3)</b> 102:21 213:3 229:1	<b>H</b>	<b>Hazleton (2)</b> 78:21 80:3
<b>go (56)</b> 15:6 16:20 19:3 38:22 39:1,12 42:9 45:12 69:21 80:21,25 87:21 88:12,22 89:2 101:3 102:14 103:18 107:6 109:15 114:19,23 117:9,12 119:22,24 127:5 130:15 140:14 146:8 149:17 175:2 189:24 190:17 197:21,22 211:21 213:22 216:4,9 218:1,4 219:7 227:23 232:6 233:10 234:14 237:25 244:8 255:7 255:11 257:11 271:9 282:2 299:18 305:16	<b>good (21)</b> 4:21 7:13 28:2,2 29:15,23,24 30:2 35:21 56:10 117:6 118:6 121:11 166:3 172:9 274:13 286:16 291:2,11,17 292:15	<b>gross (1)</b> 177:25	<b>Haake (4)</b> 2:13 5:2,2 121:19	<b>he'll (1)</b> 128:3
<b>goes (6)</b> 9:11 59:5 134:4,7 249:7 287:2	<b>Goodman (3)</b> 95:15,17 97:3	<b>group (52)</b> 17:6,14,15 21:8,12,13 21:14 75:17 79:13 88:24 90:12 91:13 92:7,11,20,23 93:1 93:6,12 94:24 101:10 104:14 108:14 129:16 137:8 182:23,25 184:16 193:1,5,20 193:23 197:13,14 197:20 214:2 218:23 221:21 243:21 245:17,19 246:21,24 250:19 250:20,22 252:14 253:17 254:4 277:19 282:13 298:22	<b>hand (4)</b> 11:11 121:17 166:7 177:10	<b>head (5)</b> 85:23,24 87:3 128:14 134:7
<b>going (60)</b> 7:20 14:5,6 16:16,21 19:20 22:14 25:25 34:6 38:15 56:9 57:21 66:12 68:10 70:25 80:8 89:9 96:11 98:3 101:4 107:24 117:12,21 120:4,6 125:25 127:4,11 140:9 155:6 159:23	<b>goodness (1)</b> 294:6	<b>groups (14)</b> 75:16 77:18 85:10 86:4 92:13,17 150:4 180:11 184:20 189:13 198:6 201:14 205:9 213:16	<b>handing (2)</b> 266:21 279:12	<b>headquartered (1)</b> 4:17
	<b>gotten (2)</b> 272:18 285:6	<b>guy (4)</b> 83:1 86:25 94:23 99:22	<b>hands (1)</b> 162:1	<b>health (4)</b> 242:23,24 256:22 301:1
	<b>gov (1)</b> 218:2	<b>guys (6)</b> 16:17 36:5 43:7 95:23	<b>hang (4)</b> 19:12 34:18 71:9 177:7	<b>hear (2)</b> 137:14 199:19
	<b>government (5)</b> 17:11 239:6 242:23 293:24 296:13		<b>happen (4)</b> 93:8 127:4 167:20 274:1	<b>heard (3)</b> 85:20 162:18 214:19
	<b>grant (1)</b> 148:9		<b>happened (1)</b> 96:22	<b>hearing (4)</b> 13:6,20 14:4,10
	<b>greater (2)</b> 218:15 254:5		<b>happening (2)</b> 162:25 195:2	<b>heavily (2)</b> 136:19 299:12
	<b>Greim (128)</b> 52:15 72:17,19,20,21 72:23,23 81:4,5,8 81:13,18,24 82:13 82:14 103:2,3,7,9 103:10,11 114:12 132:20 133:12 135:17 136:19 148:25 156:4,5,7 157:14,14,18,21 158:1,4,14 161:8,17 161:20,21 163:8,18 166:23 171:8,9,9,11 171:15,17 176:11 202:12,14,16 209:14,19 226:2,6 226:24 227:14,18 228:12,18 229:18 229:25 230:4,6,7,11		<b>happens (6)</b> 93:4,5 167:19,19 195:3 249:12	<b>Hedlund (1)</b> 2:8
			<b>happy (1)</b> 7:23	<b>held (1)</b> 4:13
			<b>hard (2)</b> 176:23 202:19	<b>help (3)</b> 67:6 183:13 282:17
			<b>Haseman (4)</b> 30:14,16 35:5,6	<b>helpful (3)</b> 68:9 92:4 290:6
			<b>hate (1)</b> 230:11	<b>hemangioma (2)</b> 11:15 12:3
			<b>haunt (1)</b> 231:17	<b>hemangiomas (14)</b> 6:1,13,16,22 7:8 11:21 24:9,12,15,17 24:23 25:18 50:24 129:7
			<b>hazard (71)</b> 34:25 105:2,3,20 106:15 111:12 143:14 144:9,24,25 146:16,25 152:19 154:20 178:17 180:19,20 188:25 193:4 206:16,17 207:7 208:2,24 212:8 216:13 217:2 222:25 243:15 247:20 248:6,12,13 248:17,23 249:4,14	<b>hemangiosarcoma (...)</b> 11:15 12:2 49:18,22 112:21 134:10,11
				<b>hemangiosarcomas ...</b> 6:1,3,12,21 11:19 23:13,19,22 24:2,4 49:25 50:12,17,19 50:23 51:1 103:24 104:18 105:7,8,18 107:22 108:1,21 110:4,13 111:5,15

112:7,16 119:6 122:5,6 123:5 125:13 235:1 <b>hepatocellular (15)</b> 26:18 55:9,14,21 56:4 56:16,19 57:14 70:2 203:9,12,19,25 204:5 207:1 <b>hereto (1)</b> 307:8 <b>hey (2)</b> 262:12 274:10 <b>high (89)</b> 6:7 29:18,25 30:4 83:19 86:3,8 90:23 97:20 107:24 108:1 108:14 110:8 119:9 119:15 128:13,18 128:21 129:15 131:7,21 132:25 133:15 134:2,7,8 137:7,7,24 138:11 140:10 146:5,9,17 146:18 147:1,10,10 147:13,23,24 148:5 149:8 151:14,16,18 151:25 152:10,11 153:24 154:6 161:14 171:3,5 176:7 181:3 182:24 183:11 184:3,12,16 187:23 188:2,16 189:13,17 190:4,6,9 193:5,20,23 198:21 198:25 214:2,5,22 215:3 216:18 218:23 219:13,17 219:20 220:10,11 221:21 250:2 251:10,13 <b>higher (16)</b> 79:15,19,20 168:6,13 184:15 194:18,24 195:3,3,6,12 214:7 216:14 219:19 295:4 <b>highest (1)</b> 146:9 <b>histopathology (1)</b> 187:15 <b>historic (3)</b> 106:22 107:14 171:4 <b>historical (26)</b> 65:23 66:6,17 67:1,2 67:6,9,10,14 78:18 107:7 130:16,19	147:11,13 148:23 149:3,23 158:12 168:23 170:12 171:6 176:10 201:19,20 211:10 <b>history (3)</b> 76:24 79:23 84:22 <b>Hogan (3)</b> 69:2 70:11 75:2 <b>Hold (1)</b> 157:25 <b>holds (1)</b> 17:5 <b>Hollingsworth (390)</b> 2:13,14 4:2,25,25 5:1 5:3,10,16,24 6:24 7:1,3,5,10,12 10:1,9 11:25 12:24 13:14 13:17 14:3,9,19 15:4,9 16:25 18:18 18:22,24 19:21 21:24 22:5,9,15 23:5,12 28:4 29:13 30:6 31:15 32:2 33:20 34:8,12 35:3 35:14,23 36:9 37:11 37:12 38:3,15 40:20 41:5,10,13 42:15 43:4,9,17 44:4,11 44:21 46:2,7,16,23 47:22 48:2 49:1,12 50:9,18 51:11,14 52:1,23 53:5 54:23 56:12,15,18 57:12 57:19 58:1 62:7,17 62:19 65:1,7,16 66:14,24 68:3 69:16 70:24 71:3,14,20,25 72:22 73:10,25 74:10 75:9,23 78:8 79:7 80:2,9,22 81:8 82:11,20 84:1 86:15 88:3,15,21 91:25 92:6 93:9 94:20 96:8 97:13 99:5 101:18 106:8 107:17 109:19,25 110:21,25 111:20 112:6 115:11 116:6 117:5,10,19 118:1,5 118:9,15,18 120:9 120:12,19,24 121:3 121:11,14,20,21 122:17,24 124:10 125:1,9,19 126:7,13 126:24 127:12,13	127:22 128:4 129:4 129:14,21 130:2 131:10 132:13 133:9,17,23 134:18 134:24 135:19 136:13 139:12,19 139:25 140:16 141:25 142:12,20 143:24 144:15,22 145:2,16 146:15,24 150:9,14,15,19,24 152:4,16 153:8 154:2,22 155:4 156:6 157:17,23 159:3,16,20 160:3 160:19 161:3 164:2 164:8 165:4 168:5 168:20 169:11 172:1,8,13,17,21 173:7,15 175:25 177:1,13,22 178:8 179:1,17 180:6 181:1,7 182:2,6 183:20 184:2,9 185:18 186:11,13 187:22 189:10,23 190:24 192:17 193:16 194:17 195:8 196:5,17 197:2,18 198:3 199:9,18 200:8,16 201:4,10,23 202:11 202:15,21 203:2 204:9,20 206:5,20 208:6 209:2,8 210:6 210:21 212:11,19 213:10 216:22 219:11 221:20 222:1,6,11 223:17 226:12 227:17 229:9,17 231:6 232:7,8,21 236:14 239:21 240:19 243:2 244:12,22 249:13 250:13 251:20 252:7,13,21 255:25 256:8,14 259:10,18 261:7 262:25 263:19 264:6,9,13,15 265:19 266:3,11 267:21 268:9 270:3 270:12,19 271:6,21 272:5,12 274:6 276:4 277:4,11 278:12,15,19,24	279:1,8,15,16 280:3 280:6,11 281:7,19 281:23,25 282:2,4 283:13,18,21 285:2 285:4,9,18,21,22,23 286:1,5,8 288:4 289:4,9,21 290:3,9 290:17,23 291:13 292:19 293:12,17 293:22 298:1 300:8 300:16,18 301:15 303:4,6 305:12,15 <b>Hollingsworth (1)</b> 3:3 <b>home (1)</b> 262:7 <b>honest (21)</b> 29:2 33:15 51:22 78:19 79:21 114:25 156:2 172:6,9,11,16 172:18,19 173:2,4 209:6 232:22 233:7 254:21 274:8 285:7 <b>hope (5)</b> 7:21 82:10 160:11 172:12 282:22 <b>Hopkins (1)</b> 94:15 <b>hour (3)</b> 56:10 117:13 306:2 <b>hours (4)</b> 229:7 286:18 289:1 290:22 <b>Huff (4)</b> 30:17,18,19 35:4 <b>human (63)</b> 8:2 17:21,23 18:2,5,8 21:13 25:14 26:11 27:11 28:18 29:5 56:1 59:14,24 61:14 63:10,10 143:23 144:14 180:25 189:9 203:22 243:14,17 244:3 246:25 247:1,24 248:9 249:7,12,16 249:20 250:23 251:3,14 252:25 254:8,17 256:22,24 257:4 260:18 261:25 262:9,13,14 292:5,17,23 293:15 296:3,4,20,25 297:2 297:4 301:1,4 303:9 304:3,23 <b>humans (89)</b>	8:9,11,15,17,23 9:3,6 9:11,19,23 10:7 11:2 13:7,22 14:11 14:18,23 15:13,16 15:20,24 16:9,14 17:3 18:9,10,11,15 19:10 20:17 21:2 22:2,17 24:3,7,10 24:18,24 25:5,20,23 26:16 27:7,10,16,22 28:2,15,21 29:7,17 55:16 58:15 61:5,18 63:1 169:18 182:10 203:14 204:1 240:22 241:1,9,20 242:19 243:2,9 246:19 247:3 248:20 250:9,17 251:4 252:2,16 253:21 254:5 257:14 291:2,17 292:15 293:6,10 294:3,8 297:6 303:15,18 304:15 <b>hundreds (1)</b> 177:9 <b>Hunter (2)</b> 3:15 278:7 <b>husbandry (1)</b> 167:19 <b>hypothesis (3)</b> 8:1,21 23:13 <hr/> <b>I</b> <hr/> <b>i.e (1)</b> 264:24 <b>IARC (117)</b> 3:13,18 16:19,25 17:4 17:17 18:7,12 19:7 19:14,16,17,23,23 19:24 20:4,22,25 21:6,12,24 22:16,22 34:25 35:12 45:4 78:10 104:13 123:21 149:21 175:4,8,10,12 185:18 217:19 230:14,21,24 231:11,19 241:11 241:22 243:13,21 244:1,2,14,15,15,25 245:9 246:10,10,16 246:21,22,23,23 247:20,23 250:14 250:25 251:24 264:12,14,18,22,24
---	--	--	--	---

265:2,3,15 266:2,5 266:13 267:4,6,12 267:16,25 268:3 269:12,13,15,20,25 271:5,15 272:2,14 272:23,25 273:6,8 273:20,22 276:9,13 276:22 277:19,20 277:22,23 280:14 282:15 299:11,12 301:6,8,11,17 302:1 303:9,22,25 304:5 304:10	<b>impacting (1)</b> 216:5 <b>implication (1)</b> 303:19 <b>implied (1)</b> 163:18 <b>implying (1)</b> 247:25 <b>important (18)</b> 67:2,7,15 68:16 107:11 109:16 115:2 139:6,10 185:25 187:4 197:1 197:4 243:24 245:4 245:9,25 267:11 <b>imposed (1)</b> 217:15 <b>impression (2)</b> 111:21 239:15 <b>inadequate (9)</b> 20:6 217:10,13,20 220:6 221:5,18,19 241:18 <b>inappropriate (1)</b> 179:16 <b>inception (1)</b> 296:11 <b>incidence (106)</b> 6:6 26:5 29:18 30:1 37:24 46:24 53:2 60:19 65:22 70:1 78:18,25 79:15,20 80:23 90:18 105:5 105:23 108:14 119:8 123:5 124:18 128:6,9,18,21 129:15 131:17,19 133:13,14 134:3,8 137:22 138:14,17 139:6 142:6 143:25 145:7,12 146:4,18 147:1,6,9,11,17,22 148:5,22 149:6 151:1,7,11 152:11 154:3 158:11 166:18 167:9 168:6 168:13,24 170:4 171:2 176:6 182:11 184:22 185:1 194:1 195:16,22 198:9,16 200:20,21 201:6,7 201:20 205:3,6,8,14 217:4 221:12 234:1 235:9,22,22 291:25 294:12,25 295:3,5 295:14 297:5	298:14,14,18,19,20 299:4,7 301:19 305:2,7 <b>incidences (20)</b> 45:13 55:5 81:14 111:14 119:7 128:15 153:25 173:23 201:19 204:10,21,24 206:3 221:1 230:8 232:16 233:11 234:7 294:24 298:7 <b>incident (2)</b> 161:13 298:14 <b>incidents (1)</b> 78:15 <b>include (24)</b> 39:16,25 45:7 49:11 54:11 55:6 56:25 60:13 64:1 65:22 72:5,7 74:1 101:13 140:22 141:7,18 173:19 181:13,24 188:15 273:18 298:13 299:5 <b>included (26)</b> 60:14,17 72:2,17,18 73:1,9,12 78:20 81:15 93:12 106:21 114:9 149:25 161:23 165:3 191:7 191:17 192:15 198:14 206:19 207:10 208:5 209:1 233:11 238:23 <b>includes (3)</b> 17:21 265:4 279:23 <b>including (10)</b> 83:18 85:1 97:2 127:7 129:23 136:5 141:11 175:14 191:13 267:24 <b>inclusion (3)</b> 206:15 207:6,25 <b>increase (60)</b> 18:5 23:20 37:24 38:25 40:4 42:13 53:1 58:10 59:20 60:19,21 63:23 84:4 103:22,24 105:6 107:4 108:8,11,20 108:24 110:6 111:5 131:16 132:24 137:10,15 138:4 141:9 142:2 144:12 147:6,8,22,24 148:1	148:5,6 149:2 151:17,25 152:1 167:11 182:11 185:8,15 189:6 195:18 198:11,25 203:18 204:4 208:3 208:6 224:20 235:6 295:17 301:13,14 301:19 <b>increased (25)</b> 26:5 39:8 55:5,22 61:10,10 65:18,21 108:12 111:14 128:6 143:19 152:11 169:6 170:4 184:22 195:15,22 203:12 217:4 221:1 291:25 295:14 297:5,6 <b>increases (6)</b> 39:10 45:5 54:10 56:24 60:9 206:8 <b>increments (1)</b> 253:14 <b>independent (1)</b> 100:24 <b>indicate (9)</b> 42:24 56:23 161:18 169:4,5 170:16 197:5 273:16 293:2 <b>indicated (32)</b> 20:2 23:18 24:14 49:2 57:18 64:5 83:24 84:6 85:6 97:18 106:24 131:13,13 161:11 165:23 171:2 172:18 175:10 178:15 201:5 233:18 234:10 236:21 238:6,19 239:8 240:15 246:4 257:17 260:12,24 296:25 <b>indicates (10)</b> 28:1 55:25 59:2,23 200:22 220:18 238:13 241:7 258:4 258:18 <b>indicating (3)</b> 150:11 273:15 298:21 <b>indication (4)</b> 68:10 163:6 217:19 273:4 <b>individual (18)</b> 10:15 17:13 75:25	76:7,9,12 101:10 165:5,16 181:8,14 181:16,18,24 191:23 192:6 232:23 245:18 <b>individually (3)</b> 106:16 189:1 209:10 <b>individuals (6)</b> 17:18 139:23 258:6 258:23 259:4 260:7 <b>induced (1)</b> 65:20 <b>industry (2)</b> 239:6 293:25 <b>infamous (1)</b> 87:2 <b>infected (2)</b> 168:15 169:6 <b>infection (22)</b> 158:16 160:25 161:9 161:18 162:6,11,13 162:16 163:7,13,19 163:21 164:17,22 165:1,19,19,24 166:3 167:1,4 170:9 <b>infections (7)</b> 161:1 162:23 165:15 166:17 167:18,23 168:15 <b>infer (1)</b> 110:9 <b>influence (1)</b> 166:17 <b>information (70)</b> 17:10,12 28:20 59:9 73:20 81:12 83:24 88:9 90:14 102:10 103:3,4 109:14,24 114:15 115:16,17 115:21 116:10 127:1 133:12 135:11 136:14,17 136:19 156:4,5 157:7,9 161:6,7 163:3,20 165:11,13 169:1,2 191:18 196:10 197:22 205:18 213:13 216:3 227:10 228:21 230:7 233:1 233:4,12,14 236:6,7 236:20,23 238:9 245:11 255:10 261:22 262:1,12,15 263:1 272:24 273:5 287:12 292:16
--	---	---	---	---

298:24,25 301:22 301:25	188:8,8,18 189:4,6 194:2,12 195:16 220:20 291:10	149:24 151:1 152:22 153:3 171:13,21 188:1 279:11 283:8	159:11 <b>Japanese (2)</b> 225:15,17	233:19 <b>kept (1)</b> 123:22
<b>informed (2)</b> 115:21 116:10	<b>introduce (1)</b> 4:20	<b>IRDC (4)</b> 79:8,22,24 80:7	<b>JCEH (1)</b> 282:22	<b>key (3)</b> 67:18 68:6 107:14
<b>initial (6)</b> 3:5 77:1,20 91:23 246:21 247:5	<b>introduced (1)</b> 14:6	<b>irrelevant (1)</b> 150:16	<b>Jensen (2)</b> 2:18 4:16	<b>kgs (7)</b> 214:15,18,24 215:3,6 216:11,17
<b>initially (4)</b> 50:22 77:3,4 250:2	<b>introduction (5)</b> 258:9 259:20,21 260:12 263:16	<b>islet (25)</b> 26:21 51:16,23 52:4,9 53:2,12 54:10 184:23,25 185:21 196:18 197:10 198:5,18 199:2 200:11,17,24 201:11,13,24 202:1 206:8 208:16	<b>Jerry (5)</b> 94:25 95:1,7 97:2 145:6	<b>kidding (1)</b> 172:20
<b>injected (1)</b> 29:5	<b>invalid (2)</b> 161:10 222:16	<b>Israeli (1)</b> 225:18	<b>Jim (2)</b> 99:25 100:4	<b>kidney (39)</b> 9:4,15 15:19 16:3,8 23:16 40:7,14,25 41:4,8,14 44:13 45:2,5,20,23 46:3 46:18,24 47:9,11 48:11,19,23 49:9,14 82:25 83:18 84:13 84:17,19 85:9 94:24 96:2 97:7,21 99:13 100:7
<b>inquire (1)</b> 226:13	<b>investigate (11)</b> 24:21 25:17 28:13 59:25 61:16 63:13 70:25 190:19 203:24 290:25 292:8	<b>issue (17)</b> 15:18 178:16 186:7 186:10,18,19 205:19,22 222:24 240:4,25 241:4,8 242:21 243:23 253:10 292:11	<b>JMPR (4)</b> 104:3,16,17 105:10	<b>killed (1)</b> 198:15
<b>instance (1)</b> 201:18	<b>investigated (7)</b> 9:7 16:2 17:24 27:14 238:25 245:2 304:16	<b>issued (2)</b> 266:19 277:25	<b>job (3)</b> 1:25 297:10,11	<b>kilogram (2)</b> 214:3 215:15
<b>instances (2)</b> 68:14 297:22	<b>investigating (4)</b> 8:6 16:6 17:23 56:3	<b>issues (5)</b> 20:18 21:20 124:11 275:17 279:11	<b>Joe (7)</b> 2:13 4:25 30:14,16 35:5 150:14,15	<b>kilograms (1)</b> 214:14
<b>Institute (2)</b> 94:3 269:9	<b>investigation (7)</b> 23:25 24:8,20 25:3,21 26:14 59:12	<b>it'll (1)</b> 286:2	<b>John (4)</b> 2:18 4:16 140:4,6	<b>kind (12)</b> 8:13,17 9:9 28:14 85:15 109:21 165:19 169:16 210:3 228:10 230:17 293:23
<b>instruct (2)</b> 16:21 244:9	<b>investigator (7)</b> 101:20 115:4,23 116:12 135:5 164:25 167:2		<b>Johns (1)</b> 94:15	<b>kinds (1)</b> 276:10
<b>instructed (2)</b> 17:15,18	<b>investigators (22)</b> 16:5 70:12,13 73:2 74:8 113:9,15 155:14,19 175:14 176:15 177:23 178:10 179:9,12 182:3 187:13 191:6 192:6 212:1 219:24 239:22	<b>J</b>	<b>Joint (1)</b> 104:7	<b>Klaus (5)</b> 85:18,21,22 86:17 159:9
<b>intake (1)</b> 218:21	<b>invitation (1)</b> 267:15	<b>James (1)</b> 30:18	<b>jointly (1)</b> 209:11	<b>Klenicki (3)</b> 2:14 5:9,9
<b>intend (2)</b> 19:4 274:1	<b>invitee (1)</b> 123:17	<b>Jameson (40)</b> 1:4,11 3:1,7 4:9 5:12 7:13 11:7 13:9,24 19:15 53:1 56:21 66:10 67:17,23 118:4 135:1 150:13 150:16 155:6 157:11 160:4 164:6 172:11 176:21 177:12 189:11 231:7 239:18 259:12 266:17 276:25 279:23,24 285:17 286:16 292:25 305:24 307:6	<b>journal (1)</b> 238:11	<b>knew (11)</b> 86:23 95:17,17,18 99:22 104:15,17 152:13,15 160:20 301:11
<b>intending (1)</b> 278:3	<b>Invoice (1)</b> 3:16	<b>Jameson's (2)</b> 5:18 153:21	<b>judge (21)</b> 72:4,12,15 73:3,7 82:7 92:8 100:20 101:25 110:14 113:20 128:10 139:2 142:7 152:17 178:9,13 179:11 212:12 254:14 294:20	<b>know (178)</b> 7:17,19 8:25 9:5,6,7 9:12 10:20 12:18 20:19 23:24 24:20
<b>interest (1)</b> 277:15	<b>involved (3)</b> 33:3 75:22 210:22	<b>January (1)</b>	<b>jointly (1)</b> 209:11	
<b>interested (2)</b> 277:16 307:12	<b>involving (27)</b> 12:12,15 29:4 38:19 38:20 40:22 42:6 46:18 48:23 53:6,17 57:4 59:14 65:9,12 68:5 79:1 85:9		<b>jointly (1)</b> 209:11	
<b>interim (2)</b> 75:17 183:17			<b>jointly (1)</b> 209:11	
<b>internal (1)</b> 161:16			<b>jointly (1)</b> 209:11	
<b>International (2)</b> 17:5 79:10			<b>jointly (1)</b> 209:11	
<b>internet (2)</b> 87:24 88:2			<b>jointly (1)</b> 209:11	
<b>interpretation (10)</b> 30:9 32:14 101:14 105:19 111:17 139:13,15,20 167:9 262:18			<b>jointly (1)</b> 209:11	
<b>interpreted (2)</b> 210:18,24			<b>jointly (1)</b> 209:11	
<b>interrupt (2)</b> 148:20 149:16			<b>jointly (1)</b> 209:11	
<b>interstitial (27)</b> 25:22 26:6,7,14 60:24 61:3,8,21 62:8 173:24 175:16 176:7,16 177:3 178:1 180:17 182:7			<b>jointly (1)</b> 209:11	

25:16 28:23 42:8,10 42:10,12 43:5 44:2 45:1 56:6 69:7 70:18 71:11,15 72:11,13,14,14 75:6 75:8,15 76:20 78:20 83:7,12,14,16 85:17 86:1 88:19 90:10 92:1 93:13,14,25 94:13,22,25 95:1,16 95:19 99:4 104:3 106:17 109:8,19 111:1,4 112:1,14,19 114:21,21 116:21 116:25 117:3 118:16 120:11 123:11,13 124:7,9 125:8,24 126:12,14 134:6,6,7 135:6,8 135:22 136:8,9,20 140:1 142:11 146:2 146:3,5,8,8,9 152:4 152:21,24 153:1,25 156:1,2,21 159:6 164:15 166:22 168:19 174:20 177:7,14 180:6,9 181:20 187:13 190:11,18 191:17 192:17,20 200:2 203:11 209:6 211:10,15 219:21 225:19 226:6,16,24 227:4,17 228:1,7,25 230:1 231:8,9 232:8 238:2,8,21 239:2,5 240:2 243:3,5,7 245:5,12 249:20 251:2,12 254:2,19 257:24 260:14 261:19 262:2,8,8,14 262:24 263:2 267:14 268:19 274:3 275:18 276:6 277:24 279:8 280:21 281:10 282:25 285:14,18 286:17 301:5 304:24	71:21 243:5 292:6 292:13 <b>known (12)</b> 9:10 94:16 95:10 123:13 182:7 256:23 260:17 261:24 262:9,13 301:3,14 <b>knows (2)</b> 43:6 92:1 <b>Kosza (3)</b> 89:25 90:3,11 <b>Kumar (15)</b> 155:14 156:8,11 157:11 158:17,19 158:24 159:10,18 160:5 164:16 166:16 170:1 173:9 173:16 <b>Kuschner (7)</b> 83:2,7,17 84:15 86:5 87:12 95:22	<b>larger (2)</b> 295:6,7 <b>late (3)</b> 117:1 241:10 248:3 <b>latest (1)</b> 302:15 <b>law (7)</b> 278:9 279:3 281:12 283:23,25 284:3,5 <b>lawsuits (2)</b> 283:7,24 <b>lawyer (3)</b> 278:7 288:19 297:13 <b>lawyers (11)</b> 127:6 136:17 278:3 279:10 280:23 283:7 289:1,16,19 289:23 290:23 <b>lays (1)</b> 278:8 <b>lead (4)</b> 113:4 155:13,13 269:10 <b>leading (16)</b> 288:4,5 289:4,9,21 290:3,9,17 291:13 292:19 293:12,17 293:22 298:1 300:8 301:15 <b>leads (1)</b> 168:9 <b>leafing (1)</b> 109:15 <b>learn (5)</b> 283:22 284:4,8,10,11 <b>learned (3)</b> 284:2,12 295:13 <b>leave (3)</b> 101:1 118:4 231:12 <b>leaving (1)</b> 283:16 <b>lecture (1)</b> 15:21 <b>lectures (1)</b> 16:1 <b>left (2)</b> 121:10,15 <b>left-hand (3)</b> 121:13 259:20 260:1 <b>legal (10)</b> 4:16 10:2 14:4,8,14 72:11 73:15 179:15 179:16,20 <b>lesion (5)</b> 78:5 85:15 89:16 91:19 145:14	<b>lesions (33)</b> 41:20 67:18 68:5,9,12 68:16,16,19,21 71:5 79:1 85:4 86:6 96:16 97:5,5 98:18 100:7,18 102:2 104:20 106:2 126:10 138:20,24 139:6 156:23 165:15 196:3,10,18 211:17 212:3 <b>let's (8)</b> 117:15 120:25 126:5 248:15 268:17 294:14 302:4 305:16 <b>letter (20)</b> 3:15,20 274:21,22 275:1,8,11,21 276:21,23 277:1,3 278:7 280:17,19,22 281:17 282:9,13,18 <b>letters (1)</b> 283:2 <b>letting (1)</b> 267:14 <b>leukemia (1)</b> 163:24 <b>level (19)</b> 30:4 39:16 42:11 43:25 49:10 84:17 84:18,20 146:18 154:1 183:5 219:20 220:10,11 223:3 239:19 251:15 253:20 254:4 <b>levels (15)</b> 216:14 245:6,7 248:20 249:16 250:9,17,23 251:3,4 251:10,11 252:2,15 254:15 <b>Liability (2)</b> 1:6 4:10 <b>likelihood (1)</b> 304:22 <b>limit (3)</b> 215:16,23,23 <b>limited (7)</b> 20:5,14,22,23 21:23 216:3 241:19 <b>limits (1)</b> 250:4 <b>line (5)</b> 6:2,11 18:6 158:8 199:15	<b>lines (1)</b> 235:4 <b>list (6)</b> 76:13 256:3,17 268:6 279:23 291:6 <b>listed (5)</b> 20:3 21:7 234:8,15 260:16 <b>listen (2)</b> 7:22 244:12 <b>listing (8)</b> 241:15,21 256:22 257:7 258:2,17 298:20 301:3 <b>lists (1)</b> 209:15 <b>literature (36)</b> 17:10 28:1,8 29:14 55:14 68:14 96:12 112:15,20 113:1 133:18 167:8,24 168:13 170:7 240:21,24 254:20 255:12,14,24 287:7 287:8,10,13 288:10 288:13,22 289:2,7 289:13,16,24,25 290:6,12 <b>litigation (11)</b> 1:6 4:10 10:4,11,12 73:4 173:14 175:1 286:21,21 307:13 <b>litigations (1)</b> 79:23 <b>little (15)</b> 27:4,11 39:13 42:20 56:9 117:15,15,18 158:14 162:18 200:1 231:20,20 234:7 294:14 <b>live (1)</b> 182:17 <b>liver (9)</b> 147:7,7,9 149:2 203:18,18,21 207:8 207:8 <b>lives (6)</b> 118:14 258:7,23 259:4 260:7 262:5 <b>living (2)</b> 30:19 95:13 <b>LLP (2)</b> 5:1,3 <b>local (2)</b> 260:9,20 <b>logic (1)</b>
<b>L</b>				
<b>L-a-n-k-a-s (1)</b> 173:20 <b>lab (7)</b> 69:7 77:23 78:14,18 79:25 155:25 237:22 <b>labeled (3)</b> 4:8 121:10 286:22 <b>laboratories (4)</b> 31:2 64:15 149:25 232:24 <b>laboratory (24)</b> 24:2 36:2 46:13 54:22 57:11 58:9 61:11 62:6 64:23 69:10 78:22,22 79:9 94:16 135:9,10 163:4 164:25 170:18,23 171:12 174:19 232:24 241:19 <b>Lakewood (3)</b> 1:12 2:4 4:14 <b>Lankas (17)</b> 173:20,20 174:2 175:14 182:22 190:2,2,5,5 193:11 193:24 194:13,15 195:15 220:11,13 220:18 <b>large (4)</b> 8:10 69:23 179:4 211:14				

18:6 <b>long (18)</b> 6:20 56:17 75:9 87:6 123:14,15 152:22 167:14 174:20,21 182:17 186:16 215:21 232:5 285:7 286:1,17 296:8 <b>long-term (12)</b> 67:19 75:11 77:12 124:18 153:3 167:8 181:19 184:3 203:13 229:19 236:3 240:12 <b>long-time (3)</b> 127:15 140:4 266:23 <b>look (115)</b> 5:22 14:20 20:7 21:5 39:1,12,22 42:19 43:3,8,13 44:15,17 44:19,19 45:12 47:13 53:6 69:21 70:22 74:23 75:25 76:3,4 80:21,25 89:22 90:16 91:10 96:9,15 97:4,4 98:12 99:20 100:9 103:2 105:3 106:16 107:1,7,9 114:24 119:22 126:25 127:4,23 136:9 138:22 146:8 147:4 149:9 153:12 156:2 161:20 166:12 175:9 177:12 179:4 179:5 184:10 190:18 197:21,23 198:9 199:16,25 200:19 202:25 205:1,2,6,7 211:21 213:9,20,22,24 215:20 218:4 227:23 228:3,6,11 229:24 230:24 231:1 233:3 236:11 237:21 238:18 239:13,25 240:7 245:14 247:8,12 248:23 249:23 250:14 251:25 253:20 255:7,12 257:11 265:2 272:23 273:12 294:11 295:13 296:3,4,20 299:17 303:24	<b>looked (58)</b> 12:19 16:9 17:20 29:1 43:20 60:16 69:3 73:21 74:5 75:3 76:6,8 87:8 89:15 90:21,22 94:24 97:1 98:18,22 99:12 100:4,6,12 101:20 101:23 103:20 110:4,15 114:6,11 114:11,12 115:14 121:7 156:3 163:5 172:2 177:2,8 178:21 183:19 190:15,16 192:4 208:12 212:22,24 213:1 223:25 234:6 238:19 272:25 273:10,21 296:23 297:7 298:25 <b>looking (26)</b> 14:24 28:13 30:2 36:19 45:3 51:9 52:2 75:19 81:23 90:8 95:23 103:20 107:23 120:14 129:9,25 157:24 175:23 176:1,2 177:21 183:25 184:1 206:13 246:11,12 <b>Los (1)</b> 2:9 <b>lot (16)</b> 46:10 69:9,9 79:21 80:14 109:24 155:24 156:5 201:8 229:4 236:10,10,20 251:11 294:18 295:20 <b>lots (1)</b> 191:24 <b>love (1)</b> 6:23 <b>low (21)</b> 83:19 86:4,7 90:24 107:24,25 119:9 148:10,10 151:11 151:11 185:8,15 195:25 196:1 198:11,19,25 217:20 251:14 253:20 <b>lower (8)</b> 161:14 194:16,19,25 195:2,5,11 251:11	<b>lunch (8)</b> 117:1,8 118:2,16 126:25 127:2,23 160:4 <b>Lundy (2)</b> 3:15 278:7 <b>lung (34)</b> 6:15 25:4,6,7,11,12 25:18 58:2 59:13,19 59:20 60:1,5,9,11 136:25 137:11,17 137:17,17,22 138:11 140:19 141:5,9,13,21 142:3 142:6,17 143:1,18 144:1 291:16 <b>Luxenberg (1)</b> 2:6 <b>lymphoma (131)</b> 8:18,23 9:6,11,17,23 10:7,14,18,19 11:2 12:6,13 13:2,7,22 14:11,17,23 15:13 15:16,20,23 16:8,14 18:15 19:10 21:16 21:18 22:17,21 23:14 24:3,10,23 25:5,20,23 26:16 27:2,4,6,6,9,10,16 27:22 28:2 29:1,6,7 29:16,16,17,25 37:5 37:13,18,19,25 38:7 38:11,12,14,18 39:3 39:10,24 40:22 49:7 55:15 56:5 58:7,15 59:3,15 60:2 61:5 61:18 63:1,15 73:18 128:7 129:16 130:17 132:25 133:20 137:7 145:3 145:7,13,18 146:19 149:7 151:1 154:3,4 154:6,6 163:25 167:10,12 168:6,10 168:14 169:7,12,15 169:25 170:18,23 171:3,12,21 178:20 203:14 204:1 235:6 240:22 241:1,9 242:19,25 243:9 246:18 247:3,19 255:1,17 292:9 301:19 <b>lymphomas (38)</b> 27:5,15 30:1,3,4 38:24,25 39:2,14,19	40:3,4 41:7 47:25 48:1,16 49:6 129:7 136:24 137:12,20 146:2,4 147:3,18,21 147:22 148:2,13 150:1,3 151:18,22 151:24 153:10,15 166:18 169:7 <b>lymphoreticular (1)</b> 70:3 <hr/> <b>M</b> <hr/> <b>m-g (1)</b> 215:6 <b>machine (1)</b> 307:8 <b>magnitude (3)</b> 251:13 253:21 254:5 <b>main (1)</b> 253:9 <b>major (1)</b> 244:25 <b>majority (1)</b> 8:10 <b>making (8)</b> 44:18 96:4 114:5 121:16 134:22 230:12 264:10 300:22 <b>male (72)</b> 6:15 26:4,6,8,10,15 37:25 38:1,12 40:7 46:19 47:10 48:23 50:13 51:1 55:1,10 55:12,14,23 56:5 57:4,15 58:3,19 59:6,14 60:25 61:8 61:9,12,17 62:14 82:25 84:13,20 85:9 90:19 96:2 98:18,22 105:24 107:22 108:4 111:15 112:7 112:16 122:7 123:5 125:23 127:16 132:25 137:4,8 138:5 143:5,18 144:10 145:23 151:21,24 169:25 170:4 171:3 182:20 189:4,6,7 199:4 200:11 201:21 203:19 <b>males (27)</b> 40:15 41:22 49:18 51:5 110:3,13 119:10 131:8	137:20,24 138:12 140:10 145:24,25 170:13,20 171:4,14 183:10 184:12,13 195:25 196:1 201:3 201:17 294:5,11 <b>malignant (48)</b> 29:17 37:24 39:24 40:21 42:1,2 97:21 128:7 129:16 130:17 132:25 133:20 136:24 137:7,12,20 145:3,7 145:12,13,18 146:2 146:4,19 147:3,20 147:22 148:2,12 149:25 151:18,22 151:24 153:10,15 154:3 167:11 169:7 169:12,25 170:18 170:23 171:3,12,21 185:24 186:21 187:6 <b>manner (2)</b> 81:22 140:18 <b>manufacture (1)</b> 135:20 <b>March (4)</b> 277:24 278:1,1 279:4 <b>Marion (1)</b> 93:22 <b>mark (8)</b> 120:20,25 121:4,7 127:7 259:10 279:21 284:19 <b>marked (6)</b> 4:1 11:6,13 266:20 278:6 281:13 <b>Martin (1)</b> 267:24 <b>Martinez (1)</b> 127:7 <b>Marvin (2)</b> 83:1,7 <b>matched (1)</b> 114:14 <b>material (14)</b> 8:5 16:2 18:2 20:15 20:17 23:17 197:5 233:25 235:19 248:14 255:14 260:16 262:6 297:25 <b>materials (14)</b> 17:8 76:17 78:13 102:18,25 111:21
---	--	---	---	--

102:18,25 111:21 162:8 232:9 256:3 261:22 262:4,5 301:3,7	<b>measured (1)</b> 239:7 <b>mechanism (4)</b> 9:9,10,10 190:8 <b>mechanistic (1)</b> 17:22 <b>media (4)</b> 4:8 230:24 231:18 273:5 <b>mediated (1)</b> 169:12 <b>medical (14)</b> 75:3 85:24,25 112:20 254:20,24 287:6,12 288:7,9,12,16 289:2 289:24 <b>medicine (1)</b> 70:16 <b>meet (5)</b> 143:12 206:14 207:5 207:25 208:21 <b>meeting (7)</b> 16:19 104:7 123:17 123:18,21 269:24 269:25 <b>meetings (1)</b> 17:6 <b>member (3)</b> 94:9 277:19 296:10 <b>members (10)</b> 21:8 96:18 98:17,21 99:10 231:11 246:11 250:14 251:25 268:3 <b>memo (1)</b> 167:3 <b>memorize (1)</b> 183:16 <b>memorized (6)</b> 51:11 202:9,18 204:18 289:12,14 <b>memory (15)</b> 33:17 34:10 36:13 37:3 71:10 99:21 100:10 149:10 153:13 177:18 183:14 198:2 227:24 236:9 239:20 <b>mention (4)</b> 39:5,6 44:13 168:23 <b>mentioned (7)</b> 52:9 88:23 89:25 92:8 158:20 177:9 234:5 <b>mentions (1)</b> 52:24	<b>message (2)</b> 282:24 283:1 <b>met (3)</b> 16:12 21:22 246:24 <b>metabolism (1)</b> 190:9 <b>method (6)</b> 81:20 124:17 206:21 228:14 300:5,14 <b>methodology (3)</b> 238:13 300:5,14 <b>methods (3)</b> 124:22 227:13 228:2 <b>mgs (7)</b> 214:15,18,23 215:3,6 216:11,17 <b>mice (137)</b> 6:3,7,16,17 11:1,24 12:7,12 15:19 16:3 16:8 23:16 24:13,16 24:17,23 29:4,17 30:1,4,5 32:18 33:3 33:5 37:5,14,20,25 38:2,12,13,14,16,19 38:19 39:24 40:7,24 45:9,20 46:19,25 47:2,10,10,12 48:11 48:19,23 49:14,15 49:18 50:19 51:1 54:7,11 55:2,6 56:19 58:3,19 59:6 59:14 61:23 62:1,14 62:18 65:12 73:3 75:18 77:13 80:17 80:20,23 90:19 98:18 105:24,24 107:22 108:4 110:11,15 111:15 112:7,16 113:12,18 116:2,16 122:7 123:5 125:23 127:16 132:25 133:21 134:1,2 137:4 138:5 140:15 143:5,19 144:11 145:7,13,18 146:5 146:19 147:2 148:3 149:8,24 151:2,21 151:22,25 153:16 154:3,4,7 155:5 156:23,24 160:13 164:3,16 169:17,25 170:5,14 171:5,13 235:8 240:17 241:18 291:1 292:9 <b>microscope (2)</b>	95:24 100:7 <b>microscopes (1)</b> 99:12 <b>microscopic (1)</b> 177:25 <b>mid (9)</b> 83:19 86:4,8 90:23 97:20 107:24 108:1 119:9 198:20 <b>middle (1)</b> 7:3 <b>midway (2)</b> 234:17,24 <b>milligrams (3)</b> 214:2,14 215:15 <b>million (24)</b> 181:4 187:24 188:3,4 189:14,18 190:5,7 193:6,21,23 214:19 215:25 216:9 218:8 218:24 219:1,4,7,12 220:10 221:22 222:2,3 <b>million-dollar (1)</b> 32:10 <b>mind (8)</b> 68:24 119:5 145:4 148:14 155:16 225:11 250:12 305:4 <b>mine (1)</b> 81:15 <b>minute (4)</b> 44:25 157:25 225:3 230:18 <b>minutes (3)</b> 159:19 251:19 286:4 <b>minutia (2)</b> 43:7,10 <b>misrepresentation (1)</b> 281:5 <b>misrepresented (1)</b> 231:5 <b>missed (2)</b> 91:23 116:3 <b>Mississippi (1)</b> 285:16 <b>misspoke (3)</b> 47:24 237:4 252:19 <b>misstates (13)</b> 44:7 80:4 82:17 83:22 143:6 144:3 154:15 171:22 188:22 219:9 232:18 253:2 267:20 <b>misstating (2)</b>	283:11,16 <b>mistaking (1)</b> 48:15 <b>model (5)</b> 27:21 29:15,23,24 30:2 <b>modified (2)</b> 28:17 29:4 <b>moment (1)</b> 294:17 <b>moments (1)</b> 196:25 <b>monograph (59)</b> 3:13,18 16:12 17:1,1 17:4,17,21 18:7 20:4 22:24 78:11 123:16 185:19 217:19 230:20,21 230:25 231:1 241:2 241:3,10 243:14,24 244:14 245:1,3,9,12 245:16,16,20,21,22 245:22,24 246:22 246:23 247:21 250:25 254:1 267:4 267:6,8,16,25 268:4 269:24 272:2 273:3 273:3,13,13,20,22 277:25 280:15 301:24 303:22 <b>monographs (5)</b> 175:4 241:23 264:24 265:2,4 <b>Monsanto (30)</b> 1:11 5:1,3,4,10 41:21 51:8 52:2 82:25 92:24,25 93:3,4,5 161:16 163:5 174:10 209:22 220:10 230:12 236:4,10,16,20 272:22 278:4 280:25 283:8,24 284:6 <b>Monsanto's (8)</b> 289:1,15,19,23 290:23 294:18 297:13 302:5 <b>months (6)</b> 75:21 183:21 192:9 222:3 284:13,18 <b>morning (6)</b> 4:21 7:13,14 40:9 121:6 133:19 <b>morphologic (1)</b> 74:19
--	---	--	---	--

<p><b>morphology (1)</b> 74:19</p> <p><b>mortality (1)</b> 192:8</p> <p><b>motion (2)</b> 222:7,8</p> <p><b>mountain (1)</b> 118:14</p> <p><b>mouse (104)</b> 3:9 8:1,22 9:4,9,16 9:17 10:18 12:21 13:2 15:15,22 23:13 24:9 27:2,2,3,14,20 28:1 29:6,14,15 30:2 31:25 33:12,23 34:17 40:15,23 41:15,23 46:4,11 47:2 48:12 50:13 54:3 58:18 60:6 62:14 66:1 68:23 70:7,8 75:24 76:1 76:24 78:2,3 81:5 83:18 84:5,13,20 85:9 94:24 96:2 97:7,7 98:13,18,23 99:8,13 100:7,11,18 102:7 106:10,12 111:23 113:3 118:19 120:18 121:10,16,18 135:2 140:11,25 141:1,22 145:21 146:7 147:14 148:11 153:11 155:5 159:5 160:7,8 161:18 169:12,13,16,18 170:9 173:9 194:3 214:23 227:20,22</p> <p><b>move (4)</b> 150:6,17 231:22 232:3</p> <p><b>MTD (7)</b> 214:12 215:9 220:5 220:21 222:22 223:6 249:25</p> <p><b>multidistrict (2)</b> 10:3 73:4</p> <p><b>multiple (5)</b> 152:6,10,21 153:2 257:10</p> <p><b>Murine (1)</b> 163:24</p> <p><b>mute (1)</b> 190:23</p> <hr/> <p style="text-align: center;"><b>N</b></p>	<p><b>N (2)</b> 2:1 3:1</p> <p><b>N.W (1)</b> 2:15</p> <p><b>name (9)</b> 4:16 83:1 93:23,24 94:11 99:24 159:9 279:24 308:2</p> <p><b>named (1)</b> 278:7</p> <p><b>National (28)</b> 93:19 94:2 167:15 215:22 217:15,17 217:22 241:14,24 242:4,9,10,15,15 243:6,8 256:15,25 258:4 265:13,20 266:6,13 295:24 303:8,22 304:6,10</p> <p><b>NCI (2)</b> 87:3 94:2</p> <p><b>NCP (1)</b> 45:13</p> <p><b>necessarily (4)</b> 64:9 81:25 96:9 211:9</p> <p><b>necessary (5)</b> 32:14 35:1 101:25 186:25 197:4</p> <p><b>need (23)</b> 39:12 40:18 42:19 47:20 100:9 109:9 109:20 118:11,15 120:4 181:15 183:17 204:25 223:2 229:24 230:23,23 240:7 245:5 259:14 262:14 263:2 271:19</p> <p><b>needed (2)</b> 226:22 274:14</p> <p><b>needs (1)</b> 262:2</p> <p><b>negative (10)</b> 217:12 223:20 224:7 225:4,8 244:23 246:2,6,7,12</p> <p><b>negatives (1)</b> 162:19</p> <p><b>neglected (1)</b> 204:23</p> <p><b>neoplasia (3)</b> 185:25 186:21 187:6</p> <p><b>neoplasm (1)</b> 133:21</p> <p><b>neoplasms (2)</b></p>	<p>70:2,4</p> <p><b>neoplastic (12)</b> 100:18 102:2 103:15 113:10,17 115:25 116:14 136:1 156:23 192:25 211:17 212:3</p> <p><b>never (6)</b> 8:2 23:7 85:20 242:21 284:2 296:6</p> <p><b>nevertheless (1)</b> 23:7</p> <p><b>new (6)</b> 2:7,7 4:18,18 247:8 303:3</p> <p><b>news (1)</b> 231:5</p> <p><b>NHL (10)</b> 8:2,19 13:12 17:3 21:1 22:1 291:2,11 291:17 292:15</p> <p><b>nice (1)</b> 116:8</p> <p><b>NIEHS (2)</b> 242:16,17</p> <p><b>night (1)</b> 206:2</p> <p><b>nine (9)</b> 75:21 149:23 190:15 227:20 234:25 277:25 286:18 290:22 291:6</p> <p><b>nodded (1)</b> 128:14</p> <p><b>nominated (1)</b> 296:5</p> <p><b>non-Hodgkin's (75)</b> 8:18,23 9:5,11,16,23 10:6,13,18,19 11:1 12:6,13 13:2,7,22 14:11,17,22 15:13 15:16,19,23 16:8,14 18:14 19:9 21:16,18 22:17,21 23:14 24:3 24:10,23 25:5,20,23 26:15 27:6,10,15,21 29:1,7,16,25 55:15 56:5 58:7,15 59:3 59:15 60:2 61:5,18 62:25 63:15 73:18 178:20 203:14 204:1 240:22 241:1 241:8 242:19,25 243:9 246:18 247:3 247:18 255:1,17 292:9 301:19</p>	<p><b>non-malignant (1)</b> 97:22</p> <p><b>non-statistically (1)</b> 123:7</p> <p><b>normal (3)</b> 175:17 176:17 177:4</p> <p><b>Northern (2)</b> 1:1 4:11</p> <p><b>Notary (3)</b> 1:13 307:5 308:25</p> <p><b>note (3)</b> 16:17 133:7 203:2</p> <p><b>notes (3)</b> 11:11 93:23 269:8</p> <p><b>notice (3)</b> 1:10 105:22 120:12</p> <p><b>noticed (2)</b> 204:23 206:1</p> <p><b>November (9)</b> 267:1 268:17,18,22 277:13 279:24,25 280:22 282:6</p> <p><b>NTP (26)</b> 30:8,22 31:5,19 32:5 33:8 35:1,7,24 75:14 215:24 218:7 218:16 219:6 242:18 295:21,23 295:24 296:2,8,10 296:17,19 297:11 301:7 302:7</p> <p><b>NTP.com (1)</b> 218:1</p> <p><b>Nufarm (10)</b> 134:25 135:14,14,19 136:14,20 141:22 143:3 144:1 220:1</p> <p><b>number (25)</b> 4:8,12 28:4 52:16 64:10 76:13 97:23 101:5 123:18,24 124:1,21 171:10 182:9 184:4 212:25 230:2 240:16 275:15,17,17 276:6 285:20 297:8 298:21</p> <p><b>numbers (8)</b> 6:6 55:10 78:19 120:22 134:21 202:10,20 299:3</p> <p><b>numerous (1)</b> 297:12</p> <p><b>nutritional (4)</b> 216:5,7 218:18,20</p>	<p style="text-align: center;"><b>O</b></p> <hr/> <p><b>o'clock (1)</b> 159:14</p> <p><b>oath (1)</b> 5:15</p> <p><b>object (136)</b> 9:24 10:8 12:17 13:10 13:25 18:16 19:12 28:3,6 31:12 33:13 35:9 38:9 40:1 42:7 43:21 45:25 46:6 48:25 50:2,14 54:17 57:6 61:24 62:15 64:4 65:5,15 78:6 79:3,18 80:18 81:7 91:22 93:7 94:18 99:1 106:4 110:16 110:24 111:8,25 122:14,21 124:20 125:6,25 127:18 129:2,10,19,24 131:9 133:22 134:15,17 135:16 136:6 139:8,16 140:13 141:24 145:15 146:20 151:8 153:4 154:25 155:21 157:12,20 158:25 160:18 164:1,4,18 168:17 169:9 173:11 180:12 181:6 182:1 183:24 184:6 185:13 186:9 187:19 188:22 189:19 192:10 193:15 194:14,22 196:4,15,24 197:16 199:6,24 200:15 201:2,15 204:7 205:16 206:11 207:21 208:19 210:4,19 212:5 213:6 216:19 221:16 222:10,18 223:16 227:6 236:5 240:14 243:1 244:18 248:11 250:10 252:3 255:19 261:4 265:16,22 267:19 270:1,15 271:19 276:1,24 277:7 278:16 279:6</p> <p><b>objection (89)</b> 14:7,13,25 18:20 21:3</p>
--	--	--	--	---

22:3 23:3,10 29:11 29:20 32:1,4,5 34:2 35:16 36:6 44:7,14 46:20 66:21 69:13 72:10 73:5,14 74:9 75:5,12 80:4 82:9 82:17 83:22 86:11 88:1 92:2 96:3 97:9 107:15 115:5 126:11,17 127:25 139:22 142:9,19 143:6 144:3,18 150:6 151:6 152:14 153:20 154:15 161:2 171:22 172:5 172:10 175:21 178:5,12 179:14 183:12 199:13 209:5 212:15 219:9 226:9 229:22 232:18 252:18 262:22 266:8 274:4 281:2 283:11 288:4 289:4,9,21 290:3,9 290:17 291:13 292:19 293:17,22 298:1 300:8,16 301:15 <b>observation (8)</b> 20:13 32:11 34:22 149:22 197:4 206:18 222:16 253:19 <b>observations (1)</b> 214:10 <b>observe (5)</b> 50:6 182:21 198:4 294:25 295:4 <b>observed (19)</b> 42:13 47:12 49:9 60:12 62:11 71:5 138:21 141:15 170:18,23 171:12 175:18 177:5 191:9 192:7 207:13 220:19 298:22 301:20 <b>obtained (2)</b> 163:4 228:21 <b>obviously (2)</b> 240:15,17 <b>occur (1)</b> 6:4 <b>occurred (5)</b> 55:10 169:25 178:1,2 197:19	<b>occurring (2)</b> 70:4 133:21 <b>occurs (2)</b> 146:12 147:2 <b>odds (1)</b> 301:13 <b>OECD (4)</b> 161:22 163:9 214:21 216:16 <b>Office (9)</b> 138:6 142:16,22 144:16 163:14 166:5 205:24 206:7 207:16 <b>oh (12)</b> 41:16 52:11 90:2 95:7 99:25 134:11 169:2 253:19 279:15 281:23 298:25 305:20 <b>okay (253)</b> 6:25 7:5,18,24,25 15:14,17 16:11,23 18:12 19:11,19,21 20:2 23:5 29:13 37:2 39:23 40:24 41:11 42:4,5 44:4 44:11,25 45:1 47:8 47:16,23 48:10 49:12 50:18 51:18 52:17,19 53:4,5,8 53:15 55:19 59:4 68:25 70:20 71:2,25 76:20 77:20 80:15 82:20 83:7,14,17 84:21,25 88:11,15 88:21 89:2,12,13,14 90:11 92:20 93:11 94:15 96:6,8,23 97:13 98:2 99:22 100:11,15,19 102:6 102:18 103:13 105:22 110:25 113:2 114:17 116:22 117:7,17,19 118:7 120:9,14,17 120:24 121:3,11 122:11,17 123:3,4 124:13 125:1,9,19 126:13 127:12,22 129:12,25 130:2,5 130:12,24 131:25 132:16 133:4 135:8 135:12,23 136:4 139:25 140:9,24 142:15 144:22	145:2,10 148:18 149:10,13 150:5 154:5 155:4 156:12 156:21 158:6,7,10 158:19,23 159:3,13 159:16,22 160:3 162:4,14,20 164:15 166:9 169:4,11,20 170:3 171:19 172:8 173:6,18,18,22 174:25 175:24 176:2,4,5 183:9 184:9,12,21 189:23 191:5,22 194:8 201:16,23 203:7,10 204:19 206:5 210:13 213:2 219:11,11 220:2,3,3 221:20 222:6 224:2 224:5,11 225:3,7,14 225:16 229:11 231:22 232:7,7,21 235:23 236:2,6 238:2 242:13 259:23 262:25 263:15 264:8,14 266:3,11,17 267:3 267:21 271:8,24 275:13 276:20 277:11 280:4 281:13 282:1,3 283:18 284:14,19 285:5,9,21 286:5,6 287:11 288:18,25 289:11,15,19 290:20 292:12 294:4,16 295:19,23 296:1,8,14 298:17 298:23 299:1,11 300:12 302:3,10 303:4 305:11,12 <b>older (1)</b> 182:18 <b>Olson (1)</b> 87:20 <b>once (6)</b> 6:12 36:6 197:24 204:14 216:4 218:17 <b>oncogenic (8)</b> 97:14 98:5 113:10,17 115:25 116:14 136:1 191:8 <b>one-eighth (1)</b> 184:4 <b>one-paragraph (1)</b>	284:21 <b>ones (8)</b> 60:17 95:21 120:15 121:2 146:9 224:9 246:4 291:20 <b>online (6)</b> 88:3 212:22,24 218:1 237:14,17 <b>onset (1)</b> 200:6 <b>Oops (1)</b> 175:23 <b>open (3)</b> 275:11,21 276:25 <b>opening (1)</b> 122:18 <b>opine (4)</b> 126:5,21 164:6 176:23 <b>opining (2)</b> 154:13 178:11 <b>opinion (82)</b> 14:16,21 19:20,20 34:9 35:15,17,25 37:6,14 48:6 58:6,8 58:13,20,22 59:1 73:1,12,16 74:4,5,6 74:7,16,17 80:8 86:10 90:17,18 100:23,24 101:8,12 101:16,17 102:4,5 103:17,19 105:8 107:22 112:6,10,12 113:22,24 124:11 125:13,15 152:20 162:12 165:25 167:4 173:20 177:16 178:17,23 178:25 180:2,5 186:18 189:25 212:7,8,10,18,18 215:12 217:9 221:15,17,18 238:9 245:14 246:17,21 247:5,13,17 271:11 300:23 <b>opinions (2)</b> 102:22 227:4 <b>opportunity (7)</b> 44:15 67:23 233:4 247:7,9 267:16 299:18 <b>opposed (4)</b> 97:22 211:2 216:8 218:21 <b>opposite (2)</b>	36:3 210:1 <b>oranges (3)</b> 35:13 144:21 154:21 <b>order (10)</b> 30:9 31:20 33:9 77:18 86:6 186:25 251:13 253:20 254:4 263:2 <b>organ (3)</b> 76:14 217:5 221:12 <b>organizations (1)</b> 236:13 <b>organs (1)</b> 294:5 <b>original (43)</b> 71:16,17 72:3,3,7 73:2,13 74:2,8,13 85:1 101:20 113:14 115:3,8,13,23 116:11 135:13,23 155:24 176:15 177:15 178:9 179:12 187:13 191:6 212:1,12 213:20,23 219:24 234:2 239:22 270:6 280:4,13,19 282:24 283:1 299:19,20,21 <b>originally (4)</b> 12:1 41:3 198:10 238:25 <b>originated (1)</b> 279:22 <b>OSHA (1)</b> 254:6 <b>out-survive (1)</b> 184:13 <b>outcome (1)</b> 307:12 <b>outlier (1)</b> 150:3 <b>outlined (5)</b> 17:19 227:14 228:13 265:18 266:2 <b>outside (2)</b> 146:21 153:20 <b>overall (7)</b> 21:9,11 59:9 153:18 188:20 191:21 213:21 <b>oversight (2)</b> 206:3 285:12 <b>overt (2)</b> 223:4 249:2 <hr/> <b>P</b> <hr/> <b>P (6)</b>
--	---	---	---	--

2:1,1 119:18 122:8 123:8 126:14 <b>p.m (20)</b> 117:23,25 159:24,25 159:25 160:2 229:13,14,14,16 256:10,11,11,13 286:10,11,11,13 305:24 306:2 <b>p=0.028 (1)</b> 6:8 <b>page (40)</b> 3:1 5:20,21 6:10,11 6:19,25 15:6,7,10 38:3 47:13,20 51:9 51:25 52:11,13,18 52:22,24 121:4 126:25 132:4,14,15 136:24 157:24 158:6 171:9,10 175:25 176:2,6 234:20,21 259:21 264:4,6 284:21 287:2 <b>pages (4)</b> 174:17,22 177:10 179:3 <b>paid (3)</b> 279:18 281:4,11 <b>pair-wise (6)</b> 108:17,19 185:16 205:15 208:8,11 <b>pancreatic (38)</b> 26:21,21 51:5,7,13,15 51:16,23 52:3,9 53:2,12,18,25 54:6 54:10,15,25 184:23 184:25 185:21 195:22 196:18 197:10,19 198:5,17 199:1 200:11,17,24 201:11,13,20,24 202:1 206:8 208:16 <b>panel (8)</b> 98:10,17,22 99:7,15 99:23 100:6 101:8 <b>panelists (1)</b> 301:11 <b>paper (75)</b> 15:18 27:13 29:3 33:22 34:1 35:3 36:7,19,21 37:1 72:19,20,21,23 103:2,3,12 145:9 156:4,5 157:14 163:9 171:17	205:19,23,25 209:14 226:8 227:8 227:13,14 228:3,6 228:12,12,13,16,18 229:21,25 230:11 230:14,16,18,20 231:1,2,10 238:10 238:14,17,18 239:2 239:13,15,25 240:13 247:10,10 247:11,13,16 272:25 273:2,3,9,10 273:14,15,16,21,21 273:23 299:23,24 <b>papers (18)</b> 26:13 30:7,13,16,21 60:2 61:19 63:16 100:3 272:23,24 299:16,17,17,18,19 299:20,21 <b>paragraph (10)</b> 6:19,20 52:22 132:6 234:23 260:1 269:8 271:10 282:12,20 <b>paraphrasing (2)</b> 20:10 126:1 <b>parenthesis (3)</b> 6:5 7:7 254:3 <b>park (1)</b> 30:8 <b>part (30)</b> 9:21 18:3 68:17 73:18 73:19 88:16 89:3 98:19,23 99:14 104:8,12 116:3 137:14 167:20,21 169:13 175:4 178:21 222:22,23 243:20,24 244:25 245:9 248:15 250:18 296:22 297:10,11 <b>partially (1)</b> 131:2 <b>participants (3)</b> 244:2,15 280:14 <b>participate (3)</b> 267:16 274:17 275:24 <b>participated (2)</b> 104:13 274:19 <b>participating (1)</b> 277:12 <b>participation (1)</b> 246:20 <b>particular (89)</b> 17:8 18:2,10,10 23:17	23:19,23 25:1 26:4 27:5 32:12,13,24 56:7 58:10,22 59:18 59:21 60:13 61:6 63:2 64:17 65:18 66:20 67:5 69:7 73:24 90:15 103:1 103:21,23 105:4 107:12 111:10,13 114:22 119:2 123:23 131:23 133:14 136:7,18 139:11 143:15 145:1,8 147:13 148:8 149:18 158:12 161:12 163:7 164:23 165:12 170:15 174:11 177:3 180:14,15 182:15 183:17 189:3,5 195:4 197:5 198:13 198:16 199:1 203:7 206:13 207:5 211:23 213:1,13 221:7 228:2 233:9 253:18,25 254:6 262:16 265:25 268:15 291:1 292:1 292:8,14 295:18 297:15 <b>parties (2)</b> 307:8,11 <b>parts (25)</b> 102:13 181:3 187:24 188:3,4 189:14,18 190:5,6 193:6,21,22 214:19 215:25 216:9 218:7,24 219:1,3,7,12 220:9 221:21 222:2,2 <b>party (1)</b> 278:18 <b>pathologist (19)</b> 74:22 75:10 85:2 87:9 89:10,15 90:1,21 91:10 93:18 95:8 99:23 101:22 113:5 115:8 177:24 187:14 194:21 238:25 <b>pathologists (12)</b> 85:1 89:22,24 90:5,16 92:21 99:11 100:5 156:17 179:24 187:15 219:25	<b>pathology (44)</b> 83:11,11 85:24 88:24 90:12 92:7,11,13,16 92:20,23 93:1 94:23 114:17,20,23 115:3 115:6,7,13 118:22 118:24,25 119:3 136:5,11 156:12,15 156:19 158:24 165:5,6,8 174:13 181:19,22 191:14 191:20 192:14 213:20,23 236:3 297:14,24 <b>patient (2)</b> 254:25 255:18 <b>Pearl (2)</b> 2:5 4:23 <b>Pedram (2)</b> 2:8 5:7 <b>peer (14)</b> 103:11 112:9,14,17 112:23 154:24 173:10 209:9 210:3 215:11 227:12 238:12,14 240:19 <b>peer-reviewed (15)</b> 17:10 80:13 81:11,16 82:3 112:20 113:1 195:9 209:15 227:11 238:11 239:24 240:23 254:20 255:14 <b>peers (1)</b> 34:14 <b>pending (1)</b> 150:22 <b>penultimate (1)</b> 259:25 <b>people (18)</b> 30:14 34:24 35:6 71:16 97:2 98:4 101:9 123:19 227:12 245:5,8 250:20 267:23,25 273:6 275:9 295:13 301:5 <b>people's (4)</b> 101:14 102:4 178:13 245:13 <b>percent (30)</b> 78:25 119:13,14 128:13,15 130:17 131:7 134:4 149:8 151:2 153:11,17 154:1 170:19,24	171:4,6,14 176:9,9 188:4,17 193:8 215:25 216:4,4 218:16,16,17 304:22 <b>percentage (2)</b> 119:15 304:25 <b>perfect (1)</b> 32:7 <b>perfectly (2)</b> 166:3 167:6 <b>perform (2)</b> 8:12 119:23 <b>performed (8)</b> 107:10 111:12 120:2 198:13 236:8,12 248:17 258:25 <b>performing (3)</b> 16:6 155:2 206:12 <b>period (3)</b> 7:8 127:24 149:24 <b>permit (2)</b> 244:1,15 <b>person (3)</b> 95:15 245:21,22 <b>personal (3)</b> 80:11,12 277:14 <b>personally (3)</b> 15:17 94:22 95:19 <b>pertaining (2)</b> 73:21 90:15 <b>pesticide (10)</b> 104:8 138:7 142:16 142:22 144:16 154:24 163:14 166:6 205:24 207:16 <b>Pesticides (1)</b> 206:7 <b>Pg (1)</b> 308:5 <b>Ph.D (7)</b> 1:4,11 3:1,7 5:12 11:8 307:6 <b>pharma (1)</b> 288:19 <b>phonetic (4)</b> 93:23 98:24 99:24 148:24 <b>phrase (1)</b> 294:17 <b>phraseology (2)</b> 79:19 129:10 <b>picking (1)</b> 126:3 <b>piece (5)</b>
---	--	--	---	--

59:8,8 107:14 115:21 116:10 <b>piecemeal (1)</b> 66:11 <b>pieces (3)</b> 102:15 126:3 287:12 <b>place (8)</b> 94:6 230:13 234:5 244:8 245:24 253:25 299:21 307:8 <b>places (5)</b> 11:14,20,23 134:17 193:19 <b>plaintiff (1)</b> 102:25 <b>plaintiffs (30)</b> 2:2 3:7 4:22,24 5:8 11:9 13:11 69:16,18 76:17 81:3 102:19 114:9 115:12 116:19 136:17 157:3,6 165:11 191:15 213:11 278:3 279:3,10 280:23,25 281:4 283:7,23 284:5 <b>plan (1)</b> 282:22 <b>planet (4)</b> 59:13 195:10 209:9 255:18 <b>play (1)</b> 21:22 <b>playing (1)</b> 295:11 <b>plays (1)</b> 169:14 <b>please (23)</b> 4:20 12:8 13:18 35:16 37:1,17 40:19 129:13 134:12 150:23 181:16 190:23 199:20 202:8 204:15 239:18 244:13 248:5 251:21 279:14 280:2 281:18 285:1 <b>pleasure (1)</b> 31:14 <b>plus (4)</b> 64:19 72:13 101:7 257:19 <b>point (10)</b> 56:11 62:2 64:7 72:16	84:15 133:15 137:12 148:15 163:20 300:2 <b>pointed (3)</b> 142:13,14 301:18 <b>poor (1)</b> 167:18 <b>population (3)</b> 10:14 18:5 21:19 <b>populations (1)</b> 18:3 <b>Portier (51)</b> 3:13,15,16,18,20,21 3:21 120:23 121:22 122:12 123:6,13 124:11 125:20 126:9 127:15 131:3 142:4 171:19 173:16 204:4 228:22,25 266:22 267:14,23 270:5 271:9 273:25 275:7 276:23 277:13,14 278:2,7,9 279:2,9 279:22 280:22 281:15 282:5,25,25 283:6,6,19 284:20 285:6,6,16 <b>Portier's (9)</b> 125:15 126:1,5,6,21 126:25 281:3 283:11,14 <b>portion (1)</b> 69:23 <b>portions (3)</b> 102:16 114:7,9 <b>pose (3)</b> 258:6,22 259:4 <b>positive (28)</b> 6:14 8:10 20:11 26:9 35:2 55:23 108:9,10 108:11,20,22,23 111:18 138:3 143:4 143:17 147:8 151:13,14,19,20,21 151:24,25 185:9 187:1 189:2 240:16 <b>possibility (5)</b> 162:5,15,22,25 262:8 <b>possible (5)</b> 16:7 31:3 153:13 154:10 246:25 <b>possibly (1)</b> 24:6 <b>potential (40)</b> 8:14 17:6,7 24:18	25:14 26:11 61:14 63:9,10 105:13 143:23 144:14 180:24 189:9 203:22 205:23 221:6 241:4 243:14 243:16 244:3,16 251:1 258:4,19 270:8,23 292:5,23 293:5 303:9,13,15 303:20,21,23,25 304:3,17,20 <b>potentially (2)</b> 59:23 304:15 <b>powerful (1)</b> 33:24 <b>preamble (15)</b> 17:16,19,20 19:17 20:3 21:5 243:13 244:1,15,24 246:10 264:18,22 265:10 303:25 <b>preclude (2)</b> 194:25 246:10 <b>predicate (4)</b> 291:2,11,17 292:15 <b>predict (1)</b> 25:4 <b>predictability (1)</b> 25:5 <b>predicting (3)</b> 12:6 27:21 29:16 <b>predictive (17)</b> 8:2,13,22 9:2,19 10:17,19 11:1 12:12 15:15,23 23:14 24:10 55:15 59:14 61:5 62:25 <b>predictor (2)</b> 28:2 294:2 <b>preminent (1)</b> 83:10 <b>prefacing (1)</b> 199:14 <b>prefer (1)</b> 33:15 <b>preferred (1)</b> 32:7 <b>premise (1)</b> 292:20 <b>premises (1)</b> 304:13 <b>preneoplastic (12)</b> 67:18 68:5,9,12,15,16 68:19,21 91:4 138:20,24 139:6	<b>preparation (3)</b> 175:1 205:2,10 <b>prepare (2)</b> 103:8 265:8 <b>prepared (3)</b> 109:13 158:24 246:3 <b>preparing (2)</b> 177:16 301:2 <b>presence (4)</b> 67:17 68:4 160:25 164:17 <b>present (2)</b> 2:17 219:22 <b>presented (1)</b> 16:20 <b>presenting (1)</b> 265:10 <b>press (2)</b> 231:4 272:23 <b>pretty (6)</b> 42:14 91:19 114:14 264:21 291:21 304:12 <b>prevent (1)</b> 244:20 <b>previous (3)</b> 133:6 178:15 307:6 <b>previously (5)</b> 20:3 36:14 65:23 172:19 186:14 <b>primary (2)</b> 233:14 290:19 <b>principal (2)</b> 164:24 167:2 <b>printing (1)</b> 285:13 <b>prior (12)</b> 12:14 19:3 65:9 78:16 105:11 124:1 150:10 214:13 241:9 242:8 269:12 269:12 <b>privy (1)</b> 112:3 <b>probable (3)</b> 246:25 261:10 303:16 <b>probably (17)</b> 34:11 45:6 55:4 57:2 86:23 88:14 116:20 117:2 118:17 124:3 136:18 140:2 141:12 174:21 258:9 285:12 286:4 <b>problem (1)</b> 272:13 <b>problems (2)</b>	271:12,22 <b>procedure (3)</b> 4:5 10:2 92:14 <b>proceed (1)</b> 92:14 <b>proceeding (5)</b> 7:19 9:20 10:2,5 14:4 <b>proceedings (3)</b> 4:3 306:1 307:10 <b>proceeds (1)</b> 52:24 <b>process (6)</b> 75:22 243:21 244:24 248:23 267:17 293:25 <b>processed (1)</b> 245:7 <b>produce (1)</b> 187:16 <b>produced (2)</b> 105:12 286:22 <b>producing (1)</b> 245:20 <b>product (2)</b> 245:17,21 <b>Products (2)</b> 1:6 4:10 <b>Professional (2)</b> 1:13 307:5 <b>professor (1)</b> 93:20 <b>program (36)</b> 45:14 87:4 153:7 166:6 167:15 205:24 206:7 215:22,22 217:15 217:17,19,22 219:7 241:14,24 242:4,6 242:10,15,16 243:7 243:8 245:1 256:15 257:1 258:4 265:13 266:6,13 272:2 295:25 303:8,23 304:6,11 <b>Program's (1)</b> 265:20 <b>Programs (6)</b> 138:7 142:16,23 144:16 163:14 207:17 <b>progress (2)</b> 196:13,19 <b>progression (12)</b> 139:5 185:20,24 186:20,25 187:5 196:3,9,12 197:1,3
---	--	---	--	--

197:7 <b>project (1)</b> 217:15 <b>pronunciation (1)</b> 85:3 <b>proper (1)</b> 169:21 <b>proposed (1)</b> 275:8 <b>proposition (1)</b> 66:25 <b>prostate (1)</b> 182:17 <b>protect (3)</b> 262:10,17 277:23 <b>protection (4)</b> 114:2 261:13,14,20 <b>protocol (3)</b> 146:25 253:12 276:17 <b>provide (15)</b> 73:16 115:12,15,17 126:20 128:2 157:6 158:23 204:15 239:18 246:16 259:9 289:16,24 290:7 <b>provided (18)</b> 69:18 102:10,11,18 102:25 114:8,13 158:21 161:8 165:13 174:24 191:14 213:12 230:16 17,22 231:10 235:25 <b>public (10)</b> 1:13 261:16,17,20,22 262:2,12 263:2 307:5 308:25 <b>publication (43)</b> 10:24 27:20 33:16 34:3,7,19 35:10,17 35:18,21 36:12 66:10,22 67:22,24 72:17 78:4 80:13 107:20 114:12 123:25 135:18 136:19 140:3 145:6 161:21 163:18 209:16,17 215:11 226:23 227:11,12 229:1 237:8,24 238:5,7,12,15 239:5 239:24 298:8 <b>publications (7)</b> 10:21 17:12 28:8 68:1 124:25 167:7,13	<b>publicly (5)</b> 17:9,12 169:1 229:3 236:16 <b>published (50)</b> 12:14,18 15:14,18 24:25 25:3 33:18 35:4 55:13 56:7 59:12 60:2 61:18 63:15,16 66:5 95:2 100:1 102:21 103:11 107:13 112:8,13,16,19,23 112:25 123:19 163:8 173:10,12 187:4 192:20 195:9 209:9,16 213:3 217:23 229:20 233:8 235:10 238:11,23 240:20 254:19,23 255:14 255:16 292:10 302:15 <b>publishing (3)</b> 26:13 27:13 204:2 <b>pull (1)</b> 126:5 <b>purpose (34)</b> 8:5,25 9:17 10:5 12:21,23,25 13:4,5 13:20 14:1,9 16:12 16:19 17:2 18:7 28:9,10 105:20 106:15 144:24 154:17 180:20 203:15 207:7 208:2 222:25 223:24 248:13 249:3 251:6 253:5 257:23 261:20 <b>purposes (7)</b> 111:11 181:2 206:15 215:19 217:1 222:21 269:5 <b>pursuant (2)</b> 1:10 4:4 <b>push (1)</b> 144:9 <b>put (20)</b> 73:22 74:6,15 79:21 80:13 100:25 101:12 103:4 109:10 113:23 133:7 171:10 190:22 204:23 206:2 226:22 227:14 259:16	299:3 304:24 <b>puts (1)</b> 101:10 <b>putting (4)</b> 123:25 187:11 227:9 228:14 <b>PWG (2)</b> 94:9 96:15 <b>PWGs (3)</b> 96:7,12,18 <hr/> <b>Q</b> <hr/> <b>question (110)</b> 7:20,23 8:21 9:15,22 10:16 13:15,19 16:17,24 18:19,24 19:2,7 22:4,6 29:10 31:16 33:14 34:12 37:9 38:17 40:13,19 41:9,11 42:16,16 44:5 47:3,4 48:2 59:4,5 72:25 73:10 86:12 89:7 95:5,6 98:12 105:12 116:4 116:9,25 126:8 127:13,19 130:6,7 130:13 137:19 139:18 150:10,20 150:22,24 151:8 162:18 164:9 168:2 168:18,21 174:5 176:13,14 177:14 186:14,16,17 189:11,11,25 192:11 199:19 212:6 214:14 231:24 240:8 242:11,14 243:19 244:10,13,19 248:4 248:16,21 249:21 250:11 251:6,21,22 251:23 252:10 253:16 255:20,25 256:2 270:16 276:25 277:8 279:1 280:8 281:8 282:3 291:12,16 292:1 300:11 <b>questioning (3)</b> 70:22 199:15 278:22 <b>questions (21)</b> 7:16,21 13:8,23 56:16 66:11 128:2 178:16 232:5 246:1 252:4 278:17 285:24 289:6 290:1,24	291:3,7,20 303:2 307:10 <b>quick (3)</b> 44:9 109:14 286:19 <b>quit (2)</b> 291:7,7 <b>quite (7)</b> 32:6 98:3 242:5 244:11 286:17 301:6 302:17 <b>quote (10)</b> 69:25 71:6 105:12 107:14 112:13 140:2 176:17 253:24 298:11,12 <b>quoting (5)</b> 67:22 70:23 126:1 176:22 264:12 <hr/> <b>R</b> <hr/> <b>R (4)</b> 1:13 2:1 307:4,18 <b>R.M (1)</b> 93:14 <b>ran (2)</b> 125:20 126:9 <b>random (1)</b> 202:9 <b>range (12)</b> 130:18 131:6 149:14 149:25 151:1,7 153:10,15 154:8 170:17,22 176:9 <b>ranging (1)</b> 149:7 <b>ranking (1)</b> 145:12 <b>ranks (2)</b> 146:6,10 <b>rare (3)</b> 42:14 78:1,5 <b>rat (77)</b> 3:10 25:22 26:17,20 26:24 27:2 33:12,24 34:17 38:20,21 39:4 39:20 42:21 43:19 44:23 46:5,19 47:5 51:5,8 52:3,8,17 53:7,23 54:1 55:1 60:5 61:22 62:9,10 62:12 66:1 120:18 121:10,15,18,19 141:22 148:25 173:21 174:9 175:19 176:19 177:6 182:22	189:12 190:2,3,13 190:25 191:1 192:21 195:14 204:12 205:9 207:12 210:7 211:20 212:2 213:4 215:2 218:24 220:1 220:10 221:8 223:25 224:13,24 225:2,5 227:20,21 246:2 291:1,10 <b>rat's (1)</b> 188:4 <b>rate (20)</b> 12:5,9,10,10,15 130:16 131:7,8 145:10,12 146:13 148:23 158:12 170:13 171:4,6 183:4 184:15 298:18,19 <b>rates (10)</b> 147:13 183:17 203:12 211:10 298:14,14 299:4,7 305:2,7 <b>ratio (1)</b> 301:13 <b>rationale (2)</b> 166:24 228:4 <b>rats (114)</b> 26:4,6,8,10,15 32:19 33:3,4 38:7,19,25 39:2,8,10,25 40:4 42:6,8,12,14,18,21 42:24 43:24 44:13 45:2,9,21,24 46:13 49:22 50:13,17 52:7 53:18 55:2,6,11,12 55:15,22,23 56:5,5 56:17 57:5,15 60:25 61:4,8,9,12,17 62:21,25 63:3,5,8 63:15 65:2,10,12 75:18 116:1,15 141:11,13 147:5,8,9 148:24 178:3 180:23 181:3 182:18,20 183:22 184:14 188:1,21 189:3,4,6,7,13 190:3,6,14 194:5 195:12 201:11,21 201:24 202:3 203:16,19,21,25 209:12 210:11,14 210:15,22,23 211:5
---	--	---	--	---

211:12,12 217:5 219:14 220:21 224:14 225:21 240:17 292:9 <b>re-assessment (2)</b> 271:22 272:1 <b>re-registration (1)</b> 138:8 <b>reach (5)</b> 49:10 108:18 214:23 295:8,15 <b>reached (17)</b> 39:16 42:11 43:25 173:10 214:9,12 215:3,10 217:9 219:23 220:5,22 222:9,11,17,22 223:6 <b>reaching (1)</b> 216:17 <b>read (104)</b> 6:2,14 12:2 13:17,19 19:5 33:16 35:18,20 36:7 38:23 40:17 44:25 47:19 67:23 69:1,3,5,11,24 70:4 71:13 74:22 78:13 78:21 86:1 87:13,19 87:22 91:15 95:20 98:16 99:9,9 100:8 103:17 104:3 113:19 114:17,25 115:2,7,9 116:9 122:20 126:6,22 127:8,10 128:1 130:25 138:6 142:24 145:6,8 152:7 155:18 156:7 156:12,16 157:2,2 157:10 159:4 161:5 165:4 166:5,8,9,23 167:3 172:7 174:2,8 174:12,13,16,23 175:1,13 179:8 192:3 193:12 198:12 205:21 228:12,13,17,17 231:7 234:18 251:21,23 260:10 261:3 265:23 268:5 268:12,13 271:20 273:13 287:20,23 308:5 <b>reader (2)</b> 260:13 265:5 <b>reading (38)</b>	31:13 45:3,3 86:1,13 86:16,19 91:17 136:2 161:25 164:5 164:10 166:11,21 176:5,25 177:2,11 177:21 178:6 196:6 204:22 206:1 232:9 258:8,13 259:19,24 263:10 264:5 270:9 270:12 272:9 286:25 287:19 307:21,23,25 <b>reads (2)</b> 282:20 308:5 <b>ready (1)</b> 133:1 <b>real (7)</b> 244:3,16 254:17 257:4 276:15 288:2 295:14 <b>really (22)</b> 6:20 9:14 19:4 35:21 36:12,25 109:9 110:10 112:3,5 148:15 150:16 151:5 164:13 167:17 229:24 266:12 273:18,18 276:19 281:9 305:14 <b>Realtime (2)</b> 1:13 307:5 <b>reanalysis (1)</b> 159:10 <b>reask (2)</b> 248:4 300:10 <b>reason (13)</b> 68:19 95:6 146:13,17 162:10 164:20 165:2 166:1 167:5 260:12 287:14 299:6 308:5 <b>reasonable (5)</b> 14:21 15:11 33:21 34:13 58:14 <b>reasonably (6)</b> 256:23 260:17 261:24 262:8,13 301:3 <b>reasons (2)</b> 28:5 251:17 <b>reassessment (2)</b> 269:11 270:21 <b>recall (56)</b> 15:25 16:4 33:18 36:20 39:9 43:18,23 43:24 66:14,16 71:3	81:1 86:16,19 88:25 91:17 92:19 94:14 99:3 107:19 114:22 115:1 119:25 136:2 139:9 141:3 155:22 160:5 165:17 166:12,15 170:11 170:22 175:11 177:20,22 187:11 188:10 190:17,24 191:11 204:8,10 211:23 212:25 227:24 228:5 234:3 238:6 246:1 255:11 263:22 268:9 274:19 281:20 282:6 <b>recalled (1)</b> 43:22 <b>recalls (1)</b> 70:25 <b>received (8)</b> 134:20 161:6 189:17 193:6,21 232:23 266:18 269:23 <b>receiving (4)</b> 218:24 219:3 221:21 268:10 <b>Recess (6)</b> 57:23 117:23 159:25 229:14 256:11 286:11 <b>recognize (1)</b> 300:13 <b>recognized (2)</b> 300:6 301:9 <b>recollection (7)</b> 232:13 242:20 274:9 282:17 284:15 289:17 290:7 <b>recommendations (1)</b> 241:21 <b>record (31)</b> 16:17 19:6 44:18 57:21,25 86:13 117:21,25 127:5,9 127:11 128:3 133:7 159:23 160:2 172:24 202:24 229:12,16 231:12 256:9,13 278:6 279:13,21 286:9,13 305:16,21,22,25 <b>recorded (1)</b> 127:16 <b>records (2)</b>	12:5 288:7 <b>recount (1)</b> 238:24 <b>reduced (1)</b> 307:9 <b>reevaluate (1)</b> 124:6 <b>reevaluated (1)</b> 198:23 <b>reevaluation (2)</b> 159:4 276:22 <b>refer (29)</b> 44:2 46:18 47:9 50:10 50:11 52:3,14 53:12 61:21 63:19 68:23 84:22 90:5 108:7 137:23 145:3 157:14,18 158:1,3 158:17 175:16 207:1 209:10,11 237:20 266:5,5,7 <b>reference (26)</b> 3:5 27:23 44:22 45:2 51:25 72:21 78:7,10 79:8 109:14,17 137:6,15 148:20 150:10 157:22 158:12 165:14 171:6,17 176:11 205:17,25 226:8 264:18 288:1 <b>referenced (2)</b> 228:22 301:24 <b>references (4)</b> 38:1 73:23 82:13 287:22 <b>referred (19)</b> 11:20 32:17 44:3 46:5 51:15,19,22 52:8,15 52:17 67:9 105:11 121:5 134:10 135:2 233:16,16,17 305:3 <b>referring (35)</b> 14:3 19:4 35:4,10,11 40:11 65:3,8 77:13 89:25 90:7 104:19 105:11 119:15 122:16,22 125:13 141:1,23 148:21 154:2 158:15 159:7 159:8 234:19 237:19 260:6 275:25 277:3 282:12 283:2,13 287:15 288:12 299:16	<b>refers (7)</b> 72:19 157:19 209:16 209:17 267:4 273:21,22 <b>reflect (2)</b> 202:24 277:22 <b>reflects (1)</b> 212:10 <b>refresh (12)</b> 33:17 36:13 37:3 99:21 100:10 149:10 153:13 183:13 227:24 282:17 289:17 290:6 <b>refuse (2)</b> 244:16 289:20 <b>refused (3)</b> 126:20 202:25 289:24 <b>refusing (1)</b> 34:4 <b>regarding (7)</b> 52:2 71:4 107:21 129:16 247:23 256:16 276:21 <b>regimen (1)</b> 214:22 <b>Registered (2)</b> 1:13 307:5 <b>registration (3)</b> 88:17 135:21 192:22 <b>regulators (1)</b> 104:16,18 129:22 130:8 131:11 149:6 150:25 153:9,9,15 154:12 269:16 270:6 <b>regulatory (9)</b> 76:24 77:6 104:5 166:10 216:23 260:9,20 269:5 276:7 <b>regurgitation (1)</b> 19:16 <b>reinterpreted (1)</b> 238:22 <b>reinterpreting (1)</b> 239:11 <b>reject (1)</b> 239:22 <b>rejected (1)</b> 103:18 <b>related (27)</b> 6:18 13:2 87:16 100:17 105:18,19 111:6,6,17,18 112:8
--	--	---	--	--

<p>115:25 142:18 175:20 182:8 207:2 207:13,19,19 208:17,17 209:13 240:11 244:6 252:4 275:18 307:11</p> <p><b>relates (4)</b> 1:8 73:17 181:18 273:14</p> <p><b>relating (2)</b> 165:23 272:21</p> <p><b>relation (2)</b> 286:20 307:7</p> <p><b>relationship (4)</b> 15:19 25:22 29:6 203:13</p> <p><b>relatively (1)</b> 146:5</p> <p><b>release (1)</b> 270:21</p> <p><b>relevance (1)</b> 281:9</p> <p><b>relevant (9)</b> 9:14 72:18 150:17 180:17 247:24 248:9 249:7,12 257:4</p> <p><b>reliable (10)</b> 80:3 81:9,12,17,25 82:4 103:9,11 298:9 298:10</p> <p><b>reliance (1)</b> 297:25</p> <p><b>relied (21)</b> 27:19 44:23 67:10 80:10 109:4 115:16 136:18 202:11,13 213:2,3 228:19,20 228:20,21 229:1 232:15,22,22 273:9 299:8</p> <p><b>rely (16)</b> 42:25 48:23 58:5 60:7 78:3 81:3 102:21 109:6 114:4 121:24 227:4 230:6,8 273:11 292:16 298:24</p> <p><b>remember (60)</b> 14:23 36:10,12 42:20 45:3 66:3,23 68:1 70:6 71:15,23 78:17 78:19 79:5 81:2 82:19 86:18 90:7 94:21 105:25 109:8 109:24 115:10</p>	<p>116:23 119:3 123:9 139:11 141:4 155:7 155:23 166:11,21 170:21 172:25 176:25 177:2 178:6 183:9 184:3 191:11 210:6 213:25 238:16 257:12 258:12 264:9 274:25 276:3,5 277:5,5 285:8 290:23 291:2,5,9,12 291:15 297:12 298:15</p> <p><b>remembers (2)</b> 44:16 202:16</p> <p><b>remind (1)</b> 96:13</p> <p><b>renal (52)</b> 8:1,22 9:8 10:17,18 10:25 12:6,12 15:15 15:22 41:20,22 42:1 42:2,6,9,13,17,21 42:24 43:19,24 44:23 71:5 77:17,25 78:15 79:1,16 80:16 82:21 83:20 84:4 87:15 91:16,19 94:24 105:23 106:2 106:10,13 121:25 121:25 122:9 125:21,22 126:9,10 126:15 127:16 170:4,8</p> <p><b>repeat (26)</b> 7:16,23 13:16 16:23 31:17 32:9,10 34:18 40:19 41:11 65:6 67:21 98:20 112:18 113:13 116:4 129:12 130:6 142:21 150:23 152:25 168:11 186:12 194:11 210:20 244:10</p> <p><b>repeated (3)</b> 36:3,15 140:11</p> <p><b>rephrase (4)</b> 139:17 146:3 173:25 288:17</p> <p><b>replicate (3)</b> 64:21,22 194:12</p> <p><b>replicated (28)</b> 30:25 33:11 34:16 38:19 39:25 46:5,19 46:25 47:4,10 48:24</p>	<p>49:14,25 50:13 51:2 54:1,3,15 55:1 57:5 57:15 61:22 62:9,13 63:21 64:12 65:3 200:12</p> <p><b>replication (14)</b> 33:22 64:2,6,8,9,10 64:16 110:12,19,22 140:24 141:20 200:23 294:10</p> <p><b>reply (2)</b> 5:15 276:23</p> <p><b>report (529)</b> 3:6,11 5:18,20,21 10:4,25 11:4,5,6,7 11:12 12:5 14:5,19 14:24 15:2 19:5,13 19:15,18,20 22:16 27:18 29:9,12 32:18 35:12 37:4,13 38:7 39:23 40:6,14,17,21 41:14 42:6,16,17,19 42:23 43:1,5,6,14 44:2,6,12,15,19,22 44:24 45:2,7,14,24 46:1,17 47:9,14,18 48:14 49:11,13,22 50:10,17,17,21,22 51:16 52:2,25 53:9 54:8,12,14,24 55:3 55:7 56:20,22,25 57:3,13 58:2,13,21 58:23 59:6 60:5,6,7 60:13,14,18 63:19 63:20 64:1,3 65:4,9 65:11,13,22 66:2 67:10,11 69:6,8,9 69:12,14,17,20,22 70:5,14,22 71:1,4,6 71:12,16,19,21,22 72:1,5,8,21 73:3,8,9 73:22,23 74:1,6,16 74:19 76:7,11,18,19 76:20,23 77:16,16 78:8,9 79:6 80:21 81:1,4,13,15,18 82:7,14,22 84:3,6 84:23 85:6,16 86:16 86:19 87:13,18,19 88:24 89:9 90:6 91:9,15 92:8 97:8 97:11,17 99:9,16,20 100:10,20,21,23,25 101:11,12,16 102:7 102:13,16 103:8 104:12,19 105:3,15</p>	<p>105:23 106:9 108:8 110:13,14 112:13 112:20,22,25 113:19,20,21,23,25 114:6,7,10,15,18,20 114:22,23 115:3,6,7 115:9 116:18,21 118:25 119:3 122:12,15,18,18,19 122:23 123:10 124:1,2 126:2,3,4,5 126:6,23 127:1,20 128:9,10,16 129:1,3 129:8,11,15,20,23 130:8,10,17,22,25 131:2,12,13 132:2,8 134:9,19 135:3 136:2,5,9,10,11,23 138:7,22 139:2 140:23 141:8,19,20 142:7,10,16,23 143:2,7 144:4,16 147:5 149:9,21 152:17,20 153:12 154:16 156:1,13,15 156:19 157:4,17 158:24 159:8 161:5 161:8,11 162:3,21 162:22 163:16 164:19 165:5,6,9 166:11,13,23 167:1 171:2 172:2,3 173:13,13,19 174:3 174:8,11,12,13,15 174:17,19,20 175:13,17,24 176:6 176:24 177:2,24,25 178:10,25 179:2,8 179:15 180:4 181:9 181:9,10,19,25 182:4,5 183:3,8 184:8,10,19 185:2 187:9,12,21 188:11 188:15,25 191:12 191:13,14,16,17,18 191:20,21 192:5,18 192:20 193:20 194:10 195:21,22 197:22 198:1 199:16 200:19 204:5,6,11,20,23,24 205:4,4,13,18 206:19,23,24 207:10,11 208:5 209:1,3 211:19,23 212:1,10 213:21,24</p>	<p>219:2 220:7 222:13 223:9 227:1 228:10 228:22,24 230:6 233:8,11,15 234:5,6 234:12,15,15 235:24 236:23 237:1,6 238:4,24 240:5,6,7,15 241:16 241:22 242:7,8,18 243:8 246:3,3,16 248:7 254:14,14,16 254:18,20,24 255:3 255:3,4,5,16,21 256:3,4,23 257:8 258:3,9,18 259:1,5 259:12 260:21,22 260:24 261:2,5 262:18 263:12,13 263:16,18,20,24 264:7,10,16,17 265:12,18,25 266:1 266:4,6,16 269:11 272:13 286:22 287:1,19,20,24 288:2,10,22,23 290:1,13 296:23 297:1,3,9,14,20,24 298:3,5,13,24 299:4 299:6 300:3,20,21 300:25 301:2,7 302:8,16 305:1,9</p> <p><b>reported (46)</b> 6:2 35:1 45:5 54:7 55:6 56:20,24 62:1 65:4,10 79:17 83:21 85:15 97:19 106:5,6 123:7 131:6,11 132:24 141:5 142:3 142:7 153:10 161:14 171:4,25 179:11 185:19,22 192:7 193:2,12,19 198:10 210:7 214:10 215:5 235:5 235:22 237:7 242:24 256:19 257:1 260:14 273:16</p> <p><b>reporter (9)</b> 1:13,13 4:19 37:22 132:11 134:12 205:20 307:5,5</p> <p><b>REPORTER'S (1)</b> 307:1</p> <p><b>reporting (4)</b> 4:17,20 74:2 256:17</p>
---	---	--	--	--

<b>reports (39)</b> 72:3 76:4 87:22,24 102:9,25 103:8 114:7,8 115:13 122:18,20 157:1 161:21 165:5 175:5 177:9 193:12 197:23 207:2 218:5 232:23,24 236:2,17 236:18 238:4,20,25 239:9 242:3 255:9 255:23 256:16 270:5 299:5,8 302:7 305:3 <b>represent (1)</b> 279:10 <b>represented (1)</b> 30:25 <b>representing (2)</b> 280:24 284:5 <b>represents (1)</b> 279:3 <b>request (13)</b> 34:19 66:9 67:22 70:21 126:21 164:6 176:20 198:1 202:8 204:15 239:18 259:8 285:19 <b>requested (2)</b> 34:5 307:21 <b>required (4)</b> 21:7 68:11 92:25 307:25 <b>requirement (1)</b> 93:10 <b>research (12)</b> 10:22 17:5 24:25 25:3 26:13 27:13 28:22 28:24 30:8 56:6 79:10 260:9 <b>reservations (1)</b> 82:12 <b>reserve (1)</b> 303:3 <b>reserved (1)</b> 182:22 <b>Residues (1)</b> 104:8 <b>resolve (2)</b> 234:10 235:8 <b>resources (1)</b> 32:8 <b>respect (7)</b> 75:24 96:16 103:9 136:1 150:12 200:11 224:12	<b>respected (1)</b> 95:11 <b>respond (6)</b> 127:21 128:1 240:7 262:24 277:2,15 <b>responded (2)</b> 131:2 149:22 <b>response (26)</b> 22:12 35:2 93:9 108:23 111:19 123:20 130:4 151:14,19 185:5,7,9 189:2 198:4,6,8 231:23 232:4 240:16 266:19 267:15 274:9 277:3 277:5 282:14 291:20 <b>responses (4)</b> 139:13,20 151:24 277:13 <b>responsibility (1)</b> 260:8 <b>responsible (1)</b> 245:20 <b>rest (2)</b> 146:10 267:22 <b>restriction (2)</b> 218:20,20 <b>restrictions (1)</b> 20:23 <b>result (6)</b> 25:11 30:24 33:23 107:8 193:2 200:10 <b>results (19)</b> 16:1 24:14 30:23 33:9 34:16,21 36:2,15 57:4 103:21 105:4 107:2 119:17 162:6 165:20 178:24 207:23 210:24 219:15 <b>retained (3)</b> 178:13 180:3 281:11 <b>rethink (1)</b> 189:16 <b>retired (1)</b> 296:13 <b>review (83)</b> 3:13,19 17:9,14,16 44:12 66:10 74:16 74:18 75:10 76:5 81:12 84:15 91:24 97:15 98:6,24 102:6 102:22 103:1 104:13,23 105:10	115:20 119:4,5 136:4 154:24 155:25 161:11 162:8 174:12 175:5 175:5,7,10,12 181:7 181:11,12,23,24 190:25 196:9 209:9 209:21 210:3 215:11 220:12,15 224:18 230:13,18 233:9 234:24 241:20 243:21,25 244:17,25 245:10 245:12,24,25 247:6 250:8 256:20 267:6 267:9 269:12,13,16 287:5 296:22 299:12,15,15,16,17 299:17,22,23 301:17 <b>reviewed (57)</b> 39:4,20 48:20 57:17 65:17 74:14 78:14 84:25 86:2 95:22,22 102:9 103:12 104:18 111:22,24 112:9,15,17,24 118:22 130:8 132:9 132:17 136:3 141:1 142:2 157:9 162:9 173:10,19 175:4 180:3,7 182:21 188:2 191:18 196:22 212:9 226:2 226:3 227:12,21,22 235:4 238:3,12 239:23 240:12,20 246:2 247:22 254:16 272:7 291:22 299:5 301:23 <b>reviewers (1)</b> 238:15 <b>reviewing (8)</b> 60:10 73:20 74:13 111:21 181:2 210:7 226:7 297:3 <b>reviews (4)</b> 17:9 75:25 112:2 299:19 <b>right (177)</b> 5:23 6:20 7:2,3,6 11:16,17 14:12 28:23 31:11 33:6,8 37:6,15 39:22 40:8 40:16 41:24 44:6,10	47:6,18 49:20 53:13 53:20 56:8,15 57:19 58:7,16 60:25 70:14 76:21 77:14,19 78:1 78:23 79:17 82:1,8 83:2,6,8,14,21 84:5 85:11 87:9,12,17 89:16 90:1,3 92:7 92:21,22 93:5 94:4 94:8,25 96:19,21 98:3 99:15,24 100:7 106:3 107:21 108:2 108:8 114:2 116:5 117:15,18 118:1,9 118:17 119:15,16 120:5 125:5 126:22 128:11,16 130:25 133:24 135:15 136:21 137:8,13 140:5 142:24 152:6 153:5,19 154:24 155:14 157:24 158:2 160:13 162:7 163:15 167:25 169:22 170:1 182:8 184:24 186:1 187:24 188:5 190:8 191:10,15 192:1,22 193:18,24 194:9 195:25 197:20 200:18 202:15,18 207:14 208:18 214:4,9,16,19,24 215:4,7 219:5 223:17 224:14,19 224:22 237:16 249:16 256:18 258:15,19 259:6 260:3 261:7 264:12 264:16 266:24 267:10,12,17 268:1 268:2,22 269:1,17 269:20 270:8,23 271:23 278:24 280:7 285:22,23 286:3 288:14 289:8 292:24 294:14 295:21 297:11 300:1 301:10 302:3 303:11 304:3,11 <b>ring (1)</b> 96:24 <b>risk (58)</b> 104:24,25 111:9,11 143:9,11 144:5,6,8 144:23 146:16,22	152:18 154:17,19 155:1,3 180:13,16 180:18 193:3,3 206:12,15 207:3,4,6 207:23,25 208:20 208:22 215:20 216:12 217:1 222:20,21 223:18 223:19,24 249:11 250:4 259:1,5 260:6 260:18,19 262:16 263:3,7 264:1,19 265:4,7,9 269:10 276:13,14,18 <b>risks (4)</b> 258:6,22 259:4 260:7 <b>road (1)</b> 133:7 <b>Robert (2)</b> 86:20 87:19 <b>Robertson (3)</b> 2:5 4:23,23 <b>Robyn (2)</b> 2:19 5:4 <b>ROC (1)</b> 301:7 <b>rodent (13)</b> 8:4 60:7,16 63:19 75:21 186:1,22,24 187:6 196:23 233:16 292:14 293:4 <b>rodents (3)</b> 124:19 293:1 294:7 <b>role (2)</b> 169:14 295:12 <b>roughly (2)</b> 296:9 302:11 <b>rounds (1)</b> 257:10 <b>Roundup (3)</b> 1:6 4:9 286:21 <b>routinely (3)</b> 28:15 260:19 296:23 <b>rules (2)</b> 4:4 19:17 <b>run (2)</b> 122:8 127:15 <hr/> <b>S</b> <hr/> <b>S (1)</b> 2:1 <b>S-a-u-e-r (1)</b> 93:16 <b>S-p-r-a-g-u-e (1)</b> 194:4
---	--	--	---	--

<b>S-t-e-m-m-e-r (1)</b> 85:22	272:8,13,19,20 273:20 281:15	50:5 51:8 54:20 55:17 57:8 59:17	271:23	201:8
<b>S-t-o-u-t (1)</b> 191:4	282:8,11,16	61:7 63:4,22 68:9 68:10,11,17,18,19	<b>selected (1)</b> 226:25	<b>sexes (6)</b> 48:24 51:2 55:1 57:15 64:9 200:23
<b>sacrifice (5)</b> 192:8,9,12,13	<b>scenarios (1)</b> 276:16	68:21 69:22 71:19 72:4,15 86:21 87:21	<b>selecting (1)</b> 228:14	<b>sheet (7)</b> 109:9,13,20 120:4,7 121:6 308:1
<b>sacrificed (1)</b> 191:25	<b>School (1)</b> 85:25	93:23 99:19 102:14 107:3,7,19 110:20	<b>selection (1)</b> 228:15	<b>sheets (1)</b> 109:12
<b>sacrifices (1)</b> 75:18	<b>Schwebda (1)</b> 160:10	110:21 114:20 115:8 119:24 121:9	<b>seminars (1)</b> 16:1	<b>shock (2)</b> 148:16 151:10
<b>safety (5)</b> 154:12 268:25 269:6 270:20,25	<b>science (7)</b> 98:10,21,24,24 100:5 249:9 295:10	124:25 127:20 132:16 134:21	<b>send (2)</b> 275:8 276:23	<b>shocked (2)</b> 150:11 151:3
<b>SAP (1)</b> 98:12	<b>scientific (18)</b> 14:21 15:11 58:14	137:1,4 140:14 142:10 164:13	<b>sending (2)</b> 277:5 282:23	<b>shocking (1)</b> 151:5
<b>sat (2)</b> 17:1 99:22	98:17 99:7,14 179:18 228:8	176:22,24 182:19 183:18 184:11	<b>sent (4)</b> 82:25 268:18 276:21 282:25	<b>shook (1)</b> 85:23
<b>satisfied (1)</b> 227:13	246:17 288:13,21 289:2,7,12,16,25 290:6,12	194:24 195:5,6 196:2,8 197:3	<b>sentence (15)</b> 6:13,19 7:6 14:20 15:5,5,7 19:5 58:12 58:20 129:12 259:25 260:5 271:20 272:10	<b>short (1)</b> 117:14
<b>Sauer (4)</b> 93:14,15 95:20 97:1	<b>scientist (8)</b> 73:1,11 101:25	199:14 200:2,19 201:6,19 203:15	<b>separate (1)</b> 121:1	<b>shorthand (1)</b> 307:8
<b>saw (34)</b> 60:21 69:14 70:23 79:8 84:6 86:6 91:2 92:4 93:24 94:11 97:15 98:6,16 104:23 123:9 149:14 164:24 166:1 167:5 190:3 198:5 219:16 220:15,17,23,24,25 220:25 221:1,3 223:8 231:10 268:20 272:18	211:22 212:23 213:23 216:7 217:21 218:7,10,11 218:19 219:20 222:13 224:17 228:4 234:4 244:13 248:14 249:12 253:15 255:8 260:1 262:5 267:2,8 268:6 268:17 270:11,18 271:12,15 272:15 274:10 275:13,21 276:25 277:2,9,19 282:7,9,11 283:1 284:21 291:23 294:1,22 295:3 297:5 303:25	201:6,19 203:15 211:22 212:23 213:23 216:7 217:21 218:7,10,11 218:19 219:20 222:13 224:17 228:4 234:4 244:13 248:14 249:12 253:15 255:8 260:1 262:5 267:2,8 268:6 268:17 270:11,18 271:12,15 272:15 274:10 275:13,21 276:25 277:2,9,19 282:7,9,11 283:1 284:21 291:23 294:1,22 295:3 297:5 303:25	<b>show (13)</b> 22:15,18 31:23 69:17 103:15 128:6 149:6 180:10 183:13 202:8 266:18 301:12,13	<b>showed (6)</b> 55:20 132:23 189:2 223:21 235:5 240:16
<b>saying (17)</b> 14:1 22:22 35:7 67:13 80:2 82:19 90:13 117:13 139:9,11 152:3 168:22,25 202:23 244:21 258:24 280:20	<b>scientists (2)</b> 34:14 179:24	222:13 224:17 228:4 234:4 244:13 248:14 249:12 253:15 255:8 260:1 262:5 267:2,8 268:6 268:17 270:11,18 271:12,15 272:15 274:10 275:13,21 276:25 277:2,9,19 282:7,9,11 283:1 284:21 291:23 294:1,22 295:3 297:5 303:25	<b>September (7)</b> 1:4,12 3:2 4:14 205:24 306:3 307:15	<b>showing (4)</b> 154:14 208:25 223:3 249:2
<b>says (54)</b> 5:25 6:12,21 9:5 10:25 14:19 15:2,10 15:15 20:14 21:17 22:18 44:16 47:14 48:13,14,18 55:14 71:21 85:16 91:9 100:24 101:9 166:6 170:8 180:2 195:10 203:11 209:10 254:15,24 255:17 258:20 260:6 264:14 268:23 269:2,14,15,18,21 270:19 271:8,10,23	<b>scope (3)</b> 146:21 153:21 301:16	228:4 234:4 244:13 248:14 249:12 253:15 255:8 260:1 262:5 267:2,8 268:6 268:17 270:11,18 271:12,15 272:15 274:10 275:13,21 276:25 277:2,9,19 282:7,9,11 283:1 284:21 291:23 294:1,22 295:3 297:5 303:25	<b>serious (2)</b> 43:10,11	<b>shown (6)</b> 8:7,8 210:2 262:13 292:21 304:1
	<b>scoured (1)</b> 44:18	297:5 303:25	<b>serve (1)</b> 236:9	<b>shows (3)</b> 167:1 234:25 304:21
	<b>screening (1)</b> 293:14	<b>seeing (9)</b> 42:21 78:17 79:5 110:8 141:4 165:17 176:25 195:1 295:9	<b>Services (2)</b> 256:22 301:2	<b>sic (1)</b> 35:19
	<b>search (1)</b> 255:22	<b>seen (37)</b> 43:24 54:25 57:1 62:18 65:11 68:15 92:3 104:12 110:11 126:10 140:11,17 140:19,20 141:14 144:10 145:17 146:7,11 153:24 161:14 165:14 168:7,14 176:8 191:9 195:6 247:22 248:8,9 254:25 255:6 257:2 272:17 278:13 284:24,25	<b>set (8)</b> 17:17 46:12 96:12,18 101:9 218:14 250:4 251:17	<b>side (9)</b> 27:4 85:23,23 261:9 261:11,13,14,20 262:21
	<b>searched (2)</b> 254:22 256:1	<b>sees (1)</b>	<b>setting (1)</b> 218:11	<b>sign (4)</b> 274:21,24 275:10 282:14
	<b>second (9)</b> 6:19,20 20:14 71:9 145:18 233:7 234:23 269:8 272:12		<b>seven (10)</b> 32:19 38:20 43:19 52:8 148:25 179:3 190:15 198:21 227:21 235:3	<b>signature (2)</b> 307:15 308:21
	<b>Secretary (2)</b> 256:22 301:1		<b>seven-line (1)</b> 284:21	<b>signed (4)</b> 275:1,6,14 282:18
	<b>section (4)</b> 243:23 245:2,23 250:24		<b>sex (9)</b> 36:3,16 64:21,22,25 65:12 110:22 201:7	<b>significance (19)</b> 39:16 42:12 43:25 87:17 108:18 153:3 194:20 199:10,17
	<b>sections (6)</b> 84:9,13,16,19 85:9,13			
	<b>see (146)</b> 7:5 8:5,12 9:1,8,18,19 11:9 12:21,25 23:17 23:25,25 24:11 25:9 26:2 31:14 32:23 33:16,16,17 35:17 36:7,13,25 42:9,20 44:1,10 45:1,4,9,10 45:17,18,20,20 46:9			

199:21 294:15,21 294:22,24 295:2,8 295:11,15 305:8 <b>significant (98)</b> 6:4,8,14 23:20 37:24 38:24 39:10 40:3 45:6 49:10 53:1 54:10 55:5,10 56:24 57:2 58:10 59:20 60:8,12,15,21 63:6 63:6,23 84:4 86:9 91:19 103:22,24 105:6 108:15 119:18 123:7 125:14,16,24 126:16 128:19 129:17 131:19 132:24 133:15 137:25 138:2,4,12 138:15,18 140:18 140:21,22 141:9 142:2 143:3 147:21 147:24 148:1,4,6 149:2 151:14,17,25 152:1,12 171:20 183:21 184:19 185:8,12,15,17 188:20 189:5 195:18 196:22 198:11,20,22,24 201:7 203:3,5 205:15 206:9,18 208:8,10 220:20 224:19 234:25 235:6,13,15 295:16 301:13,21 <b>significantly (11)</b> 39:7 55:22 61:10 65:18,21 128:22 141:6,15 149:1 182:24 188:14 <b>signing (4)</b> 280:17 307:21,23,25 <b>signs (2)</b> 105:13 213:16 <b>similar (8)</b> 9:10 23:15 25:25 27:6 114:6 266:1,14 301:6 <b>similarly (1)</b> 31:1 <b>single (8)</b> 58:18 59:7 61:22 62:9 76:1 188:11 232:11 239:23 <b>single-spaced (1)</b>	287:2 <b>sir (51)</b> 11:5 23:12 27:19 38:4 40:9 42:15 43:17 44:22 45:22 47:13 48:18 52:1 55:8 57:20 58:1 60:4 63:18 65:1 71:15 72:22 81:18 83:13 92:6 93:17 102:12 102:20 111:3 118:18 119:21 121:23 128:4 155:8 155:17 158:5 160:6 173:18 176:1 180:8 206:5 210:10 215:8 226:14 232:1,8 243:20 256:14 264:10 279:17,20 280:12 303:7 <b>sister (1)</b> 149:25 <b>sit (6)</b> 16:12 43:17 66:25 186:4 247:12 302:11 <b>site (13)</b> 27:12 37:16 45:10,11 62:3,5 64:5,24 76:15 175:18 176:18 177:5 218:4 <b>sites (7)</b> 18:4,10 46:9 54:20 60:18 64:11 203:8 <b>sitting (5)</b> 82:14 170:10 234:3 238:16 255:10 <b>situated (1)</b> 31:1 <b>situation (5)</b> 12:16 23:15 32:8 49:8 162:24 <b>six (15)</b> 75:21 84:9 128:10,18 129:15 174:22 195:14 200:17,22 201:12 202:4 284:13,17 288:25 302:12 <b>sixth (1)</b> 158:8 <b>skimmed (1)</b> 172:6 <b>skimming (2)</b> 44:1,9 <b>skin (1)</b>	165:15 <b>slash (2)</b> 215:6,6 <b>slides (34)</b> 74:19,22,23 75:3,10 75:20 76:1,3,4,5 83:1,18 85:4,11 86:2 87:8 90:16,22 91:11 94:25 95:21 95:23,25 96:2,10,15 96:24 97:3,7 98:6 98:23 99:2 101:21 101:23 <b>slight (1)</b> 301:14 <b>slightly (2)</b> 8:16 224:23 <b>small (1)</b> 117:8 <b>so-called (1)</b> 231:8 <b>solely (1)</b> 218:21 <b>somebody (2)</b> 74:5 101:8 <b>sooner (3)</b> 118:11 274:15 284:16 <b>sorry (103)</b> 9:25 13:16 14:1 16:23 18:22 19:24 22:12 25:18 31:18 36:21 37:22,23 41:1,5 42:1,4 47:24 48:1 55:3 65:6 70:18 77:11 80:1 82:16 83:9,16 84:8,10,10 85:19 88:7 92:19 95:25 96:25 98:20 100:10 110:20 112:18 113:13 116:3,4 118:22,25 119:13 122:22 123:1,2 129:25 130:21 132:11 134:14 137:12,14 139:17 142:21 148:19 149:16 152:24 162:17 164:4 167:24 168:4 168:11,11,24 169:4 173:25 174:7 175:24 179:22 186:6 190:15 193:14,16 196:6,16 200:9 205:5,7,20,21 205:22 210:20	214:17 224:9 227:21 240:13 242:11 246:25 248:2 250:12 252:12 259:17 271:3,7 277:10 280:10 281:23,25 288:7,13 299:7 304:9 <b>sort (3)</b> 109:22 197:25 294:20 <b>sound (4)</b> 36:22 194:18 230:13 300:14 <b>sounded (1)</b> 186:15 <b>sounds (5)</b> 83:6 153:13 166:21 186:2 187:20 <b>source (16)</b> 81:11,16 82:3,4,7 119:24 158:1 228:23 229:3 232:25 233:6,7,10 233:14 239:6,6 <b>speak (4)</b> 28:23 75:13 134:12 183:16 <b>spearheading (1)</b> 275:17 <b>special (4)</b> 28:21,21 123:15,17 <b>specialist (1)</b> 4:17 <b>species (33)</b> 28:18 31:8,10,24 32:13 33:2,11 34:17 34:22 35:2 39:25 45:10,11,17,19 46:10,19 50:1,6,7 51:2 54:15 57:5,9 57:10 62:4,5 64:2 64:10,14,22,25 66:1 <b>specific (11)</b> 8:17 9:22 28:14 50:10 51:24 78:19 119:2 226:25 241:12 289:7 290:1 <b>specifically (14)</b> 8:23 39:1 49:15 68:22 114:4 120:13 127:7 182:4 266:15 269:20 288:16 290:25 292:13 300:2 <b>specifics (1)</b>	141:4 <b>speculate (2)</b> 88:20 124:8 <b>speculation (6)</b> 75:12 226:10 229:23 274:5 276:2 300:19 <b>speed (1)</b> 51:25 <b>spell (1)</b> 160:12 <b>spelled (1)</b> 160:11 <b>spend (1)</b> 226:20 <b>spent (4)</b> 226:7,17 241:14 295:20 <b>spoke (1)</b> 249:21 <b>sponsor (7)</b> 100:13 113:3 118:21 135:15 160:10 220:1 224:22 <b>sponsored (4)</b> 102:8 155:9 174:10 209:22 <b>spontaneous (9)</b> 70:4 133:21 134:8 146:4,7,10,13 149:7 154:6 <b>spontaneously (1)</b> 147:2 <b>sporadically (1)</b> 178:2 <b>Sprague (1)</b> 194:4 <b>Sprague-Dawley (16)</b> 51:20,20 52:3,7 53:7 53:23 174:9 191:1 194:4 203:16 210:14,23 211:1,11 224:14 225:21 <b>spurious (2)</b> 71:7 107:8 <b>Squire (4)</b> 86:20,20,22,23 <b>ss (1)</b> 307:2 <b>stamp (1)</b> 259:14 <b>stand (1)</b> 295:23 <b>standard (14)</b> 181:19 214:21 216:18 216:19,22 217:14 217:22 248:22
--	--	---	---	---

253:12 254:5,6 257:18,20 293:23 <b>standards (2)</b> 244:14 304:11 <b>standpoint (3)</b> 81:10 163:10 239:10 <b>stands (2)</b> 79:10 295:24 <b>start (6)</b> 4:7 41:9 84:10 216:5 218:18 304:18 <b>started (6)</b> 5:17 177:16 234:17 277:12 278:2 290:22 <b>starting (2)</b> 241:9 244:6 <b>starts (1)</b> 234:24 <b>state (38)</b> 5:13 28:16 37:12 40:5 45:8 46:8 49:13 57:8 58:13,17 59:1 96:6 132:2,8 138:10 139:13,20 143:2 154:5 164:19 167:9 168:6 169:24 171:11 176:6 205:13 240:21 249:9 260:8,20 263:23 264:4,18 285:16 295:9 305:6 307:2,5 <b>stated (13)</b> 49:3 50:4 73:7 96:13 96:14 143:2,25 162:20 179:22 184:18 213:15 228:5 232:14 <b>statement (16)</b> 69:24 70:5,6 93:10 96:4 151:3 154:23 163:17,18,23 164:14 241:13 263:5,20 264:10 265:11 <b>states (19)</b> 1:1 4:10 10:5 27:20 57:13 78:23 83:12 98:11 114:1 142:16 142:22 168:13 242:22 255:15 270:17 280:24 283:7,24 284:6 <b>stating (4)</b> 36:10 66:15,16	113:16 <b>statistic (1)</b> 228:2 <b>statistical (22)</b> 42:11 43:25 84:2 87:17 108:18 124:22 129:23 130:9 142:5 153:2 165:21 206:21 227:19 294:15,20 294:22,24 295:2,8 295:11,15 305:8 <b>statistically (47)</b> 6:4,7 45:6 54:9 55:4 55:10 56:23 57:2 60:15 84:4 86:9 108:14 125:14,15 125:24 126:15 128:19,22 129:17 131:19 132:24 133:14 137:24 138:2,3,12,15,18 141:9 143:2 147:21 147:24 148:1 151:13,17 152:5,12 171:20 185:7,12,17 198:11 208:8 224:19 235:6 301:12,21 <b>statistician (2)</b> 124:5 153:22 <b>statisticians (12)</b> 119:23 120:2 124:12 125:20 126:9 127:15 206:23 227:25,25 228:16 228:17,23 <b>Stemmer (6)</b> 85:18,22 86:17,17 87:11 95:22 <b>step (2)</b> 84:16 253:6 <b>steps (4)</b> 250:1 253:7 262:10 262:17 <b>stick (1)</b> 252:11 <b>sticker (1)</b> 259:16 <b>stimulate (2)</b> 272:3,4 <b>Stonehocker (4)</b> 1:13 4:19 307:4,18 <b>Stoneybrook (1)</b> 83:15 <b>stop (7)</b>	57:20 118:15 230:23 230:23 231:5 286:3 286:5 <b>stopping (1)</b> 56:10 <b>Stout (14)</b> 53:10,11 191:1,3,7 193:17,19 195:21 204:12 207:12 209:12,15,17,22 <b>Stout's (1)</b> 194:2 <b>straight (2)</b> 81:23 233:20 <b>strain (14)</b> 31:10,10,24 32:12 62:3 66:20 133:25 145:21 146:7 175:19 176:18 177:6 194:3 224:24 <b>strains (9)</b> 31:8,23 33:3,4,5 46:25 164:3 211:5 211:12 <b>Strandberg (4)</b> 94:10,11,11,13 <b>Street (1)</b> 2:15 <b>strength (2)</b> 271:14 272:1 <b>strengthen (3)</b> 31:4 32:11 35:25 <b>strengthened (1)</b> 247:13 <b>strengthens (1)</b> 34:22 <b>strike (4)</b> 150:7,17 231:22 288:7 <b>string (1)</b> 202:10 <b>strong (4)</b> 38:13 64:17,23 148:14 <b>stuck (1)</b> 265:6 <b>studied (9)</b> 10:20 61:4 209:12 241:2,7 242:4 250:7 253:18 291:16 <b>studies (196)</b> 12:18 16:2 23:17 28:9 28:10,19 30:9 31:7 32:11,18 36:4 37:5 37:14,25 38:1,11,17 38:20,21 39:4,13,20	40:8,10,11,12,15,15 40:22,24 41:15 43:19 45:4 46:4 48:19 49:18 50:7,13 51:6,19 52:8,14 53:16,17,22 54:1,4 55:1,11,12,17,20,21 56:2,25 57:10 60:7 60:10,11,16 61:23 62:1,5,10,12,14 63:16,19,23 64:13 64:14 65:17,20 78:20 81:21,23 98:23 106:19 115:14,19 124:23 132:20 135:2 140:11,18,20,25 141:1,5,14 147:12 149:23 152:22 153:24 155:23 158:14 160:8 167:16,16,21,22 171:8,13 175:3 176:11 178:22,23 178:24 180:4 186:24 188:1,7,13 188:19 189:1,12 190:4,14,15,16,18 190:19 195:7,14 196:11 198:23 201:9 211:13 212:25 214:23 215:21 216:15 218:12 220:24 224:1,6 226:3,7 227:15,20,20,21,22 228:14 229:4 230:1 230:2 231:2 232:24 233:16,20,22,24 234:2 236:3,4,7,12 236:15,20 238:4,23 239:23 240:16,20 246:2,14 247:4,10 247:15,22,25 248:7 249:11 250:3,4 251:9 254:16 255:8 255:10 257:3,3,5,10 257:16,18 273:15 287:16,21 290:25 291:9,22 292:7 294:11 299:9 305:4 <b>study (477)</b> 6:5,16,17 7:7,8 8:5,12 9:8,12,17 10:24 11:23 12:11,15,21 12:23,25 13:4 15:14	16:6 23:18,20,23 24:3,11,14 25:9,11 26:1,4 28:11 29:3 30:25 31:7 33:9,23 33:23 36:4,15 38:2 38:16 41:22,23 42:8 42:12,21 43:23 45:4 45:5,9 46:10,13 48:12,13,18 51:20 51:21,23 52:3,5,6,7 52:9,16,17,20 53:3 53:6,7,9 57:13,16 58:3,18,19 59:7,16 59:18,21,25 60:6,25 61:7,16,22 62:9,23 63:2,13 64:21 65:3 65:11,14 67:3,4,6 68:17,23 69:1,3,4,5 69:6 70:8,8 71:17 72:3,8,16,18 73:3 73:21,24 74:2 75:4 75:15,24 76:2,24 78:16 81:4,5 84:5 84:14 85:4 98:13 99:8 100:11,13,18 101:23 102:2,6,7,9 102:11 103:1,8,15 103:21 104:11,16 105:4,7 106:1,10,12 106:16,18,19,25 107:6,9,12,23 110:17,20 111:1,10 111:13,23 112:8 113:3,5,6,8,12,15 114:7,7,8,18,22 115:1,10 118:19,22 118:24 119:1,3,6 123:6,6 125:23 126:10 127:17 128:5 130:9,10 131:14,14 132:20 134:25 135:13,14 135:14,25 136:5,7,8 136:15,20 137:3 138:21 141:8,22,22 142:1,6,18 143:3,15 144:1,1,11 145:1,3 146:14 147:5,14 148:3,8,11,20,22,24 148:25 149:11,18 150:2 151:19,21 154:13 155:5,5,9,16 155:19,20 156:18 156:23 157:1,4,11 157:15,16 159:5,10 159:18 160:5,7,12
---	---	---	--	---

160:13,16,16,20,24 161:4,10,12,15,19 161:21,23 162:6,9 162:10,12,16 163:9 163:11,21 164:16 164:21 165:3,7,12 165:16,21,23 166:1 166:4,6,10,14,16,22 166:24 167:2,5,6 169:20 170:1,5,15 173:9,16,21 174:3,4 174:10,14,25 175:6 176:8,15 179:13 180:7,15 181:2,9 182:22 183:1,5,13 183:17 184:22 185:10,20 187:16 187:16 189:3,5,17 190:3,6,25 191:1,7 191:9,13,16,21 192:8,21 193:5,13 193:24 194:3,11,13 194:16 195:9,9,15 195:20 197:20 198:13 199:1,11 200:14,24 203:4,11 203:15,24 204:12 205:9 206:14 207:12,17 208:17 209:15,16,18,22 210:2,7,11,18,22,25 211:16,17,19,24 212:2,4,20,23 213:4 213:8,9,13,14,21 215:1,2,10 216:1,10 217:6,7,10,12,13,20 218:5,13,16,24 219:15 220:1,4,11 220:13,18,19,22 221:5,7,9,18,19,25 222:16 223:2,5,7,13 223:20,21 224:13 224:13,18,23 225:8 225:10,20,24 227:1 232:11,23 233:9 234:9,13,16,16 235:24 236:8,10,15 236:16,17,18 237:1 237:5,22,23 238:3 238:19 239:3,8,10 239:18 251:9,16 253:9,13 254:7,9,11 255:13 257:21 273:18 290:16 292:2 297:14,15,20 297:23,25 301:12	301:17,20,22 304:21 <b>studying (1)</b> 218:22 <b>stuff (3)</b> 89:3 109:21 192:3 <b>subgroup (2)</b> 21:13 245:18 <b>subject (5)</b> 3:22 82:22 215:11 230:10 286:18 <b>subjected (1)</b> 210:2 <b>submission (1)</b> 88:17 <b>submit (2)</b> 17:13 282:22 <b>submitted (16)</b> 10:4 50:22 69:6 76:21 88:16 111:2 114:1 122:12,19 136:21 160:21 173:13 192:18 212:20 221:9 223:9 <b>subpoena (1)</b> 266:19 <b>subscribe (2)</b> 36:23 264:20 <b>SUBSCRIBED (1)</b> 308:22 <b>subsequent (1)</b> 124:4 <b>substance (17)</b> 29:19 30:10 31:21 33:25 36:1,18 69:25 244:17 250:7,16,16 252:1,1 258:3,23 260:16 304:1 <b>substances (2)</b> 256:23 258:18 <b>sufficient (19)</b> 18:13 19:8,25 20:1,5 20:7 21:1 22:1,25 23:6 37:6 162:12 163:11 208:5 241:18,20 246:17 257:9 297:1 <b>sufficiently (2)</b> 22:13 219:13 <b>suggested (2)</b> 31:20 172:15 <b>suggesting (3)</b> 19:13 90:11 186:17 <b>suggestion (2)</b> 99:1 283:15 <b>suggests (1)</b>	272:14 <b>Sugimoto (20)</b> 113:4,25 115:4,23 116:12 118:19 122:3 123:6 128:5 132:21,22,23 234:16,23 235:11 235:24 236:15 237:1,6,7 <b>suing (1)</b> 280:25 <b>suit (1)</b> 278:3 <b>summaries (8)</b> 132:17 158:4,13 171:7 191:24 235:4 299:13,15 <b>summarize (2)</b> 73:22 273:14 <b>summarized (1)</b> 109:14 <b>summary (24)</b> 3:9,10 39:11,21 47:14 47:17 48:3,4,5 116:20 132:9 158:17,19 181:8,13 181:15,17,24 229:18 230:1 232:10,11 235:10 299:24 <b>supplement (1)</b> 237:17 <b>support (6)</b> 3:7 11:8 37:6 58:5 236:12 257:2 <b>supporting (1)</b> 103:3 <b>supportive (1)</b> 58:20 <b>supports (2)</b> 30:23 37:14 <b>supposed (6)</b> 71:10 72:11 262:19 285:13 302:9,14 <b>supposedly (1)</b> 72:18 <b>sure (38)</b> 10:1 31:19 40:20 72:14 73:8 89:6,8 112:19 113:14 118:5 121:16 122:15 127:10 130:14 136:12 150:21 156:7 157:8 179:7 226:21 228:9 228:11 229:9,25	233:5 239:14 240:5 245:15 251:20 256:8 259:10 268:6 278:15 279:15 285:2 286:8 303:24 305:11 <b>Suresh (2)</b> 210:11 213:8 <b>surprise (4)</b> 151:10,12 153:17 231:9 <b>surprised (4)</b> 51:12 148:15 151:22 231:19 <b>surprising (13)</b> 45:21 46:15 47:6 54:19 68:18 150:2,8 150:8,15,17 184:15 199:4 204:17 <b>survival (11)</b> 161:14 166:17 182:23 182:24 183:4,19,21 184:20 214:11 219:17 221:1 <b>suspected (1)</b> 69:25 <b>Swenberg (3)</b> 99:24,25 100:4 <b>Swiss (15)</b> 38:2,13,16 41:23 47:2 47:12 48:12 155:5 156:23 159:4 160:13 169:17 170:13 171:13 173:8 <b>sworn (3)</b> 5:13 307:7 308:22 <b>symptoms (1)</b> 70:3 <b>Syngenta (6)</b> 224:3,22,22,23 225:7 225:12 <b>system (10)</b> 27:21 28:1 29:15,15 168:9,16 169:13,17 190:10,20 <b>systems (2)</b> 169:8 190:14	76:6,7,11,12,12 81:5 102:17,17 114:10 114:21 136:9 156:2 156:3,11 157:13 165:7 171:16 176:12 183:18 191:17,19 192:16 227:15 229:19 230:1 233:3,23 234:9,25 235:11 236:24 237:10,11 237:13,15,21,22 247:11 298:6 <b>tabular (1)</b> 76:14 <b>take (44)</b> 7:17 12:13 43:2,15,16 45:13 56:11 75:10 79:25 102:24 106:11 114:15 117:1,8,10,14,15,15 117:17 151:4 189:1 229:7,24 233:1,4,12 237:23 242:12 247:9,21 248:8 251:18 252:25 253:22,22 254:7 256:6 257:1 262:10 262:17 286:2,7 290:21 302:13 <b>talk (16)</b> 1:11 4:4 57:23 59:1 75:21 117:23 159:25 171:15 190:12 229:14 244:7 245:24 256:11 269:10 286:11 307:8 <b>talk (9)</b> 38:15 72:23 173:15 200:10 208:7 216:21 274:6 294:14 302:4 <b>talked (4)</b> 40:13 76:23 193:23 232:12 <b>talking (40)</b> 8:17 25:6 27:9 40:25 41:7 47:20 51:13,14 52:21 64:8 108:4 109:11 111:1 118:19 122:2,3,4 125:17 129:6 140:15 145:21,22 145:24 147:18 149:18,20 158:9
--	---	--	---	---

160:4 176:17 182:14 184:11 193:17 214:15 215:2 234:17,24 263:17 264:11 275:2 297:15 <b>technical (1)</b> 45:14 <b>telephone (1)</b> 5:6 <b>telephonically (1)</b> 2:10 <b>tell (20)</b> 43:14 74:12 101:25 127:2 139:4 166:13 178:8,13 187:3,8,9 192:5 211:25 212:11 231:17 234:19 263:15 294:19,19 298:17 <b>telling (2)</b> 219:6 230:23 <b>tells (1)</b> 150:1 <b>term (5)</b> 11:14 152:23 249:18 303:12 304:20 <b>terminal (1)</b> 192:13 <b>terminology (1)</b> 181:20 <b>terms (2)</b> 195:11 200:23 <b>test (37)</b> 12:11 28:18 31:21,23 33:10 34:9 68:5 69:25 71:10 108:9 108:10 109:1,10 111:7 116:7 119:18 119:20 120:3 121:22,24 124:17 125:2,22 177:19 198:2 219:13 221:4 239:20 250:16 252:1 290:25 291:10 293:2,8,10 293:15,25 <b>tested (7)</b> 8:2,24 23:14 54:21 61:7 63:3 292:14 <b>testes (7)</b> 26:6,15 61:3 176:7,16 182:7 220:20 <b>testicular (24)</b> 25:22 60:24 61:9,17 61:21 62:1,8 173:24	175:20 177:3 182:14,19 184:14 184:16 188:8,9,18 189:15,16 194:2,12 194:19 195:16 291:10 <b>testified (17)</b> 5:14 40:9 75:6 99:6 118:23 133:18 196:25 230:17 252:19 259:12,19 281:3 295:19 296:1 297:17,18 300:1 <b>testify (2)</b> 14:6 307:7 <b>testifying (7)</b> 23:8 86:12 94:19 96:4 97:10 153:22 175:22 <b>testimony (28)</b> 10:16 44:8 49:2 80:5 82:18 126:2,21 146:21 150:7,18 153:21 171:23 205:2 219:10 231:4 232:19 236:22 244:6 253:2 273:8 281:3,6 283:12,14 283:17 286:25 298:15 307:10 <b>testing (4)</b> 34:10 83:12 163:4 292:25 <b>tests (1)</b> 293:14 <b>thank (15)</b> 16:11 30:6 44:4 46:23 56:8 57:20 60:4 71:25 120:19,24 121:20 132:16 261:7 266:17 294:6 <b>thanks (3)</b> 134:22 167:25 231:6 <b>Thanksgiving (1)</b> 281:15 <b>thereabouts (1)</b> 278:1 <b>thing (11)</b> 8:16 41:6 70:23 107:11 125:5 126:6 139:11 175:23 224:21 230:8 257:11 <b>things (8)</b> 93:8 97:6 250:1 275:15,16,17,23	276:6 <b>think (85)</b> 11:6 16:9 24:24 28:16 31:17 32:18 33:4 41:3 45:12,15,16 48:21 52:18 60:10 69:11 70:6 79:5,10 80:19,19 81:24,25 86:1 93:13 98:2 100:3 101:24 109:7 109:7 118:3 121:21 126:2 133:19 135:1 136:7,18 138:24 139:5,9,23 141:12 145:8 147:5,7,14 153:24 154:9,17 155:13,22 157:21 158:15 159:8 161:6 161:10 162:10,18 166:3 174:11 179:10 181:17 188:19 202:17 209:2 219:12 220:9 226:4 233:2,18 234:4 236:21 237:22 243:20 244:8 249:14 265:1 265:1 273:6 281:21 284:12 286:2 287:11 298:11 302:15 304:12 <b>thinking (1)</b> 47:25 <b>third (7)</b> 4:18 5:22 22:4 113:3 137:12 145:19 235:3 <b>thought (15)</b> 36:5 40:25 43:4 51:22 97:3 99:5 134:18 139:7 161:10,22 165:2 172:18,22 189:21 255:1 <b>three (40)</b> 5:17,18 6:23 11:14,22 11:23 37:5,14 40:7 40:10,11,12,15,15 40:22,24 41:15,19 46:4,4 77:19 78:14 84:12,19 85:8 86:8 90:23 97:6,25 134:17 194:5,7 201:14 203:3 223:25 224:6 236:4 246:1,14 302:19 <b>threw (2)</b>	145:1 148:21 <b>throw (2)</b> 148:16 151:23 <b>throwing (1)</b> 275:16 <b>thyroid (10)</b> 26:24 62:20 205:3,8 205:14 207:12,18 207:24 208:4,7 <b>Tier (9)</b> 132:9,17 158:3,13 171:7,15 176:11 234:6 235:4 <b>time (67)</b> 22:4 33:18 35:12 43:3 43:15,16 45:19 46:14 50:8 54:21 56:12 57:11,22,25 62:6 79:2 83:6 84:3 87:6 117:4,22,25 123:14,15 126:19 127:6,9 134:13 159:24 160:2 170:19,24 192:8 200:2,3 203:1 226:6 226:17,19,21 229:13,16 230:19 241:3 242:15 247:11 256:10,13 268:12,13,14,20 269:19 273:1,17 274:13 275:16,20 283:4,20 286:10,13 288:2 295:20 301:23 305:24 307:8 <b>times (9)</b> 23:11 46:11 64:15 81:19 202:25 233:17 251:11 273:23 297:12 <b>tissues (1)</b> 220:21 <b>title (5)</b> 123:16 265:2,3,3,6 <b>titled (1)</b> 11:7 <b>today (22)</b> 14:2 16:20 23:8 35:15 43:18 66:25 68:4 139:7,10 170:10 172:11 173:3 186:4 202:8 234:3 238:16 255:11 288:25 294:18 295:19 297:12 300:2	<b>told (7)</b> 21:8 103:10 127:25 134:16 236:25 267:18 274:12 <b>tolerate (8)</b> 216:10 218:11,13,15 219:8 221:5 223:3 249:2 <b>tolerated (16)</b> 214:9 215:10 216:14 217:9 218:7 219:19 220:5 222:8,14,17 223:5 248:25 249:1 253:13,14 257:21 <b>tool (3)</b> 8:13 9:2,19 <b>top (4)</b> 134:7 176:5 193:20 221:4 <b>tossed (1)</b> 294:17 <b>total (4)</b> 66:10 188:5,17 193:8 <b>totally (7)</b> 213:2,3,7 230:6,9,14 232:16 <b>toto (1)</b> 201:14 <b>Tox (18)</b> 217:15,22 241:24 242:4,16 243:6,8 256:15 257:1 258:4 265:13,20 266:6,13 303:8,23 304:6,11 <b>toxicity (3)</b> 124:23 223:4 249:2 <b>toxicologist (3)</b> 64:20 101:6 153:22 <b>toxicologists (2)</b> 179:24 292:16 <b>toxicology (21)</b> 67:3 167:15,21,21 195:7 211:13 215:22 217:17 241:14 242:10 249:9 257:18 287:8 287:9 293:20,24 295:10,24 300:7,13 304:13 <b>Tracy (9)</b> 1:13 4:19 13:18 84:11 116:6 160:11 251:21 307:4,18 <b>traditional (1)</b> 124:17 <b>transcript (2)</b>
---	---	--	--	---

126:22 307:9 <b>transplant (1)</b> 28:18 <b>treat (1)</b> 223:2 <b>treated (14)</b> 103:25 107:2,4 178:3 180:11 197:9 198:6 203:12 212:4 214:1 219:17 295:3,5 298:21 <b>treating (1)</b> 214:22 <b>treatment (17)</b> 71:8 77:18 86:4,7 87:16 111:5,16 137:3,8 142:18 144:2 150:4 203:20 207:13,19 208:17 240:11 <b>treatment-related (6)</b> 138:20 183:4 192:25 213:15,17 221:12 <b>tremendous (1)</b> 231:9 <b>trend (29)</b> 6:5,14 108:9,10,11,20 108:21,24 109:1,10 111:15 123:7 131:16 137:10,16 138:4 143:17,19 144:12 148:1,6 151:20 152:1 171:20 185:14 203:18 208:10,25 235:1 <b>trends (4)</b> 70:1 203:3,5 208:3 <b>triangle (1)</b> 30:8 <b>trip (2)</b> 34:20 202:20 <b>tripping (1)</b> 202:21 <b>true (107)</b> 27:25 30:12 31:2 32:19 33:12 39:20 42:3 46:19 48:20 49:15 50:13 51:2,6 52:10 53:23,24 54:8 54:16 55:11 58:3 60:16 62:17,21,22 63:21 64:7 65:4,13 66:1 76:25 77:1 78:11 79:2 83:5 84:15 85:15 86:15	96:5,20 97:16 98:7 98:14,19,25 100:18 104:22 108:5,13 110:15 128:7 136:1 137:20 141:25 154:14 165:21 175:20 185:21 187:18 191:21 192:18 193:1,13 195:23 196:5,23 197:10 198:6,8 200:25 201:12,14 209:13 213:14 221:13 224:8 225:21 226:3 229:25 230:15,22 233:15,18 241:25 242:4 243:10 244:4 257:4 258:2,23 268:4 269:13 272:25 282:15 292:25 293:4,8 294:4,6,7,10 299:11 299:14 302:4,6 303:10 304:23 307:9 <b>truly (1)</b> 33:25 <b>truth (13)</b> 5:13 30:23 31:6,21 33:10 34:1,14 36:1 36:17 65:25 66:7,18 307:7 <b>try (6)</b> 88:13 239:16 249:25 250:20,22 286:18 <b>trying (10)</b> 34:20 123:9 151:9 174:6 202:6,20 248:25 250:11 269:7 277:22 <b>TSG (2)</b> 4:17,19 <b>tubule (15)</b> 41:20 71:5 77:17 78:15 79:1,16 80:16 82:21 83:20 84:4 105:23 106:2,10,13 121:25 <b>tubules (3)</b> 77:25 91:16,19 <b>Tuesday (1)</b> 267:1 <b>tumor (105)</b> 6:6 9:4,8 18:4 27:5,12 28:14 37:16 44:13	45:2,9,11,17,18 46:9 50:5 54:20 57:8,9 58:11 60:18 60:24 62:3,4,9 64:5 64:11,12,12,18,24 65:18 66:19 76:6,12 76:12 80:20 81:14 89:21,23 90:18 91:1 91:12 102:17 107:4 108:11 110:8,9 114:10,21 133:13 133:14 136:9 139:13,20 145:14 145:17 148:2,7 152:2 156:2,3,11 157:13 165:7 166:18 184:14,14 187:1 191:17,19 192:15 197:6 200:7 201:7 203:3,7 226:25 227:19 230:7 232:11,16,25 233:3,3,11,23 234:1 234:9,25 235:9,11 236:24 237:9,11,13 237:21,22 239:12 291:1 292:1 294:12 294:23 298:6,6 <b>tumors (181)</b> 8:1,22 9:15 10:17,18 11:1 12:7,12 15:15 15:19,23 16:3,8 18:5,11 23:16,21 25:23 26:6,8,10,15 26:21,24 40:7,14,25 41:4,8,14 42:6,9,13 42:17,21,24 43:19 43:24 44:23 45:5,13 45:19,20,23 46:4,11 46:12,18,24 47:9,11 48:11,19,23 49:9,14 51:5,13,15,23 53:18 53:25 54:7,10,15,25 55:5 56:24 60:11 61:3,9,17,21 62:1 62:20,25 63:5,8,14 63:21,24 65:2,8,10 65:20 68:15,20 70:2 71:7 85:7 87:16 97:21,23,24,24,25 99:13 103:23 105:5 106:6 108:25 121:25,25 122:9 124:18 138:5,14 140:19 141:5,13,13 143:21 144:13	146:7,10 147:2,7,7 147:9 149:2 151:17 151:20 173:24 175:16,18,20 176:7 176:9,16,18 177:3,5 178:2 180:17,22,22 180:23 182:7,9,11 182:14,19 185:21 188:13,18 189:4,6,7 191:24 192:7 194:2 194:12,19,24 195:16,19 198:25 199:2 203:21 206:13 207:1,5,8,9 207:13,18 208:7,16 208:23 209:11 221:2 229:19 247:15 291:10,11 292:8,14 293:1 297:5 298:20,22 <b>turn (1)</b> 295:1 <b>Turns (1)</b> 245:3 <b>twice (1)</b> 176:8 <b>twist (1)</b> 245:13 <b>two (63)</b> 33:2,4,4 34:21 35:2 37:25 38:1,11,17 46:10,25 49:18 50:12 51:5,19 53:15 53:16,17,22 55:11 55:12 74:1 86:4 91:10 97:19 98:17 98:21 99:10 100:3,5 105:24,24 106:13 119:9,10,12 121:1,4 121:4 122:18 128:10,10 151:21 151:23 185:1,1,11 185:11 188:13 194:5,5,6,7,7 219:16 229:7 251:13 268:19 271:11,22 302:9,15 302:17 <b>two-way (1)</b> 246:24 <b>two-year (4)</b> 139:14,21 215:24 224:13 <b>type (15)</b> 9:12 16:7 18:10 25:17 27:5 28:23 66:19	195:4 221:2 227:10 230:8 241:16 257:19 261:1 292:15 <b>typed (3)</b> 287:1,2,20 <b>types (4)</b> 46:11 146:6 203:3 254:6 <b>typewritten (1)</b> 307:9 <b>typical (1)</b> 77:12 <b>typo (3)</b> 6:18 12:1 134:16 <b>typos (1)</b> 5:17 <hr/> <b>U</b> <hr/> <b>U.S (3)</b> 160:21 166:5 212:20 <b>uh-huh (19)</b> 8:20 11:10 32:20 53:11,19 70:15 84:24 118:20 135:4 152:8 155:12 160:9 191:5 258:14,16 271:13 284:23 285:25 298:4 <b>ultimately (1)</b> 167:17 <b>unanimous (1)</b> 98:4 <b>unclear (1)</b> 168:20 <b>uncommon (1)</b> 216:9 <b>underlying (1)</b> 238:3 <b>understand (26)</b> 7:15 8:18 9:20 10:2,9 13:5,8,20,23 14:12 14:15 31:15,17 47:1 47:5 50:9 59:4 109:20 125:16 132:12 133:1 174:4 214:15 243:18 244:11 276:9 <b>understandable (1)</b> 48:17 <b>understanding (5)</b> 10:12 83:3 90:14 155:2 276:12 <b>understood (1)</b> 82:12 <b>unethical (1)</b>
--	---	--	--	--

293:10				
<b>unhappiness (1)</b>				
230:11				
<b>United (13)</b>				
1:1 4:10 78:22 83:12				
98:11 114:1 142:15				
142:22 242:22				
280:24 283:7,23				
284:6				
<b>University (2)</b>				
85:25 93:20				
<b>unlimited (2)</b>				
32:8,9				
<b>unquote (4)</b>				
70:4 71:8 105:13				
176:19				
<b>unrelated (3)</b>				
71:7 178:3 281:4				
<b>unreliable (3)</b>				
79:25 82:7 297:25				
<b>unsigned (1)</b>				
279:7				
<b>unusual (8)</b>				
45:8 46:9 50:5 57:8				
62:2 101:7 201:6				
302:18				
<b>updated (3)</b>				
302:8,9,19				
<b>updates (1)</b>				
302:7				
<b>upgrade (1)</b>				
97:24				
<b>upgraded (1)</b>				
97:25				
<b>upper (5)</b>				
121:13,15 215:16,23				
215:23				
<b>upwards (1)</b>				
75:19				
<b>use (21)</b>				
21:9 27:23 34:25 58:8				
67:4 81:20,21 107:5				
119:20 206:20				
213:6 229:4 230:7				
233:10 248:25				
251:10 262:6				
276:18 299:15,17				
304:20				
<b>uses (2)</b>				
249:4 301:6				
<b>usual (1)</b>				
102:17				
<b>usually (7)</b>				
32:23 45:15,16 103:5				
114:14 237:20,25				
	<b>V</b>			
	<b>vaguely (1)</b>			
	141:4			
	<b>valid (3)</b>			
	27:21 181:2 223:7			
	<b>validity (1)</b>			
	239:7			
	<b>valuable (1)</b>			
	34:16			
	<b>value (8)</b>			
	119:18 122:9 123:8			
	123:10 126:14			
	161:14 216:12			
	218:18			
	<b>variability (1)</b>			
	154:6			
	<b>variables (1)</b>			
	190:11			
	<b>variation (2)</b>			
	175:18 177:5			
	<b>variations (1)</b>			
	176:18			
	<b>various (5)</b>			
	33:3 146:6 191:24			
	193:19 305:4			
	<b>Varma (1)</b>			
	87:20			
	<b>vast (1)</b>			
	145:11			
	<b>verify (1)</b>			
	298:7			
	<b>version (8)</b>			
	11:12 86:13 281:16			
	282:9 302:15,22,24			
	302:25			
	<b>versions (2)</b>			
	302:12,20			
	<b>versus (5)</b>			
	103:25 107:2 181:16			
	219:17 224:20			
	<b>veterinarian (1)</b>			
	156:17			
	<b>veterinary (9)</b>			
	70:16 75:2,10 83:11			
	92:21 99:11 113:4			
	177:24 219:25			
	<b>video (1)</b>			
	4:17			
	<b>video-recorded (1)</b>			
	4:8			
	<b>Videographer (15)</b>			
	2:18 4:7 57:21,24			
	117:21,24 159:23			
	160:1 229:12,15			
	256:9,12 286:9,12			
	305:22			
		<b>videotape (3)</b>		
		1:4,10 305:23		
		<b>view (1)</b>		
		186:7		
		<b>viral (26)</b>		
		158:16 160:25 161:9		
		161:13,18 162:6,11		
		162:13,15,23 163:6		
		163:12,19,20		
		164:17,22 165:1,18		
		165:24 166:2,16		
		167:1,4,10,23		
		168:15		
		<b>virulent (2)</b>		
		195:11 197:8		
		<b>virus (3)</b>		
		168:8,8 169:5		
		<b>viruses (2)</b>		
		163:24 170:9		
		<b>vitae (1)</b>		
		241:7		
		<b>vol (2)</b>		
		3:13,18		
		<b>volume (1)</b>		
		267:4		
		<b>votes (1)</b>		
		245:22		
		<b>W</b>		
		<b>W (10)</b>		
		1:4,11,12 2:4 3:1,6		
		4:9 5:12 305:23		
		307:6		
		<b>W-e-b-e-r (1)</b>		
		159:9		
		<b>Wagstaff (357)</b>		
		2:3,3 3:4 4:21,22 5:5		
		5:16,25 6:25 7:2,4,6		
		9:24 10:8 11:22		
		12:17 13:10,25 14:7		
		14:13,25 15:6 16:16		
		18:16,20 19:12 21:3		
		22:3,7,11 23:3,10		
		28:3,6 29:11,20		
		31:12 32:1,4 33:13		
		34:2,10,18 35:9,16		
		36:6 37:9 38:9 40:1		
		40:17 41:3,9 42:7		
		43:2,6,11,21 44:7		
		44:14 45:25 46:6,20		
		47:19,23 48:25 49:4		
		50:2,14 51:9,12,24		
		52:21 54:17 56:9,14		
		57:6 61:24 62:15		
		64:4 65:5,15 66:9		
		66:21 67:21 69:13		
			70:21 71:9,18 72:10	
			73:5,14 74:9 75:5	
			75:12 78:6 79:3,18	
			80:4,18 81:7 82:9	
			82:17 83:22 86:11	
			88:1,19 91:22 92:2	
			93:7 94:18 96:3	
			97:9 99:1 101:2	
			106:4 107:15	
			109:16,22 110:16	
			110:18,24 111:8,25	
			115:5 116:8,24	
			117:7,12,20 118:3	
			118:13 120:5,11,14	
			120:17,20 121:1,9	
			121:15 122:14,21	
			124:7,20 125:6,18	
			125:25 126:11,17	
			127:3,18,25 129:2	
			129:10,19,24 131:9	
			133:5,22 134:15	
			135:16 136:6 139:8	
			139:16,22 140:13	
			141:24 142:9,19	
			143:6 144:3,18	
			145:15 146:20	
			150:6,13,21 151:6	
			152:14 153:4,20	
			154:15,25 155:21	
			157:12,20 158:25	
			159:14,17,22	
			160:18 161:2 164:1	
			164:4,18 168:2,17	
			169:9 171:22 172:5	
			172:10,15,20,23	
			173:2,6,11 175:21	
			176:20 177:7,18	
			178:5,12 179:14,20	
			180:12 181:6 182:1	
			183:12,24 184:6	
			185:13 186:9	
			187:19 188:22	
			189:19 190:22	
			192:10 193:15	
			194:14,22 196:4,15	
			196:24 197:16,24	
			199:6,13,24 200:15	
			201:2,15 202:7,13	
			202:17,23 204:7,14	
			204:17 205:16	
			206:11 207:21	
			208:19 209:5 210:4	
			210:19 212:5,15	
			213:6 216:19 219:9	
			221:16,24 222:4,10	
			222:18 223:16	
			226:9 227:6 229:6	
			229:11,22 232:3,18	
			236:5 239:17	
			240:14 243:1 244:5	
			244:18 248:11	
			250:10 251:17	
			252:3,9,18 253:2	
			255:19 256:6 259:8	
			259:16 261:4	
			262:22 263:17	
			264:4,8,11 265:16	
			265:22 266:8	
			267:19 268:7 270:1	
			270:9,15 271:4,17	
			271:19 272:3,9	
			274:4 276:1,24	
			277:7 278:11,14,16	
			278:21 279:6,14	
			280:2,8 281:2,18,21	
			281:24 282:1	
			283:10,15 285:1,3	
			285:10,19,25 286:3	
			286:6,15 288:6	
			289:5,11,23 290:5	
			290:11,20 291:15	
			292:24 293:13,19	
			294:4 298:4 300:10	
			301:10,25 303:2	
			305:7,14,16,20	
			<b>wait (4)</b>	
			150:6 157:25 225:3	
			278:14	
			<b>waived (1)</b>	
			307:23	
			<b>want (44)</b>	
			5:22 7:16,17 19:3	
			43:2,14,15 44:17,19	
			72:15 88:23 89:2	
			109:18 117:1,1,2,4	
			117:7,9,10,14 118:2	
			120:20 126:20	
			127:4,10,23 128:1	
			133:5 159:15,17,19	
			183:13 199:18	
			201:18 218:9 228:7	
			230:5 231	

<b>wants (1)</b> 218:7	88:4,9,14	<b>wondering (4)</b> 82:15 122:8 236:17 285:11	<b>writeup (1)</b> 39:17	302:17
<b>Ward (4)</b> 94:25 95:1,7 97:2	<b>websites (1)</b> 88:8	<b>Wood (10)</b> 135:5,6,24 136:15,21 220:1,2 221:8,25 223:5	<b>writing (7)</b> 258:12 287:24 288:1 288:10,23 291:7 300:20	<b>years (26)</b> 35:19 64:19 77:8,8 93:19 94:3,16 101:7 106:18 139:7 217:16 219:16 241:14,25 242:2,6,8 249:8,8,8 257:19 296:15,16,19 302:9 302:15
<b>Ward's (1)</b> 145:6	<b>week (1)</b> 268:19	<b>word (9)</b> 5:19 6:23 11:20 110:18 265:4,7 299:2 303:23 304:17	<b>written (19)</b> 30:7,13 32:2,6 92:13 92:16 115:13 134:19 183:7 184:8 185:23 186:3,16 187:21 196:21 233:8 245:16 260:11 299:19	<b>Yep (12)</b> 7:1,10 31:5 37:8 90:20 132:5,7 140:7 234:22 235:2,7 263:14
<b>Washington (5)</b> 2:15 86:25 93:19,20 94:17	<b>weeks (1)</b> 198:15	<b>worded (1)</b> 68:1	<b>wrong (15)</b> 36:22 41:6 49:1,4 127:2 134:10,15,17 134:19,22 175:23 200:5 249:18 296:12 299:2	<b>York (4)</b> 2:7,7 4:18,18
<b>wasn't (42)</b> 12:25 13:4 16:12 19:16 23:6 45:6 47:3 49:4 62:11,13 62:18 65:21 80:24 87:1 90:9 101:19,21 102:3 105:1 112:2 134:15 148:8 155:24 171:17,24 172:19 174:21 178:12 188:12,14 220:21 231:23 235:13,19 245:25 278:5 279:5 284:17 297:19 298:9,23 302:1	<b>weigh (1)</b> 299:12	<b>working (36)</b> 17:6,14,15 21:8,12,12 21:14 88:24 90:12 92:7,11,13,16,20,23 93:1 94:23 104:13 243:21 245:17,19 246:21,23 250:19 250:20,22 253:17 277:19 278:2 279:2 280:23 283:6,20,22 295:21 296:2	<b>wrote (22)</b> 31:6,13,14 34:11 35:24 87:18 97:7,11 113:15 114:15 175:15 180:4 258:15,17 259:13 260:3,5 280:22,22 281:24 291:5 298:11	<b>Yup (2)</b> 5:24 225:5
<b>was't (42)</b> 12:25 13:4 16:12 19:16 23:6 45:6 47:3 49:4 62:11,13 62:18 65:21 80:24 87:1 90:9 101:19,21 102:3 105:1 112:2 134:15 148:8 155:24 171:17,24 172:19 174:21 178:12 188:12,14 220:21 231:23 235:13,19 245:25 278:5 279:5 284:17 297:19 298:9,23 302:1	<b>weight (6)</b> 213:17 214:11 215:15 219:16 220:25 299:21	<b>worked (5)</b> 123:14 241:24 242:8 242:15 252:15	<b>X</b>	<b>Z</b>
<b>way (20)</b> 5:22 13:11 96:18 134:19,20 144:25 162:13 196:20 199:7 210:18,24 211:7 221:21 231:3 249:22 272:22 293:9,15 296:12 303:23	<b>Weitz (1)</b> 2:6	<b>work (9)</b> 123:19 241:2,9 246:22 254:4 257:19 262:7 275:20 281:3	<b>X (2)</b> 3:1 307:25	<b>zero (38)</b> 77:19,19,19 80:24,24 80:24 86:7 97:6 105:24,24 107:25 107:25,25 110:7,7 119:8,9,9,10,10,10 128:10 148:9 149:7 149:11,14 150:1,3 151:2,4 185:1,11 194:5,7 200:18,22 201:12,25
<b>we'll (2)</b> 7:19 121:3	<b>well-known (1)</b> 124:13	<b>world (8)</b> 32:7 244:3,16 254:17 276:16 293:20,24 301:9	<b>Y</b>	<b>0</b>
<b>we're (21)</b> 9:20 10:3 14:4 41:11 77:13 111:1 117:5,5 117:6,12 141:23 145:22 174:9 193:17 210:14 215:2 220:2 230:4 230:10 244:6 305:17	<b>weren't (14)</b> 39:6,7 53:25 54:3 57:1 60:12 65:3 82:23 140:10,19,21 141:6,14 184:5	<b>worldwide (1)</b> 216:18	<b>yeah (49)</b> 10:11 22:19 37:11 41:2,18,20 47:25 52:23 66:12 70:7 72:6 81:20 84:1 86:21 90:2 91:5,8 92:5 93:16 96:25 98:2 99:9 101:24 105:25,25 106:1 117:20 119:7 125:17 131:22 133:17 134:4 150:23 152:16 156:9,10 164:12 174:19 183:2 186:11 191:23 211:8 235:16 237:3 237:14 272:5 280:19 302:8 305:15	<b>Zoo (1)</b> 93:19
<b>we've (7)</b> 56:9 64:11 126:18 202:24 229:6 278:21 286:17	<b>West (1)</b> 4:14	<b>worry (7)</b> 248:19 249:15,18 252:15,20,22 253:5	<b>year (1)</b>	<b>0.62 (1)</b> 126:14
<b>weaken (1)</b> 272:1	<b>whatsoever (2)</b> 85:4 135:25	<b>wouldn't (15)</b> 36:23 50:4 51:12 72:6 74:25 79:21 106:23 109:15 184:14 202:19 211:4 228:7 238:8 240:2 274:11		<b>06 (1)</b> 123:8
<b>weakens (1)</b> 271:14	<b>WHEREOF (1)</b> 307:14	<b>wow (1)</b> 68:18		<b>1</b>
<b>Weber (1)</b> 159:9	<b>who've (1)</b> 29:4	<b>write (2)</b> 48:8 274:10		<b>1 (1)</b> 159:14
<b>website (3)</b>	<b>wide (2)</b> 91:16,18			<b>1-5 (1)</b> 222:5
	<b>widely (3)</b> 211:13 300:6 301:8			<b>1,000 (8)</b> 214:2,7,14,23 215:3 215:15 216:11,17
	<b>Wilshire (1)</b> 2:9			<b>1,500 (2)</b> 85:11,13
	<b>Wistar (9)</b> 148:25 210:11,15,22 211:2,11 219:14 225:2,5			<b>1.1 (1)</b> 301:14
	<b>withheld (1)</b> 302:1			<b>1:00 (4)</b> 117:8 118:7 159:24 159:25
	<b>witness (15)</b> 100:21 150:14 195:22 204:15 207:2 212:1 244:7 248:7 252:5 260:22 263:20,23 264:7 305:3 307:14			
	<b>witness's (1)</b> 150:10			

<b>10 (6)</b> 35:6 81:19 106:18 190:4 267:1 268:18	2:9 <b>12th (1)</b> 274:12	100:12 102:7 104:11 106:12 224:3,10	<b>21 (6)</b> 1:4,12 3:2 4:14 158:18 268:7	3:16,18 <b>28 (5)</b> 6:10,12 38:5 47:13 48:3
<b>10,000 (3)</b> 75:20 188:3,16	<b>130141 (1)</b> 1:25	<b>1996 (6)</b> 210:7,10 211:20 212:2 213:4 215:2	<b>21st (1)</b> 306:3	<b>281 (1)</b> 3:20
<b>10/19/15 (1)</b> 3:17	<b>1350 (1)</b> 2:15	<b>1997 (13)</b> 116:2,16 118:19 122:4 123:6 125:23 126:10 128:5 129:23 224:4 225:10,12,20	<b>22 (8)</b> 5:20,21 129:4 132:4 132:14,15 234:21 268:8	<b>284 (1)</b> 3:21
<b>10:17 (2)</b> 57:22,23	<b>14 (5)</b> 170:24 233:16 239:23 240:12,13		<b>22-1 (4)</b> 3:6 11:6 286:22,23	<b>286 (1)</b> 3:4
<b>10:34 (2)</b> 57:23,25	<b>14th (1)</b> 302:16	<hr/> <b>2</b> <hr/>	<b>22-10 (3)</b> 3:21 284:20 285:3	<b>29 (6)</b> 6:19,25 47:20 48:3 277:24 279:4
<b>100 (1)</b> 297:8	<b>15 (4)</b> 222:2,4,5 278:1		<b>22-2 (3)</b> 3:8 121:5,16	<hr/> <b>3</b> <hr/>
<b>10003 (1)</b> 2:7	<b>15th (1)</b> 145:19	<b>2 (1)</b> 193:8	<b>22-3 (3)</b> 3:10 121:12,14	<b>3 (2)</b> 188:4,17
<b>101 (3)</b> 287:6,21 290:12	<b>16-md-02741-VC (2)</b> 1:2 4:12	<b>2:06 (2)</b> 159:25 160:2	<b>22-4 (5)</b> 3:11 259:11 302:5,6 302:25	<b>3.4 (1)</b> 176:9
<b>11 (6)</b> 3:6 39:20 60:6 63:19 82:13 233:16	<b>18 (2)</b> 171:4 183:21	<b>20 (3)</b> 158:17 278:1 286:4	<b>22-5 (4)</b> 3:12 266:21 280:5 285:15	<b>3/29/15 (1)</b> 3:15
<b>11/10/15 (1)</b> 3:14	<b>18-month-old (1)</b> 183:10	<b>20,000 (2)</b> 193:6,21	<b>22-6 (2)</b> 3:15 278:6	<b>3:46 (2)</b> 229:13,14
<b>11/16/15 (1)</b> 3:20	<b>19 (2)</b> 35:18 130:17	<b>20005 (1)</b> 2:15	<b>22-7 (2)</b> 3:16 279:13	<b>30 (5)</b> 64:19 94:16 101:6 170:19 171:14
<b>11/9/15 (1)</b> 3:19	<b>197 (1)</b> 296:11	<b>2001 (7)</b> 148:24 155:11 160:7 224:3,22,25 225:8	<b>22-8 (3)</b> 3:18 279:21 281:22	<b>30,000 (2)</b> 188:3,17
<b>11:45 (1)</b> 116:25	<b>1970's (1)</b> 79:9	<b>2004 (5)</b> 3:11 258:13 259:9,13 302:10	<b>22-9 (3)</b> 3:20 281:14,24	<b>300 (7)</b> 181:3 187:23,25 189:17 190:6 193:22 220:9
<b>11:50 (3)</b> 117:13,22,23	<b>1981 (14)</b> 51:20 52:6,17,20 53:22 173:20 174:9 177:24 178:10 182:22 193:24 194:13 195:15 220:10	<b>2008 (1)</b> 296:13	<b>22nd (1)</b> 307:15	<b>300-page (1)</b> 164:5
<b>112 (12)</b> 16:12,19 17:1 78:11 241:2,3,10 267:5,6 267:8 269:24 280:15	<b>1983 (16)</b> 41:22 68:23 70:9 73:2 75:24 76:1,20,24 81:5 83:4 84:5 94:24 98:14,23 99:8 106:10	<b>2009 (7)</b> 135:14 136:21 141:22 143:3 144:2 220:1 221:8	<b>23 (3)</b> 129:5 136:24 159:11	<b>303 (1)</b> 3:3
<b>112-EFSA (2)</b> 3:13,19	<b>1986 (4)</b> 98:25 99:8,14 100:6	<b>201 (1)</b> 171:9	<b>24 (6)</b> 52:18,22 157:24 158:6 192:9 222:3	<b>32 (8)</b> 149:7,8,15 150:1 151:2 153:11,17 154:1
<b>11th (4)</b> 3:11 259:11 302:22 302:24	<b>1988 (4)</b> 35:4,8,15 36:11	<b>2014 (1)</b> 241:10	<b>24-month (2)</b> 77:12 183:22	<b>32-page (1)</b> 287:20
<b>12 (14)</b> 32:17 60:15 115:13 123:16 128:13,15 131:7 132:20 229:19 234:16 238:22 240:13 254:16 307:19	<b>1990 (12)</b> 51:8,20 52:2,6 53:6 53:23 190:25 192:21 195:20 204:12 207:12 209:21	<b>2015 (15)</b> 171:8 241:10 267:1 268:18,22 277:14 277:24 278:2 279:4 279:9,24,25 280:23 281:15 282:6	<b>25 (5)</b> 52:24 176:3,6 202:25 286:4	<b>32nd (1)</b> 287:2
<b>12/6/15 (1)</b> 3:22	<b>1991 (1)</b> 194:3	<b>2016 (7)</b> 138:8 142:17,23 144:17 151:2 205:22,25	<b>259 (1)</b> 3:11	<b>35 (5)</b> 257:19 296:14,15,16 296:19
<b>12:02 (2)</b> 117:23,25	<b>19924009337 (1)</b> 307:5	<b>2017 (9)</b> 1:4,12 3:2 4:15 159:11 302:11 306:3 307:15 308:23	<b>25th (1)</b> 202:8	<hr/> <b>4</b> <hr/>
<b>120 (1)</b> 3:8	<b>1993 (6)</b>	<b>2020 (1)</b> 307:19	<b>26 (1)</b> 282:6	<b>4 (5)</b> 119:13,14 130:17 153:11,17
<b>121 (1)</b> 3:10			<b>266 (1)</b> 3:12	<b>4,000 (1)</b> 177:10
<b>12100 (1)</b>			<b>271 (2)</b> 1:2 286:20	<b>4:08 (2)</b> 229:14,16
			<b>278 (1)</b> 3:15	
			<b>279 (2)</b>	

<p><b>4:47 (2)</b> 256:10,11 <b>40 (3)</b> 296:15,16,19 <b>40,000 (5)</b> 189:14 190:4 219:1,3 219:12 <b>41 (3)</b> 126:25 127:22 171:6 <b>42 (3)</b> 126:25,25 127:23 <b>43 (2)</b> 198:17,18 <b>45 (1)</b> 198:19 <b>48 (1)</b> 198:21 <b>49 (1)</b> 198:20</p>	<hr/> <p style="text-align: center;"><b>7</b></p> <hr/> <p><b>7 (3)</b> 3:3 198:6 285:16 <b>7.1 (1)</b> 78:25 <b>700 (2)</b> 2:6 174:22 <b>70s (1)</b> 296:12 <b>7171 (3)</b> 1:12 2:4 4:13 <b>74 (1)</b> 7:7 <b>747 (1)</b> 4:18 <b>75 (1)</b> 297:8 <b>77 (1)</b> 296:11 <b>78 (4)</b> 6:16,21 7:7 296:11</p>			
<hr/> <p style="text-align: center;"><b>5</b></p> <hr/> <p><b>5 (8)</b> 198:6 215:25 216:3,4 218:15,16,17 264:6 <b>5,000 (2)</b> 174:17,18 <b>5:01 (2)</b> 256:11,13 <b>5:41 (2)</b> 286:10,11 <b>50 (3)</b> 134:4 222:4 304:22 <b>50,000 (4)</b> 215:25 216:9 218:7 219:7 <b>51 (1)</b> 148:10 <b>54 (1)</b> 198:15 <b>55 (1)</b> 198:15 <b>58 (1)</b> 170:24</p>	<hr/> <p style="text-align: center;"><b>8</b></p> <hr/> <p><b>8 (2)</b> 198:6 285:16 <b>80's (1)</b> 79:9 <b>800 (1)</b> 179:3 <b>80226 (2)</b> 1:12 2:4 <b>83 (1)</b> 70:10 <b>84 (1)</b> 83:4 <b>86 (1)</b> 6:3 <b>87 (1)</b> 158:12</p>			
<hr/> <p style="text-align: center;"><b>6</b></p> <hr/> <p><b>6 (2)</b> 170:19 171:14 <b>6.7 (1)</b> 176:9 <b>6:02 (2)</b> 286:11,13 <b>6:25 (2)</b> 305:24 306:2 <b>60 (1)</b> 85:10</p>	<hr/> <p style="text-align: center;"><b>9</b></p> <hr/> <p><b>9 (4)</b> 268:22 279:24,25 285:16 <b>9:03 (2)</b> 1:12 4:15 <b>90's (1)</b> 79:9 <b>90025 (1)</b> 2:9</p>			

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

IN RE: ROUNDUP PRODUCTS  
LIABILITY LITIGATION


MDL No. 2741

Case No. 16-md-02741-VC

This document relates to:

ALL ACTIONS

**EXPERT REPORT OF DR. CHARLES W. JAMESON, Ph.D.  
IN SUPPORT OF GENERAL CAUSATION  
ON BEHALF OF PLAINTIFFS**



Charles William Jameson, Ph.D.  
Independent Consultant  
May 12, 2017

**Statement of Purpose**

I have been asked to provide my expert opinions regarding the carcinogenic potential of glyphosate and glyphosate-based formulations. As a chemist and toxicologist, I evaluated the association of cancer, including non-Hodgkin's lymphoma ("NHL"), with exposure to glyphosate and/or glyphosate-based formulations. In performing my analysis, I relied on standard methods used in toxicology. I reviewed published, peer-reviewed scientific literature, publically available Government and Industry documents, and internal company documents and studies provided to me. All my opinions expressed in this report are based on a reasonable degree of scientific certainty. I reserve the right to supplement this report if additional information becomes available that are relevant to my opinions.

**Qualifications**

I am a private consultant in environmental toxicology specializing in carcinogenesis. I received my undergraduate degree in chemistry in 1970 from Mount Saint Mary's College, Emmitsburg, Maryland, and my Ph.D. in Organic Chemistry in 1975 from the University of Maryland, College Park. I started my career in 1965 where, as a rising high school senior, I spent the summer at a bioassay research laboratory first as a mouse room tech cleaning cages and later as an assistant in the chemistry lab mixing pesticides in rodent feed for the bioassay studies. Upon completion of my Ph.D. and a brief post-doc at the University of Maryland, I began working in 1976 as a contractor to the National Institutes of Health's (NIH) National Cancer Institute (NCI), serving as a senior chemist in support of NCI's Rodent Bioassay Program. In this capacity I was responsible for helping to monitor and evaluate the chemistry performed at the NCI's contract bioassay laboratories. In addition, I also provided support to the NCI staff for the identification of new substances to be studied in the NCI Bioassay Program. This

support included preparing and providing the background data from the scientific literature concerning exposure and the carcinogenic potential of the substance of interest. I was recruited by, and joined, the NCI in 1979 to serve as the chief chemist for their Rodent Bioassay Program and was responsible for directing and monitoring all chemistry activities, participating in the development of experimental protocols for the 2 year rodent bioassays conducted at the contract laboratories, and doing on-site inspections of all bioassay contract labs to insure they were following our protocols. In addition, I took over the responsibility as secretary for the NCI's Chemical Selection Working Group (CSWG) where I coordinated all activities for the identification of new substances to be studied in the Bioassay Program, including the oversight of the scientific literature searching, gathering and summarization process, documentation of the CSWG's review of the data and recommendations for study by the NCI, and the forwarding of the recommendation to the Director of the NCI Bioassay Program.

Following the formation of the National Toxicology Program (NTP) in 1978, the NCI Rodent Bioassay Program was transferred to the NIH's National Institute of Environmental Health Sciences (NIEHS) in 1980 where I transferred to and assumed the responsibility for all chemistry aspects of the NIEHS Division of Toxicology Research and Testing. I served as the program leader for chemistry in the National Toxicology Program (NTP) from 1978 until 1990. While chemistry program leader, I developed chemistry standards for bioassay studies that were widely accepted as an integral part of many toxicology-testing programs. I am listed as a contributor for the evaluation, interpretation and reporting of results for more than 100 chemicals studied in chronic two-year bioassay studies by the National Toxicology Program as published in the Technical Report Series (1980-1990). These bioassay studies were peer reviewed by the NTP Board of Scientific Counselors.

In 1990, I transferred to the NIEHS Director's Office and became involved with the NTP's Report on Carcinogens (RoC), working on it for more than 18 years, serving as its Director for 13 years before retiring from the NIEHS in February of 2008. The RoC is prepared in response to Section 301(b)(4) of the Public Health Service Act, which stipulates that the Secretary of the Department of Health and Human Services (DHHS) shall publish a report which contains a list of all substances which either are known or may reasonably be anticipated to be human carcinogens; and to which a significant

number of persons residing in the United States are exposed. This responsibility has been delegated by the Secretary to the Director, NTP. As Director of the RoC, I was responsible for the report's overall preparation, review and approval for the Director, NIEHS/NTP. In this capacity, I coordinated all review activities related to the RoC, which is one of the most visible and highly scrutinized activities of the NTP and the DHHS. I oversaw the identification and review of all new nominations for listing and delisting in upcoming editions of the RoC. I served as Chairman of the NIEHS RoC Review Committee, Chairman of the NTP Executive Committee's Interagency Working Group for the RoC, and Advisor to the NTP's Board of Scientific Counselors' Subcommittee for the RoC. I supervised the review of each nomination to the RoC, insuring all relevant information and data for each nomination was available for the review committees and managed the reviews by the three scientific review committees. Shortly after I became Director of the RoC in 1995, the Director, NTP, ordered that a review of the RoC be done to broaden input into its preparation, broaden the scope of scientific review associated with the Report, and provide review of the criteria used for inclusion of substances in the RoC. I coordinated this activity, which lead to revised criteria for the RoC being approved by the Secretary, DHHS in July of 1996. I served as Project Officer for the resource support contract for the preparation of the RoC, which included providing technical direction and coordination of the preparation of the documents prepared for each new nomination to the RoC as well as the preparation of 4 editions of the RoC for submission to the DHHS Secretary for approval.

I am the Senior Author for 69 NTP Report on Carcinogens Background Documents, which contained all available data concerning the exposure and potential carcinogenic activity of the substance being reviewed for possible listing in the RoC. I maintained a continuing liaison with other government agencies, private industries, other non-government research organizations and international organizations to keep abreast of work being done in chemical carcinogenesis, priorities for the listing of substances in the RoC, and resources available for the review of substances nominated for listing in the RoC. I served as the point of contact and focus for all RoC activities which included interacting with stakeholders from national and international government, industry, legal, consumer advocate, and other private concerns. I responded to requests for information from both the national and international press and private individuals on a

routine basis. Upon my retirement in 2008, I established CWJ Consulting LLC as a vehicle for providing expert consulting services in environmental toxicology specializing in carcinogenesis.

During my career, I participated as a Working Group Member for the United Nations' World Health Organization (WHO) International Agency for Research on Cancer (IARC). On several occasions, I served as either overall Chair of the Working Group or Chair of the Subgroup for Cancer in Experimental Animals evaluating cancer data and publishing monographs of the evaluation. I served as a consultant to the WHO, serving as a Task Group member to develop Environmental Health Criteria documents for partially halogenated chlorofluorocarbons (freons).

I am the author or co-author of over 80 peer reviewed scientific publications and nine book chapters. The vast majority of these publications relate to studies conducted in support of animal carcinogenesis bioassay programs. As mentioned above, I was the editor of four editions of the RoC, senior author for 69 NTP RoC Background Documents for substances reviewed for listing in the Report and listed as a contributor for the evaluation, interpretation and reporting of results for more than 100 chemicals studied in chronic two-year bioassay studies by the NTP as published in the Technical Report Series (1980-1990). I co-edited two books: "Chemistry for Toxicity Testing" and "Health and Safety for Toxicity Testing." A copy of my current curriculum vitae is attached as Exhibit A.

### **International Agency for Research on Cancer (IARC)**

As an introduction, I would like to explain the International Agency for Research on Cancer's (IARC) review of glyphosate to assess its potential carcinogenicity, and the development of Monograph 112. The Working Group classified glyphosate as "probably carcinogenic to humans" (Group 2A) at their meeting in March of 2015. Following this meeting, there have been a number of publications (including, but not limited to, Williams et al.<sup>1, 2</sup>; Chang and Delzell<sup>3</sup>, Solomon<sup>4</sup>) criticizing the IARC review process and conclusions.

The purpose of the *Monographs* is to render critical reviews and evaluations of carcinogenicity evidence of a wide range of human exposures.<sup>5</sup> The *Monographs*

represent a hazard identification that involves examination of all relevant information to assess the strength of the available evidence that an agent can cause human cancer. Identifying carcinogens is a key step in cancer prevention, and this activity represents an important international activity towards improving public health. The IARC Preamble<sup>5</sup> states that a “cancer ‘hazard’ is an agent that can cause cancer under some circumstances, while a cancer ‘risk’ is an estimate of the carcinogenic effects expected from exposure to a cancer hazard. The *Monographs* are an exercise in evaluating cancer hazards, despite the historical presence of the word ‘risks’ in the title. The distinction between hazard and risk is important, and the *Monographs* identify cancer hazards even when risks are very low at current exposure levels, because new uses or unforeseen exposures could engender risks that are significantly higher.” In other words, hazard assessment determines whether an agent can cause cancer.

For the review of glyphosate as it relates to Monograph 112, IARC performed a search for all relevant biological and epidemiological data from publically available sources and sent copies of the materials found to the Working Group participants approximately six months prior to the start of the meeting. In addition to the materials sent from IARC, Working Group participants perform their own independent search of the scientific literature. As the IARC Preamble notes, “with regard to epidemiological studies, cancer bioassays, and mechanistic and other relevant data, only reports that have been published or accepted for publication in the openly available scientific literature were reviewed.”<sup>5</sup> IARC also considers relevant and publically available material from US Environmental Protection Agency (“EPA”). Studies determined to be irrelevant, inadequate, or published too late to be adequately evaluated were cited but were not summarized. This process of data collection is typical of all IARC *Monographs* and is the body of literature used by the Working Group participants during each Monograph analysis.

The IARC Working Group meeting takes place at its headquarters in Lyon, France and lasts for approximately seven to eight days, where the Working Group will then finalize the texts and formulate its final evaluations. Participants are assigned to one of four subgroups covering either exposure data, cancer in humans, cancer in experimental animals, or mechanistic and other relevant data. Working Group participants are also assigned individual chemicals or agents being evaluated and asked to prepare preliminary

working papers for their specific subgroup that are then distributed prior to the meeting. The subgroups prepare joint drafts and summaries in breakout sessions during the first few days. The entire Working Group meets in brief plenary sessions every day to get updates on the progress of each individual subgroup and to discuss any issues the subgroups may have identified. The final days of the meeting consists of plenary session meetings to discuss all relevant data, review the subgroup drafts and develop the final evaluations. The entire Monograph volume is considered the joint product of the Working Group, and there are no individually authored sections.<sup>5</sup>

For Monograph 112, I served as Chairman of the subgroup for Cancer in Experimental Animals to assess the carcinogenicity of several organophosphate pesticides that included glyphosate, the active ingredient in Roundup®. This meeting was held March 3-10, 2015 and the Working Group classified glyphosate as “probably carcinogenic to humans” (Group 2A). This classification was based on limited evidence in humans for the carcinogenicity of glyphosate where a positive association has been observed for NHL, sufficient evidence in experimental animals for the carcinogenicity of glyphosate and that mechanistic and other relevant data support the classification of glyphosate in Group 2A. To provide a better understanding of this, I will: discuss the process used by the Working Group to arrive at this classification, define terms, explain the types of evidence considered, explain the scientific criteria that guide the evaluations, and explain how conclusions were reached throughout the process.

The following summary of the Working Group’s evaluation of the available literature is offered here, but also found in the IARC’s Preamble<sup>5</sup>:

- Exposure Data: The Working Group concluded there is wide spread exposure to glyphosate based on its use as the active ingredient in Roundup® which is a broad-spectrum herbicide. Glyphosate is the most heavily used herbicide in the world<sup>6</sup> and can be found in soil, air, surface water, groundwater, and food. According to several studies, glyphosate has also been detected in urine from persons around the world.<sup>7-10</sup> The general population is mainly exposed to glyphosate through diet and from use as a household weed control.

- Cancer in Humans: The Working Group identified seven reports from the Agricultural Health Study (AHS) cohort and numerous reports from case-control studies

in the evaluation of the epidemiological studies reporting on cancer risks associated with exposure to glyphosate. This Working Group applied the Bradford Hill criteria in its analyses and determined that in several case–control studies there was an increased risks for NHL due to glyphosate exposure.<sup>11-18</sup> The Working Group further noted that the increased risk for NHL persisted in the studies that adjusted for exposure to other pesticides. The Working Group concluded a positive association has been observed for exposure to glyphosate and NHL and that there is “limited evidence” in humans for the carcinogenicity of glyphosate. IARC determines limited evidence of carcinogenicity for an agent when “a positive association has been observed between exposure to the agent and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or confounding could not be ruled out with reasonable confidence.”<sup>5</sup>

•**Cancer in Experimental Animals:** The Working Group reviewed scientific literature and reports including two studies in which glyphosate was reported to be tested for carcinogenicity in male and female mice by dietary administration, five studies that tested glyphosate in male and female rats by dietary administration and in drinking-water in one study. Studies of a glyphosate-based formulation tested in drinking-water in one study in male and female rats and by skin application in one initiation–promotion study in male mice were also reviewed. They observed that in one feeding study in male CD-1 mice,<sup>19-22</sup> glyphosate induced a positive trend in the incidence of kidney renal tubule carcinoma, a rare tumor in this strain of mice. A second feeding study<sup>23</sup> reported a positive trend for hemangiosarcoma (a blood vessel tumor) in male mice. Glyphosate also increased pancreatic islet-cell adenoma in male rats in two feeding studies.<sup>24-26</sup> The Working Group concluded there is “sufficient evidence” in experimental animals for the carcinogenicity of glyphosate. IARC defines “sufficient evidence” in experimental animals is as “a causal relationship has been established between the agent and an increased incidence of malignant neoplasms or of an appropriate combination of benign and malignant neoplasms in (a) two or more species of animals or (b) two or more independent studies in one species carried out at different times or in different laboratories or under different protocols.”<sup>5</sup>

•**Mechanistic and Other Relevant Data:** The Working Group reported the mechanistic data literature contained strong evidence that glyphosate causes genotoxicity

and oxidative stress. The strong evidence of genotoxicity came from studies conducted in human cells in vitro,<sup>27-32</sup> in mammalian model systems in vivo<sup>27,32</sup> and in vitro,<sup>33,34</sup> and from studies in other non-mammalian organisms<sup>29,35,36,37</sup>, all of which yielded largely positive results. The Working Group also found strong evidence for genotoxicity caused by glyphosate-based formulations. There were three studies of genotoxicity end-points in community residents exposed to glyphosate-based formulations, two of which reported positive associations.<sup>38,39</sup> Strong evidence for oxidative stress was determined by studies conducted in human cells in vitro<sup>28,40,41</sup> and in many rodent tissues in vivo.<sup>32,42,43</sup> The Working Group found weak evidence that glyphosate or glyphosate-based formulations induce receptor-mediated effects,<sup>44,45</sup> may affect cell proliferation or death,<sup>44,46</sup> and may also affect the immune system in rodents<sup>47</sup> and fish.<sup>48,49</sup> The Working Group considered the body of evidence described above as a whole and reached an overall evaluation of Group 2A: glyphosate is probably carcinogenic to humans. IARC uses this category when evidence of carcinogenicity in humans is limited and evidence of carcinogenicity in experimental animals is sufficient.<sup>5</sup>

IARC uses the hazard identification process for its review, and this was done for Monograph 112. Hazard identification reflects the toxicological “law” of specificity of effects<sup>50</sup>. Hazard identification uses a strength of the evidence approach. As applied, the Working Groups for Monograph 112 rigorously assessed the toxicological, mechanistic, and epidemiological data to form a judgment regarding the likelihood that the agent produces cancer.

### **Information Reviewed**

During the course of work on this case, I reviewed the following materials:

- scientific literature relating to the carcinogenicity of glyphosate and/or glyphosate-based formulations;
- government documents relevant to assessing the carcinogenic hazard and risks associated with glyphosate and/or glyphosate-based formulations; and,
- various studies and documents produced in the litigation.

For a list of additional materials I reviewed, please see Exhibit B.

## **Description of the Methodology Used to Assess Carcinogenic Potential Associated with Exposure to Glyphosate and/or Glyphosate-Based Formulations.**

Toxicologists routinely assess the hazards to human health related to exposure to chemicals in the everyday environment using a process called hazard identification. A hazard is any agent that can cause harm or damage to humans, property, or the environment.<sup>51</sup> In other words, a hazard is any agent that can cause a specific damage. In this case, the hazard being examined is glyphosate and/or glyphosate-based formulations, the specific damage is NHL, and the hazard assessment I am making is to determine whether or not glyphosate and/or glyphosate-based formulations can cause NHL. The terms hazard and risk are often used interchangeably; however, these are two distinct terms. Risk is defined as the probability that exposure to a hazard will lead to a negative consequence, or more simply,  $\text{risk} = \text{hazard} \times \text{dose (exposure)}$ .<sup>52</sup>

Toxicology is the basis on which hazard identification is established. Hazard assessment has been used for over four decades by a wide variety of governmental and nongovernmental organizations to evaluate the potential adverse health effects from chemical exposures. Hazard identification is a standard tool used by toxicologists when they are trying to determine if exposure to a chemical(s) can cause an adverse health effect in humans and is the first step in risk analysis. Hazard identification is performed by identifying the chemical someone has been exposed to and then reviewing the available toxicity data to outline the spectrum of adverse effects that would be associated with exposure to that particular chemical.<sup>53</sup> The toxicity data could be from studies in humans, in whole animals, or in cells, or could be data collected on chemically-similar substances when data on the chemical of interest are limited.

I used the following criteria for my hazard based assessment of glyphosate and/or glyphosate-based formulations, that is based on the criteria I developed for the Report on Carcinogens<sup>54</sup> and is the same as defined and characterized by IARC<sup>5</sup>:

- Cancer in Humans – Numerous case-control studies and the Agricultural Health Study (AHS) cohort reporting on possible associations of cancer and exposure to glyphosate were evaluated for any evidence of a causal relationship between glyphosate and human cancer.

- “Sufficient” evidence is defined as when a causal relationship was established between exposure to glyphosate and cancer and that chance, bias and confounding could be ruled out.<sup>5</sup>
  - “Limited” evidence is defined as a positive association has been observed between exposure to glyphosate and cancer and a causal interpretation is credible but alternative explanations such as chance, bias or confounding could not be ruled out.<sup>5</sup>
  - “Inadequate” evidence is defined as available studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding a causal association between glyphosate exposure and cancer.<sup>5</sup>
- Cancer in Experimental Animals – the experimental animal studies reporting on possible associations of cancer and exposure to glyphosate were evaluated for any evidence of a causal relationship between glyphosate and cancer.
- “Sufficient” evidence is defined as a causal relationship between exposure to glyphosate and an increased incidence of malignant and/or a combination of malignant and benign tumors, in multiple species or at multiple tissue sites or from multiple studies, or by multiple routes of exposure, or to an unusual degree with regard to incidence, site, or type of tumor, or age at onset.<sup>5</sup>
  - “Limited” evidence is defined as the data suggest a carcinogenic effect but are limited for making a definitive evaluation because, e.g. the evidence of carcinogenicity is restricted to a single experiment; there are unresolved questions regarding the adequacy of the design, conduct or interpretation of the studies; or the agent increases the incidence only of benign neoplasms or lesions of uncertain neoplastic potentials.<sup>5</sup>
  - “Inadequate” evidence is defined as studies that cannot be interpreted to show either the presence or absence of a positive carcinogenic effect because of major qualitative or quantitative limitations such as inadequate numbers of animals, lack of adequate pathology, poor survival, major impurities in the test agent, too low a dose to see an effect, etc. It should be noted that although animal testing is routinely used to identify cancer hazard, the sites

of cancer observed in animals do not always correlate directly with the sites of cancer that would be observed in humans<sup>55</sup>. This can be due to the differences in metabolism in laboratory animals and humans, differences in pharmacokinetics, or differences in tissue reactivity (pharmacodynamics) between species. Animal studies, instead, are used to identify a threat of cancer that is applied to human health hazard assessment<sup>55</sup>. All chemicals known to induce cancer in humans, that have been studied under adequate experimental conditions, also cause cancer in laboratory animals<sup>55</sup> and underscores the concept that chemicals found to cause cancer in laboratory animals must be considered capable of causing cancer in humans.<sup>5</sup>

- Mechanistic and other data – studies containing data relevant to the possible mechanism(s) of glyphosate carcinogenesis (genetic toxicity, epigenetic effects, etc.) were also evaluated. Mechanistic data may provide evidence of carcinogenicity and help in assessing the relevance and importance of findings of cancer in animals and humans.<sup>5</sup>

### **Hazard Assessment of the Human Data for Glyphosate and/or Glyphosate-Based Formulations**

Before discussing the human data for glyphosate and/or glyphosate-based formulations, I will define the type of epidemiology studies that were reviewed:

- Case-Control Study - In a case-control study, investigators start by enrolling a group of people with disease. As a comparison group, the investigator then enrolls a group of people without disease (controls). Investigators then compare previous exposures between the two groups. The control group provides an estimate of the baseline or expected amount of exposure in that population. If the amount of exposure among the case group is substantially higher than the amount you would expect based on the control group, then illness is said to be associated with that exposure. The key in a case-control study is to identify an appropriate control group, comparable to the case group in most respects, to provide a reasonable estimate of the baseline or expected exposure.<sup>56</sup>

- Cohort Study - According to Centers for Disease Control and Prevention (CDC),<sup>57</sup> in a cohort study the epidemiologist records whether each study participant is exposed or not, and then tracks the participants to see if they develop the disease of interest. After a

period, the investigator compares the disease rate in the exposed group with the disease rate in the unexposed group. The unexposed group serves as the comparison group or control, providing an estimate of the baseline or expected amount of disease occurrence in the community. If the disease rate is substantively different in the exposed group compared to the unexposed group, the exposure is said to be associated with illness.

- **Meta-Analysis** – A meta-analysis is an important component of systematic review procedure that combines and analyzes quantitative and qualitative data from several separate but similar experiments or studies to test the pooled data for statistical significance. Combining the results of multiple studies produces a weighted average of the included study results and leads to a conclusion with greater statistical power and point estimate than would be possible from any individual study.

### **Case Control Studies**

- Cantor et al. (1992)<sup>14</sup> evaluated the incidence of NHL among males located in Iowa and Minnesota. A total of 622 men and 1245 population-based controls were included in the study. The association with farming occupation and specific agricultural exposures were evaluated. When compared with non-farmers, the positive associations (odds ratios) for NHL were significant at 1.2 (95% CI, 1.0–1.5) for men who had ever farmed, and not significant at 1.1 (95% CI, 0.7–1.9) for 26 exposed cases for ever handling glyphosate and adjusted for confounders (vital status, age, state, cigarette smoking status, family history of lymphohaematopoietic cancer, high-risk occupations, and high-risk exposures).

- DeRoos et al. (2003)<sup>11</sup> pooled the data from three case–control studies<sup>12–14</sup> to study pesticide exposures as risk factors for NHL in men. Of a total study population of 870 cases and 2569 controls, there were 650 cases and 1933 controls included for the analysis of 47 pesticides that also controlled for potential confounding by other pesticides. A positive association (odds ratios) for the association between exposure to glyphosate and NHL in the 36 cases exposed was reported to be significant at 2.1 (95% CI, 1.1–4.0) in the logistic regression analyses but not in the hierarchical regression analysis (which uses a more conservative adjustment estimate) at 1.6 (95% CI, 0.9–2.8).

- The effect of asthma as a modifier of the association between pesticide exposure and NHL was reported on by Lee et al. (2004)<sup>58</sup>. The study contained 872 cases diagnosed

with NHL, 45 of which had been told they also had asthma and 2381 matched controls, 132 reporting to have asthma. Individuals in the study group with a history of asthma had a non-significantly lower risk of NHL than non-asthmatics and no effect was seen with pesticide exposure. A positive associations (odds ratio) for NHL associated with glyphosate use were reported but were not significant at 1.4 (95% CI, 0.98–2.1; 53 exposed cases) among non-asthmatics and 1.2 (95% CI, 0.4–3.3; 6 exposed cases) for asthmatics, when compared with non-asthmatic non-exposed farmers.

- The associations between exposure to pesticides and NHL was studied by McDuffie et al. (2001)<sup>15</sup> in a multicenter population-based study that included 517 cases and 1506 controls among men of six Canadian provinces. A non-significant positive association (odds ratios) of 1.26 (95% CI, 0.87–1.80; 51 exposed cases; adjusted for age and province) and 1.20 (95% CI, 0.83–1.74, adjusted for age, province, high-risk exposures) were observed for exposure to glyphosate. In an analysis by frequency of exposure to glyphosate, participants with more than 2 days of exposure per year had a statistically significant positive association (odds ratio) of 2.12 (95% CI, 1.20–3.73, 23 exposed cases) compared with those with some, but less than 2 days of exposure.

- Nordstrom et al (1998)<sup>59</sup> conducted a study in Sweden on hairy cell leukemia (considered to be a subtype of NHL). There were 121 cases in men and 484 controls matched for age and sex. A non-significant age-adjusted positive association (odds ratio) of 3.1 (95% CI, 0.8–12; 4 exposed cases) was reported for exposure to glyphosate.

- Hardell and Eriksson (1999)<sup>60</sup> reported on the results of the incidence of NHL in men associated with pesticide exposure in four northern counties in Sweden and included 404 cases and 741 controls. The authors reported a non-significant positive association (odds ratio) for ever-use of glyphosate of 2.3 (95% CI, 0.4–13; 4 exposed cases) in an analysis of glyphosate only, and 5.8 (95% CI, 0.6–54) in a multivariable analysis.

- Hardell et al. (2002)<sup>17</sup> performed a pooled analysis of two case–control studies, one on NHL<sup>60</sup> and another on hairy cell leukemia.<sup>59</sup> These pooled analyses were based on 515 cases and 1141 controls. A significant positive association was found for exposure to glyphosate compared to controls (odds ratio, 3.04; 95% CI, 1.08–8.52; 8 exposed cases), but the positive association (odds ratio) decreased to a non-significant 1.85 (95% CI, 0.55–6.20) when study area, and vital status were considered.

•A large population based case–control study of exposure to pesticides as a risk factor for NHL in Sweden was conducted by Eriksson et al. (2008)<sup>18</sup>. There were 910 cases and 1016 controls included in the study. The association (odds ratio) for exposure to glyphosate to NHL was positive and significant at 2.02 (95% CI, 1.10–3.71) compared to controls, but positive and non-significant at 1.51 (95% CI, 0.77–2.94) when confounders that included exposure to other pesticides, age, sex, and year of diagnosis or enrolment were included in the analysis. When exposure to glyphosate for more than 10 days per year was considered, the positive association (odds ratio) was significant at 2.36 (95% CI, 1.04–5.37). Considering a latency period of greater than 10 years gave a positive association (odds ratio) that was also significant at 2.26 (95% CI, 1.16–4.40). The authors also reported an association with exposure to glyphosate and lymphoma subtypes. Positive associations were reported for most of the cancer forms, including B-cell lymphoma (odds ratio of 1.87; 95% CI, 0.998–3.51, non-significant) and the subcategory of small lymphocytic lymphoma/chronic lymphocytic leukemia (odds ratio of 3.35; 95% CI, 1.42–7.89, significant). These odds ratios were not adjusted for other pesticides.

•Orsi et al. (2009)<sup>61</sup> reported the results of a case–control study conducted in France. The study included 491 cases (244 cases of NHL, 87 cases of Hodgkin lymphoma, 104 of lymphoproliferative syndrome, and 56 cases of multiple myeloma), and 456 age- and sex-matched controls. Positive, non-significant associations (odds ratios) for any exposure to glyphosate were reported: 1.2 (95% CI, 0.6–2.1; 27 exposed cases) for all lymphoid neoplasms combined, 1.0 (95% CI, 0.5–2.2; 12 exposed cases) for NHL, 0.6 (95% CI, 0.2–2.1; 4 exposed cases) for lymphoproliferative syndrome, 2.4 (95% CI, 0.8–7.3) for multiple myeloma, and 1.7 (95% CI, 0.6–5.0; 6 exposed cases) for Hodgkin lymphoma, after adjusting for age, and socioeconomic category.

•Cocco et al. (2013)<sup>62</sup> performed a pooled analysis of case–control studies from six European countries to investigate the role of occupational exposure to specific groups of chemicals in the causation of lymphoma overall, B-cell lymphoma, and its most prevalent subtypes. A total of 2348 incident cases of lymphoma and 2462 controls were included in the study. Analyses were conducted for lymphoma and the most prevalent lymphoma subtypes and adjusted for age, sex, and education. A positive, non-significant association (odds ratio) of 3.1 (95% CI, 0.6–17.1) was reported for exposure to glyphosate and B-cell lymphoma.

I would note that the findings in the McDuffie et al. (2001)<sup>15</sup>; and Eriksson et al.<sup>18</sup> studies is significant because their results are supported by the results reported for micronucleus formation studies in the bone marrow of mice by Rank et al. (1993)<sup>63</sup> where a single dose caused no effect while Bolognesi et al. (1997)<sup>32</sup> and Manas et al. (2009)<sup>27</sup> reported that two daily doses of glyphosate did cause micronucleus formation in the bone marrow of mice in their studies. This implies that level of exposure is an important consideration in the formation of NHL from exposure to glyphosate.

### **Cohort Studies**

The Agricultural Health Study (AHS)<sup>64</sup> is a large prospective study of cancer and other health outcomes in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural, lifestyle and genetic factors affect the health of farming populations. More than 89,000 farmers and their spouses in Iowa and North Carolina have participated in the study. It is the only cohort study to date to have published findings on exposure to glyphosate and the risk of cancer at many different sites. My summary of the 7 papers available evaluating cancer incidence associated with pesticide use in the AHS cohort follows:

- No risk estimates and no significant exposure-response associations with cancer of the prostate and exposure to glyphosate were reported by Alavanja et al (1996).<sup>65</sup>

- DeRoos et al. (2005)<sup>66,67</sup> evaluated associations between glyphosate exposure and the incidence of cancer at multiple sites in this cohort including lung, melanoma, multiple myeloma, and NHL, oral cavity, colon, rectum, pancreas, kidney, bladder, prostate, and leukemia. No significant exposure–response association with cancer at any of these sites was found.

- Flower et al.,<sup>68</sup> reported the results of the analyses of risk of childhood cancer associated with pesticide application by the parents of 17,357 children of Iowa pesticide applicators from the AHS cohort. For all the children of the pesticide applicators, the risk of cancer was increased for all childhood cancers combined, for all lymphomas combined, and for Hodgkin lymphoma, compared with the general population. A non-significant association (odds ratio) for use of glyphosate and risk of childhood cancer was reported to be 0.61 (95% CI, 0.32–1.16; 13 exposed cases) for maternal use and 0.84 (95% CI, 0.35–

2.34; 6 exposed cases) for paternal use.

- The incidence of cancer of the breast among farmers' wives in the AHS cohort, which included 30,454 women with no history of cancer of the breast before enrolment was reported by Engel et al.,<sup>69</sup>. There was no difference in incidence of breast cancer for women who reported ever applying pesticides compared with the general population. A non-significant association (relative risk) for cancer of the breast was reported to be 0.9 (95% CI, 0.7–1.1; 82 cases) among women who had personally used glyphosate and a non-significant positive association (relative risk) of 1.3 (95% CI, 0.8–1.9; 109 cases) among women who never used pesticides but whose husband had used glyphosate.

- Lee et al.,<sup>70</sup> studied the relationship between exposure to agricultural pesticides and incidence of cancer of the colorectum in the AHS cohort. Non-significant positive associations (relative risks) with exposure to glyphosate was reported to be 1.2 (95% CI, 0.9–1.6) for cancers of the colorectum, and 1.6 (95% CI, 0.9–2.9) for cancers of the rectum. A non-positive association of 1.0 (95% CI, 0.7–1.5) was reported for cancers of the colon.

- Andreotti et al.,<sup>71</sup> used a case–control analysis nested in the AHS cohort to study associations between the use of pesticides and cancer of the pancreas. For pancreatic cancer, a positive association (odds ratio) for ever- versus never-exposure to glyphosate was found but not significant at 1.1 (95% CI, 0.6–1.7; 55 exposed cases) and for highest category of level of intensity-weighted lifetime days was also found but not significant at 1.2 (95% CI, 0.6–2.6; 19 exposed cases).

- Dennis et al.,<sup>72</sup> reported that exposure to glyphosate was not associated with cutaneous melanoma within the AHS cohort but did not report a risk estimate.

### **Meta-Analyses**

- Schinasi & Leon<sup>73</sup> conducted a systematic review and meta-analysis of NHL and occupational exposure to agricultural pesticides, including glyphosate. The meta-analysis for glyphosate included six studies (McDuffie et al.,<sup>15</sup> Hardell et al.,<sup>17</sup> DeRoos et al.,<sup>67,11</sup> Eriksson et al.,<sup>18</sup> and Orsi et al.<sup>61</sup>) and yielded a significant positive association (meta risk-ratio) of 1.5 (95% CI, 1.1–2.0) for exposure to glyphosate and NHL.

- IARC<sup>74</sup> conducted an additional meta-analysis of NHL and occupational exposure to agricultural pesticides, including glyphosate using data from Schinasi & Leon<sup>73</sup> and

included the fully adjusted risk estimates from the studies published by Hardell et al.,<sup>17</sup> and Eriksson et al.<sup>18</sup> After considering the adjusted estimates of the two Swedish studies in the meta-analysis, the positive association ( meta risk-ratio) was still significant at 1.3 (95% CI, 1.03–1.65).

•Chang and Delzell<sup>3</sup> also conducted a systematic review and meta-analysis to examine the relationship between glyphosate exposure and risk of lymphohematopoietic cancer including NHL, Hodgkin lymphoma, multiple myeloma, and leukemia. Their analysis showed a positive association (meta-relative risks or meta-RRs) and was statistically significant for the association between any versus no use of glyphosate and risk of NHL (meta-RR=1.3, 95% confidence interval (CI)=1.0–1.6, based on six studies) and multiple myeloma (meta-RR =1.4, 95% CI=1.0–1.9; four studies). The authors conducted four meta-analyses for NHL, all reporting to have a significant positive association (meta-RR) of 1.3 or 1.4 with 95% CIs ranging from (1.0-1.6) to (1.0-1.8). The authors concluded “we found marginally significant positive meta-RRs for the association between glyphosate use and risk of NHL.”

### Summary for Human Data

I have evaluated available epidemiology data. Based on my experience doing hazard assessments, I learned that epidemiologists consider case–control studies particularly valuable for determining the carcinogenicity of an agent because their design facilitates exposure assessment and reduces the potential for certain biases. My review of the literature finds that the two case-control studies from the United States and Canada, and the two case–control studies from Sweden indicated statistically significant positive associations between exposure to glyphosate and NHL. The Canadian study, McDuffie (2001)<sup>15</sup>, reported a positive association between glyphosate exposure and NHL for those case subjects with more than two days/year of exposure (odds ratio of 2.12 (95% CI, 1.20–3.73) when compared to those with less than two days exposure. Three studies reported excesses for NHL associated with exposure to glyphosate, after adjustment for other pesticides, De Roos (2003) reported a significant positive association (odds ratio) for a pooled US study<sup>11</sup> at 2.1 (95% CI, 1.1–4.0).; and the two Swedish studies (Hardell (2002)<sup>17</sup>, Eriksson (2008)<sup>18</sup>) reported significant positive associations of 3.04; 95% CI, 1.08–8.52

and 2.36 (95% CI, 1.04–5.37). The positive association from Hardell (2002)<sup>17</sup> decreased to non-significance (1.85 (95% CI, 0.55–6.2)) when study area, and vital status were considered. Subtype-specific analyses in a Eriksson (2008)<sup>18</sup> indicated positive associations for total NHL, as well as all subtypes, but this association was statistically significant only for the subgroup of lymphocytic lymphoma/chronic lymphocytic leukemia (odds ratio, 3.35; 95% CI, 1.42–7.89). A European study<sup>62</sup> based on few cases also indicated an elevated risk (OR, 3.1; 95% CI, 0.6–17.1) for B-cell lymphoma. A French hospital-based case–control study<sup>61</sup> did not find an association between exposure to glyphosate and NHL (OR, 1.0; 95% CI, 0.5–2.2) based on few exposed cases. For the evaluation of glyphosate, the Agricultural Health Study (AHS) is currently the only cohort study available providing information on its potential carcinogenicity and did not show an excess of NHL. There were three groups that did meta-analyses of the human data for an association between glyphosate use and NHL. Schinasi and Leon<sup>73</sup> reported a significant positive association (meta-RR) of 1.5 (95% CI, 1.1–2.0). The IARC study<sup>74</sup> showed a positive association (meta-RR) of 1.3 (95% CI, 1.03–1.65). Chang and Delzel<sup>3</sup> provided four separate meta-analyses, all of which are reported as having a significant association (meta-RR) of either 1.3 or 1.4 with CIs ranging from (1.0–1.6) to (1.0–1.8). When the data across all epidemiological studies are combined, results indicate a positive association between glyphosate exposure and NHL in humans.

Interpreting the epidemiology findings requires one to properly weight studies according to quality rather than simply count the number of positives and negatives. The pooled case–control analysis from the USA<sup>11</sup> contained 650 cases of NHL. It follows that the case-control studies provide a stronger assessment of the potential carcinogenicity of glyphosate. The case-control studies in the US<sup>11</sup>, Canada<sup>15</sup> and Sweden<sup>17,18</sup> indicate a significant positive association for NHL with exposure to glyphosate. This positive association was also observed in the studies that adjusted for other pesticides. The AHS cohort did not show an excess of NHL; however it reports on only 92 NHL cases in the unadjusted analysis.<sup>64</sup> The three meta-analyses I reviewed are good examples of objective evaluations and show a consistent positive association between glyphosate and NHL. Drawing on the Bradford-Hill criteria<sup>75</sup> for causality, I would state that the observations are consistent (relative risks and meta analyses are positive for the case control studies), significant, not specific, temporally observed, shows a biological gradient, and is coherent

with the animal evidence (discussed below). Using my stated criteria, I conclude there is “Limited” evidence for the carcinogenicity of glyphosate in humans, because a positive association has been observed between exposure to glyphosate and NHL, and a causal interpretation is creditable but alternative explanations such as chance, bias or confounding could not be completely ruled out.

### Hazard Assessment of the Experimental Animal Data for Glyphosate and/or Glyphosate-Based Formulations

Before discussing the experimental animal data for glyphosate and/or glyphosate-based formulations, I will define what is involved in a cancer bioassay in experimental animals. The basic cancer bioassay design has remained relatively constant for more than 40 years and consists of groups of 50 male and female mice and rats in each dose and control group. Treatment traditionally lasts for 24 months and commences when the animals are 6–8 weeks of age. Early bioassay studies involved two treatment groups plus a control group. The first treatment group was a high dose, referred to as a maximally tolerated dose (MTD), and the second treatment group was half that dose. More recent studies typically include three (and sometimes up to five) treatment groups plus the control group.

In the bioassays, I reviewed the nature and extent of impurities or contaminants, the animal species, strain, sex, numbers per group, age at start of treatment, route of exposure, dose levels, duration of exposure, survival and information on tumors. With regard to the tumors, I evaluated the incidence, latency, severity or multiplicity of neoplasms or preneoplastic lesions. Studies in experimental animals that I determined to be inadequate for evaluation (e.g. too short a duration, too few animals, poor survival) can be found at the end of my reference list.

#### **Cancer Bioassays in Mice**

•Knezevich and Hogan<sup>76</sup> (1983) were the authors of a report submitted to the Environmental Protection Agency (EPA)<sup>77</sup> by Monsanto in support of the registration of glyphosate as an herbicide. This report was also discussed in the paper by Greim<sup>78</sup> (referred to as Study 10). For 24 months, groups of 50 male and 50 female CD-1 mice received diets containing glyphosate (purity, 99.7%) at a concentration of 0, 1000, 5000,

or 30,000 ppm, ad libitum. The study observed no treatment-related effect on body weight in male and female mice at the lowest or intermediate dose, but a slight reduction in body weight in the male and female mice at the highest dose compared with controls. Survival in all dose groups was similar to controls. (It does not appear that a MTD was reached). There was a positive trend<sup>79</sup> ( $p = 0.016$ , trend test) in the incidence of renal tubule adenoma in dosed male mice: 0/49, 0/49, 1/50 (2%), 3/50 (6%). Renal tubule adenoma is a rare tumor in CD-1 mice. Historical control data from 14 studies conducted between 1977 and 1981 at the testing laboratory indicated that the mouse renal tumors ranged from 0 to 3% and the incidence in the current study (3/50; 6%) exceeded the upper limit of the historical control range by a factor of two. The rarity of this tumor in CD-1 mice is documented in a publication by Chandra and Frith<sup>80</sup> that reports only 1 out of 725 [0.14%] CD-1 male mice in their large historical database had developed renal cell tumors (one carcinoma). No tumors of the kidney were observed in the female mice. No other tumor sites were identified.

A re-evaluation of the original renal section was conducted by a Monsanto consulting pathologist who reported a small renal tubule adenoma in one control male mouse, which was not diagnosed as such in the original pathology report.<sup>81</sup> This finding was contrary to the initial findings of Bio/dynamics lab, the lab commissioned to complete this report. Following Monsanto's submission of the consulting pathologist's report, the EPA reported there was no difference in diagnoses between his and other pathologists' diagnoses with respect to kidney tumors in mid- and high-dose groups (i.e. 0/49, 0/49, 1/50 (2%), 3/50 (6%)). The EPA pathologist also indicated in his report<sup>79</sup> this data also shows a positive trend ( $p = 0.016$ , trend test) in the incidence of renal tubule adenoma in the dosed male mice. Regarding the questionable male control kidney, it was his opinion that the presence of a tumor cannot definitely be established. Nonetheless, the EPA requested additional renal sections be cut and evaluated from all male mice in the control and treated groups; this additional review found no additional tumors.<sup>81</sup> The EPA also requested that a pathology working group (PWG) be convened to evaluate the tumors of the kidney observed in male mice treated with glyphosate, including the additional renal sections.<sup>82</sup> Monsanto sponsored a PWG that reported the incidence of adenoma of the renal tubule was 1/49 (2%), 0/49, 0/50, 1/50 (2%)(not statistically significant); the incidence of carcinoma of the renal tubule was 0/49, 0/49, 1/50 (2%),

2/50 (4%) (which gives a significant  $p = 0.037$ , trend test for carcinoma); and the incidence of adenoma or carcinoma (combined) of the renal tubule was 1/49 (2%), 0/49, 1/50 (2%), 3/50 (6%) (which gives a significant  $p = 0.034$ , trend test for combined). The PWG did not discuss their finding of an adenoma in the control male mice or address the previous opinion that the presence of a tumor in the control male mice cannot definitely be established and concluded the kidney tumors were not compound related.<sup>83</sup> It is important to note that the renal tumor identified in the controls by the PWG after re-evaluation of the original slides was not seen in the re-sectioned kidney slides. My conclusion of the results discussed above is that there was a significant increase in the incidence of these rare kidney tumors in the CD-1 mouse, with a dose-related trend, which is caused by glyphosate. For the purpose of this hazard identification the increase the incidence of carcinoma of the renal tubule and the incidence of adenoma or carcinoma (combined) of the renal tubule in male mice is due to treatment with glyphosate that caused a significant, dose related increase of these rare tumors in male CD-1 mice.

•Atkinson et al.<sup>84</sup> (1993) were the authors of a report submitted to the EPA in support of the re-registration of glyphosate as an herbicide. This study was also discussed in the paper by Greim<sup>78</sup> (Study 11). Groups of 50 male and 50 female CD-1 mice were given diets containing glyphosate (purity, 98.6%) at a concentration that was adjusted weekly for the first 13 weeks and every 4 weeks thereafter to give doses of 0, 100, 300, or 1000 mg/kg bw, ad libitum, for 104 weeks. There was no treatment-related effect on body weight or survival in any of the dosed groups indicating a maximum tolerated dose was not achieved. The EPA reported<sup>77</sup> a statistically significant increase in the incidence of hemangiosarcoma (blood vessel tumor) in males – 0/47, 0/45, 0/50, 4/45 (9%) ( $p < 0.01$ , trend test), and non-significant increase in females – 0/50, 2/50 (4%), 0/50, 1/50 (2%). The EPA pointed out that the incidence in the high dose males was near the upper limit (0-8%) for the performing laboratory. However, if one looks at excerpts from the full report,<sup>84</sup> Table 15 (page 97) indicates that as few as 2 animals per dose group were examined histologically for this tumor. This would lead one to consider that the incidence of this tumor could have been higher in this study as more of these tumors could have been found if all 50 animals per dose group were examined. There was also reported a non-significant increase in the incidence of histiocytic sarcoma in the lymphoreticular/haemopoietic tissue in males – 0/50, 2/50 (4%), 0/50, 2/50 (4%), and

in females – 0/50, 3/50 (6%), 3/50 (6%), 1/50 (2%). The EPA stated<sup>77</sup> that for their risk analysis, the increase in hemangiosarcomas in male mice was not considered to be treatment-related. For the purpose of this hazard identification, I determined the increased incidence of hemangiosarcomas in male mice is due to the treatment with glyphosate that caused a significant dose related increase in the incidence of hemangiosarcoma in male CD-1 mice. This association may have been stronger if all the animals in this study had been examined histologically for this tumor.

•Greim<sup>78</sup> (Study 12, Sugimoto, K.) reported on a study submitted by Arysta Life Sciences to the EPA in support of the re-registration of glyphosate as an herbicide. Groups of ICR-CD-1 mice (50/sex/group) received diets containing glyphosate (94.6–97.6% pure) at 0, 1600, 8000 or 40,000 ppm for 18 months. Parameters evaluated included clinical signs, body weight, food consumption, hematology, clinical chemistry, and urinalysis, organ weights, gross necropsy and histopathological examination. The EPA reported<sup>77</sup> no adverse effects on survival were observed in either sex across the doses tested and there were no statistically significant increases in any tumor type in this study based on details provided by Greim<sup>78</sup>. A review of the tumor tables for this study (Sugimoto<sup>85</sup>) shows that there was a significant trend for the development of hemangiosarcomas in male mice (0/50; 0/50; 0/50; 2/50 (4%)) with a p-value for trend of 0.008, Chi-Square test; a significant trend for the development of malignant lymphomas in male mice (2/50 (4%); 2/50 (4%); 0/50; 6/50 (12%)) with a p-value for trend of 0.008, Chi-Square test; and a significant trend for the development of renal adenomas (0/50; 0/50; 0/50; 2/50 (4%)) with a p-value for trend of 0.008, Chi-Square test seen in male mice. The EPA also reported<sup>86</sup> that hemangiosarcomas<sup>mas</sup> in female mice were found to occur with a statistically significant trend in this study (0/50; 0/50; 2/50, (4%); 5/50, (10%) p=0.002, Trend test), and the tumor incidence in the high-dose female mice was statistically significant with p=0.028 as compared to concurrent controls. I also reviewed the Tier II Summaries for Glyphosate Carcinogenicity Studies from Greim, et al.<sup>87</sup> for Study 12, Sugimoto, which showed a reported statistically significant increase in malignant lymphoma in high dose male mice – 0/26, 0/34, 1/27(4%), 5/29(17%) (p<0.05 Fisher's exact test); however I could not resolve the difference in the tumor incidence between the Greim Tier II Summary<sup>87</sup>, the published Greim et al, 2015<sup>78</sup> and the Sugimoto<sup>85</sup> tumor tables. These appear to be low response rates but this is only an 18-month study where low rates of

tumors are not unusual. For the purpose of this hazard identification there was an increased incidence of malignant and/or a combination of malignant and benign tumors, at multiple tissue sites in male and female CD-1 mice in this study. The significant increase in malignant lymphoma in high dose male mice, and the significant trend in the development of hemangiosarcomas, malignant lymphomas, and renal adenomas in male mice is due to treatment with glyphosate that caused these cancers in male CD-1 mice. The significant trend in the development of hemangiosarcomas in female mice is also related to treatment with glyphosate that caused this cancer in female CD-1 mice.

•Greim<sup>78</sup> (Study 14, Wood, et al. 2009b) reported on a study submitted by Nufarm to the EPA in support of the re-registration of glyphosate as an herbicide. Groups of 51 male and 51 female CD-1 mice were given diets containing glyphosate (purity, 94.6–97.6%) at a concentration of 0, 500, 1500, or 5000 ppm for 18 months. Parameters evaluated included clinical signs, body weight, food consumption, organ weights, gross necropsy and histopathological examination. There was no treatment-related effect on survival. In male mice at the high dose there was a significant increase in the incidence of malignant lymphomas (0/51, 1/50(10%), 2/51(4%), 5/51(10%)  $p < 0.05$ , pair-wise comparison,  $p < 0.01$  for trend) and a significant increase in the trend of formation of adenocarcinomas of the lung (5/51(10%), 5/51(10%), 7/51(14%), 11/51(22%)  $p < 0.01$  for trend<sup>86</sup>). For the purpose of this hazard identification, I determined the formation of malignant lymphomas and the formation of adenocarcinomas of the lung in male mice in this study is due to treatment with glyphosate that caused a significant increase in the incidence of malignant lymphoma in high dose male CD-1 mice and an increase in the trend of formation of the adenocarcinomas of the lung and malignant lymphomas in male CD-1 mice.

•Greim<sup>78</sup> (Study 13, Kumar) reported on a study submitted by Feinchemie Schwebda to the EPA in support of the re-registration of glyphosate as an herbicide. Groups of 50 male and 50 female Swiss albino mice [age at start not reported] were given diets containing glyphosate (purity >95%) at a concentration of 0, 100, 1000, or 10,000 ppm for 18 months. There were no treatment-related effects on clinical signs, behavior, body weight, body weight gain, food consumption, and differential white blood cell counts in both sexes. There was a slightly higher mortality rate observed in the high dose groups. There was a significant increase in malignant lymphoma reported in high dose male mice

(10/50, 20%; 15/50, 30%; 16/50, 32%; 19/50, 38%,  $p < 0.05$  pair wise) and female mice (18/50, 36%; 20/50, 40%; 19/50, 38%; 25/50, 50%,  $p < 0.05$  pair wise). There was also a significant increased trend (one-sided  $p$ -value for trend = 0.05) for the formation of this tumor in males. The incidence of malignant lymphoma in the high dose male was double the historical rate, reported to be 18%<sup>87</sup> for males, and for high dose female mice the incidence was well above the historical rate of 41%<sup>87</sup>. There was also a significant increased trend in the incidence of kidney renal cell adenomas reported<sup>88</sup> in males (0/50; 0/26; 1/26 (4%); 2/50 (4%); one-sided  $p$ -value for trend  $p = 0.04$ ). I would note that the EPA stated<sup>77</sup> this study was not included in their review due to the report by Greim (2015)<sup>78</sup> that there was possibly a viral infection within the colony, which confounded the interpretation of the study findings. EPA also stated although the incidences in this study were within or near the normal variation of background occurrence. It is not clear whether or not the viral component may have contributed to incidence value reported or the lower survival seen at the high dose in the study.<sup>89</sup> An internal Monsanto email among the authors of Greim would indicate there was no viral infection in the mouse colony during this study. Further, Greim<sup>78</sup> (table 18, p. 201) considers this study GLP and OECD compliant. For the purpose of this hazard identification, I determined formation of malignant lymphoma in the male and female mice and the renal cell adenomas in males in this study is due to treatment with glyphosate that caused a significant increase in the incidence of malignant lymphoma in high dose male and female Swiss albino mice and renal cell adenomas in male Swiss albino mice.

### **Cancer Bioassays in Rats**

•Greim<sup>78</sup> reported on a Bio/dynamics study (Study 1, Lankas, et al.) submitted by Monsanto to the EPA in support of the registration of glyphosate as an herbicide. Groups of 50 male and 50 female Sprague-Dawley rats were fed diets containing glyphosate (98.7%, pure) at concentrations of 0, 30, 100 or 300 ppm for 26 months. These concentrations were adjusted during the course of the study so that actual doses of 0, 3, 10, and 31 mg/kg/day in males and 0, 3, 11, and 34 mg/kg/day in females were maintained. There were no treatment-related effects on body weight or survival at any dose level. An MTD was not achieved. There was a significant increase reported in the incidences of interstitial cell tumors in the testes of male rats: controls 0/50, 0%; low dose

3/5, 6%; mid dose 1/50, 2%; high dose 6/50; 12%;  $p=0.013$  by pairwise comparison<sup>77</sup>. The incidence of interstitial cell tumors in the testes in the high dose animals in this study is almost twice that seen in the range of this tumor (3.4% to 6.7%) in control animals (historical controls) from 5 contemporary studies<sup>87</sup>. There was also a significant increase in the incidence of pancreatic islet cell adenoma reported in males at the low dose: controls, 0/50; low dose 5/49, 10% ( $p < 0.05$  Fisher exact test); mid dose 2/50, 4%; high dose 2/50, 4%. For the purpose of this hazard identification, I determined the increase in the incidence of interstitial cell tumors in the testes and pancreatic cell tumors in male rats is due to the treatment with glyphosate that caused a significant increase in the incidence of interstitial cell tumors in the testes and pancreatic islet cell tumors in male Sprague-Dawley rats.

• Greim<sup>78</sup> reported on a study (Study 2, Stout, et al.) submitted by Monsanto to the EPA in support of the registration of glyphosate as an herbicide. Groups of 60 male and 60 female Sprague-Dawley rats were given diets containing glyphosate (technical grade; purity, 96.5%) at a concentration of 0 ppm, 2000 ppm, 8000 ppm, or 20,000 ppm, ad libitum, for 24 months. No compound-related effect on survival was observed. There was no statistically significant decreases in body-weight gain in male rats. The study reported significant decreases in body-weight gain in females at the highest dose, beginning on day 51. There was a statistically significant increase in the incidence of pancreatic islet cell adenoma in males at the lowest dose compared with controls: control 1/58, 2%; low dose 8/57, 14% ( $p \leq 0.05$  Fisher exact test); mid dose 5/60, 8%; high dose 7/59, 12%. The EPA<sup>77</sup> did additional analysis of this data for pancreatic islet cell adenoma by excluding rats that died or were killed before week 55 and then using statically analyses (Cochran–Armitage trend test and Fisher exact test) that gave a statistically significant higher incidence of these tumors in males at the lowest and highest doses compared with controls: control 1/43, 2%; low dose 8/45, 18% ( $p = 0.018$ ; pairwise test); mid dose 5/49, 10%; high dose 7/48, 15% ( $p = 0.042$ ; pairwise test). The incidence of these adenomas in the low (18%) and high (15%) dose males was almost twice that seen in historical controls. The range for historical controls for pancreatic islet cell adenoma reported in males at this laboratory was 1.8–8.5%<sup>77</sup>. One should note that there was no statistically significant positive trend in the incidence of these tumors, and no apparent progression to carcinoma. There was also a statistically significant positive trend ( $p = 0.016$ ) in the

incidence of hepatocellular adenoma observed in male rats<sup>86</sup> and a statistically significant positive trend of thyroid follicular cell adenomas ( $p = 0.031$ ) and thyroid follicular cell adenomas and carcinomas combined ( $p=0.033$ ) observed in female rats<sup>86</sup> reported in this study. For the purpose of this hazard identification, I determined that the increase in the incidence of pancreatic islet cell adenoma in male rats is due to the treatment with glyphosate that caused a significant positive increase in the incidence of pancreatic islet cell adenomas of male Sprague-Dawley rats. Glyphosate also caused a significant increase in the trend for formation of hepatocellular adenomas in male Sprague-Dawley rats and of thyroid follicular cell adenomas and follicular cell adenomas and carcinomas combined in female Sprague-Dawley rats.

•Greim<sup>78</sup> reported on a study (Study 3, Atkinson, et al.) submitted by Cheminova to the EPA in support of the registration of glyphosate as an herbicide. Groups of 50 male and 50 female Sprague-Dawley rats were given diets containing glyphosate, purity, 98.7–98.9%, at a concentration that were adjusted to provide doses of 0, 10, 100, 300, or 1,000 mg/kg bw/day, ad libitum, for 104 weeks. Decreased body-weight gain was observed in males and females at the highest dose. There was no significant decrease in survival reported at any dose level. Neoplasms were noted in control and treated groups, but dose-responses were not evident, and no statistically significant increases versus controls were noted for any tumor type. Additionally, EPA's evaluation<sup>86</sup> of this study indicated there were no treatment-related increases in the occurrence of any tumor type in this study.

•Greim<sup>78</sup> reported on a study (Study 7, Brammer) submitted by Syngenta to the EPA in support of the re-registration of glyphosate as an herbicide. Groups of 52 male and 52 female Wistar rats received diets containing 0, 2,000, 6,000, and 20,000 ppm glyphosate (97.6% pure), ad libitum, for 24 months. Survival in the high dose group males was significantly better than the other dose groups throughout the study while survival in the females was similar across all dose groups. The bodyweights of the high dose males and females were statistically significantly lower than controls throughout the study. The study's author reported no significant increase in tumor incidence in any of the treated groups. The EPA's evaluation<sup>77</sup> of this study indicated there was a significant increase in the incidence of hepatocellular adenomas in male rats at the high dose when compared to controls (control 0/52, 0%; low dose 2/52, 4%; mid dose 0/52, 0%; high dose 5/52, 10%,  $p=0.03$ ). There was also a significant trend ( $p=0.008$ ) in the formation of this tumor in

male rats. The EPA goes on to state the incidences observed were within the range (0–11.5%) of historical controls for this strain of rats in 26 studies conducted during the relevant time period (1984–2003) at the testing laboratory indicating this increase was not considered to be related to treatment with glyphosate. For the purpose of this hazard identification, I determined the increase in the formation of hepatocellular adenomas in male Wistar rats could not be attributed to exposure to glyphosate in this study despite the fact that there was an observation of increased incidence of hepatocellular adenomas in male rats.

•Greim<sup>78</sup> reported on a study (Study 4, Suresh) submitted by Feinchemie Schwebda to the EPA in support of the registration of glyphosate as an herbicide. Groups of 50 male and 50 female Wistar rats received diets containing 0, 100, 1,000, and 10,000 ppm glyphosate (97.6% pure), ad libitum, for 24 months. There were no treatment-related deaths or clinical signs in any of the dose-groups and there were no treatment related effects on body weight gain or food consumption noted. This suggests that the MTD was not reached, and this study is inadequate for the evaluation of the carcinogenicity of glyphosate.

•Greim<sup>78</sup> reported on a study (Study 6, Enomoto) submitted by Arista Life Sciences to the EPA in support of the registration of glyphosate as an herbicide. Groups of 50 male and 50 female Sprague-Dawley rats received diets containing 0, 3,000, 10,000, or 30,000 ppm glyphosate (94.6–97.6% pure) for 24 months. Decreases in body weight were observed in both sexes in the mid and high dose group along with a lower food consumption. Survival in the high dose males was lower than controls while there was no compound-related effect on survival in any other dose group. There were no statistically significant increases in any tumor type reported for this study.

•Greim<sup>82</sup> reported on a study (Study 8, Wood 2009a) submitted by Nufarm to the EPA in support of the registration of glyphosate as an herbicide. Groups of 51 male and 51 female Wistar rats received diets containing 0, 3,000, 10,000, or 15,000 ppm glyphosate (95.7% pure) for 24 months, the highest dose level was progressively increased to 24000 ppm by week 40. There were no treatment-related deaths or clinical signs in any of the dose-groups. No significant treatment-related effects on mortality were observed during the study. This suggests that the MTD was not reached, and this study is inadequate for the evaluation of the carcinogenicity of glyphosate.

•Chruscielska et al.<sup>90</sup> gave groups of 55 male and 55 female Wistar rats drinking-water containing an ammonium salt of glyphosate (purity not given) that was used to make drinking water solutions of 0, 300, 900, and 2700 mg/L, for 24 months. The authors reported that survival and body-weight gain were similar in treated and control animals and that no significant increase in tumor incidence was observed in any of the treated groups. There was limited information provided on dosing regimen, histopathological examination method, and tumor incidences that makes this study inadequate for the purpose of this hazard assessment.

### Summary for Experimental Animal Data

I reviewed a total of five dose feed bioassays of glyphosate in mice. Four of these studies (Study 12 and Study 14 in Greim<sup>78</sup>, Knezevich and Hogan (1983)<sup>76</sup>, and Atkinson<sup>84</sup>) were in male and female CD-1 mice, and one study<sup>78(Study13)</sup> was in male and female Swiss albino mice. Glyphosate caused a significant increase in the incidence of adenoma or carcinoma (combined) and a significant positive trend for the formation of adenoma or carcinoma (combined) of the renal tubule in male CD-1 mice in one study<sup>76</sup>, and a significant positive trend for the formation of adenomas of the renal tubule in male CD-1 mice in another study<sup>78(Study 12)</sup>. Glyphosate also caused a significant increase in the incidence of renal cell adenomas in male Swiss albino mice<sup>78(Study13)</sup>. Adenoma and carcinoma of the renal tubule constitutes a morphological continuum in the development and progression of renal neoplasia in mice<sup>91,92</sup>. It is important to note that renal tubule carcinoma is a very rare tumor in CD1 mice<sup>80</sup> and that this tumor was caused by exposure to glyphosate in two different strains of mice (CD-1 and Swiss). Glyphosate caused a significant increase in the incidence of malignant lymphoma in male CD-1 mice in two studies<sup>78(Study 12, Study 14)</sup> and in male and female Swiss albino mice in another study<sup>78 (Study 12)</sup>. Glyphosate also caused a significant positive trend for the formation of malignant lymphoma in one of these studies in male CD-1 mice<sup>78(Study 12)</sup> and caused a significant positive trend for the formation of hemangiosarcomas in 2 separate studies in male CD-1 mice<sup>78(Study 12),84</sup>. There was also a significant positive trend for the formation of adenocarcinomas of the lung in male CD-1 mice in one study<sup>78(Study 14)</sup> and hemangiosarcomas in female CD-1 mice in another study<sup>82(Study 12)</sup>.

I reviewed a total of 7 dosed feed and 2 drinking water bioassays of glyphosate in rats. Four of the feed studies and one drinking water study were in male and female Sprague-Dawley rats and three feed studies and one drinking water study were in male and female Wistar rats. Glyphosate caused a significant increase in the incidence of pancreatic islet cell adenoma in two feeding studies in male Sprague-Dawley rats<sup>78(Study 1 and Study 2)</sup>. Glyphosate caused a significant increase in the incidence of thyroid tumors in male Sprague-Dawley rats in one feeding study<sup>78(Study 1)</sup> and a significant positive trend for the formation of thyroid tumors in female Sprague-Dawley rats in another feeding study<sup>78(Study 2)</sup>. Glyphosate caused a significant increase in the incidence of interstitial cell tumors in the testes of male Sprague-Dawley rats in one feeding study and a significant positive trend for the formation of hepatocellular adenomas in male Sprague-Dawley rats in another feeding study<sup>78(Study 1)</sup>.

To state my findings more concisely, I determined that in CD-1 mice, glyphosate exposure causes kidney tumors in males in two separate studies<sup>76,78(Study 12)</sup>, hemangiosarcomas in males in two separate studies,<sup>78(Study 12),84</sup> malignant lymphoma in males in two separate studies<sup>78(Study 12, Study 14)</sup>, adenocarcinomas of the lung in males in one study<sup>78(Study 14)</sup>, and hemangiosarcomas<sup>mas</sup> in females in one study<sup>78(Study 12)</sup>. In one study<sup>78(Study 13)</sup> in Swiss albino mice, exposure to glyphosate causes malignant lymphoma in males and females and kidney tumors in males.

I also determined that in Sprague-Dawley rats, glyphosate exposure causes pancreatic cell tumors in males in one study<sup>78(Study 2)</sup>, interstitial cell tumors in the testes in males in one study<sup>78(Study 1)</sup>, hepatocellular adenomas in males in two studies<sup>78(Study 2, Study 7)</sup>, and thyroid follicular cell tumors in females in one study<sup>78(Study 2)</sup>.

Considering all data from the mice and rat studies I reviewed, there is “Sufficient” evidence that shows glyphosate is carcinogenic in experimental animals causing kidney tumors, hemangiosarcomas, malignant lymphoma, adenocarcinomas of the lung, and hemangiomas in mice and pancreatic cell tumors, interstitial cell tumors in the testes, hepatocellular adenomas, and thyroid follicular cell tumors in rats. This statement is based on my stated criteria of a causal relationship between exposure to glyphosate and an increased incidence of malignant and/or a combination of malignant and benign tumors, in multiple species, at multiple tissue sites, from multiple studies, and to an unusual degree with regard to incidence, site, or type of tumor.

## **Hazard Assessment of the Mechanistic and Other Data for Glyphosate and Glyphosate-Based Formulations**

Data on the absorption of glyphosate via intake of food and water in humans could not be found in the published literature. Glyphosate has been found in the urine of agricultural workers. In a study by Acquavella<sup>7</sup>, 60% of farmers had detectable levels of glyphosate in 24-hour composite urine samples taken on the day they had applied a glyphosate-based formulation. Wearing protective gear such as rubber gloves reduced the concentrations of glyphosate in the urine. This implies that dermal absorption is a relevant route of exposure. Curwin<sup>8</sup> demonstrated that glyphosate is also present in the urine of non-farm families. No data in humans on the distribution of glyphosate in systemic tissues other than blood were found in the available published literature. In cases of accidental or deliberate intoxication involving ingestion of glyphosate-based formulations, glyphosate was measured in blood.

Strong evidence indicates that glyphosate is genotoxic. As noted in Monograph 112, studies in human cells<sup>27,31,32</sup>, mammalian model systems<sup>27,32,33</sup>, and in non-mammalian organisms<sup>35,37</sup> have given positive results. The end-points evaluated in these studies included biomarkers of DNA adducts and various types of chromosomal damage. Tests in bacterial assays gave consistently negative results.

The evidence for genotoxicity caused by glyphosate-based formulations is also strong. As noted in Monograph 112, three studies<sup>39,93,94</sup> reported examining genotoxic end-points in community residents exposed to glyphosate-based formulations and two of these studies reported positive associations. One study<sup>39</sup> looked at micronucleus formation in circulating blood cells before and after aerial spraying with glyphosate-based formulations to determine chromosomal damage in exposed individuals. This study revealed a significant increase in micronucleus formation after exposure in three out of four different geographical areas. Additional positive evidence came from *in vitro* studies with positive results in human cells<sup>32,45</sup>, *in vivo*<sup>27,32</sup> and *in vitro*<sup>95</sup> studies in mammalian systems, and studies in non-mammalian organisms<sup>35,96</sup> such as fish. Biomarkers of DNA adducts and different types of chromosomal damage were examined in these studies. The pattern of tissue specificity of genotoxicity end-points observed with glyphosate-based

formulations is similar to that observed with glyphosate. Tests of glyphosate-based formulations in bacterial assays gave generally negative results.

There is strong evidence that glyphosate and glyphosate-based formulations induce oxidative stress. As noted in Monograph 112, evidence of oxidative stress comes from *in vitro* studies in human cells<sup>97,98</sup> and in many *in vivo* studies<sup>32-42</sup>, examining rodent tissues. Studies of oxidative stress and glyphosate in non-human mammalian experimental systems were conducted in rats and mice, and examined a range of exposure durations, doses, preparations (glyphosate and glyphosate-based formulations), administration routes and tissues. In these studies glyphosate caused free radicals and oxidative stress in mouse and rat tissues through alteration of antioxidant enzyme activity, depletion of glutathione, and increases in lipid peroxidation. In at least one of the studies in human cells the oxidative stress caused by glyphosate was ameliorated by co-administration of antioxidants<sup>40</sup>. Similar findings of oxidative stress have been reported in fish and other aquatic species providing additional evidence for glyphosate-induced oxidative stress<sup>99</sup>. Molecular epidemiology studies<sup>100,101</sup> have documented that oxidative stress is a pathway to the formation of NHL in humans. Further, the *in vitro* studies in human cells and *in vivo* and *in vitro* studies in rodents provides evidence that exposure to glyphosate causes oxidative stress. Logically it follows that there is a positive association between oxidative stress caused by glyphosate and glyphosate-based formulations and NHL observed in humans exposed to glyphosate-based formulations and that a causal interpretation is credible.

### **Hazard Assessment Conclusion**

Based on the significant positive association observed in the studies discussed above, I conclude that there is evidence that glyphosate and glyphosate-based formulations are carcinogenic in humans. First, the human study data supports a positive association between exposure to glyphosate and glyphosate-based formulations and the development of NHL. Second, all the data from the animal bioassay studies provide evidence that glyphosate is carcinogenic in experimental animals. Third, the mechanistic data show that glyphosate and glyphosate-based formulations cause genotoxicity and oxidative stress in humans and animals. Therefore, I conclude to a reasonable degree of

scientific certainty that glyphosate and glyphosate-based formulations are probable human carcinogens. I also conclude to a reasonable degree of scientific certainty that glyphosate and glyphosate-based formulations cause NHL in humans.

### **Compensation and Testimony**

My billing rate is \$400/hr plus travel fees and expenses. I have not testified in any case in the last four years.

  
\_\_\_\_\_  
Charles W. Jameson, Ph.D.

## **References**

- <sup>1</sup> Williams et al. (2016) A review of the carcinogenic potential of glyphosate by four independent expert panels and comparison to the IARC assessment. *Critical Reviews in Toxicology*, VOL. 46, NO. S1, 3–20
- <sup>2</sup> Williams et al. (2016) Glyphosate rodent carcinogenicity bioassay expert panel review. *Critical Reviews in Toxicology*, VOL. 46, NO. S1, 44–55
- <sup>3</sup> Chang ET, and Delzell, E (2016) Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers. *J Environ Sci Health B* ;51(6):402-34.
- <sup>4</sup> Solomon KR, (2016) Glyphosate in the general population and in applicators: a critical review of studies on exposures *Critical Reviews in Toxicology*. VOL. 46, NO. S1, 21–27
- <sup>5</sup> See, IARC Preamble, <http://monographs.iarc.fr/ENG/Preamble/index.php> (2015)
- <sup>6</sup>[http://www.prweb.com/releases/glyphosate\\_agrochemical/technical\\_glyphosate/prweb8857231.htm](http://www.prweb.com/releases/glyphosate_agrochemical/technical_glyphosate/prweb8857231.htm)
- <sup>7</sup> Acquavella JF, Alexander BH, Mandel JS, Gustin C, Baker B, Chapman P et al. (2004). Glyphosate biomonitoring for farmers and their families: results from the Farm Family Exposure Study. *Environ Health Perspect*, 112(3):321–6.
- <sup>8</sup> Curwin BD, Hein MJ, Sanderson WT, Striley C, Heederik D, Kromhout H et al. (2007). Urinary pesticide concentrations among children, mothers and fathers living in farm and non-farm households in Iowa. *Ann Occup Hyg*, 51(1):53–65.
- <sup>9</sup> MLHB (2013). Determination of glyphosate residues in human urine samples from 18 European countries. Bremen: Medical Laboratory of Bremen. Available from: [https://www.foeeurope.org/sites/default/files/glyphosate\\_studyresults\\_june12.pdf](https://www.foeeurope.org/sites/default/files/glyphosate_studyresults_june12.pdf),
- <sup>10</sup> Varona M, Henao GL, Díaz S, Lancheros A, Murcia A, Rodríguez N et al. (2009). Evaluación de los efectos del glifosato y otros plaguicidas en la salud humana en zonas objeto del programa de erradicación de cultivos ilícitos. [Effects of aerial applications of the herbicide glyphosate and insecticides on human health] *Biomedica*, 29(3):456–75.
- <sup>11</sup> De Roos AJ, Zahm SH, Cantor KP, Weisenburger DD, Holmes FF, Burmeister LF et al. (2003). Integrative assessment of multiple pesticides as risk factors for non-Hodgkin's lymphoma among men. *Occup Environ Med*, 60(9):E11
- <sup>12</sup> Zahm SH, Weisenburger DD, Babbitt PA, Saal RC, Vaught JB, Cantor KP et al. (1990). A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. *Epidemiology*, 1(5):349–56.
- <sup>13</sup> Hoar SK, Blair A, Holmes FF, Boysen CD, Robel RJ, Hoover R et al. (1986). Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. *JAMA*, 256(9):1141–7.

- <sup>14</sup> Cantor KP, Blair A, Everett G, Gibson R, Burmeister LF, Brown LM et al. (1992). Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. *Cancer Res*, 52(9):2447-55.
- <sup>15</sup> McDuffie HH, Pahwa P, McLaughlin JR, Spinelli JJ, Fincham S, Dosman JA et al. (2001). Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health. *Cancer Epidemiol Biomarkers Prev*, 10(11):1155-63
- <sup>16</sup> Kachuri L, Demers PA, Blair A, Spinelli JJ, Pahwa M, McLaughlin JR et al. (2013). Multiple pesticide exposures and the risk of multiple myeloma in Canadian men. *Int J Cancer*, 133(8):1846-58
- <sup>17</sup> Hardell L, Eriksson M, Nordstrom M (2002). Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies. *Leuk Lymphoma*, 43(5):1043-9
- <sup>18</sup> Eriksson M, Hardell L, Carlberg M, Akerman M (2008). Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. *Int J Cancer*, 123(7):1657-63.
- <sup>19</sup> EPA (1985a). Glyphosate; EPA Reg.#: 524-308; Mouse oncogenicity study. Document No. 004370. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from: <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/reviews/103601/103601-183.pdf>, accessed 10 March 2015.
- <sup>20</sup> EPA (1985b). EPA Reg.#: 524-308; Roundup; glyphosate; pathology report on additional kidney sections. Document No. 004855. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from: <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/clearedreviews/reviews/103601/103601-206.pdf>.
- <sup>21</sup> EPA (1986). Glyphosate; EPA Registration No. 524-308; Roundup; additional histopathological evaluations of kidneys in the chronic feeding study of glyphosate in mice. Document No. 005590. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from: <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/>
- <sup>22</sup> EPA(1991a). Second peer review of glyphosate. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from: <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/reviews/103601/103601-265.pdf>
- <sup>23</sup> JMPR (2006). Glyphosate. In: Joint FAO/WHO Meeting on Pesticide Residues. Pesticide residues in food - 2004: toxicological evaluations. Report No. WHO/PCS/06.1. Geneva: World Health Organization; pp. 95-169. Available from: [http://whqlibdoc.who.int/publications/2006/9241665203\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2006/9241665203_eng.pdf?ua=1)
- <sup>24</sup> EPA (1991b). Glyphosate; 2-year combined chronic toxicity/carcinogenicity study in Sprague-Dawley rats - List A pesticide for reregistration. Document No. 008390.

Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from:

<http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/reviews/103601/103601-263.pdf>, see also <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/reviews/103601/103601-268.pdf>

<sup>25</sup> EPA (1991c). Peer review on glyphosate. Document No. 008527. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency.

<sup>26</sup> EPA (1991d). Glyphosate – EPA registration No. 524–308 – 2-year chronic feeding/oncogenicity study in rats with technical glyphosate. Document No. 008897. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. Available from:

<http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/cleared-reviews/reviews/103601/103601-268.pdf>,

<sup>27</sup> Manas F, Peralta L, Raviolo J, Ovando HG, Weyers A, Ugnia L et al. (2009). Genotoxicity of glyphosate assessed by the comet assay and cytogenetic tests. *Environ Toxicol Pharmacol*, 28(1):37–41.

<sup>28</sup> Mladinic M, Berend S, Vrdoljak AL, Kopjar N, Radic B, Zeljezic D (2009). Evaluation of genome damage and its relation to oxidative stress induced by glyphosate in human lymphocytes in vitro. *Environ Mol Mutagen*, 50(9):800–7

<sup>29</sup> Alvarez-Moya C, Silva MR, Ramírez CV, Gallardo DG, Sánchez RL, Aguirre AC et al. (2014). Comparison of the in vivo and in vitro genotoxicity of glyphosate isopropylamine salt in three different organisms. *Genet Mol Biol*, 37(1):105–10.

<sup>30</sup> Monroy CM, Cortés AC, Sicard DM, de Restrepo HG (2005). Cytotoxicity and genotoxicity of human cells exposed in vitro to glyphosate. *Biomedica*, 25(3):335–45.

<sup>31</sup> Koller VJ, Fürhacker M, Nersesyan A, Mišák M, Eisenbauer M, Knasmueller S (2012). Cytotoxic and DNA-damaging properties of glyphosate and Roundup in human-derived buccal epithelial cells. *Arch Toxicol*, 86(5):805–13.

<sup>32</sup> Bolognesi C, Bonatti S, Degan P, Gallerani E, Peluso M, Rabboni R et al. (1997). Genotoxic activity of glyphosate and its technical formulation Roundup. *J Agric Food Chem*, 45(5):1957–62.

<sup>33</sup> Lioi MB, Scarfi MR, Santoro A, Barbieri R, Zeni O, Di Bernardino D et al. (1998). Genotoxicity and oxidative stress induced by pesticide exposure in bovine lymphocyte cultures in vitro. *Mutat Res*, 403(1–2):13–20.

<sup>34</sup> Roustan A, Aye M, De Meo M, Di Giorgio C (2014). Genotoxicity of mixtures of glyphosate and atrazine and their environmental transformation products before and after photoactivation. *Chemosphere*, 108:93–100.

- <sup>35</sup> Moreno NC, Sofia SH, Martinez CB (2014). Genotoxic effects of the herbicide Roundup Transorb and its active ingredient glyphosate on the fish *Prochilodus lineatus*. *Environ Toxicol Pharmacol*, 37(1):448–54
- <sup>36</sup> Guilherme S, Gaivão I, Santos MA, Pacheco M (2010). European eel (*Anguilla anguilla*) genotoxic and pro-oxidant responses following short-term exposure to Roundup – a glyphosate-based herbicide. *Mutagenesis*, 25(5):523–30.
- <sup>37</sup> Lopes FM, Varela Junior AS, Corcini CD, da Silva AC, Guazzelli VG, Tavares G et al. (2014). Effect of glyphosate on the sperm quality of zebrafish *Danio rerio*. *Aquat Toxicol*, 155:322–6.
- <sup>38</sup> Paz-y-Mino C, Sanchez ME, Areval M, Munoz MJ, Witte T, De-la-Carrera GO et al. (2007). Evaluation of DNA damage in an Ecuadorian population exposed to glyphosate. *Genet Mol Biol*, 30(2):456–60.
- <sup>39</sup> Bolognesi C, Carrasquilla G, Volpi S, Solomon KR, Marshall EJ (2009). Biomonitoring of genotoxic risk in agricultural workers from five Colombian regions: association to occupational exposure to glyphosate. *J Toxicol Environ Health A*, 72(15–16):986–97.
- <sup>40</sup> Gehin A, Guillaume YC, Millet J, Guyon C, Nicod L (2005). Vitamins C and E reverse effect of herbicide-induced toxicity on human epidermal cells HaCaT: a biochemometric approach. *Int J Pharm*, 288(2):219–26.
- <sup>41</sup> Elie-Caille C, Heu C, Guyon C, Nicod L (2010). Morphological damages of a glyphosate-treated human keratinocyte cell line revealed by a micro- to nanoscale microscopic investigation. *Cell Biol Toxicol*, 26(4):331–9
- <sup>42</sup> Astiz M, de Alaniz MJ, Marra CA (2009b). Antioxidant defense system in rats simultaneously intoxicated with agrochemicals. *Environ Toxicol Pharmacol*, 28(3):465–73.
- <sup>43</sup> George J, Prasad S, Mahmood Z, Shukla Y (2010). Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach. *J Proteomics*, 73(5):951–64.
- <sup>44</sup> Thongprakaisang S, Thiantanawat A, Rangkadilok N, Suriyo T, Satayavivad J (2013). Glyphosate induces human breast cancer cells growth via estrogen receptors. *Food Chem Toxicol*, 59:129–36.
- <sup>45</sup> Gasnier C, Dumont C, Benachour N, Clair E, Chagnon MC, Séralini GE (2009). Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines. *Toxicology*, 262(3):184–91.
- <sup>46</sup> George J, Shukla Y (2013). Emptying of intracellular calcium pool and oxidative stress imbalance are associated with the glyphosate-induced proliferation in human skin keratinocytes HaCaT cells. *ISRNDermatol*, 2013:825180

<sup>47</sup> Chan P, Mahler J (1992). NTP technical report on the toxicity studies of glyphosate (CAS No. 1071-83-6) administered in dosed feed to F344/N rats and B6C3F1 mice. *Toxic Rep Ser*, 16:1-58.

<sup>48</sup> Kreutz LC, Gil Barcellos LJ, de Faria Valle S, de Oliveira Silva T, Anziliero D, Davi dos Santos E et al. (2011). Altered hematological and immunological parameters in silver catfish (*Rhamdia quelen*) following short term exposure to sublethal concentration of glyphosate. *Fish Shellfish Immunol*, 30(1):51-7.

<sup>49</sup> el-Gendy KS, Aly NM, el-Sebae AH (1998). Effects of edifenphos and glyphosate on the immune response and protein biosynthesis of boliti fish (*Tilapia nilotica*). *J Environ Sci Health B*, 33(2):135-49.

<sup>50</sup> Reference Manual on Scientific Evidence, Third Edition, Committee on Science, Technology, and Law Policy and Global Affairs, FEDERAL JUDICIAL CENTER The National Academies Press.

<sup>51</sup> Sperber, William H. (2001). "Hazard identification: from a quantitative to a qualitative approach". *Food Control*. 12: 223-228.

<sup>52</sup> Ropeik, David (2002). *Risk*. New York, New York, USA: Houghton Mifflin Company.

<sup>53</sup> Casarett & Doull 's *Toxicology: The Basic Science of Poisons* (8<sup>th</sup> edition). 2008. C.D. Klaassen (ed.). McGraw-Hill: New York. (Chapter 4).

<sup>54</sup> NTP, RoC Process and Listing Criteria  
<https://ntp.niehs.nih.gov/pubhealth/roc/process/index.html>

<sup>55</sup> Huff JE, McConnell EE, Haseman JK, Boorman GA, Eustis SL, Schwetz BA, Rao GN, Jameson CW, Hart LG, Rall DP. Carcinogenesis studies: results of 398 experiments on 104 chemicals from the U.S. National Toxicology Program. *Ann N Y Acad Sci*; 534:1-30.

<sup>56</sup> Centers for Disease Control and Prevention. *Principles of Epidemiology in Public Health Practice, Third Edition. An Introduction to Applied Epidemiology and Biostatistics*. Available from:  
<https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section7.html>

<sup>57</sup> Centers for Disease Control and Prevention. *Principles of Epidemiology in Public Health Practice, Third Edition. An Introduction to Applied Epidemiology and Biostatistics*. Available from:  
<https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section7.html>

<sup>58</sup> Lee WJ, Cantor KP, Berzofsky JA, Zahm SH, Blair A (2004). Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. *Int J Cancer*, 111(2):298-302

<sup>59</sup> Nordstrom M, Hardell L, Magnuson A, Hagberg H, Rask-Andersen A (1998). Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukemia evaluated in a case-control study. *Br J Cancer*, 77(11):2048–52.

<sup>60</sup> Hardell L, Eriksson M (1999). A case-control study of non-Hodgkin lymphoma and exposure to pesticides. *Cancer*, 85(6):1353–60.

<sup>61</sup> Orsi L, Delabre L, Monnereau A, Delval P, Berthou C, Fenaux P et al. (2009). Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. *Occup Environ Med*, 66(5):291–8.

<sup>62</sup> Cocco P, Satta G, Dubois S, Pili C, Pilleri M, Zucca M et al. (2013). Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study. *Occup Environ Med*, 70(2):91–8.

<sup>61</sup> Karunanayake CP, Spinelli JJ, McLaughlin JR, Dosman JA, Pahwa P, McDuffie HH (2012). Hodgkin lymphoma and pesticides exposure in men: a Canadian case-control study. *J Agromed*, 17(1):30–9.

<sup>62</sup> Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM et al. (1990). Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. *Cancer Res*, 50(20):6585–91.

<sup>63</sup> Rank J, Jensen AG, Skov B, Pedersen LH, Jensen K (1993). Genotoxicity testing of the herbicide Roundup and its active ingredient glyphosate isopropylamine using the mouse bone marrow micronucleus test, Salmonella mutagenicity test, and phase-telephase test. *Mutat Res*, 300(1):29–36.

<sup>64</sup> <https://aghealth.nih.gov/about/index.html>

<sup>65</sup> Alavanja MC, Sandler DP, McMaster SB, Zahm SH, McDonnell CJ, Lynch CF et al. (1996). The Agricultural Health Study. *Environ Health Perspect*, 104(4):362–9

<sup>66</sup> De Roos AJ, Blair A, Rusiecki JA, Hoppin JA, Svec M, Dosemeci M et al. (2005). Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study. *Environ Health Perspect*, 113(1):49–54.

<sup>67</sup> De Roos AJ, Svec MA, Blair A, Rusiecki JA, Dosemeci M, Alavanja MC et al. (2005). Glyphosate results revisited. *Environ Health Perspect*, 113(6):A366–7

<sup>68</sup> Flower KB, Hoppin JA, Lynch CF, Blair A, Knott C, Shore DL et al. (2004). Cancer risk and parental pesticide application in children of Agricultural Health Study participants. *Environ Health Perspect*, 112(5):631–5.

<sup>69</sup> Engel LS, Hill DA, Hoppin JA, Lubin JH, Lynch CF, Pierce J et al. (2005). Pesticide use and breast cancer risk among farmers' wives in the Agricultural Health Study. *Am J Epidemiol*, 161(2): 121 –35.

<sup>70</sup> Lee WJ, Sandler DP, Blair A, Samanic C, Cross AJ, Alavanja MC (2007). Pesticide use and colorectal cancer risk in the Agricultural Health Study. *Int J Cancer*, 121(2):339–46.

<sup>71</sup> Andreotti G, Freeman LE, Hou L, Coble J, Rusiecki J, Hoppin JA et al. (2009). Agricultural pesticide use and pancreatic cancer risk in the Agricultural Health Study Cohort. *Int J Cancer*, 124(10):2495–500

<sup>72</sup> Dennis LK, Lynch CF, Sandler DP, Alavanja MC (2010). Pesticide use and cutaneous melanoma in pesticide applicators in the Agricultural Health Study. *Environ Health Perspect*, 118(6):812–7

<sup>73</sup> Schinasi L, Leon ME (2014). Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. *Int J Environ Res Public Health*, 11(4):4449–527.

<sup>74</sup> IARC (2015). International Agency for Research on Cancer. Monograph on Glyphosate. Volume 112

<sup>75</sup> Hill, Austin Bradford (1965). "The Environment and Disease: Association or Causation?". *Proceedings of the Royal Society of Medicine*. 58 (5): 295–300.

<sup>76</sup> Knezevich, A.L and Hogan, G. K. (1983). A chronic feeding study of glyphosate in mice. Unpublished report prepared by Bio/Dynamic Inc., dated July 21, 1983. Report No. 77-2011. EPA Accession No. 251007 – 251009, and 251014

<sup>77</sup> EPA (2015) Glyphosate: Report of the Cancer Assessment Review Committee. EPA's Office of Pesticide Programs, Health Effects Division. October 1, 2015.

<sup>78</sup> Greim H, Saltmiras D, Mostert V, Strupp C (2015). Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies. *Crit Rev Toxicol*, 45(3):185–208.

<sup>79</sup> EPA (1985b). EPA Reg.#: 524–308; Roundup; glyphosate; pathology report on additional kidney sections. Document No. 004855. Washington (DC): Office of Pesticides and Toxic Substances, United States Environmental Protection Agency. At: <http://www.epa.gov/pesticides/chemicalsearch/chemical/foia/clearedreviews/reviews/103601/103601-206.pdf>

<sup>80</sup> Chandra M, Frith CH (1994). Spontaneous renal lesions in CD-1 and B6C3F1 mice. *Exp Toxicol Pathol*, 46(3):189–98.

<sup>81</sup> EPA Memo, Glyphosate; EPA Registration No. 524-308; Roundup; Additional Histopathological Evaluations of Kidneys in the Chronic Feeding Study of Glyphosate in Mice, Toxicology Branch/HED. 11 Mar. 1986.

<sup>82</sup> EPA Memo, Glyphosate EPA Reg. 524-308, 2 year chronic feeding/oncogenicity study in rats with technical glyphosate. 1986.

<sup>83</sup> Sauer, Robert M., *Pathology Working Group Report on Glyphosate in CD-1 Mice*, PATHCO, Inc., 10 Oct. 1985.

<sup>84</sup> Atkinson, C., Martin, T., Hudson, P., and Robb, D. (1993). Glyphosate: 104 week dietary carcinogenicity study in mice. Unpublished report prepared by Inveresk Research International April 7, 1993, Tranent, EH33 2NE, Scotland. IRI Project No. 438618. April 7, 1993. MRID 49631702.

<sup>85</sup> Sugimoto, K. (1997). 18-Month Oral Oncogenicity Study in Mice, Vol. 1 and 2. The Institute of Environmental Toxicology, 2-772, Suzuki-cho, Kodaira-shi, Tokyo, 187, Japan, Study No.:IET 94-0151.

<sup>86</sup> EPA (2016) Glyphosate Issue Paper: Evaluation of Carcinogenic Potential. EPA's Office of Pesticide Programs, September 12, 2016

<sup>87</sup> MONGLY02466412, Tier II Summaries for Glyphosate Carcinogenicity Studies from Greim et al., 2015 Paper, 9 November 2015.

<sup>88</sup> Kumar summary: Tables 20 and 21 from Feinchemie Schwebda 2001, Carcinogenicity Study with Glyphosate Technical in Swiss Albino Mice., unpublished, Study No.: Toxi: 1559.CARCI- M, Rallis India Ltd., Bangalore, India.

<sup>89</sup> David Saltmiras Deposition Ex. 5-29.

<sup>90</sup> Chruscielska K, Brzezinski J, Kita K, Kalthorn D, Kita I, Graffstein B et al. (2000). Glyphosate - Evaluation of chronic activity and possible far-reaching effects. Part 1. Studies on chronic toxicity. *Pestycydy (Warsaw)*, 3-4:11-20.

<sup>91</sup> Hard GC (1984). High frequency, single-dose model of renal adenoma/carcinoma induction using dimethylnitrosamine in Crl:(W) BR rats. *Carcinogenesis* 5:1047-1050

<sup>92</sup> Lipsky ML and Trump BF (1988). Chemically induced renal epithelial neoplasia in experimental animals. *Int. Rev. Exp. Pathol.* 30:357-383

<sup>93</sup> Paz-y-Mino C, Sanchez ME, Areval M, Munoz MJ, Witte T, De-la-Carrera GO et al. (2007). Evaluation of DNA damage in an Ecuadorian population exposed to glyphosate. *Genet Mol Biol*, 30(2):456-60.

<sup>94</sup> Paz-y-Miño C, Muñoz MJ, Maldonado A, Valladares C, Cumbal N, Herrera C et al. (2011). Baseline determination in social, health, and genetic areas in communities affected by glyphosate aerial spraying on the northeastern Ecuadorian border. *Rev Environ Health*, 26(1):45-51.

<sup>95</sup> Sivikova K, Dianovsky J (2006). Cytogenetic effect of technical glyphosate on cultivated bovine peripheral lymphocytes Int J Hyg Environ Health, 209(1):15–20

<sup>96</sup> Guilherme S, Gaivão I, Santos MA, Pacheco M (2010). European eel (*Anguilla anguilla*) genotoxic and pro-oxidant responses following short-term exposure to Roundup—a glyphosate-based herbicide. Mutagenesis, 25(5):523–30.

<sup>97</sup> Gehin A, Guillaume YC, Millet J, Guyon C, Nicod L (2005). Vitamins C and E reverse effect of herbicide-induced toxicity on human epidermal cells HaCaT: a biochemometric approach. Int J Pharm, 288(2):219–26.

<sup>98</sup> Kwiatkowska M, Huras B, Bukowska B (2014). The effect of metabolites and impurities of glyphosate on human erythrocytes (in vitro). Pestic Biochem Physiol, 109:34– 43

<sup>99</sup> Slaninova A, Smutna M, Modra H, Svobodova Z (2009). A review: oxidative stress in fish induced by pesticides. Neuro Endocrinol Lett, 30:Suppl 1: 2–12.

<sup>100</sup> Wang SS , Davis S , Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ, and Rothman N. (2006) Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis vol.27 no.9 pp.1828–1834, 2006

<sup>101</sup> Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer, Boyle P, Chanock S. (2007) Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 121:161–168

*Studies I reviewed but determined inadequate for use:*

Greim<sup>78</sup> reported on a study (Study 4, Suresh): Greim H, Saltmiras D, Mostert V, Strupp C (2015). Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies. Crit Rev Toxicol, 45(3):185–208.

Greim<sup>78</sup> reported on a study (Study 8, Wood 2009a) : Greim H, Saltmiras D, Mostert V, Strupp C (2015). Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies. Crit Rev Toxicol, 45(3):185–208.

Chruscielska K, Brzezinski J, Kita K, Kalhorn D, Kita I, Graffstein B et al. (2000). Glyphosate - Evaluation of chronic activity and possible far-reaching effects. Part 1. Studies on chronic toxicity. Pestycydy (Warsaw), 3–4:11–20.

Seralini GE, Clair E, Mesnage R, Gress S, Defarge N, Manuela Malatesta M et al. (2014). Republished study: long-term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize. Environmental Sciences Europe, 26(1):1–14

George J, Prasad S, Mahmood Z, Shukla Y (2010). Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach. J Proteomics, 73(5):951–64.

# EXHIBIT A

*C W Jameson - Curriculum Vitae and Bibliography*

Name Charles William Jameson

Mailing Address:

Date And Place Of Birth:

Citizenship:

Marital Status:

Education:

B.S. 1970  
Chemistry,  
Mount Saint Mary's College  
Emmitsburg, Maryland

Ph.D. 1975  
Organic Chemistry, Physical Chemistry minor  
University of Maryland  
College Park, Maryland

Brief Chronology of Employment:

1965 Chemistry Laboratory Technician, Bionetics Research Laboratories, Falls Church, Virginia

1968 – 1969: Organic Chemistry Laboratory Assistant, Mount Saint Mary's College, Emmitsburg, Maryland

1969 – 1970: Organic Chemistry Laboratory Instructor, Mount Saint Mary's College, Emmitsburg, Maryland

1970 – 1973: Graduate Teaching Assistant, Chemistry Dept., University of Maryland College Park, Maryland

1973 – 1975: Graduate Research Assistant, Center of Materials Research, University of Maryland, College Park, Maryland

1975 – 1976 Faculty Graduate Assistant, Chemistry Dept., University of Maryland, College Park, Maryland

1976 – 1979: Senior Chemist, Tracor Jitco, Inc., Rockville, Maryland

1979 – 1980: Chemist, Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland

*C W Jameson - Curriculum Vitae and Bibliography*

- 1980 – 1983: Head, Chemistry Section, Program Resources Branch, National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), NIH, Research Triangle Park, North Carolina
- 1983 – 1985: Acting Chief, Program Resources Branch, NTP, NIEHS, NIH, Research Triangle Park, North Carolina
- 1985 – 1989: Head, Program Resources Group, Carcinogenesis and Toxicologic Evaluation Branch, NTP, NIEHS, NIH, Research Triangle Park, North Carolina
- 1989 – 1990: Supervisory Chemist, Experimental Toxicology Branch, NTP, NIEHS, NIH, Research Triangle Park, North Carolina
- 1990 – 1995: Senior Chemist, Office of the Senior Scientific Advisor to the Director NIEHS, NIH, Research Triangle Park, North Carolina
- 1995 – 2008 Director, Report on Carcinogens, NTP, NIEHS, NIH, Research Triangle Park, North Carolina
- 2008 – present Principal, CWJ Consulting, LLC, Cape Coral, Florida

Department of Health and Human Services Activities

Chairman, National Toxicology Program’s Executive Committee’s Interagency Working Group for the Report on Carcinogens, 1995 to 2005

National Institutes of Health Activities

NIEHS Representative to the Deafness and Other Communication Disorders Interagency Coordination Committee, 1990 - 1996.

NIEHS Representative on the Task Force on Aging Research, 1990-1994.

National Institutes of Environmental Health Sciences Activities

Chairman, NIEHS/NTP Review Committee for the Report on Carcinogens, 1995 to 2005

Chairman, Search Committee for NIEHS Tenure / Tenure Track Staff Epidemiologist 1998

Peer-Review Panel Member for Draft Report on Carcinogens Monograph on Cobalt and Certain Cobalt Compounds. July, 2015

Member and Chairman for the Special Emphasis Panel to review proposals responding to RFP ES2015038, “Scientific Information Management and Literature-Based Evaluations for the National

*C W Jameson - Curriculum Vitae and Bibliography*

Toxicology Program (NTP).” The objective of this contract is to provide scientific and technical expertise and support for the NTP to compile, review, and analyze information and data from the scientific literature and other sources regarding the effects of environmental substances and other issues that may impact public health. October, 2015

International Activities

Member, WHO Task Group on Environmental Health Criteria for Fully Halogenated Chlorofluorocarbons, Neuherberg, Federal Republic of Germany, November 21 – 25, 1988.

Member, WHO Task Group on Environmental Health Criteria for Partially Halogenated Chlorofluorocarbons (Ethane Derivatives), Carshalton, Surrey, United Kingdom, September 30 – October 5, 1991.

NIEHS representative to the WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 82 on the Carcinogenic Risks To Humans Of Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene And Styrene, Lyon, France, February 11 – 20, 2002

Member, IARC *Monographs* Advisory Group for Five Year Plan, Lyon, France, 18-21 February 2003

NIEHS representative to the WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 87 on The Carcinogenic Risks To Humans Of Lead And Lead Compounds, Lyon, France, February 8 – 18, 2004

NIEHS representative to the WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 91 on The Carcinogenic Risks To Humans Of Combined Oral Contraceptives And Estrogen-Progestogen Replacement Therapy, Lyon, France, June 4-15, 2005.

NIEHS representative to the WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 93 on The Carcinogenic Risks To Humans Of Carbon Black, Titanium Dioxide And Non-Asbestiform Talc, Lyon, France, February 4 – 15, 2006

Member, WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 97 on The Carcinogenic Risks To Humans Of 1,3 –Butadiene, Ethylene Oxide, And Vinyl Halides (Vinyl Fluoride, Vinyl Chloride And Vinyl Bromide), Lyon, France, June 6-15, 2007.

Member and Chair of Experimental Animal Data Subgroup, WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 99 on The Carcinogenic Risks To Humans Of Some Industrial And Cosmetic Dyes And Related Exposures, Lyon, France, February 4-13, 2008.

Member, WHO’s International Agency for Research on Cancer (IARC) Workgroup preparing Monograph 100A on A Review Of Human Carcinogens - Pharmaceuticals (Anti-Cancer Drugs – Hormonal Drugs & Therapies – Others), Lyon, France, October 14 – 21, 2008.

*C W Jameson - Curriculum Vitae and Bibliography*

Member and Chair of Experimental Animal Data Subgroup, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 100F on A Review Of Human Carcinogens - Chemical Agents And Related Occupations, Lyon, France, October 20 – 27, 2009.

Member and Chair of Experimental Animal Data Subgroup, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 103 on Bitumen And Bitumen Fumes, And Some Heterocyclic Aromatic Hydrocarbons, Lyon, France, October 11 - 18, 2011.

Member and Chair of Experimental Animal Data Subgroup, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 105 on Diesel And Gasoline Exhausts And Some Nitroarenes, Lyon, France, June 5 - 12, 2012.

Member WHO's International Agency for Research on Cancer (IARC) Workshop on Tumour Concordance And Mechanisms Of Carcinogenesis: Lessons Learned From Volume 100 of the IARC Monographs, Lyon, France: April 16-18, 2012 and November 28-30, 2012

Member and Chair of Experimental Animal Data Subgroup, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 108 On Some Drugs And Herbal Medicines, Lyon, France, June 4 - 11, 2013.

Member and Chair of Experimental Animal Data Subgroup, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 112 on Some Organophosphate Insecticides And Herbicides, Lyon, France, March 3-10, 2015.

Member and overall Chair, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph Vol. 115 on Some Industrial Chemicals, Lyon, France, February 2-9, 2016.

Member, WHO's International Agency for Research on Cancer (IARC) Workgroup preparing Monograph 116 on Coffee, Mate And Very Hot Beverages, Lyon, France, May 24 – 31, 2016.

### Honors and Awards

President, Student Affiliate Chapter of the American Chemical Society, Mount Saint Mary's College, 1969; Vice President, 1968.

National Toxicology Program Representative to American Chemical Society's Committee on Regulatory Affairs 1982 – 1992.

National Institutes of Health Special Achievement Cash Award (Spy Dust Project): 1986.

Merit Pay Cash Award for Sustained High Quality Work Performance, NIEHS: 1982, 1989

Performance Award for Sustained High Quality Work Performance, NIEHS: 1991, 1992, 1993, 1995, 1996, 2001, 2002, 2003, 2004, 2006, 2007.

*C W Jameson - Curriculum Vitae and Bibliography*

Special Act or Service Award, NIEHS: 1996 (Review of Report on Carcinogens criteria); 1997 (Publication of 8<sup>th</sup> Report on Carcinogens); 1998 (Recruitment of NTP Staff Epidemiologist), 1998 (Restructuring of lead biokinetics contract and establishment of new Report on Carcinogens support contract)

Staff Recognition Award, NIEHS: 1999 (Preparation of final draft of 9<sup>th</sup> Report on Carcinogens)

NIEHS Director's Award, NIEHS: 2000 (Review of nominations for the 9<sup>th</sup> Report on Carcinogens)

Special Training

American Chemical Society, Short Course: "Chemical Carcinogenesis," 1978.

National Institutes of Health (NIH) Training Course: "Project Officers Civil Rights Contract Compliance," 1979.

Department of Health and Human Services Training (DHHS) Course: "Program Officials Guide to Contracting," 1980.

U. S. Office of Personnel Management (OPM) Training Course: "EEO - Its Place in the Federal Government," 1983.

U. S. OPM Training Course: "Introduction to Supervision," 1984.

NIH Training Course: "Employee Performance Management System Training," 1984.

DHHS Training Course: "Advanced Project Officer Training," 1985.

National Institute of Environmental Health Sciences Training Course: "Care and Handling of Laboratory Animals," 1986.

Rockhurst College Continuing Education Center: "How to Manage Projects, Priorities and Deadlines," 1992.

NIH Training Course: "PHS Animal Welfare Policy for HSA's," 1993.

Fred Pryor Seminars: "Total Quality Management," 1994.

Fred Pryor Seminars: "How to Manage Priorities and Meet Deadlines," 1994.

NIH Training Course: "Workplace Violence," 1994.

NIH Training Course: "NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research," 1994.

NIH Training Course: "Workplace Issues Associated with HIV/AIDS," 1994.

The Bookings Institution Course: "Issues in Science and Technology Policy", 1996

*C W Jameson - Curriculum Vitae and Bibliography*

Professional Society Memberships and Activities

American Chemical Society

- Division of Analytical Chemistry
- Division of Chemical Health and Safety
- National Toxicology Program Representative to American Chemical Society's Committee on Regulatory Affairs 1982 – 1992
- Overall Co-Organizer and Co-Chairman of a symposium entitled "Chemistry and Safety for Toxicity Testing of Environmental Chemicals," sponsored by the Divisions of Chemical Health and Safety, Analytical Chemistry and Environmental Chemistry at the 183rd National American Chemical Society Meeting, Las Vegas, NV, March 1982.

Society of Toxicology

Research interests:

Chemical Carcinogenesis  
Analytical chemistry methods development to support toxicology studies.

Reviewer for Scientific Journals

Analytical Chemistry  
Bulletin of Environmental Contamination & Toxicology (Member of Editorial Board)  
Environmental Health Perspectives (Contributing Editor)  
Fundamental and Applied Toxicology  
Journal of the National Cancer Institute  
Science

Invited Papers

Invited to be Session Chairman and to present paper entitled "Analytical Chemistry Requirements for Toxicity Testing of Environmental Chemicals" at the Symposium on Chemistry and Safety for Toxicity Testing of Environmental Chemicals, at the 183rd National American Chemical Society Meeting, Las Vegas, NV, March 1982.

Invited to serve as a panelist on the NBC nationally televised series "Health Field" with Dr. Frank Field. A two-day series was filmed on Environmental Chemistry and Chemical Health Concerns, 1982.

*C W Jameson - Curriculum Vitae and Bibliography*

Invited to give a seminar entitled "Analytical Chemistry Requirements for Toxicity Testing." Duke University, Durham, NC, July 1982.

Invited to present a paper entitled "Practical Aspects of Analytical Chemistry Support for Toxicity Testing" at the Symposium on the Role of the Analytical Chemist in Animal and Molecular Toxicology, at the Federation of Analytical Chemistry and Spectroscopy Societies Meeting XI, Philadelphia, PA. September 16-21, 1984.

Invited to present a paper entitled "Application of Microencapsulation in Toxicity Testing" at the NIEHS Center Directors Meeting, Research Triangle Park, North Carolina, November 1984.

Invited to be Session Chairman and to present paper entitled "Chemical Quality Assurance Techniques for Toxicity Testing of Environmental Chemicals" at the Symposium on Accurate Measurements of Environmental Pollutants, at the 1984 International Chemical Congress of Pacific Basin Societies, Honolulu, Hawaii, December 16-21, 1984.

Invited to present a paper entitled "Lack of Evidence for Involvement of Cyanide in Methyl Isocyanate (MIC) Toxicity" at the Society of Toxicology Meeting, New Orleans, LA, March 3-7, 1986.

Invited to present a paper entitled "Toxicology From A Chemist's Viewpoint" at the Mount Saint Mary's College Science Alumni Homecoming, Emmitsburg, Maryland, October 23-26, 1986.

Invited to be Session Chairman and to present paper entitled "Application of Microencapsulation for Toxicity Studies" at the Symposium on Techniques for Microencapsulation of Chemicals at the 198th National Meeting of the American Chemical Society, Dallas, Texas, April 10-14, 1989.

Invited to be Session Chairman and to present paper entitled "Application of a Fischer Rat Leukemia Transplant Model as a Screen for the Leukemogenic Potential of Chemicals" at the International Symposium on Toxicology, Beijing, P. R. China, October 16-19, 1990.

Invited to present a paper entitled "Investigation of Alternative Vehicles for Use in Toxicology Research: Use of Microencapsulated and Molecular Encapsulated Chemicals in Toxicity Studies" at the Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, P. R. China, October 20, 1990.

Invited to present a paper entitled "Toxicology and Carcinogenicity Studies of d- Limonene in Male and Female F344 Rats and B6C3F1 Mice" at the Symposium on Food Phytochemicals for Cancer Chemoprevention at the 204th National Meeting of the American Chemical Society, Washington, D.C., August 23-28, 1992.

Invited to be a Faculty Member and to present talk entitled " The National Toxicology Program's Report on Carcinogens " at the Toxicology Forum, Washington, DC, February 1995.

Invited to be a Faculty Member and to present talk entitled " The Report On Carcinogens (RoC): Status Of The Review Of The Criteria For Listing Substances In The RoC " at the Toxicology Forum, Washington, DC, February 1996.

*C W Jameson - Curriculum Vitae and Bibliography*

Invited to be a Faculty Member and to present talk entitled " Update of 1997 review of Nominations for the 9<sup>th</sup> Report on Carcinogens " at the Toxicology Forum, Washington, DC, February 1998.

Invited to be a Faculty Member and to present talk entitled " NTP Report on Carcinogens: History and the Process " at the Toxicology Forum, Aspen, CO, July 1999.

## **BIBLIOGRAPHY**

### Publications

1. Mazzocchi PH, Ammon HL, **Jameson CW**. Lanthanide Shift Reagents III: Errors Resulting from the Neglect of Angle Dependence, *Tetrahedron Letters*, 573, 1973.
2. **Jameson CW**. I. Study of Lanthanide shift Reagent - Substrate Interaction in Solution. II. Competitive Photochemical Type I and Type II Reactions of Amides and Imides. Dissertation Abstracts, 1975.
3. Ennis DM, Kramer A, Mazzocchi PH, **Jameson CW**, Bailey WJ. Synthetic N-Releasing Biodegradable Soil Conditioners I, *Hort Science*, 10, 505, 1975.
4. Ammon HL, Mazzocchi PH, Colicelli E, **Jameson CW**, Liu L. A Convenient Method for Mixing <sup>2</sup>H and <sup>13</sup>C Lanthanide Induced Shift (LIS) Calculations, A Technique for Facilitating <sup>13</sup>C Assignments, *Tetrahedron Letters*, 1745, 1976.
5. Ennis DM, Kramer A, **Jameson CW**, Mazzocchi PH, Bailey WJ. Structural Factors Influencing the Biodegradation of Imides, *Appl Environ Microbiology*, 35, 51, 1978.
6. Murrill EA, Woodhouse EJ, Olin SS, **Jameson CW**. Carcinogenesis Testing and Analytical Chemistry, *Analytical Chemistry*, 52, 1188A, 1980.
7. Douglas JF, Hamm TE, **Jameson CW**, Mahar H, Stinson S, Whitmire CE. Monitoring Guidelines for the Conduct of Carcinogen Bioassays. US Department of Health and Human Services. DHHS Publication No. (NIH) 81-1774. Washington, DC, US Government Printing Office, 80 pp., 1981.
8. Dieter MP, Luster MI, Boorman GA, **Jameson CW**, Dean JH, Cox JW. Immunological and Biochemical Responses in Mice Treated with Mercuric Chloride, *Toxicol Appl Pharmacol*, 68, 218, 1983.
9. **Jameson CW**, Dunnick JK, Brown RD, Murrill EA. Chemical Characterization of Psoralens Used in the National Toxicology Program Research Projects, *National Cancer Institute Monograph*, 66, 103, 1984.
10. Timmons L, Cannon M, Grese D, Brown R, Haile C, Murrill E, **Jameson CW**. Identification of Chlorinated Phenyl and Phenoxy Substituted Dibenzodioxin, Dibenzofuran and Diphenyl Ether Homologs in Commercial Grade Pentachlorophenol, *Analytical Letters*, 17(A4), 277-296, 1984.

*C W Jameson - Curriculum Vitae and Bibliography*

11. Timmons L, Steel D, Cannon M, Grese D, Brown R, Murrill E, **Jameson CW**. Identification of Bromotertrachlorophenol in Commercial Pentachlorophenol Samples, *Journal of Chromatography*, V 314, 476-481, 1984.
12. Dunnick JK, **Jameson CW**, Benson JM. Toxicology and Carcinogenesis Studies of Nickel Oxide, Nickel Subsulfide and Nickel Sulfate. *Annals of Clinical and Laboratory Science*. V14.N5. 400-401, 1984.
13. Lamb JC, IV, **Jameson CW**, Choudury H, Gulati D K. Fertility Assessment by Continuous Breeding: Evaluation of Diethylstilbestrol and a Comparison of Results from Two Laboratories. *J Amer Coll Toxicol* 4, 173, 1985.
14. Thigpen JE, Liu LA, Richter CB, Lebetkin EH, Haseman JK, **Jameson CW**. The Comparative Estrogenic Activity of Semipurified, Certified, Standard and Open Formula Rodent Diets. *Laboratory Animal Science*, V35, N5, 526-527, 1985.
15. Kline DA, Hanna GR, Kuhn GO, Honaker CB, **Jameson CW**. Preparation and Stability of Animal Feed Mixtures Dosed with Rotenone, *J Asso Off Anal Chem*, Vol. 69, #4, 660-663, 1986.
16. **Jameson CW**, Moseman RF, Collins BJ, Hooper ND. Spy Dust: Methods for the Detection and Cleanup of a Chemical Tracking Agent. *Analytical Chemistry*, 58, 915A, 1986.
17. Agarwal DK, Eustis S, Lamb JC, **Jameson CW**, Kluwe WM. Influence of Dietary Zinc on Di(2-ethylhexyl)phthalate-Induced Testicular Atrophy and Zinc Depletion in Adult-Rats. *Toxicology and Applied Pharmacology*, V84, N1, 12-24, 1986.
18. Boorman GA, Hong HL, **Jameson CW**, Yoshitomi K, Maronpot, RP. Regression of Methyl Bromide Induced Forestomach Lesions in the Rat. *Toxicology and Applied Pharmacology*, 86, 131-139, 1986.
19. Collins B, Goehl TJ, **Jameson CW**, Kuhn G, Dux T. Analytical Methods for the Analysis of Microencapsulated Trichloroethylene in Corn Oil, Feed Dosage Formulations and Rat Whole Blood. *J. of Analytical Toxicology*, 10, 236, 1986.
20. **Jameson CW**, NTP Technical Report on the Toxicology and Carcinogenesis Studies of Tetrakis(hydroxymethyl)phosphonium sulfate (THPS) and Tetrakis(hydroxymethyl)phosphonium Chloride (THPC) in F344/N Rats and B6C3F1 Mice (Gavage Studies). NIH Publication No. 296, 1987.
21. Dunnick J K, **Jameson CW**, Montgomery CA. Subchronic Toxicity of Propantheline Bromide Administered in the Feed to Fischer 344/N Rats and B6C3F1 Mice. *Fundamental and Applied Toxicology*, V9, N3, 496-503, 1987.
22. Germolec DR, Bureson GR, **Jameson CW**, Ackermann MF, Lamm KR, Hayes HT, Luster MI. Depression of Natural-Killer Cell-Activity by Ochratoxin-A. *Environmental Health Perspectives*, V75, No. 5, 145-145, 1987.

*C W Jameson - Curriculum Vitae and Bibliography*

23. **Jameson CW**, Moseman RF, Hooper ND, Collins BJ. Spy Dust - Detecting a Chemical Tracking Agent. *Environmental Health Perspectives*, V75, No. 5, 143-143, 1987.
24. Melnick RL, **Jameson CW**, Goehl TJ. Application of Microencapsulation for Toxicology Studies - Stability, Bioavailability, and Toxicity of Microencapsulated Trichloroethylene. *Environmental Health Perspectives*, V75, No. 5, 142-142, 1987.
25. Melnick RL, **Jameson CW**, Goehl TJ, Kuhn GO. Application of Microencapsulation for Toxicology Studies. 1. Principles and Stabilization of Trichloroethylene In Gelatin-Sorbitol Microcapsules. *Fundamental and Applied Toxicology*, V8, N4, 425-431, 1987.
26. Melnick RL, **Jameson CW**, Goehl TJ, Maronpot RR, Collins BJ, Greenwell A, Harrington FW, Wilson RE, Tomaszewski KE, Agarwal DW. Application of Microencapsulation for Toxicology Studies. 2. Toxicity of Microencapsulated Trichloroethylene in Fischer 344 Rats. *Fundamental and Applied Toxicology*, V8, N4, 432-442, 1987.
27. Thigpen JE, Lung-An L, Richter CB, Lebetkin, EH, Haseman, JK, **Jameson CW**. The Mouse Bioassay Test for the Detection of Estrogenic Activity in Feeds and Foodstuffs. Part I: A Standardized Method for Conducting the Mouse Bioassay using the CD-1 Mouse. *Laboratory Animal Science*, V37, N5, 596-601, 1987.
28. Thigpen JE, Lung-An L, Richter CB, Lebetkin EH, **Jameson CW**. The Mouse Bioassay Test for the Detection of Estrogenic Activity in Feeds and Foodstuffs. Part II: The Comparative Estrogenic Activity of Purified, Certified Standard, Open and Closed Formula Rodent Diets. *Laboratory Animal Science*, V37, N5, 602-605, 1987.
29. Bucher JR, Gupta BN, Adkins B, Thompson M, **Jameson CW**, Thigpen J E, Schwetz BA. The Toxicity of Inhaled Methyl Isocyanate in F344/N Rats and B6C3F1 Mice. I: Acute Exposure and Recovery Studies. *Environmental Health Perspectives*, V72, 53-61, 1987.
30. Luster MI, Germolec DR, Burleson GR, **Jameson CW**, Ackermann MF, Lamm KR, Hayes HT. Selective Immunosuppression in Mice of Natural Killer Cell Activity by Ochratoxin A. *Cancer Research*, Vol. 47, 2259-2263, 1987.
31. Dieter MP, **Jameson CW**, Tucker AN, Luster MI, French JE, Hong, HL, Boorman, GA. Evaluation of Tissue Disposition, Myelopoietic and Immunologic Responses in Mice After Long-term Exposure to Nickel Sulfate in the Drinking Water. *Journal of Toxicology and Environmental Health*, V24, 357-372, 1988.
32. Huff JE, McConnell EE, Haseman JK, Boorman GA, Eustis SL, Schwetz BA, Rao GN, **Jameson CW**, Hart LG, Rall DP. Carcinogenesis Studies Results of 398 Experiments on 104 Chemicals from the U. S. National Toxicology Program. *Annals of the New York Academy of Sciences* V534, 1-30, 1988.
33. Shan A, Harben D, **Jameson CW**. Analyses of Two Azo Dyes by High Performance Liquid Chromatography. *Journal of Chromatographic Science*, V26, 439-442, 1988.

*C W Jameson - Curriculum Vitae and Bibliography*

34. Hong HL, Canipe J, **Jameson CW**, Boorman GA: Comparative Effects of Ethylene Glycol and Ethylene Glycol Monomethyl Ether Exposure on Hematopoiesis and Histopathology in B6C3F1 Mice. *Journal of Environmental Pathology, Toxicology, and Oncology*, V8, N7, 27-38, 1988.
35. Hong HL, **Jameson CW**, Boorman GA. Residual Hematopoietic Effect of Ochratoxin A in Mice Exposed to Irradiation. *Toxicology*, V53, 57-67, 1988.
36. Dieter MP, **Jameson CW**, French JE, Gangjee S, Stefanski SA, Chan, PC. Development and Validation of a Cellular Transplant Model for Leukemia in Fischer Rats: A Short-term Assay for Potential Anti-leukemic Chemicals. *Leukemia Research*, V13, 841-849, 1989.
37. Timmons L, Brown R, Arneson DW, **Jameson CW**. Rapid Determination of Low pg/mg Amounts of N-Nitrosodiethylamine in Rodent Body Fluid and Tissue Samples by Isotope-Dilution High Resolution Mass Spectrometry. *J. Anal. Tox.*, V13, N6, 333-336, 1989.
38. Heindel JJ, Lamb JC, Chapin RE, Gulati DK, Hope E, George J, **Jameson CW**, Teague J, Schwetz BA. Reproductive Toxicity Testing by Continuous Breeding Test Protocol in CD-1 Mice. DHHS Publication No. (NIH) 89 Washington, DC, US Government Printing Office, 1989.
39. Cannon JM, Brown D, Murrill EM, **Jameson CW**. Identification of Components in Iodinated Glycerol. *Journal of Pharmaceutical Sciences*, V78, N1, 48-51, 1989.
40. Morgan DL, **Jameson CW**, Mennear JH, Prejean JD. 14-Day and 90-Day Toxicity Studies of C.I. Pigment Red 3 in Fischer 344 Rats and B6C3F1 Mice. *Fd. Chem. Toxic.*, V27, N12, 793-800, 1989.
41. Morgan DL, **Jameson CW**, Mennear JH, Ulland BM. Thirteen-Week Toxicity Studies of CI Direct Blue 15 and 3,3'-Dimethoxybenzidine in the Fischer 344 Rat. *Toxicology*, V59, 297-309, 1989.
42. Dieter MP, **Jameson CW**, Maronpot RR, Langenbach RJ, Braun AG. The Chemotherapeutic Potential of Glycol Alkyl Ethers: Structure-Activity Studies of Nine Compounds in a Fischer Rat Leukemia Transplant Model. *Cancer Chemother. Pharmacol.*, 26, 173-180, 1990.
43. Gorski T, Goehl TJ, **Jameson CW**, Collins BJ. Sources of Error in the Determination of Trichloroethylene in Blood. *Bull. Environ. Contam. Toxicol.*, V45, 1-5, 1990.
44. Dieter MP, Boorman GA, **Jameson CW**, Matthews HB, Huff JE. The Carcinogenic Activity of Commercial Grade Toluene Diisocyanate in Rats and Mice in Relation to the Metabolism of the 2,4- and 2,6-TDI Isomers. *Toxicology and Industrial Health*, V6, No. 6, 599-621, 1990.
45. Morrissey RE, Fowler BA, Harris MA, Moorman MP, **Jameson CW**, Schwetz BA. Arsine: Absence of Developmental Toxicity in Rats and Mice. *Fundamental and Applied Toxicology* 15, 350-356, 1990.
46. **Jameson CW**, NTP Technical Report on the Toxicology and Carcinogenesis Studies of d-Limonene in F344/N Rats and B6C3F1 Mice (Gavage Studies). NIH Publication No. 347, 1990.
47. Gorski T, Goehl TJ, **Jameson CW**, Collins BJ, Bursey J, Moseman R. Gas Chromatic Determination of 2-Ethylhexanol and 2-Ethylhexanoic Acid as Derivatives suitable for Electron Capture and Nitrogen-

*C W Jameson - Curriculum Vitae and Bibliography*

- Phosphorus Detection After Single Reaction with Heptafluorobutyrimidazole. *Journal of Chromatography*, 509, 383-389, 1990
48. Yuan J, **Jameson CW**, Goehl TJ, Collins BJ, Corniffee G, Kuhn G, Castro C. Effects of Physical Binding of o-Nitroanisole with Feed Upon its Systemic Availability in Male F344 Rats. *Bulletin of Environmental Contamination and Toxicology*, 47: 152-159, 1991.
  49. Yuan J, **Jameson CW**, Goehl TJ, Collins BJ, Purde W, Judd L. Application of Molecular Encapsulation for Toxicity Studies: Toxicokinetics of p-Chloro- $\alpha,\alpha,\alpha$ -trifluorotoluene in  $\beta$ -Cyclodextrin or Corn Oil Vehicles in Male F344 Rats. *Toxicology and Applied Pharmacology*, 111, 107-115, 1991.
  50. Dieter MP, **Jameson CW**, Elwell M, Lodge JW, Hejtmancik M, Grumbein SL, Ryan M, Peters AC. Comparative Toxicity and Tissue Distribution of Antimony Potassium Tartrate in Rats and Mice Dosed by Drinking Water and Intraperitoneal Injection. *Journal of Toxicology and Environmental Health*, 34, 51-82, 1991.
  51. Yuan J, Bucher JR, Goehl TJ, Dieter MP, **Jameson CW**. Quantitation of Cinnamaldehyde and Cinnamic Acid in Blood by HPLC. *Journal of Analytical Toxicology*, 16, N6: 359-362, 1992.
  52. Yuan J, **Jameson CW**, Goehl TJ, Elwell MR, Leininger JR, Thompson MB, Corniffe G, Carleton T. Application of Molecular Encapsulation for Toxicology Studies: Comparative Toxicity of p-Chloro- $\alpha,\alpha,\alpha$ -trifluorotoluene in  $\beta$ -Cyclodextrin Vehicle versus Corn Oil Vehicle in Male and Female Fischer 344 Rats and B6C3F1 Mice. *Fundamental and Applied Toxicology*, 18, 460-470, 1992.
  53. Dieter MP, Maronpot RR, **Jameson CW**, Ward SM. The Effects of Iodinated Glycerol, Trichlorfon, Acetaminophen on Tumor Progression in a Fischer Rat Leukemia Transplant Model. *Cancer Detection and Prevention*, V16, No. 3, 173-183, 1992.
  54. Yuan J, Dieter MP, Bucher JR, **Jameson CW**. Toxicokinetics of Cinnamaldehyde in F344 Rats. *Food and Chemical Toxicology*, 30, N12: 997-1004, 1992.
  55. Yuan J, **Jameson CW**, Goehl TJ, Collins BJ. Molecular Encapsulator: A Novel Vehicle for Toxicology Studies. *Toxicology Methods*, V1, No.4, 231-241, 1992.
  56. Dieter MP, Boorman GA, **Jameson CW**, Eustis SL. Development of Renal Toxicity in F344 Rats gavaged with Mercuric Chloride for 2 Weeks, or 2, 4, 6, 15, and 24 Months. *Journal of Toxicology and Environmental Health*, 36, 319-340, 1992.
  57. Yuan J, Dieter MP, Bucher JR, **Jameson CW**. Application of Microencapsulation for Toxicology Studies III, Bioavailability of Microencapsulated Cinnamaldehyde. *Fundamental and Applied Toxicology*, 20, N1: 83-87, 1993.
  58. Dieter MP, Goehl TJ, **Jameson CW**, Elwell MR, Hildebrant PK, Yuan J. Comparison of the Toxicity of Citral in F344 Rats and B6C3F1 Mice When Administered by Microencapsulation in Feed or by Corn Oil Gavage. *Food and Chemical Toxicology*, 31, N7: 463-474, 1993.

*C W Jameson - Curriculum Vitae and Bibliography*

59. Arneson DA, Kuhn GO, **Jameson CW**. Analysis of Feed Blends Containing Microencapsulated 2-Ethyl-1-hexanol: Verification of Homogeneity and Stability. *Journal of Applied Toxicology*, 15 (1), 1-4, 1995.
60. **Jameson CW**, Ed. Conference on Beryllium Related Diseases. *Environmental Health Perspectives*, Vol. 104, S5, 935-998, 1996.
61. **Jameson CW**. Introduction to the Conference on Beryllium Related Diseases. *Environmental Health Perspectives*, Vol. 104, S5, 935-936, 1996.
62. Gulson BL, **Jameson CW**, Mahaffey KR, Mizon KJ, Korsch MJ, Vimpani, G. Pregnancy increases mobilization of lead from maternal skeleton. *J Lab Clin Med.*, 130, 51-62, 1997.
63. Gulson BL, Gillings BR, **Jameson CW**. Stable lead isotopes in teeth as indicators of past domicile - a potential new tool in forensic science. *J Forensic Sciences*, 42, 787-791, 1997.
64. Gulson BL, Mahaffey KR, **Jameson CW**, Vidal M, Law AJ, Mizon KJ, Korsch MJ. Dietary Intake for Mother-Child Pairs and Implications for Pharmacokinetic Models. *Environ Health Persp.*, 105, 1334-1342, 1997.
65. Gulson BL, Cameron MA, Smith AJ, Mizon KJ, Korsch MJ, Vimpani G, McMichael AJ, Pisaniello D, **Jameson CW**, Mahaffey KR. Blood lead-urine relationships in adults and children. *Environ Res. Section A* 78, 152-160, 1998.
66. Gulson BL, **Jameson CW**, Mahaffey KR, Mizon KJ, Korsch MJ, Cameron MA, Eisman JA. Mobilization of lead from the skeleton during the post-natal period is larger than during pregnancy. *J Lab Clin Med.*, 131, 324-329, 1998.
67. Gulson BL, **Jameson CW**, Mahaffey KR, Mizon KJ, Patison N, Law JL, Korsch MJ, Salter MA. Relationship of Lead in Breast Milk to Lead in Blood, Urine, and Diet of the Infant and Mother. *Environ Health Persp.*, 106, 667-674, 1998.
68. Gulson BL, Gray B, Mahaffey KR, **Jameson CW**, Mizon KJ, Patison N, Korsch MJ. Comparison of the rates of exchange of lead in the blood of newly born infants and their mothers with lead from their current environment, *J Lab Clin Med.*, 133, Vol. 2, 171-178, 1999.
69. Gulson BL, Mahaffey KR, **Jameson CW**, Patison N, Law JL, Mizon KJ, Korsch MJ, Pederson, D. Impact of Diet on Lead in Blood and Urine in Female Adults and Relevance to Mobilization of Lead from Bone Stores. *Environ Health Persp.*, 107, N4, 257-263, 1999.
70. Bucher JR, **Jameson CW**. Environmental tobacco smoke epidemiology. *Environ Health Perspect.* 107(8): A395, 1999.
71. Waalkes, M. P. and **Jameson, C. W.**: Evaluation of nickel compounds for listing in the Report on Carcinogens. In: Vernet, P. G. (ed.). *Proceedings of the Sixth International Symposium on Metal Ions in Biology and Medicine*. Montrouge, France, John Libby Eurotext, Ltd. In press, 2000.

*C W Jameson - Curriculum Vitae and Bibliography*

72. Gulson BL, Mizon KJ, Palmer JM, Korsch MJ, Patison N, **Jameson CW**, Donnelly JB. Urinary lead isotopes during pregnancy and postpartum indicate no preferential partitioning of endogenous lead into plasma. *J Lab Clin Med.*, 136(3): 236-42, 2000.
73. Portier CJ, et al. Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA) *J Epidemiol Community Health* August Vol 70 No 8: 741-745, 2016.

Listed as a contributor for the evaluation, interpretation and reporting of results for more than 100 chemicals studied in chronic two-year bioassay studies by the National Toxicology Program as published in the Technical Report Series (1980-1990).

BOOKS

**Jameson CW** and Walters DB, Eds. *Chemistry for Toxicity Testing*, Butterworth Publishers, Boston, MA, 1984.

Walters DB and **Jameson CW**, Eds. *Health and Safety for Toxicity Testing*, Butterworth Publishers, Boston, MA, 1984.

REPORTS

**Jameson CW**, Editor, *Report on Carcinogens, Eighth Edition*, U.S. Department of Health and Human Services, Public Health Service, 1998.

**Jameson CW**, Editor, *Report on Carcinogens, Ninth Edition*, U.S. Department of Health and Human Services, Public Health Service, 2000.

**Jameson CW**, Editor, *Report on Carcinogens, Tenth Edition*, U.S. Department of Health and Human Services, Public Health Service, 2002.

**Jameson CW**, Editor, *Report on Carcinogens, Eleventh Edition*, U.S. Department of Health and Human Services, Public Health Service, 2004.

**Jameson CW**, Senior Author for following NTP Report on Carcinogens Background Documents:

1. Alcoholic Beverage Consumption - 1999
2. 1-Amino-2,4-dibromoanthraquinone - 2002
3. 2-Amino-3,4-dimethylimidazo[4-5-f]quinoline (MeIQ) - 2002
4. 2-Amino-3,8-dimethylimidazo[4-5-f]quinoxaline (MeIQx) - 2002
5. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) - 2002
6. 2-Amino-3-methylimidazo[4,5-f]quinoline (IQ) - 2002
7. Azacitidine - 1996
8. Beryllium and Beryllium Compounds - 2000

*C W Jameson - Curriculum Vitae and Bibliography*

9. 2,2-bis-(bromomethyl)-1,3-propanediol (BBMP) (Technical Grade) - 2000
10. Boot & Shoe Manufacturing - 1998
11. 1,3- Butadiene - 1997
12. Cadmium and Cadmium Compounds - 1997
13. Chloramphenicol - 2000
14. Chloroprene - 1997
15. Chlorozotocin - 1996
16. p -Chloro-o-toluidine and its Hydrochloride Salt - 1996
17. Cobalt Sulfate - 2002
18. Cyclosporin A - 1996
19. Danthron (1,8-Dihydroxyanthraquinone) - 1996
20. Diazoaminobenzene - 2002
21. 2,3-Dibromo-1-propanol - 2000
22. Diesel Exhaust Particulates - 1998
23. Diethanolamine - 2002
24. 1,6-Dinitropyrene & 1,8-Dinitropyrene - 1996
25. Disperse Blue 1 - 1996
26. Dyes Metabolized to Benzidine (Benzidine Dyes as a Class) - 1997
27. Dyes metabolized to 3,3'-Dimethoxybenzidine (DMOB) - 2000
28. Dyes metabolized to 3,3'-Dimethylbenzidine (DMB) - 2000
29. Environmental Tobacco Smoke - 1998
30. Estrogens, Steroidal - 2000
31. Ethyl Acrylate - 1998
32. Ethylene Oxide - 1998
33. Furan - 1996
34. Hepatitis B Virus (HBV) - 2003
35. Hepatitis C Virus (HCV) - 2003
36. Human Papillomaviruses (HPV): Some Genital-Mucosal Types - 2003
37. Isoprene - 1998
38. Lead and Lead Compound - 2003
39. Methyleugenol - 2000
40. Methyl-t-Butyl Ether (MtBE) - 1998
41. Naphthalene - 2002
42. Nickel Compounds - 1998
43. Nickel (Metallic) and Certain Nickel Alloys - 2000
44. o-Nitroanisole - 1996
45. Nitrobenzene - 2002
46. 6-Nitrochrysene - 1996
47. Nitromethane - 2002
48. 1-Nitropyrene - 1996
49. 4-Nitropyrene - 1996
50. Phenolphthalein - 1997
51. Saccharin - 1997
52. Silica, Crystalline (Respirable Size) - 1998
53. Smokeless Tobacco - 1997
54. Solar Radiation & Exposure to Sunlamps or Sunbeds - 1997
55. Strong Inorganic Acid Mists Containing Sulfuric Acid - 1997
56. Styrene-7,8-oxide - 2000

*C W Jameson - Curriculum Vitae and Bibliography*

57. Tamoxifen - 1997
58. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) - 1997
59. Tetrafluoroethylene - 1997
60. 4,4'-Thiodianiline - 2002
61. Thiotepa - 1996
62. Tobacco Smoking - 1997
63. 1,2,3-Trichloropropane - 1996
64. Trichloroethylene - 1997, 2000
65. Ultraviolet (UV) Radiation, Broad Spectrum and UVA, UVB, and UVC - 2000
66. Vinyl Bromide - 2000
67. Vinyl Fluoride - 2000
68. Wood Dust - 2000
69. X-Radiation & Gamma Radiation and Neutrons – 2003

**Jameson CW** Contributor to the following NTP Report on Carcinogens Background Documents:

1. Aristolochic Acid Related Exposures (2 Candidate Substances) - 2008
  - a. Botanical Products Containing Aristolochic Acid
  - b. Aristolochic Acid
2. Captafol – 2008
3. ortho-Nitrotoluene – 2008
4. Riddelliine - 2008
5. Styrene - 2008
6. Cobalt – Tungsten Carbide; Powders and Hard Metals – 2009
7. Glass Wool Fibers – 2009

BOOK CHAPTERS

1. **Jameson CW**. Analytical Chemistry Requirements for Toxicity Testing of Environmental Chemicals, in Chemistry for Toxicity Testing, pp. 3-14, Butterworth Publishers, Boston, MA, 1984.
2. **Jameson CW**, Rollheiser JJ, Kuhn GO. Stability Determinations of Chemical/Vehicle Mixtures, in Chemistry for Toxicity Testing, pp. 107-114, Butterworth Publishers, Boston, MA, 1984.
3. Kuhn GO, Rollheiser JJ, Schworer BA, **Jameson CW**. Methods Development for Mixing Chemicals in Rodent Feed, in Chemistry for Toxicity Testing, pp. 59-81, Butterworth Publishers, Boston, MA, 1984.
4. Murrill EA, Kuhn GO, Rollheiser JJ, **Jameson CW**. Analysis of Dose Feed Mixtures, in Chemistry for Toxicity Testing, pp. 91-106, Butterworth Publishers, Boston, MA, 1984.
5. Woodhouse EJ, Murrill EA, Stelting KM, **Jameson CW**. Problems of Testing Commercial-Grade Chemicals, in Chemistry for Toxicity Testing, pp. 31-50, Butterworth Publishers, Boston, MA, 1984.

*C W Jameson - Curriculum Vitae and Bibliography*

6. Graves SW, Woodhouse EJ, Stelting KM, **Jameson CW**: Bulk Chemical Management for chronic Toxicity Studies, in Health and Safety for Toxicity Testing, pp. 221-240, Butterworth Publishers, Boston, MA, 1984.
7. Huff JE, McConnell EE, Haseman JK, Boorman GA, Eustis SL, Schwetz BA, Rao GA, **Jameson CW**, Hart LG, Rall DP. Carcinogenesis Studies: Results of 398 Experiments on 104 Chemicals from the U. S. National Toxicology Program, in Living in a Chemical World, Occupational and Environmental Significance of Industrial Carcinogens, Annals of the New York Academy of Sciences, V 534, pp. 1-31, 1988.
8. Fouts JR, **Jameson CW**. Hazard Identification, The First Step, in Proceedings of the National Minority Health Conference, Atlanta GA, December 1990.
9. **Jameson CW**, Goehl TJ. Chemistry Requirements for the Toxicologic and Carcinogenicity Evaluation of Chemicals, in the Handbook of Carcinogen Testing, Second Edition, pp. 286-297, Noyes Publications, Park Ridge, NJ, 1994.

ABSTRACTS/PRESENTATIONS

1. Mazzocchi PH, **Jameson CW**, Nishiyama T. Competing Processes in the Photochemistry of Alkyl Imides. Proceedings of the 178th National Meeting of the American Chemical Society, Washington, DC, September 1979.
2. **Jameson CW**. An Overview of Analytical Chemistry Requirements for Toxicity Testing. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
3. **Jameson CW**, Rollheiser JJ, Kuhn GO. Stability Determinations of Chemical/Vehicle Mixtures. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
4. **Jameson CW**, Grieshaber CK, Whitmire CE. Effect of GLPs on Chemistry Requirements for Toxicity Testing. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
5. Kuhn GO, Rollheiser JJ, Schworer BA, **Jameson CW**. Methods Development for Mixing Chemicals in Rodent Feed. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
6. Murrill EA, Kuhn GO, Rollheiser JJ, **Jameson CW**. Analysis of Dose Feed Mixtures. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
7. Woodhouse EJ, Murrill EA, Brown RD, **Jameson CW**. The Problems of Testing Commercial Grade Chemicals. Proceedings of the 183rd National Meeting of the American Chemical Society, NV, March 1982.

*C W Jameson - Curriculum Vitae and Bibliography*

8. Graves SW, Woodhouse EJ, Stelting KM, **Jameson CW**. Bulk Chemical Management for Chronic Toxicity Studies. Proceedings of the 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 1982.
9. **Jameson CW**, Castro CA, Kuhn GO, Murrill EA. Quality Assurance Techniques for Reference laboratory Analysis of Dosage Formulations. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
10. Pallas FE, DuSold DE, Murrill EA, **Jameson CW**. HPLC Determination of Benzidine and its Congeners in Direct Dyes. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
11. Rollheiser JJ, Stelting KM, Woodhouse EJ, **Jameson CW**. Microcomputer Applications in a Bioanalytical Chemistry Laboratory. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
12. Fanska CB, Pittman LW, Murrill EA, **Jameson CW**, Dieter MP. HPLC Determination of Benzo(a)pyrene and Benzo(e)pyrene in Mouse Tissues. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
13. Cannon JM, Wyatt LL, Brown RD, Murrill EA, **Jameson CW**, Dieter MP. Analysis of Titanium in Tissues by IP Spectroscopy. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
14. Pittman LW, Lillich MA, Walters KM, Murrill EA, **Jameson CW**. HPLC Purity Analysis of Benzidine Congener-Based Dyes. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
15. Brown RD, Murrill EA, Stelting KM, Woodhouse EJ, **Jameson CW**. Selection of Analytical Methods for Characterization of Commercial Chemicals. Proceedings of the 184th National Meeting of the American Chemical Society, Kansas City, MO, September 1982.
16. Dieter MP, Luster MI, Dean JH, Boorman GA, **Jameson CW**. Immunotoxicity of Mercuric Chloride in B6C3F1 Mice. *The Toxicologist*, 2, 92, 1982.
17. Rollheiser JJ, Stelting KM, Woodhouse EJ, Kuhn GO, **Jameson CW**. A Systematic Procedure for the Development of Chromatographic Methods of Analysis of Dosed Feed Mixtures. Proceedings of the 184th National Meeting of the American Chemical Society, Seattle, WA, March 1983.
18. Minor CM, Graves SW, Stelting KM, Woodhouse EJ, **Jameson CW**. Microcomputer Uses in Quality Assurance. Proceedings of the 184th National Meeting of the American Chemical Society, Seattle, WA, March 1983.
19. Fanska CB, Shan A, Murrill EA, **Jameson CW**. HPLC Determination of Chloramphenicol and its Monosuccinate Esters in Rat and Mouse Sera. Proceedings of the 186th National Meeting of the American Chemical Society, Washington, DC, August 1983.

*C W Jameson - Curriculum Vitae and Bibliography*

20. Kuhn GO, Stelting KM, Dux T, **Jameson CW**. Analysis of o-Nitroanisole in Aged Feed Blends. Proceedings of the 186th National Meeting of the American Chemical Society, Washington, DC, August 1983.
21. Kuhn GO, Stelting KM, Kline DA, Murrill EA, **Jameson CW**. Determination of Sub-PPB Levels of Diethylstilbestrol in Feeds. Proceedings of the 184th National Meeting of the American Chemical Society, Washington, DC, August 1983.
22. Cannon JM, Brown RD, Fanska C, Woodhouse EJ, Murrill EA, **Jameson CW**. Chemical Characterization of a Commercial Dye for Use in Bioassay Studies. Proceedings of the 186th National Meeting of the American Chemical Society, Washington, DC, August 1983.
23. Timmons L, Cannon M, Grese D, Brown RD, Murrill EA, **Jameson CW**. Identification of Chlorinated Phenyl Ethers of Dibenzodioxins and Diphenyl Ethers in Commercial Grade Pentachlorophenol. Proceedings of the 186th National Meeting of the American Chemical Society, Washington, DC, August 1983.
24. Melnick RL, **Jameson CW**, Goehl TJ, Kuhn GO. Microencapsulation of Chemicals for Toxicologic Studies. *The Toxicologist*, 4, 49, 1984.
25. Onstot J, Timmons L, Murrill E A, **Jameson CW**. HRGC/HRMS Identification of Chlorinated Phenyl and Phenoxy Substituted Dioxins, Furans and Diphenyl Ethers in Commercial Grade Pentachlorophenol. Proceedings of the American Society for Mass Spectrometry Symposium, San Antonio, TX, May 1984.
26. Rollheiser J, Buchanan RC, Maune C, **Jameson CW**. Determination of Salicylazosulfapyridine in Rodent Feed. Proceedings of the 189th National Meeting of the American Chemical Society, Philadelphia, PA, August 1984.
27. Kuhn GO, Ridlen RL, Dix TP, Stelting, KM, **Jameson CW**. Conformance Testing of Microencapsulated Chemicals for Use in Bioassay Studies. Proceedings of the 189th National Meeting of the American Chemical Society, Philadelphia, PA, August 1984.
28. Kuhn GO, Arneson D, Kline DA, Shan YA, Nguyen PTH, **Jameson CW**. Determination of Metabolites of Benzidine-Based Dyes in Rodent Urine. Proceedings of the 189th National Meeting of the American Chemical Society, Philadelphia, PA, August 1984.
29. Dunnick JK, **Jameson CW**, Benson JM. Toxicology and Carcinogenesis Studies of Nickel Oxide, Nickel Subulfide and Nickel Sulfate. Proceedings of the Third International Conference on Nickel Metabolism and Toxicology, Paris, France, September 1984.
30. **Jameson CW**. Practical Aspects of Analytical Chemistry Support for Toxicity Studies. Proceedings of the XI Federation of Analytical Chemistry and Spectroscopy Societies, Meeting, Philadelphia, PA, September 1984.

*C W Jameson - Curriculum Vitae and Bibliography*

31. Brown RD, Arneson DW, Stelting KM, **Jameson CW**. The Importance of Complementary Techniques in the Analysis of Commercial Chemicals for Toxicity Testing. Proceedings of the XI Federation of Analytical Chemistry and Spectroscopy Societies Meeting, Philadelphia, PA, September 1984.
32. Ridlen RL, Castro C, Rollheiser JJ, Kuhn GO, **Jameson CW**. Development of Analytical Methods for a Referee Dosage Analysis Program. Proceedings of the XI Federation of Analytical Chemistry and Spectroscopy Societies Meeting, Philadelphia, PA, September 1984.
33. **Jameson CW**, Goehl TJ, Davies CL. Chemical Quality Assurance Techniques for Toxicity Testing of Environmental Chemicals. Proceedings of the 1984 International Chemical Congress of Pacific Basin Societies, American Chemical Society, Honolulu, HI, December 1984.
34. Melnick RL, **Jameson CW**, Goehl TJ, Collins BJ, Maronpot RR, Greenwell A, Harrington F, Wilson R, Tomaszewski K, Agarwal D. Microencapsulation of Trichloroethylene: Stability, Bioavailability and Toxicity. North Carolina Chapter of the Society of Toxicology Annual Meeting, Research Triangle Park, NC, February 1985.
35. Dieter MP, **Jameson CW**, French JE, Brown RD, Lilya H. Target Organ Accumulation and Toxicity of Titanocene Dichloride (TDC) in F344 Rats. *The Toxicologist*, 5, 89, 1985.
36. Melnick RL, Goehl TJ, Collins B, **Jameson CW**, Maronpot R, Greenwell A, Harrington F, Wilson R, Tomaszewski K, Agarwal D. Toxicity of Microencapsulated Trichloroethylene (TCE) in Rats. *The Toxicologist*, 5, T228, 1985.
37. Kuhn GO, Dux TP, Ridlen RL, Stelting KM, **Jameson CW**. Analytical Procedures for Microencapsulated Trichloroethylene (TCE) In Rodent Feed. Proceedings of the 191st National Meeting of the American Chemical Society, Chicago, IL, September 1985.
38. Thigpen JE, Li LA, Richter CB, Lebetkin EH, Haseman JK, **Jameson CW**. The Comparative Estrogenic Activity of Semipurified, Certified, Standard and Open Formula Rodent Diets. American Association for Laboratory Animal Science, Baltimore, MD, November 1985.
39. **Jameson CW**, Schwetz BA, Goehl TJ, Moorman CR, Collins BJ. Lack of Evidence for Involvement of Cyanide in Methyl Isocyanate (MIC) Toxicity. *The Toxicologist*, 6, 76, 1986.
40. Dieter MP, **Jameson CW**, Tucker AN, Luster MI, French JE, Boorman GA. Immunotoxic Effects of Nickel Sulfate in Mice. *The Toxicologist*, 6, 263, 1986.
41. Ridlen RL, Kuhn GO, Arneson DW, **Jameson CW**. Effect of Microencapsulation Processes on Chemicals for Toxicology Studies. *The Toxicologist* 6, 304, 1986.
42. **Jameson CW**, Moseman RF, Collins BJ, Hooper ND. Spy Dust: Detection and Cleanup. Proceedings of the 193rd National Meeting of the American Chemical Society, Anaheim, CA, September 1986.
43. Moseman RF, **Jameson CW**, Hooper ND, Collins BJ. Analysis and Stability of 5-(4-Nitrophenyl)-pentadienal (NPPD) in Various Sample Materials. Proceedings of the 193rd National Meeting of the American Chemical Society, Anaheim, CA, September 1986.

*C W Jameson - Curriculum Vitae and Bibliography*

44. Dieter MP, French JE, **Jameson CW**, Stefanski SA, Chhabra RS. Evaluation of Mononuclear Cell Leukemia Using a Cellular Transplant Model in Rats: Studies of Pyridine, Trichlorophenol, Ethoxyethanol and Hexylresorcinol. *J. Cell. Biochem.*, 12C, 86, 1988.
45. **Jameson CW**, Goehl TJ, Gorski T, Collins BJ, Melnick RN, Kuhn GO, Harrington F. Microencapsulation of 1,1,1-Trichloroethane (TCE) and 2-Ethylhexanol (2 EH) for Toxicity Studies; Stability, Palatability and Evaluation of Chemical Availability. *The Toxicologist*, 8, 264, 1988.
46. Dieter MP, **Jameson CW**, Lodge JW, Hejtmancik M, Grumbein SL, Peters. Comparative Toxicity and Tissue Distribution of Antimony Potassium Tartrate in Rats and Mice Dosed by Drinking Water (DW) or Intraperitoneal Injection (IP). *The Toxicologist*, 8, 20, 1988.
47. Abdo KM, Thompson M, Bucher J, **Jameson CW**, Seely JC, Seilkop S, Prillaman J. Influence of Diet and Route of Administration on Vitamin E Toxicity in Male 344 Rats. *FASEB Journal*, V2, N5, 1097, 1988.
48. Yang RSH, Goehl TJ, **Jameson CW**, Germolec D, Luster MI, Chapin R, Morressey RE, Schwetz BA, Harris R, Chatham A, Arneson DW, Moseman R, Collinsworth N, Bigelow D. Chemical Stability and Biological Suitability of a 25-Chemical Mixture of Groundwater Contaminants for Animal Toxicology Studies. *The Toxicologist*, 9, 216, 1989.
49. Dieter MP, **Jameson CW**, French JE, Maronpot RR, Chhabra RS, Chan PC. Investigation of Structure Activity Relationships Between NTP Test Chemicals and Mononuclear Cell Leukemia Using a Cellular Transplant Model. *The Toxicologist*, 9, 124, 1989.
50. Michael LC, Martin-Goldberg M, Handy RW, **Jameson CW**. Determination of Lead and Cadmium in Rat Liver by Square Wave Stripping Voltammetry. Pittsburgh Conference, 1989.
51. Dieter MP, **Jameson CW**, Maronpot RR, Braun AG. The Chemotherapeutic Potential of Glycol Ethers. Structure Activity Studies with a Cellular Transplant Model of Leukemia in Rats. *Proc. Amer. Assoc. Cancer Res.*, 30, 615, 1989.
52. Bursley J, Moseman R, Parker C, Tomer K, **Jameson CW**. GC/MS and LC/MS in the Analysis of NPPD (Spy Dust). Proceedings of the Annual Meeting of The American Society of Mass Spectrometry, 1989.
53. Dieter MP, **Jameson CW**, Maronpot RR, French JE. Utilization of a Fischer Rat Leukemia Transplant Model as a Short-Term Assay to Screen Chemicals for Leukemogenesis or for Potential Anti-Leukemic Activity. Proceedings, XIVth International Symposium for Comparative Research on Leukemia and Related Disease, 1989.
54. Dieter MP, **Jameson CW**, Elwell MR. Structural Alerts for Leukemia: The Alkyl Phosphonic Ester (APE) Structure. *Proc. Amer. Assoc. Cancer Res.*, 1990.
55. **Jameson CW**, Eustis SL, Hong LH. Toxicology and Carcinogenicity Studies of d-Limonene in Male and Female F344 Rats and B6C3F1 Mice. *The Toxicologist*, 10, 142, 1990.

*C W Jameson - Curriculum Vitae and Bibliography*

56. Yuan J, **Jameson CW**, Goehl TJ, Collins BJ, Corniffee G. Systemic Availability of o-Nitroanisole in Male F344 Rats from Aged and Fresh Feed Formulations. *The Toxicologist*, 10, 337, 1990.
57. Dieter MP, Matthews HB, **Jameson CW**, Jeffcoat AR. Comparative Metabolism of 2,4- and 2,6-Isomers of Toluene Diisocyanate in F344 Rats. *The Toxicologist*, 10, 334, 1990.
58. Graves S, LeMunyon JM, Hardbeck EC, Arnold WT, Karrenbrock AH, Arneson DW, **Jameson CW**. Dose Formulation Studies of Microencapsulated 1,1,2,2,-Tetrachloroethane. *The Toxicologist*, 10, 255, 1990.
59. Abu-Shakra A, Johnson L, Earley K, Gupta R, **Jameson CW**, Kari F, Langenbach R. Separation of the Mutagenic Components from the Carcinogen HC Blue 1. *Proc. Environ. Mutagen. Soc. Annual Meeting*, 1990.
60. **Jameson CW**, Dieter MP, Maronpot RR, French JE. "Application of a Fischer Rat Leukemia Transplant Model as a Screen for the Leukemogenic Potential of Chemicals". *Proc. of The International Symposium on Toxicology, Beijing, P. R. China, October 16-19, 1990.*
61. Elwell MR, **Jameson CW**, Thompson MB, Yuan J, Carleton T. Toxicity of 4-Chloro-  $\alpha,\alpha,\alpha$ -trifluorotoluene. *Proc. American College of Veterinary Pathologists Annual Meeting*, 1990.
62. Yuan J, **Jameson CW**, Goehl TJ, Elwell MR, Thompson MB, Corniffe G, Carleton T. Application of Molecular Encapsulation for Toxicology Studies I: Molecular Encapsulation of 4-Chloro- $\alpha,\alpha,\alpha$ -trifluoro-toluene with  $\beta$   $\square$ Cyclodextrin. *The Toxicologist*, 11, 1991.
63. **Jameson CW**, Yuan J, Goehl TJ, Elwell MR, Thompson MB, Corniffe G, Carleton T. Application of Molecular Encapsulation for Toxicology Studies II: 14 Day Toxicity Study of 4-Chloro-  $\alpha,\alpha,\alpha$ -trifluoro-toluene in Male and Female F344 rats and B6C3F1 Mice Using  $\beta$  Cyclodextrin and Corn Oil Vehicles. *The Toxicologist*, 11, 1991.
64. Moseman RF, Brink RE, **Jameson CW**, Treinen KA, Chapin RE. Methods Development and Validation for the Determination of ppm Levels of Boron in Rat Tissues. *The Toxicologist*, 11, 1991.
65. Dixon DB, Moseman RF, **Jameson CW**, DeMartin FL, Heil TP, Foster SC. Method Development and Validation for the Determination of ppm Levels of Hildebrant Acid in Blood. *The Toxicologist*, 11, 1991.
66. **Jameson CW**, Elwell M, Eustis SL, Hong LH. Toxicology and Carcinogenicity Studies of d- Limonene in Male and Female F344 Rats and B6C3F1 Mice. *Proceedings of the 204th National Meeting of the American Chemical Society, Washington, DC, August 23-28, 1992.*
67. **Jameson CW**, Lucier GW, Barrett J C. The Biennial Report On Carcinogens (BRC): Review and Revision of the Criteria for Listing Substances in the BRC. *The Toxicologist*, 30, No.1, 1996.

*C W Jameson - Curriculum Vitae and Bibliography*

68. Mahaffey K, Gulson B, **Jameson CW**, Vidal M, Law A, Mizon K, Smith A, Korsch M. Dietary Lead Intakes For Mother-Child Pairs And Relevance To Pharmacokinetic Models. *The Toxicologist*, 42, No.1-S, 1998.
69. Gulson B, Mahaffey K, **Jameson CW**, Mizon K, Korsch M, Cameron M, Eisman, J. Lead Mobilisation From The Maternal Skeleton Is Greater During The Post-Pregnancy Period Than During Pregnancy. *The Toxicologist*, 42, No.1-S, 1998.
70. Gulson BL, Mizon KJ, Patison N, Law AJ, Korsch MJ, **Jameson CW**, Mahaffey KR, Donnelly J. Contribution Of Lead From Formula And Food To Lead In Blood And Urine Of Newly Born Infants And Relationship To Skeletal Mobilization. *The Toxicologist*, 48, No.1-S, 1999.
71. **Jameson CW**. Report on Carcinogens: History and Process. Abstracts of Papers of the American Chemical Society, 228: U303-U303, 2004.

# EXHIBIT B

## Additional References

1. Robin Mesnage , George Renney , Gilles-Eric Séralini , Malcolm Ward & Michael N. Antoniou. (2017) Multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of Roundup herbicide. Scientific Reports ([www.nature.com/scientificreports](http://www.nature.com/scientificreports)) | 7:39328 | DOI: 10.1038/srep39328
2. Lisbeth E. Knudsen, Pernille Winton Hansen, Seher Mizrak, Heidi K. Hansen, Thit A. Morck, Flemming Nielsen, Volkert Siersma and Line Mathiesen. (2017) Biomonitoring of Danish school children and mothers including biomarkers of PBDE and glyphosate. Rev Environ Health 2017; aop DOI 10.1515/reveh-2016-0067
3. Niall Shanks, Ray Greek and Jean Greek.(2019) Are animal models predictive for humans? Philosophy, Ethics, and Humanities in Medicine, 4:2 doi:10.1186/1747-5341-4-2
4. Timothy L Lash (2007). Bias analysis applied to Agricultural Health Study publications to estimate non-random sources of uncertainty. Journal of Occupational Medicine and Toxicology, 2:15
5. Gilles-Eric Seralini, Robin Mesnage, Nicolas Defarge, and Joel Spiroux de Vendomois (2014) Conflicts of interests, confidentiality and censorship in health risk assessment: the example of an herbicide and a GMO. Environmental Sciences Europe 26:13
6. EPA, R.E.D. Facts sheet: Glyphosate (1993) EPA-738-F-93-011
7. EPA, Reregistration Eligibility Decision (RED); Glyphosate, (1993) EPA 738-R-93-014
8. EPA, Glyphosate; Pesticide Tolerances, Federal Register: April 11, 1997 (Volume 62, Number 70)
9. EPA, Glyphosate Final Work Plan (WFP) Registration Review Case No. 0178, December 2009
10. EPA, Glyphosate Summary Document Registration Review: Initial Docket, June 2009
11. David Brusick, Marilyn Aardema, Larry Kier, David Kirkland & Gary Williams (2016) Genotoxicity Expert Panel review: weight of evidence evaluation of the genotoxicity of glyphosate, glyphosate-based formulations, and aminomethylphosphonic acid. CRITICAL REVIEWS IN TOXICOLOGY, 2016 VOL. 46, NO. S1, 56–74

12. Keith Fluegge (2016) Overlooking relevant confounders in the assessment of pesticides and human health: a reply to Mostafalou and Abdollahi. Arch Toxicol. Published on line December 28, 2016.
13. John Acquavella, David Garabrant, Gary Marsh, Tom Sorahan & Douglas L. Weed (2016) Glyphosate epidemiology expert panel review: a weight of evidence systematic review of the relationship between glyphosate exposure and non-Hodgkin's lymphoma or multiple myeloma. CRITICAL REVIEWS IN TOXICOLOGY, 2016 VOL. 46, NO. S1, 28-43
14. Donna R. Farmer, Timothy L. Lash, John F. Acquavella (2005) Glyphosate Results Revisited. Environmental Health Perspectives/Correspondence • VOLUME 113 | NUMBER 6 | June 2005
15. Anneclaire J. De Roos and Megan A. Svec, Aaron Blair, Jennifer A. Rusiecki, Mustafa Dosemeci, and Michael C. Alavanja, Jane A. Hoppin and Dale P. Sandler (2005) Glyphosate Results Revisited: De Roos et al. Respond Environmental Health Perspectives/Correspondence • VOLUME 113 | NUMBER 6 | June 2005
16. Jose V. Tarazona, Daniele Court-Marques, Manuela Tiramani, Hermine Reich, Rudolf Pfeil, Frederique Istace, Federica Crivellente Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its differences with IARC. Arch Toxicol. Published on line December 28, 2016.
17. Channa Jayasumana, Sarath Gunatilake, and Priyantha Senanayake, Glyphosate, Hard Water and Nephrotoxic Metals: Are They the Culprits Behind the Epidemic of Chronic Kidney Disease of Unknown Etiology in Sri Lanka? Int. J. Environ. Res. Public Health 2014, 11, 2125-2147.
18. Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. www.thelancet.com/oncology Vol 16 May 2015
19. Tom Sorahan. Multiple Myeloma and Glyphosate Use: A Re-Analysis of US Agricultural Health Study (AHS) Data. Int. J. Environ. Res. Public Health 2015, 12, 1548-1559
20. John Peterson Myers, Michael N. Antoniou, Bruce Blumberg, Lynn Carroll, Theo Colborn, Lorne G. Everett, Michael Hansen, Philip J. Landrigan, Bruce P. Lanphear, Robin Mesnage, Laura N. Vandenberg, Frederick S. vom Saal, Wade V. Welshons and Charles M. Benbrook Concerns over use of glyphosate-based herbicides and risks associated with exposures: a consensus statement. Environmental Health (2016) 15:19
21. NTP: Glyphosate Research Scoping (2016). Downloaded from: [https://ntp.niehs.nih.gov/ntp/about\\_ntp/bsc/2016/june/presentations/glyphosate\\_508.pdf](https://ntp.niehs.nih.gov/ntp/about_ntp/bsc/2016/june/presentations/glyphosate_508.pdf)

22. NTP Glyphosate and Glyphosate Formulations Research (2017) Downloaded from: <https://ntp.niehs.nih.gov/results/areas/glyphosate/index.html>
23. Toxicology and Carcinogenesis Studies of Vinylidene Chloride (CAS No. 75-35-4) in F344/N Rats and B6C3F1/N Mice (Inhalation Studies). Technical Report Series No. 582. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC., and Bethesda, MD.
24. John Acquavella, Donna Farmer, and Mark R. Cullen (1999) A Case–Control Study of Non-Hodgkin Lymphoma and Exposure to Pesticides. *CANCER/Correspondence* August, 15 1999 / Volume 86 / Number 4
25. Lennart Hardell, Mikael Eriksson (1999) A Case–Control Study of Non-Hodgkin Lymphoma and Exposure to Pesticides - Author Reply. *CANCER/Correspondence* August, 15 1999 / Volume 86 / Number 4
26. Shahla Hosseini Bai<sup>1</sup> & Steven M. Ogbourne<sup>1</sup>(2016) Glyphosate: environmental contamination, toxicity and potential risks to human health via food contamination. *Environ Sci Pollut Res* (2016) 23:18988–19001
27. Goen, T., et al., Efficiency control of dietary pesticide intake reduction by human biomonitoring. *Int. J. Hyg. Environ. Health* (2016),
28. Pamela J. Mink, Jack S. Mandel, Bonnielin K. Scurman, Jessica I. Lundin Epidemiologic studies of glyphosate and cancer: A review *Regulatory Toxicology and Pharmacology* 63 (2012) 440–452
29. Lennart Hardell, Mikael Eriksson & Marie Nordström (2002) Exposure to Pesticides as Risk Factor for Non-Hodgkin's Lymphoma and Hairy Cell Leukemia: Pooled Analysis of Two Swedish Case-control Studies, *Leukemia & Lymphoma*, 43:5, 1043-1049
30. Celia P.M. Bento, Dirk Goossens, Mahrooz Rezaei, Michel Riksen, Hans G.J. Mol, Coen J. Ritsema, Violette Geissen. Glyphosate and AMPA distribution in wind-eroded sediment derived from loss soil *Environmental Pollution* 220 (2017) 1079-1089.
31. Kathryn Z. Guyton, Dana Loomis, Kurt Straif Reply to “the critical role of pre-publication peer review—a case study of glyphosate” by FN Dost LETTER TO THE EDITOR/ *Environ Sci Pollut Res* published on line 10 October 2016
32. Jasmine Jomichen, Sonia El-Zaemey, Jane S Heyworth, Renee N Carey, Ellie Darcey, Alison Reid, Deborah C Glass, Tim Driscoll, Susan Peters, Michael Abramson<sup>3</sup> Lin Fritschi Australian work exposures studies: occupational exposure to pesticides. *Occup Environ Med* 2017;74:46–51

33. Christina Avgerinou, Ioanna Giannezi, Stela Theodoropoulou, Vasileios Lazaris, Georgia Kolliopoulou, Panagiotis Zikos, Yannis Alamanos, Michalis Leotsinidis & Argiris Symeonidis (2017): Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece, Hematology, DOI: 10.1080/10245332.2016.1277006
34. Cristina Fortes, Simona Mastroeni, Marjorie M. Segatto, Clarissa Hohmann, Lucia Miligi, Lucio Bakos, and Renan Bonamigo. Occupational Exposure to Pesticides With Occupational Sun Exposure Increases the Risk for Cutaneous Melanoma. JOEM Volume 58, Number 4, April 2016
35. Robert E. Tarone. On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen. European Journal of Cancer Prevention 2016
36. Gemma Arjo, Manuel Portero, Carme Pinol, Juan Vinas, Xavier Matias-Guiu, Teresa Capell, Andrew Bartholomaeus, Wayne Parrott, Paul Christou. Plurality of opinion, scientific discourse and pseudoscience: an in depth analysis of the Seralini et al. study claiming that Roundup™ Ready corn or the herbicide Roundup™ cause cancer in rats. Transgenic Res (2013) 22:255–267
37. R. Mesnage, N. Defarge, J. Spiroux de Vendomois, G.E. Seralini. Potential toxic effects of glyphosate and its commercial formulations below regulatory limits Food and Chemical Toxicology 84 (2015) 133-153
38. Seralini GE, Clair E, Mesnage R, Gress S, Defarge N, Manuela Malatesta M et al. (2014). Republished study: long-term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize. Environmental Sciences Europe, 26(1):1–14
39. Jacob GS, Garbow JR, Hallas LE, Kimack NM, Kishore GM, Schaefer J (1988). Metabolism of glyphosate in Pseudomonas sp. strain LBr. Appl Environ Microbiol, 54(12):2953–8
40. Tomlin CDS, editor (2000). The pesticide manual: a world compendium. 12th ed. Croydon: British Crop Protection Council. Available from: <http://trove.nla.gov.au/work/6273016>.
41. Gary M. Williams, Robert Kroes, and Ian C. Munro. Safety Evaluation and Risk Assessment of the Herbicide Roundup<sub>1</sub> and Its Active Ingredient, Glyphosate, for Humans. Regulatory Toxicology and Pharmacology 31, 117–165 (2000)
42. Scott Weichenthal, Connie Moase, and Peter Chan. A Review of Pesticide Exposure and Cancer Incidence in the Agricultural Health Study Cohort Environmental Health Perspectives • volume 118 | number 8 | August 2010

43. Scot L. Eustis, James R. Hailey, Gary A. Boorman and Joseph K. Haseman. The Utility of Multiple-Section Sampling in the Histopathological Evaluation of the Kidney for Carcinogenicity Studies. *Toxicologic Pathology* Vol. 22, No. 5, 1994
44. Townsend, M., Peck, C., Meng, W., Heaton, M., Robison, R., O'Neill, K., Evaluation of various glyphosate concentrations on DNA damage in human Raji cells and its impact on cytotoxicity, *Regulatory Toxicology and Pharmacology* (2017), doi: 10.1016/j.yrtph.2017.02.002.
45. Isis Coalova, María del Carmen Ríos de Molina, Gabriela Chaufan. Influence of the spray adjuvant on the toxicity effects of a glyphosate formulation. *Toxicology in Vitro* 28 (2014) 1306–1311
46. Lei Luo, Fei Wang, Yiyuan Zhang, Ming Zeng, Caigao Zhong & Fang Xiao (2017): In vitro cytotoxicity assessment of roundup (glyphosate) in L-02 hepatocytes, *Journal of Environmental Science and Health, Part B*, DOI: 10.1080/03601234.2017.1293449
47. Gary L. Diamond Effects of Surfactants on the Toxicity of Glyphosate, with Specific Reference to RODEO. SERA TR 97-206-1b February 6, 1997
48. Robert Owagboriaye, Gabriel Dedeke, Kehinde Ademolu, Olarenwaju Olujimi, Joseph Ashidi, Aladesida Adeyinka (2017): Reproductive toxicity of Roundup herbicide exposure in male albino rat. *Experimental and Toxicologic Pathology*, <http://dx.doi.org/10.1016/j.etp.2017.04.007>
49. Karunanayake CP, Spinelli JJ, McLaughlin JR, Dosman JA, Pahwa P, McDuffie HH (2012). Hodgkin lymphoma and pesticides exposure in men: a Canadian case-control study. *J Agromed*, 17(1):30–9.
50. Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM et al. (1990). Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. *Cancer Res*, 50(20):6585–91.
51. Lee WJ, Lijinsky W, Heineman EF, Markin RS, Weisenburger DD, Ward MH (2004). Agricultural pesticide use and adenocarcinomas of the stomach and esophagus. *Occup Environ Med*, 61(9):743–9.
52. Carreon T, Butler MA, Ruder AM, Waters MA, Davis- King KE, Calvert GM et al. ; Brain Cancer Collaborative Study Group(2005). Gliomas and farm pesticide exposure in women: The Upper Midwest Health Study. *Environ Health Perspect*, 113(5):546–51.
53. Lee WJ, Colt JS, Heineman EF, McComb R, Weisenburger DD, Lijinsky W et al. (2005). Agricultural pesticide use and risk of glioma in Nebraska, United States. *Occup Environ Med*, 62(11):786–92.

54. Pahwa P, Karunanayake CP, Dosman JA, Spinelli JJ, McLaughlin JR; Cross-Canada Group (2011). Soft-tissue sarcoma and pesticides exposure in men: results of a Canadian case-control study. *J Occup Environ Med*, 53(11):1279–86.
55. Band PR, Abanto Z, Bert J, Lang B, Fang R, Gallagher RP et al. (2011). Prostate cancer risk and exposure to pesticides in British Columbia farmers. *Prostate*, 71(2):168–83
56. Kachuri L, Demers PA, Blair A, Spinelli JJ, Pahwa M, McLaughlin JR et al. (2013). Multiple pesticide exposures and the risk of multiple myeloma in Canadian men. *Int J Cancer*, 133(8):1846–58
57. Brown LM, Burmeister LF, Everett GD, Blair A (1993). Pesticide exposures and multiple myeloma in Iowa men. *Cancer Causes Control*, 4(2):153–6
58. Lee WJ, Lijinsky W, Heineman EF, Markin RS, Weisenburger DD, Ward MH (2004). Agricultural pesticide use and adenocarcinomas of the stomach and esophagus. *Occup Environ Med*, 61(9):743–9.
59. Carreon T, Butler MA, Ruder AM, Waters MA, Davis-King KE, Calvert GM et al. ; Brain Cancer Collaborative Study Group(2005). Gliomas and farm pesticide exposure in women: The Upper Midwest Health Study. *Environ Health Perspect*, 113(5):546–51.
60. Julie Marc, Odile Mulner-Lorillon, Sandrine Boulben, Dorothee Hureau, Gael Durand, Robert Belle. Pesticide Roundup Provokes Cell Division Dysfunction at the Level of CDK1/Cyclin B Activation. *Chem. Res. Toxicol.* 2002, 15, 326-331.
61. Julie Marc, Robert Belle, Julia Morales, Patrick Cormier, Odile Mulner-Lorillon. Formulated Glyphosate Activates the DNA-Response Checkpoint of the Cell Cycle Leading to the Prevention of G2/M Transition. *Toxicological Sciences*, 82, 436-442 (2004).
62. Julie Marc, Magali Le Breton, Patrick Cormier, Julia Morales, Robert Belle, Odile Mulner-Lorillon. A glyphosate-based pesticide impinges on transcription. *Toxicology and Applied Pharmacology* 203 (2005) 1-8.
63. Breanna Ford, Leslie Bateman, Leilani Gutierrez-Palominos, Robin Park, Daniel Nomura. Mapping Proteome-wide Targets of Glyphosate in Mice. *Cell Chemical Biology* (2016).
64. Maria Lioi, Maria Scarfi, Antonietta Santoro, Roccina Barbieri, Olga Zeni, Francesca Salvemini, Dino Berardino, Matilde Ursini. Cytogenetic Damage and Induction of Pro-Oxidant State in Human Lymphocytes Exposed In Vitro to Glyphosate, Vinclozolin, Atrazine, and DPX-E9636. *Environmental and Molecular Mutagenesis* 32:39-46 (1998).

65. Claudia Bolognesi, Amadeu Creus, Patricia Ostrosky-Wegman, Ricard Marcos. Micronuclei and pesticide exposure. *Mutagenesis*, vol. 26, no. 1, pp. 19-26, 2011.
66. Claudia Bolognesi, Nina Holland. The use of the lymphocyte cytokinesis-block micronucleus assay for monitoring pesticide-exposed populations. *Mutation Research* 770 (2016) 183-203.
67. Larry D. Kier, David J. Kirkland. Review of genotoxicity studies of glyphosate and glyphosate-based formulations. *Crit. Rev. Toxicol.*, 2013; 43(4): 283-315.
68. James Bus. IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation. *Regulatory Toxicology and Pharmacology* 86 (2017) 157-166.
69. Marco Peluso, Armelle Munnia, Claudia Bolognesi, Silvio Parodi. <sup>32</sup>P-Postlabeling Detection of DNA Adducts in Mice Treated With the Herbicide Roundup. *Environmental and Molecular Mutagenesis* 31:55-59 (1998).
70. William Heydens, Charles Healy, Kathy Hotz, Larry Kier, Mark Martens, Alan Wilson, Donna Farmer. Genotoxic Potential of Glyphosate Formulations: Mode-of-Action Investigations. *J. Agric. Food Chem.* 2008, 56, 1517-1523.
71. MONGLY01767038
72. MONGLY00586054
73. MONGLY00593610
74. MONGLY01830003 – MONGLY01830100
75. Deposition Transcripts and Exhibits of Donna Farmer, Jan 11-12, 2017.
76. Deposition Transcripts and Exhibits of Daniel Goldstein, Jan 18, 2017.
77. Deposition Transcripts and Exhibits of William Heydens, Jan. 23-24, 2017.
78. Deposition Transcripts and Exhibits of David Saltmiras, Jan 31- Feb 2, 2017.
79. Deposition Transcript and Exhibits of Aaron Blair, March 20, 2017.
80. Deposition Transcript and Exhibits of Mark Martens, April 7, 2017.



## CWJ/Greim Experimental Animal Summary

## Mouse

Study	Strain	Dose	Tumors	Significance	Evaluation
Greim: Knezevich and Hogan (1983) (Study 10)	Mouse, CD-1 (males)	0, 1,000, 5,000, or 30,000 ppm in feed for 24 months	Renal tubule adenoma: 1/49 (2%), 0/49, 0/50, 1/50 (2%) Renal tubule carcinoma: 0/49, 0/49, 1/50 (2%), 2/50 (4%) Renal tubule adenoma or carcinoma (combined): 1/49 (2%), 0/49, 1/50 (2%), 3/50 (6%)	$P$ for trend = 0.037 (EPA) $P$ for trend = 0.034 (EPA)	Historical control data from 14 studies conducted between 1977 and 1981 at the testing laboratory indicated that the mouse renal tumors ranged from 0 to 3% and the incidence in the current study (3/50; 6%) exceeded the upper limit of the historical control range by a factor of two. For the purpose of this hazard identification the increase the incidence of carcinoma of the renal tubule and the incidence of adenoma or carcinoma (combined) of the renal tubule in male mice is due to treatment with glyphosate
Greim: Atkinson <i>et al.</i> (1993) (Study 11)	Mouse, CD-1 (males)	0, 100, 300, 1000 mg/kg bw in feed for 104wk	Males: Haemangiosarcoma: 0/50, 0/50, 0/50, 4/50 (8%)	$P$ for trend < 0.01 (EPA)	The EPA pointed out that the incidence in the high dose males was near the upper limit (0-8%) for the performing laboratory. For the purpose of this hazard identification the increased incidence of hemangiosarcomas in male mice is due to the treatment with glyphosate
Greim: Sugimoto, (1997) (Study 12)	Mouse, CD-1 (M&F)	0, 1600, 8000, or 40000 ppm in feed for 18 months	Males: Hemangiosarcomas: 0/50, 0/50, 0/50, 2/50 (4%) Kidney: renal cell adenomas 0/50; 0/50; 0/50; 2/50 (4%) Malignant lymphoma 2/50 (4%), 2/50 (4%), 0/50, 6/50 (12%) [0/26, 0/34, 1/27 (4%), 5/29* (17%) – Greim Tier II] Females: Hemangiomas: (0/50; 0/50; 2/50, (4%); 5/50*, (10%)	$P$ for trend = 0.008 (Portier) $P$ for trend = 0.008 (Portier) $P$ for trend = 0.008 (Portier) [* $P$ < 0.05, Greim Tier II] * $P$ = 0.028, (EPA) $P$ for trend = 0.002	The significant increase in malignant lymphoma in high dose male mice, and the significant trend in the development of hemangiosarcomas, malignant lymphomas, and renal adenomas in male mice is due to treatment with glyphosate that caused these cancers in male CD-1 mice. The significant trend in the development of hemangiosarcomas in female mice is also related to treatment with glyphosate that caused this cancer in female CD-1 mice.
Greim: Kumar (2001) (Study 13)	Mouse-Swiss (M&F)	0, 100, 1000, or 10000 ppm in feed for 18 months.	Males: Malignant lymphoma: 10/50 (20%), 15/50 (30%), 16/50 (32%), 19/50* (38%) Kidney: renal cell adenomas: 0/50, 0/26, 1/26 (4%), 2/50 (4%)	* $P$ < 0.05, $P$ for trend = 0.05 (Portier) $P$ for trend = 0.04 (Portier)	The incidence of malignant lymphoma in the high dose male was double the historical rate, reported to be 18% for males, and for high dose female mice the incidence was well above the historical rate of 41%.

Exhibit No.: 02-2  
Deponent: Jensen  
Date/RPR: 1-21-17  
Hunter + Geist, Inc.

			<p>Females: Malignant lymphoma: 18/50 (36%), 20/50 (40%), 19/50 (38%), 25/50* (50%)</p>	<p>*<math>P &lt; 0.05</math>, <math>P</math> for trend=0.05 (Portier)</p>	<p>For the purpose of this hazard identification the formation of malignant lymphoma in the male and female mice and the renal cell adenomas in males in this study is due to treatment with glyphosate</p>
Greim: Wood (2009) (Study14)	Mouse, CD-1(males)	0, 500, 1500, or 5000 ppm in feed for 18 months.	<p>Malignant lymphomas: 0/51, 1/50(10%), 2/51(4%), 5/51*(10%) Lung: Adenocarcinomas: 5/51(10%), 5/51(10%), 7/51(14%), 11/51(22%)</p>	<p>*<math>P &lt; 0.05</math>, <math>P</math> for trend&lt;0.01 (EPA)</p> <p><math>P</math> for trend&lt;0.01 (EPA)</p>	<p>For the purpose of this hazard identification the formation of malignant lymphomas and the formation of adenocarcinomas of the lung in this study is due to treatment with glyphosate</p>

## CWJ/Greim Experimental Animal Summary

## Rat

Study	Strain	Dose	Tumors	Significance	Evaluation
Greim: Lankas, <i>et al.</i> (1981) (Study 1)	Rat, Sprague-Dawley (Males & Females)	0, 30, 100, 300 ppm in feed for up to 26 months	Males: Testes: Interstitial cell tumors 0/50, 3/5 (6%), 1/50 (2), 6/50* (12%) Pancreas (islet cell): Adenoma: 0/50, 5/49** (10%), 2/50 (4%), 2/50 (4%)	* $P=0.013$ (EPA)  ** $P<0.05$ (EPA)	The incidence of interstitial cell tumors in the testes in the high dose animals in this study is almost twice that seen in the range of this tumor (3.4% to 6.7%) in control animals (historical controls) from 5 contemporary studies <sup>87</sup> For the purpose of this hazard identification the increase in incidence of testes interstitial cell tumors and pancreatic cell tumors in male rats are due to the treatment with glyphosate
Greim: Stout, <i>et al.</i> (1990) (Study 2)	Rat, Sprague-Dawley (Males & Females)	0, 2000, 8000, or 20,000 ppm in feed for 24 months	Males: Pancreas (islet cell): Adenoma: 1/58 (2%), 8/57 (14%)*, 5/60 (8%), 7/59 (12%)  Liver: Hepatocellular adenoma: 2/60 (3%), 2/60 (3%), 3/60 (6%), 7/60 (12%)  Females: Thyroid: C-cell adenoma: 2/60 (3%), 2/60 (3%), 6/60 (10%), 6/60 (10%)	* $P<0.05$ (EPA performed additional analyses excluding animals that died or were killed before wk 54-55: Adenoma: 1/43 (2%), 8/45 (18%; $P=0.018$ ), 5/49 (10%), 7/48 (15%; $P=0.042$ )  P for trend = 0.016 (EPA)  P for trend = 0.033 (EPA)	The incidence of these adenomas in the low (18%) and high (15%) dose males was almost twice that seen in historical controls. The range for historical controls for pancreatic islet cell adenoma reported in males at this laboratory was 1.8–8.5% <sup>77</sup> For the purpose of this hazard identification glyphosate caused an increase in incidence of pancreatic islet cell adenoma in male rats. Glyphosate also caused a significant increase in the trend for formation of hepatocellular adenomas in male Sprague-Dawley rats and of thyroid follicular cell adenomas and adenomas and carcinomas combined in female Sprague-Dawley rats.
Greim: Atkinson <i>et al.</i> (1993)(Study 3)	Rat, Sprague-Dawley (Males & Females)	0, 10, 100, 300, or 1,000 mg/kg bw/day in feed for 104 weeks			Neoplasms were noted in control and treated groups, but dose responses were not evident, and no statistically significant increase versus controls were noted for any tumor type.
Greim: Suresh (1996) (Study 4)	Rat-Wistar (Males & Females)	0, 1600, 8000, or 40 000 ppm in feed for 18 months			There were no treatment related deaths or clinical signs in any of the dose-groups and no treatment related effects on body weight gain or food consumption noted. This suggests that the MTD was not reached, and this study is inadequate for the

Exhibit No.: 22-3  
Deponent: Jamison  
Date/RPR: 9-21-17  
Hunter + Geist, Inc.

					evaluation of the carcinogenicity of glyphosate.
Greim: Excel (1997) (Study 5)	Rat, Sprague-Dawley (Males & Females)	0, 3000, 15 000, and 25 000 ppm in feed for 24 months			Concur with Greim that study is unreliable for carcinogenicity evaluation
Greim: Enomoto (1997) (Study 6)	Rat, Sprague-Dawley (Males & Females)	0, 3,000, 10,000, or 30,000 ppm in feed for 24 months			There were no statistically significant increases in any tumor type reported for this study.
Greim: Brammer (2001) (Study 7)	Rat, Wistar (Males & Females)	0, 2,000, 6,000, and 20,000 ppm in feed for 24 months	Males: Liver: hepatocellular adenomas 0/52, 2/52, (4%), 0/52, 5/52* (10%)	* $P=0.03$ (EPA) $P$ for trend = 0.008 (EPA)	The incidences of liver tumors observed were within the historical range (0–11.5%) for this strain of rats in 26 studies conducted during the relevant time period (1984–2003) at the testing laboratory. For the purpose of this hazard identification, the increase in hepatocellular adenomas in male Wistar rats could not be attributed to exposure to glyphosate despite the fact that there was an observation of increased incidence of hepatocellular adenomas in male rats.
Greim: Wood (2009) (Study 8)	Rat, Wistar (Males & Females)	0, 3,000, 10,000, or 15,000 ppm in feed for 24 months			There were no treatment-related deaths or clinical signs in any of the dose-groups. No significant treatment-related effects on mortality were observed during the study. This suggests that the MTD was not reached, and this study is inadequate for the evaluation of the carcinogenicity of glyphosate.
Greim: Chruscielska <i>et al.</i> (2000) (Study 9)	Rat, Wistar (Males & Females)	0, 300, 900, and 2700 mg/L in drinking water for 24 months			There was limited information provided on dosing regimen, histopathological examination method, and tumor incidences that makes this study inadequate for the purpose of this hazard assessment

# 11

th

# Report on Carcinogens

2004



U.S. Department of  
Health and Human Services

Public Health Service

National Toxicology Program

Pursuant to Section 301(b) (4)  
of the Public Health Service Act  
as Amended by Section 262, PL 95-622

Exhibit No.: 22-4  
Deponent: Jameson  
Date/RPR: 9-21-17  
Hunter + Geist, Inc. 70

**Report on Carcinogens, Eleventh Edition**  
**Carcinogen Profiles**  
**2004**

U.S. Department of Health and Human Services  
Public Health Service  
National Toxicology Program

Prepared for the  
National Institute of Environmental Health Sciences  
Research Triangle Park, North Carolina

Prepared by  
Constella Group, Incorporated  
Durham, North Carolina  
Under Contract Number NO1- ES-35505

## Table of Contents Volume I

	Page
<b>I. Introduction</b> .....	I-1
<b>II. Carcinogens Listed in the Eleventh Report</b>	
<b>A. Known to be Human Carcinogens</b> .....	II-1
<b>B. Reasonably Anticipated to be Human Carcinogens</b> .....	II-2
<b>III. Substance Profiles</b>	
Acetaldehyde .....	III-1
2-Acetylaminofluorene .....	III-3
Acrylamide .....	III-4
Acrylonitrile .....	III-6
Adriamycin® (Doxorubicin Hydrochloride) .....	III-8
Aflatoxins .....	III-8
Alcoholic Beverage Consumption .....	III-10
2-Aminoanthraquinone .....	III-12
<i>o</i> -Aminoazotoluene .....	III-12
4-Aminobiphenyl .....	III-13
1-Amino-2,4-dibromoanthraquinone .....	III-15
1-Amino-2-methylanthraquinone .....	III-16
Amitrole .....	III-16
<i>o</i> -Anisidine Hydrochloride .....	III-17
Arsenic Compounds, Inorganic .....	III-18
Asbestos .....	III-21
Azacitidine .....	III-24
Azathioprine .....	III-25
Benzene .....	III-26
Benzidine and Dyes Metabolized to Benzidine	III-28
Benzidine .....	III-28
Dyes Metabolized to Benzidine .....	III-29
Benzotrichloride .....	III-31
Beryllium and Beryllium Compounds .....	III-32
Bromodichloromethane .....	III-35
2,2-bis(Bromomethyl)-1,3-propanediol (Technical Grade) .....	III-36
1,3-Butadiene .....	III-37
1,4-Butanediol Dimethylsulfonate (Myleran®) .....	III-39
Butylated Hydroxyanisole (BHA) .....	III-40
Cadmium and Cadmium Compounds .....	III-42
Carbon Tetrachloride .....	III-44
Ceramic Fibers (Respirable Size) .....	III-46
Chlorambucil .....	III-47
Chloramphenicol .....	III-48
Chlorendic Acid .....	III-50
Chlorinated Paraffins (C <sub>12</sub> , 60% Chlorine) .....	III-51
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea .....	III-52
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea .....	III-53
bis(Chloroethyl) Nitrosourea .....	III-53
Chloroform .....	III-54
bis(Chloromethyl) Ether and Technical-Grade Chloromethyl Methyl Ether .....	III-56
3-Chloro-2-methylpropene .....	III-57
4-Chloro- <i>o</i> -phenylenediamine .....	III-58
Chloroprene .....	III-59
<i>p</i> -Chloro- <i>o</i> -toluidine and <i>p</i> -Chloro- <i>o</i> -toluidine Hydrochloride .....	III-60
Chlorozotocin .....	III-62
Chromium Hexavalent Compounds .....	III-63
C.I. Basic Red 9 Monohydrochloride .....	III-66
Cisplatin .....	III-67
Coal Tars and Coal Tar Pitches .....	III-68
Cobalt Sulfate .....	III-70
Coke Oven Emissions .....	III-71
<i>p</i> -Cresidine .....	III-72
Cupferron .....	III-73
Cyclophosphamide .....	III-74
Cyclosporin A .....	III-75
Dacarbazine .....	III-76
Danthron (1,8-Dihydroxyanthraquinone) .....	III-77
2,4-Diaminoanisole Sulfate .....	III-78

## TABLE OF CONTENTS

## III. Substance Profiles (Continued)

2,4-Diaminotoluene	III-79
Diazoaminobenzene	III-80
1,2-Dibromo-3-chloropropane	III-81
1,2-Dibromoethane (Ethylene Dibromide)	III-82
2,3-Dibromo-1-propanol	III-84
tris(2,3-Dibromopropyl) Phosphate	III-84
1,4-Dichlorobenzene	III-85
3,3'-Dichlorobenzidine and 3,3'-Dichlorobenzidine Dihydrochloride	III-87
Dichlorodiphenyltrichloroethane (DDT)	III-89
1,2-Dichloroethane (Ethylene Dichloride)	III-90
Dichloromethane (Methylene Chloride)	III-91
1,3-Dichloropropene (Technical Grade)	III-93
Diepoxybutane	III-94
Diesel Exhaust Particulates	III-95
Diethyl Sulfate	III-97
Diethylstilbestrol	III-98
Diglycidyl Resorcinol Ether	III-100
3,3'-Dimethoxybenzidine and Dyes Metabolized to 3,3'-Dimethoxybenzidine	III-101
3,3'-Dimethoxybenzidine	III-101
Dyes Metabolized to 3,3'-Dimethoxybenzidine	III-102
4-Dimethylaminoazobenzene	III-103
3,3'-Dimethylbenzidine and Dyes Metabolized to 3,3'-Dimethylbenzidine	III-104
3,3'-Dimethylbenzidine	III-104
Dyes Metabolized to 3,3'-Dimethylbenzidine	III-106
Dimethylcarbamoyl Chloride	III-107
1,1-Dimethylhydrazine	III-107
Dimethyl Sulfate	III-109
Dimethylvinyl Chloride	III-110
1,4-Dioxane	III-110
Disperse Blue 1	III-112
Epichlorohydrin	III-113
Erionite	III-114
Estrogens, Steroidal	III-115
Ethylene Oxide	III-118
Ethylene Thiourea	III-122
di(2-Ethylhexyl) Phthalate	III-123
Ethyl Methanesulfonate	III-124
Formaldehyde (Gas)	III-125
Furan	III-127
Glass Wool (Respirable Size)	III-129
Glycidol	III-130
Hepatitis B Virus	III-131
Hepatitis C Virus	III-133
Heterocyclic Amines (Selected)	III-135
2-Amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ)	III-135
2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)	III-135
2-Amino-3-methylimidazo[4,5-f]quinoline (IQ)	III-136
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)	III-136
Hexachlorobenzene	III-138
Hexachloroethane	III-140
Hexamethylphosphoramide	III-141
Human Papillomaviruses: Some Genital-Mucosal Types	III-142
Hydrazine and Hydrazine Sulfate	III-145
Hydrazobenzene	III-146
Ionizing Radiation	III-147
X-Radiation and Gamma Radiation	III-147
Neutrons	III-150
Radon	III-152
Thorium Dioxide	III-154
Iron Dextran Complex	III-155
Isoprene	III-156
Kepone® (Chlordecone)	III-158
Lead and Lead Compounds	III-158
Lindane and Other Hexachlorocyclohexane Isomers	III-162
Melphalan	III-164
Methoxsalen with Ultraviolet A Therapy (PUVA)	III-165
2-Methylaziridine (Propylenimine)	III-166
4,4'-Methylenebis(2-chloroaniline)	III-167
4,4'-Methylenebis(N,N-dimethyl)benzenamine	III-168
4,4'-Methylenedianiline and its Dihydrochloride Salt	III-169

## TABLE OF CONTENTS

## III. Substance Profiles (Continued)

Methyleugenol	III-170
Methyl Methanesulfonate	III-171
<i>N</i> -Methyl- <i>N'</i> -nitro- <i>N</i> -nitrosoguanidine	III-172
Metronidazole	III-173
Michler's Ketone (4,4'-(Dimethylamino)benzophenone)	III-173
Mineral Oils (Untreated and Mildly Treated)	III-174
Mirex	III-175
Mustard Gas	III-176
Naphthalene	III-177
2-Naphthylamine	III-179
Nickel Compounds and Metallic Nickel	III-180
Nickel Compounds	III-181
Metallic Nickel	III-181
Nitrilotriacetic Acid	III-184
<i>o</i> -Nitroanisole	III-185
Nitroarenes (selected)	III-186
1,6-Dinitropyrene	III-186
1,8-Dinitropyrene	III-187
6-Nitrochrysene	III-188
1-Nitropyrene	III-189
4-Nitropyrene	III-190
Nitrobenzene	III-190
Nitrofen (2,4-Dichlorophenyl- <i>p</i> -nitrophenyl Ether)	III-192
Nitrogen Mustard Hydrochloride	III-192
Nitromethane	III-193
2-Nitropropane	III-194
<i>N</i> -Nitrosodi- <i>n</i> -butylamine	III-196
<i>N</i> -Nitrosodiethanolamine	III-197
<i>N</i> -Nitrosodiethylamine	III-198
<i>N</i> -Nitrosodimethylamine	III-199
<i>N</i> -Nitrosodi- <i>n</i> -propylamine	III-200
<i>N</i> -Nitroso- <i>N</i> -ethylurea	III-201
4-( <i>N</i> -Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	III-202
<i>N</i> -Nitroso- <i>N</i> -methylurea	III-203
<i>N</i> -Nitrosomethylvinylamine	III-204
<i>N</i> -Nitrosomorpholine	III-205
<i>N</i> -Nitrosornicotine	III-206
<i>N</i> -Nitrosopiperidine	III-206
<i>N</i> -Nitrosopyrrolidine	III-207
<i>N</i> -Nitrososarcosine	III-208
Norethisterone	III-208
Ochratoxin A	III-209
4,4'-Oxydianiline	III-210
Oxymetholone	III-211
Phenacetin and Analgesic Mixtures Containing Phenacetin	III-212
Phenacetin	III-212
Analgesic Mixtures Containing Phenacetin	III-212
Phenazopyridine Hydrochloride	III-213
Phenolphthalein	III-214
Phenoxybenzamine Hydrochloride	III-216
Phenytoin	III-216
Polybrominated Biphenyls (PBBs)	III-217
Polychlorinated Biphenyls (PCBs)	III-218
Polycyclic Aromatic Hydrocarbons, 15 Listings	III-220
Benz[ <i>a</i> ]anthracene	
Benzo[ <i>b</i> ]fluoranthene	
Benzo[ <i>j</i> ]fluoranthene	
Benzo[ <i>k</i> ]fluoranthene	
Benzo[ <i>a</i> ]pyrene	
Dibenz[ <i>a,h</i> ]acridine	
Dibenz[ <i>a,i</i> ]acridine	
Dibenz[ <i>a,h</i> ]anthracene	
7 <i>H</i> -Dibenzo[ <i>c,g</i> ]carbazole	
Dibenzo[ <i>a,e</i> ]pyrene	
Dibenzo[ <i>a,h</i> ]pyrene	
Dibenzo[ <i>a,i</i> ]pyrene	
Dibenzo[ <i>a,l</i> ]pyrene	
Indeno[1,2,3- <i>cd</i> ]pyrene	
5-Methylchrysene	
Procabazine Hydrochloride	III-222

## TABLE OF CONTENTS

## III. Substance Profiles (Continued)

Progesterone . . . . .	III-223
1,3-Propane Sultone . . . . .	III-225
$\beta$ -Propiolactone . . . . .	III-225
Propylene Oxide . . . . .	III-226
Propylthiouracil . . . . .	III-227
Reserpine . . . . .	III-228
Safrole . . . . .	III-229
Selenium Sulfide . . . . .	III-230
Silica, Crystalline (Respirable Size) . . . . .	III-231
Soots . . . . .	III-233
Streptozotocin . . . . .	III-234
Strong Inorganic Acid Mists Containing Sulfuric Acid . . . . .	III-234
Styrene-7,8-oxide . . . . .	III-237
Sulfallate . . . . .	III-238
Tamoxifen . . . . .	III-239
2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (TCDD); "Dioxin" . . . . .	III-241
Tetrachloroethylene (Perchloroethylene) . . . . .	III-243
Tetrafluoroethylene . . . . .	III-245
Tetranitromethane . . . . .	III-246
Thioacetamide . . . . .	III-247
4,4'-Thiodianiline . . . . .	III-248
Thiotepa . . . . .	III-249
Thiourea . . . . .	III-250
Tobacco Related Exposures . . . . .	III-251
Environmental Tobacco Smoke . . . . .	III-251
Smokeless Tobacco . . . . .	III-253
Tobacco Smoking . . . . .	III-255
Toluene Diisocyanate . . . . .	III-256
<i>o</i> -Toluidine and <i>o</i> -Toluidine Hydrochloride . . . . .	III-258
Toxaphene . . . . .	III-259
Trichloroethylene . . . . .	III-261
2,4,6-Trichlorophenol . . . . .	III-263
1,2,3-Trichloropropane . . . . .	III-264
Ultraviolet Radiation Related Exposures . . . . .	III-266
Solar Radiation . . . . .	III-266
Sunlamps or Sunbeds, Exposure to . . . . .	III-266
Broad-Spectrum Ultraviolet (UV) Radiation . . . . .	III-266
Ultraviolet A Radiation . . . . .	III-266
Ultraviolet B Radiation . . . . .	III-267
Ultraviolet C Radiation . . . . .	III-267
Urethane . . . . .	III-270
Vinyl Bromide . . . . .	III-271
Vinyl Chloride . . . . .	III-272
4-Vinyl-1-cyclohexene Diepoxide . . . . .	III-274
Vinyl Fluoride . . . . .	III-275
Wood Dust . . . . .	III-276
<b>IV. Tables</b>	
Table 1. Chemicals Nominated to the NTP for In-Depth Toxicological Evaluation or Carcinogenesis Testing in Fiscal Years 1988-2001 . . . . .	IV-1
Table 2. CDC/NIOSH Response to Inquiries about Carcinogens Listed in the <i>Eleventh Report on Carcinogens</i> . . . . .	IV-40
<b>V. Report on Carcinogens Nomination Review Procedures</b> . . . . .	V-1
<b>Appendices</b>	
A. Manufacturing Processes, Occupations, and Exposure Circumstances Classified by IARC as Category 1, <i>Carcinogenic to Humans</i> . . . . .	A-1
B. Agents, Substances, Mixtures, or Exposure Circumstances Delisted from the Report on Carcinogens . . . . .	A-2
C. Agents, Substances, Mixtures, or Exposure Circumstances Reviewed but not Recommended for Listing in the Report on Carcinogens . . . . .	A-6
D. List of Participants . . . . .	A-7
E. Glossary . . . . .	A-11
F. Acronyms and Abbreviations . . . . .	A-23
G. Units of Measurement . . . . .	A-25
<b>Indexes</b>	
A. Names and Synonyms used in RoC Substance Profiles . . . . .	A-29
B. CAS Registry Numbers . . . . .	A-31

## Introduction

The probability that a resident of the United States will develop cancer at some point in his or her lifetime is 1 in 2 for men and 1 in 3 for women (ACS 2004). Nearly everyone's life has been directly or indirectly affected by cancer. Most scientists involved in cancer research believe that the environment in which we live and work may be a major contributor to the development of cancer (Lichtenstein *et al.* 2000). In this context, the "environment" is anything that people interact with, including exposures resulting from lifestyle choices, such as what we eat, drink, or smoke; natural and medical radiation, including exposure to sunlight; workplace exposures; drugs; socioeconomic factors that affect exposures and susceptibility; and substances in air, water, and soil (OTA 1981, IOM 2001). Other factors that play a major role in cancer development are infectious diseases, aging, and individual susceptibility, such as genetic predisposition (Montesano 2001). We rarely know what environmental factors and conditions are responsible for the onset and development of cancers; however, we have some understanding of how some types of cancer develop, especially cancers related to certain occupational exposures or the use of specific drugs. Many experts firmly believe that much of the cancer associated with the environment may be avoided (Tomatis *et al.* 1997).

The people of the United States, concerned about the relationship between their environment and cancer, have asked, through the U.S. Congress, for information about substances that are known or appear likely to cause cancer (i.e., to be carcinogenic). Section 301(b)(4) of the Public Health Service Act, as amended, provides that the Secretary of the Department of Health and Human Services (DHHS) shall publish a biennial report that contains the following information:

- A) A list of all substances (1) which either are known to be human carcinogens or may reasonably be anticipated to be human carcinogens and (2) to which a significant number of persons residing in the United States are exposed.
- B) Information concerning the nature of such exposure and the estimated number of persons exposed to such substances.
- C) A statement identifying (1) each substance contained in this list for which no effluent, ambient, or exposure standard has been established by a Federal agency and (2) for each effluent, ambient, or exposure standard established by a Federal agency with respect to a substance contained in this list, the extent to which such standard decreases the risk to public health from exposure to the substance.
- D) A description of (1) each request received during the year to conduct research into, or testing for, the carcinogenicity of a substance and (2) how the Secretary and other responsible entities responded to each request.

The Report on Carcinogens (RoC) is an informational scientific and public health document that identifies and discusses agents, substances, mixtures, or exposure circumstances that may pose a hazard to human health by virtue of their carcinogenicity. It serves as a meaningful and useful compilation of data on (1) the carcinogenicity (ability to cause cancer), genotoxicity (ability to damage genes), and biologic mechanisms (modes of action in the body) of the listed substances in humans and/or in animals, (2) the potential for human exposure to these substances, and (3) Federal regulations to limit exposures. The RoC does not present quantitative assessments of the risks of cancer associated with these substances. Thus listing of substances in the RoC only indicates a potential hazard and does not establish the exposure conditions that would pose cancer risks to individuals in their daily lives. Such formal risk assessments are the responsibility of the appropriate federal, state, and local health regulatory and research agencies.

The substances listed in the RoC are either known or reasonably anticipated to cause cancer in humans in certain situations. With many listed substances, cancer may develop only after prolonged exposure. For

example, smoking tobacco is known to cause cancer in humans, but not all people who smoke develop smoking-related cancer. With some substances or exposure circumstances, however, cancer may develop after even brief exposure. Examples include certain occupational exposures to asbestos or bis(chloromethyl) ether. The cancer hazard that listed substances pose to any one person depends on many factors. Among these are the intrinsic carcinogenicity of the substance, the amount and duration of exposure, and an individual's susceptibility to the carcinogenic action of the substance. Because of these considerations, the RoC does not attempt to rank substances according to the relative cancer hazards they pose.

### Potential Beneficial Effects of Listed Carcinogens

As stated above, the purpose of the RoC is to identify hazards to human health posed by carcinogenic substances; therefore, it is not within the scope of this report to address potential *benefits* of exposure to certain carcinogenic substances in special situations. For example, numerous drugs typically used to treat cancer or other medical conditions have been shown to increase the frequency of primary or secondary cancers in patients undergoing treatment for specific diseases. In these cases, the benefits of using the drug to treat or prevent a specific disease outweigh the added cancer risks associated with its use. Personal decisions concerning voluntary exposure to carcinogenic substances should be based on information that is beyond the scope of the RoC. Individuals should not make decisions concerning the use of a given drug, or any other listed substance, based solely on the information contained in the RoC. Such decisions should be made only after consultation with a physician or other appropriate specialist.

### Identification of Carcinogens

For many years, government research agencies (including the National Toxicology Program), industries, academia, and other research organizations have studied various substances to identify those that may cause cancer. Much of this information on specific chemicals or occupational exposures has been published in the scientific literature or in publicly available and peer-reviewed technical reports. This literature is a primary source of information for identifying and evaluating substances for listing in the RoC. Many of the listed substances also have been reviewed and evaluated by other organizations, including the International Agency for Research on Cancer (IARC) in Lyon, France, the Environmental Protection Agency of the State of California, and other U.S. Federal and international agencies.

Both human and laboratory animal studies are used to evaluate whether substances are possible human carcinogens. The strongest evidence for establishing a relationship between exposure to any given substance and cancer in humans comes from epidemiological studies—studies of the occurrence of a disease in a defined population and the factors that affect its occurrence (Bradford 1971). Epidemiological studies of human exposure and cancer are difficult (Rothman 1986). They must rely on natural, not experimental, human exposures and must therefore consider many factors that may affect cancer prevalence besides the exposure under study. One such factor is the latency period for cancer development. The exposure to a carcinogen often occurs many years (sometimes 20 to 30 years or more) before the first sign of cancer appears. Another valuable method for identifying substances as potential human carcinogens is the long-term animal bioassay. These studies provide accurate information about dose and duration of exposure and they are less affected than epidemiology studies by possible interaction of the test substance with other chemicals or modifying factors (Huff 1999). In these studies, the substance is given to one or (usually) two species of laboratory rodents over a range of doses for nearly the animals' entire lives.

Experimental cancer research is based on the scientific assumption that substances causing cancer in animals will have similar effects in humans. It is not possible to predict with complete certainty from

## INTRODUCTION

animal studies alone which substances will be carcinogenic in humans. However, known human carcinogens that have been tested adequately in laboratory animals also cause cancer in laboratory animals (Fung *et al.* 1995). In many cases, a substance first was found to cause cancer in animals and later confirmed to cause cancer in humans (Huff 1993). How laboratory animals respond to substances, including developing cancer and other illnesses, does not always strictly correspond to how people will respond. Nevertheless, laboratory animal studies remain the best tool for detecting potential human health hazards of all kinds, including cancer (OTA 1981, Tomatis *et al.* 1997).

### Listing Criteria

The criteria for listing an agent, substance, mixture, or exposure circumstance in the RoC are as follows:

#### *Known To Be Human Carcinogen:*

There is sufficient evidence of carcinogenicity from studies in humans\*, which indicates a causal relationship between exposure to the agent, substance, or mixture, and human cancer.

#### *Reasonably Anticipated To Be Human Carcinogen:*

There is limited evidence of carcinogenicity from studies in humans\*, which indicates that causal interpretation is credible, but that alternative explanations, such as chance, bias, or confounding factors, could not adequately be excluded,

or

there is sufficient evidence of carcinogenicity from studies in experimental animals, which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors (1) in multiple species or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site, or type of tumor, or age at onset,

or

there is less than sufficient evidence of carcinogenicity in humans or laboratory animals; however, the agent, substance, or mixture belongs to a well-defined, structurally related class of substances whose members are listed in a previous Report on Carcinogens as either known to be a human carcinogen or reasonably anticipated to be a human carcinogen, or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.

Conclusions regarding carcinogenicity in humans or experimental animals are based on scientific judgment, with consideration given to all relevant information. Relevant information includes, but is not limited to, dose response, route of exposure, chemical structure, metabolism, pharmacokinetics, sensitive sub-populations, genetic effects, or other data relating to mechanism of action or factors that may be unique to a given substance. For example, there may be substances for which there is evidence of carcinogenicity in laboratory animals, but there are compelling data indicating that the agent acts through mechanisms which do not operate in humans and would therefore not reasonably be anticipated to cause cancer in humans.

\*This evidence can include traditional cancer epidemiology studies, data from clinical studies, and/or data derived from the study of tissues or cells from humans exposed to the substance in question that can be useful for evaluating whether a relevant cancer mechanism is operating in people.

The listing criteria presented here were first adopted for use in the *Eighth Report on Carcinogens*, which was published in 1998. The clarification noted above was issued in a *Federal Register* notice dated April 2, 1999 (see 64FR15983-15984, see also *Federal Register* notice dated April 19, 1999: 64FR 19188-19189). Listing criteria for substances listed in earlier editions of the RoC are outlined in the introductions to those editions.

### Preparation of the RoC

Within the DHHS, the Secretary has delegated the responsibility for preparing the RoC to the National Toxicology Program (NTP). The process used to prepare the RoC involves several levels of review of the nominations considered for listing in or delisting (removal) from the report. Opportunities for public comment and participation are an integral part of the review process.

Nominations for listing in or delisting from the RoC are received from a number of sources. Periodic requests for nominations from the public are published in the *Federal Register*, the NTP Update newsletter, and other appropriate publications. The NTP actively solicits nominations from member agencies of the NTP Executive Committee.<sup>1</sup> Nominations for the RoC also come from reviews of the literature performed by the NTP. Potential nominations are identified from such sources as the NTP Technical Reports, the IARC *Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, the California Environmental Protection Agency's Carcinogen List, and other similar sources.

Two Federal scientific review groups and one non-governmental scientific peer-review body (a standing subcommittee of the NTP Board of Scientific Counselors) evaluate the nominations for listing in or delisting from the RoC. Each group reviews the relevant data on the carcinogenicity of the substances nominated and the exposure of U.S. residents to the substances. The members of these three review groups may be found in Appendix D, List of Participants.

The nominations for listing in the *Eleventh Report on Carcinogens* initially were evaluated by a Report on Carcinogens Review Committee (RG1), composed of scientists from the National Institute of Environmental Health Sciences. For each nomination, the RG1 determined whether the information available was sufficient for applying the criteria for listing and whether the nomination warranted formal consideration by the NTP. This committee received the information submitted with each nomination and any relevant supplemental materials identified by RoC staff. For each nomination the committee reviewed this information and made a formal recommendation to the Director, NTP, either to continue with the formal review for listing or delisting or not to pursue the nomination at that time. The criterion for not pursuing a nomination was the lack of sufficient information for applying the listing criteria. Those nominations not accepted for review were returned to the original nominator who was invited to resubmit the nomination with additional justification, such as new cancer data or exposure information. The NTP Executive Committee and the NTP Board of Scientific Counselors were informed of all nominations not accepted for review.

Upon approval of the nominations by the Director, the NTP announced its intent to review the nominations for the *Eleventh Report on Carcinogens* and solicited public comment on all nominations through announcements in the *Federal Register* and NTP publications. The NTP then initiated an independent search and

<sup>1</sup>Agencies represented on the NTP Executive Committee include: Agency for Toxic Substances and Disease Registry (ATSDR), Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food and Drug Administration (FDA), National Center for Environmental Health (NCEH/CDC), National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), and National Institute of Environmental Health Sciences/NTP (NIEHS/NTP).

## INTRODUCTION

review of the scientific literature and prepared a background document for each nomination under consideration. The comments received in response to the public announcement were used to help identify issues that should be addressed in the background documents. Whenever possible, the background documents were prepared with the assistance of a consultant or a panel of consultants with recognized expertise on the nomination.

The RG1 then conducted the initial scientific review of a nomination for listing in the *Eleventh Report on Carcinogens*. The RG1 first reviewed the background document prepared for each nomination and determined whether it was adequate for use in reviewing the nomination and applying the criteria for listing in the RoC. After acceptance of the background document the RG1 then proceeded with scientific review of the nomination. It considered the information in the background document and all public comments received in response to the announcement of the nomination, and made a formal recommendation to the NTP Director for its listing in the RoC. Upon acceptance of the background document by the RG1, it was considered the final document of record and was placed on the NTP RoC web site with a notice published on the NTP list-serv and the NTP home web site announcing its availability.

The NTP Executive Committee's Interagency Working Group for the Report on Carcinogens (RG2), a governmental interagency scientific review group, conducted a second review of the nominations. For each nomination, the RG2 assessed whether relevant information was available and sufficient for its listing in the RoC. The RG2 considered the original nomination, the background document, and all public comments received in response to announcements of the nominations. Upon completion of its review, the RG2 made its formal recommendations to the NTP Director for listing the nominations in the RoC.

The third review of the nominations was an independent external scientific peer review by a standing subcommittee of the NTP Board of Scientific Counselors (the RoC Subcommittee). The RoC Subcommittee assessed whether the relevant information available for each nomination was sufficient for its listing in the RoC. This review was conducted in an open public meeting. A notice of the review announcing the meeting and the availability of the background documents, and soliciting public comment on the nominations was published in the *Federal Register* and NTP publications. The notice invited interested groups or individuals to submit written comments and/or address the RoC Subcommittee during the public meeting. Upon completion of its review, the RoC Subcommittee made its formal recommendations to the NTP Director for listing the nominations in the RoC.

Following completion of the reviews by the RG1, RG2 and RoC Subcommittee, the NTP published the nominations and the review groups' recommendations for each nomination in the *Federal Register*, and solicited the third and final round of public comment and input on the nominations.

The recommendations of the RG1, RG2, and RoC Subcommittee and all public comments received were presented to the NTP Executive Committee for review and comment. The NTP Executive Committee reviewed the information on each nomination and provided to the NTP Director a recommendation on its listing in the RoC.

The NTP Director received the independent recommendations of the RG1, RG2 and RoC Subcommittee, the opinion of the NTP Executive Committee, and all public comments concerning the nominations. The NTP Director evaluated this input and any other relevant information on the nominations and developed recommendations to the Secretary, DHHS regarding whether to list or not to list the nominations in the RoC.

The NTP prepared the final draft of the RoC based on the NTP Director's recommendations and submitted it to the Secretary, DHHS,

for review and approval. Upon approval of the RoC, the Secretary submitted it to the U. S. Congress as a final document. Submittal of the RoC to Congress constituted publication of the report, and it became available to the public at that time. The NTP published a notice of the publication and availability of the Eleventh Edition of the RoC, indicating all newly listed agents, substances, mixtures or exposure circumstances in the *Federal Register* and NTP publications.

### Estimation of Exposure

The RoC is required to list only substances to which a significant number of people living in the United States are exposed; therefore, substances to which very few people are exposed are generally not listed. Some substances that have been banned or restricted in use (e.g., safrole, arsenical pesticides, and mirex) are listed either because people who were previously exposed remain potentially at risk or because these substances still are present in the environment.

The RoC also is required to provide information about the nature of exposures and the estimated numbers of people exposed to listed substances. Four of the agencies participating with the NTP in preparation of the *Eleventh Report on Carcinogens*—the Consumer Product Safety Commission (CPSC), U.S. Environmental Protection Agency (EPA), Food and Drug Administration (FDA), and Occupational Safety and Health Administration (OSHA)—are responsible for regulating hazardous substances and limiting the exposure to and use of such substances. Information on use, production, and exposure in each entry of the RoC was reviewed by staff members from these four regulatory agencies. Because little information typically is available, estimating the number of people who could be exposed, and the route, intensity, and duration of exposure for each substance is a very difficult task. This RoC attempts to respond to these questions, and adequate answers that could be obtained are included in the individual profiles for each listing.

The National Institute for Occupational Safety and Health (NIOSH) has conducted two occupational exposure surveys: the National Occupational Hazard Survey (NOHS), conducted from 1972 to 1974, and the National Occupational Exposure Survey (NOES), conducted from 1981 to 1983. These surveys yielded data on potential exposure to many listed substances. Although dated, NOES estimates are provided in the profiles of the listings when available, and NOHS figures are given in some profiles if no other exposure data were available.

### Regulations and Guidelines

The RoC is required to identify each listed substance for which no standard for exposure or release into the environment has been established by a Federal Agency. The *Eleventh Report on Carcinogens* addresses this requirement by providing in each profile a summary of the regulations and guidelines that are likely to decrease exposure to that substance. Some of these regulations and guidelines have been enacted for reasons other than the substance's carcinogenicity (for example, to prevent adverse health effects other than cancer or to prevent accidental poisoning of children). These regulations are included in the profiles, because reduction of exposure to a carcinogen will likely reduce the risk for cancer. In earlier editions of the RoC, each profile contained a summary of relevant regulations with a cumulative list of the *Code of Federal Regulations* and *Federal Register* citations for each listing published in a separate volume. All regulations have been researched and presented in the *Eleventh Report on Carcinogens* using a new format. Starting with this edition, the regulations for a listing are organized by regulatory agencies and major acts, and are provided at the end of the profile rather than in a separate volume.

The majority of the regulations cited in the RoC were enacted by the following federal agencies: CPSC, the U.S. Department of Transportation, the EPA, the FDA, and OSHA. The guidelines cited

## INTRODUCTION

in the RoC are primarily those published by NIOSH and the American Conference of Governmental Industrial Hygienists. Additionally, regulations and guidelines enacted by other governmental agencies not listed above are cited if their likely outcome is to reduce exposure to the substance. It is beyond the scope of this report to provide detailed information or interpretation concerning the implementation of each regulatory act, and no attempt is made to do so. Some commonly used regulatory terms are defined in the glossary (Appendix F), and links to the websites for the *Code of Federal Regulations* and for each of the major regulatory agencies are provided in the reference section of this Introduction for those wishing to obtain additional information on these agencies and their regulations.

Two regulations were identified that apply to all substances listed in the RoC:

1. OSHA's Hazard Communication Standard  
This regulation is intended to communicate the hazards of chemicals and appropriate protective measures to protect employees. The program includes maintenance of a list of hazardous chemicals, labeling of containers in the workplace, and preparation and distribution of material safety data sheets to employees. The rule states that chemicals shall be considered "hazardous" if they have been listed as a carcinogen or potential carcinogen in (1) the NTP's RoC (latest edition) or (2) the IARC Monographs (latest editions) or (3) OSHA's Occupational Safety and Health Standards, Subpart Z – Toxic and Hazardous Substances.
2. EPA's Criteria for the Evaluation of Permit Applications for Ocean Dumping of Materials under the Toxic Substances Control Act (TSCA)  
This regulation prohibits ocean dumping of materials containing "known carcinogens, mutagens, or teratogens or materials suspected to be carcinogens, mutagens, or teratogens by responsible scientific opinion" as other than trace contaminants.

Because both of these regulations apply to all substances listed in the RoC, they are not identified individually in the listing profiles. However, the reader should be aware that these regulations pertain to all substances listed in the RoC, and that their likely outcome is to reduce exposure to listed substances.

Two OSHA regulations identified in some of the listing profiles require clarification:

1. Specific substances are listed as having "comprehensive standards" if, in addition to the permissible exposure limit (PEL), OSHA has regulations for the substance that include provisions for: exposure monitoring, engineering and work practice controls, use of respirators and protective garments and equipment, hygiene facilities, information and training, labeling of substance containers and worker areas in which the substance is used, and health screening programs.
2. The OSHA PEL identified in the profiles for glass wool (respirable size), ceramic fibers (respirable size), and wood dust are based on the standard for Particulates Not Otherwise Regulated (PNOR). This standard sets limits applicable to all inert or nuisance dusts, whether mineral, inorganic, or organic, not identified specifically by substance name. OSHA recommended that the profiles for these three substances include the PEL established by the PNOR standard.

### Estimation of Risk Reduction

For each effluent, ambient, or exposure standard established by a Federal agency for a listed substance, the RoC is required to state the extent to which, on the basis of available medical, scientific, or other

data, the implementation of that standard decreases the public's risk for cancer. This statement requires quantitative information on how much protection from cancer the public is afforded by established Federal standards.

Estimating the extent to which listing a substance in the RoC protects public health is perhaps the most difficult task in preparing the RoC. The carcinogenic risk (i.e., the probability of developing cancer) depends on many things, including the intensity, route, and duration of exposure to a carcinogen. People may respond differently to similar exposures, depending on their age, sex, nutritional status, overall health, genetics, and many other factors. Only in a few instances can risk for cancer be estimated with complete confidence, and these estimations require studies of long-term human exposures and cancer incidence in restricted environments, which rarely are available.

One possible way to provide quantitative estimates of risk reduction might be to assume that the cancer risk is directly proportional to exposure. This approach also presumes that data exists on past and present exposure levels, or that all workplace conditions comply with regulations. It is rare that one has information supporting these assumptions. Despite these limitations, it is reasonable and prudent to accept that reducing exposure, for any reason, particularly to substances shown to be carcinogenic in experimental animals, will decrease the incidence of cancer in people (Tomatis *et al.* 1997, Montesano *et al.* 2001). This relationship is the basis of current regulatory policies that aim to lower human exposure to cancer-causing substances, and thereby, improve public health.

Major environmental pollution prevention acts, such as the EPA's Resource Conservation and Recovery Act, Clean Water Act and Clean Air Act, were passed in the early 1970s. These laws have led to the reduction in exposure to a number of substances listed in the RoC. Although one can not draw a direct cause and effect relationship between pollution reduction and cancer incidence, recent data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute show decreasing cancer trends for many cancers, although others are increasing (SEER 2003). The "Annual Report to the Nation on the Status of Cancer, 1975-2000" (Wier *et al.* 2003) is based in part on the most recent SEER data and provides an update on cancer mortality (death rates), incidence rates (new cases), and trends in the United States. The report is issued annually by the Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), the National Cancer Institute (NCI) of the National Institutes of Health, and the North American Association of Central Cancer Registries (NAACCR). This report indicates that overall, cancer death rates (for men and women combined) were stable from 1998 through 2000 - that is, rates neither increased nor decreased. Before this time, death rates increased through 1990, stabilized through 1994, and declined from 1994 through 1998. Throughout the late 1990s, trends for women stabilized, while death rates for men continued to decline. Lung, colorectal, breast and prostate cancers have the highest prevalence in the United States and account for more than half of all cancer cases:

- Lung cancer is the leading cause of death from cancer in men and women in the United States. Lung cancer death rates among white and black men declined throughout the 1990s, while the rate of increase in deaths among women slowed during the same period, reflecting reductions in tobacco smoking. It is interesting to note that recently published studies have shown a rise in lung cancer and cardiopulmonary disease due to air pollution (Montesano *et al.* 2001).
- Colorectal cancer death rates have been declining for both white and black men and women beginning in the 1970s, with steeper declines beginning in the mid-1980s. This decline is attributed to better screening and treatment methods for this cancer.

## INTRODUCTION

- Breast cancer death rates continue to fall despite a gradual, long-term increase in incidence rates. Decreasing rates in deaths from breast cancer and increasing incidence rates during the 1990s have been attributed, in part, to increased use of mammography screening and the availability of improved therapies.
- Prostate cancer death rates have been declining since 1994, while incidence rates have been rising since 1995, with a 3.0 percent per year increase in incidence in white men and a 2.3 percent per year increase in black men. No currently recognized risk factors account for the decline in prostate cancer mortality, although the decrease might reflect improvements in treatment combined with improved detection using a blood test for prostate specific antigen (PSA).

Cancer sites without significant improvement in survival rates in the past 25 years include the uterine corpus, cervix, larynx, liver, lung, pancreas, stomach, and esophagus (Jemal *et al.* 2004).

Cancer incidence rates for all types of cancer combined increased from the mid-1970s through 1992, declined from 1992 through 1995, and then stabilized (a non-significant increase) from 1995 through 2000. Increases in incidence rates in breast cancer and prostate cancer offset long-term decreases in lung cancer in men (Wier *et al.* 2003). The SEER data also indicate that the incidences of liver, thyroid, melanoma of the skin and kidney cancers increased over the time interval between 1992 and 2000 (SEER 2003).

#### Listing Substances in the *Eleventh Report on Carcinogens*

The *Eleventh Report on Carcinogens* contains 246 entries, 17 of which have not appeared in earlier editions of the RoC.

The *Eleventh Report on Carcinogens* lists lead and lead compounds as *reasonably anticipated to be human carcinogens*. This listing of lead and lead compounds supersedes the listings of individual lead compounds (including lead acetate and lead phosphate) in previous editions of the RoC and applies to lead and all lead compounds.

The heterocyclic amines 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), are listed for the first time in the *Eleventh Report on Carcinogens* as *reasonably anticipated to be human carcinogens*. Another heterocyclic amine, 2-amino-3-methylimidazo [4,5-f]quinoline (IQ) was listed in the *Tenth Report on Carcinogens*, also as *reasonably anticipated to be a human carcinogen*. These four listings have been grouped together as a family under the title "Selected Heterocyclic Amines." The listing first gives evidence for the carcinogenicity for each heterocyclic amine separately, and then presents a combined section that discusses other information relevant to carcinogenicity, properties, use, production, exposure and regulations.

Three types of ionizing radiation (X-radiation, gamma radiation, and neutrons) are listed as *known to be human carcinogens* for the first time in the *Eleventh Report on Carcinogens*. The radioactive compound thorium dioxide, which decays by emission of alpha particles, was first listed in the *Second Annual Report on Carcinogens* (1981). Radon and its most common isotopic forms (radon-220 and radon-222), which also emit primarily alpha particles, were first listed in the *Seventh Annual Report on Carcinogens* (1994). The profiles for these sources of ionizing radiation have been placed together as a family of profiles under the title "Ionizing Radiation."

Diethanolamine was nominated for possible listing in the *Eleventh Report on Carcinogens*, but after a formal scientific review of all relevant information pertaining to its possible carcinogenicity, was not recommended for listing. The basis for the recommendation not to list diethanolamine is summarized in Appendix C of the *Eleventh Report on Carcinogens*.

Section II lists the names of all the agents, substances, mixtures, or exposure circumstances listed in the *Eleventh Report on Carcinogens*. It has two parts: Section II.A identifies 58 substances as *known to be*

*human carcinogens*, and Section II.B identifies 188 substances as *reasonably anticipated to be human carcinogens*.

Section III, Substance Profiles, contains a brief description of each substance with a summary of the evidence for its carcinogenicity; relevant information on properties, use, production and exposure; and a summary of the regulations and guidelines that are likely to decrease the exposure to the substance. These profiles are in alphabetical order and include references to scientific literature used to support the listings.

The substances listed in the *Eleventh Report on Carcinogens* may constitute only a fraction of actual human carcinogens. The RoC lists only those nominated agents, substances, mixtures or exposure circumstances for which relevant data exist and have been reviewed and found to meet the listing criteria defined above. As additional substances are nominated, they will be considered and reviewed for possible listing in future editions of the RoC.

Certain manufacturing processes, occupations, and exposure circumstances have been considered by IARC and are classified by that agency as known to be carcinogenic to humans because of associated increased incidences of cancer among workers in these settings. However, certain aspects of occupational exposures may differ in different parts of the world or may have changed over time; therefore, the manufacturing processes and occupations reviewed by IARC may not be applicable to past or current occupational exposures in the United States. The NTP has not yet reviewed the data supporting the listing of these occupational situations as posing a cancer hazard. In the interest of public health and for completeness, these occupational exposures are identified in Appendix A of the RoC with the corresponding IARC references.

#### Other Information Provided in this RoC

Section IV provides tables listing requests to the DHHS for research, testing, and other information relating to carcinogenicity, either from other Federal agencies or from within the DHHS, and how the DHHS responded to the requests. Section V details the listing and delisting procedures for the RoC.

The *Eleventh Report on Carcinogens* also includes seven appendices and an index:

- Appendix A lists manufacturing processes, occupations, and exposure circumstances classified by IARC as known to be carcinogenic to humans.
- Appendix B lists the agents, substances, mixtures, or exposure circumstances that have been delisted from the RoC.
- Appendix C lists the agents, substances, mixtures, or exposure circumstances that have been reviewed but not recommended for listing in the RoC.
- Appendix D lists participants who collaborated in preparing the *Eleventh Report on Carcinogens*.
- Appendices E, F, and G are, respectively, a glossary of terms, a list of acronyms and abbreviations, and a list of units of measurement used frequently in the RoC.
- The index (a feature introduced in the *Eleventh Report on Carcinogens*) allows the user to search for listings by commonly used synonyms or abbreviations included in the profiles or by CAS Registry Numbers of chemical substances discussed in the profiles.

The eleventh edition of the RoC was prepared following procedures that maximized the quality, objectivity, utility and integrity of the information contained in the report. Although not anticipated, factual errors or omissions in this report may be identified after its distribution. If this should happen, these errors or omissions will be addressed by the NTP. Where appropriate, corrections will initially be posted on the RoC web site at <http://ntp-server.niehs.nih.gov/NewHomeRoc/AboutRoC.html> and then made in the next edition of

**INTRODUCTION**

the RoC. For more information on the Eleventh Edition of the RoC, including how to order a printed copy or access it on the Internet, visit the NTP RoC web site at the address above or contact Dr. C. W. Jameson, Head, Report on Carcinogens, National Toxicology Program, MD EC-14, P.O. Box 12233, Research Triangle Park, NC 27709; telephone (919) 541-4096; fax (919) 541-0144; e-mail jameson@niehs.nih.gov.

**REFERENCES**

- ACS. 2004. Cancer Facts and Figures 2004: Basic Cancer Facts. American Cancer Society. <http://cancer.org/statistics/cff04/basicfacts.html#risk>.
- Bradford, H.A. 1971. Principles of Medical Statistics. The Lancet Ltd, London.
- Fung, V.A., Barrett, J.C., and Huff, J.E. 1995. The Carcinogenesis Bioassay in Perspective: Application in Defining Human Cancer Hazards. Environ Health Perspect. 103: 660-663.
- Huff, J.E. 1993. Chemicals and Cancer in Humans: First evidence in experimental animals. Environ. Health Perspect. 100: 201-210.
- Huff, J.E. 1999. Value, validity, and historical development of carcinogenesis studies for predicting and confirming carcinogenic risks to humans. In: Carcinogenicity Testing, Predicting, and Interpreting Chemical Effects. K.T. Kitchin, ed. Marcel Dekker: New York. pp. 21-123.
- IOM. 2001. Rebuilding the Unity of Health and the Environment: A New Vision of Environmental Health for the 21st Century. Workshop Summary. Institute of Medicine, National Academy Press: Washington, D.C.
- Jemal A., Tiwari, R.C., Murray T., Samuels A., Samuels A., Ward E., Feuer E.J., and Thun M.J. 2004. Cancer Statistics 2004, CA Cancer J Clin: 54: 8-29
- Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., *et al.* Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med. Vol. 13, 2000, pp. 76-85.

Montesano, R., and Hall, J. 2001. Environmental Causes of Human Cancers. European Journal of Cancer. 37: 57-67.


- OTA. 1981. Assessment of Technologies for Determining Cancer Risks from the Environment. Office of Technology Assessment, U.S. Government Printing Office: Washington, DC
- Rothman, K.J. 1986. Modern Epidemiology. Little, Brown and Co., Boston.
- Tomatis L., Huff J., Hertz-Picciotto I., Sandler D., Bucher J., Boffetta P., Axelson O., Blair A., Taylor J., Stayner L., and Barrett, J.C. 1997. Avoided and Avoidable Risks of Cancer. Carcinogenesis. 18: 97-105.
- Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Incidence - SEER 9 Regs, Nov 2002 Sub (1973-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.

**WEBSITES**

- Consumer Product Safety Commission <http://www.cpsc.gov/>
- Department of Transportation <http://www.dot.gov/>
- Environmental Protection Agency <http://www.epa.gov/>
- Food and Drug Administration <http://www.fda.gov/>
- Occupational Safety and Health Administration <http://www.osha.gov/>
- American Conference of Governmental Industrial Hygienists <http://www.acgih.org/home.htm>
- National Institute for Occupational Safety and Health: Pocket Guide to Chemical Hazards <http://www.osd.gov/niosh/homepage.html>
- Code of Federal Regulations (CFR): <http://www.gpoaccess.gov/cfr/index.html>

Tuesday, September 13, 2016 at 4:25:18 PM Eastern Daylight Time

**Subject:** Re: IARC Monograph vol 112- EFSA Review of Glyphosate  
**Date:** Tuesday, November 10, 2015 at 7:38:53 AM Eastern Standard Time  
**From:** drjameson  
**To:** Chris Portier  
**CC:** [REDACTED]  
**Priority:** High



Chris,

I would like the opportunity to review and participate in this but am pretty much tied up until Thursday (11/12). I'll try to get something to you before Friday.

Please give Mikie our regards.

Bill

-----Original Message-----

**From:** Chris Portier <[REDACTED]>  
**Date:** Monday, November 9, 2015 at 6:05 AM  
**To:** Isabelle Baldi <[REDACTED]>, Aaron Blair <[REDACTED]>, "Egeghy, Peter" <[REDACTED]>, "Forastiere, Francesco" <[REDACTED]>, Lin Fritschi <[REDACTED]>, Gloria Jahnke <[REDACTED]>, Bill Jameson <[REDACTED]>, "Kromhout, J. (Hans)" <[REDACTED]>, frank lecurieux <[REDACTED]>, Matt Martin <[REDACTED]>, John McLaughlin <[REDACTED]>, Teresa Rodriguez <[REDACTED]>, Matthew Ross <[REDACTED]>, "Rusyn, Ivan" <[REDACTED]>, Consolato Sergi <[REDACTED]>, "Mannetje, Andrea" <[REDACTED]>, Lauren Zeise <[REDACTED]>  
**Cc:** Kate Guyton <[REDACTED]>  
**Subject:** IARC Monograph vol 112- EFSA Review of Glyphosate

Dear all,

This week, the European Food Safety Agency (EFSA) will release their reassessment of glyphosate. In this review, they will conclude that glyphosate has no carcinogenic potential. This creates two problems as I see it. The first is that this weakens the strength of the IARC Monograph Program to stimulate change in how some of these agents are reviewed and addressed. The second is that it suggests we did not do our assessment adequately and that, had we seen all of the data they saw, we would have gotten a different answer. I do not intend to let this happen.

The German Federal Institute for Risk Assessment (BfR) was the lead

country agency in drafting the reassessment report. This report was drafted prior to the IARC review. In August of this year, following the release of the full Monograph on glyphosate, the BfR drafted an Addendum to their report that specifically addresses the Monograph review. I have decided to draft a letter that I intend to try to get published in Carcinogenesis that addresses the points made by the BfR in their review. Failing my ability to get this into Carcinogenesis, EHP or some other Journal, I intend to send it as an open letter to the European Commission. I am enclosing both the BfR Addendum and my response for you to look over. I would like as many members of the Working Group to be co-authors on this as possible. If you wish to see changes made to the letter I can certainly work on that. If you are uncomfortable signing on to such a letter, I can appreciate that as in my previous job this would have been impossible. Please let me know by Friday November 13 if you can or cannot join me in this endeavor.

Sincerely,

Christopher Portier

**Privileged and Confidential  
Attorney Client Privilege  
Attorney Work Product**

**In re Glyphosate/Roundup Litigation**

March 29, 2015

Hunter W. Lundy  
LUNDY, LUNDY SOILEAU & SOUTH, LLP  
501 Broad Street  
Lake Charles, LA 70601  
Email: [hlundy@lundylawllp.com](mailto:hlundy@lundylawllp.com)  
Telephone: 337 439-0707 / Fax: 337 439-1029

Expert Name

Christopher J. Portier, Ph.D.


Email [REDACTED]

Dear Dr. Portier:

This will confirm that Hunter W. Lundy, acting on behalf of the law firms of Lundy, Lundy, Soileau and South, LLP and Weitz & Luxenberg, PC ("Attorneys" or "Firms"), has retained you for the sole purpose of consulting with these Attorneys in connection with anticipated litigation involving claims arising from injury or damage caused, or potentially caused, by exposure to Roundup and/or other herbicides containing Glyphosate (the "Engagement"). The terms of the Engagement are as follows:

1. You are hereby engaged to provide expert consultation and analysis in connection with the cases to be filed (the "Roundup Cases"), relating to, without limitation, any area of expertise that you have or possess pertaining to the question of whether Roundup and/or Glyphosate-containing herbicides can cause adverse biological/physiological health effects in humans; relevant mechanisms of injury; any research or scientific studies that you have conducted or participated in conducting; and any other related issues.

Page 1 of 4



**Privileged and Confidential  
Attorney Client Privilege  
Attorney Work Product**

2. All work conducted in connection with this Engagement as a consulting expert and/or a testifying expert witness pursuant to the direction, authority, and/or funding of the referenced Attorneys, including any reports, drafts, data, notes, work papers, correspondence, or other work documents you may generate or receive in connection with the Roundup Cases shall be considered and treated as confidential work product. All such documents and materials (and any information they contain that is not publicly available data or previously available to you) may be used only for purposes of this Engagement and may not be disclosed to anyone without our written consent in advance. This Engagement does not pertain to nor shall it affect your research and/or scientific studies, and it is expressly understood and acknowledged that we have not, nor will we fund, participate, sponsor or be involved in any of your past, present or future research or scientific studies.
  
3. In recognition of the confidential nature of this Engagement and subject to the terms of paragraph 2, you agree to not discuss or share any of this work, work product, analysis and/or opinions developed or prepared in connection with this Engagement with anyone else including, but not limited to, media organizations, trade journals, professional publications, members of the public, other purported experts, etc., and to notify us promptly if you receive:
  - a. Any request to reveal information related to this Engagement or to examine, inspect or copy any documents you generate or receive; or
  - b. Any actual or attempted service of a subpoena, summons or order purporting to require the disclosure of any such information or documents; and
  - c. In consequence of such requests, subpoena(s), summons or order to require disclosure, the above-named law firm shall provide whatever legal services that are required to Christopher J. Portier without fee, any resultant out-of-pocket expenses, and payment of hourly rate.

**Privileged and Confidential  
Attorney Client Privilege  
Attorney Work Product**

4. You have assured us that you do not have any conflict of interest which might interfere with your performance of services contemplated by this Engagement, and you agree to avoid any such conflict during the term of this Engagement. More specifically, it is understood that until this matter is resolved (including any appeals), you will not accept any Roundup and/or Glyphosate-related engagement with any law firm that is a party to Roundup and/or Glyphosate-related litigation without our written consent in advance. However, if written consent is requested by Christopher J. Portier regarding another matter outside the specifics of this litigation, such consent shall not be unreasonably withheld. The request shall list the reasons why consent is requested. Should requested consent be withheld by Firms, they shall supply specific written reasons referencing the specific reasons listed in the written consent request. If Expert and Firms cannot agree, a single arbiter agreed upon by both parties shall decide.
5. Your fee for specific consultation, analysis and any requested report(s) shall be \$450.00 (US Dollars) per hour in addition to reimbursement for any out-of-pocket expenses. You shall receive a retainer of \$5,000.00 from which charges shall be drawn. You will send a monthly invoice as necessitated by the requested work which identifies the time spent and services rendered. Upon the depletion of the \$5,000.00 retainer, payment will be made within 30 days from receipt of your invoice. Bills should be issued to the attention of Hunter W. Lundy at Lundy, Lundy, Soileau & South, LLP, 501 Broad Street, Lake Charles, LA 70601.
6. You will be working under the exclusive direction of Hunter W. Lundy, Matthew E. Lundy and Kristie M. Hightower with the law firm of Lundy, Lundy, Soileau & South, LLP, and Robin L. Greenwald with the law firm of Weitz and Luxenberg, PC.
7. Any and all work product created by you or on your behalf in whole or in part during the course of this Engagement, authorized by the Committee, shall be considered a work for hire and the property of the Firms.
8. You or we may terminate this agreement in writing at any time, in which event

**Privileged and Confidential  
Attorney Client Privilege  
Attorney Work Product**

you must stop work and bill only for the work performed up until receipt of the written termination. However, in the event of such termination, the restrictions described in paragraphs 2, 3 and 4 (related to work product generated) above will remain in effect absent a mutual agreement to the contrary. Such mutual agreement shall not be unreasonably withheld.

9. Any controversy, dispute or claim arising out of or relating to this Engagement or breach of this Agreement, shall be decided by a single arbitrator to be mutually selected in a privately administered arbitration to be held in \_\_\_\_\_, using the rules of the American Arbitration Association. The Firms and you expressly consent to personal jurisdiction in the courts of \_\_\_\_\_, and waive any objection thereto.

Please acknowledge that you accept these terms by signing the enclosed copy of this letter and returning it to us.

Sincerely,

LUNDY, LUNDY, SOILEAU & SOUTH, LLP

By: \_\_\_\_\_  
Hunter W. Lundy

Agreed to by:

\_\_\_\_\_  
Christopher J. Portier, Ph.D.

Dated: \_\_\_\_\_

# INVOICE

**Christopher Portier**

Regarding:

**Bill to:**  
 Glyphosate/Roundup Litigation  
 Attn: Hunter W. Lundy  
 LUNDY, LUNDY SOILEAU & SOUTH, LLP  
 501 Broad Street  
 Lake Charles, LA 70601  
 Email: hlundy@lundylawllp.com  
 Telephone: 337 439-0707 / Fax: 337 439-1029

Invoice Date: 10/19/2015  
 Invoice #: 15002

Quantity	Date	Unit	Description	Rate	Amount Due
0.5	6/17/15	hr	Meet with H. Lundy at BIOEM meeting, general issues regarding Glyphosate	\$450.00	\$225.00
1	6/19/15	hr	Meet with H. Lundy and Robin Greenwald in Davis, CA, general issues regarding Glyphosate	\$450.00	\$450.00
2	7/9/15	hr	Background research on glyphosate and AML, cancers in the Ag. Health Study and onset time for NHL	\$450.00	\$900.00
3.5	10/19/15	hr	Reduce value of retainer (balance \$5000.00) by cost this invoice (new balance \$3425.00)	-\$450.00	-\$1575.00
				Total	\$0.00

**Reimbursement Information:**

Name: Christopher Portier

[Redacted]

[Redacted]

Signature:




Exhibit No.: 22-7  
 Deponent: Jameson  
 Date/RPR: 9-21-17  
 Hunter + Geist, Inc: TD

005071

**From:** [Consolato, Sergi](#)  
**To:** [Chris Portier](#)  
**Cc:** [Kate Guyton](#); [Ross, Matthew](#); [Egeghy, Peter](#); [Teresa Rodriguez](#); [frank lecuvioux](#); [Kromhout, J. \(Hans\)](#); [Rusyn, Ivan](#); [John McLaughlin](#); [Aaron Blair](#); [Lauren Zeise](#); [Matt Martin](#); [Jahnke, Gloria \(NIH/NIEMHS\) \(E\)](#); [Isabelle Baldi](#); [Bill Jameson](#); [Mannette, Andrea](#); [REDACTED]; [Ulf Fritschl](#); [Forastiere, Francesco](#)  
**Subject:** Re: IARC Monograph vol 112- EFSA Review of Glyphosate  
**Date:** Monday, November 9, 2015 6:24:56 AM

---

Dear Chris,

Thank you for your email and your wise counteroffensive policy. I will sign the letter, but I would like to read the letter probably today and I will send you my comments by the end of the day.

Thank you again!

Best regards

Consolato

On Nov 9, 2015 4:05 AM, "Chris Portier" <[REDACTED]> wrote:


Dear all,

This week, the European Food Safety Agency (EFSA) will release their reassessment of glyphosate. In this review, they will conclude that glyphosate has no carcinogenic potential. This creates two problems as I see it. The first is that this weakens the strength of the IARC Monograph Program to stimulate change in how some of these agents are reviewed and addressed. The second is that it suggests we did not do our assessment adequately and that, had we seen all of the data they saw, we would have gotten a different answer. I do not intend to let this happen.

The German Federal Institute for Risk Assessment (BfR) was the lead country agency in drafting the reassessment report. This report was drafted prior to the IARC review. In August of this year, following the release of the full Monograph on glyphosate, the BfR drafted an Addendum to their report that specifically addresses the Monograph review. I have decided to draft a letter that I intend to try to get published in Carcinogenesis that addresses the points made by the BfR in their review. Failing my ability to get this into Carcinogenesis, EHP or some other Journal, I intend to send it as an open letter to the European Commission. I am enclosing both the BfR Addendum and my response for you to look over. I would like as many members of the Working Group to be co-authors on this as possible. If you wish to see changes made to the letter I can certainly work on that. If you are uncomfortable signing on to such a letter, I can appreciate that as in my previous job this would have been impossible. Please let me know by Friday November 13 if you can or cannot join me in this endeavor.

Sincerely,

Christopher Portier



Tuesday, September 13, 2016 at 4:24:23 PM Eastern Daylight Time

**Subject:** Re: Final Glyphosate Letter

**Date:** Thursday, November 26, 2015 at 6:57:38 AM Eastern Standard Time

**From:** drjameson

**To:** Chris Portier

Thanks Chris and Happy Thanksgiving!

Bill

-----Original Message-----

**From:** Chris Portier <[REDACTED]>

**Date:** Thursday, November 26, 2015 at 1:30 AM

**To:** Chris Portier <[REDACTED]>

**Subject:** Final Glyphosate Letter

Dear Colleagues,


Attached is the final version of the Glyphosate letter. I plan to mail it out tomorrow morning. If you have concerns or need something changed, please write back and I will try, but I must have these before 8:00 am CET on Friday, November 25. I want to thank you all for your efforts in drafting this letter.


I will cc all of you when I release the document. It will be going to everyone on the cc line as well as Mr. Andriukaitis. In addition, it will also be circulated to several other groups with an embargo of Monday so that the recipients actually have time to read the letter before being blasted with media inquiries. There is a meeting in Brussels on Tuesday morning that I will attend, but not be speaking. Kurt Straif and Kate Guyton from IARC will be there and will testify. Following this will be a lunchtime debate that I will be participating in where I hope to raise many of the issues that are contained in this letter. I will also let you know of any response I receive from Mr. Andriukaitis or the other recipients, although I doubt we will see a formal response. If any press on this comes my way, I will share that as well.

For those of you who will be co-authors on the Commentary I plan to submit to JCEH, I hope to have that available to you sometime on Monday for your review and editing.

Thanks.

C.





003136

**From:** Chris Portier  
**To:** [REDACTED]  
**Subject:** Glyphosate  
**Date:** Sunday, December 6, 2015 8:21:23 AM  
**Attachments:** [s\\_2014\\_2019\\_plmrep\\_COMMITTEES\\_ENVI\\_DV\\_2015\\_12-01\\_Glyphosate\\_1\\_Dec\\_2015\\_EFSA\\_presentation\\_EN.pdf](#)  
[ATT00001.htm](#)  
[s\\_2014\\_2019\\_plmrep\\_COMMITTEES\\_ENVI\\_DV\\_2015\\_12-01\\_IARC\\_20151201\\_EN.pdf](#)  
[ATT00002.htm](#)

I promised to keep you updated on the press etc. These are below. During the EU Parliament discussion of glyphosate, the letter got a lot of attention. The Executive Director of EFSA got quite upset and referred to us as "Facebook" Scientists. He was implying we sign onto a letter just to see how many responses we can get. The debate following the hearing is given below. I mentioned the Facebook comment since the EFSA ED was in the audience. I have received correspondence from the Commissioner asking for a meeting. Nothing is set yet.

C.

Link to the lunch debate in Brussels.

<http://www.greens-efa-service.org/medialib/mcinfo/pub/en/scc/4289>

Media

<http://www.sueddeutsche.de/wirtschaft/streit-um-glyphosat-brisanter-brief-nach-bruessel-1.2759599>

[http://www.farminguk.com/news/Over-90-scientists-challenge-EFSA-claim-of-glyphosate-safety\\_37926.html](http://www.farminguk.com/news/Over-90-scientists-challenge-EFSA-claim-of-glyphosate-safety_37926.html)

<http://gmwatch.org/news/latest-news/16568-scientists-challenge-efsa-claim-of-glyphosate-safety>

<http://www.amisdelaterre.org/Glyphosate-et-cancer-la-decision.html>

[https://news.google.com/news/story?cf=all&hl=de&pz=1&ned=de&q=glyphosat&scoring=d&cf=all&ncl=duZQ\\_tq1z42TItMUQj7BwnxwIbJM&start=0](https://news.google.com/news/story?cf=all&hl=de&pz=1&ned=de&q=glyphosat&scoring=d&cf=all&ncl=duZQ_tq1z42TItMUQj7BwnxwIbJM&start=0)

<http://www.zeit.de/wissen/umwelt/2015-11/glyphosat-pflanzenschutzmittel-krebs-risiko>

<http://www.keine-gentechnik.de/nachricht/31426/>

<http://www.sueddeutsche.de/wirtschaft/streit-um-unkrautvernichtungsmittel-wissenschaftler-protestieren-gegen-glyphosat-bewertung-1.2759599>

<http://www.dw.com/en/independent-scientists-warn-over-monsanto-pesticide/a->

003137

[18886833](#)

[http://switchboard.nrdc.org/blogs/jsass/glyphosate\\_-\\_iarc\\_got\\_it\\_right.html](http://switchboard.nrdc.org/blogs/jsass/glyphosate_-_iarc_got_it_right.html)

BfR

### **Wie schätzt das BfR den „Offenen Brief“ einiger Wissenschaftler an den EU-Kommissar für Gesundheit und Lebensmittelsicherheit ein?**

Besagter „Offener Brief“ richtet sich an den zuständigen EU-Kommissar, nachdem nunmehr die Risikobewertung durch die in der EU zuständigen wissenschaftlichen Institutionen abgeschlossen und publiziert ist. Eine erste Überprüfung des Schreibens zeigt, dass dort keine neuen wissenschaftlichen Erkenntnisse aufgeführt werden, die nicht bereits von der EFSA und den europäischen Mitgliedstaaten im Rahmen der EU-Wirkstoffprüfung bewertet wurden. Die in dem Brief getroffenen Aussagen zur Kanzerogenität von Glyphosat kann das Bundesinstitut für Risikobewertung (BfR) wissenschaftlich nicht nachvollziehen. Diese Aussagen kontrastieren, wie auch die Schlussfolgerungen des IARC, sämtliche Bewertungen der zuständigen nationalen und internationalen Institutionen einschließlich des WHO/FAO Joint Meeting on Pesticide Residues (JMPR). Die gesundheitliche Bewertung des Pflanzenschutzmittelwirkstoffes Glyphosat ergab nach Prüfung aller vorliegender Studien durch diese Institutionen, dass sich nach der derzeitigen Datenlage bei bestimmungsgemäßer Anwendung von Glyphosat kein krebserzeugendes Risiko für den Menschen ableiten lässt. Zu der Einschätzung kommen auch die amerikanische Umweltbehörde (US-EPA) und die kanadische Behörde (Canada Health). Unterzeichner des offenen Briefes ist nicht die IARC selbst. Der Initiator und Verfasser des Briefes ist nach eigenen Angaben aktives Mitglied des Environmental Defense Fund, einer US-amerikanischen Nichtregierungsorganisation.

Das BfR empfiehlt grundsätzlich, Diskussionen über wissenschaftliche Studien auf wissenschaftlicher Ebene, selbstverständlich auch wenn nötig kontrovers, zu führen. Ein integraler Bestandteil der Wissenschaft ist dabei der wissenschaftliche Publikationsprozess. Thesen oder Kommentare zu Studien können dem wissenschaftlichen Diskurs nur zugeführt werden, wenn diese publiziert wurden und die entsprechenden Schlussfolgerungen transparent nachvollziehbar sind. Da die wissenschaftliche Bewertung des Wirkstoffes Glyphosat durch die zuständige EU-Behörde und die Risikobewertungsbehörden der Mitgliedstaaten abgeschlossen ist, können die zuständigen politischen Gremien in der EU nun auf Basis der wissenschaftlichen Bewertung entscheiden.